01998000000000385000450099100020000070000020000270600020000470100020000609100090
00081300034000171510021000510350010000724800043000820300022001259300004001471170
00800151085000500159935001000164032000600174036000700180042000200187200000200189
06500090019112200030020004800140020304800140021704800240023104300550025504300550
0310043005500365540038800420540040200808540039601210541000601606#1#0#i#1#2011040
8#Revista Brasileira de Psiquiatria#Rev. bras. psiquiatr#1516-4446#Associação Br
asileira de Psiquiatria - ABP#Rev. Bras. Psiquiatr.#RBP#vancouv#decs#1516-4446#a
head#201150#1#0#20110000#14#^les^hSumario#^lpt^hSumário#^len^hTable of Contents#
^les^tRev. Bras. Psiquiatr.^nno.ahead^cSão Paulo^a2011#^lpt^tRev. Bras. Psiquiat
r.^nno.ahead^cSão Paulo^a2011#^len^tRev. Bras. Psiquiatr.^nno.ahead^cSão Paulo^a
2011#^t<a rel="license" href="http://creativecommons.org/licenses/by-nc/3.0/"><i
mg alt="Creative Commons License" style="border-width:0" src="http://i.creativec
ommons.org/l/by-nc/3.0/80x15.png" /></a> Todo el contenido de esta revista, exce
pto dónde está identificado, est&#225; bajo una <a rel="license" href="http://cr
eativecommons.org/licenses/by-nc/3.0/">Licencia Creative Commons</a>^les#^t<a re
l="license" href="http://creativecommons.org/licenses/by-nc/3.0/"><img alt="Crea
tive Commons License" style="border-width:0" src="http://i.creativecommons.org/l
/by-nc/3.0/80x15.png" /></a> Todo o conteúdo deste periódico, exceto onde est&#2
25 identificado, est&#225; licenciado sob uma <a rel="license" href="http://crea
tivecommons.org/licenses/by-nc/3.0/">Licen&#231;a Creative Commons</a>^lpt#^t<a 
rel="license" href="http://creativecommons.org/licenses/by-nc/3.0/"><img alt="Cr
eative Commons License" style="border-width:0" src="http://i.creativecommons.org
/l/by-nc/3.0/80x15.png" /></a> All the contents of this journal, except where ot
herwise noted, is licensed under a <a rel="license" href="http://creativecommons
.org/licenses/by-nc/3.0/">Creative Commons Attribution License</a>^len#BY-NC##
00284000000000169000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790910009000810920007000900020013000977030
00400110#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#o#1#1#
article#1#20110302#145834#aop-0111.htm#136##
05091000000000685000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000500099038000400104121000300108049000300111158000300114
03000220011703200060013906500090014501400070015403500100016122300090017101201170
01800120107002970100036004040100037004400100031004770100043005080100034005510100
03200585070007000617070012000687083174800807085001002555085002302565085004202588
08500340263008500350266408500230269908314420272208500100416408500240417408500440
41980850034042420850035042760850023043111170008043340720003043421120009043451110
01404354114000904368113001504377002001304392#2011nahead#V:\SciELO\serial\rbp\201
1nahead\markup\aop-0111.htm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#03#nd#n
d#Rev. Bras. Psiquiatr.#ahead#20110000#^f0^l0#1516-4446#20110311#Associations be
tween polymorphic variants of the tryptophan hydroxylase 2 gene and obsessive-co
mpulsive disorder^len#Associação entre polimorfismos do gene da triptofano hidro
xilase 2 e o transtorno obsessivo-compulsivo^lpt#^rND^1A01^nFelipe Filardi da^sR
ocha#^rND^1A01^nNathália Bueno^sAlvarenga#^rND^1A01^nNaira Vassalo^sLage#^rND^1A
01 A02^nMarco Aurélio^sRomano-Silva#^rND^1A01^nLuiz Armando de^sMarco#^rND^1A01 
A02^nHumberto^sCorrêa#Universidade Federal de Minas Gerais^iA01^cBelo Horizonte^
sMG^pBrazil#Universidade Federal de Minas Gerais^iA02^1Faculty of Medicine^2Depa
rtment of Mental Health^cBelo Horizonte^sMG^pBrazil#^len^aOBJECTIVE: A substanti
al body of evidence suggests that obsessive-compulsive disorder has a genetic co
mponent, and substantial candidate genes for the disorder have been investigated
 through association analyses. A particular emphasis has been placed on genes re
lated to the serotonergic system, which is likely to play an important role in t
he pathogenesis of obsessive-compulsive disorder. The gene for tryptophan hydrox
ylase 2, which is a rate limiting enzyme in serotonin synthesis is considered an
 important candidate gene associated with psychiatric disorders. METHOD: Our sam
ple consisted of 321 subjects (107 diagnosed with obsessive-compulsive disorder 
and 214 healthy controls), which were genotyped for eight tagSNPs (rs4448731, rs
4565946, rs11179000, rs7955501, rs10506645, rs4760820, rs1487275 and rs10879357)
 covering the entire human tryptophan hydroxylase 2 gene. Statistical analyses w
ere performed using UNPHASED, version 3.0.12, and Haploview ((R)). RESULTS: Sing
le markers, genotype analysis did not show a significant genetic association wit
h obsessive-compulsive disorder. A significant association between the T-C-T (rs
4448731, rs4565946, rs10506645) and C-A-T (rs4565946, rs7955501, rs10506645) hap
lotypes and obsessive-compulsive disorder was observed, as well as a strong link
age disequilibrium between SNPs rs4448731 and rs4565946, and SNPs rs10506645 and
 4760820. DISCUSSION: Our research has not demonstrated the existence of associa
tions between the eight SNPs of TPH2 and obsessive-compulsive disorder. However,
 two LD and two haplotypes areas were demonstrated, thus suggesting that more st
udies in TPH2 are needed to investigate the role of tryptophan hydroxylase 2 var
iants in obsessive-compulsive disorder.#^ddecs^i1#^tm^len^kPsychiatry^i1#^tm^len
^kObsessive-compulsive disorder^i1#^tm^len^kPolymorphism, genetic^i1#^tm^len^kTr
yptophan hydroxylase^i1#^tm^len^kHaplotypes^i1#^lpt^aOBJETIVO: Diversos estudos 
demonstram que o transtorno obsessivo-compulsivo apresenta considerável contribu
ição genética, com diversos genes candidatos tendo sido estudados por meio de es
tudos de associação. Como alterações do sistema serotonérgico estão associadas a
o transtorno obsessivo-compulsivo, o gene da triptofano hidroxilase 2, enzima li
mitante da síntese da serotonina, é plausível candidato para estudos. MÉTODO: No
ssa amostra é composta de 321 sujeitos (107 pacientes com transtorno obsessivo-c
ompulsivo e 214 controles) e investigamos oito tagSNPs (rs4448731, rs4565946, rs
11179000, rs7955501, rs10506645, rs4760820, rs1487275 e rs10879357) do gene da t
riptofano hidroxilase 2. Análise estatística foi realizada com os programas UNPH
ASED e Haploview. RESULTADOS: Análise de frequência alélica e genotípica entre c
asos e controles não evidenciaram diferenças estatisticamente significativas. No
 entanto, observamos maior prevalência dos haplótiposT-C-T (rs4448731, rs4565946
, rs10506645) e C-A-T (rs4565946, rs7955501, rs10506645) entre os pacientes, ass
im como duas regiões com importantes desequilíbrios de ligação (SNPs rs4448731 e
 rs4565946; SNPs rs10506645 e 4760820). DISCUSSÃO: Nossos achados não demonstrar
am uma associação entre os SNPs do gene da TPH2 e o transtorno obsessivo-compuls
ivo, porém mais estudos são necessários, já que fortes desequilíbrios de ligação
 foram demonstrados, assim como dois haplótipos.#^ddecs^i2#^tm^lpt^kPsiquiatria^
i2#^tm^lpt^kTranstorno obsessivo-compulsivo^i2#^tm^lpt^kPolimorfismo genético^i2
#^tm^lpt^kTriptofano hidroxilase^i2#^tm^lpt^kHaplótipos^i2#vancouv#16#20100723#J
uly 23, 2010#20100802#August 2, 2010#aop-0111.htm##
05161000000000685000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000500099038000400104121000300108049000300111158000300114
03000220011703200060013906500090014501400070015403500100016122300090017101201240
01800120114003040100036004180100037004540100031004910100043005220100034005650100
03200599070007000631070012000701083177600821085001002597085002302607085004202630
08500340267208500350270608500230274108314700276408500100423408500240424408500440
42680850034043120850035043460850023043811170008044040720003044121120009044151110
01404424114000904438113001504447002001304462#2011nahead#V:\SciELO\serial\rbp\201
1nahead\markup\aop-0111.htm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#03#nd#n
d#Rev. Bras. Psiquiatr.#ahead#20110000#^f0^l0#1516-4446#20110311#<b>Associations
 between polymorphic variants of the tryptophan hydroxylase 2 gene and obsessive
-compulsive disorder</b>^len#<b>Associação entre polimorfismos do gene da tripto
fano hidroxilase 2 e o transtorno obsessivo-compulsivo</b>^lpt#^rND^1A01^nFelipe
 Filardi da^sRocha#^rND^1A01^nNathália Bueno^sAlvarenga#^rND^1A01^nNaira Vassalo
^sLage#^rND^1A01 A02^nMarco Aurélio^sRomano-Silva#^rND^1A01^nLuiz Armando de^sMa
rco#^rND^1A01 A02^nHumberto^sCorrêa#Universidade Federal de Minas Gerais^iA01^cB
elo Horizonte^sMG^pBrazil#Universidade Federal de Minas Gerais^iA02^1Faculty of 
Medicine^2Department of Mental Health^cBelo Horizonte^sMG^pBrazil#^len^a<b>OBJEC
TIVE:</b> A substantial body of evidence suggests that obsessive-compulsive diso
rder has a genetic component, and substantial candidate genes for the disorder h
ave been investigated through association analyses. A particular emphasis has be
en placed on genes related to the serotonergic system, which is likely to play a
n important role in the pathogenesis of obsessive-compulsive disorder. The gene 
for tryptophan hydroxylase 2, which is a rate limiting enzyme in serotonin synth
esis is considered an important candidate gene associated with psychiatric disor
ders. <b>METHOD:</b> Our sample consisted of 321 subjects (107 diagnosed with ob
sessive-compulsive disorder and 214 healthy controls), which were genotyped for 
eight tagSNPs (rs4448731, rs4565946, rs11179000, rs7955501, rs10506645, rs476082
0, rs1487275 and rs10879357) covering the entire human tryptophan hydroxylase 2 
gene. Statistical analyses were performed using UNPHASED, version 3.0.12, and Ha
ploview ((R)). <b>RESULTS:</b> Single markers, genotype analysis did not show a 
significant genetic association with obsessive-compulsive disorder. A significan
t association between the T-C-T (rs4448731, rs4565946, rs10506645) and C-A-T (rs
4565946, rs7955501, rs10506645) haplotypes and obsessive-compulsive disorder was
 observed, as well as a strong linkage disequilibrium between SNPs rs4448731 and
 rs4565946, and SNPs rs10506645 and 4760820. <b>DISCUSSION:</b> Our research has
 not demonstrated the existence of associations between the eight SNPs of TPH2 a
nd obsessive-compulsive disorder. However, two LD and two haplotypes areas were 
demonstrated, thus suggesting that more studies in TPH2 are needed to investigat
e the role of tryptophan hydroxylase 2 variants in obsessive-compulsive disorder
.#^ddecs^i1#^tm^len^kPsychiatry^i1#^tm^len^kObsessive-compulsive disorder^i1#^tm
^len^kPolymorphism, genetic^i1#^tm^len^kTryptophan hydroxylase^i1#^tm^len^kHaplo
types^i1#^lpt^a<b>OBJETIVO:</b> Diversos estudos demonstram que o transtorno obs
essivo-compulsivo apresenta considerável contribuição genética, com diversos gen
es candidatos tendo sido estudados por meio de estudos de associação. Como alter
ações do sistema serotonérgico estão associadas ao transtorno obsessivo-compulsi
vo, o gene da triptofano hidroxilase 2, enzima limitante da síntese da serotonin
a, é plausível candidato para estudos. <b>MÉTODO:</b> Nossa amostra é composta d
e 321 sujeitos (107 pacientes com transtorno obsessivo-compulsivo e 214 controle
s) e investigamos oito tagSNPs (rs4448731, rs4565946, rs11179000, rs7955501, rs1
0506645, rs4760820, rs1487275 e rs10879357) do gene da triptofano hidroxilase 2.
 Análise estatística foi realizada com os programas UNPHASED e Haploview. <b>RES
ULTADOS:</b> Análise de frequência alélica e genotípica entre casos e controles 
não evidenciaram diferenças estatisticamente significativas. No entanto, observa
mos maior prevalência dos haplótiposT-C-T (rs4448731, rs4565946, rs10506645) e C
-A-T (rs4565946, rs7955501, rs10506645) entre os pacientes, assim como duas regi
ões com importantes desequilíbrios de ligação (SNPs rs4448731 e rs4565946; SNPs 
rs10506645 e 4760820). <b>DISCUSSÃO:</b> Nossos achados não demonstraram uma ass
ociação entre os SNPs do gene da TPH2 e o transtorno obsessivo-compulsivo, porém
 mais estudos são necessários, já que fortes desequilíbrios de ligação foram dem
onstrados, assim como dois haplótipos.#^ddecs^i2#^tm^lpt^kPsiquiatria^i2#^tm^lpt
^kTranstorno obsessivo-compulsivo^i2#^tm^lpt^kPolimorfismo genético^i2#^tm^lpt^k
Triptofano hidroxilase^i2#^tm^lpt^kHaplótipos^i2#vancouv#16#20100723#July 23, 20
10#20100802#August 2, 2010#aop-0111.htm##
05214000000000709000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790640007000810710003000880400003000910010
00600094042000200100120000400102038000500106038000400111121000300115049000300118
15800030012103000210012403200060014506500090015101400070016003500100016722300090
01770120117001860120107003030100036004100100037004460100031004830100043005140100
03400557010003200591070007200623070012200695083174800817085001002565085002302575
08500420259808500340264008500350267408500230270908314420273208500100417408500240
41840850044042080850034042520850035042860850023043211170008043440720003043521120
00904355111001404364114000904378113001504387002001304402008008904415#2011nahead#
V:\SciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#l#4#1#article#1#^a2011#oa#
en#br1.1#1#4.0#ilus#tab#03#nd#nd#Rev. bras. psiquiatr#ahead#20110000#^f0^l0#1516
-4446#20110311#Associations between polymorphic variants of the tryptophan hydro
xylase 2 gene and obsessive-compulsive disorder^len#Associação entre polimorfism
os do gene da triptofano hidroxilase 2 e o transtorno obsessivo-compulsivo^lpt#^
rND^1A01^nFelipe Filardi da^sRocha#^rND^1A01^nNathália Bueno^sAlvarenga#^rND^1A0
1^nNaira Vassalo^sLage#^rND^1A01 A02^nMarco Aurélio^sRomano-Silva#^rND^1A01^nLui
z Armando de^sMarco#^rND^1A01 A02^nHumberto^sCorrêa#^iA01^1Universidade Federal 
de Minas Gerais^cBelo Horizonte^sMG^pBrazil#^iA02^1Universidade Federal de Minas
 Gerais^2Faculty of Medicine^3Department of Mental Health^cBelo Horizonte^sMG^pB
razil#^len^aOBJECTIVE: A substantial body of evidence suggests that obsessive-co
mpulsive disorder has a genetic component, and substantial candidate genes for t
he disorder have been investigated through association analyses. A particular em
phasis has been placed on genes related to the serotonergic system, which is lik
ely to play an important role in the pathogenesis of obsessive-compulsive disord
er. The gene for tryptophan hydroxylase 2, which is a rate limiting enzyme in se
rotonin synthesis is considered an important candidate gene associated with psyc
hiatric disorders. METHOD: Our sample consisted of 321 subjects (107 diagnosed w
ith obsessive-compulsive disorder and 214 healthy controls), which were genotype
d for eight tagSNPs (rs4448731, rs4565946, rs11179000, rs7955501, rs10506645, rs
4760820, rs1487275 and rs10879357) covering the entire human tryptophan hydroxyl
ase 2 gene. Statistical analyses were performed using UNPHASED, version 3.0.12, 
and Haploview ((R)). RESULTS: Single markers, genotype analysis did not show a s
ignificant genetic association with obsessive-compulsive disorder. A significant
 association between the T-C-T (rs4448731, rs4565946, rs10506645) and C-A-T (rs4
565946, rs7955501, rs10506645) haplotypes and obsessive-compulsive disorder was 
observed, as well as a strong linkage disequilibrium between SNPs rs4448731 and 
rs4565946, and SNPs rs10506645 and 4760820. DISCUSSION: Our research has not dem
onstrated the existence of associations between the eight SNPs of TPH2 and obses
sive-compulsive disorder. However, two LD and two haplotypes areas were demonstr
ated, thus suggesting that more studies in TPH2 are needed to investigate the ro
le of tryptophan hydroxylase 2 variants in obsessive-compulsive disorder.#^ddecs
^i1#^tm^len^kPsychiatry^i1#^tm^len^kObsessive-compulsive disorder^i1#^tm^len^kPo
lymorphism, genetic^i1#^tm^len^kTryptophan hydroxylase^i1#^tm^len^kHaplotypes^i1
#^lpt^aOBJETIVO: Diversos estudos demonstram que o transtorno obsessivo-compulsi
vo apresenta considerável contribuição genética, com diversos genes candidatos t
endo sido estudados por meio de estudos de associação. Como alterações do sistem
a serotonérgico estão associadas ao transtorno obsessivo-compulsivo, o gene da t
riptofano hidroxilase 2, enzima limitante da síntese da serotonina, é plausível 
candidato para estudos. MÉTODO: Nossa amostra é composta de 321 sujeitos (107 pa
cientes com transtorno obsessivo-compulsivo e 214 controles) e investigamos oito
 tagSNPs (rs4448731, rs4565946, rs11179000, rs7955501, rs10506645, rs4760820, rs
1487275 e rs10879357) do gene da triptofano hidroxilase 2. Análise estatística f
oi realizada com os programas UNPHASED e Haploview. RESULTADOS: Análise de frequ
ência alélica e genotípica entre casos e controles não evidenciaram diferenças e
statisticamente significativas. No entanto, observamos maior prevalência dos hap
lótiposT-C-T (rs4448731, rs4565946, rs10506645) e C-A-T (rs4565946, rs7955501, r
s10506645) entre os pacientes, assim como duas regiões com importantes desequilí
brios de ligação (SNPs rs4448731 e rs4565946; SNPs rs10506645 e 4760820). DISCUS
SÃO: Nossos achados não demonstraram uma associação entre os SNPs do gene da TPH
2 e o transtorno obsessivo-compulsivo, porém mais estudos são necessários, já qu
e fortes desequilíbrios de ligação foram demonstrados, assim como dois haplótipo
s.#^ddecs^i2#^tm^lpt^kPsiquiatria^i2#^tm^lpt^kTranstorno obsessivo-compulsivo^i2
#^tm^lpt^kPolimorfismo genético^i2#^tm^lpt^kTriptofano hidroxilase^i2#^tm^lpt^kH
aplótipos^i2#vancouv#16#20100723#July 23, 2010#20100802#August 2, 2010#aop-0111.
htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462
011005000003##
00462000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704022000083002001300303#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#5#1#article#116#<p><font siz
e="4" face="Verdana, Arial, Helvetica, sans-serif"><a name="ad1"></a><b>Associat
ions between polymorphic variants of the tryptophan hydroxylase 2 gene and obses
sive-compulsive disorder</b></font></p>     ^cY#aop-0111.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#6#2#article#116#<p>&nbsp;</p
>     ^cY#aop-0111.htm##
00448000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704020600083002001300289#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#7#3#article#116#<p><font siz
e="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Associa&ccedil;&atilde;o e
ntre polimorfismos do gene da triptofano hidroxilase 2 e o transtorno obsessivo-
compulsivo</b></font></p>     ^cY#aop-0111.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#8#4#article#116#<p>&nbsp;</p
>     ^cY#aop-0111.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#9#5#article#116#<p>&nbsp;</p
>     ^cY#aop-0111.htm##
00577000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704033400084002001300418#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#10#6#article#116#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Felipe Filardi da Rocha<s
up>I</sup>; Nath&aacute;lia Bueno Alvarenga<sup>I</sup>; Naira Vassalo Lage<sup>
II</sup>; Marco Aur&eacute;lio Romano-Silva<sup>I,II,III</sup>; Luiz Armando de 
Marco<sup>I</sup>; Humberto Corr&ecirc;a<sup>I,II,III</sup></b></font></p>     ^
cY#aop-0111.htm##
00426000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704018300084002001300267#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#11#7#article#116#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Medicine Molecul
ar Program, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Bra
zil     ^cY#aop-0111.htm##
00364000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704012100084002001300205#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#12#8#article#116#<br>   <sup
>II</sup>Neuroscience Program, Universidade Federal de Minas Gerais (UFMG), Belo
 Horizonte, MG, Brazil    ^cY#aop-0111.htm##
00405000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704016200084002001300246#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#13#9#article#116#<br>   <sup
>III</sup>Department of Mental Health, Faculty of Medicine, Universidade Federal
 de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil</font></p>     ^cY#aop-0111.
htm##
00359000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011500085002001300200#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#14#10#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondenc
e</a></font></p>     ^cY#aop-0111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#15#11#article#116#<p>&nbsp;<
/p>     ^cY#aop-0111.htm##
00288000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704004400085002001300129#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#16#12#article#116#<p>&nbsp;<
/p> <hr size="1" noshade>     ^cY#aop-0111.htm##
00342000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704009800085002001300183#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#17#13#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p> 
    ^cY#aop-0111.htm##
00888000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704064400085002001300729#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#18#14#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>OBJECTIVE:</b> A substan
tial body of evidence suggests that obsessive-compulsive disorder has a genetic 
component, and substantial candidate genes for the disorder have been investigat
ed through association analyses. A particular emphasis has been placed on genes 
related to the serotonergic system, which is likely to play an important role in
 the pathogenesis of obsessive-compulsive disorder. The gene for tryptophan hydr
oxylase 2, which is a rate limiting enzyme in serotonin synthesis is considered 
an important candidate gene associated with psychiatric disorders.    ^cY#aop-01
11.htm##
00667000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704042300085002001300508#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#19#15#article#116#<br>   <b>
METHOD:</b> Our sample consisted of 321 subjects (107 diagnosed with obsessive-c
ompulsive disorder and 214 healthy controls), which were genotyped for eight tag
SNPs (rs4448731, rs4565946, rs11179000, rs7955501, rs10506645, rs4760820, rs1487
275 and rs10879357) covering the entire human tryptophan hydroxylase 2 gene. Sta
tistical analyses were performed using UNPHASED, version 3.0.12, and Haploview (
(R)).    ^cY#aop-0111.htm##
00688000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704044400085002001300529#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#20#16#article#116#<br>   <b>
RESULTS:</b> Single markers, genotype analysis did not show a significant geneti
c association with obsessive-compulsive disorder. A significant association betw
een the T-C-T (rs4448731, rs4565946, rs10506645) and C-A-T (rs4565946, rs7955501
, rs10506645) haplotypes and obsessive-compulsive disorder was observed, as well
 as a strong linkage disequilibrium between SNPs rs4448731 and rs4565946, and SN
Ps rs10506645 and 4760820.    ^cY#aop-0111.htm##
00627000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704038300085002001300468#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#21#17#article#116#<br>   <b>
DISCUSSION:</b> Our research has not demonstrated the existence of associations 
between the eight SNPs of TPH2 and obsessive-compulsive disorder. However, two L
D and two haplotypes areas were demonstrated, thus suggesting that more studies 
in TPH2 are needed to investigate the role of tryptophan hydroxylase 2 variants 
in obsessive-compulsive disorder.</font></p>     ^cY#aop-0111.htm##
00470000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704022600085002001300311#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#22#18#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Descriptors:</b> Psychia
try; Obsessive-compulsive disorder; Polymorphism, genetic; Tryptophan hydroxylas
e;  Haplotypes</font></p> <hr size="1" noshade>     ^cY#aop-0111.htm##
00340000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704009600085002001300181#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#23#19#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>   
  ^cY#aop-0111.htm##
00830000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704058600085002001300671#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#24#20#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b> OBJETIVO:</b> Diversos 
estudos demonstram que o transtorno obsessivo-compulsivo apresenta consider&aacu
te;vel contribui&ccedil;&atilde;o gen&eacute;tica, com diversos genes candidatos
 tendo sido estudados por meio de estudos de associa&ccedil;&atilde;o. Como alte
ra&ccedil;&otilde;es do sistema seroton&eacute;rgico est&atilde;o associadas ao 
transtorno obsessivo-compulsivo, o gene da triptofano hidroxilase 2, enzima limi
tante da s&iacute;ntese da serotonina, &eacute; plaus&iacute;vel candidato para 
estudos.    ^cY#aop-0111.htm##
00641000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704039700085002001300482#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#25#21#article#116#<br>   <b>
M&Eacute;TODO:</b> Nossa amostra &eacute; composta de 321 sujeitos (107 paciente
s com transtorno obsessivo-compulsivo e 214 controles) e investigamos oito tagSN
Ps (rs4448731, rs4565946, rs11179000, rs7955501, rs10506645, rs4760820, rs148727
5 e rs10879357) do gene da triptofano hidroxilase 2. An&aacute;lise estat&iacute
;stica foi realizada com os programas UNPHASED e Haploview.    ^cY#aop-0111.htm#
#
00769000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704052500085002001300610#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#26#22#article#116#<br>   <b>
RESULTADOS:</b> An&aacute;lise de frequ&ecirc;ncia al&eacute;lica e genot&iacute
;pica entre casos e controles n&atilde;o evidenciaram diferen&ccedil;as estatist
icamente significativas. No entanto, observamos maior preval&ecirc;ncia dos hapl
&oacute;tiposT-C-T (rs4448731, rs4565946, rs10506645) e C-A-T (rs4565946, rs7955
501, rs10506645) entre os pacientes, assim como duas regi&otilde;es com importan
tes desequil&iacute;brios de liga&ccedil;&atilde;o (SNPs rs4448731 e rs4565946; 
SNPs rs10506645 e 4760820).    ^cY#aop-0111.htm##
00610000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704036600085002001300451#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#27#23#article#116#<br>   <b>
DISCUSS&Atilde;O:</b> Nossos achados n&atilde;o demonstraram uma associa&ccedil;
&atilde;o entre os SNPs do gene da TPH2 e o transtorno obsessivo-compulsivo, por
&eacute;m mais estudos s&atilde;o necess&aacute;rios, j&aacute; que fortes deseq
uil&iacute;brios de liga&ccedil;&atilde;o foram demonstrados, assim como dois ha
pl&oacute;tipos.</font></p>     ^cY#aop-0111.htm##
00486000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704024200085002001300327#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#28#24#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Descritores:</b> Psiquia
tria; Transtorno obsessivo-compulsivo; Polimorfismo gen&eacute;tico; Triptofano 
hidroxilase; Hapl&oacute;tipos</font></p> <hr size="1" noshade>     ^cY#aop-0111
.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#29#25#article#116#<p>&nbsp;<
/p>     ^cY#aop-0111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#30#26#article#116#<p>&nbsp;<
/p>     ^cY#aop-0111.htm##
00346000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010200085002001300187#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#31#27#article#116#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Introduction</b></font><
/p>     ^cY#aop-0111.htm##
00682000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704043800085002001300523#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#32#28#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A substantial body of evide
nce suggests that obsessive-compulsive disorder (OCD) has a genetic component, a
nd substantial candidate genes have been investigated through  association analy
ses. A particular emphasis has been placed on genes related to the serotonin sys
tem, which is likely to play an important role in the pathogenesis of OCD.<sup>1
-4</sup></font></p>     ^cY#aop-0111.htm##
00825000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704058100085002001300666#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#33#29#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">The gene for tryptophan hyd
roxylase (TPH), the rate-limiting step in serotonin (5-HT) synthesis, is an inte
resting candidate for association analyses. The TPH gene was first identified in
 1990 and was believed to be unique.<sup>5</sup> However, the presence of normal
 levels of 5-HT in the brains of TPH-deficient mice led to the identification of
 a second TPH gene (TPH2), which is predominantly expressed in the brain and reg
ulates the effects of 5-HT in the central nervous system.<sup>5,6</sup></font></
p>     ^cY#aop-0111.htm##
00566000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704032200085002001300407#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#34#30#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Genetic variation in the TP
H2 gene may contribute to susceptibility to numerous psychiatric disorders, incl
uding major depression,<sup>7-9</sup> panic disorder,<sup>10</sup> suicidal beha
vior, and bipolar affective disorder.<sup>7-11</sup></font></p>     ^cY#aop-0111
.htm##
01036000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704079200085002001300877#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#35#31#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A review of the psychiatric
 literature published over the past years has shown that studies on the genetic 
variants of the TPH1 gene have yielded negative results. In the two studies cond
ucted with OCD patients, results were also negative.<sup>3,7,12</sup> These find
ings must be reinterpreted in view of the fact that TPH1 is responsible for 5-HT
 synthesis in peripheral organs, while TPH2 controls the synthesis of 5-HT in th
e brain. Although only two studies investigated the role of TPH2 in OCD,<sup>13,
14</sup> one demonstrated promising results. M&ouml;ssner et al. studied two TPH
2 SNPs (rs4570625 and rs4565946) and observed an important contribution of rs456
5946 to the total risk of early-onset OCD.</font></p>     ^cY#aop-0111.htm##
00596000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704035200085002001300437#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#36#32#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Based on the few studies th
at have assessed TPH2 and OCD and the one whose result was positive, we sought t
o investigate the association between OCD and eight TagSNPs of the TPH2 gene in 
a sample of 107 Brazilian-Caucasian OCD patients and 214 matched healthy control
s.</font></p>     ^cY#aop-0111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#37#33#article#116#<p>&nbsp;<
/p>     ^cY#aop-0111.htm##
00340000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704009600085002001300181#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#38#34#article#116#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Method</b></font></p>   
  ^cY#aop-0111.htm##
00343000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704009900085002001300184#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#39#35#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>1. Sample</b></font></p>
     ^cY#aop-0111.htm##
01207000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704096300085002001301048#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#40#36#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">1) Patient group: 107 OCD B
razilians of Caucasian descent as determined by self and/or clinical evaluation 
between the ages of 18 and 65 years participated in this study. Participants sat
isfied DSM-IV criteria for a diagnosis of OCD and were recruited from a speciali
zed OCD clinic at the Medical School of UFMG, Belo Horizonte-MG, Brazil, by a co
nsultant psychiatrist. The diagnosis was made by a trained psychiatrist using th
e following resources: (1) the structured MINI-PLUS interview,<sup>15</sup> whic
h follows the DSM-IV criteria, (2) complete review of the patients' medical reco
rds, and (3) an interview with at least one close relative. We excluded particip
ants who currently had mild/moderate/severe major depressive disorders, bipolar 
disorders, substance-related disorders, psychotic disorders, or a lifetime histo
ry of traumatic brain injury/vascular brain disorder.</font></p>     ^cY#aop-011
1.htm##
00759000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704051500085002001300600#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#41#37#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">2) Control group: 214 healt
hy controls were recruited among university students and locals through local ad
vertisements and subsequently screened using the MINI-PLUS interview. The subjec
ts were free of psychiatric illness and had no family history of Axis I psychiat
ric disorder in first-degree relatives (self-report). They were also of Brazilia
n-Caucasian descent. This data was obtained using both self-report and clinical 
data.</font></p>     ^cY#aop-0111.htm##
00558000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704031400085002001300399#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#42#38#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">The study was completed in 
accordance with the guidelines of the Helsinki Declaration and approved by the L
ocal Ethics Committee. Subjects were given a complete description of the study b
efore written informed consent was obtained.</font></p>     ^cY#aop-0111.htm##
00347000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010300085002001300188#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#43#39#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>2. Genotyping</b></font>
</p>     ^cY#aop-0111.htm##
00877000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704063300085002001300718#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#44#40#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">We selected eight tagSNPs, 
which were provided in a made-to-order assay from Applied Biosystems TaqMan<sup>
&reg;</sup> SNP Genotyping Assays. The probes corresponded to the following poly
morphisms: rs4448731 (intergenic), rs4565946 (intron 2), rs11179000 (intron 4), 
rs7955501 (intron 5), rs10506645 (intron 7), rs4760820 (intron 8), rs1487275 (in
tron 8) and rs10879357 (intron 8). All polymorphisms were chosen using Hapmap (a
t website: <a href="http://www.hapmap.org" target="_blank">www.hapmap.org</a>) a
nd were selected to analyze the whole gene.</font></p>     ^cY#aop-0111.htm##
00865000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704062100085002001300706#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#45#41#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Genotyping was performed us
ing real time PCR in a mode of allelic discrimination (Strategene Mx3005 - MxPro
 QPCR- Software, 2007). PCR protocols followed the instructions of the TaqMan<su
p>&reg;</sup> Genotyping Master Mix (Applied Biosystems, Foster City, CA). The P
CR conditions were 1 cycle (95ºC for 10 min) and 50 cycles (95ºC) for 15s, 60ºC 
for 1 min). Protocol: 3.5&#181;l of mix, 0.1&#181;l of probe, 3.4&#181;l of deio
nized water and 1.0&#181;l of DNA at a concentration of 50ng/&#181;l. Retypes we
re done for 10% of the samples.</font></p>     ^cY#aop-0111.htm##
00357000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011300085002001300198#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#46#42#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>3. Statistical analysis<
/b></font></p>     ^cY#aop-0111.htm##
00493000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704024900085002001300334#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#47#43#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Statistical analyses were p
erformed using the Unphased software package, version 3.0.12. Pairwise linkage d
isequilibrium was established using Haploview 4.1 software.</font></p>     ^cY#a
op-0111.htm##
00658000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704041400085002001300499#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#48#44#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">We used chi-square tests to
 compare categorical data between groups. Haplotypes frequencies were evaluated 
based on Bayes' theorem and Poisson distribution. A logistic regression analysis
 with factors such as gender and age of onset of the disorder was performed to e
valuate the influence of these features on the genetic analyses.</font></p>     
^cY#aop-0111.htm##
00688000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704044400085002001300529#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#49#45#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">The power to detect signifi
cant associations between cases and controls was calculated with the software Ge
netic Power Calculator. Based on an OCD prevalence of 2%, an addictive genetic m
odel, the number of cases and controls, and an estimated genotype relative risk 
of 1.5, the power varies based on the allelic frequency of the variant and range
s from 32-56%.</font></p>     ^cY#aop-0111.htm##
00391000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704014700085002001300232#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#50#46#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Results were considered sig
nificant for p-values less than 0.05.</font></p>     ^cY#aop-0111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#51#47#article#116#<p>&nbsp;<
/p>     ^cY#aop-0111.htm##
00341000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704009700085002001300182#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#52#48#article#116#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Results</b></font></p>  
   ^cY#aop-0111.htm##
00371000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012700085002001300212#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#53#49#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>1. Single marker associa
tion analysis</b></font></p>     ^cY#aop-0111.htm##
00588000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704034400085002001300429#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#54#50#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">We found no differences bet
ween OCD patients and controls in terms of the allele and genotype distribution 
of the SNPs (<a href="/img/revistas/rbp/2011nahead/aop-0111tab01.jpg">Table 1</a
>). All of the genotypic distributions were in Hardy-Weinberg equilibrium.</font
></p>     ^cY#aop-0111.htm##
00367000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012300085002001300208#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#55#51#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>2. Haplotype association
 analysis</b></font></p>     ^cY#aop-0111.htm##
00577000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704033300085002001300418#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#56#52#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">We observed three haplotype
s. The T-C-T (rs4448731, rs4565946, rs10506645) and the C-A-T (rs4565946, rs7955
501, rs10506645) haplotypes were more frequent in patients (p &lt; 0.05); <a hre
f="/img/revistas/rbp/2011nahead/aop-0111tab02.jpg">Table 2</a>.</font></p>     ^
cY#aop-0111.htm##
00356000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011200085002001300197#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#57#53#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>3. Logistic regression</
b></font></p>     ^cY#aop-0111.htm##
00552000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704030800085002001300393#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#58#54#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Logistic regressions were p
erformed in all association analysis to exclude the influence of the following f
eatures: gender, age of onset of disease and presence of comorbidities (anxiety 
disorders). No alterations were found.</font></p>     ^cY#aop-0111.htm##
00359000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011500085002001300200#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#59#55#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>4. Linkage disequilibriu
m</b></font></p>     ^cY#aop-0111.htm##
00626000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704038200085002001300467#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#60#56#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">As all SNPs studied showed 
a minor allele frequency of more than 5%, they are comparable to common disease 
susceptibility polymorphisms with power to detect LD. Strong LD was observed twi
ce: between SNPs rs4448731 and rs4565946 and between SNPs rs10506645 and 4760820
 (<a href="#fig1">Figure 1</a>).</font></p>     ^cY#aop-0111.htm##
00279000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003500085002001300120#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#61#57#article#116#<p><a name
="fig1"></a></p>     ^cY#aop-0111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#62#58#article#116#<p>&nbsp;<
/p>     ^cY#aop-0111.htm##
00333000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008900085002001300174#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#63#59#article#116#<p align="
center"><img src="/img/revistas/rbp/2011nahead/aop-0111fig01.jpg"></p>     ^cY#a
op-0111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#64#60#article#116#<p>&nbsp;<
/p>     ^cY#aop-0111.htm##
00344000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010000085002001300185#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#65#61#article#116#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Discussion</b></font></p
>     ^cY#aop-0111.htm##
00889000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704064500085002001300730#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#66#62#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Several studies have previo
usly attempted to evaluate the association between OCD and polymorphisms in sero
tonergic genes. The most commonly studied polymorphism, 5-HTTLPR (serotonin-tran
sporter-linked promoter region), is a functional insertion/deletion variant in t
he promoter region of SLC6A4, the gene that codes for the serotonin transporter.
 Though association studies have revealed inconsistent findings, additional vari
ants have recently been identified for this polymorphism (alleles La and Lg), no
tably associating the allele La with OCD.<sup>1,2</sup></font></p>     ^cY#aop-0
111.htm##
00670000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704042600085002001300511#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#67#63#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">In the present study, we in
vestigated polymorphic variants of TPH2 (which codes for the rate-limiting 5-HT 
synthesizing enzyme in the brain) in a sample of 107 OCD patients. Analogous to 
the impact of other candidate genes of the serotonergic pathway on disease risk,
 a small to moderate effect of polymorphic variants of TPH2 was anticipated.</fo
nt></p>     ^cY#aop-0111.htm##
00695000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704045100085002001300536#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#68#64#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">The studied SNPs are intron
ic. Thus, they do not affect amino acid coding and probably do not directly affe
ct protein function. Associations between OCD patients and controls should be in
terpreted as the presence of LD between these SNPs and other SNPs in exons (resu
lting in functional polymorphism) or in regulatory regions (affecting the expres
sion of these genes).</font></p>     ^cY#aop-0111.htm##
00720000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704047600085002001300561#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#69#65#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A significant association b
etween the T-C-T (rs4448731, rs4565946, rs10506645) and C-A-T (rs4565946, rs7955
501, rs10506645) haplotypes was observed with OCD. Moreover, important LD was ob
served between two pairs of SNPs, suggesting that TPH2 should be a plausible sus
ceptibility gene for OCD (<a href="/img/revistas/rbp/2011nahead/aop-0111tab02.jp
g">Table 2</a>; <a href="#fig1">Figure 1</a>).</font></p>     ^cY#aop-0111.htm##
00816000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704057200085002001300657#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#70#66#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">In order to corroborate the
 possible association between TPH2 polymorphisms and OCD, M&ouml;ssner et al. st
udied two TPH2 variations: two SNPs located in the putative transcriptional cont
rol region (SNP rs4570625) and in intron 2 (rs4565946). They evaluated a unique 
family-based sample of OCD patients with onset of the disease in childhood and a
dolescence comprising 71 complete independent trios.The SNPs were in LD, and ear
ly-onset OCD was related to allele C (rs4565946) transmission.</font></p>     ^c
Y#aop-0111.htm##
00775000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704053100085002001300616#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#71#67#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Given that this study has s
everal methodological limitations, caution should be taken when generalizing the
se results. Our study may be underpowered and may be lacking the required statis
tical power to detect potential associations due to its small sample size. This 
may explain the small sample of haplotypes found. Further studies with large sam
ple sizes estimated by power calculations are necessary to confirm the findings 
of the present study.</font></p>     ^cY#aop-0111.htm##
00605000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704036100085002001300446#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#72#68#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Although there is a high co
morbidity of DSM-IV axis I and II disorders in OCD, not all possible comorbiditi
es (anxiety disorders) were considered as exclusion criteria. These comorbiditie
s, which may be associated with the serotonergic system, might have influenced o
ur results.</font></p>     ^cY#aop-0111.htm##
00917000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704067300085002001300758#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#73#69#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Furthermore, it has become 
clear that OCD is not a simple and homogeneous disorder but rather a heterogeneo
us disorder mediated by a range of different factors including age of onset, gen
der, and commorbidities.<sup>1,2</sup> Moreover, some hypothesize that there may
 be several additive genes, each contributing to the OCD phenotype.<sup>1-4</sup
> Thus, the chance of detecting these putative genes may be reduced in a relativ
ely small sample of patients. Therefore, larger and more homogeneous groups are 
needed to achieve a more accurate characterization of the genetic component of O
CD.</font></p>     ^cY#aop-0111.htm##
00578000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704033400085002001300419#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#74#70#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Finally, although our sampl
e comprised only self-declared Caucasian Brazilians, race as determined by self 
and/or clinical evaluation is a poor predictor of ancestry in Brazil. Therefore,
 an ethnic stratification bias cannot be ruled out.<sup>16</sup></font></p>     
^cY#aop-0111.htm##
00632000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704038800085002001300473#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#75#71#article#116#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">In conclusion, our research
 has not demonstrated associations between the eight SNPs of TPH2 and OCD. Howev
er, it did demonstrate two LD areas and two haplotypes that were more frequent i
n patients, thus suggesting the need for further studies on TPH2 to elucidate th
e role played by TPH2 variants in OCD.</font></p>     ^cY#aop-0111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#76#72#article#116#<p>&nbsp;<
/p>     ^cY#aop-0111.htm##
00460000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704021600085002001300301#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#77#73#article#116#<p align="
center"><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><a href="/im
g/revistas/rbp/2011nahead/aop-0111img01.jpg"><img src="/img/revistas/rbp/2011nah
ead/aop-0111img01tamb.jpg" border="0">    ^cY#aop-0111.htm##
00291000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704004700085002001300132#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#78#74#article#116#<br>   Cli
ck to enlarge</a></font></p>     ^cY#aop-0111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#79#75#article#116#<p>&nbsp;<
/p>     ^cY#aop-0111.htm##
00344000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010000085002001300185#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#80#76#article#116#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>References</b></font></p
>     ^cY#aop-0111.htm##
00598000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704034000087002001300427#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#81#77#article#11
6#1#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">1. da Rocha F
F, Malloy-Diniz L, Lage NV, Romano-Silva MA, de Marco LA, Correa H. Decision-mak
ing impairment is related to serotonin transporter promoter polymorphism in a sa
mple of patients with obsessive-compulsive disorder. <i>Behav Brain Res</i>. 200
8;195(1):159-63.    ^cY#aop-0111.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#82#78#article#116#</font></p
>     ^cY#aop-0111.htm##
00479000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704022100087002001300308#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#83#79#article#11
6#2#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">2. da Rocha F
F, Romano-Silva MA, de Marco LA, Corr&ecirc;a H. Obsessive-compulsive disorder a
nd 5-HTTLPR.<i> Rev Bras Psiquiatr</i>. 2009;31(3):287-8.    ^cY#aop-0111.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#84#80#article#116#</font></p
>     ^cY#aop-0111.htm##
00710000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704045200087002001300539#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#85#81#article#11
6#3#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Walitza S,
 Wewetzer C, Gerlach M, Klampfl K, Geller F, Barth N, Hahn F, Herpertz-Dahlmann 
B, G&ouml;ssler M, Fleischhaker C, Schulz E, Hebebrand J, Warnke A, Hinney A. Tr
ansmission disequilibrium studies in children and adolescents with obsessive-com
pulsive disorders pertaining to polymorphisms of genes of the serotonergic pathw
ay. <i>J Neural Transm</i>. 2004;111(7):817-925.    ^cY#aop-0111.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#86#82#article#116#</font></p
>     ^cY#aop-0111.htm##
00539000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704028100087002001300368#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#87#83#article#11
6#4#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">4. da Rocha F
F, Malloy-Diniz L, Lage NV, Correa H. Positive association between MET allele (B
DNF Val66Met polymorphism) and obsessive-compulsive disorder. <i>Rev Bras Psiqui
atr</i>. 2010;32(3):323-4</font></p>     ^cY#aop-0111.htm##
00470000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704021200087002001300299#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#88#84#article#11
6#5#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Invernizzi
 RW. Role of TPH-2 in brain function: news from behavioral and pharmacologic stu
dies. <i>J Neurosci Res</i>. 2007;85(14):3030-5.    ^cY#aop-0111.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#89#85#article#116#</font></p
>     ^cY#aop-0111.htm##
00499000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704024100087002001300328#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#90#86#article#11
6#6#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Breidentha
l SE, White DJ, Glatt CE. Identification of genetic variants in the neuronal for
m of tryptophan hydroxylase (TPH2). <i>Psychiatr Genet</i>. 2004;14(2):69-72.   
 ^cY#aop-0111.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#91#87#article#116#</font></p
>     ^cY#aop-0111.htm##
00678000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704042000087002001300507#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#92#88#article#11
6#7#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Han L, Nie
lsen DA, Rosenthal NE, Jefferson K, Kaye W, Murphy D, Altemus M, Humphries J, Ca
ssano G, Rotondo A, Virkkunen M, Linnoila M, Goldman D. No coding variant of the
 tryptophan hydroxylase gene detected in seasonal affective disorder, obsessive-
compulsive disorder, anorexia nervosa, and alcoholism. <i>Biol Psychiatry</i>. 1
999;45(5):615-9.    ^cY#aop-0111.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#93#89#article#116#</font></p
>     ^cY#aop-0111.htm##
00543000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704028500087002001300372#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#94#90#article#11
6#8#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Harvey M, 
Shink E, Tremblay M, Gagn&eacute; B, Raymond C, Labb&eacute; M, Walther DJ, Bade
r M, Barden N. Support for the involvement of TPH2 gene in affective disorders. 
<i>Mol Psychiatry</i>. 2004;9(11):980-91.    ^cY#aop-0111.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#95#91#article#116#</font></p
>     ^cY#aop-0111.htm##
00576000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704031800087002001300405#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#96#92#article#11
6#9#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Bach-Mizra
chi H, Underwood MD, Tin A, Ellis SP, Mann JJ, Arango V. Elevated expression of 
tryptophan hydroxylase-2 mRNA at the neuronal level in the dorsal and median rap
he nuclei of depressed suicides. <i>Mol Psychiatry</i>. 2008;13(5):507-13.    ^c
Y#aop-0111.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#97#93#article#116#</font></p
>     ^cY#aop-0111.htm##
00495000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704023600088002001300324#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#98#94#article#11
6#10#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Kim YK, 
Lee HJ, Yang JC, Hwang JA, Yoon HK. A tryptophan hydroxylase 2 gene polymorphism
 is associated with panic disorder. <i>Behav Genet</i>. 2009;39(2):170-5.    ^cY
#aop-0111.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#99#95#article#116#</font></p
>     ^cY#aop-0111.htm##
00571000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082888000300086704031100089002001300400#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#100#96#article#1
16#11#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Ferreir
a A de A, Neves FS, da Rocha FF, Silva GS, Romano-Silva MA, Miranda DM, De Marco
 L, Correa H. The role of 5-HTTLPR polymorphism in antidepressant-associated man
ia in bipolar disorder. <i>J Affect Disord</i>. 2009;112(1-3):267-72.    ^cY#aop
-0111.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704002000086002001300106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#101#97#article#116#</font></
p>     ^cY#aop-0111.htm##
00675000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082888000300086704041500089002001300504#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#102#98#article#1
16#12#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Frisch 
A, Michaelovsky E, Rockah R, Amir I, Hermesh H, Laor N, Fuchs C, Zohar J, Lerer 
B, Buniak SF, Landa S, Poyurovsky M, Shapira B, Weizman R. Association between o
bsessive-compulsive disorder and polymorphisms of genes encoding components of t
he serotonergic and dopaminergic pathways. <i>Eur Neuropsychopharmacol</i>. 2000
;10(3):205-9.    ^cY#aop-0111.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704002000086002001300106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#103#99#article#116#</font></
p>     ^cY#aop-0111.htm##
00705000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704044400090002001300534#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#104#100#article#
116#13#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Delorm
e R, Durand CM, Betancur C, Wagner M, Ruhrmann S, Grabe HJ, Nygren G, Gillberg C
, Leboyer M, Bourgeron T, Courtet P, Jollant F, Buresi C, Aubry JM, Baud P, Bond
olfi G, Bertschy G, Perroud N, Malafosse A. No human tryptophan hydroxylase-2 ge
ne R441H mutation in a large cohort of psychiatric patients and control subjects
. <i>Biol Psychiatry</i>. 2006;60(2):202-3.    ^cY#aop-0111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#105#101#article#116#</font><
/p>     ^cY#aop-0111.htm##
00735000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704047400090002001300564#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#106#102#article#
116#14#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. M&ouml
;ssner R, Walitza S, Geller F, Scherag A, Gutknecht L, Jacob C, Bogusch L, Remsc
hmidt H, Simons M, Herpertz-Dahlmann B, Fleischhaker C, Schulz E, Warnke A, Hinn
ey A, Wewetzer C, Lesch KP. Transmission disequilibrium of polymorphic variants 
in the tryptophan hydroxylase-2 gene in children and adolescents with obsessive-
compulsive disorder. <i>Int J Neuropsychopharmacol</i>. 2006;9(4):437-42.    ^cY
#aop-0111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#107#103#article#116#</font><
/p>     ^cY#aop-0111.htm##
00512000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704025100090002001300341#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#108#104#article#
116#15#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Amorim
 P. Mini International Neuropsychiatric Interview (MINI): validation of a short 
structured diagnostic psychiatric interview. <i>Rev Bras Psiquiatr.</i> 2000;22(
3):106-15.    ^cY#aop-0111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#109#105#article#116#</font><
/p>     ^cY#aop-0111.htm##
00496000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704023500090002001300325#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#110#106#article#
116#16#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Parra 
FC, Amado RC, Lambertucci JR, Rocha J, Antunes CM, Pena SD. Color and genomic an
cestry in Brazilians. <i>Proc Natl Acad Sci U S A.</i> 2003;100(1):177-82.    ^c
Y#aop-0111.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#111#107#article#116# </font>
</p>     ^cY#aop-0111.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#112#108#article#116#<p>&nbsp
;</p>     ^cY#aop-0111.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#113#109#article#116#<p>&nbsp
;</p>     ^cY#aop-0111.htm##
00436000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704019000087002001300277#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#114#110#article#116#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href=
"#ad1"><img src="/img/revistas/rbp/2011nahead/seta.jpg" border="0"></a><b> Corre
spondence:</b>    ^cY#aop-0111.htm##
00288000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704004200087002001300129#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#115#111#article#116#<br>   D
r. Felipe Filardi da Rocha    ^cY#aop-0111.htm##
00304000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704005800087002001300145#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#116#112#article#116#<br>   R
ua Sapucaia, 83 - Cond. Retiro das Pedras     ^cY#aop-0111.htm##
00293000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704004700087002001300134#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#117#113#article#116#<br>   3
5460-000 Brumadinho, MG, Brasil    ^cY#aop-0111.htm##
00340000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704009400087002001300181#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#118#114#article#116#<br>   E
mail: <a href="mailto:fil_bh@yahoo.com.br">fil_bh@yahoo.com.br</a></font></p>   
  ^cY#aop-0111.htm##
00342000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704009600087002001300183#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#119#115#article#116#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">Submitted: July 23, 2010 
    ^cY#aop-0111.htm##
00297000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704005100087002001300138#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#p#120#116#article#116#<br>   A
ccepted: August 2, 2010</font></p>     ^cY#aop-0111.htm##
00777000000000337000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100019000860100022001050100
01500127010002300142010001900165010001600184012014800200030001600348065000900364
06400050037303100040037803200020038201400070038486500090039100200130040003500100
0413801001600423#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0111.htm#
S#c#121#1#article#16#1#^rND^sda Rocha^nFF#^rND^sMalloy-Diniz^nL#^rND^sLage^nNV#^
rND^sRomano-Silva^nMA#^rND^sde Marco^nLA#^rND^sCorrea^nH#Decision-making impairm
ent is related to serotonin transporter promoter polymorphism in a sample of pat
ients with obsessive-compulsive disorder^len#Behav Brain Res#20080000#2008#195#1
#159-63#20110000#aop-0111.htm#0166-4328#Behav Brain Res##
00580000000000301000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100019000860100023001050100
01900128010001600147012004700163030001900210710000200229065000900231064000500240
031000300245032000200248014000600250865000900256002001300265#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop-0111.htm#S#c#122#2#article#16#2#^rND^sda Roch
a^nFF#^rND^sRomano-Silva^nMA#^rND^sde Marco^nLA#^rND^sCorrêa^nH#Obsessive-compul
sive disorder and 5-HTTLPR^len#Rev Bras Psiquiatr#2#20090000#2009#31#3#287-8#201
10000#aop-0111.htm##
01028000000000433000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100018001030100
01700121010001700138010001600155010001500171010001400186010002700200010001700227
01000220024401000160026601000190028201000160030101000160031701201690033303000160
05020650009005180640005005270310004005320320002005360140008005388650009005460020
01300555035001000568801001600578#2011nahead#V:\SciELO\serial\rbp\2011nahead\mark
up\aop-0111.htm#S#c#123#3#article#16#3#^rND^sWalitza^nS#^rND^sWewetzer^nC#^rND^s
Gerlach^nM#^rND^sKlampfl^nK#^rND^sGeller^nF#^rND^sBarth^nN#^rND^sHahn^nF#^rND^sH
erpertz-Dahlmann^nB#^rND^sGössler^nM#^rND^sFleischhaker^nC#^rND^sSchulz^nE#^rND^
sHebebrand^nJ#^rND^sWarnke^nA#^rND^sHinney^nA#Transmission disequilibrium studie
s in children and adolescents with obsessive-compulsive disorders pertaining to 
polymorphisms of genes of the serotonergic pathway^len#J Neural Transm#20040000#
2004#111#7#817-925#20110000#aop-0111.htm#0300-9564#J Neural Transm##
00635000000000301000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100019000860100022001050100
01500127010001600142012010700158030001900265710000200284065000900286064000500295
031000300300032000200303014000600305865000900311002001300320#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop-0111.htm#S#c#124#4#article#16#4#^rND^sda Roch
a^nFF#^rND^sMalloy-Diniz^nL#^rND^sLage^nNV#^rND^sCorrea^nH#Positive association 
between MET allele (BDNF Val66Met polymorphism) and obsessive-compulsive disorde
r^len#Rev Bras Psiquiatr#2#20100000#2010#32#3#323-4#20110000#aop-0111.htm##
00558000000000277000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100021000860120084001070300
01500191065000900206064000500215031000300220032000300223014000700226865000900233
002001300242035001000255801001500265#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop-0111.htm#S#c#125#5#article#16#5#^rND^sInvernizzi^nRW#Role of TPH-2 in
 brain function: news from behavioral and pharmacologic studies^len#J Neurosci R
es#20070000#2007#85#14#3030-5#20110000#aop-0111.htm#0360-4012#J Neurosci Res##
00624000000000301000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100022000860100016001080100
01600124012009300140030001600233065000900249064000500258031000300263032000200266
014000600268865000900274002001300283035001000296801001600306#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop-0111.htm#S#c#126#6#article#16#6#^rND^sBreiden
thal^nSE#^rND^sWhite^nDJ#^rND^sGlatt^nCE#Identification of genetic variants in t
he neuronal form of tryptophan hydroxylase (TPH2)^len#Psychiatr Genet#20040000#2
004#14#2#69-72#20110000#aop-0111.htm#0955-8829#Psychiatr Genet##
00983000000000421000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100013000860100018000990100
02000117010001900137010001400156010001600170010001700186010001900203010001700222
01000170023901000190025601000180027501000170029301201620031003000160047206500090
04880640005004970310003005020320002005050140006005078650009005130020013005220350
01000535801001600545#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0111.
htm#S#c#127#7#article#16#7#^rND^sHan^nL#^rND^sNielsen^nDA#^rND^sRosenthal^nNE#^r
ND^sJefferson^nK#^rND^sKaye^nW#^rND^sMurphy^nD#^rND^sAltemus^nM#^rND^sHumphries^
nJ#^rND^sCassano^nG#^rND^sRotondo^nA#^rND^sVirkkunen^nM#^rND^sLinnoila^nM#^rND^s
Goldman^nD#No coding variant of the tryptophan hydroxylase gene detected in seas
onal affective disorder, obsessive-compulsive disorder, anorexia nervosa, and al
coholism^len#Biol Psychiatry#19990000#1999#45#5#615-9#20110000#aop-0111.htm#0006
-3223#Biol Psychiatry##
00761000000000373000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100015001020100
01800117010001500135010001700150010001500167010001800182010001500200010001600215
01200680023103000150029906500090031406400050032303100020032803200030033001400070
0333865000900340002001300349035001000362801001500372#2011nahead#V:\SciELO\serial
\rbp\2011nahead\markup\aop-0111.htm#S#c#128#8#article#16#8#^rND^sHarvey^nM#^rND^
sShink^nE#^rND^sTremblay^nM#^rND^sGagné^nB#^rND^sRaymond^nC#^rND^sLabbé^nM#^rND^
sWalther^nDJ#^rND^sBader^nM#^rND^sBarden^nN#Support for the involvement of TPH2 
gene in affective disorders^len#Mol Psychiatry#20040000#2004#9#11#980-91#2011000
0#aop-0111.htm#1359-4184#Mol Psychiatry##
00754000000000337000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100023000860100020001090100
01300129010001600142010001500158010001600173012013900189030001500328065000900343
06400050035203100030035703200020036001400070036286500090036900200130037803500100
0391801001500401#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0111.htm#
S#c#129#9#article#16#9#^rND^sBach-Mizrachi^nH#^rND^sUnderwood^nMD#^rND^sTin^nA#^
rND^sEllis^nSP#^rND^sMann^nJJ#^rND^sArango^nV#Elevated expression of tryptophan 
hydroxylase-2 mRNA at the neuronal level in the dorsal and median raphe nuclei o
f depressed suicides^len#Mol Psychiatry#20080000#2008#13#5#507-13#20110000#aop-0
111.htm#1359-4184#Mol Psychiatry##
00652000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100014000880100014001020100
01500116010001600131010001500147012008300162030001200245065000900257064000500266
03100030027103200020027401400060027686500090028200200130029103500100030480100120
0314#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#c#130#10#a
rticle#16#10#^rND^sKim^nYK#^rND^sLee^nHJ#^rND^sYang^nJC#^rND^sHwang^nJA#^rND^sYo
on^nHK#A tryptophan hydroxylase 2 gene polymorphism is associated with panic dis
order^len#Behav Genet#20090000#2009#39#2#170-5#20110000#aop-0111.htm#0001-8244#B
ehav Genet##
00785000000000361000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100023000880100016001110100
01900127010001600146010002300162010001800185010001800203010001600221012009300237
03000160033006500090034606400050035503100040036003200040036401400070036886500090
0375002001300384035001000397801001600407#2011nahead#V:\SciELO\serial\rbp\2011nah
ead\markup\aop-0111.htm#S#c#131#11#article#16#11#^rND^sFerreira A^nde A#^rND^sNe
ves^nFS#^rND^sda Rocha^nFF#^rND^sSilva^nGS#^rND^sRomano-Silva^nMA#^rND^sMiranda^
nDM#^rND^sDe Marco^nL#^rND^sCorrea^nH#The role of 5-HTTLPR polymorphism in antid
epressant-associated mania in bipolar disorder^len#J Affect Disord#20090000#2009
#112#1-3#267-72#20110000#aop-0111.htm#0165-0327#J Affect Disord##
01006000000000433000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100022001040100
01600126010001400142010001700156010001400173010001500187010001500202010001500217
01000170023201000150024901000200026401000170028401000170030101201470031803000250
04650650009004900640005004990310003005040320002005070140006005098650009005150020
01300524035001000537801002500547#2011nahead#V:\SciELO\serial\rbp\2011nahead\mark
up\aop-0111.htm#S#c#132#12#article#16#12#^rND^sFrisch^nA#^rND^sMichaelovsky^nE#^
rND^sRockah^nR#^rND^sAmir^nI#^rND^sHermesh^nH#^rND^sLaor^nN#^rND^sFuchs^nC#^rND^
sZohar^nJ#^rND^sLerer^nB#^rND^sBuniak^nSF#^rND^sLanda^nS#^rND^sPoyurovsky^nM#^rN
D^sShapira^nB#^rND^sWeizman^nR#Association between obsessive-compulsive disorder
 and polymorphisms of genes encoding components of the serotonergic and dopamine
rgic pathways^len#Eur Neuropsychopharmacol#20000000#2000#10#3#205-9#20110000#aop
-0111.htm#0924-977X#Eur Neuropsychopharmacol##
01116000000000493000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100017001050100
01800122010001600140010001800156010001600174010001600190010001800206010001700224
01000190024101000170026001000170027701000160029401000160031001000140032601000180
03400100018003580100017003760100019003930120121004120300016005330650009005490640
00500558031000300563032000200566014000600568865000900574002001300583035001000596
801001600606#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0111.htm#S#c#
133#13#article#16#13#^rND^sDelorme^nR#^rND^sDurand^nCM#^rND^sBetancur^nC#^rND^sW
agner^nM#^rND^sRuhrmann^nS#^rND^sGrabe^nHJ#^rND^sNygren^nG#^rND^sGillberg^nC#^rN
D^sLeboyer^nM#^rND^sBourgeron^nT#^rND^sCourtet^nP#^rND^sJollant^nF#^rND^sBuresi^
nC#^rND^sAubry^nJM#^rND^sBaud^nP#^rND^sBondolfi^nG#^rND^sBertschy^nG#^rND^sPerro
ud^nN#^rND^sMalafosse^nA#No human tryptophan hydroxylase-2 gene R441H mutation i
n a large cohort of psychiatric patients and control subjects^len#Biol Psychiatr
y#20060000#2006#60#2#202-3#20110000#aop-0111.htm#0006-3223#Biol Psychiatry##
01051000000000445000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100017001050100
01600122010001700138010001900155010001500174010001700189010002000206010001600226
01000270024201000220026901000160029101000160030701000160032301000180033901000160
03570120156003730300027005297100002005560650009005580640005005670310002005720320
00200574014000700576865000900583002001300592#2011nahead#V:\SciELO\serial\rbp\201
1nahead\markup\aop-0111.htm#S#c#134#14#article#16#14#^rND^sMössner^nR#^rND^sWali
tza^nS#^rND^sGeller^nF#^rND^sScherag^nA#^rND^sGutknecht^nL#^rND^sJacob^nC#^rND^s
Bogusch^nL#^rND^sRemschmidt^nH#^rND^sSimons^nM#^rND^sHerpertz-Dahlmann^nB#^rND^s
Fleischhaker^nC#^rND^sSchulz^nE#^rND^sWarnke^nA#^rND^sHinney^nA#^rND^sWewetzer^n
C#^rND^sLesch^nKP#Transmission disequilibrium of polymorphic variants in the try
ptophan hydroxylase-2 gene in children and adolescents with obsessive-compulsive
 disorder^len#Int J Neuropsychopharmacol#2#20060000#2006#9#4#437-42#20110000#aop
-0111.htm##
00563000000000265000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880120124001040300
01900228710000200247065000900249064000500258031000300263032000200266014000700268
865000900275002001300284#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0
111.htm#S#c#135#15#article#16#15#^rND^sAmorim^nP#Mini International Neuropsychia
tric Interview (MINI): validation of a short structured diagnostic psychiatric i
nterview^len#Rev Bras Psiquiatr#2#20000000#2000#22#3#106-15#20110000#aop-0111.ht
m##
00682000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100016001040100
02200120010001500142010001800157010001500175012004500190030002500235065000900260
06400050026903100040027403200020027801400070028086500090028700200130029603500100
0309801002500319#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0111.htm#
S#c#136#16#article#16#16#^rND^sParra^nFC#^rND^sAmado^nRC#^rND^sLambertucci^nJR#^
rND^sRocha^nJ#^rND^sAntunes^nCM#^rND^sPena^nSD#Color and genomic ancestry in Bra
zilians^len#Proc Natl Acad Sci U S A#20030000#2003#100#1#177-82#20110000#aop-011
1.htm#0027-8424#Proc Natl Acad Sci U S A##
00284000000000169000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790910009000810920007000900020013000977030
00400110#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#o#1#1#
article#1#20110321#094312#aop-0211.htm#173##
04595000000000661000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000400099121000300103049000300106158000300109030002200112
03200060013406500090014001400070014903500100015622300090016601201190017501201150
02940100030004090100024004390100028004630100032004910100034005230700099005570700
12800656083139800784085001002182085004202192085002302234085002102257085003002278
08500190230808313810232708500100370808500440371808500220376208500210378408500370
38050850019038421170008038610720003038691120009038721110017038811140009038981130
01303907002001303920#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0211.
htm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#TAB#02#nd#nd#Rev. Bras. Psiquiatr.#ahead
#20110000#^f0^l0#1516-4446#20110311#Psychometric properties of the Brazilian Por
tuguese version of the Obsessive-Compulsive Inventory: Revised (OCI-R)^len#Propr
iedades psicométricas da versão em português do Brasil da Obsessive-Compulsive I
nventory: Revised (OCI-R)^lpt#^rND^1A01^nFernanda P.^sSouza#^rND^1A02^nEdna B.^s
Foa#^rND^1A01^nElisabeth^sMeyer#^rND^1A01^nKátia G.^sNiederauer#^rND^1A01^nArist
ides V.^sCordioli#Universidade Federal do Rio Grande do Sul^iA01^1Department of 
Psychiatry^cPorto Alegre^sRS^pBrazil#University of Pennsylvania^iA02^1Department
 of Psychiatry^2Center for the Treatment and Study of Anxiety^cPhiladelphia^sPA^
pUSA#^len^aOBJECTIVE: The present study was designed to evaluate the psychometri
c properties of the Brazilian Portuguese version of the Obsessive-Compulsive Inv
entory - Revised. METHOD: The Obsessive-Compulsive Inventory - Revised was admin
istered toa total of 260 participants: a clinical sample of 130 patients with an
xiety disorders (64 with a diagnosis of obsessive-compulsive disorder patients, 
33 diagnosed with social phobia, and 33 with panic disorder) and a sample of 130
 non-clinical subjects. RESULTS: The findings indicate that the Obsessive-Compul
sive Inventory - Revised is a valid measure for identifying and assessing the se
verity of the six symptom subtypes in obsessive-compulsive disorder.The original
 factor structure of the instrument was replicated in an exploratory factor anal
ysis. Test-retest reliability was examined using data from 64 obsessive-compulsi
ve disorder patients who completed the inventory on two different occasions. In 
each sample, the overall and subscale scores showed moderate to good internal co
nsistency, good convergent and divergent validity, and sensitivity to changes re
sulting from cognitive-behavioral group therapy changes. CONCLUSION: Our finding
s indicate that the Brazilian Portuguese version of the Obsessive-Compulsive Inv
entory - Revised retains the psychometric properties of its original version and
 the Spanish, German and Iceland versions.#^ddecs^i1#^tm^len^kObsessive-compulsi
ve disorder^i1#^tm^len^kEvaluation^i1#^tm^len^kSymptoms^i1#^tm^len^kAnxiety diso
rders^i1#^tm^len^kBrazil^i1#^lpt^aOBJETIVO: O presente estudo foi delineado para
 avaliar as propriedades psicométricas da versão em português do Brasil do Obses
sive-Compulsive Inventory - Revised. MÉTODO: O Obsessive-Compulsive Inventory - 
Revised foi aplicado em um total de 260 indivíduos: em uma amostra clínica de 13
0 pacientes (64 pacientes com transtorno obsessivo-compulsivo, 33 pacientes com 
fobia social e 33 pacientes com transtorno do pânico) mais uma amostra não clíni
ca de 130 sujeitos. RESULTADOS: Os resultados indicam que o Obsessive-Compulsive
 Inventory - Revised é uma medida válida para identificar e avaliar a severidade
 dos seis subtipos de sintomas do transtorno obsessivo-compulsivo. A estrutura f
atorial do instrumento foi replicada em uma análise fatorial exploratória. A con
fiabilidade teste-reteste foi examinada usando os dados de 64 pacientes com tran
storno obsessivo-compulsivo que completaram o inventário em dois momentos difere
ntes. Em cada amostra, os escores total e das subescalas mostraram consistência 
interna de boa a moderada, boa validade concorrente e discriminante, e sensibili
dade para as mudanças da terapia cognitivo-comportamental em grupo. CONCLUSÃO: N
ossos achados indicam que a versão para o português do Brasil do Obsessive-Compu
lsive Inventory - Revised manteve as propriedades psicométricas da versão origin
al e das versões em espanhol, alemão e islandês.#^ddecs^i2#^tm^lpt^kTranstorno o
bsessivo-compulsivo^i2#^tm^lpt^kAvaliação^i2#^tm^lpt^kSintomas^i2#^tm^lpt^kTrans
tornos de ansiedade^i2#^tm^lpt^kBrasil^i2#vancouv#24#20100209#February 9, 2010#2
0100312#May 12, 2010#aop-0211.htm##
04707000000000661000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000400099121000300103049000300106158000300109030002200112
03200060013406500090014001400070014903500100015622300090016601201330017501201290
03080100030004370100024004670100028004910100032005190100034005510700099005850700
12800684083142600812085001002238085004202248085002302290085002102313085003002334
08500190236408314370238308500100382008500440383008500220387408500210389608500370
39170850019039541170008039730720003039811120009039841110017039931140009040101130
01304019002001304032#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0211.
htm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#TAB#02#nd#nd#Rev. Bras. Psiquiatr.#ahead
#20110000#^f0^l0#1516-4446#20110311#<b>Psychometric properties of the Brazilian 
Portuguese version of the Obsessive-Compulsive Inventory</b>: <b>Revised (OCI-R)
</b>^len#<b>Propriedades psicométricas da versão em português do Brasil da Obses
sive-Compulsive Inventory</b>: <b>Revised (OCI-R)</b>^lpt#^rND^1A01^nFernanda P.
^sSouza#^rND^1A02^nEdna B.^sFoa#^rND^1A01^nElisabeth^sMeyer#^rND^1A01^nKátia G.^
sNiederauer#^rND^1A01^nAristides V.^sCordioli#Universidade Federal do Rio Grande
 do Sul^iA01^1Department of Psychiatry^cPorto Alegre^sRS^pBrazil#University of P
ennsylvania^iA02^1Department of Psychiatry^2Center for the Treatment and Study o
f Anxiety^cPhiladelphia^sPA^pUSA#^len^a<b>OBJECTIVE:</b> The present study was d
esigned to evaluate the psychometric properties of the Brazilian Portuguese vers
ion of the Obsessive-Compulsive Inventory - Revised. <b>METHOD:</b> The Obsessiv
e-Compulsive Inventory - Revised was administered toa total of 260 participants:
 a clinical sample of 130 patients with anxiety disorders (64 with a diagnosis o
f obsessive-compulsive disorder patients, 33 diagnosed with social phobia, and 3
3 with panic disorder) and a sample of 130 non-clinical subjects. <b>RESULTS:</b
> The findings indicate that the Obsessive-Compulsive Inventory - Revised is a v
alid measure for identifying and assessing the severity of the six symptom subty
pes in obsessive-compulsive disorder.The original factor structure of the instru
ment was replicated in an exploratory factor analysis. Test-retest reliability w
as examined using data from 64 obsessive-compulsive disorder patients who comple
ted the inventory on two different occasions. In each sample, the overall and su
bscale scores showed moderate to good internal consistency, good convergent and 
divergent validity, and sensitivity to changes resulting from cognitive-behavior
al group therapy changes. <b>CONCLUSION:</b> Our findings indicate that the Braz
ilian Portuguese version of the Obsessive-Compulsive Inventory - Revised retains
 the psychometric properties of its original version and the Spanish, German and
 Iceland versions.#^ddecs^i1#^tm^len^kObsessive-compulsive disorder^i1#^tm^len^k
Evaluation^i1#^tm^len^kSymptoms^i1#^tm^len^kAnxiety disorders^i1#^tm^len^kBrazil
^i1#^lpt^a<b>OBJETIVO:</b> O presente estudo foi delineado para avaliar as propr
iedades psicométricas da versão em português do Brasil do <i>Obsessive-Compulsiv
e Inventory - Revised</i>. <b>MÉTODO:</b> O <i>Obsessive-Compulsive Inventory - 
Revised</i> foi aplicado em um total de 260 indivíduos: em uma amostra clínica d
e 130 pacientes (64 pacientes com transtorno obsessivo-compulsivo, 33 pacientes 
com fobia social e 33 pacientes com transtorno do pânico) mais uma amostra não c
línica de 130 sujeitos. <b>RESULTADOS:</b> Os resultados indicam que o <i>Obsess
ive-Compulsive Inventory - Revised</i> é uma medida válida para identificar e av
aliar a severidade dos seis subtipos de sintomas do transtorno obsessivo-compuls
ivo. A estrutura fatorial do instrumento foi replicada em uma análise fatorial e
xploratória. A confiabilidade teste-reteste foi examinada usando os dados de 64 
pacientes com transtorno obsessivo-compulsivo que completaram o inventário em do
is momentos diferentes. Em cada amostra, os escores total e das subescalas mostr
aram consistência interna de boa a moderada, boa validade concorrente e discrimi
nante, e sensibilidade para as mudanças da terapia cognitivo-comportamental em g
rupo. <b>CONCLUSÃO:</b> Nossos achados indicam que a versão para o português do 
Brasil do <i>Obsessive-Compulsive Inventory - Revised</i> manteve as propriedade
s psicométricas da versão original e das versões em espanhol, alemão e islandês.
#^ddecs^i2#^tm^lpt^kTranstorno obsessivo-compulsivo^i2#^tm^lpt^kAvaliação^i2#^tm
^lpt^kSintomas^i2#^tm^lpt^kTranstornos de ansiedade^i2#^tm^lpt^kBrasil^i2#vancou
v#24#20100209#February 9, 2010#20100312#May 12, 2010#aop-0211.htm##
04714000000000685000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790640007000810710003000880400003000910010
00600094042000200100120000400102038000400106121000300110049000300113158000300116
03000210011903200060014006500090014601400070015503500100016222300090017201201190
01810120115003000100029004150100023004440100028004670100031004950100033005260700
10100559070013000660083139800790085001002188085004202198085002302240085002102263
08500300228408500190231408313810233308500100371408500440372408500220376808500210
37900850037038110850019038481170008038670720003038751120009038781110017038871140
00903904113001303913002001303926008008903939#2011nahead#V:\SciELO\serial\rbp\201
1nahead\markup\aop-0211.htm#S#l#4#1#article#1#^a2011#oa#en#br1.1#1#4.0#tab#02#nd
#nd#Rev. bras. psiquiatr#ahead#20110000#^f0^l0#1516-4446#20110311#Psychometric p
roperties of the Brazilian Portuguese version of the Obsessive-Compulsive Invent
ory: Revised (OCI-R)^len#Propriedades psicométricas da versão em português do Br
asil da Obsessive-Compulsive Inventory: Revised (OCI-R)^lpt#^rND^1A01^nFernanda 
P^sSouza#^rND^1A02^nEdna B^sFoa#^rND^1A01^nElisabeth^sMeyer#^rND^1A01^nKátia G^s
Niederauer#^rND^1A01^nAristides V^sCordioli#^iA01^1Universidade Federal do Rio G
rande do Sul^2Department of Psychiatry^cPorto Alegre^sRS^pBrazil#^iA02^1Universi
ty of Pennsylvania^2Department of Psychiatry^3Center for the Treatment and Study
 of Anxiety^cPhiladelphia^sPA^pUSA#^len^aOBJECTIVE: The present study was design
ed to evaluate the psychometric properties of the Brazilian Portuguese version o
f the Obsessive-Compulsive Inventory - Revised. METHOD: The Obsessive-Compulsive
 Inventory - Revised was administered toa total of 260 participants: a clinical 
sample of 130 patients with anxiety disorders (64 with a diagnosis of obsessive-
compulsive disorder patients, 33 diagnosed with social phobia, and 33 with panic
 disorder) and a sample of 130 non-clinical subjects. RESULTS: The findings indi
cate that the Obsessive-Compulsive Inventory - Revised is a valid measure for id
entifying and assessing the severity of the six symptom subtypes in obsessive-co
mpulsive disorder.The original factor structure of the instrument was replicated
 in an exploratory factor analysis. Test-retest reliability was examined using d
ata from 64 obsessive-compulsive disorder patients who completed the inventory o
n two different occasions. In each sample, the overall and subscale scores showe
d moderate to good internal consistency, good convergent and divergent validity,
 and sensitivity to changes resulting from cognitive-behavioral group therapy ch
anges. CONCLUSION: Our findings indicate that the Brazilian Portuguese version o
f the Obsessive-Compulsive Inventory - Revised retains the psychometric properti
es of its original version and the Spanish, German and Iceland versions.#^ddecs^
i1#^tm^len^kObsessive-compulsive disorder^i1#^tm^len^kEvaluation^i1#^tm^len^kSym
ptoms^i1#^tm^len^kAnxiety disorders^i1#^tm^len^kBrazil^i1#^lpt^aOBJETIVO: O pres
ente estudo foi delineado para avaliar as propriedades psicométricas da versão e
m português do Brasil do Obsessive-Compulsive Inventory - Revised. MÉTODO: O Obs
essive-Compulsive Inventory - Revised foi aplicado em um total de 260 indivíduos
: em uma amostra clínica de 130 pacientes (64 pacientes com transtorno obsessivo
-compulsivo, 33 pacientes com fobia social e 33 pacientes com transtorno do pâni
co) mais uma amostra não clínica de 130 sujeitos. RESULTADOS: Os resultados indi
cam que o Obsessive-Compulsive Inventory - Revised é uma medida válida para iden
tificar e avaliar a severidade dos seis subtipos de sintomas do transtorno obses
sivo-compulsivo. A estrutura fatorial do instrumento foi replicada em uma anális
e fatorial exploratória. A confiabilidade teste-reteste foi examinada usando os 
dados de 64 pacientes com transtorno obsessivo-compulsivo que completaram o inve
ntário em dois momentos diferentes. Em cada amostra, os escores total e das sube
scalas mostraram consistência interna de boa a moderada, boa validade concorrent
e e discriminante, e sensibilidade para as mudanças da terapia cognitivo-comport
amental em grupo. CONCLUSÃO: Nossos achados indicam que a versão para o portuguê
s do Brasil do Obsessive-Compulsive Inventory - Revised manteve as propriedades 
psicométricas da versão original e das versões em espanhol, alemão e islandês.#^
ddecs^i2#^tm^lpt^kTranstorno obsessivo-compulsivo^i2#^tm^lpt^kAvaliação^i2#^tm^l
pt^kSintomas^i2#^tm^lpt^kTranstornos de ansiedade^i2#^tm^lpt^kBrasil^i2#vancouv#
24#20100209#February 9, 2010#20100312#May 12, 2010#aop-0211.htm#Internet^ihttp:/
/www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462011005000002##
00465000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704022300083002001300306#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#5#1#article#145#<p><font siz
e="4" face="Verdana, Arial, Helvetica, sans-serif"><a name="ad1"></a><b>Psychome
tric properties of the Brazilian Portuguese version of the Obsessive-Compulsive 
Inventory - Revised (OCI-R)</b></font></p>     ^cY#aop-0211.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#6#2#article#145#<p>&nbsp;</p
>     ^cY#aop-0211.htm##
00463000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704022100083002001300304#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#7#3#article#145#<p><font siz
e="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Propriedades psicom&eacute
;tricas da vers&atilde;o em portugu&ecirc;s do Brasil da Obsessive-Compulsive In
ventory - Revised (OCI-R)</b></font></p>     ^cY#aop-0211.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#8#4#article#145#<p>&nbsp;</p
>     ^cY#aop-0211.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#9#5#article#145#<p>&nbsp;</p
>     ^cY#aop-0211.htm##
00492000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704024900084002001300333#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#10#6#article#145#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Fernanda P. Souza<sup>I</
sup>; Edna B. Foa<sup>II</sup>; Elisabeth Meyer<sup>I</sup>; K&aacute;tia G. Nie
derauer<sup>I</sup>; Aristides V. Cordioli<sup>I</sup></b></font></p>     ^cY#ao
p-0211.htm##
00454000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704021100084002001300295#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#11#7#article#145#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Anxiety Disorder
s Program, Department of Psychiatry, Universidade Federal do Rio Grande do Sul (
UFRGS), Porto Alegre, RS, Brazil    ^cY#aop-0211.htm##
00405000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704016200084002001300246#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#12#8#article#145#<br>   <sup
>II</sup>Center for the Treatment and Study of Anxiety, Department of Psychiatry
, University of Pennsylvania, Philadelphia, PA, USA</font></p>     ^cY#aop-0211.
htm##
00358000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704011500084002001300199#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#13#9#article#145#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence
</a></font></p>     ^cY#aop-0211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#14#10#article#145#<p>&nbsp;<
/p>     ^cY#aop-0211.htm##
00288000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704004400085002001300129#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#15#11#article#145#<p>&nbsp;<
/p> <hr size="1" noshade>     ^cY#aop-0211.htm##
00342000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704009800085002001300183#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#16#12#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p> 
    ^cY#aop-0211.htm##
00488000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704024400085002001300329#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#17#13#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>OBJECTIVE:</b> The prese
nt study was designed to evaluate the psychometric properties of the Brazilian P
ortuguese version of the Obsessive-Compulsive Inventory - Revised.    ^cY#aop-02
11.htm##
00591000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704034700085002001300432#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#18#14#article#145#<br>   <b>
METHOD:</b> The Obsessive-Compulsive Inventory - Revised was administered toa to
tal of 260 participants: a clinical sample of 130 patients with anxiety disorder
s (64 with a diagnosis of obsessive-compulsive disorder patients, 33 diagnosed w
ith social phobia, and 33 with panic disorder) and a sample of 130 non-clinical 
subjects.    ^cY#aop-0211.htm##
00938000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704069400085002001300779#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#19#15#article#145#<br>   <b>
RESULTS:</b> The findings indicate that the Obsessive-Compulsive Inventory - Rev
ised is a valid measure for identifying and assessing the severity of the six sy
mptom subtypes in obsessive-compulsive disorder.The original factor structure of
 the instrument was replicated in an exploratory factor analysis. Test-retest re
liability was examined using data from 64 obsessive-compulsive disorder patients
 who completed the inventory on two different occasions. In each sample, the ove
rall and subscale scores showed moderate to good internal consistency, good conv
ergent and divergent validity, and sensitivity to changes resulting from cogniti
ve-behavioral group therapy changes.    ^cY#aop-0211.htm##
00503000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704025900085002001300344#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#20#16#article#145#<br>   <b>
CONCLUSION:</b> Our findings indicate that the Brazilian Portuguese version of t
he Obsessive-Compulsive Inventory - Revised retains the psychometric properties 
of its original version and the Spanish, German and Iceland versions.</font></p>
     ^cY#aop-0211.htm##
00447000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704020300085002001300288#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#21#17#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Descriptors:</b> Obsessi
ve-compulsive disorder; Evaluation; Symptoms; Anxiety disorders; Brazil</font></
p> <hr size="1" noshade>     ^cY#aop-0211.htm##
00340000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704009600085002001300181#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#22#18#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>   
  ^cY#aop-0211.htm##
00512000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704026800085002001300353#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#23#19#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b> OBJETIVO:</b> O present
e estudo foi delineado para avaliar as propriedades psicom&eacute;tricas da vers
&atilde;o em portugu&ecirc;s do Brasil do <i>Obsessive-Compulsive Inventory - Re
vised</i>.    ^cY#aop-0211.htm##
00616000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704037200085002001300457#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#24#20#article#145#<br>   <b>
M&Eacute;TODO:</b> O <i>Obsessive-Compulsive Inventory - Revised</i> foi aplicad
o em um total de 260 indiv&iacute;duos: em uma amostra cl&iacute;nica de 130 pac
ientes (64 pacientes com transtorno obsessivo-compulsivo, 33 pacientes com fobia
 social e 33 pacientes com transtorno do p&acirc;nico) mais uma amostra n&atilde
;o cl&iacute;nica de 130 sujeitos.    ^cY#aop-0211.htm##
01008000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704076400085002001300849#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#25#21#article#145#<br>   <b>
RESULTADOS:</b> Os resultados indicam que o <i>Obsessive-Compulsive Inventory - 
Revised</i> &eacute; uma medida v&aacute;lida para identificar e avaliar a sever
idade dos seis subtipos de sintomas do transtorno obsessivo-compulsivo. A estrut
ura fatorial do instrumento foi replicada em uma an&aacute;lise fatorial explora
t&oacute;ria. A confiabilidade teste-reteste foi examinada usando os dados de 64
 pacientes com transtorno obsessivo-compulsivo que completaram o invent&aacute;r
io em dois momentos diferentes. Em cada amostra, os escores total e das subescal
as mostraram consist&ecirc;ncia interna de boa a moderada, boa validade concorre
nte e discriminante, e sensibilidade para as mudan&ccedil;as da terapia cognitiv
o-comportamental em grupo.    ^cY#aop-0211.htm##
00559000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704031500085002001300400#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#26#22#article#145#<br>   <b>
CONCLUS&Atilde;O:</b> Nossos achados indicam que a vers&atilde;o para o portugu&
ecirc;s do Brasil do <i>Obsessive-Compulsive Inventory - Revised</i> manteve as 
propriedades psicom&eacute;tricas da vers&atilde;o original e das vers&otilde;es
 em espanhol, alem&atilde;o e island&ecirc;s.</font></p>     ^cY#aop-0211.htm##
00469000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704022500085002001300310#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#27#23#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Descritores:</b> Transto
rno obsessivo-compulsivo; Avalia&ccedil;&atilde;o; Sintomas; Transtornos de ansi
edade; Brasil</font></p> <hr size="1" noshade>     ^cY#aop-0211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#28#24#article#145#<p>&nbsp;<
/p>     ^cY#aop-0211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#29#25#article#145#<p>&nbsp;<
/p>     ^cY#aop-0211.htm##
00346000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010200085002001300187#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#30#26#article#145#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Introduction</b></font><
/p>     ^cY#aop-0211.htm##
00804000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704056000085002001300645#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#31#27#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Obsessive-compulsive disord
er (OCD) is characterized by repetitive behaviors that develop as attempts to re
lieve the anxiety provoked by intrusive and persistent thoughts. Patients may pr
esent one or more OCD symptoms at the same time (for instance, concerns about co
ntamination and washing) and several studies have reported the importance of con
densing these symptoms into specific subgroups.<sup>1-3</sup> In addition, the i
ntensity of symptoms may vary within each subtype.</font></p>     ^cY#aop-0211.h
tm##
01445000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704120100085002001301286#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#32#28#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">One measure that has been d
esigned to correspond with the symptom-based structural model of OCD is the Obse
ssive-Compulsive Inventory -Revised (OCI-R),<sup>4</sup> an 18-item self-report 
instrument which is a revised and shortened version of the Obsessive-Compulsive 
Inventory (OCI).<sup>5</sup> The18 items of the shortened version are rated on a
 five-point Likert Scale that supplies scores on six subscales, and it offers im
provements over the first version in three aspects: (1) it eliminates the redund
ant scale of "frequency"; (2) it simplifies subscales scores; and (3) it reduces
 overlapping subscales. It should be pointed out that the OCI-R has demonstrated
 a higher level of reliability than the longer version,<sup>4</sup> and was prov
en to have good psychometric properties in both clinical and non-clinical sample
s. Also, the OCI-R showed a satisfactory discrimination between OCD patients and
 anxious and non-anxious individuals.<sup>4</sup> In addition to providing an ov
erall score, the OCI-R also scores six dimensions individually: checking, washin
g, ordering, hoarding, obsessing, and neutralizing.</font></p>     ^cY#aop-0211.
htm##
01178000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704093400085002001301019#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#33#29#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Some studies with American 
samples have examined the psychometric properties of the OCI-R. Huppert et al. v
alidated the subscales in a clinical sample of 186 patients diagnosed with OCD a
nd 17 patients diagnosed with generalized anxiety disorder (GAD), and the result
s indicated that the subscales of the OCI-R were valid measures of six symptom s
ubtypes of OCD.<sup>6</sup> Hajcak et al. studied the inventory in two samples o
f undergraduate students and found that the OCI-R had good internal consistency,
 convergent validity, and test-retest reliability.<sup>7</sup> Abramowitz et al.
 replicated and extended previous OCI-R findings with OCD patients and patients 
with other anxiety disorders and recommended the inventory as an empirically val
idated instrument that can be used in a range of OCD-related clinical and resear
ch settings.<sup>8</sup></font></p>     ^cY#aop-0211.htm##
01284000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704104000085002001301125#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#34#30#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Several studies carried out
 in different countries examined the psychometric properties of the OCI-R, with 
results consonant with those originally found by Foa et al.<sup>4</sup> The Span
ish research by Fullana et al. based on a non-clinical student sample, showed th
at the total scale and each of the subscales presented moderate to good internal
 consistency and test-retest reliability, and moderate convergent validity and g
ood divergent validity.<sup>9</sup> G&ouml;nner et al. examined the outcomes obt
ained from a sample of patients with OCD, other anxiety disorders, and depressiv
e disorders with the German version of the inventory, and found good convergent,
 divergent, and known-groups validity for the full scale and the subscales in th
e three samples.<sup>10</sup> Sm&aacute;ri et al. administered the Icelandic OCI
-R version to a sample of college students and found strong psychometric propert
ies of the scale for this population.<sup>11</sup></font></p>     ^cY#aop-0211.h
tm##
01515000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704127100085002001301356#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#35#31#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Although the OCI-R has been
 translated into Portuguese, its psychometric properties have not been examined 
in clinical and non-clinical Brazilian samples. This study addressed the psychom
etric properties and factor structure of the Brazilian Portuguese version of the
 OCI-R (total scale and subscales) in a sample comprising patients diagnosed wit
h OCD, patients with other anxiety disorders, and healthy controls. We conducted
 a confirmatory factor analysis of the OCI-R and investigated the evidence for i
ts convergent and divergent validity in comparison with another measure of obses
sive-compulsive symptoms (Yale-Brown Obsessive-Compulsive Scale -Y-BOCS), a meas
ure of depression symptoms (Beck Depression Inventory - BDI) and a measure of an
xiety symptoms (Beck Anxiety Inventory - BAI). Apart from the above, the test-re
test reliability of the OCI-R total scale and subscales was investigated. In add
ition, we wished to examine the sensitivity of the OCI-R administered prior to a
nd after cognitive behavioral group therapy (CBGT) for OCD outpatients in compar
ison with the Y-BOCS. Finally, we compared its psychometric features with the or
iginal and adapted versions of the scale.</font></p>     ^cY#aop-0211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#36#32#article#145#<p>&nbsp;<
/p>     ^cY#aop-0211.htm##
00340000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704009600085002001300181#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#37#33#article#145#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Method</b></font></p>   
  ^cY#aop-0211.htm##
00349000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010500085002001300190#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#38#34#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>1. Participants</b></fon
t></p>     ^cY#aop-0211.htm##
00566000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704032200085002001300407#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#39#35#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">The sample consisted of 260
 adults, of whom 64 were outpatients diagnosed with OCD, 33 were outpatients wit
h panic disorder (PD), 33 were outpatients with social phobia (SP), and 130 were
 healthy controls (HC) according to DSM-IV criteria.</font></p>     ^cY#aop-0211
.htm##
00347000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010300085002001300188#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#40#36#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>2. Procedures</b></font>
</p>     ^cY#aop-0211.htm##
01196000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704095200085002001301037#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#41#37#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">All participants were evalu
ated by trained master level psychologists with extensive clinical experience in
 OCD. Participants were evaluated using a clinical interview and the Brazilian v
ersion<sup>12</sup> of the Structured Clinical Interview for DSM-IV (SCID-IV).<s
up>13</sup> Inclusion criteria were established as follows: (1) only OCD, PD and
 SP adult outpatients selected among those currently under going treatment in th
e Anxiety Disorder Outpatient Program (PROTAN) of the Hospital de Cl&iacute;nica
s de Porto Alegre (HCPA), Universidade Federal de Rio Grande do Sul (UFRGS), Bra
zil, who had been diagnosed at the time of admission and had already been evalua
ted and considered eligible to begin the treatment were included; (2) patients w
ith PD or SP were only included if they were not diagnosed with comorbid OCD; (3
) absence of psychiatric disorders for HC.</font></p>     ^cY#aop-0211.htm##
00718000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704047400085002001300559#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#42#38#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">The 64 OCD patients complet
ed the Brazilian version<sup>14</sup> of the Y-BOCS<sup>15</sup> in order to con
firm diagnosis. All OCD patients attended 12 weekly sessions of CBGT as part of 
the PROTAN. In addition to the OCI-R, patients were also assessed with theY-BOCS
, the Brazilian version<sup>16</sup> of the BDI<sup>17</sup> and the Brazilian v
ersion<sup>16</sup> of the BAI.<sup>18</sup></font></p>     ^cY#aop-0211.htm##
00620000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704037600085002001300461#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#43#39#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">SP and PD patients were dia
gnosed using the SCID-IV<sup>13</sup> and referred to treatment in the PROTAN. T
he control group comprised healthy volunteers matched to treatment in age, educa
tion, and gender. HC were all employees at the HCPA and were also assessed using
 the SCID-IV.<sup>13</sup></font></p>     ^cY#aop-0211.htm##
00425000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704018100085002001300266#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#44#40#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">All sample subsets (SP, PD,
 and HC) completed the same instruments administered to the OCD sample.</font></
p>     ^cY#aop-0211.htm##
00760000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704051600085002001300601#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#45#41#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">CBGT was based on a structu
red manual-based approach developed by one of the authors (AVC) and used in prev
ious trials.<sup>19-21</sup> CBGT consisted of 12 weekly two-hour sessions. The 
treatment approach emphasizes psycho-education, ERP techniques, cognitive techni
ques to change dysfunctional thoughts and beliefs, strategies to prevent relapse
s, and group techniques. Details on the manual can be found elsewhere.<sup>20,22
</sup></font></p>     ^cY#aop-0211.htm##
00689000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704044500085002001300530#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#46#42#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Data were collected between
 March 2006 and July 2007. The Ethics Committee of the HCPA approved the researc
h protocol (Process: 05/505). Written informed consent was obtained from all par
ticipants, after a thorough description of the study and reassurance was given t
hat their decision to participate or not in the study would not interfere with t
heir treatment.</font></p>     ^cY#aop-0211.htm##
00345000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010100085002001300186#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#47#43#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>3. Measures</b></font></
p>     ^cY#aop-0211.htm##
00379000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704013500085002001300220#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#48#44#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">The following scales were u
sed to evaluate outcomes:</font></p>     ^cY#aop-0211.htm##
00843000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704059900085002001300684#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#49#45#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">1) OCI-R:<sup>4</sup> trans
lated and adapted to Brazilian Portuguese by Souza et al.<sup>23</sup> This is a
n 18-item self-report questionnaire which assesses the distress associated with 
obsessive-compulsive symptoms. In the original version, it has shown good psycho
metric properties in patients with anxiety disorders. A complete description of 
the translation and back-translation procedures is available elsewhere<sup>23</s
up> and the final version of the OCI-R in Brazilian Portuguese is available upon
 request.</font></p>     ^cY#aop-0211.htm##
00730000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704048600085002001300571#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#50#46#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">2) Y-BOCS:<sup>15</sup> tra
nslated and adapted to Brazilian Portuguese by Asbahr et al.<sup>14</sup> This s
cale assesses obsessions and compulsions and is considered to be the "gold stand
ard" for the evaluation of the severity of symptoms. It is based on a Likert sca
le ranging from 0 (without symptoms) to 4 (very severe). Five questions evaluate
 obsession and another five measure compulsive features.</font></p>     ^cY#aop-
0211.htm##
00632000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704038800085002001300473#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#51#47#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">3) BDI:<sup>17</sup> transl
ated, adapted and validated for the Brazilian population by Gorenstein et al.<su
p>16</sup> This instrument gaugesthe presence and intensity of depressive sympto
ms. It is a self-report scale with 21 items, each with four severity alternative
s (minimal, mild, moderate or severe).</font></p>     ^cY#aop-0211.htm##
00620000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704037600085002001300461#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#52#48#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">4) Structured Clinical Inte
rview for DSM-IV (SCID-IV): proposed in 1997 by First et al. and translated and 
adapted to Portuguese by Tavares, it is a semi-structured interview developed fo
r use in research and for the diagnosis of Axis I disorders, according to DSM-IV
 criteria.<sup>12,13</sup></font></p>     ^cY#aop-0211.htm##
00583000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704033900085002001300424#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#53#49#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">5) BAI:<sup>18</sup> transl
ated, adapted, and validated for the Brazilian population by Gorenstein et al. T
his is a self-report scale with 21 items commonly used to evaluate clinical anxi
ety. It returns a total score which varies from 0 to 63.<sup>16</sup></font></p>
     ^cY#aop-0211.htm##
00357000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011300085002001300198#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#54#50#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>4. Statistical analysis<
/b></font></p>     ^cY#aop-0211.htm##
01966000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704172200085002001301807#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#55#51#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Statistical analyses were c
arried out with the Statistical Package for the Social Sciences (SPSS) version 1
2.0 for Windows (SPSS Inc., Chicago, Illinois). Means and standard deviations (s
ymmetric distribution) or median and interquartile ranges (asymmetric distributi
on) were computed for all measures and differences between OCD patients, patient
s with other anxiety disorders, and HCwere examined. We tested the equality of t
he distributions using the non-parametric Kolmogorov-Smirnov test. Analyses of v
ariance (ANOVA) were conducted using Tukey test adjusted for multiple comparison
s between groups. The Kruskal-Wallis test was applied to asymmetric data and the
 analysis was completed using the Mann-Whitney test. In order to control for typ
e I errors, the software package Programs for Epidemiologists (PEPI), version 4.
0, was used to apply Finner adjustment to p values. Pearson's Chi square was use
d to assess associations between qualitative variables. In cases of statistical 
significance, the adjusted residues test was applied. In addition, Cronbach's al
pha was calculated for each subscale to determine internal consistency. Spearman
's correlation coefficient was calculated to assess test-retest reliability and 
agreement between scales. The Wilcoxon test was used to evaluate pre-/post-treat
ment changes in the sample of OCD patients. Test-retest reliability was evaluate
d using the same interval as in the original study (seven days).<sup>4</sup> To 
examine the six-factor structure of the OCI-R, a factor analysis with Varimax ro
tation was conducted. Statistical associations were considered significant when 
p &lt; 0.05.</font></p>     ^cY#aop-0211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#56#52#article#145#<p>&nbsp;<
/p>     ^cY#aop-0211.htm##
00341000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704009700085002001300182#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#57#53#article#145#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Results</b></font></p>  
   ^cY#aop-0211.htm##
00345000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010100085002001300186#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#58#54#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>1. Subjects</b></font></
p>     ^cY#aop-0211.htm##
00632000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704038800085002001300473#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#59#55#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">The sample comprised 187 fe
males and 73 males. Since gender differences were not our primary concern, male 
and female samples were not analyzed separately. Age and other sociodemographic 
variables for the whole samples are presented in <a href="/img/revistas/rbp/2011
nahead/aop-0211tab01.jpg">Table 1</a>.</font></p>     ^cY#aop-0211.htm##
00357000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011300085002001300198#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#60#56#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>2. Internal consistency<
/b></font></p>     ^cY#aop-0211.htm##
01074000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704083000085002001300915#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#61#57#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Our finding demonstrated a 
high internal consistency for the whole OCI-R in all samples, ranging from 0.70 
(SP sample) to 0.94 (OCD sample). All subscales presented high internal consiste
ncy for the whole sample, and good internal consistency for patients with OCD an
d SP, with four out of six coefficients exceeding 0.70. In the PD sample, the su
bscales had low to moderate internal consistency, except for the ordering subsca
le, which demonstrated good internal consistency. In relation to the control gro
up, good internal consistency was found for the whole OCI-R and the washing and 
checking subscales and moderate for the rest of subscales. Alpha coefficients ar
e shown in <a href="/img/revistas/rbp/2011nahead/aop-0211tab02.jpg">Table 2</a>.
</font></p>     ^cY#aop-0211.htm##
00360000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011600085002001300201#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#62#58#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>3. Test-retest reliabili
ty</b></font></p>     ^cY#aop-0211.htm##
00669000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704042500085002001300510#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#63#59#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Sixty-four OCD patients wer
e included in this phase of the study. A non-significant difference (p = 0.085) 
was found between test (median = 29; P25 = 10; P75 = 41.5) and retest (median = 
27; P25 = 10; P75 = 42.5). The test-retest reliability for the overall score was
 0.98, and for the subscales the correlations ranged between 0.95 and 0.99.</fon
t></p>     ^cY#aop-0211.htm##
00370000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012600085002001300211#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#64#60#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>4. Convergent and diverg
ent validity</b></font></p>     ^cY#aop-0211.htm##
00822000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704057800085002001300663#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#65#61#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Spearman correlation coeffi
cients between the OCI-R and the Y-BOCS, BDI, and BAI scores are presented in <a
 href="#tab3">Table 3</a>. Data from these scales were positively correlated wit
h to the OCI-R total score and all the other measures. Our findings demonstrated
 a moderate correlation between the OCI-R obsession subscale and the Y-BOCS obse
ssion score, and a low correlation with the BDI and the BAI. The highest correla
tion was found between the total scores in the OCI-R and the Y-BOCS.</font></p> 
    ^cY#aop-0211.htm##
00279000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003500085002001300120#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#66#62#article#145#<p><a name
="tab3"></a></p>     ^cY#aop-0211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#67#63#article#145#<p>&nbsp;<
/p>     ^cY#aop-0211.htm##
00333000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008900085002001300174#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#68#64#article#145#<p align="
center"><img src="/img/revistas/rbp/2011nahead/aop-0211tab03.jpg"></p>     ^cY#a
op-0211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#69#65#article#145#<p>&nbsp;<
/p>     ^cY#aop-0211.htm##
00939000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704069500085002001300780#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#70#66#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">In order to examine the abi
lity of the OCI-R to discriminate the OCD sample from other samples we compared 
medians and interquartile ranges using the Kruskal-Wallis H test. The same abili
ty was also evaluated by applying the Mann-Whitney test with Finner adjustment. 
As shown in <a href="/img/revistas/rbp/2011nahead/aop-0211tab04.jpg">Table 4</a>
, the Kruskal-Wallis test results showed differences in the total score for all 
samples. The Mann-Whitney test demonstrated that OCD patients were significantly
 more distressed than individuals from other samples according to both the total
 scale and all subscales.</font></p>     ^cY#aop-0211.htm##
00421000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704017700085002001300262#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#71#67#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>5. Sensitivity to treatm
ent-related changes of the scales used to evaluate OCD patients</b></font></p>  
   ^cY#aop-0211.htm##
01231000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704098700085002001301072#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#72#68#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Sensitivity to change was e
valuated by comparing changes in the total score of the OCI-R administered befor
e and after CBGT and by comparing these to changes in Y-BOCS scores. Median (m) 
and interquartile ranges (iq) of the OCI-R total score before (m = 33.5; iq = 10
.5) and after (m = 6.5; iq = 10.5) treatment were significantly different (p &lt
; 0.001). The same level of statistical significance (p &lt; 0.001) was found fo
r the mean and standard deviation in Y-BOCS total scores before (m = 30.5; iq = 
4.3) and after (m = 9.9; iq = 6.2) treatment. The association between the Y-BOCS
 and OCI-R scores was adequate prior to treatment (r = 0.5; p &lt; 0.001) and hi
gher after treatment (r = 0.7; p &lt; 0.001). The OCI-R also demonstrated a good
 ability to discriminate between OCD patients and other groups of patients with 
anxiety disorders, with the exception of the hoarding and ordering subscales.</f
ont></p>     ^cY#aop-0211.htm##
00377000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704013300085002001300218#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#73#69#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>6. Exploratory factor an
alysis of the OCI-R</b></font></p>     ^cY#aop-0211.htm##
00929000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704068500085002001300770#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#74#70#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">To test the factor stabilit
y of the six subscales of the OCI-R in the total sample (n = 260), an explorator
y factor analysis was performed. The six-factor structure of the OCI-R was confi
rmed in the sample. The model had a significant chi-square, </font>&#967;<font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><sup>2</sup> (153, n = 64) 
= 4065, p &lt; 0.001, and a goodness-of-fit index of 0.918 indicating an excelle
nt fit for the model. As shown in <a href="/img/revistas/rbp/2011nahead/aop-0211
tab05.jpg">Table 5</a>, all items had very high factor loadings on the factor th
ey belonged to.</font></p>     ^cY#aop-0211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#75#71#article#145#<p>&nbsp;<
/p>     ^cY#aop-0211.htm##
00344000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010000085002001300185#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#76#72#article#145#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Discussion</b></font></p
>     ^cY#aop-0211.htm##
00949000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704070500085002001300790#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#77#73#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">The main goal of this study
 was to examine the psychometric properties of the Brazilian Portuguese version 
of the OCI-R. Therefore, a clinical sample including three groups with different
 anxiety disorders and a non-clinical sample were recruited. We also aimed at ex
amining the performance of each subscale in the OCD sample in addition to observ
ing the results before and after CBGT. Moreover, we correlated the OCI-R with ot
her commonly used measures. Additionally, we compared our results with those of 
the original version,<sup>4</sup> the Spanish version<sup>9</sup> and the German
 version<sup>10</sup> of the OCI-R.</font></p>     ^cY#aop-0211.htm##
00982000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704073800085002001300823#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#78#74#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Overall, the Brazilian Port
uguese version of the OCI-R displayed excellent psychometric properties. The fin
dings indicated that our patients had higher OCI-R mean (M) scores (M = 33.0; SD
 = 13.9) than those in the samples studied by Huppert et al. (M = 26.3; SD = 12.
8), G&ouml;nner et al. (M = 26.1; SD = 13.3), Foa et al. (M = 28.0; SD = 13.5) a
nd Abramowitz et al. (M = 27.0; SD = 13.2); SD for standard deviation.<sup>4,6,8
,10</sup> This suggests that the Brazilian Portuguese version of the OCI-R is a 
useful screening instrument able to discriminate between patients diagnosed with
 OCD, patients with other anxiety disorders and healthy individuals.</font></p> 
    ^cY#aop-0211.htm##
01010000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704076600085002001300851#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#79#75#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Concerning the OCI-R subsca
les, we found internal consistency values for the checking, hoarding, neutralizi
ng and ordering subscale scores in our OCD group similar to those reported by Hu
ppert et al. and higher than those found by G&ouml;nner et al.<sup>6,10</sup> Wh
en we consulted the results of the Spanish version of the OCI-R, we found very s
imilar estimates for the total score, and for the hoarding, ordering, checking, 
and neutralizing subscales.<sup>9</sup> Moreover, our results were quite similar
 to those found by Hajcak et al., only differing in relation to the ordering sub
scale (0.62 in the Brazilian study and 0.84 in the non-clinical sample of studen
ts).<sup>7</sup></font></p>     ^cY#aop-0211.htm##
01468000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704122400085002001301309#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#80#76#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Convergent validity was dem
onstrated by significant correlations between the Brazilian Portuguese versions 
of the OCI-R and the Y-BOCS. In the OCD sample, the OCI-R total score and all th
e subscale scores also demonstrated moderate to good convergent validity with th
e Y-BOCS. Divergent validity was established by low correlations between the OCI
-R and the BDI and the BAI, which are instruments that were not specifically dev
eloped to assess OCD. These results are in line with previous findings.<sup>4,7,
8,10</sup> In addition, the correlation between the OCI-R obsession subscale and
 the Y-BOCS was lower in our study as compared to theoriginal version<sup>4</sup
> (0.53), similar to that of the German version<sup>10</sup> (0.40), and higher 
than the results published by Abramowitz et al.<sup>8</sup>(0.22). The correlati
on with the BDI was similar to the German version<sup>10</sup> (0.32) and close 
to the results reported by Hajcak et al. (0.39) and Abramowitz et al. (0.41).<su
p>7,8</sup> In relation to the correlation between the OCI-R and the BAI, the da
ta were similar to those found for the German version<sup>10</sup> (0.42).</font
></p>     ^cY#aop-0211.htm##
00651000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704040700085002001300492#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#81#77#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Furthermore, the test-retes
t reliability for the overall score was excellent and higher than those reported
 by Hajcak et al.<sup>7</sup> (0.7) and for the Spanish version<sup>1</sup> (0.6
7). On the other hand, the correlations of the subscales were similar to those f
ound by Foa et al. ranging from 0.74 to 0.91.<sup>4</sup></font></p>     ^cY#aop
-0211.htm##
00813000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704056900085002001300654#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#82#78#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">The OCI-R showed a good abi
lity to assess the effects of treatment in OCD patients and might thus be helpfu
l for measuring treatment outcomes. Our findings are in agreement with those rep
orted by Abramowitz et al.<sup>24</sup> Additionally, our results demonstrate th
at the Brazilian Portuguese version of the OCI-R produces results that are quite
 stable over time. The total score and each subscale had correlation values high
er than 0.95, suggesting that the OCI-R is a reliable tool.</font></p>     ^cY#a
op-0211.htm##
00541000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704029700085002001300382#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#83#79#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Finally, our exploratory fa
ctor analysis suggested an adequate fit for a six-factor structure, thus replica
ting previous results on the OCI-R in both clinical<sup>4,6,8</sup> and non-clin
ical<sup>7,9</sup> samples.</font></p>     ^cY#aop-0211.htm##
00618000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704037400085002001300459#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#84#80#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Some limitations of the pre
sent study should be highlighted: (1) the number of patients in each group was s
mall; (2) included participants came from a single center, located in a universi
ty hospital; and (3) the sensitivity of the specific subscales to treatment effe
cts remains to examined.</font></p>     ^cY#aop-0211.htm##
00795000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704055100085002001300636#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#85#81#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Further research should inv
estigate the convergent validity of the six subscales of the OCI-R and the corre
sponding six OCD subtypes derived from the Y-BOCS checklist and, for instance, f
rom the Dimensional Yale-Brown Obsessive-Compulsive Scale (DY-BOCS)<sup>3</sup> 
which evaluates obsessive-compulsive symptoms according to six specific dimensio
ns. Additional research is required to establish adequate cut-off scores for Bra
zilian clinical and non-clinical samples.</font></p>     ^cY#aop-0211.htm##
00637000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704039300085002001300478#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#86#82#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">In summary, the Brazilian P
ortuguese version of the OCI-R strongly correlates with the original version of 
the scale and with versions in other languages, and can be recommended as a vali
d measure. It is appropriate to be used with clinical and non-clinical populatio
ns, and for clinical and research purposes.</font></p>     ^cY#aop-0211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#87#83#article#145#<p>&nbsp;<
/p>     ^cY#aop-0211.htm##
00460000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704021600085002001300301#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#88#84#article#145#<p align="
center"><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><a href="/im
g/revistas/rbp/2011nahead/aop-0211img01.jpg"><img src="/img/revistas/rbp/2011nah
ead/aop-0211img01tamb.jpg" border="0">    ^cY#aop-0211.htm##
00291000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704004700085002001300132#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#89#85#article#145#<br>   Cli
ck to enlarge</a></font></p>     ^cY#aop-0211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#90#86#article#145#<p>&nbsp;<
/p>     ^cY#aop-0211.htm##
00344000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010000085002001300185#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#91#87#article#145#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>References</b></font></p
>     ^cY#aop-0211.htm##
00578000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704032000087002001300407#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#92#88#article#14
5#1#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Fullana MA
, Tortella-Feliu M, Caseras X, Taberner J, Torrubia R, Mataix-Cols D. Temporal s
tability of obsessive-compulsive symptom dimensions in an undergraduate sample: 
a prospective 2-year follow-up study. <i>Behav Modif</i>. 2007;31(6):815-24.    
^cY#aop-0211.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#93#89#article#145#</font></p
>     ^cY#aop-0211.htm##
00546000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704028800087002001300375#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#94#90#article#14
5#2#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Mataix-Col
s D, Fullana MA, Alonso P, Mench&oacute;n JM, Vallejo J. Convergent and discrimi
nant Validity of the Yale-Brown Obsessive-Compulsive Scale Symptom Checklist. <i
>Psychother Psychosom</i>. 2004;73(3):190-6.    ^cY#aop-0211.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#95#91#article#145#</font></p
>     ^cY#aop-0211.htm##
00666000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704040800087002001300495#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#96#92#article#14
5#3#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Rosario-Ca
mpos MC, Miguel EC, Quatrano S, Chacon P, Ferrao Y, Findley D, Katsovich L, Scah
ill L, King RA, Woody SR, Tolin D, Hollander E, Kano Y, Leckman JF. The Dimensio
nal Yale-Brown Obsessive-Compulsive Scale (DY-BOCS): an instrument for assessing
 obsessive-compulsive symptom dimensions. <i>Mol Psychiatry</i>. 2006;11(5):495-
504.    ^cY#aop-0211.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#97#93#article#145#</font></p
>     ^cY#aop-0211.htm##
00533000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704027500087002001300362#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#98#94#article#14
5#4#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Foa EB, Hu
ppert JD, Leiberg S, Langner R, Kichic R, Hajcak G, Salkovskis PM. The Obsessive
-Compulsive Inventory: development and validation of a short version. <i>Psychol
 Assess</i>. 2002;14(4):485-96.    ^cY#aop-0211.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#99#95#article#145#</font></p
>     ^cY#aop-0211.htm##
00501000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082888000200086704024200088002001300330#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#100#96#article#1
45#5#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Foa EB, K
ozak MJ, Salkovskis PM. The validation of a new Obsessive-Compulsive Disorder Sc
ale: The Obsessive-Compulsive Inventory. <i>Psychol Assess</i>. 1998;10:206-14. 
   ^cY#aop-0211.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704002000086002001300106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#101#97#article#145#</font></
p>     ^cY#aop-0211.htm##
00514000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082888000200086704025500088002001300343#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#102#98#article#1
45#6#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Huppert J
D, Walther MR, Hajcak G, Yadin E, Foa EB, Simpson HB, Liebowitz MR.The OCI-R: va
lidation of the subscales in a clinical sample. <i>J Anxiety Disord</i>. 2007;21
(3):394-406.    ^cY#aop-0211.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704002000086002001300106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#103#99#article#145#</font></
p>     ^cY#aop-0211.htm##
00474000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704021400089002001300303#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#104#100#article#
145#7#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Hajcak G
, Huppert JD, Simons RF, Foa EB. Psychometric properties of the OCI-R in a colle
ge sample. <i>Behav Res Ther</i>. 2004;42(1):115-23.    ^cY#aop-0211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#105#101#article#145#</font><
/p>     ^cY#aop-0211.htm##
00548000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704028800089002001300377#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#106#102#article#
145#8#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Abramowi
tz JS, Deacon BJ. Psychometric properties and construct validity of the Obsessiv
e-Compulsive Inventory-Revised: replication and extension with a clinical sample
. <i>J Anxiety Disord</i>. 2006;20(8):1016-35.    ^cY#aop-0211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#107#103#article#145#</font><
/p>     ^cY#aop-0211.htm##
00582000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704032200089002001300411#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#108#104#article#
145#9#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Fullana 
MA, Tortella-Feliu M, Caseras X, Andi&oacute;n O, Torrubia R, Mataix-Cols D. Psy
chometric properties of the Spanish version of the Obsessive-Compulsive Inventor
y-Revised in a non-clinical sample. <i>J Anxiety Disord</i>. 2005;19(8):893-903.
    ^cY#aop-0211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#109#105#article#145#</font><
/p>     ^cY#aop-0211.htm##
00578000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704031700090002001300407#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#110#106#article#
145#10#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. G&ouml
;nner S, Leonhart R, Ecker W.The Obsessive-Compulsive Inventory-Revised (OCI-R):
 validation of the German version in a sample of patients with OCD, anxiety diso
rders, and depressive disorders. <i>J Anxiety Disord</i>. 2008;22(4):734-49.    
^cY#aop-0211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#111#107#article#145#</font><
/p>     ^cY#aop-0211.htm##
00564000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704030300090002001300393#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#112#108#article#
145#11#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Sm&aac
ute;ri J, &Oacute;lason DT, Eyp&oacute;rsd&oacute;ttir A, Fr&ouml;lunde MB. Psyc
hometric properties of the Obsessive Compulsive Inventory-Revised among Icelandi
c college students. <i>Scand J Psychol</i>. 2007;48(2):127-33.    ^cY#aop-0211.h
tm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#113#109#article#145#</font><
/p>     ^cY#aop-0211.htm##
00653000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704039200090002001300482#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#114#110#article#
145#12#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Tavare
s M. <i>Entrevista cl&iacute;nica estruturada para diagn&oacute;stico dos Transt
ornos do Eixo I do DSM-IV - Edi&ccedil;&atilde;o do paciente</i>, vers&atilde;o 
2.0 (SCID-I/P, Vers&atilde;o 2.0). Bras&iacute;lia:Tradu&ccedil;&atilde;o brasil
eira, Instituto de Psicologia da Universidade de Bras&iacute;lia; 1996.    ^cY#a
op-0211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#115#111#article#145#</font><
/p>     ^cY#aop-0211.htm##
00528000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026700090002001300357#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#116#112#article#
145#13#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. First 
MB, Spitzer RL, Gibbon M, Williams JBW. <i>Structured clinical interview for DSM
-IV axis I disorders</i> - clinician version (SCID-CV). Washington (DC): America
n Psychiatric Press; 1997.    ^cY#aop-0211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#117#113#article#145#</font><
/p>     ^cY#aop-0211.htm##
00557000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029600090002001300386#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#118#114#article#
145#14#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Asbahr
 FR, Lotufo Neto F, Turecki GX, Del Porto JA, Rodr&iacute;guez LR, Baruzzi M, Li
ma MA, Gentil V. <i>Escala Yale-Brown de Sintomas Obsessivo-Compulsivos</i>, tra
du&ccedil;&atilde;o brasileira, S&atilde;o Paulo; 1992.    ^cY#aop-0211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#119#115#article#145#</font><
/p>     ^cY#aop-0211.htm##
00560000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029900090002001300389#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#120#116#article#
145#15#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Goodma
n WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Ch
arney DS. The Yale-Brown Obsessive-Compulsive Scale: I. Development, use, and re
liability. <i>Arch Gen Psychiatr</i>. 1989;46(11):1006-11.    ^cY#aop-0211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#121#117#article#145#</font><
/p>     ^cY#aop-0211.htm##
00535000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704027400090002001300364#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#122#118#article#
145#16#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Gorens
tein C, Andrade L. Validation of a Portuguese version of the Beck Depression Inv
entory and the State-Trait Anxiety Inventory in Brazilian subjects. <i>Braz J Me
d Biol Res</i>. 1996;29(4):453-7.    ^cY#aop-0211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#123#119#article#145#</font><
/p>     ^cY#aop-0211.htm##
00467000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704020600090002001300296#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#124#120#article#
145#17#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Beck A
T, Ward CH, Mendelson M, Mock J, Eerbaugh J. An inventory for measuring depressi
on. <i>Arch Gen Psychiatry</i>. 1961;4:53-63.    ^cY#aop-0211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#125#121#article#145#</font><
/p>     ^cY#aop-0211.htm##
00491000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704023000090002001300320#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#126#122#article#
145#18#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Beck A
T, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: ps
ychometric properties. <i>J Consult Clin Psych</i>. 1988;56(6):893-7.    ^cY#aop
-0211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#127#123#article#145#</font><
/p>     ^cY#aop-0211.htm##
00506000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704024500090002001300335#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#128#124#article#
145#19#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Braga 
D, Cordioli AV, Manfro GG. Cognitive-behavioral group therapy for obsessive-comp
ulsive disorder: a 1 year follow-up. <i>Acta Psychiatr Scand</i>. 2005;112(3):18
0-6.    ^cY#aop-0211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#129#125#article#145#</font><
/p>     ^cY#aop-0211.htm##
00569000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704030800090002001300398#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#130#126#article#
145#20#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Cordio
li AV, Heldt E, Bochi DB, Margis R, Sousa MB, Tonello JF, Manfro GG, Kapczinski 
F. Cognitive-behavioral group therapy in obsessive-compulsive disorder: a random
ized clinical trial. <i>Psychother Psychosom</i>. 2003;72(4):211-6.    ^cY#aop-0
211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#131#127#article#145#</font><
/p>     ^cY#aop-0211.htm##
00565000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704030400090002001300394#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#132#128#article#
145#21#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Sousa 
MB, Isolan LR, Oliveira RR, Manfro GG, Cordioli AV. A randomized clinical trial 
on cognitive-behavioral group therapy and sertraline in the treatment of obsessi
ve-compulsive disorder. <i>J Clin Psych</i>. 2006;67(7):1133-9.    ^cY#aop-0211.
htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#133#129#article#145#</font><
/p>     ^cY#aop-0211.htm##
00570000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704030900090002001300399#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#134#130#article#
145#22#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Cordio
li AV, Heldt E, Bochi DB, Margis R, Sousa MB, Juliano F, Tonello JF, Teruchkin B
, Kapczinski F. Cognitive-behavioral group therapy in obsessive-compulsive disor
der: a clinical trial. <i>Rev Bras Psiquiatr</i>. 2002;24(3):113-20.    ^cY#aop-
0211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#135#131#article#145#</font><
/p>     ^cY#aop-0211.htm##
00596000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704033500090002001300425#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#136#132#article#
145#23#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Souza 
FP, Foa EB, Meyer E, Niederauer KG, Raffin AL, Cordioli AV. Obsessive-Compulsive
 Inventory and Obsessive-Compulsive Inventory-Revised Scales: translation into B
razilian Portuguese and cross-cultural adaptation. <i>Rev Bras Psiquiatr</i>. 20
08;30(1):42-6.    ^cY#aop-0211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#137#133#article#145#</font><
/p>     ^cY#aop-0211.htm##
00460000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704019900090002001300289#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#138#134#article#
145#24#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">24. Abramo
witz J, McKay D, Taylor S. Special series subtypes of obsessive-compulsive disor
der. <i>Behav Ther</i>. 2005;36:367-9.    ^cY#aop-0211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#139#135#article#145#</font><
/p>     ^cY#aop-0211.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#140#136#article#145#<p>&nbsp
;</p>     ^cY#aop-0211.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#141#137#article#145#<p>&nbsp
;</p>     ^cY#aop-0211.htm##
00436000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704019000087002001300277#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#142#138#article#145#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href=
"#ad1"><img src="/img/revistas/rbp/2011nahead/seta.jpg" border="0"></a> <b>Corre
spondence:</b>    ^cY#aop-0211.htm##
00287000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704004100087002001300128#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#143#139#article#145#<br>   F
ernanda Pasquoto de Souza    ^cY#aop-0211.htm##
00296000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704005000087002001300137#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#144#140#article#145#<br>   R
. Ramiro Barcelos, 2350, Room 400N    ^cY#aop-0211.htm##
00290000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704004400087002001300131#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#145#141#article#145#<br>   P
hone/fax: (+55 51) 3331+4668    ^cY#aop-0211.htm##
00295000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704004900087002001300136#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#146#142#article#145#<br>   9
0035-903 Porto Alegre, RS, Brazil    ^cY#aop-0211.htm##
00331000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704008500087002001300172#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#147#143#article#145#<br>   E
mail: <a href="mailto:fegps@terra.com">fegps@terra.co</a></font></p>     ^cY#aop
-0211.htm##
00345000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704009900087002001300186#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#148#144#article#145#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">Submitted: February 9, 20
10     ^cY#aop-0211.htm##
00295000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704004900087002001300136#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#p#149#145#article#145#<br>   A
ccepted: May 12, 2010</font></p>     ^cY#aop-0211.htm##
00753000000000337000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100018000860100024001040100
01700128010001800145010001800163010002100181012013100202030001200333065000900345
06400050035403100030035903200020036201400070036486500090037100200130038003500100
0393801001200403#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0211.htm#
S#c#150#1#article#24#1#^rND^sFullana^nMA#^rND^sTortella-Feliu^nM#^rND^sCaseras^n
X#^rND^sTaberner^nJ#^rND^sTorrubia^nR#^rND^sMataix-Cols^nD#Temporal stability of
 obsessive-compulsive symptom dimensions in an undergraduate sample: a prospecti
ve 2-year follow-up study^len#Behav Modif#20070000#2007#31#6#815-24#20110000#aop
-0211.htm#0145-4455#Behav Modif##
00705000000000325000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100021000860100018001070100
01600125010001800141010001700159012010400176030002100280065000900301064000500310
03100030031503200020031801400060032086500090032600200130033503500100034880100210
0358#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#c#151#2#ar
ticle#24#2#^rND^sMataix-Cols^nD#^rND^sFullana^nMA#^rND^sAlonso^nP#^rND^sMenchón^
nJM#^rND^sVallejo^nJ#Convergent and discriminant Validity of the Yale-Brown Obse
ssive-Compulsive Scale Symptom Checklist^len#Psychother Psychosom#20040000#2004#
73#3#190-6#20110000#aop-0211.htm#0033-3190#Psychother Psychosom##
00988000000000433000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100025000860100017001110100
01800128010001600146010001600162010001700178010001900195010001700214010001500231
01000160024601000150026201000190027701000140029601000180031001201370032803000150
04650650009004800640005004890310003004940320002004970140008004998650009005070020
01300516035001000529801001500539#2011nahead#V:\SciELO\serial\rbp\2011nahead\mark
up\aop-0211.htm#S#c#152#3#article#24#3#^rND^sRosario-Campos^nMC#^rND^sMiguel^nEC
#^rND^sQuatrano^nS#^rND^sChacon^nP#^rND^sFerrao^nY#^rND^sFindley^nD#^rND^sKatsov
ich^nL#^rND^sScahill^nL#^rND^sKing^nRA#^rND^sWoody^nSR#^rND^sTolin^nD#^rND^sHoll
ander^nE#^rND^sKano^nY#^rND^sLeckman^nJF#The Dimensional Yale-Brown Obsessive-Co
mpulsive Scale (DY-BOCS): an instrument for assessing obsessive-compulsive sympt
om dimensions^len#Mol Psychiatry#20060000#2006#11#5#495-504#20110000#aop-0211.ht
m#1359-4184#Mol Psychiatry##
00694000000000337000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100014000860100018001000100
01700118010001700135010001600152010001600168010002100184012008600205030001500291
71000020030606500090030806400050031703100030032203200020032501400070032786500090
0334002001300343#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0211.htm#
S#c#153#4#article#24#4#^rND^sFoa^nEB#^rND^sHuppert^nJD#^rND^sLeiberg^nS#^rND^sLa
ngner^nR#^rND^sKichic^nR#^rND^sHajcak^nG#^rND^sSalkovskis^nPM#The Obsessive-Comp
ulsive Inventory: development and validation of a short version^len#Psychol Asse
ss#2#20020000#2002#14#4#485-96#20110000#aop-0211.htm##
00578000000000277000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100014000860100016001000100
02100116012010000137030001500237710000200252065000900254064000500263031000300268
014000700271865000900278002001300287#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop-0211.htm#S#c#154#5#article#24#5#^rND^sFoa^nEB#^rND^sKozak^nMJ#^rND^sS
alkovskis^nPM#The validation of a new Obsessive-Compulsive Disorder Scale: The O
bsessive-Compulsive Inventory^len#Psychol Assess#2#19980000#1998#10#206-14#20110
000#aop-0211.htm##
00712000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100018000860100018001040100
01600122010001500138010001400153010001800167010002000185012006400205030001700269
06500090028606400050029503100030030003200020030301400080030586500090031300200130
0322035001000335801001700345#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\a
op-0211.htm#S#c#155#6#article#24#6#^rND^sHuppert^nJD#^rND^sWalther^nMR#^rND^sHaj
cak^nG#^rND^sYadin^nE#^rND^sFoa^nEB#^rND^sSimpson^nHB#^rND^sLiebowitz^nMR#The OC
I-R: validation of the subscales in a clinical sample^len#J Anxiety Disord#20070
000#2007#21#3#394-406#20110000#aop-0211.htm#0887-6185#J Anxiety Disord##
00614000000000313000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100018001020100
01700120010001400137012006100151030001500212065000900227064000500236031000300241
032000200244014000700246865000900253002001300262035001000275801001500285#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#c#156#7#article#24#7#^
rND^sHajcak^nG#^rND^sHuppert^nJD#^rND^sSimons^nRF#^rND^sFoa^nEB#Psychometric pro
perties of the OCI-R in a college sample^len#Behav Res Ther#20040000#2004#42#1#1
15-23#20110000#aop-0211.htm#0005-7967#Behav Res Ther##
00654000000000289000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100021000860100017001070120
14700124030001700271065000900288064000500297031000300302032000200305014000800307
865000900315002001300324035001000337801001700347#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop-0211.htm#S#c#157#8#article#24#8#^rND^sAbramowitz^nJS#^rND
^sDeacon^nBJ#Psychometric properties and construct validity of the Obsessive-Com
pulsive Inventory-Revised: replication and extension with a clinical sample^len#
J Anxiety Disord#20060000#2006#20#8#1016-35#20110000#aop-0211.htm#0887-6185#J An
xiety Disord##
00753000000000337000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100018000860100024001040100
01700128010001600145010001800161010002100179012012200200030001700322065000900339
06400050034803100030035303200020035601400080035886500090036600200130037503500100
0388801001700398#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0211.htm#
S#c#158#9#article#24#9#^rND^sFullana^nMA#^rND^sTortella-Feliu^nM#^rND^sCaseras^n
X#^rND^sAndión^nO#^rND^sTorrubia^nR#^rND^sMataix-Cols^nD#Psychometric properties
 of the Spanish version of the Obsessive-Compulsive Inventory-Revised in a non-c
linical sample^len#J Anxiety Disord#20050000#2005#19#8#893-903#20110000#aop-0211
.htm#0887-6185#J Anxiety Disord##
00698000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100018001040100
01500122012016700137030001700304065000900321064000500330031000300335032000200338
014000700340865000900347002001300356035001000369801001700379#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop-0211.htm#S#c#159#10#article#24#10#^rND^sGönne
r^nS#^rND^sLeonhart^nR#^rND^sEcker^nW#The Obsessive-Compulsive Inventory-Revised
 (OCI-R): validation of the German version in a sample of patients with OCD, anx
iety disorders, and depressive disorders^len#J Anxiety Disord#20080000#2008#22#4
#734-49#20110000#aop-0211.htm#0887-6185#J Anxiety Disord##
00672000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100017001030100
02200120010001900142012010700161030001600268065000900284064000500293031000300298
032000200301014000700303865000900310002001300319035001000332801001600342#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#c#160#11#article#24#11
#^rND^sSmári^nJ#^rND^sÓlason^nDT#^rND^sEypórsdóttir^nA#^rND^sFrölunde^nMB#Psycho
metric properties of the Obsessive Compulsive Inventory-Revised among Icelandic 
college students^len#Scand J Psychol#20070000#2007#48#2#127-33#20110000#aop-0211
.htm#0036-5564#Scand J Psychol##
00575000000000229000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850160017000880180143001050660
00900248062005200257065000900309064000500318865000900323002001300332#2011nahead#
V:\SciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#c#161#12#article#24#12#^rN
D^sTavares^nM#Entrevista clínica estruturada para diagnóstico dos Transtornos do
 Eixo I do DSM-IV: Edição do paciente, versão 2.0 (SCID-I/P, Versão 2.0)^lpt#Bra
sília#Instituto de Psicologia da Universidade de Brasília#19960000#1996#20110000
#aop-0211.htm##
00593000000000265000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850160016000880160018001040160
01600122016002000138018009100158066001500249062002700264065000900291064000500300
865000900305002001300314#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0
211.htm#S#c#162#13#article#24#13#^rND^sFirst^nMB#^rND^sSpitzer^nRL#^rND^sGibbon^
nM#^rND^sWilliams^nJBW#Structured clinical interview for DSM-IV axis I disorders
: clinician version (SCID-CV)^len#Washington^eDC#American Psychiatric Press#1997
0000#1997#20110000#aop-0211.htm##
00646000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850160017000880160021001050160
01800126016002000144016002000164016001700184016001500201016001600216018008800232
065000900320064000500329865000900334002001300343#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop-0211.htm#S#c#163#14#article#24#14#^rND^sAsbahr^nFR#^rND^s
Lotufo Neto^nF#^rND^sTurecki^nGX#^rND^sDel Porto^nJA#^rND^sRodríguez^nLR#^rND^sB
aruzzi^nM#^rND^sLima^nMA#^rND^sGentil^nV#Escala Yale-Brown de Sintomas Obsessivo
-Compulsivos: tradução brasileira, São Paulo^lpt#19920000#1992#20110000#aop-0211
.htm##
00776000000000361000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100016001060100
02000122010001600142010002200158010001500180010001900195010001800214012008400232
03000190031606500090033506400050034403100030034903200030035201400080035586500090
0363002001300372035001000385801001900395#2011nahead#V:\SciELO\serial\rbp\2011nah
ead\markup\aop-0211.htm#S#c#164#15#article#24#15#^rND^sGoodman^nWK#^rND^sPrice^n
LH#^rND^sRasmussen^nSA#^rND^sMazure^nC#^rND^sFleischmann^nRL#^rND^sHill^nCL#^rND
^sHeninger^nGR#^rND^sCharney^nDS#The Yale-Brown Obsessive-Compulsive Scale: I. D
evelopment, use, and reliability^len#Arch Gen Psychiatr#19890000#1989#46#11#1006
-11#20110000#aop-0211.htm#0003-990X#Arch Gen Psychiatr##
00644000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100017001080120
13200125030002000257065000900277064000500286031000300291032000200294014000600296
865000900302002001300311035001000324801002000334#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop-0211.htm#S#c#165#16#article#24#16#^rND^sGorenstein^nC#^rN
D^sAndrade^nL#Validation of a Portuguese version of the Beck Depression Inventor
y and the State-Trait Anxiety Inventory in Brazilian subjects^len#Braz J Med Bio
l Res#19960000#1996#29#4#453-7#20110000#aop-0211.htm#0100-879X#Braz J Med Biol R
es##
00619000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100015001030100
01900118010001400137010001800151012004200169030002000211065000900231064000500240
031000200245014000600247865000900253002001300262035001000275801002000285#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#c#166#17#article#24#17
#^rND^sBeck^nAT#^rND^sWard^nCH#^rND^sMendelson^nM#^rND^sMock^nJ#^rND^sEerbaugh^n
J#An inventory for measuring depression^len#Arch Gen Psychiatry#19610000#1961#4#
53-63#20110000#aop-0211.htm#0003-990X#Arch Gen Psychiatry##
00596000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100017001030100
01500120010001600135012007300151030002100224710000200245065000900247064000500256
031000300261032000200264014000600266865000900272002001300281#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop-0211.htm#S#c#167#18#article#24#18#^rND^sBeck^
nAT#^rND^sEpstein^nN#^rND^sBrown^nG#^rND^sSteer^nRA#An inventory for measuring c
linical anxiety: psychometric properties^len#J Consult Clin Psych#2#19880000#198
8#56#6#893-7#20110000#aop-0211.htm##
00634000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100019001030100
01700122012009300139030002100232065000900253064000500262031000400267032000200271
014000600273865000900279002001300288035001000301801002100311#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop-0211.htm#S#c#168#19#article#24#19#^rND^sBraga
^nD#^rND^sCordioli^nAV#^rND^sManfro^nGG#Cognitive-behavioral group therapy for o
bsessive-compulsive disorder: a 1 year follow-up^len#Acta Psychiatr Scand#200500
00#2005#112#3#180-6#20110000#aop-0211.htm#0001-690X#Acta Psychiatr Scand##
00787000000000361000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100015001070100
01600122010001600138010001600154010001800170010001700188010002000205012010100225
03000210032606500090034706400050035603100030036103200020036401400060036686500090
0372002001300381035001000394801002100404#2011nahead#V:\SciELO\serial\rbp\2011nah
ead\markup\aop-0211.htm#S#c#169#20#article#24#20#^rND^sCordioli^nAV#^rND^sHeldt^
nE#^rND^sBochi^nDB#^rND^sMargis^nR#^rND^sSousa^nMB#^rND^sTonello^nJF#^rND^sManfr
o^nGG#^rND^sKapczinski^nF#Cognitive-behavioral group therapy in obsessive-compul
sive disorder: a randomized clinical trial^len#Psychother Psychosom#20030000#200
3#72#4#211-6#20110000#aop-0211.htm#0033-3190#Psychother Psychosom##
00688000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100017001040100
01900121010001700140010001900157012013500176030001300311710000200324065000900326
064000500335031000300340032000200343014000700345865000900352002001300361#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#c#170#21#article#24#21
#^rND^sSousa^nMB#^rND^sIsolan^nLR#^rND^sOliveira^nRR#^rND^sManfro^nGG#^rND^sCord
ioli^nAV#A randomized clinical trial on cognitive-behavioral group therapy and s
ertraline in the treatment of obsessive-compulsive disorder^len#J Clin Psych#2#2
0060000#2006#67#7#1133-9#20110000#aop-0211.htm##
00765000000000361000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100015001070100
01600122010001600138010001600154010001700170010001800187010001900205010002000224
01200900024403000190033471000020035306500090035506400050036403100030036903200020
0372014000700374865000900381002001300390#2011nahead#V:\SciELO\serial\rbp\2011nah
ead\markup\aop-0211.htm#S#c#171#22#article#24#22#^rND^sCordioli^nAV#^rND^sHeldt^
nE#^rND^sBochi^nDB#^rND^sMargis^nR#^rND^sSousa^nMB#^rND^sJuliano^nF#^rND^sTonell
o^nJF#^rND^sTeruchkin^nB#^rND^sKapczinski^nF#Cognitive-behavioral group therapy 
in obsessive-compulsive disorder: a clinical trial^len#Rev Bras Psiquiatr#2#2002
0000#2002#24#3#113-20#20110000#aop-0211.htm##
00737000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100014001040100
01500118010002100133010001700154010001900171012015400190030001900344710000200363
06500090036506400050037403100030037903200020038201400050038486500090038900200130
0398#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0211.htm#S#c#172#23#a
rticle#24#23#^rND^sSouza^nFP#^rND^sFoa^nEB#^rND^sMeyer^nE#^rND^sNiederauer^nKG#^
rND^sRaffin^nAL#^rND^sCordioli^nAV#Obsessive-Compulsive Inventory and Obsessive-
Compulsive Inventory-Revised Scales: translation into Brazilian Portuguese and c
ross-cultural adaptation^len#Rev Bras Psiquiatr#2#20080000#2008#30#1#42-6#201100
00#aop-0211.htm##
00567000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100015001080100
01600123012006100139030001100200065000900211064000500220031000300225014000600228
865000900234002001300243035001000256801001100266#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop-0211.htm#S#c#173#24#article#24#24#^rND^sAbramowitz^nJ#^rN
D^sMcKay^nD#^rND^sTaylor^nS#Special series subtypes of obsessive-compulsive diso
rder^len#Behav Ther#20050000#2005#36#367-9#20110000#aop-0211.htm#0005-7894#Behav
 Ther##
00284000000000169000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790910009000810920007000900020013000977030
00400110#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#o#1#1#
article#1#20110302#145853#aop-0311.htm#248##
05318000000000685000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000500099038000400104121000300108049000300111158000300114
03000220011703200060013906500090014501400070015403500100016122300090017101201900
01800120192003700100032005620100029005940100036006230100029006590100025006880700
08800713070009400801070008500895083156900980085001002549085003802559085003202597
08500390262908500270266808500240269508316450271908500100436408500540437408500330
44280850042044610850027045030850027045301170008045570720003045651120009045681110
01504577114000904592113001804601002001304619#2011nahead#V:\SciELO\serial\rbp\201
1nahead\markup\aop-0311.htm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#04#nd#n
d#Rev. Bras. Psiquiatr.#ahead#20110000#^f0^l0#1516-4446#20110311#Brief motivatio
nal interview and educational brochure in emergency room settings for adolescent
s and young adults with alcohol related problems: a randomized single blind clin
ical trial^len#Intervenção motivacional breve e brochura educacional em pronto-s
ocorro para adolescentes e adultos jovens com problemas relacionados ao álcool: 
um ensaio clínico simples cego randomizado^lpt#^rND^1A01^nMaria Luiza^sSegatto#^
rND^1A02^nSolange^sAndreoni#^rND^1A02^nRebeca de^sSouza e Silva#^rND^1A03^nAless
andra^sDiehl#^rND^1A03^nIlana^sPinsky#Universidade Federal de Uberlândia^iA01^1C
ompulsion Care Sector^cUberlândia^sMG^pBrazil#Universidade Federal de São Paulo^
iA02^1Preventive Medicine Department^cSão Paulo^sSP^pBrazil#Universidade Federal
 de São Paulo^iA03^1Psychiatry Department^cSão Paulo^sSP^pBrazil#^len^aOBJECTIVE
: To evaluate the effectiveness of brief motivational interviewing and an educat
ional brochure when delivered in emergency room to reduce alcohol abuse and rela
ted problems among adolescents and young adults. METHOD: a randomized single bli
nd clinical trial with a 3 month follow-up was carried out at three emergency ro
oms from October 2004 to November 2005; subjects assessed were 16-25 years old t
reated for alcohol related events up to 6 hours after consumption. Socio-demogra
phic data, quantity, frequency and negative consequences of alcohol consumption,
 motivation to change habits and future risk preception were evaluated. Statisti
cal analysis was performed on subjects who completed follow up (completers). ANC
OVA model was used to analyze the difference between the intervention groups wit
h statistical significance level &#945; = 5% and Confidence Interval (CI) 95%. R
ESULTS: 186 subjects formed the initial sample, being n = 175 included and rando
mized to educational brochure group (n = 88) or motivational interviewing group 
(n = 87). Follow-up assessment was performed in 85.2% sample. No significant dif
ference between groups was observed. However, significant reductions (p < 0.01) 
in related problems and alcohol abuse were found in both groups. CONCLUSION: In 
this sample a reduction of alcohol use and related problems was observed. Prelim
inary data indicates that controlled clinical trials with motivational interview
ing, educational brochure and nonintervention should be of future interest among
 Brazilian adolescent population.#^ddecs^i1#^tm^len^kAlcohol related disorders^i
1#^tm^len^kCrisis intervention^i1#^tm^len^kEmergency medical services^i1#^tm^len
^kClinical trial^i1#^tm^len^kYoung adult^i1#^lpt^aOBJETIVO: Avaliar a efetividad
e da entrevista motivacional breve e de uma brochura educativa quando aplicadas 
em prontos-socorros para reduzir o abuso e problemas relacionados ao álcool entr
e os jovens. MÉTODO: Um ensaio clínico randomizado simples-cego com três meses d
e seguimento foi realizado em três prontos-socorros de outubro de 2004 a novembr
o de 2005, com indivíduos de 16-25 anos tratados por eventos relacionados ao álc
ool com até 6 horas após o consumo. Dados sociodemográficos, quantidade, frequên
cia e consequências negativas, motivação para mudanças de hábitos e percepção pa
ra riscos do consumo de álcool foram avaliados. A análise estatística foi realiz
ada em indivíduos que completaram o seguimento (completados). Modelo de ANCOVA f
oi utilizado para analisar a diferença entre os grupos de intervenção, com nível
 de significância estatística &#945; = 5% e intervalo de confiança (IC) 95%. RES
ULTADOS: 186 indivíduos formaram a amostra inicial, sendo n =175 incluídos e ran
domizados para brochura educativa (n = 88) ou grupo entrevista motivacional brev
e (n = 87). O seguimento de avaliação foi realizado em 85,2% da amostra. Não foi
 observada diferença significativa entre os grupos. No entanto, uma redução sign
ificativa (p < 0,01) em problemas relacionados eo abuso de álcool foram encontra
dos em ambos os grupos. CONCLUSÃO: Nesta amostra, a redução do abuso de álcool e
 problemas relacionados foi observada. Dados preliminares indicam que os ensaios
 clínicos controlados com entrevista motivacional breve, brochura educativa e nã
o-intervenção deveriam ser de futuro interesse entre a população adolescente bra
sileira.#^ddecs^i2#^tm^lpt^kTranstornos relacionados ao uso de álcool^i2#^tm^lpt
^kIntervenção na crise^i2#^tm^lpt^kServiços médicos de emegência^i2#^tm^lpt^kEns
aio clínico^i2#^tm^lpt^kAdultos jovens^i2#vancouv#40#20100327#March 27, 2010#201
01129#November 29, 2010#aop-0311.htm##
05408000000000685000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000500099038000400104121000300108049000300111158000300114
03000220011703200060013906500090014501400070015403500100016122300090017101202040
01800120206003840100032005900100029006220100036006510100029006870100025007160700
08800741070009400829070008500923083160001008085001002608085003802618085003202656
08500390268808500270272708500240275408316760277808500100445408500540446408500330
45180850042045510850027045930850027046201170008046470720003046551120009046581110
01504667114000904682113001804691002001304709#2011nahead#V:\SciELO\serial\rbp\201
1nahead\markup\aop-0311.htm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#04#nd#n
d#Rev. Bras. Psiquiatr.#ahead#20110000#^f0^l0#1516-4446#20110311#<b>Brief motiva
tional interview and educational brochure in emergency room settings for adolesc
ents and young adults with alcohol related problems</b>: <b>a randomized single 
blind clinical trial</b>^len#<b>Intervenção motivacional breve e brochura educac
ional em pronto-socorro para adolescentes e adultos jovens com problemas relacio
nados ao álcool</b>: <b>um ensaio clínico simples cego randomizado</b>^lpt#^rND^
1A01^nMaria Luiza^sSegatto#^rND^1A02^nSolange^sAndreoni#^rND^1A02^nRebeca de^sSo
uza e Silva#^rND^1A03^nAlessandra^sDiehl#^rND^1A03^nIlana^sPinsky#Universidade F
ederal de Uberlândia^iA01^1Compulsion Care Sector^cUberlândia^sMG^pBrazil#Univer
sidade Federal de São Paulo^iA02^1Preventive Medicine Department^cSão Paulo^sSP^
pBrazil#Universidade Federal de São Paulo^iA03^1Psychiatry Department^cSão Paulo
^sSP^pBrazil#^len^a<b>OBJECTIVE:</b> To evaluate the effectiveness of brief moti
vational interviewing and an educational brochure when delivered in emergency ro
om to reduce alcohol abuse and related problems among adolescents and young adul
ts. <b>METHOD:</b> a randomized single blind clinical trial with a 3 month follo
w-up was carried out at three emergency rooms from October 2004 to November 2005
; subjects assessed were 16-25 years old treated for alcohol related events up t
o 6 hours after consumption. Socio-demographic data, quantity, frequency and neg
ative consequences of alcohol consumption, motivation to change habits and futur
e risk preception were evaluated. Statistical analysis was performed on subjects
 who completed follow up (completers). ANCOVA model was used to analyze the diff
erence between the intervention groups with statistical significance level &#945
; = 5% and Confidence Interval (CI) 95%. <b>RESULTS:</b> 186 subjects formed the
 initial sample, being n = 175 included and randomized to educational brochure g
roup (n = 88) or motivational interviewing group (n = 87). Follow-up assessment 
was performed in 85.2% sample. No significant difference between groups was obse
rved. However, significant reductions (p &lt; 0.01) in related problems and alco
hol abuse were found in both groups. <b>CONCLUSION:</b> In this sample a reducti
on of alcohol use and related problems was observed. Preliminary data indicates 
that controlled clinical trials with motivational interviewing, educational broc
hure and nonintervention should be of future interest among Brazilian adolescent
 population.#^ddecs^i1#^tm^len^kAlcohol related disorders^i1#^tm^len^kCrisis int
ervention^i1#^tm^len^kEmergency medical services^i1#^tm^len^kClinical trial^i1#^
tm^len^kYoung adult^i1#^lpt^a<b>OBJETIVO:</b> Avaliar a efetividade da entrevist
a motivacional breve e de uma brochura educativa quando aplicadas em prontos-soc
orros para reduzir o abuso e problemas relacionados ao álcool entre os jovens. <
b>MÉTODO:</b> Um ensaio clínico randomizado simples-cego com três meses de segui
mento foi realizado em três prontos-socorros de outubro de 2004 a novembro de 20
05, com indivíduos de 16-25 anos tratados por eventos relacionados ao álcool com
 até 6 horas após o consumo. Dados sociodemográficos, quantidade, frequência e c
onsequências negativas, motivação para mudanças de hábitos e percepção para risc
os do consumo de álcool foram avaliados. A análise estatística foi realizada em 
indivíduos que completaram o seguimento (completados). Modelo de ANCOVA foi util
izado para analisar a diferença entre os grupos de intervenção, com nível de sig
nificância estatística &#945; = 5% e intervalo de confiança (IC) 95%. <b>RESULTA
DOS:</b> 186 indivíduos formaram a amostra inicial, sendo n =175 incluídos e ran
domizados para brochura educativa (n = 88) ou grupo entrevista motivacional brev
e (n = 87). O seguimento de avaliação foi realizado em 85,2% da amostra. Não foi
 observada diferença significativa entre os grupos. No entanto, uma redução sign
ificativa (p &lt; 0,01) em problemas relacionados eo abuso de álcool foram encon
trados em ambos os grupos. <b>CONCLUSÃO:</b> Nesta amostra, a redução do abuso d
e álcool e problemas relacionados foi observada. Dados preliminares indicam que 
os ensaios clínicos controlados com entrevista motivacional breve, brochura educ
ativa e não-intervenção deveriam ser de futuro interesse entre a população adole
scente brasileira.#^ddecs^i2#^tm^lpt^kTranstornos relacionados ao uso de álcool^
i2#^tm^lpt^kIntervenção na crise^i2#^tm^lpt^kServiços médicos de emegência^i2#^t
m^lpt^kEnsaio clínico^i2#^tm^lpt^kAdultos jovens^i2#vancouv#40#20100327#March 27
, 2010#20101129#November 29, 2010#aop-0311.htm##
05491000000000709000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790640007000810710003000880400003000910010
00600094042000200100120000400102038000500106038000400111121000300115049000300118
15800030012103000210012403200060014506500090015101400070016003500100016722300090
01770120190001860120192003760100032005680100029006000100036006290100029006650100
02500694070009000719070009600809070008700905083159000992085001002582085003802592
08500320263008500390266208500270270108500240272808316720275208500100442408500540
44340850033044880850042045210850027045630850027045901170008046170720003046251120
00904628111001504637114000904652113001804661002001304679008008904692#2011nahead#
V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#l#4#1#article#1#^a2011#oa#
en#br1.1#1#4.0#ilus#tab#04#nd#nd#Rev. bras. psiquiatr#ahead#20110000#^f0^l0#1516
-4446#20110311#Brief motivational interview and educational brochure in emergenc
y room settings for adolescents and young adults with alcohol related problems: 
a randomized single blind clinical trial^len#Intervenção motivacional breve e br
ochura educacional em pronto-socorro para adolescentes e adultos jovens com prob
lemas relacionados ao álcool: um ensaio clínico simples cego randomizado^lpt#^rN
D^1A01^nMaria Luiza^sSegatto#^rND^1A02^nSolange^sAndreoni#^rND^1A02^nRebeca de^s
Souza e Silva#^rND^1A03^nAlessandra^sDiehl#^rND^1A03^nIlana^sPinsky#^iA01^1Unive
rsidade Federal de Uberlândia^2Compulsion Care Sector^cUberlândia^sMG^pBrazil#^i
A02^1Universidade Federal de São Paulo^2Preventive Medicine Department^cSão Paul
o^sSP^pBrazil#^iA03^1Universidade Federal de São Paulo^2Psychiatry Department^cS
ão Paulo^sSP^pBrazil#^len^aOBJECTIVE: To evaluate the effectiveness of brief mot
ivational interviewing and an educational brochure when delivered in emergency r
oom to reduce alcohol abuse and related problems among adolescents and young adu
lts. METHOD: a randomized single blind clinical trial with a 3 month follow-up w
as carried out at three emergency rooms from October 2004 to November 2005; subj
ects assessed were 16-25 years old treated for alcohol related events up to 6 ho
urs after consumption. Socio-demographic data, quantity, frequency and negative 
consequences of alcohol consumption, motivation to change habits and future risk
 preception were evaluated. Statistical analysis was performed on subjects who c
ompleted follow up (completers). ANCOVA model was used to analyze the difference
 between the intervention groups with statistical significance level &#945; = 5 
percent and Confidence Interval (CI) 95 percent. RESULTS: 186 subjects formed th
e initial sample, being n = 175 included and randomized to educational brochure 
group (n = 88) or motivational interviewing group (n = 87). Follow-up assessment
 was performed in 85.2 percent sample. No significant difference between groups 
was observed. However, significant reductions (p < 0.01) in related problems and
 alcohol abuse were found in both groups. CONCLUSION: In this sample a reduction
 of alcohol use and related problems was observed. Preliminary data indicates th
at controlled clinical trials with motivational interviewing, educational brochu
re and nonintervention should be of future interest among Brazilian adolescent p
opulation.#^ddecs^i1#^tm^len^kAlcohol related disorders^i1#^tm^len^kCrisis inter
vention^i1#^tm^len^kEmergency medical services^i1#^tm^len^kClinical trial^i1#^tm
^len^kYoung adult^i1#^lpt^aOBJETIVO: Avaliar a efetividade da entrevista motivac
ional breve e de uma brochura educativa quando aplicadas em prontos-socorros par
a reduzir o abuso e problemas relacionados ao álcool entre os jovens. MÉTODO: Um
 ensaio clínico randomizado simples-cego com três meses de seguimento foi realiz
ado em três prontos-socorros de outubro de 2004 a novembro de 2005, com indivídu
os de 16-25 anos tratados por eventos relacionados ao álcool com até 6 horas apó
s o consumo. Dados sociodemográficos, quantidade, frequência e consequências neg
ativas, motivação para mudanças de hábitos e percepção para riscos do consumo de
 álcool foram avaliados. A análise estatística foi realizada em indivíduos que c
ompletaram o seguimento (completados). Modelo de ANCOVA foi utilizado para anali
sar a diferença entre os grupos de intervenção, com nível de significância estat
ística &#945; = 5 por cento e intervalo de confiança (IC) 95 por cento. RESULTAD
OS: 186 indivíduos formaram a amostra inicial, sendo n =175 incluídos e randomiz
ados para brochura educativa (n = 88) ou grupo entrevista motivacional breve (n 
= 87). O seguimento de avaliação foi realizado em 85,2 por cento da amostra. Não
 foi observada diferença significativa entre os grupos. No entanto, uma redução 
significativa (p < 0,01) em problemas relacionados eo abuso de álcool foram enco
ntrados em ambos os grupos. CONCLUSÃO: Nesta amostra, a redução do abuso de álco
ol e problemas relacionados foi observada. Dados preliminares indicam que os ens
aios clínicos controlados com entrevista motivacional breve, brochura educativa 
e não-intervenção deveriam ser de futuro interesse entre a população adolescente
 brasileira.#^ddecs^i2#^tm^lpt^kTranstornos relacionados ao uso de álcool^i2#^tm
^lpt^kIntervenção na crise^i2#^tm^lpt^kServiços médicos de emegência^i2#^tm^lpt^
kEnsaio clínico^i2#^tm^lpt^kAdultos jovens^i2#vancouv#40#20100327#March 27, 2010
#20101129#November 29, 2010#aop-0311.htm#Internet^ihttp://www.scielo.br/scielo.p
hp?script=sci_arttext&pid=S1516-44462011005000004##
00535000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704029300083002001300376#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#5#1#article#204#<p><font siz
e="4" face="Verdana, Arial, Helvetica, sans-serif"><a name="ad1"></a><b>Brief mo
tivational interview and educational brochure in emergency room settings for ado
lescents and young adults with alcohol related problems: a randomized single bli
nd clinical trial</b></font></p>     ^cY#aop-0311.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#6#2#article#204#<p>&nbsp;</p
>     ^cY#aop-0311.htm##
00547000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704030500083002001300388#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#7#3#article#204#<p><font siz
e="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Interven&ccedil;&atilde;o 
motivacional breve e brochura educacional em pronto-socorro para adolescentes e 
adultos jovens com problemas relacionados ao &aacute;lcool: um ensaio cl&iacute;
nico simples cego randomizado</b></font></p>     ^cY#aop-0311.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#8#4#article#204#<p>&nbsp;</p
>     ^cY#aop-0311.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#9#5#article#204#<p>&nbsp;</p
>     ^cY#aop-0311.htm##
00493000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704025000084002001300334#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#10#6#article#204#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Maria Luiza Segatto<sup>I
</sup>; Solange Andreoni<sup>II</sup>; Rebeca de Souza e Silva<sup>II</sup>; Ale
ssandra Diehl<sup>III</sup>; Ilana Pinsky<sup>III</sup></b></font></p>     ^cY#a
op-0311.htm##
00426000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704018300084002001300267#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#11#7#article#204#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Compulsion Care 
Sector, Universidade Federal de Uberl&acirc;ndia (UFU), Uberl&acirc;ndia, MG, Br
azil    ^cY#aop-0311.htm##
00383000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704014000084002001300224#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#12#8#article#204#<br>   <sup
>II</sup>Preventive Medicine Department, Universidade Federal de S&atilde;o Paul
o (UNIFESP), S&atilde;o Paulo, SP, Brazil    ^cY#aop-0311.htm##
00387000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704014400084002001300228#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#13#9#article#204#<br>   <sup
>III</sup>Psychiatry Department, Universidade Federal de S&atilde;o Paulo (UNIFE
SP), S&atilde;o Paulo, SP, Brazil</font></p>     ^cY#aop-0311.htm##
00359000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011500085002001300200#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#14#10#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondenc
e</a></font></p>     ^cY#aop-0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#15#11#article#204#<p>&nbsp;<
/p>     ^cY#aop-0311.htm##
00288000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704004400085002001300129#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#16#12#article#204#<p>&nbsp;<
/p> <hr size="1" noshade>     ^cY#aop-0311.htm##
00342000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704009800085002001300183#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#17#13#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p> 
    ^cY#aop-0311.htm##
00540000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704029600085002001300381#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#18#14#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b> OBJECTIVE:</b> To evalu
ate the effectiveness of brief motivational interviewing and an educational broc
hure when delivered in emergency room to reduce alcohol abuse and related proble
ms among adolescents and young adults.    ^cY#aop-0311.htm##
01002000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704075800085002001300843#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#19#15#article#204#<br>   <b>
METHOD:</b> a randomized single blind clinical trial with a 3 month follow-up wa
s carried out at three emergency rooms from October 2004 to November 2005; subje
cts assessed were 16-25 years old treated for alcohol related events up to 6 hou
rs after consumption. Socio-demographic data, quantity, frequency and negative c
onsequences of alcohol consumption, motivation to change habits and future risk 
preception were evaluated. Statistical analysis was performed on subjects who co
mpleted follow up (completers). ANCOVA model was used to analyze the difference 
between the intervention groups with statistical significance level </font>&#945
;<font size="2" face="Verdana, Arial, Helvetica, sans-serif"> = 5% and Confidenc
e Interval (CI) 95%.    ^cY#aop-0311.htm##
00654000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704041000085002001300495#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#20#16#article#204#<br>   <b>
RESULTS:</b> 186 subjects formed the initial sample, being n = 175 included and 
randomized to educational brochure group (n = 88) or motivational interviewing g
roup (n = 87). Follow-up assessment was performed in 85.2% sample. No significan
t difference between groups was observed. However, significant reductions (p &lt
; 0.01) in related problems and alcohol abuse were found in both groups.    ^cY#
aop-0311.htm##
00566000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704032200085002001300407#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#21#17#article#204#<br>   <b>
CONCLUSION:</b> In this sample a reduction of alcohol use and related problems w
as observed. Preliminary data indicates that controlled clinical trials with mot
ivational interviewing, educational brochure and nonintervention should be of fu
ture interest among Brazilian adolescent population.</font></p>     ^cY#aop-0311
.htm##
00472000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704022800085002001300313#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#22#18#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Descriptors:</b> Alcohol
 related disorders; Crisis intervention; Emergency medical services; Clinical tr
ial; Young adult</font></p> <hr size="1" noshade>     ^cY#aop-0311.htm##
00340000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704009600085002001300181#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#23#19#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>   
  ^cY#aop-0311.htm##
00531000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704028700085002001300372#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#24#20#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>OBJETIVO:</b> Avaliar a 
efetividade da entrevista motivacional breve e de uma brochura educativa quando 
aplicadas em prontos-socorros para reduzir o abuso e problemas relacionados ao &
aacute;lcool entre os jovens.    ^cY#aop-0311.htm##
01227000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704098300085002001301068#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#25#21#article#204#<br>   <b>
M&Eacute;TODO:</b> Um ensaio cl&iacute;nico randomizado simples-cego com tr&ecir
c;s meses de seguimento foi realizado em tr&ecirc;s prontos-socorros de outubro 
de 2004 a novembro de 2005, com indiv&iacute;duos de 16-25 anos tratados por eve
ntos relacionados ao &aacute;lcool com at&eacute; 6 horas ap&oacute;s o consumo.
 Dados sociodemogr&aacute;ficos, quantidade, frequ&ecirc;ncia e consequ&ecirc;nc
ias negativas, motiva&ccedil;&atilde;o para mudan&ccedil;as de h&aacute;bitos e 
percep&ccedil;&atilde;o para riscos do consumo de &aacute;lcool foram avaliados.
 A an&aacute;lise estat&iacute;stica foi realizada em indiv&iacute;duos que comp
letaram o seguimento (completados). Modelo de ANCOVA foi utilizado para analisar
 a diferen&ccedil;a entre os grupos de interven&ccedil;&atilde;o, com n&iacute;v
el de signific&acirc;ncia estat&iacute;stica </font>&#945;<font size="2" face="V
erdana, Arial, Helvetica, sans-serif"> = 5% e intervalo de confian&ccedil;a (IC)
 95%.    ^cY#aop-0311.htm##
00758000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704051400085002001300599#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#26#22#article#204#<br>   <b>
RESULTADOS:</b> 186 indiv&iacute;duos formaram a amostra inicial, sendo n =175 i
nclu&iacute;dos e randomizados para brochura educativa (n = 88) ou grupo entrevi
sta motivacional breve (n = 87). O seguimento de avalia&ccedil;&atilde;o foi rea
lizado em 85,2% da amostra. N&atilde;o foi observada diferen&ccedil;a significat
iva entre os grupos. No entanto, uma redu&ccedil;&atilde;o significativa (p &lt;
 0,01) em problemas relacionados eo abuso de &aacute;lcool foram encontrados em 
ambos os grupos.    ^cY#aop-0311.htm##
00652000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704040800085002001300493#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#27#23#article#204#<br>   <b>
CONCLUS&Atilde;O:</b> Nesta amostra, a redu&ccedil;&atilde;o do abuso de &aacute
;lcool e problemas relacionados foi observada. Dados preliminares indicam que os
 ensaios cl&iacute;nicos controlados com entrevista motivacional breve, brochura
 educativa e n&atilde;o-interven&ccedil;&atilde;o deveriam ser de futuro interes
se entre a popula&ccedil;&atilde;o adolescente brasileira.</font></p>     ^cY#ao
p-0311.htm##
00543000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704029900085002001300384#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#28#24#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Descritores:</b> Transto
rnos relacionados ao uso de &aacute;lcool; Interven&ccedil;&atilde;o na crise; S
ervi&ccedil;os m&eacute;dicos de emeg&ecirc;ncia; Ensaio cl&iacute;nico; Adultos
 jovens</font></p> <hr size="1" noshade>     ^cY#aop-0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#29#25#article#204#<p>&nbsp;<
/p>     ^cY#aop-0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#30#26#article#204#<p>&nbsp;<
/p>     ^cY#aop-0311.htm##
00346000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010200085002001300187#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#31#27#article#204#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Introduction</b></font><
/p>     ^cY#aop-0311.htm##
00668000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704042400085002001300509#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#32#28#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Scientific evidence support
s that Emergency Room (ER) is an important site for identifying individuals with
 alcohol related  problems and to initiate an intervention.<sup>1,2</sup> Adoles
cents with alcohol related incidents and a positive history of problematic  drin
king represent a high-risk subgroup which deserves  attention.<sup>3</sup></font
></p>     ^cY#aop-0311.htm##
00838000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704059400085002001300679#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#33#29#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Adolescents with drinking p
roblems are at greater risk for several complications such as increase in the ri
sk of injuries, violence, school dropout, drunk driving and unprotected sex amon
g other harmful situations.<sup>4-6</sup> Alcohol consumption may also be relate
d to mood disorder, self harm and suicide.<sup>7</sup> Association between early
 alcohol abuse and facilitated access to alcohol in this group increases the pro
bability of adopting heavier patterns of alcohol abuse in the adulthood.<sup>8</
sup></font></p>     ^cY#aop-0311.htm##
01485000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704124100085002001301326#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#34#30#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Therapeutic interventions f
or substance abuse have been effective in reducing alcohol abuse in adolescents 
and young adults<sup>7-9</sup> intervention conduction for this specific populat
ion in ER is a "window of opportunities", especially for risk groups, which, due
 to a series of factors, would hardly seek help. Grenard et al., reviewed 17 cli
nical studies reported in the literature on brief motivational interviewing (MI)
 applied to adolescents (ages 13 to 18 years) and young adults (ages 19 to 25 ye
ars) using alcohol or other psychoactive substances. This review revealed mixed 
findings for the efficacy of brief MI among these populations. However, in 29% o
f the studies (5 of 17), there was a clear advantage of the brief MI demonstrate
d compared to standard care or other programming.<sup>10</sup> Other authors hav
e also shown the effectiveness of the motivational intervention applied to young
sters and teenagers brought to ERs, as it reduces harm and alcohol consumption,<
sup>7,9,11</sup> effect size may decrease as length of follow-up increases.<sup>
2,9</sup> Behavior-oriented treatments have shown promising long-term effects.<s
up>10</sup></font></p>     ^cY#aop-0311.htm##
00585000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704034100085002001300426#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#35#31#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">There are few studies evalu
ating interventions in ER clinical settings to reduce adolescent alcohol abuse<s
up>7,8,11</sup> despite evidence of considerable prevalence (12% to 50%) of alco
hol related problems in the adolescent population admitted.<sup>3</sup></font></
p>     ^cY#aop-0311.htm##
00593000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704034900085002001300434#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#36#32#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A positive relation after t
he ER intervention visit and reduction of alcohol consumption seems to exist,<su
p>12,13</sup> however, ER visits by themselves may be stressful enough as to red
uce alcohol abuse pattern and hazardous behavior in the short-term.<sup>2</sup><
/font></p>     ^cY#aop-0311.htm##
00719000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704047500085002001300560#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#37#33#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Studies indicate that brief
 MI may be effective among harmful drinking adolescents and young adults in the 
reduction of alcohol consumption and negative consequences.<sup>14,15</sup> Comp
onents common to successful brief MI include one-on-one sessions and feedback on
 substance abuse. Interviewer empathy has shown to be an essential component in 
studies in adult populations.<sup>14,16</sup></font></p>     ^cY#aop-0311.htm##
01212000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704096800085002001301053#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#38#34#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A randomized controlled tri
al with follow-up assessments at 6 and 12 months were carried out by Monti el al
. with a total of 198 (18-24-year-old) patients who were either alcohol positive
 upon hospital admission or met screening criteria for alcohol problems were ass
igned randomly to receive a one-session of MI that included personalized feedbac
k, or the personalized feedback report only. All participants received additiona
l telephone contact 1 month and 3 months after baseline. Six months after the in
tervention MI participants drank on fewer days, had fewer heavy drinking days an
d drank fewer drinks per week in the past months when compared to non MI group.<
sup>13</sup> Other authors have also shown the effectiveness of the motivational
 intervention applied to adults, youngsters and teenagers brought to ERs, as it 
reduces harm and alcohol consumption.<sup>9,10,13,14</sup></font></p>     ^cY#ao
p-0311.htm##
00616000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704037200085002001300457#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#39#35#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Brief interventions are als
o known to be effective in changing substance abuse and other health-hazardous b
ehaviors. Motivational counseling skills to encourage reduction in alcohol consu
mption compose brief interventions which are time-limited and focused on behavio
r change.<sup>17</sup></font></p>     ^cY#aop-0311.htm##
00985000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704074100085002001300826#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#40#36#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Alcohol abuse among young p
eople<sup>18,19</sup> associated to a lack of substantial effective intervention
s and studies designed for this population, justify the relevance and purpose of
 this clinical trial in Brazil.<sup>20,21</sup> Substantiating to the fact, main
ly in Brazil, that minimal interventions may have an important role from the pub
lic health standpoint when applied in emergency situations to extremely vulnerab
le populations such as adolescents.The authors hypothesis is that MI plus Educat
ion Brochure (EB), may be more effective than EB alone in reducing alcohol abuse
 by incorporating non confrontational concepts and interviewer empathy.</font></
p>     ^cY#aop-0311.htm##
00549000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704030500085002001300390#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#41#37#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">This clinical trial aims to
 evaluate the effectiveness of a brief motivational interviewing and an educatio
nal brochure when delivered in ER clinical settings to reduce alcohol abuse and 
related problems among adolescents.</font></p>     ^cY#aop-0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#42#38#article#204#<p>&nbsp;<
/p>     ^cY#aop-0311.htm##
00340000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704009600085002001300181#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#43#39#article#204#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Method</b></font></p>   
  ^cY#aop-0311.htm##
00351000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010700085002001300192#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#44#40#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>1. Ethical issues</b></f
ont></p>     ^cY#aop-0311.htm##
00673000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704042900085002001300514#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#45#41#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">This study was approved by 
the Universidade Federal de S&atilde;o Paulo (UNIFESP) and Universidade Federal 
de Uberl&acirc;ndia (UFU) Ethics Committee, protocol number 0767/04 and 104/03 r
espectively. All subjects signed an informed consent form and an authorization b
y the parents or legal guardians was requested for subjects under 18 years old.<
/font></p>     ^cY#aop-0311.htm##
00349000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010500085002001300190#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#46#42#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>2. Study design</b></fon
t></p>     ^cY#aop-0311.htm##
00414000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704017000085002001300255#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#47#43#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Single blind randomized cli
nical trial with 3 month follow-up assessment from baseline.</font></p>     ^cY#
aop-0311.htm##
00344000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010000085002001300185#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#48#44#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>3. Setting</b></font></p
>     ^cY#aop-0311.htm##
00808000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704056400085002001300649#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#49#45#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">The study was carried out a
t three ER settings (central, south and north) located at Uberl&acirc;ndia (630.
368 inhabitants, 135km<sup>2</sup>) in the southeast region of Brazil from Octob
er 2004 to November 2005.<sup>22</sup> These seven day a week, 24hr ERs provide 
assistance for adults and children with low or high complexity cases. They were 
selected as sites for this study in order to reduce selection bias which would h
ave resulted from specialized trauma center selection.</font></p>     ^cY#aop-03
11.htm##
00356000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011200085002001300197#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#50#46#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>4. Sample participants</
b></font></p>     ^cY#aop-0311.htm##
00452000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704020800085002001300293#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#51#47#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">All subjects were 16-25 yea
rs old treated for alcohol related events and admitted to ER up to 6 hours after
 last alcohol use.</font></p>     ^cY#aop-0311.htm##
00355000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011100085002001300196#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#52#48#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>5. Inclusion criteria</b
></font></p>     ^cY#aop-0311.htm##
00619000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704037500085002001300460#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#53#49#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">(1) Men or women, (2) 16-25
 years old, (3) screening criteria for recent alcohol consumption related to ER 
visit, within 6 hours prior to ER visit, (4) permanent residents in Uberl&acirc;
ndia, (5) volunteers in this clinical trial, (6) to be able to read or understan
d and sign consent forms.</font></p>     ^cY#aop-0311.htm##
00355000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011100085002001300196#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#54#50#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>6. Exclusion criteria</b
></font></p>     ^cY#aop-0311.htm##
00821000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704057700085002001300662#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#55#51#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">(1) Subjects without a perm
anent address in the city, (2) interview impossible due to severe physical condi
tion (e.g. unconscious or pain), (3) psychotic disorders or mentally challenged 
at clinical anamnesis evaluation, (4) evident cognitive damage at clinical anamn
esis evaluation, (5) subjects under arrest, (6) subjects being assisted or under
going treatment at addiction care centers, (7) refusal to participate or to sign
 consent form, (8) alcohol use more than 6 hours prior to ER visit.</font></p>  
   ^cY#aop-0311.htm##
00347000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010300085002001300188#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#56#52#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>7. Procedures</b></font>
</p>     ^cY#aop-0311.htm##
01379000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704113500085002001301220#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#57#53#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">The research team was forme
d by thre e trained psychologist junior researchers (post-graduate or Master stu
dents) and one senior psychologist. The junior researchers were responsible for 
screening and EB intervention. The senior psychologist was previously trained ac
cording to the MI principles first proposed by Miller and Rollnick,<sup>17</sup>
 and was responsible for MI intervention. During the data selection period junio
r researchers alternated shifts 24 hours a day, seven days a week. A pilot trial
 previous to the beginning of the research protocol carried out with eleven subj
ects. A screening questionnaire (four multiple choice questions elaborated by re
searchers on alcohol consumption within 6 hours prior to ER visit) was applied t
o subjects aged 16 to 25 treated at ER services through patient self-report and 
information from family members and caregivers in order to detect if the medical
 visit was associated with alcohol consumption. Positive case subjects were invi
ted to participate after being submitted to routine medical care.</font></p>    
 ^cY#aop-0311.htm##
00687000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704044300085002001300528#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#58#54#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Eligible subjects were rand
omized at baseline to one of two groups: motivational interviewing group (MI) pl
us educational brochure group (EB) or EB alone. A lottery system was employed an
d it was performed by ER personnel not linked to the clinical trial in order to 
avoid selection bias (<a href="/img/revistas/rbp/2011nahead/aop-0311fig01.jpg">F
igure 1</a>).</font></p>     ^cY#aop-0311.htm##
00883000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704063900085002001300724#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#59#55#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Discharging patients from t
he ER was contingent on clinical status improvement it is important to note that
 patients were no longer under the influence of alcohol at intervention implemen
tation time, Tradu&ccedil;&atilde;o do portugu&ecirc;s para ingl&ecirc;s, assure
d by both the permenence time in intervention setting, in general more than 6 ho
urs, and by clinical evaluation by the physician doctor. Interventions took plac
e at different times from admission to ER, due to individual clinical factors. P
atients were blinded to the intervention applied.</font></p>     ^cY#aop-0311.ht
m##
00677000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704043300085002001300518#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#60#56#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Groups were invited to a fo
llow-up assessment three months after baseline, when the instruments were applie
d by an independent researcher. This means the person who conducted the follow-u
p was not a baseline recruiter or interventionist, nor was intervention conditio
n masked.If return visit was not possible, a home visit or interview call was ma
de.</font></p>     ^cY#aop-0311.htm##
01595000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704135100085002001301436#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#61#57#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">The EB group received an in
formative general guidance consisting of three pages on the risks of alcohol con
sumption and possible ways or "tips" to consider reduction or to avoid problems 
related to alcohol abuse (e.g. "have fun without drink, avoid drinking competiti
ons, think about the establishing a limit and what was expected from drinking").
 It was read by the patient and discussed with the psychologist Junior researche
rs. Procedure duration was 5 minutes maximum.The MI group received a single 45-m
inute motivational session. Motivational interviewing uses a number of person-ce
ntered techniques to create a favorable climate for change. There are five gener
al principles which underlie motivational interviewing: roll with resistance, ex
press empathy, avoid argumentation, develop discrepancy and support self-efficac
y. This method is intended to help subjects develop skills and arguments in favo
r of change and encompasses the following elements: to evaluate and present the 
results, to offer information and guidance, to remove barriers, to counsel and e
ncourage reflection, to establish a plan for change and follow-up plan developme
nt.<sup>11</sup> After the MI session, participants also received the informativ
e brochure, which was read and discussed.</font></p>     ^cY#aop-0311.htm##
00359000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011500085002001300200#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#62#58#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>8. Socio-demographic dat
a</b></font></p>     ^cY#aop-0311.htm##
01237000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704099300085002001301078#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#63#59#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Data were collect on age, g
ender, educational level, ethnicity, marital status, reason for ER visit. <i>S</
i>emi-structured clinical interviewing from SCID-1/P (version 2.0) exploring the
 issues of use, abuse and dependence of psychoactive substances and not the enti
re instrument was used according to the DSM-IV diagnosis criteria (4th revised e
dition of the Diagnostic and Statistical Manual of Mental Disorders). The module
 is composed by 16 questions, divided into 3 areas: episodic use, abuse and depe
ndence. According to DSM-IV operational criteria, the alcohol dependence syndrom
e comprises a group of cognitive behavioral and physiological disturbances, in t
he last 12 months. The presence of 3 or more symptoms in the period fulfils alco
hol dependence diagnosis criteria. Otherwise it is diagnosed as harmful behavior
 or use episode. Agreement of this structured interview (Kappa = 0.6).<sup>23</s
up></font></p>     ^cY#aop-0311.htm##
00358000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011400085002001300199#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#64#60#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>9. Main outcome measures
</b></font></p>     ^cY#aop-0311.htm##
00722000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704047800085002001300563#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#65#61#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">- Alcohol Consumption Quest
ionnaire (ACQ): 8 questions which evaluate the pattern of alcohol consumption ov
er the previous three months, considering the number of abstinent days, and amou
nt of alcohol consumed. This questionnaire classifies subjects in four categorie
s; abstainers, lighter (One to 4 units/day), moderate (5 to 9 units/day) and hea
vy drinkers (10 or more units/day).<sup>24</sup></font></p>     ^cY#aop-0311.htm
##
01058000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704081400085002001300899#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#66#62#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">- Rutgers Alcohol Problem I
ndex (RAPI): unidimensional, 23-item scale which is a popular measure of alcohol
-related problems in adolescent studies.<sup>25</sup> It evaluates drinking beha
vior and negative consequences associated with alcohol abuse in the previous 3 m
onths. Response to items may range from 0 to 4 (0 = none, 1 = 1-2 times, 2 = 3-4
 times, 3 = 6-10 times, 4 = more than 10 times). The scores range from 0 to 92 p
oints. The internal scale consistency for this sample is 0.92 (high).<sup>26</su
p> This scale has been validated in many countries and was adapted as a structur
ed interview in Brazil from an adolescent university student sample in order to 
measure the negative consequences of alcohol abuse.<sup>27</sup></font></p>     
^cY#aop-0311.htm##
00830000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704058600085002001300671#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#67#63#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">- Alcohol Consumption Risk 
Questionnaire (ACRQ): 15 items developed by researchers to complement informatio
n about the risks associated with alcohol abuse, related to four domains: traffi
c violations (6 questions), police involvement (3 questions), physical health (3
 questions) and sexuality (3 questions). Responses may range from 0 to 4 (0 = no
ne, 1 = 1-2 times, 2 = 3-4 times, 3 = 6-10 times, 4 = more than 10 times). It is
 not a validated scale. Cronbach's alpha for this sample is 0.44 (moderate).</fo
nt></p>     ^cY#aop-0311.htm##
00827000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704058300085002001300668#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#68#64#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">- Alcohol Perception of Ris
k Assessment (APRA): 16 items developed to investigate the perception of future 
risks associated with excessive alcohol ingestion considering that the pattern o
f alcohol abuse does not change within 3 months. Response to the items may range
 from 1 to 7 (1 = highly improbable, 2 = moderately improbable, 3 = slightly imp
robable, 4 = neutral, 5 = slightly probable, 6 = moderately probable, 7 = highly
 probable).<sup>28</sup> Cronbach's alpha for this sample is 0.90 (high).</font>
</p>     ^cY#aop-0311.htm##
00649000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704040500085002001300490#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#69#65#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">- Readiness to Change Quest
ionnaire (RTCQ): 12 items about the motivational stage to change behavior. Subje
cts were classified into one of three status categories: precontemplation, conte
mplation and action. Each question answered in a likert scale of 5 points.<sup>2
9</sup> Cronbach's alpha for this sample is 0.29 (low).</font></p>     ^cY#aop-0
311.htm##
00351000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010700085002001300192#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#70#66#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>10. Data analyses</b></f
ont></p>     ^cY#aop-0311.htm##
01846000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704160200085002001301687#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#71#67#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Analyses were performed to 
subjects who completed the process ("completers"). A total mean score was comput
ed for each scale analyzed in the following manner: the sum of the individual it
em responses divided by the number of item questions result was used to calculat
e total mean scores of RAPI and APRA scales. Final mean scores of ACRQ scale wer
e calculated as the total mean from the mean of each domain. In this way, the to
tal mean scores presented are in the same value range as the original scale used
. All the answers to questionnaire items were analyzed but only the total scale 
score results are presented. Comparisons between the intervention groups regardi
ng categorical variables at baseline (socio-demographical data, general informat
ion on the medical intercurrence and SCID-1) were performed using </font>&#967;<
font size="2" face="Verdana, Arial, Helvetica, sans-serif"><sup>2</sup> tests. T
he <i>t</i> test for independent samples was used for mean comparison of numeric
 variables at baseline. Initially, a general regression model was used having as
 explanatory variables the type of intervention, the baseline value of the varia
ble and the interaction between the baseline value and intervention type. The in
teraction term was not significant in all models, so the comparisons of mean cha
nges from the baseline of ACQ, RAPI, ACRQ and APRA scales between the two groups
 were performed using ANCOVA (Analysis of Covariance) models which evaluated the
 final results in relation to baseline.<sup>30</sup></font></p>     ^cY#aop-0311
.htm##
00728000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704048400085002001300569#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#72#68#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Comparisons concerning chan
ges in RTCQ within each intervention group were performed through generalized Mc
Nemar test and between groups, the </font>&#967;<font size="2" face="Verdana, Ar
ial, Helvetica, sans-serif"><sup>2</sup> test. Statistical significance level us
ed was 0.05 (</font>&#945;<font size="2" face="Verdana, Arial, Helvetica, sans-s
erif"> = 5%) and confidence interval 95%.<sup>31</sup></font></p>     ^cY#aop-03
11.htm##
00478000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704023400085002001300319#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#73#69#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Information collected was s
tored in databases using Statistical Package for Social Sciences (SPSS) software
, version 13 (SPSS, Inc., Chicago, IL, USA).</font></p>     ^cY#aop-0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#74#70#article#204#<p>&nbsp;<
/p>     ^cY#aop-0311.htm##
00341000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704009700085002001300182#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#75#71#article#204#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Results</b></font></p>  
   ^cY#aop-0311.htm##
00349000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010500085002001300190#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#76#72#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>1. Participants</b></fon
t></p>     ^cY#aop-0311.htm##
00790000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704054600085002001300631#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#77#73#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A total of n = 186 subjects
 were eligible for the clinical trial, but n = 4 refused to participate due to p
hysical pain, fatigue or lack of interest and n= 7 did not meet inclusion criter
ia (<a href="/img/revistas/rbp/2011nahead/aop-0311fig01.jpg">Figure 1</a>). The 
randomized sample was n = 175 subjects (MI, n = 87; and EB, n = 88), age 21.8±2.
6 (mean±SD) years old (ranging from 16 to 25), most subjects were male (90.3%, n
 = 158) and single (72.6%; n = 127).</font></p>     ^cY#aop-0311.htm##
00346000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010200085002001300187#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#78#74#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>2. Drop outs</b></font><
/p>     ^cY#aop-0311.htm##
00682000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704043800085002001300523#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#79#75#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">From a total of 87 subjects
 randomized to the MI group, 13 subjects (14.9%) were not interviewed at the 3 m
onth follow-up visit. Reasons: address change (5 subjects, 5.8%), refusal to par
ticipate in the second interview (3 subjects, 3.5%), hospitalization due to alco
hol dependence treatment (2 subjects, 2.3%) and could not be located (3 subjects
, 3.5%).</font></p>     ^cY#aop-0311.htm##
00738000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704049400085002001300579#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#80#76#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">From a total of 88 subjects
 randomized to the EB group, 13 subjects (14.8%) were not interviewed at 3 month
 follow-up visit. The reasons were: address change (3 subjects, 3.4%), refusal t
o participate in the second interview (3 subjects, 3.4%), hospitalization due to
 alcohol dependence treatment (1 subject, 1.1%) and EB 15.38%, n = 2), could not
 be located (4 subjects, 4.5%) and in prison (2 subjects, 2.3%).</font></p>     
^cY#aop-0311.htm##
00366000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012200085002001300207#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#81#77#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>3. Baseline and follow-u
p return</b></font></p>     ^cY#aop-0311.htm##
00925000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704068100085002001300766#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#82#78#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Comparative analyses of soc
io-demographical data, reason for ER visit and frequency of disorders related to
 alcohol abuse and dependence (SCID) between two groups are shown in <a href="/i
mg/revistas/rbp/2011nahead/aop-0311tab01A.jpg">Table 1A</a>. No significant diff
erence between groups was found in relation to gender, ethnicity, marital status
, school status, reason for ER visit and SCID. No significant differences betwee
n groups were found in relation to age, RAPI, QRCA, and APRA total mean scores g
ender at baseline (<a href="/img/revistas/rbp/2011nahead/aop-0311tab01B.jpg">Tab
le 1b</a>).</font></p>     ^cY#aop-0311.htm##
00692000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704044800085002001300533#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#83#79#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Baseline subjects interview
ed at follow-up visit was 85.1% (n = 149).This was similar in the two groups &#9
1;EB, 85.2% (n = 75); and MI, 85.1% (n = 74); </font>&#967;<font size="2" face="
Verdana, Arial, Helvetica, sans-serif"><sup>2</sup> = 0.03; p = 0.8625&#93;. No 
difference between completers and non-completers was found regarding any baselin
e characteristics.</font></p>     ^cY#aop-0311.htm##
00350000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010600085002001300191#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#84#80#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>4. Main outcomes</b></fo
nt></p>     ^cY#aop-0311.htm##
00346000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010200085002001300187#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#85#81#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">1) Alcohol use days</font><
/p>     ^cY#aop-0311.htm##
00885000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704064100085002001300726#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#86#82#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">No significant difference w
as found between MI and EB groups regarding changes in alcoholic beverage intake
 at 3 month follow up. Groups changed equally as seen in <a href="/img/revistas/
rbp/2011nahead/aop-0311tab02.jpg">Table 2</a>. However, a decrease in consumptio
n was found at the 3 month follow up evaluation regarding days of alcohol use (-
10.0 days, p &lt; 0.01, 95% CI &#91;-13.9; -6.1&#93;), days with moderate use: (
-4.8 days, p &lt; 0.01, 95% CI &#91;-7.5; -2.0&#93;) and days with heavy use (-4
.5 days, p &lt; 0.01, 95% CI &#91;-7.5; -1.4&#93;).</font></p>     ^cY#aop-0311.
htm##
00334000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704009000085002001300175#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#87#83#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">2) RAPI</font></p>     ^cY#
aop-0311.htm##
00730000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704048600085002001300571#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#88#84#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><a href="/img/revistas/rbp/
2011nahead/aop-0311tab02.jpg">Table 2</a> shows the total mean scores of the RAP
I at 3 month follow up. The two groups had changed in the same way (p = 0.63). N
evertheless, when the time effect was evaluated, a significant reduction of nega
tive consequences (p &lt; 0.01) was observed, 3 months after the first interview
, in both groups (-0.38, 95% CI &#91;-0.49; -0.28&#93;).</font></p>     ^cY#aop-
0311.htm##
00334000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704009000085002001300175#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#89#85#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">3) QRCA</font></p>     ^cY#
aop-0311.htm##
00627000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704038300085002001300468#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#90#86#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Both groups changed equally
 (p = 0.09) during the 3 month follow up period. Regarding the effects of time, 
a significant reduction in the total score of negative consequences associated t
o alcohol use was found, similar in both groups at follow-up (-0.37, p &lt; 0.01
, 95% CI &#91;-0.42; -0.32&#93;).</font></p>     ^cY#aop-0311.htm##
00666000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704042200085002001300507#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#91#87#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">MI group and the EB changed
 equally (p = 0.54) after 3 months, as shown in <a href="/img/revistas/rbp/2011n
ahead/aop-0311tab02.jpg">Table 2</a>. However, different from the previous resul
ts, there was no significant long term change in risk perception associated with
 alcohol in either group (-0.07, p = 0.56, 95%CI &#91;-0.32; 0.17&#93;).</font><
/p>     ^cY#aop-0311.htm##
00334000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704009000085002001300175#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#92#88#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">4) RTCQ</font></p>     ^cY#
aop-0311.htm##
00779000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704053500085002001300620#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#93#89#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Analysis was performed by c
lassifying the subjects into the following motivational stages: pre-contemplatio
n, contemplation and action at the initial and 3 month follow up period. Compari
ng groups, no significant difference was found after 90 days (p = 0.90, <a href=
"#tab3">Table 3</a>). However, intra-group analysis was significant (MI p &lt; 0
.01 and BE p &lt; 0.01) as shown in <a href="/img/revistas/rbp/2011nahead/aop-03
11tab04.jpg">Table 4</a>.</font></p>     ^cY#aop-0311.htm##
00279000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003500085002001300120#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#94#90#article#204#<p><a name
="tab3"></a></p>     ^cY#aop-0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#95#91#article#204#<p>&nbsp;<
/p>     ^cY#aop-0311.htm##
00333000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008900085002001300174#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#96#92#article#204#<p align="
center"><img src="/img/revistas/rbp/2011nahead/aop-0311tab03.jpg"></p>     ^cY#a
op-0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#97#93#article#204#<p>&nbsp;<
/p>     ^cY#aop-0311.htm##
00344000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010000085002001300185#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#98#94#article#204#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Discussion</b></font></p
>     ^cY#aop-0311.htm##
00783000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704053900085002001300624#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#99#95#article#204#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">While brief motivational in
terventions for substance abuse have been widely tested, this is one of the firs
t randomized trials to be conducted in Brazil in ER clinical settings with a con
siderable sample size for adolescents and young adults, which may be considered 
difficult to reach.<sup>32-35</sup> Data from the 3-month follow up suggests tha
t intervention groups improved, but intervention effects were limited to differe
ntial reductions favoring MI.</font></p>     ^cY#aop-0311.htm##
00682000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704043700086002001300523#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#100#96#article#204#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">It may be suggested that o
ne of the circumstances that may have influenced this result is the fact that br
ief interventions designed in the literature usually target risk populations at 
an early stage of alcohol related problems.<sup>1,11</sup> Our sample was compos
ed of approximately 40% of alcohol dependents in each group (MI = 37.9% and EB =
 35.2%).</font></p>     ^cY#aop-0311.htm##
00613000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704036800086002001300454#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#101#97#article#204#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">MI alone does not seem abl
e to promote significant and lasting changes, especially when other vulnerabilit
ies may be interfering with the drinking behavior of these young people, such as
 social expectation of use and the easy access of alcoholic beverages such as it
 is in our country.</font></p>     ^cY#aop-0311.htm##
00755000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704051000086002001300596#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#102#98#article#204#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">Yet a high rate of subject
s in this trial completed the 3 month follow up. Drop out rates and compliance t
o interventions appears to be a problem in many studies, especially in the addic
tion field.<sup>36</sup> This very often compromises data extrapolation. It may 
be worth to mention on the fact that the proportion of males was quite high in t
his sample, as it tends to fall between 65 and 75% in other studies.<sup>37</sup
></font></p>     ^cY#aop-0311.htm##
00762000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704051700086002001300603#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#103#99#article#204#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">It is important to note th
at groups had significantly improved, observing more youths in action stage duri
ng the follow up period &#91;MI action stage 50% (final) vs. 13.5% (baseline) an
d EB action stage 46.7% (final) vs. 16.0% (baseline)&#93; which might be connect
ed to clinical implications for intervention. Any reduction in consumption direc
tly implicates on various risks associated with use within a harm reduction pers
pective.</font></p>     ^cY#aop-0311.htm##
00664000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704041800087002001300505#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#104#100#article#204#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">Furthermore, it may be th
at experiencing an alcohol-related ER visit itself was the trigger to modify sho
rt-term alcohol consumption. However, the fact we did not observe a significant 
reduction in problems related to alcohol consumption or relevant behavioral chan
ge may be associated with a short or not long enough observation time.</font></p
>     ^cY#aop-0311.htm##
01177000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704093100087002001301018#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#105#101#article#204#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">Encouraging results were 
found in another recent Brazilian study, a clinical Trial of brief intervention 
in 145 Brazilian college students deemed to be "risky" drinkers. Treated student
s had reduced the amount of alcohol abused per occasion after a 24-month follow-
up, and lowered Alcohol Abuse Disorder Identification Test (AUDIT) and RAPI scor
es in comparison with the non-intervention group.<sup>38</sup> These results rei
nforce the idea that brief intervention strategies may be an intervention option
 for youths. The fact that in this study a minimal intervention as the brochure 
was effective in reducing alcohol consumption deserves to be highlighted. These 
findings have implications on how alcohol related problems should be taken into 
consideration by public health officials, researches and emergency patient care 
protocols.<sup>39</sup></font></p>     ^cY#aop-0311.htm##
01450000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704120400087002001301291#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#106#102#article#204#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">The main limitation of th
is clinical trial was its exclusive reliance on self-report in evaluating interv
ention effects. Self-reports could be biased. The findings would have been enhan
ced if objective indices (e.g., hepatic function, blood alcohol concentration) o
r self-report corroboration (e.g., relative report) could have been obtained.<su
p>39</sup> Complementary exam was not performed because it would have led to an 
increase in costs. Our option was for a homogenous sample procedure in case a re
lative was not available at follow up assessment. Another limitation to mention 
is the lack of a placebo control group (nonintervention), which would have been 
more informative and may have brought more precise conclusions. The experimental
 intervention was implemented solely by one researcher. This may brings to the s
tudy bias issues as well as difficulty in separating intervention effect from th
erapist effect. Additional limitations worth to mention are: intent to treat ana
lyses were not conducted and only a 3 month follow-up when differential findings
 may emerge later as it has been shown in other studies.</font></p>     ^cY#aop-
0311.htm##
00841000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704059500087002001300682#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#107#103#article#204#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">In the long term the effe
ctiveness of brief intervention may deteriorate.<sup>40</sup> It would be approp
riate to test which components of MI are most responsible for maintaining long-t
erm changes, as well as efficacy predictors such as: gender, marital status, men
tal health and readiness to change. Data suggests that groups improved with brie
f intervention. Besides the limitations of this study, MI and EB are possible ap
proaches for young people with alcohol related problems who are treated in ER se
ttings.</font></p>     ^cY#aop-0311.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#108#104#article#204#<p>&nbsp
;</p>     ^cY#aop-0311.htm##
00346000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704010000087002001300187#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#109#105#article#204#<p><font
 size="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Conclusion</b></font><
/p>     ^cY#aop-0311.htm##
00574000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704032800087002001300415#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#110#106#article#204#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">In this sample a reductio
n of alcohol use and related problems was observed. This preliminary data indica
tes that controlled clinical trials with MI and non- intervention should be of f
uture interest among Brazilian adolescents and young adults.</font></p>     ^cY#
aop-0311.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#111#107#article#204#<p>&nbsp
;</p>     ^cY#aop-0311.htm##
00351000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704010500087002001300192#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#112#108#article#204#<p><font
 size="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Acknowledgement</b></f
ont></p>     ^cY#aop-0311.htm##
00483000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704023700087002001300324#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#113#109#article#204#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">To Professor Ronaldo Lara
njeira (UNIAD/UNIFESP): for his attention and cooperation in the running of this
 project, our sincere gratitude and appreciation.</font></p>     ^cY#aop-0311.ht
m##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#114#110#article#204#<p>&nbsp
;</p>     ^cY#aop-0311.htm##
00462000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704021600087002001300303#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#115#111#article#204#<p align
="center"><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><a href="/
img/revistas/rbp/2011nahead/aop-0311img01.jpg"><img src="/img/revistas/rbp/2011n
ahead/aop-0311img01tamb.jpg" border="0">    ^cY#aop-0311.htm##
00293000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704004700087002001300134#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#116#112#article#204#<br>   C
lick to enlarge</a></font></p>     ^cY#aop-0311.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#117#113#article#204#<p>&nbsp
;</p>     ^cY#aop-0311.htm##
00346000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704010000087002001300187#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#118#114#article#204#<p><font
 size="3" face="Verdana, Arial, Helvetica, sans-serif"><b>References</b></font><
/p>     ^cY#aop-0311.htm##
00548000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704028800089002001300377#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#119#115#article#
204#1#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">1. D'Onofri
o G, Degutis LC. Preventive care in the emergency department: screening and brie
f intervention for alcohol problems in the emergency department: a systematic re
view. <i>Acad Emerg Med.</i> 2002;9(6):627-38.    ^cY#aop-0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#120#116#article#204#</font><
/p>     ^cY#aop-0311.htm##
00498000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704023800089002001300327#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#121#117#article#
204#2#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Dauer AR
, Rubio ES, Coris ME, Valls JM. Brief intervention in alcohol-positive traffic c
asualties: is it worth the effort? <i>Alcohol Alcohol.</i> 2006;41(1):76-83.    
^cY#aop-0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#122#118#article#204#</font><
/p>     ^cY#aop-0311.htm##
00547000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704028700089002001300376#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#123#119#article#
204#3#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Nilsen P
, Baird J, Mello MJ, Nirenberg T, Woolard R, Bendtsen P, Longabaugh R. A systema
tic review of emergency care brief alcohol interventions for injury patients.<i>
 J Subst Abuse Treat.</i> 2008;35(2):184-201.    ^cY#aop-0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#124#120#article#204#</font><
/p>     ^cY#aop-0311.htm##
00474000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704021400089002001300303#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#125#121#article#
204#4#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Cherpite
l CJ. Alcohol and injuries: a review of international emergency room studies sin
ce 1995. <i>Drug Alcohol Rev.</i> 2007;26(2):201-14.    ^cY#aop-0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#126#122#article#204#</font><
/p>     ^cY#aop-0311.htm##
00566000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704030600089002001300395#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#127#123#article#
204#5#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Cherpite
l CJ, Ye Y. Drug use and problem drinking associated with primary care and emerg
ency room utilization in the US general population: data from the 2005 national 
alcohol survey. <i>Drug Alcohol Depend.</i> 2008;1;97(3):226-30.    ^cY#aop-0311
.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#128#124#article#204#</font><
/p>     ^cY#aop-0311.htm##
00562000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704030200089002001300391#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#129#125#article#
204#6#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Havard A
, Shakeshaft A, Sanson-Fisher R. Systematic review and meta-analyses of strategi
es targeting alcohol problems in emergency departments: interventions reduce alc
ohol related injuries. <i>Addiction.</i> 2008;103(3):368-76.    ^cY#aop-0311.htm
##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#130#126#article#204#</font><
/p>     ^cY#aop-0311.htm##
00490000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704023000089002001300319#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#131#127#article#
204#7#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Burke PJ
, O'Sullivan J, Vaughan BL. Adolescent substance use: brief interventions by eme
rgency care providers. <i>Pediatr Emerg Care</i>. 2005;21(11):770-6.    ^cY#aop-
0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#132#128#article#204#</font><
/p>     ^cY#aop-0311.htm##
00598000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704033800089002001300427#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#133#129#article#
204#8#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Spirito 
A, Monti PM, Barnett NP, Colby SM, Sindelar H, Rohsenow DJ, Lewander W, Myers M.
 A randomized clinical trial of a brief motivational intervention for alcohol-po
sitive adolescents treated in an emergency of department. <i>J Pediatr</i>. 2004
;145(3):396-402.    ^cY#aop-0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#134#130#article#204#</font><
/p>     ^cY#aop-0311.htm##
00551000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704029100089002001300380#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#135#131#article#
204#9#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Monti PM
, Barnett NP, Colby SM, Gwaltney CJ, Spirito A, Rohsenow DJ, Woolard R. Motivati
onal interviewing versus feedback only in emergency care for young adult problem
 drinking. <i>Addiction.</i> 2007;102(8):1234-43.    ^cY#aop-0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#136#132#article#204#</font><
/p>     ^cY#aop-0311.htm##
00515000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704025400090002001300344#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#137#133#article#
204#10#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Grenar
d JL, Ames SL, Pentz MA, Sussman S. Motivational interviewing with adolescents a
nd young adults for drug-related problems. <i>Int J Adolesc Med Health</i>. 2006
;18(1):53-67.    ^cY#aop-0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#138#134#article#204#</font><
/p>     ^cY#aop-0311.htm##
00522000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026100090002001300351#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#139#135#article#
204#11#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Tevyaw
 TO, Monti PM. Motivational enhancement and other brief interventions for adoles
cent substance abuse: foundations, applications and evaluations. <i>Addiction</i
>. 2004;99(2):63-75.    ^cY#aop-0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#140#136#article#204#</font><
/p>     ^cY#aop-0311.htm##
00472000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704021100090002001300301#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#141#137#article#
204#12#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Miller
 WR, Rollinick S. <i>Motivational interviewing: preparing people to change addic
tive behavior</i>. Guilford Press: New York; 1991.    ^cY#aop-0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#142#138#article#204#</font><
/p>     ^cY#aop-0311.htm##
00493000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704023200090002001300322#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#143#139#article#
204#13#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Cherpi
tel CJ, Borges GL, Wilcox HC. Acute alcohol use and suicidal behavior: a review 
of the literature. <i>Alcohol Clin Exp Res</i>. 2004;28(5 Suppl):18-28.    ^cY#a
op-0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#144#140#article#204#</font><
/p>     ^cY#aop-0311.htm##
00561000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704030000090002001300390#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#145#141#article#
204#14#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Jessor
 R, Costa FM, Krueger PM, Turbin MS. A developmental study of heavy episodic dri
nking among college students: the role of psychosocial and behavioral protective
 and risk factors. <i>J Stud Alcohol</i>. 2006;67(1):86-94.    ^cY#aop-0311.htm#
#
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#146#142#article#204#</font><
/p>     ^cY#aop-0311.htm##
00623000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704036200090002001300452#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#147#143#article#
204#15#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Carbal
lo JJ, Oquendo MA, Garcia-Moreno M, Poza B, Giner L, Baca E, Zalsman G, Roche AM
, Sher L. Demographic and clinical features of adolescents and young adults with
 alcohol related disorders admitted to the psychiatric emergency room. <i>Int J 
Adolesc Med Health.</i> 2006;18(1):87-96.    ^cY#aop-0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#148#144#article#204#</font><
/p>     ^cY#aop-0311.htm##
00537000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704027600090002001300366#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#149#145#article#
204#16#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Noto A
R. Os indices de consumo de psicotr&oacute;picos entre adolescentes no Brasil. I
n: Pinsky I, Bessa M, organizers. <i>Adolesc&ecirc;ncia e drogas</i>. S&atilde;o
 Paulo, SP: Editora Contexto; 2004.    ^cY#aop-0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#150#146#article#204#</font><
/p>     ^cY#aop-0311.htm##
00576000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704031500090002001300405#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#151#147#article#
204#17#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Saito 
MI. Adolesc&ecirc;ncia cultura e vulnerabilidade e risco. A preven&ccedil;&atild
e;o em quest&atilde;o. In: Saito MI, Silva LEV. <i>Adolesc&ecirc;ncia preven&cce
dil;&atilde;o e risco</i>. S&atilde;o Paulo: Editora Ateneu; 2001. p.33-8.    ^c
Y#aop-0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#152#148#article#204#</font><
/p>     ^cY#aop-0311.htm##
00443000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704018200090002001300272#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#153#149#article#
204#18#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Pinsky
 I, Laranjeira R. Alcohol in Brazil: recent public health aspects. <i>Addiction.
</i> 2005;100(2):264.    ^cY#aop-0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#154#150#article#204#</font><
/p>     ^cY#aop-0311.htm##
00526000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026500090002001300355#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#155#151#article#
204#19#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Instit
uto Brasileiro de Geografia e Estat&iacute;stica - IBGE. &#91;citado 18 jun 2009
&#93;. Dispon&iacute;vel em: <a href="http://www.ibge.gov.b" target="_blank">htt
p://www.ibge.gov.br</a>.    ^cY#aop-0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#156#152#article#204#</font><
/p>     ^cY#aop-0311.htm##
00488000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704022700090002001300317#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#157#153#article#
204#20#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Americ
an Psychiatric Association - APA. <i>Diagnostic and statistical manual of mental
 disorders.</i> 4th. ed. Text revision. Washington, DC: APA; 2000.    ^cY#aop-03
11.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#158#154#article#204#</font><
/p>     ^cY#aop-0311.htm##
00559000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029800090002001300388#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#159#155#article#
204#21#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Heland
er A, Tabakoff B. Biochemical markers of alcohol use and abuse: experiences from
 the pilot study of the WHO/ISBRA collaborative project on state and trait marke
rs of alcohol. <i>Alcohol Alcohol</i>. 1996;32(2):133-44.    ^cY#aop-0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#160#156#article#204#</font><
/p>     ^cY#aop-0311.htm##
00477000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704021600090002001300306#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#161#157#article#
204#22#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Earley
wine M, LaBrie JW, Pedersen ER. A brief rutgers alcohol problem index less poten
tial for bias. <i>Addict Behav</i>. 2008;33(9):1249-53.    ^cY#aop-0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#162#158#article#204#</font><
/p>     ^cY#aop-0311.htm##
00572000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704031100090002001300401#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#163#159#article#
204#23#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Formig
oni MLOS. Seguimento de avalia&ccedil;&atilde;o. In: Formigoni MLOS, organizador
. <i>A interven&ccedil;&atilde;o breve na depend&ecirc;ncia de drogas: a experi&
ecirc;ncia brasileira.</i> S&atilde;o Paulo: Contexto; 1992; p.108-18.    ^cY#ao
p-0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#164#160#article#204#</font><
/p>     ^cY#aop-0311.htm##
00486000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704022500090002001300315#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#165#161#article#
204#24#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">24. Marque
s ACPR, Furtado EF. Interven&ccedil;&otilde;es breves para problemas relacionado
s ao &aacute;lcool. <i>Rev Bras Psiquiatr</i>. 2004;26(1):28-32.    ^cY#aop-0311
.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#166#162#article#204#</font><
/p>     ^cY#aop-0311.htm##
00572000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704031100090002001300401#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#167#163#article#
204#25#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">25. Duthie
 LA, Baer JS, Marlatt GA. High risk status and personal risk perception for alco
hol problems among college students. Poster presented at the annual convention o
f the Association for Advancement of Behavior Therapy. New York; 1991.    ^cY#ao
p-0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#168#164#article#204#</font><
/p>     ^cY#aop-0311.htm##
00541000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704028000090002001300370#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#169#165#article#
204#26#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">26. Rollni
ck S, Heather N, Gold R, Hall W. Development of a short readiness to change' que
stionnaire for use in brief, opportunist interventions among excessive drinkers.
 <i>Br J Addict.</i> 1992;87(5):743-54.    ^cY#aop-0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#170#166#article#204#</font><
/p>     ^cY#aop-0311.htm##
00446000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704018500090002001300275#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#171#167#article#
204#27#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">27. Bussab
 WO, Morettin PB. <i>Estat&iacute;stica b&aacute;sica</i>. 4a ed. S&atilde;o Pau
lo: Atual Editora; 1993.    ^cY#aop-0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#172#168#article#204#</font><
/p>     ^cY#aop-0311.htm##
00524000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026300090002001300353#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#173#169#article#
204#28#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">28. Miller
 WR, Benefield RG, Tonigan JS. Enhancing motivation for change in problem drinki
ng: a controlled comparison of two therapist styles. <i>J Consult Clin Psychol</
i>. 1993;61(3):455-61.    ^cY#aop-0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#174#170#article#204#</font><
/p>     ^cY#aop-0311.htm##
00559000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029800090002001300388#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#175#171#article#
204#29#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">29. McCamb
ridge J, Slym RL, Strang J. Randomized controlled trial of motivational intervie
wing compared with drug information and advice for early intervention among youn
g cannabis users. <i>Addiction.</i> 2008;103(11):1809-18.    ^cY#aop-0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#176#172#article#204#</font><
/p>     ^cY#aop-0311.htm##
00524000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026300090002001300353#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#177#173#article#
204#30#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">30. Vasila
ki EI, Hosier SG, Cox WM. The efficacy of motivational interviewing as a brief i
ntervention for excessive drinking: a meta-analytic review. <i>Alcohol Alcohol.<
/i> 2006;41(3):328-35.    ^cY#aop-0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#178#174#article#204#</font><
/p>     ^cY#aop-0311.htm##
00600000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704033900090002001300429#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#179#175#article#
204#31#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">31. McCamb
ridge J, Strang J. The efficacy of single session motivational interviewing in r
educing drug consumption and perceptions of drug-related risk and harm among you
ng people: results from a multi-site cluster randomized trial. <i>Addiction</i>.
 2004;99(1):39-52.    ^cY#aop-0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#180#176#article#204#</font><
/p>     ^cY#aop-0311.htm##
00505000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704024400090002001300334#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#181#177#article#
204#32#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">32. Babor 
TF, Higgens-Biddle JC. Alcohol screening and brief intervention: dissemination s
trategies for medical practice and public health. <i>Addiction</i>. 2000;95:677-
86.    ^cY#aop-0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#182#178#article#204#</font><
/p>     ^cY#aop-0311.htm##
00480000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704021900090002001300309#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#183#179#article#
204#33#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">33. Ker K,
 Chinnock P. Interventions in the alcohol server setting for preventing injuries
. <i>Cochrane Database Syst Rev</i>. 2008;16:(3):CD005244.    ^cY#aop-0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#184#180#article#204#</font><
/p>     ^cY#aop-0311.htm##
00582000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704032100090002001300411#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#185#181#article#
204#34#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">34. Sim&at
ilde;o MO, Kerr-Corr&ecirc;a F, Smaira SI, Trinca LA, Floripes TM, Dalben I, Mar
tins RA, Oliveira JB, Cavariani MB, Tucci AM. Prevention of "risky" drinking amo
ng students at a Brazilian university. <i>Alcohol Alcohol</i>. 2008;43(4):470-6.
    ^cY#aop-0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#186#182#article#204#</font><
/p>     ^cY#aop-0311.htm##
00455000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704019400090002001300284#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#187#183#article#
204#35#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 35. Melon
i JN, Laranjeira R. The social and health burden of alcohol abuse. <i>Rev Bras P
siquiatr</i>. 2005;Suppl 1:S7-10.    ^cY#aop-0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#188#184#article#204#</font><
/p>     ^cY#aop-0311.htm##
00573000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704031200090002001300402#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#189#185#article#
204#36#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">36. Colby 
SM, Barnett NP, Eaton CA, Spirito A, Woolard R, Lewander W, Rohsenow DJ, Monti P
M. Potential biases in case detection of alcohol involvement among adolescents i
n an emergency department. <i>Pediatr Emerg Care</i>. 2002;18(5):350-4.    ^cY#a
op-0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#190#186#article#204#</font><
/p>     ^cY#aop-0311.htm##
00509000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704024800090002001300338#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#191#187#article#
204#37#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">37. Tripod
i SJ, Bender K, Litschge C, Vaughn MG. Interventions for reducing adolescent alc
ohol abuse: a meta-analytic review. <i>Arch Pediatr Adolesc Med</i>. 2010;164(1)
:85-91.    ^cY#aop-0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#192#188#article#204#</font><
/p>     ^cY#aop-0311.htm##
00529000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026800090002001300358#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#193#189#article#
204#38#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">38. Kelly 
TM, Donovan JE, Kinnane JM, Taylor DM. A comparison of alcohol screening instrum
ents among under-aged drinkers treated in emergency departments. <i>Alcohol Alco
hol</i>. 2002;37(5):444-50.    ^cY#aop-0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#194#190#article#204#</font><
/p>     ^cY#aop-0311.htm##
00587000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704032600090002001300416#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#195#191#article#
204#39#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">39. Kelly 
TM, Donovan JE, Chung T, Cook RL, Delbridge TR. Alcohol use disorders among emer
gency department-treated older adolescents: a new brief screen (RUFT-Cut) using 
the AUDIT, CAGE, CRAFFT, and RAPS-QF. <i>Alcohol Clin Exp Res</i>. 2004;28(5):74
6-53.    ^cY#aop-0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#196#192#article#204#</font><
/p>     ^cY#aop-0311.htm##
00526000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026500090002001300355#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#197#193#article#
204#40#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">40. McCamb
ridge J, Strang J. Deterioration over time in effect of Motivational Interviewin
g in reducing drug consumption and related risk among young people. <i>Addiction
</i>. 2005;100(4):470-8.    ^cY#aop-0311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#198#194#article#204#</font><
/p>     ^cY#aop-0311.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#199#195#article#204#<p>&nbsp
;</p>     ^cY#aop-0311.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#200#196#article#204#<p>&nbsp
;</p>     ^cY#aop-0311.htm##
00436000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704019000087002001300277#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#201#197#article#204#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href=
"#ad1"><img src="/img/revistas/rbp/2011nahead/seta.jpg" border="0"></a> <b>Corre
spondence:</b>    ^cY#aop-0311.htm##
00277000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704003100087002001300118#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#202#198#article#204#<br>   A
lessandra Diehl    ^cY#aop-0311.htm##
00295000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704004900087002001300136#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#203#199#article#204#<br>   R
. Botucatu, 394 - Vila Clementino    ^cY#aop-0311.htm##
00300000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704005400087002001300141#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#204#200#article#204#<br>   0
4038-001 S&atilde;o Paulo, SP, Brazil     ^cY#aop-0311.htm##
00290000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704004400087002001300131#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#205#201#article#204#<br>   P
hone/Fax: (+55 11) 5579-5643    ^cY#aop-0311.htm##
00344000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704009800087002001300185#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#206#202#article#204#<br>   E
mail: <a href="mailto:alediehl@terra.com.br">alediehl@terra.com.br</a></font></p
>     ^cY#aop-0311.htm##
00342000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704009600087002001300183#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#207#203#article#204#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">Submitted: March 27, 2010
    ^cY#aop-0311.htm##
00300000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704005400087002001300141#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#p#208#204#article#204#<br>   A
ccepted: November 29, 2010</font></p>     ^cY#aop-0311.htm##
00652000000000289000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100019000860100018001050120
15200123030001500275065000900290064000500299031000200304032000200306014000700308
865000900315002001300324035001000337801001500347#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop-0311.htm#S#c#209#1#article#40#1#^rND^sD'Onofrio^nG#^rND^s
Degutis^nLC#Preventive care in the emergency department: screening and brief int
ervention for alcohol problems in the emergency department: a systematic review^
len#Acad Emerg Med#20020000#2002#9#6#627-38#20110000#aop-0311.htm#1069-6563#Acad
 Emerg Med##
00640000000000313000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100016001020100
01600118010001600134012008700150030001600237065000900253064000500262031000300267
032000200270014000600272865000900278002001300287035001000300801001600310#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#c#210#2#article#40#2#^
rND^sDauer^nAR#^rND^sRubio^nES#^rND^sCoris^nME#^rND^sValls^nJM#Brief interventio
n in alcohol-positive traffic casualties: is it worth the effort?^len#Alcohol Al
cohol#20060000#2006#41#1#76-83#20110000#aop-0311.htm#0703-2951#Alcohol Alcohol##
00746000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100015001020100
01600117010001900133010001700152010001800169010002000187012009000207030002000297
06500090031706400050032603100030033103200020033401400080033686500090034400200130
0353035001000366801002000376#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\a
op-0311.htm#S#c#211#3#article#40#3#^rND^sNilsen^nP#^rND^sBaird^nJ#^rND^sMello^nM
J#^rND^sNirenberg^nT#^rND^sWoolard^nR#^rND^sBendtsen^nP#^rND^sLongabaugh^nR#A sy
stematic review of emergency care brief alcohol interventions for injury patient
s^len#J Subst Abuse Treat#20080000#2008#35#2#184-201#20110000#aop-0311.htm#0740-
5472#J Subst Abuse Treat##
00525000000000265000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100020000860120086001060300
01700192710000200209065000900211064000500220031000300225032000200228014000700230
865000900237002001300246#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0
311.htm#S#c#212#4#article#40#4#^rND^sCherpitel^nCJ#Alcohol and injuries: a revie
w of international emergency room studies since 1995^len#Drug Alcohol Rev#2#2007
0000#2007#26#2#201-14#20110000#aop-0311.htm##
00673000000000289000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100020000860100012001060120
16700118030002000285065000900305064000500314031000300319032000200322014000700324
865000900331002001300340035001000353801002000363#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop-0311.htm#S#c#213#5#article#40#5#^rND^sCherpitel^nCJ#^rND^
sYe^nY#Drug use and problem drinking associated with primary care and emergency 
room utilization in the US general population: data from the 2005 national alcoh
ol survey^len#Drug Alcohol Depend#20080000#2008#97#3#226-30#20110000#aop-0311.ht
m#0376-8716#Drug Alcohol Depend##
00679000000000301000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100020001020100
02300122012015300145030001000298065000900308064000500317031000400322032000200326
014000700328865000900335002001300344035001000357801001000367#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop-0311.htm#S#c#214#6#article#40#6#^rND^sHavard^
nA#^rND^sShakeshaft^nA#^rND^sSanson-Fisher^nR#Systematic review and meta-analyse
s of strategies targeting alcohol problems in emergency departments: interventio
ns reduce alcohol related injuries^len#Addiction#20080000#2008#103#3#368-76#2011
0000#aop-0311.htm#0965-2140#Addiction##
00616000000000301000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100020001020100
01800122012007800140030001900218065000900237064000500246031000300251032000300254
014000600257865000900263002001300272035001000285801001900295#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop-0311.htm#S#c#215#7#article#40#7#^rND^sBurke^n
PJ#^rND^sO'Sullivan^nJ#^rND^sVaughan^nBL#Adolescent substance use: brief interve
ntions by emergency care providers^len#Pediatr Emerg Care#20050000#2005#21#11#77
0-6#20110000#aop-0311.htm#0749-5161#Pediatr Emerg Care##
00805000000000361000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100016001030100
01800119010001600137010001800153010001900171010001800190010001500208012014000223
03000100036306500090037306400050038203100040038703200020039101400080039386500090
0401002001300410035001000423801001000433#2011nahead#V:\SciELO\serial\rbp\2011nah
ead\markup\aop-0311.htm#S#c#216#8#article#40#8#^rND^sSpirito^nA#^rND^sMonti^nPM#
^rND^sBarnett^nNP#^rND^sColby^nSM#^rND^sSindelar^nH#^rND^sRohsenow^nDJ#^rND^sLew
ander^nW#^rND^sMyers^nM#A randomized clinical trial of a brief motivational inte
rvention for alcohol-positive adolescents treated in an emergency of department^
len#J Pediatr#20040000#2004#145#3#396-402#20110000#aop-0311.htm#0022-3476#J Pedi
atr##
00740000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100018001020100
01600120010001900136010001700155010001900172010001700191012010200208030001000310
06500090032006400050032903100040033403200020033801400080034086500090034800200130
0357035001000370801001000380#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\a
op-0311.htm#S#c#217#9#article#40#9#^rND^sMonti^nPM#^rND^sBarnett^nNP#^rND^sColby
^nSM#^rND^sGwaltney^nCJ#^rND^sSpirito^nA#^rND^sRohsenow^nDJ#^rND^sWoolard^nR#Mot
ivational interviewing versus feedback only in emergency care for young adult pr
oblem drinking^len#Addiction#20070000#2007#102#8#1234-43#20110000#aop-0311.htm#0
965-2140#Addiction##
00665000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100015001060100
01600121010001700137012009000154030002500244065000900269064000500278031000300283
032000200286014000600288865000900294002001300303035001000316801002500326#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#c#218#10#article#40#10
#^rND^sGrenard^nJL#^rND^sAmes^nSL#^rND^sPentz^nMA#^rND^sSussman^nS#Motivational 
interviewing with adolescents and young adults for drug-related problems^len#Int
 J Adolesc Med Health#20060000#2006#18#1#53-67#20110000#aop-0311.htm#0334-0139#I
nt J Adolesc Med Health##
00621000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100016001050120
13300121030001000254065000900264064000500273031000300278032000200281014000600283
865000900289002001300298035001000311801001000321#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop-0311.htm#S#c#219#11#article#40#11#^rND^sTevyaw^nTO#^rND^s
Monti^nPM#Motivational enhancement and other brief interventions for adolescent 
substance abuse: foundations, applications and evaluations^len#Addiction#2004000
0#2004#99#2#63-75#20110000#aop-0311.htm#0965-2140#Addiction##
00503000000000241000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850160017000880160019001050180
07700124062001500201066000900216065000900225064000500234865000900239002001300248
#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#c#220#12#artic
le#40#12#^rND^sMiller^nWR#^rND^sRollinick^nS#Motivational interviewing: preparin
g people to change addictive behavior^len#Guilford Press#New York#19910000#1991#
20110000#aop-0311.htm##
00617000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100017001080100
01700125012007200142030002100214065000900235064000500244031000300249032000400252
014000600256865000900262002001300271035001000284801002100294#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop-0311.htm#S#c#221#13#article#40#13#^rND^sCherp
itel^nCJ#^rND^sBorges^nGL#^rND^sWilcox^nHC#Acute alcohol use and suicidal behavi
or: a review of the literature^len#Alcohol Clin Exp Res#20040000#2004#28#^s5#18-
28#20110000#aop-0311.htm#0145-6008#Alcohol Clin Exp Res##
00701000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100016001040100
01800120010001700138012014500155030001500300065000900315064000500324031000300329
032000200332014000600334865000900340002001300349035001000362801001500372#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#c#222#14#article#40#14
#^rND^sJessor^nR#^rND^sCosta^nFM#^rND^sKrueger^nPM#^rND^sTurbin^nMS#A developmen
tal study of heavy episodic drinking among college students: the role of psychos
ocial and behavioral protective and risk factors^len#J Stud Alcohol#20060000#200
6#67#1#86-94#20110000#aop-0311.htm#0096-882X#J Stud Alcohol##
00863000000000373000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100018001070100
02300125010001400148010001500162010001400177010001700191010001600208010001400224
01201440023803000250038206500090040706400050041603100030042103200020042401400060
0426865000900432002001300441035001000454801002500464#2011nahead#V:\SciELO\serial
\rbp\2011nahead\markup\aop-0311.htm#S#c#223#15#article#40#15#^rND^sCarballo^nJJ#
^rND^sOquendo^nMA#^rND^sGarcia-Moreno^nM#^rND^sPoza^nB#^rND^sGiner^nL#^rND^sBaca
^nE#^rND^sZalsman^nG#^rND^sRoche^nAM#^rND^sSher^nL#Demographic and clinical feat
ures of adolescents and young adults with alcohol related disorders admitted to 
the psychiatric emergency room^len#Int J Adolesc Med Health#20060000#2006#18#1#8
7-96#20110000#aop-0311.htm#0334-0139#Int J Adolesc Med Health##
00568000000000265000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880120072001030160
01700175016001600192018002700208066001400235062001700249065000900266064000500275
865000900280002001300289#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0
311.htm#S#c#224#16#article#40#16#^rND^sNoto^nAR#Os indices de consumo de psicotr
ópicos entre adolescentes no Brasil^lpt#^rORG^sPinsky^nI#^rORG^sBessa^nM#Adolesc
ência e drogas.^lpt#São Paulo^eSP#Editora Contexto#20040000#2004#20110000#aop-03
11.htm##
00591000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880120075001040160
01600179016001700195018003500212066001000247062001500257014000500272065000900277
064000500286865000900291002001300300#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop-0311.htm#S#c#225#17#article#40#17#^rND^sSaito^nMI#Adolescência cultur
a e vulnerabilidade e risco. A prevenção em questão^lpt#^rND^sSaito^nMI#^rND^sSi
lva^nLEV#Adolescência prevenção e risco^lpt#São Paulo#Editora Ateneu#33-8#200100
00#2001#20110000#aop-0311.htm##
00542000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100020001040120
05200124030001000176065000900186064000500195031000400200032000200204014000400206
865000900210002001300219035001000232801001000242#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop-0311.htm#S#c#226#18#article#40#18#^rND^sPinsky^nI#^rND^sL
aranjeira^nR#Alcohol in Brazil: recent public health aspects^len#Addiction#20050
000#2005#100#2#264#20110000#aop-0311.htm#0965-2140#Addiction##
00415000000000205000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850170048000881100009001361090
01900145037002300164865000900187002001300196#2011nahead#V:\SciELO\serial\rbp\201
1nahead\markup\aop-0311.htm#S#c#227#19#article#40#19#Instituto Brasileiro de Geo
grafia e Estatística#20090618#citado 18 jun 2009#http://www.ibge.gov.br#20110000
#aop-0311.htm##
00484000000000241000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850170039000880180058001270630
00200185066001500187062000400202065000900206064000500215865000900220002001300229
#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#c#228#20#artic
le#40#20#American Psychiatric Association - APA#Diagnostic and statistical manua
l of mental disorders^len#4#Washington^eDC#APA#20000000#2000#20110000#aop-0311.h
tm##
00664000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100018001060120
16000124030001600284065000900300064000500309031000300314032000200317014000700319
865000900326002001300335035001000348801001600358#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop-0311.htm#S#c#229#21#article#40#21#^rND^sHelander^nA#^rND^
sTabakoff^nB#Biochemical markers of alcohol use and abuse: experiences from the 
pilot study of the WHO/ISBRA collaborative project on state and trait markers of
 alcohol^len#Alcohol Alcohol#19960000#1996#32#2#133-44#20110000#aop-0311.htm#070
3-2951#Alcohol Alcohol##
00597000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100017001080100
01900125012006600144030001300210065000900223064000500232031000300237032000200240
014000800242865000900250002001300259035001000272801001300282#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop-0311.htm#S#c#230#22#article#40#22#^rND^sEarle
ywine^nM#^rND^sLaBrie^nJW#^rND^sPedersen^nER#A brief rutgers alcohol problem ind
ex less potential for bias^len#Addict Behav#20080000#2008#33#9#1249-53#20110000#
aop-0311.htm#0306-4603#Addict Behav##
00564000000000265000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100022000880120028001100160
02300138018007500161066001000236062000900246014000700255065000900262064000500271
865000900276002001300285#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0
311.htm#S#c#231#23#article#40#23#^rND^sFormigoni^nMLOS#Seguimento de avaliação^l
pt#^rORG^sFormigoni^nMLOS#A intervenção breve na dependência de drogas: a experi
ência brasileira^lpt#São Paulo#Contexto#108-18#19920000#1992#20110000#aop-0311.h
tm##
00534000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100018001080120
06200126030001900188710000200207065000900209064000500218031000300223032000200226
014000600228865000900234002001300243#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop-0311.htm#S#c#232#24#article#40#24#^rND^sMarques^nACPR#^rND^sFurtado^n
EF#Intervenções breves para problemas relacionados ao álcool^lpt#Rev Bras Psiqui
atr#2#20040000#2004#26#1#28-32#20110000#aop-0311.htm##
00616000000000253000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850160017000880160015001050160
01800120018009400138053007600232056001200308055001200320054000800332865000900340
002001300349#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#c#
233#25#article#40#25#^rND^sDuthie^nLA#^rND^sBaer^nJS#^rND^sMarlatt^nGA#High risk
 status and personal risk perception for alcohol problems among college students
^len#annual convention of the Association for Advancement of Behavior Therapy^i1
#New York^i1#19910000^i1#1991^i1#20110000#aop-0311.htm##
00678000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100017001060100
01400123010001400137012013100151030001200282065000900294064000500303031000300308
032000200311014000700313865000900320002001300329035001000342801001200352#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#c#234#26#article#40#26
#^rND^sRollnick^nS#^rND^sHeather^nN#^rND^sGold^nR#^rND^sHall^nW#Development of a
 short readiness to change' questionnaire for use in brief, opportunist interven
tions among excessive drinkers^len#Br J Addict#19920000#1992#87#5#743-54#2011000
0#aop-0311.htm#0952-0481#Br J Addict##
00463000000000253000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850160017000880160019001050180
02300124063000200147066001000149062001400159065000900173064000500182865000900187
002001300196#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#c#
235#27#article#40#27#^rND^sBussab^nWO#^rND^sMorettin^nPB#Estatística básica^lpt#
4#São Paulo#Atual Editora#19930000#1993#20110000#aop-0311.htm##
00654000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100020001050100
01800125012010500143030002300248065000900271064000500280031000300285032000200288
014000700290865000900297002001300306035001000319801002300329#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop-0311.htm#S#c#236#28#article#40#28#^rND^sMille
r^nWR#^rND^sBenefield^nRG#^rND^sTonigan^nJS#Enhancing motivation for change in p
roblem drinking: a controlled comparison of two therapist styles^len#J Consult C
lin Psychol#19930000#1993#61#3#455-61#20110000#aop-0311.htm#0022-006X#J Consult 
Clin Psychol##
00676000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100021000880100015001090100
01600124012015300140030001000293065000900303064000500312031000400317032000300321
014000800324865000900332002001300341035001000354801001000364#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop-0311.htm#S#c#237#29#article#40#29#^rND^sMcCam
bridge^nJ#^rND^sSlym^nRL#^rND^sStrang^nJ#Randomized controlled trial of motivati
onal interviewing compared with drug information and advice for early interventi
on among young cannabis users^len#Addiction#20080000#2008#103#11#1809-18#2011000
0#aop-0311.htm#0965-2140#Addiction##
00647000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100017001070100
01400124012011700138030001600255065000900271064000500280031000300285032000200288
014000700290865000900297002001300306035001000319801001600329#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop-0311.htm#S#c#238#30#article#40#30#^rND^sVasil
aki^nEI#^rND^sHosier^nSG#^rND^sCox^nWM#The efficacy of motivational interviewing
 as a brief intervention for excessive drinking: a meta-analytic review^len#Alco
hol Alcohol#20060000#2006#41#3#328-35#20110000#aop-0311.htm#0703-2951#Alcohol Al
cohol##
00699000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100021000880100016001090120
20700125030001000332065000900342064000500351031000300356032000200359014000600361
865000900367002001300376035001000389801001000399#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop-0311.htm#S#c#239#31#article#40#31#^rND^sMcCambridge^nJ#^r
ND^sStrang^nJ#The efficacy of single session motivational interviewing in reduci
ng drug consumption and perceptions of drug-related risk and harm among young pe
ople: results from a multi-site cluster randomized trial^len#Addiction#20040000#
2004#99#1#39-52#20110000#aop-0311.htm#0965-2140#Addiction##
00593000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100025001040120
11000129030001000239065000900249064000500258031000300263014000700266865000900273
002001300282035001000295801001000305#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop-0311.htm#S#c#240#32#article#40#32#^rND^sBabor^nTF#^rND^sHiggens-Biddl
e^nJC#Alcohol screening and brief intervention: dissemination strategies for med
ical practice and public health^len#Addiction#20000000#2000#95#677-86#20110000#a
op-0311.htm#0965-2140#Addiction##
00527000000000265000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100013000880100018001010120
07200119030002700191710000200218065000900220064000500229031000300234032000200237
865000900239002001300248#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0
311.htm#S#c#241#33#article#40#33#^rND^sKer^nK#^rND^sChinnock^nP#Interventions in
 the alcohol server setting for preventing injuries^len#Cochrane Database Syst R
ev#2#20080000#2008#16#3#20110000#aop-0311.htm##
00818000000000385000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100021001040100
01700125010001700142010001900159010001600178010001800194010001900212010002000231
01000160025101200760026703000160034306500090035906400050036803100030037303200020
0376014000600378865000900384002001300393035001000406801001600416#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#c#242#34#article#40#34#^rND^sS
imão^nMO#^rND^sKerr-Corrêa^nF#^rND^sSmaira^nSI#^rND^sTrinca^nLA#^rND^sFloripes^n
TM#^rND^sDalben^nI#^rND^sMartins^nRA#^rND^sOliveira^nJB#^rND^sCavariani^nMB#^rND
^sTucci^nAM#Prevention of "risky" drinking among students at a Brazilian univers
ity^len#Alcohol Alcohol#20080000#2008#43#4#470-6#20110000#aop-0311.htm#0703-2951
#Alcohol Alcohol##
00508000000000265000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100020001050120
05000125030001900175710000200194065000900196064000500205032000400210014000600214
865000900220002001300229#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0
311.htm#S#c#243#35#article#40#35#^rND^sMeloni^nJN#^rND^sLaranjeira^nR#The social
 and health burden of alcohol abuse^len#Rev Bras Psiquiatr#2#20050000#2005#^s1#S
7-10#20110000#aop-0311.htm##
00789000000000361000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100018001040100
01600122010001700138010001700155010001800172010001900190010001600209012010700225
03000190033206500090035106400050036003100030036503200020036801400060037086500090
0376002001300385035001000398801001900408#2011nahead#V:\SciELO\serial\rbp\2011nah
ead\markup\aop-0311.htm#S#c#244#36#article#40#36#^rND^sColby^nSM#^rND^sBarnett^n
NP#^rND^sEaton^nCA#^rND^sSpirito^nA#^rND^sWoolard^nR#^rND^sLewander^nW#^rND^sRoh
senow^nDJ#^rND^sMonti^nPM#Potential biases in case detection of alcohol involvem
ent among adolescents in an emergency department^len#Pediatr Emerg Care#20020000
#2002#18#5#350-4#20110000#aop-0311.htm#0749-5161#Pediatr Emerg Care##
00659000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100016001060100
01800122010001700140012008000157030002500237065000900262064000500271031000400276
032000200280014000600282865000900288002001300297035001000310801002500320#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#c#245#37#article#40#37
#^rND^sTripodi^nSJ#^rND^sBender^nK#^rND^sLitschge^nC#^rND^sVaughn^nMG#Interventi
ons for reducing adolescent alcohol abuse: a meta-analytic review^len#Arch Pedia
tr Adolesc Med#20100000#2010#164#1#85-91#20110000#aop-0311.htm#1072-4710#Arch Pe
diatr Adolesc Med##
00670000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100018001040100
01800122010001700140012010900157030001600266065000900282064000500291031000300296
032000200299014000700301865000900308002001300317035001000330801001600340#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#c#246#38#article#40#38
#^rND^sKelly^nTM#^rND^sDonovan^nJE#^rND^sKinnane^nJM#^rND^sTaylor^nDM#A comparis
on of alcohol screening instruments among under-aged drinkers treated in emergen
cy departments^len#Alcohol Alcohol#20020000#2002#37#5#444-50#20110000#aop-0311.h
tm#0703-2951#Alcohol Alcohol##
00751000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100018001040100
01500122010001500137010002000152012015300172030002100325065000900346064000500355
03100030036003200020036301400070036586500090037200200130038103500100039480100210
0404#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop-0311.htm#S#c#247#39#a
rticle#40#39#^rND^sKelly^nTM#^rND^sDonovan^nJE#^rND^sChung^nT#^rND^sCook^nRL#^rN
D^sDelbridge^nTR#Alcohol use disorders among emergency department-treated older 
adolescents: a new brief screen (RUFT-Cut) using the AUDIT, CAGE, CRAFFT, and RA
PS-QF^len#Alcohol Clin Exp Res#20040000#2004#28#5#746-53#20110000#aop-0311.htm#0
145-6008#Alcohol Clin Exp Res##
00625000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100021000880100016001090120
13200125030001000257065000900267064000500276031000400281032000200285014000600287
865000900293002001300302035001000315801001000325#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop-0311.htm#S#c#248#40#article#40#40#^rND^sMcCambridge^nJ#^r
ND^sStrang^nJ#Deterioration over time in effect of Motivational Interviewing in 
reducing drug consumption and related risk among young people^len#Addiction#2005
0000#2005#100#4#470-8#20110000#aop-0311.htm#0965-2140#Addiction##
00282000000000169000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780910009000800920007000890020012000967030
00400108#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#o#1#1#a
rticle#1#20110302#145906#aop0411.htm#218##
04654000000000661000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780710003000800400003000830010006000860420
00200092120000400094038000500098038000400103121000300107049000300110158000300113
03000220011603200060013806500090014401400070015303500100016022300090017001201240
01790120127003030100044004300100041004740700073005150700118005880831333007060850
01002039085002802049085002202077085003902099085003202138085003102170083144902201
08500100365008500300366008500240369008500400371408500370375408500300379105800220
38210580078038431170008039210720003039291120009039321110016039411140009039571130
01403966002001203980#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.h
tm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#01#nd#nd#Rev. Bras. Psiquiatr.#a
head#20110000#^f0^l0#1516-4446#20110311#Quality of life, diagnosis, and treatmen
t of patients with major depression: a prospective cohort study in primary care^
len#Qualidade de vida, diagnóstico e tratamento de pacientes com depressão maior
: uma coorte prospectiva em cuidados primários^lpt#^rND^1A01^nAna Flávia Barros 
da Silva^sLima#^rND^1A02^nMarcelo Pio de Almeida^sFleck#Universidade Federal do 
Rio Grande do Sul^iA01^cPorto Alegre^sRS^pBrazil#Universidade Federal do Rio Gra
nde do Sul^iA02^1Department of Legal Medicine and Psychiatry^cPorto Alegre^sRS^p
Brazil#^len^aOBJECTIVE: To describe the demographic and clinical characteristics
, adequacy of antidepressant treatment, and changes in quality of life of patien
ts with major depression receiving follow-up care from primary care centers. MET
HOD: A cohort study was performed in which major depression patients were follow
ed-up over a nine-month period. Several evaluation instruments were used, includ
ing the World Health Organization Quality of Life and the Quality of Life-Depres
sion, Centers for Epidemiologic Studies-Depression questionnaires. RESULTS: The 
sample comprised 179 individuals, mostly female (73%), with a mean age of 38 yea
rs and mean education of 9 years. At the end of the follow-up period, 42% of the
 individuals still presented with major depression, 25% had complete symptom rem
ission, and only 9% were properly treated with antidepressants. In relation to q
uality of life, there were significant differences especially between baseline a
nd after nine months in almost all measures. CONCLUSION: This study demonstrated
 that depressive symptoms are poorly recognized and that treatment is often inad
equate for patients followed-up in primary care units in the south of Brazil. Mo
st of the patients continued to have symptoms of depression over the nine-month 
period which were associated with impaired quality of life.#^ddecs^i1#^tm^len^kQ
uality of life^i1#^tm^len^kDiagnosis^i1#^tm^len^kDepressive disorder, major^i1#^
tm^len^kPrimary health care^i1#^tm^len^kSigns and symptoms^i1#^lpt^aOBJETIVO: De
screver o seguimento de usuários de serviços de cuidados primários com depressão
 maior em relação as suas características demográficas, clínicas, tratamento ant
idepressivo potencialmente adequado, assim como mudanças encontradas na qualidad
e de vida ao longo do acompanhamento. MÉTODO: Foi realizado um estudo de coorte,
 no qual os sujeitos com depressão maior foram acompanhados ao longo de nove mes
es. Foram incluídas diversas medidas de avaliação, como World Health Organizatio
n Quality of Life, Quality of Life-Depression, Centers for Epidemiologic Studies
- Depression Instrument, entre outras. RESULTADOS: A amostra foi constituída por
 179 sujeitos, a maioria do sexo feminino (73%), com uma idade média de 38 anos 
e 9 anos de escolaridade. Aos nove meses do estudo, 42% dos sujeitos ainda apres
entavam um quadro compatível com depressão maior, 25% com remissão completa dos 
sintomas e somente 9% foram tratados com antidepressivo de forma adequada. Em re
lação à qualidade de vida, ocorreu diferenças significativas principalmente entr
e o período de baseline e nove meses para quase todas as medidas. CONCLUSÃO: Est
e estudo demonstrou que pacientes com sintomas depressivos dificilmente são reco
nhecidos ou recebem tratamentos adequados em unidades de cuidados primários no s
ul do Brasil. A grande maioria dos pacientes permaneceu com sintomas depressivos
 ao longo dos nove meses, apresentando prejuízos na qualidade de vida.#^ddecs^i2
#^tm^lpt^kQualidade de vida^i2#^tm^lpt^kDiagnóstico^i2#^tm^lpt^kTranstorno depre
ssivo maior^i2#^tm^lpt^kAtenção primária à saúde^i2#^tm^lpt^kSinais e sintomas^i
2#Eli Lilly and Company#Hospital de Clínicas de Porto Alegre^dFundo de Incentivo
 à Pesquisa e Eventos#vancouv#42#20090830#August 30, 2009#20100720#July 20, 2010
#aop0411.htm##
04759000000000661000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780710003000800400003000830010006000860420
00200092120000400094038000500098038000400103121000300107049000300110158000300113
03000220011603200060013806500090014401400070015303500100016022300090017001201380
01790120141003170100044004580100041005020700073005430700118006160831361007340850
01002095085002802105085002202133085003902155085003202194085003102226083148402257
08500100374108500300375108500240378108500400380508500370384508500300388205800220
39120580092039341170008040260720003040341120009040371110016040461140009040621130
01404071002001204085#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.h
tm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#01#nd#nd#Rev. Bras. Psiquiatr.#a
head#20110000#^f0^l0#1516-4446#20110311#<b>Quality of life, diagnosis, and treat
ment of patients with major depression</b>: <b>a prospective cohort study in pri
mary care</b>^len#<b>Qualidade de vida, diagnóstico e tratamento de pacientes co
m depressão maior</b>: <b>uma coorte prospectiva em cuidados primários</b>^lpt#^
rND^1A01^nAna Flávia Barros da Silva^sLima#^rND^1A02^nMarcelo Pio de Almeida^sFl
eck#Universidade Federal do Rio Grande do Sul^iA01^cPorto Alegre^sRS^pBrazil#Uni
versidade Federal do Rio Grande do Sul^iA02^1Department of Legal Medicine and Ps
ychiatry^cPorto Alegre^sRS^pBrazil#^len^a<b>OBJECTIVE:</b> To describe the demog
raphic and clinical characteristics, adequacy of antidepressant treatment, and c
hanges in quality of life of patients with major depression receiving follow-up 
care from primary care centers. <b>METHOD:</b> A cohort study was performed in w
hich major depression patients were followed-up over a nine-month period. Severa
l evaluation instruments were used, including the World Health Organization Qual
ity of Life and the Quality of Life-Depression, Centers for Epidemiologic Studie
s-Depression questionnaires. <b>RESULTS:</b> The sample comprised 179 individual
s, mostly female (73%), with a mean age of 38 years and mean education of 9 year
s. At the end of the follow-up period, 42% of the individuals still presented wi
th major depression, 25% had complete symptom remission, and only 9% were proper
ly treated with antidepressants. In relation to quality of life, there were sign
ificant differences especially between baseline and after nine months in almost 
all measures. <b>CONCLUSION:</b> This study demonstrated that depressive symptom
s are poorly recognized and that treatment is often inadequate for patients foll
owed-up in primary care units in the south of Brazil. Most of the patients conti
nued to have symptoms of depression over the nine-month period which were associ
ated with impaired quality of life.#^ddecs^i1#^tm^len^kQuality of life^i1#^tm^le
n^kDiagnosis^i1#^tm^len^kDepressive disorder, major^i1#^tm^len^kPrimary health c
are^i1#^tm^len^kSigns and symptoms^i1#^lpt^a<b>OBJETIVO:</b> Descrever o seguime
nto de usuários de serviços de cuidados primários com depressão maior em relação
 as suas características demográficas, clínicas, tratamento antidepressivo poten
cialmente adequado, assim como mudanças encontradas na qualidade de vida ao long
o do acompanhamento. <b>MÉTODO:</b> Foi realizado um estudo de coorte, no qual o
s sujeitos com depressão maior foram acompanhados ao longo de nove meses. Foram 
incluídas diversas medidas de avaliação, como <i>World Health Organization Quali
ty of Life, Quality of Life-Depression, Centers for Epidemiologic Studies- Depre
ssion Instrument</i>, entre outras. <b>RESULTADOS:</b> A amostra foi constituída
 por 179 sujeitos, a maioria do sexo feminino (73%), com uma idade média de 38 a
nos e 9 anos de escolaridade. Aos nove meses do estudo, 42% dos sujeitos ainda a
presentavam um quadro compatível com depressão maior, 25% com remissão completa 
dos sintomas e somente 9% foram tratados com antidepressivo de forma adequada. E
m relação à qualidade de vida, ocorreu diferenças significativas principalmente 
entre o período de baseline e nove meses para quase todas as medidas. <b>CONCLUS
ÃO:</b> Este estudo demonstrou que pacientes com sintomas depressivos dificilmen
te são reconhecidos ou recebem tratamentos adequados em unidades de cuidados pri
mários no sul do Brasil. A grande maioria dos pacientes permaneceu com sintomas 
depressivos ao longo dos nove meses, apresentando prejuízos na qualidade de vida
.#^ddecs^i2#^tm^lpt^kQualidade de vida^i2#^tm^lpt^kDiagnóstico^i2#^tm^lpt^kTrans
torno depressivo maior^i2#^tm^lpt^kAtenção primária à saúde^i2#^tm^lpt^kSinais e
 sintomas^i2#Eli Lilly and Company#<i>Hospital de Clínicas de Porto Alegre</i>^d
<i>Fundo de Incentivo à Pesquisa e Eventos</i>#vancouv#42#20090830#August 30, 20
09#20100720#July 20, 2010#aop0411.htm##
04841000000000685000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780640007000800710003000870400003000900010
00600093042000200099120000400101038000500105038000400110121000300114049000300117
15800030012003000210012303200060014406500090015001400070015903500100016622300090
01760120124001850120127003090100044004360100041004800700075005210700120005960831
36100716085001002077085002802087085002202115085003902137085003202176085003102208
08314850223908500100372408500300373408500240376408500400378808500370382808500300
38650580022038950580078039171170008039950720003040031120009040061110016040151140
00904031113001404040002001204054008008904066#2011nahead#V:\SciELO\serial\rbp\201
1nahead\markup\aop0411.htm#S#l#4#1#article#1#^a2011#oa#en#br1.1#1#4.0#ilus#tab#0
1#nd#nd#Rev. bras. psiquiatr#ahead#20110000#^f0^l0#1516-4446#20110311#Quality of
 life, diagnosis, and treatment of patients with major depression: a prospective
 cohort study in primary care^len#Qualidade de vida, diagnóstico e tratamento de
 pacientes com depressão maior: uma coorte prospectiva em cuidados primários^lpt
#^rND^1A01^nAna Flávia Barros da Silva^sLima#^rND^1A02^nMarcelo Pio de Almeida^s
Fleck#^iA01^1Universidade Federal do Rio Grande do Sul^cPorto Alegre^sRS^pBrazil
#^iA02^1Universidade Federal do Rio Grande do Sul^2Department of Legal Medicine 
and Psychiatry^cPorto Alegre^sRS^pBrazil#^len^aOBJECTIVE: To describe the demogr
aphic and clinical characteristics, adequacy of antidepressant treatment, and ch
anges in quality of life of patients with major depression receiving follow-up c
are from primary care centers. METHOD: A cohort study was performed in which maj
or depression patients were followed-up over a nine-month period. Several evalua
tion instruments were used, including the World Health Organization Quality of L
ife and the Quality of Life-Depression, Centers for Epidemiologic Studies-Depres
sion questionnaires. RESULTS: The sample comprised 179 individuals, mostly femal
e (73 percent), with a mean age of 38 years and mean education of 9 years. At th
e end of the follow-up period, 42 percent of the individuals still presented wit
h major depression, 25 percent had complete symptom remission, and only 9 percen
t were properly treated with antidepressants. In relation to quality of life, th
ere were significant differences especially between baseline and after nine mont
hs in almost all measures. CONCLUSION: This study demonstrated that depressive s
ymptoms are poorly recognized and that treatment is often inadequate for patient
s followed-up in primary care units in the south of Brazil. Most of the patients
 continued to have symptoms of depression over the nine-month period which were 
associated with impaired quality of life.#^ddecs^i1#^tm^len^kQuality of life^i1#
^tm^len^kDiagnosis^i1#^tm^len^kDepressive disorder, major^i1#^tm^len^kPrimary he
alth care^i1#^tm^len^kSigns and symptoms^i1#^lpt^aOBJETIVO: Descrever o seguimen
to de usuários de serviços de cuidados primários com depressão maior em relação 
as suas características demográficas, clínicas, tratamento antidepressivo potenc
ialmente adequado, assim como mudanças encontradas na qualidade de vida ao longo
 do acompanhamento. MÉTODO: Foi realizado um estudo de coorte, no qual os sujeit
os com depressão maior foram acompanhados ao longo de nove meses. Foram incluída
s diversas medidas de avaliação, como World Health Organization Quality of Life,
 Quality of Life-Depression, Centers for Epidemiologic Studies- Depression Instr
ument, entre outras. RESULTADOS: A amostra foi constituída por 179 sujeitos, a m
aioria do sexo feminino (73 por cento), com uma idade média de 38 anos e 9 anos 
de escolaridade. Aos nove meses do estudo, 42 por cento dos sujeitos ainda apres
entavam um quadro compatível com depressão maior, 25 por cento com remissão comp
leta dos sintomas e somente 9 por cento foram tratados com antidepressivo de for
ma adequada. Em relação à qualidade de vida, ocorreu diferenças significativas p
rincipalmente entre o período de baseline e nove meses para quase todas as medid
as. CONCLUSÃO: Este estudo demonstrou que pacientes com sintomas depressivos dif
icilmente são reconhecidos ou recebem tratamentos adequados em unidades de cuida
dos primários no sul do Brasil. A grande maioria dos pacientes permaneceu com si
ntomas depressivos ao longo dos nove meses, apresentando prejuízos na qualidade 
de vida.#^ddecs^i2#^tm^lpt^kQualidade de vida^i2#^tm^lpt^kDiagnóstico^i2#^tm^lpt
^kTranstorno depressivo maior^i2#^tm^lpt^kAtenção primária à saúde^i2#^tm^lpt^kS
inais e sintomas^i2#Eli Lilly and Company#Hospital de Clínicas de Porto Alegre^d
Fundo de Incentivo à Pesquisa e Eventos#vancouv#42#20090830#August 30, 2009#2010
0720#July 20, 2010#aop0411.htm#Internet^ihttp://www.scielo.br/scielo.php?script=
sci_arttext&pid=S1516-44462011005000001##
00467000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704022700082002001200309#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#5#1#article#172#<p><font size
="4" face="Verdana, Arial, Helvetica, sans-serif"><a name="ad1"></a><b>Quality o
f life, diagnosis, and treatment of patients with major depression: a prospectiv
e cohort study in primary care</b></font></p>     ^cY#aop0411.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#6#2#article#172#<p>&nbsp;</p>
     ^cY#aop0411.htm##
00473000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704023300082002001200315#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#7#3#article#172#<p><font size
="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Qualidade de vida, diagn&oa
cute;stico e tratamento de pacientes com depress&atilde;o maior: uma coorte pros
pectiva em cuidados prim&aacute;rios</b></font></p>     ^cY#aop0411.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#8#4#article#172#<p>&nbsp;</p>
     ^cY#aop0411.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#9#5#article#172#<p>&nbsp;</p>
     ^cY#aop0411.htm##
00424000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704018300083002001200266#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#10#6#article#172#<p><font siz
e="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Ana Fl&aacute;via Barros d
a Silva Lima<sup>I</sup>; Marcelo Pio de Almeida Fleck<sup>II</sup></b></font></
p>     ^cY#aop0411.htm##
00433000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704019200083002001200275#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#11#7#article#172#<p><font siz
e="2" face="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Post-Graduate Psy
chiatry Program, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre
, RS, Brazil    ^cY#aop0411.htm##
00401000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704016000083002001200243#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#12#8#article#172#<br>   <sup>
II</sup>Department of Legal Medicine and Psychiatry, Universidade Federal do Rio
 Grande do Sul (UFRGS), Porto Alegre, RS, Brazil</font></p>     ^cY#aop0411.htm#
#
00356000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704011500083002001200198#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#13#9#article#172#<p><font siz
e="2" face="Verdana, Arial, Helvetica, sans-serif"><a href="#ad">Correspondence<
/a></font></p>     ^cY#aop0411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#14#10#article#172#<p>&nbsp;</
p>     ^cY#aop0411.htm##
00286000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704004400084002001200128#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#15#11#article#172#<p>&nbsp;</
p> <hr size="1" noshade>     ^cY#aop0411.htm##
00340000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009800084002001200182#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#16#12#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>ABSTRACT</b></font></p>  
   ^cY#aop0411.htm##
00544000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704030200084002001200386#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#17#13#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b> OBJECTIVE:</b> To descri
be the demographic and clinical characteristics, adequacy of antidepressant trea
tment, and changes in quality of life of patients with major depression receivin
g follow-up care from primary care centers.    ^cY#aop0411.htm##
00573000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704033100084002001200415#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#18#14#article#172#<br>   <b>M
ETHOD:</b> A cohort study was performed in which major depression patients were 
followed-up over a nine-month period. Several evaluation instruments were used, 
including the World Health Organization Quality of Life and the Quality of Life-
Depression, Centers for Epidemiologic Studies-Depression questionnaires.    ^cY#
aop0411.htm##
00721000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704047900084002001200563#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#19#15#article#172#<br>   <b>R
ESULTS:</b> The sample comprised 179 individuals, mostly female (73%), with a me
an age of 38 years and mean education of 9 years. At the end of the follow-up pe
riod, 42% of the individuals still presented with major depression, 25% had comp
lete symptom remission, and only 9% were properly treated with antidepressants. 
In relation to quality of life, there were significant differences especially be
tween baseline and after nine months in almost all measures.    ^cY#aop0411.htm#
#
00610000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704036800084002001200452#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#20#16#article#172#<br>   <b>C
ONCLUSION:</b> This study demonstrated that depressive symptoms are poorly recog
nized and that treatment is often inadequate for patients followed-up in primary
 care units in the south of Brazil. Most of the patients continued to have sympt
oms of depression over the nine-month period which were associated with impaired
 quality of life.</font></p>     ^cY#aop0411.htm##
00462000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704022000084002001200304#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#21#17#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Descriptors:</b> Quality 
of life; Diagnosis; Depressive disorder, major; Primary health care; Signs and s
ymptoms</font></p> <hr size="1" noshade>     ^cY#aop0411.htm##
00338000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009600084002001200180#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#22#18#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>    
 ^cY#aop0411.htm##
00680000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704043800084002001200522#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#23#19#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b> OBJETIVO:</b> Descrever 
o seguimento de usu&aacute;rios de servi&ccedil;os de cuidados prim&aacute;rios 
com depress&atilde;o maior em rela&ccedil;&atilde;o as suas caracter&iacute;stic
as demogr&aacute;ficas, cl&iacute;nicas, tratamento antidepressivo potencialment
e adequado, assim como mudan&ccedil;as encontradas na qualidade de vida ao longo
 do acompanhamento.    ^cY#aop0411.htm##
00626000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704038400084002001200468#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#24#20#article#172#<br>   <b>M
&Eacute;TODO:</b> Foi realizado um estudo de coorte, no qual os sujeitos com dep
ress&atilde;o maior foram acompanhados ao longo de nove meses. Foram inclu&iacut
e;das diversas medidas de avalia&ccedil;&atilde;o, como <i>World Health Organiza
tion Quality of Life, Quality of Life-Depression, Centers for Epidemiologic Stud
ies- Depression Instrument</i>, entre outras.    ^cY#aop0411.htm##
00840000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704059800084002001200682#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#25#21#article#172#<br>   <b>R
ESULTADOS:</b> A amostra foi constitu&iacute;da por 179 sujeitos, a maioria do s
exo feminino (73%), com uma idade m&eacute;dia de 38 anos e 9 anos de escolarida
de. Aos nove meses do estudo, 42% dos sujeitos ainda apresentavam um quadro comp
at&iacute;vel com depress&atilde;o maior, 25% com remiss&atilde;o completa dos s
intomas e somente 9% foram tratados com antidepressivo de forma adequada. Em rel
a&ccedil;&atilde;o &agrave; qualidade de vida, ocorreu diferen&ccedil;as signifi
cativas principalmente entre o per&iacute;odo de baseline e nove meses para quas
e todas as medidas.    ^cY#aop0411.htm##
00629000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704038700084002001200471#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#26#22#article#172#<br>   <b>C
ONCLUS&Atilde;O:</b> Este estudo demonstrou que pacientes com sintomas depressiv
os dificilmente s&atilde;o reconhecidos ou recebem tratamentos adequados em unid
ades de cuidados prim&aacute;rios no sul do Brasil. A grande maioria dos pacient
es permaneceu com sintomas depressivos ao longo dos nove meses, apresentando pre
ju&iacute;zos na qualidade de vida. </font></p>     ^cY#aop0411.htm##
00513000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704027100084002001200355#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#27#23#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Descritores:</b> Qualidad
e de vida; Diagn&oacute;stico; Transtorno depressivo maior; Aten&ccedil;&atilde;
o prim&aacute;ria &agrave; sa&uacute;de; Sinais e sintomas</font></p> <hr size="
1" noshade>     ^cY#aop0411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#28#24#article#172#<p>&nbsp;</
p>     ^cY#aop0411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#29#25#article#172#<p>&nbsp;</
p>     ^cY#aop0411.htm##
00344000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010200084002001200186#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#30#26#article#172#<p><font si
ze="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Introduction</b></font></
p>     ^cY#aop0411.htm##
00828000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704058600084002001200670#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#31#27#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">Recent studies with depresse
d patients in primary care settings have demonstrated that these patients have s
everal depression-related problems such as high rates of comorbidity, low functi
onal levels, and increased use of medical resources.<sup>1,2</sup> Despite their
 strong impact on the patients' lives, the recognition of depression-related pro
blems is still poor in the primary sector, where 50% to 60% of the cases are not
 detected and do not receive adequate and specific treatment.<sup>1-3</sup></fon
t></p>     ^cY#aop0411.htm##
00943000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704070100084002001200785#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#32#28#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">Several studies have demonst
rated the impact of depression on quality of life (QOL), with depressed patients
 displaying QOL impairments which are equal to or greater than those of patients
 with other chronic conditions.<sup>4-6</sup> Another relevant aspect of this as
sociation is that the severity of the depressive disorder affects all QOL dimens
ions, even when controlled for other variables such as age.<sup>7,8</sup> Althou
gh this association is well-established, most of the measures come from cross-se
ctional studies that do not permit an understanding of the causal relationship b
etween the variables involved.</font></p>     ^cY#aop0411.htm##
00786000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704054400084002001200628#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#33#29#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">There are few observational 
studies or clinical tests with antidepressants based on the longitudinal investi
gation of the associations between depression and QOL measures in primary care.<
sup>8-14</sup> There is evidence suggesting the existence of a time gap between 
changes in depressive symptoms and QOL measures. In other words, the improvement
 in symptoms and in quality of life do not occur simultaneously, but rather at d
ifferent times.<sup>8,13-15</sup></font></p>     ^cY#aop0411.htm##
00600000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704035800084002001200442#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#34#30#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">The objective of this study 
is to describe the characteristics of a sample of Brazilian individuals with maj
or depression seeking treatment in primary care units, as well as any changes in
 QOL over a nine-month follow-up period and its relation with antidepressant tre
atment.</font></p>     ^cY#aop0411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#35#31#article#172#<p>&nbsp;</
p>     ^cY#aop0411.htm##
00338000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009600084002001200180#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#36#32#article#172#<p><font si
ze="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Method</b></font></p>    
 ^cY#aop0411.htm##
00493000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704025100084002001200335#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#37#33#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">This study was carried out u
sing a cohort obtained from the Longitudinal Investigation of Depression Outcome
s (LIDO) study, the methodology of which is described below.</font></p>     ^cY#
aop0411.htm##
00346000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010400084002001200188#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#38#34#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>1. Description</b></font>
</p>     ^cY#aop0411.htm##
00610000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704036800084002001200452#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#39#35#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">The LIDO project was a multi
-center cohort study carried out in six centers (Australia, Brazil, Spain, Israe
l, United States, and Russia) where primary care service users presenting with a
 diagnosis of major depressive disorder - current episode were accompanied for a
 one-year period.</font></p>     ^cY#aop0411.htm##
00614000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704037200084002001200456#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#40#36#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">This article describes the r
esults of a cohort study based exclusively on data from the follow-up of Brazili
an patients. The study was approved by the ethics committees of the <i>Hospital 
de Cl&iacute;nicas</i> and the <i>Hospital Concei&ccedil;&atilde;o</i>, both in 
Porto Alegre, Brazil.</font></p>     ^cY#aop0411.htm##
00351000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010900084002001200193#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#41#37#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>2. Sample selection</b></
font></p>     ^cY#aop0411.htm##
01080000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704083800084002001200922#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#42#38#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">A screening interview was pe
rformed with 2,475 users of three primary care services in Porto Alegre that par
ticipated in the study in a consecutive manner, starting with their arrival at t
he health center between August 1998 and March 1999. The individuals were initia
lly screened for depression using the Center for Epidemiologic Studies Depressio
n Scale (CES-D; Radloff et al., 1977). Individuals with a CES-D score <u>&gt;</u
> 16 were invited for a more detailed interview to confirm a recent major depres
sive episode. This interview (called "baseline") was held up to two weeks after 
the initial contact by trained interviewers. The diagnosis of depression was con
firmed in this interview using the Composite International Diagnostic Interview 
(CIDI).</font></p>     ^cY#aop0411.htm##
01306000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704106400084002001201148#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#43#39#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">Individuals who were diagnos
ed as having current major depression according to the CIDI (CIDI+), aged 18 to 
75, living in the geographical area of the health center, and available over the
 next 12 months were invited to participate in the follow-up study. Individuals 
in treatment for depression or who had been in treatment up to three months befo
re the study, those presenting with any psychiatric disorders such as psychosis 
or organic cerebral syndromes, and those who had any other condition that the ma
in investigator felt could interfere in the study were excluded. Participants we
re assessed at baseline, six weeks, and three and nine months after baseline. Af
ter confirmation of the depression diagnosis, the physician responsible for the 
patient's care was informed by letter of the probable diagnosis of major depress
ion. The decision to treat the depressive episode was left exclusively to the at
tending physician, since the study had a naturalistic observation design.</font>
</p>     ^cY#aop0411.htm##
00394000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704015200084002001200236#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#44#40#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>3. Definition of potentia
lly adequate antidepressant treatment</b></font></p>     ^cY#aop0411.htm##
00607000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704036500084002001200449#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#45#41#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">Potentially adequate antidep
ressant treatment was defined as treatments based on the smallest doses recommen
ded by the U.S. Agency for Health Care Policy and Research Guidelines for the Tr
eatment of Depression in Primary Care (for example, 75mg of imipramine or 20mg o
f fluoxetine).</font></p>     ^cY#aop0411.htm##
00346000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010400084002001200188#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#46#42#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>4. Instruments</b></font>
</p>     ^cY#aop0411.htm##
00928000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704068600084002001200770#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#47#43#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Center for Epidemiologic 
Studies - Depression Scale (CES-D):</b> The CES-D is a 20-item scale that has th
e objective of measuring depression symptoms in community populations.<sup>16</s
up> It is useful to screen for symptoms of depression, but not for confirming di
agnosis. The subject answers questions based on the week preceding the evaluatio
n using a four-point scale ranging from 0 (rarely) to 3 (most of the time). The 
total score is calculated using a simple sum that varies from 0 to 60. The cutof
f point considered to differentiate individuals with symptoms of depression is 1
6.<sup>16</sup></font></p>     ^cY#aop0411.htm##
00658000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704041600084002001200500#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#48#44#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Quality of Life Depressio
n Scale (QLDS):</b> The QLDS is a specific measure of QOL for patients with depr
ession. It consists of 34 items rated as true or false. False answers indicate a
n adverse effect on QOL, whereas true answers indicate a positive impact on QOL.
 The scores vary from 0 (good QOL) to 34 (poor QOL).<sup>17</sup></font></p>    
 ^cY#aop0411.htm##
00558000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704031600084002001200400#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#49#45#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Composite International D
iagnostic Interview (CIDI):</b> The CIDI is a structured interview developed to 
detect a variety of mental problems in primary care settings. This study used th
e depression module version 2.1.<sup>18</sup></font></p>     ^cY#aop0411.htm##
01037000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704079500084002001200879#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#50#46#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Brief version of the Worl
d Health Organization instrument to assess quality of life (WHOQOL-BREF):</b> Th
is is a reduced version of the 100-question World Health Organization instrument
 designed to assess QOL, the WHOQOL-100. This instrument was conjointly develope
d at 15 international centers and has been validated for the Portuguese language
. The reduced version, with 26 questions, encompasses four domains (physical, ps
ychological, social relations, and environment). There are four scales to assess
 intensity, capacity, frequency, and evaluation, with scores ranging from zero t
o four. In each scale, the scores range from 0 to 100, with higher scores sugges
ting better quality of life.<sup>19,20</sup></font></p>     ^cY#aop0411.htm##
00946000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704070400084002001200788#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#51#47#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Medical Outcomes Study Sh
ort-Forms (SF-12) and MHI-5 subscales of the SF-36:</b> The SF-12 is an abbrevia
ted version of the SF-36, with 12 items that assess two dimensions: physical and
 mental. The SF-36 is an instrument that assesses functional status and well-bei
ng and is divided into eight areas (physical functions, physical role limitation
s, emotional role limitations, social functioning, bodily pain, general mental h
ealth, vitality, and general health perceptions). Scores range from 0 to 100 in 
each area. The MHI-5 is a subscale of the SF-36, consisting of five items that a
ssess mental health.<sup>21</sup></font></p>     ^cY#aop0411.htm##
00573000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704033100084002001200415#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#52#48#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Use of Health Resources:<
/b> Identifies the use of health resources in three categories: primary care or 
outpatient service, day hospital, and in-patient service. It also describes the 
use of medications during the follow-up period.<sup>22</sup></font></p>     ^cY#
aop0411.htm##
00355000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704011300084002001200197#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#53#49#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>5. Statistical analysis</
b></font></p>     ^cY#aop0411.htm##
00464000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704022200084002001200306#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#54#50#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">The chi-square test was used
 to compare category variables. A <i>t</i> test was used to compare continuous v
ariables for dependent samples.</font></p>     ^cY#aop0411.htm##
00482000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704024000084002001200324#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#55#51#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">Mixed models were used for r
epeated-measures analysis with the visit as a fixed effect and diagonal variance
-covariance matrix for comparison between groups.</font></p>     ^cY#aop0411.htm
##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#56#52#article#172#<p>&nbsp;</
p>     ^cY#aop0411.htm##
00339000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009700084002001200181#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#57#53#article#172#<p><font si
ze="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Results</b></font></p>   
  ^cY#aop0411.htm##
01242000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704100000084002001201084#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#58#54#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">The sample consisted of 179 
individuals, mostly female (73%), with a mean age of 38 years and mean education
 of 9. The other demographic and clinical characteristics recorded in the baseli
ne visit are described in <a href="/img/revistas/rbp/2011nahead/aop0411tab01.jpg
">Table 1</a>. At the end of the nine-month follow-up, 42% of the individuals st
ill presented major depression (CIDI+), 68% presented depressive symptoms (CES-D
 <u>&gt;</u> 16), and only 25% presented complete symptom remission (CIDI- and C
ES-D &lt; 16). In relation to treatment, 73% of the patients did not receive any
 treatment during the study and only 9% were adequately treated with antidepress
ants. With regard to QOL, at the beginning of the study, 54.2% considered it to 
be good or very good, whereas 50.3% considered it to be good or very good at the
 end of the follow-up period, with no significant differences between these meas
urements.</font></p>     ^cY#aop0411.htm##
00939000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704069700084002001200781#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#59#55#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">Still concerning QOL, there 
were significant differences in almost all measures between the baseline visit a
nd the final assessment and between the 6-week visit and the final assessment. O
nly the overall domain presented no significant differences between visits. The 
variation in the average WHOQOL scores was greater for the physical domain (55.6
 to 64.9) and smaller for the environmental domain (50.30 to 54.14). The mean QO
L and CES-D scores are described in <a href="/img/revistas/rbp/2011nahead/aop041
1fig01.jpg">Figures 1</a> and <a href="/img/revistas/rbp/2011nahead/aop0411fig02
.jpg">2</a>, respectively.</font></p>     ^cY#aop0411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#60#56#article#172#<p>&nbsp;</
p>     ^cY#aop0411.htm##
00342000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010000084002001200184#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#61#57#article#172#<p><font si
ze="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Discussion</b></font></p>
     ^cY#aop0411.htm##
00926000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704068400084002001200768#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#62#58#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">This study presents two main
 findings. First, depression symptoms were poorly identified and poorly treated 
in the primary care network. At the end of the study, 42% of the individuals sti
ll presented major depression, and only 9% were in adequate treatment with antid
epressants. Second, individuals with depression presented little improvement in 
QOL measures throughout the nine-month follow-up. The biggest difference in rela
tion to the mean QOL scores was found between baseline and the nine-month visit,
 demonstrating that any changes occurring in these patients' life are not quickl
y observable.</font></p>     ^cY#aop0411.htm##
01323000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704108100084002001201165#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#63#59#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">In relation to the sample's 
clinical characteristics, 68% persisted with important symptoms of depression at
 the end of the study. The mean baseline CES-D score was 32 points, falling to 2
3 points at the last follow-up visit, with a small effect size between these mea
sures. Another important fact is that only 27% of the individuals received any t
ype of treatment such as counseling or medication for depression, and only 9% we
re adequately treated with antidepressants. It is important to underscore that t
he attending physicians were informed by letter of a probable diagnosis of depre
ssion identified by a standardized diagnostic instrument by the researchers. Thu
s, the data obtained in this study suggest that these subjects were either not i
dentified as having depression symptoms - although the physicians had been advis
ed about the probable diagnosis -, that their physicians prescribed no proper tr
eatment, or that these patients had difficulties accessing the health resources 
available.</font></p>     ^cY#aop0411.htm##
01133000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704089100084002001200975#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#64#60#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">The poor detection of depres
sion symptoms found here is in agreement with previous evidence suggesting that 
51% of the patients treated in primary care continue to have these symptoms, and
 that only some years later are they referred to specialized care.<sup>23</sup> 
The benefits of the treatment with antidepressants have been broadly demonstrate
d in the literature through clinical trials and in studies like the one by Skevi
ngton et al., where 74% of the participants received treatment with adequate ant
idepressants for an eight-week period and showed improvements in QOL.<sup>24</su
p> Beyond the medical perspective, there is also evidence that the therapy with 
antidepressants reduces the indirect costs of depression by decreasing the numbe
r of workdays lost and increasing productivity.<sup>25</sup></font></p>     ^cY#
aop0411.htm##
00530000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704028800084002001200372#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#65#61#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">Therefore, the low rate of c
omplete remission in our study, of around 25%, is probably mainly due to the dif
ficulty in identifying the diagnosis of depression, as well as the lack of appro
priate treatment.</font></p>     ^cY#aop0411.htm##
01269000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704102700084002001201111#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#66#62#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">There is a great variability
 in relation to the remission indexes found in previous studies, with rates rang
ing from 24% to 68%.<sup>9,10,26-29</sup> The recruitment of different populatio
ns, as well as the diversity of instruments and criteria used to evaluate remiss
ion, probably contribute to these differences.<sup>26</sup> In relation to the o
ther centers that participated in our study, our center had the lowest rate of r
emission, compared to 32% in St. Petersburg and 48% in Barcelona. This probably 
occurred due to the two abovementioned factors (non-identification of cases or i
nadequate treatment) or to the difficulty in the access to the health resources 
available. Vinamaki et al. performed a two-year follow-up study about the recove
ry from symptoms of depression in which 65% of the participants remained depress
ive, with the insufficient use of health services as a significant factor associ
ated with non-recovery.<sup>26</sup></font></p>     ^cY#aop0411.htm##
01231000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704098900084002001201073#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#67#63#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">This variable deserves a mor
e detailed study since Brazil has serious problems regarding the access to healt
h resources and to specialized treatment, especially due to economic barriers.<s
up>30</sup> Previous studies show that the costs of medication, the difficulties
 to obtain specialized care, and the barriers to reach healthcare units (long di
stances and transportation issues) are preponderant factors hindering the access
 to adequate treatment.<sup>21,31</sup> Additionally, there is a number of varia
bles that affect the treatment and that have complex interactions which are not 
fully understood to date, such as the perception, attitudes, and preferences of 
patients regarding depression and its treatment and the attitudes and training o
f physicians, all of which are likely to have an influence on the adherence to t
he treatment and the outcomes of therapeutic interventions.<sup>21,31,32</sup></
font></p>     ^cY#aop0411.htm##
01609000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704136700084002001201451#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#68#64#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">Concerning the assessment of
 QOL, all measures showed little change over the nine-month period, with small e
ffect sizes between baseline and the final visit. In relation to the WHOQOL-BREF
, the major differences were found in the physical, psychological, and social di
mensions. Since the participants were selected while seeking medical care and si
nce 95% of them had some clinical comorbidity, it is probable that the presence 
of these clinical conditions also had an impact on QOL, especially in what conce
rns the physical domain. In this study the authors used the SF-36 subscale and t
he WHOQOL-BREF because they measure different aspects of QOL and can function as
 complementary questionnaires. The WHOQOL-BREF is a generic measure of QOL and r
efers to the well-being of the individual, and the SF-36 is a health-related QOL
 measure that gauges functional status. Another aspect that must have contribute
d to the small improvement in QOL is the persistence of depression symptoms at t
he end of the study. This is in agreement with earlier evidence showing that emo
tional status exerts a great impact on QOL assessments, with a resulting varianc
e of 20% in the overall WHOQOL scores, and that persistent negative mood affects
 all the domains measured by the WHOQOL.<sup>33,34</sup></font></p>     ^cY#aop0
411.htm##
01440000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704119800084002001201282#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#69#65#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">Our study had some limitatio
ns. The participants were selected while seeking assistance at primary healthcar
e units. Therefore, the sample probably comprised individuals with light to mode
rate depression, which restricts the generalization of these data to samples wit
h more severe depression or seeking specialized services. Furthermore, the compa
rison of data related to QOL is further hampered by other factors. First, althou
gh the association between QOL and depression has already been extensively demon
strated in the literature,<sup>35-39</sup> there are few studies in Latin Americ
a investigating this association with the same instruments used in this study.<s
up>40,41</sup> The WHOQOL has already been validated to several languages, but i
t is still little used in psychiatry, with only 12 articles assessing QOL in pat
ients with major depression over the past 10 years. There is also a lack of norm
ative data for QOL-related instruments such as the WHOQOL and the QLDS. All thes
e factors make it difficult to interpret our results as well as to establish cut
off points for the comparison between measures.</font></p>     ^cY#aop0411.htm##
01150000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704090800084002001200992#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#70#66#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">Another aspect to be conside
red in the interpretation of the findings presented here is that most of the pre
vious studies were cross-sectional, thus not permitting a better understanding o
f the association between QOL and depression. Naturalistic follow-up studies inv
olving individuals with depression in the community or in primary care settings 
are scarce, generally covering a short period of time and comprising patients re
ferred to specialized treatment.<sup>9</sup> Over the past 10 years, there has b
een a growing interest in the study of variables related to QOL, with a more exp
ressive number of one-year or longer follow-ups. However, there is still much co
nfusion in the articles with regard to the concepts of QOL, recovery, and remiss
ion of symptoms, which in turn leads to confounding conclusions.<sup>42</sup></f
ont></p>     ^cY#aop0411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#71#67#article#172#<p>&nbsp;</
p>     ^cY#aop0411.htm##
00407000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704016500084002001200249#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#72#68#article#172#<p align="c
enter"><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><a href="/img
/revistas/rbp/2011nahead/aop0411tab02.jpg">Table 2</a></font></p>     ^cY#aop041
1.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#73#69#article#172#<p>&nbsp;</
p>     ^cY#aop0411.htm##
00342000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010000084002001200184#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#74#70#article#172#<p><font si
ze="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Conclusion</b></font></p>
     ^cY#aop0411.htm##
01274000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704103200084002001201116#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#75#71#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">This study demonstrated that
 patients with symptoms of depression are poorly diagnosed and rarely receive ad
equate treatment in primary care units in the south of Brazil. Most of the patie
nts continued to have symptoms of depression over the nine-month period of the s
tudy, with consequent QOL impairments. Since primary care services are generally
 the most used means of access to health care, especially in a country lacking s
pecialized service, the non-detection of depressive disorders, as well as the no
n-provision of specific and adequate treatment, may cause important problems for
 the clinical evolution of depression and for QOL, potentially increasing indire
ct costs to society in general. This study warns of the need to implement traini
ng measures for health professionals in primary care settings so that they are a
ble to detect and treat this disorder at an early stage and improve the QOL of i
ndividuals suffering from these symptoms.</font></p>     ^cY#aop0411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#76#72#article#172#<p>&nbsp;</
p>     ^cY#aop0411.htm##
00348000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010600084002001200190#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#77#73#article#172#<p><font si
ze="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Acknowledgements</b></fon
t></p>     ^cY#aop0411.htm##
00637000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704039500084002001200479#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#78#74#article#172#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">The data described in this p
aper are part of the multicenter "Longitudinal Investigation Depression Outcome"
 study (LIDO). The authors thank Eli Lilly and Company for sponsoring the resear
ch and the <i>Fundo de Incentivo &agrave; Pesquisa e Eventos do Hospital de Cl&i
acute;nicas de Porto Alegre</i> (FIPE/HCPA).</font></p>     ^cY#aop0411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#79#75#article#172#<p>&nbsp;</
p>     ^cY#aop0411.htm##
00456000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704021400084002001200298#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#80#76#article#172#<p align="c
enter"><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><a href="/img
/revistas/rbp/2011nahead/aop0411img01.jpg"><img src="/img/revistas/rbp/2011nahea
d/aop0411img01tamb.jpg" border="0">    ^cY#aop0411.htm##
00289000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704004700084002001200131#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#81#77#article#172#<br>   Clic
k to enlarge</a></font></p>     ^cY#aop0411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#82#78#article#172#<p>&nbsp;</
p>     ^cY#aop0411.htm##
00342000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010000084002001200184#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#83#79#article#172#<p><font si
ze="3" face="Verdana, Arial, Helvetica, sans-serif"><b>References</b></font></p>
     ^cY#aop0411.htm##
00532000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704027600086002001200362#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#84#80#article#172
#1#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Wells KB, M
anning WG Jr, Valdez RB. The effects of insurance generosity on the psychologica
l distress and psychological well-being of a general population. <i>Arch Gen Psy
chiatry</i>. 1989;46(4):315-20.    ^cY#aop0411.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#85#81#article#172#</font></p>
     ^cY#aop0411.htm##
00510000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704025400086002001200340#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#86#82#article#172
#2#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Wells KB, G
olding JM, Burnam MA. Psychiatric disorder in a sample of the general population
 with and without chronic medical conditions. <i>Am J Psychiatry</i>. 1988;145(8
):976-81.    ^cY#aop0411.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#87#83#article#172#</font></p>
     ^cY#aop0411.htm##
00508000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704025200086002001200338#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#88#84#article#172
#3#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">3. McQuaid JR,
 Stein MB, Laffaye C, McCahill ME. Depression in a primary care clinic: the prev
alence and impact of an unrecognized disorder. <i>J Affect Disord</i>. 1999;55(1
):1-10.    ^cY#aop0411.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#89#85#article#172#</font></p>
     ^cY#aop0411.htm##
00540000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704028400086002001200370#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#90#86#article#172
#4#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Wells KB, S
herbourne CD. Functioning and utility for current health of patients with depres
sion or chronic medical conditions in managed, primary care practices. <i>Arch G
en Psychiatry</i>. 1999;56(10):897-904.    ^cY#aop0411.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#91#87#article#172#</font></p>
     ^cY#aop0411.htm##
00569000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704031300086002001200399#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#92#88#article#172
#5#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Spitzer RL,
 Kroenke K, Linzer M, Hahn SR, Williams JB, deGruy FV 3rd, Brody D, Davies M. He
alth-related quality of life in primary care patients with mental disorders. Res
ults from the PRIME-MD 1000 Study. <i>JAMA</i>. 1995;274(19):1511-7.    ^cY#aop0
411.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#93#89#article#172#</font></p>
     ^cY#aop0411.htm##
00534000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704027800086002001200364#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#94#90#article#172
#6#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Bonicatto S
C, Dew MA, Zaratiegui R, Lorenzo L, Pecina P. Adult outpatients with depression:
 worse quality of life than in other chronic medical diseases in Argentina. <i>S
oc Sci Med</i>. 2001;52(6):911-9.    ^cY#aop0411.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#95#91#article#172#</font></p>
     ^cY#aop0411.htm##
00544000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704028800086002001200374#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#96#92#article#172
#7#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Ravindran A
V, Matheson K, Griffiths J, Merali Z, Anisman H. Stress, coping, uplifts, and qu
ality of life in subtypes of depression: a conceptual frame and emerging data. <
i>J Affect Disord</i>. 2002;71(1-3):121-30.    ^cY#aop0411.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#97#93#article#172#</font></p>
     ^cY#aop0411.htm##
00482000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704022600086002001200312#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#98#94#article#172
#8#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">8. McCall WV, 
Cohen W, Reboussin B, Lawton P. Effects of mood and age on quality of life in de
pressed inpatients. <i>Affect Disord</i>. 1999;55(23):107-14.    ^cY#aop0411.htm
##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#99#95#article#172#</font></p>
     ^cY#aop0411.htm##
00574000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081888000200085704031700087002001200404#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#100#96#article#17
2#9#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Van Weel-B
aumgarten EM, Schers HJ, van den Bosch WJ, van den Hoogen HJ, Zitman FG. Long-te
rm follow-up of depression among patients in the community and in family practic
e settings. A systematic review. <i>J Fam Pract</i>. 2000;49(12):1113-20.    ^cY
#aop0411.htm##
00263000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081704002000085002001200105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#101#97#article#172#</font></p
>     ^cY#aop0411.htm##
00567000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081888000300085704030900088002001200397#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#102#98#article#17
2#10#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Ezquiaga
 E, Garcia-Lopez A, de Dios C, Leiva A, Bravo M, Montejo J. Clinical and psychos
ocial factors associated with the outcome of unipolar major depression: a one ye
ar prospective study. <i>J Affect Disord</i>. 2004;79 (1-3):63-70.    ^cY#aop041
1.htm##
00263000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081704002000085002001200105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#103#99#article#172#</font></p
>     ^cY#aop0411.htm##
00577000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704031800089002001200407#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#104#100#article#1
72#11#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Koivuma
a-Honkanen H, Honkanen R, Antikainen R, Hintikka J, Laukkanen E, Honkalampi K, V
iinam&auml;ki H. Self-reported life satisfaction and recovery from depression in
 a 1-year prospective study. <i>Acta Psychiatr Scand</i>. 2001;103(1):38-44.    
^cY#aop0411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#105#101#article#172#</font></
p>     ^cY#aop0411.htm##
00606000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704034700089002001200436#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#106#102#article#1
72#12#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. De Alme
ida Fleck MP, Simon G, Herrman H, Bushnell D, Martin M, Patrick D; Longitudinal 
Investigation of Depression Outcomes Group. Major depression and its correlates 
in primary care settings in six countries.9-month follow-up study. <i>Br J Psych
iatry</i>. 2005;186:41-7.    ^cY#aop0411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#107#103#article#172#</font></
p>     ^cY#aop0411.htm##
00573000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704031400089002001200403#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#108#104#article#1
72#13#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Diehr P
H, Derleth AM, McKenna SP, Martin ML, Bushnell DM, Simon G, Patrick DL. Synchron
y of change in depressive symptoms, health status, and quality of life in person
s with clinical depression. <i>Health Qual Life Outcomes</i>. 2006;4:27.    ^cY#
aop0411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#109#105#article#172#</font></
p>     ^cY#aop0411.htm##
00625000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704036600089002001200455#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#110#106#article#1
72#14#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Berlim 
MT, Fleck MP. Quality of life and major depression: current findings and future 
perspectives. In: Ritsner MS, Awad G, editors. <i>Quality of life impairment in 
schizophrenia, mood and anxiety disorders: New perspectives on research and trea
tment.</i> Berlim: Springer; 2007. p.241-52.    ^cY#aop0411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#111#107#article#172#</font></
p>     ^cY#aop0411.htm##
00537000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704027800089002001200367#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#112#108#article#1
72#15#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Papakos
tas GI, Petersen T, Mahal Y, Mischoulon D, Nierenberg AA, Fava M. Quality of lif
e assessments in major depressive disorder: a review of the literature. <i>Gen H
osp Psychiatry</i>. 2004;26(1):13-7.    ^cY#aop0411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#113#109#article#172#</font></
p>     ^cY#aop0411.htm##
00475000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704021600089002001200305#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#114#110#article#1
72#16#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Radloff
 LS. The CES-D scale: a self-report depression scale for research in the general
 population. <i>Appl Psychol Meas.</i> 1977;1:385-401.    ^cY#aop0411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#115#111#article#172#</font></
p>     ^cY#aop0411.htm##
00467000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704020800089002001200297#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#116#112#article#1
72#17#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Hunt SM
, McKenna SP. The QLDS: a scale for the measurement of quality of life in depres
sion. <i>Health Policy.</i> 1992;22(3):307-19.    ^cY#aop0411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#117#113#article#172#</font></
p>     ^cY#aop0411.htm##
00604000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704034500089002001200434#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#118#114#article#1
72#18#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Weiller
 E, Lecrubier Y, Maier W, Ustun TB. The relevance of recurrent brief depression 
in primary care. A report from the WHO project on Psychological Problems in Gene
ral Health Care conducted in 14 countries. <i>Eur Arch Psychiatry Clin Neurosci.
</i> 1994;244(4):182-9.    ^cY#aop0411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#119#115#article#172#</font></
p>     ^cY#aop0411.htm##
00555000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704029600089002001200385#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#120#116#article#1
72#19#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Fleck M
P, Louzada S, Xavier M, Chachamovich E, Vieira G, Santos L, Pinzon V. Applicatio
n of the Portuguese version of the abbreviated instrument of quality of life WHO
QOL-bref. <i>Rev Saude Publica</i>. 2000;34(2):178-83.    ^cY#aop0411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#121#117#article#172#</font></
p>     ^cY#aop0411.htm##
00474000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704021500089002001200304#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#122#118#article#1
72#20#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. The WHO
QOL GROUP. Development of the World Health Organization WHOQOL-BREF quality of l
ife assessment. <i>Psychol Med</i>. 1998;28(3):551-8.    ^cY#aop0411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#123#119#article#172#</font></
p>     ^cY#aop0411.htm##
00490000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704023100089002001200320#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#124#120#article#1
72#21#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Ware JE
 Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Concept
ual framework and item selection. <i>Med Care</i>. 1992;30(6):473-83.    ^cY#aop
0411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#125#121#article#172#</font></
p>     ^cY#aop0411.htm##
00499000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704024000089002001200329#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#126#122#article#1
72#22#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Beechma
m JK, Knapp MRJ. In: Wing J, Thornicroft G, Brewin C, editors. <i>Costing psychi
atric interventions. Measuring mental health needs</i>. London: Gaskell; 1992.  
  ^cY#aop0411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#127#123#article#172#</font></
p>     ^cY#aop0411.htm##
00509000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704025000089002001200339#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#128#124#article#1
72#23#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Paykel 
ES, Watters L, Abbott R, Wadsworth M. Do treated psychiatric patients become lat
er community cases? A prospective cohort study. <i>Eur Psychiatry</i>. 2006;21(5
):315-8.    ^cY#aop0411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#129#125#article#172#</font></
p>     ^cY#aop0411.htm##
00524000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704026500089002001200354#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#130#126#article#1
72#24#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">24. Skeving
ton SM, Wright A. Changes in the quality of life of patients receiving antidepre
ssant medication in primary care: validation of the WHOQOL-100. <i>Br J Psychiat
ry.</i> 2001;178:261-7.    ^cY#aop0411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#131#127#article#172#</font></
p>     ^cY#aop0411.htm##
00505000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704024600089002001200335#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#132#128#article#1
72#25#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">25. von Kno
rring L, Akerblad AC, Bengtsson F, Carlsson A, Ekselius L. Cost of depression: e
ffect of adherence and treatment response. <i>Eur Psychiatry</i>. 2006;21(6):349
-54.    ^cY#aop0411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#133#129#article#172#</font></
p>     ^cY#aop0411.htm##
00569000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704031000089002001200399#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#134#130#article#1
72#26#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">26. Viinam&
auml;ki H, Tanskanen A, Honkalampi K, Koivumaa-Honkanen H, Antikainen R, Haatain
en K, Hintikka J.Recovery from depression: a two-year follow-up study of general
 population subjects. <i>Int J Soc Psychiatry</i>. 2006;52(1):19-28.    ^cY#aop0
411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#135#131#article#172#</font></
p>     ^cY#aop0411.htm##
00509000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704025000089002001200339#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#136#132#article#1
72#27#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">27. Goldber
g JF, Harrow M. Consistency of remission and outcome in bipolar and unipolar moo
d disorders: a 10-year prospective follow-up. <i>J Affect Disord.</i> 2004;81(2)
:123-31.    ^cY#aop0411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#137#133#article#172#</font></
p>     ^cY#aop0411.htm##
00528000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704026900089002001200358#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#138#134#article#1
72#28#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">28. Kuehner
 C, Buerger C. Determinants of subjective quality of life in depressed patients:
 the role of self-esteem, response styles, and social support. <i>J Affect Disor
d</i>. 2005;86(2-3):205-13.    ^cY#aop0411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#139#135#article#172#</font></
p>     ^cY#aop0411.htm##
00523000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704026400089002001200353#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#140#136#article#1
72#29#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">29. Sk&atil
de;rs&atilde;ter I, Baigi A, Haglund L. Functional status and quality of life in
 patients with first-episode major depression. <i>J Psychiatr Ment Health Nurs</
i>. 2006;13(2):205-13.    ^cY#aop0411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#141#137#article#172#</font></
p>     ^cY#aop0411.htm##
00520000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704026100089002001200350#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#142#138#article#1
72#30#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">30. Simon G
E, Fleck M, Lucas R, Bushnell DM; LIDO Group Prevalence and predictors of depres
sion treatment in an international primary care study. <i>Am J Psychiatry</i>. 2
004;161(9):1626-34.    ^cY#aop0411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#143#139#article#172#</font></
p>     ^cY#aop0411.htm##
00515000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704025600089002001200345#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#144#140#article#1
72#31#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">31. Simon G
E, Goldberg D, Tiemens BG, Ustun TB. Outcomes of recognized and unrecognized dep
ression in an international primary care study. <i>Gen Hosp Psychiatry</i>. 1999
;21(2):97-105.    ^cY#aop0411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#145#141#article#172#</font></
p>     ^cY#aop0411.htm##
00471000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704021200089002001200301#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#146#142#article#1
72#32#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">32. Weich S
, Morgan L, King M, Nazareth I. Attitudes to depression and its treatment in pri
mary care. <i>Psychol Med</i>. 2004;37(9):1239-48.    ^cY#aop0411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#147#143#article#172#</font></
p>     ^cY#aop0411.htm##
00495000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704023600089002001200325#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#148#144#article#1
72#33#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">33. Heinone
n H, Aro AR, Aalto AM, Uutela A. Is the evaluation of the global quality of life
 determined by emotional status? <i>Qual Life Res</i>. 2004;13(8):1347-56.    ^c
Y#aop0411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#149#145#article#172#</font></
p>     ^cY#aop0411.htm##
00581000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704032200089002001200411#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#150#146#article#1
72#34#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">34. Picardi
 A, Rucci P, de Girolamo G, Santone G, Borsetti G, Morosini P. The quality of li
fe of the mentally ill living in residential facilities: findings from a nationa
l survey in Italy. <i>Eur Arch Psychiatry Clin Neurosci</i>. 2006;256(6):372-81.
    ^cY#aop0411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#151#147#article#172#</font></
p>     ^cY#aop0411.htm##
00485000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704022600089002001200315#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#152#148#article#1
72#35#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">35. Rapapor
t MK, Clary C, Fayard R, Endicort J. Quality of life impairment in depressive an
d anxiety disorders. <i>Am J Psychiatry</i>. 2005;162(6):1171-8.    ^cY#aop0411.
htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#153#149#article#172#</font></
p>     ^cY#aop0411.htm##
00497000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704023800089002001200327#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#154#150#article#1
72#36#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">36. Kessler
 RC, Foster CL, Saunders WB, Stang PE. Social consequences of psychiatric disord
ers. I: Educational attainment. <i>Am J Psychiatry</i>. 1995;152(7):1026-32.    
^cY#aop0411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#155#151#article#172#</font></
p>     ^cY#aop0411.htm##
00504000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704024500089002001200334#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#156#152#article#1
72#37#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">37. Kessler
 RC, Walters EE, Forthofer MS. The social consequences of psychiatric disorders.
 III: probability of marital stability. <i>Am J Psychiatry</i>. 1998;155(8):1092
-6.    ^cY#aop0411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#157#153#article#172#</font></
p>     ^cY#aop0411.htm##
00573000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704031400089002001200403#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#158#154#article#1
72#38#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">38. Spitzer
 RL, Kroenke K, Linzer M, Hahn SR, Williams JB, deGruy FV 3rd, Brody D, Davies M
. Health-related quality of life in primary care patients with mental disorders.
 Results from the PRIME-MD 1000 Study. <i>JAMA.</i> 1995;274(19):1511-7.    ^cY#
aop0411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#159#155#article#172#</font></
p>     ^cY#aop0411.htm##
00513000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704025400089002001200343#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#160#156#article#1
72#39#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">39. Ormel J
, Vonkorff M, Oldehinkel AJ, Simon G, Tiemens BG, Ustun TB. Onset of disability 
in depressed and non-depressed primary care patients. <i>Psychol Med</i>. 1999;2
9(4):847-53.    ^cY#aop0411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#161#157#article#172#</font></
p>     ^cY#aop0411.htm##
00545000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704028600089002001200375#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#162#158#article#1
72#40#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">40. Gazalle
 FK, Andreazza AC, Hallal PC, Kauer-Sant'anna M, Ceres&eacute;r KM, Soares JC, S
antin A, Kapczinski F. Bipolar depression: the importance of being on remission.
 <i>Rev Bras Psiquiatr</i>. 2006;28(2):93-6.    ^cY#aop0411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#163#159#article#172#</font></
p>     ^cY#aop0411.htm##
00527000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704026800089002001200357#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#164#160#article#1
72#41#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">41. Berlim 
MT, Pavanello DP, Caldieraro MA, Fleck MP. Reliability and validity of the WHOQO
L BREF in a sample of Brazilian outpatients with major depression. <i>Qual Life 
Res</i>. 2005;14(2):561-4.    ^cY#aop0411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#165#161#article#172#</font></
p>     ^cY#aop0411.htm##
00495000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704023600089002001200325#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#166#162#article#1
72#42#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">42. Bagby R
M, Ryder AG, Cristi C. Psychosocial and clinical predictors of response to pharm
acotherapy for depression. <i>J Psychiatry Neurosci</i>. 2002;27(4):250-7.    ^c
Y#aop0411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#167#163#article#172#</font></
p>     ^cY#aop0411.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#168#164#article#172#<p>&nbsp;
</p>     ^cY#aop0411.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#169#165#article#172#<p>&nbsp;
</p>     ^cY#aop0411.htm##
00434000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704019000086002001200276#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#170#166#article#172#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif"><a name="ad"></a><a href="
#ad1"><img src="/img/revistas/rbp/2011nahead/seta.jpg" border="0"></a> <b>Corres
pondence:</b>    ^cY#aop0411.htm##
00297000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704005300086002001200139#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#171#167#article#172#<br>   An
a Fl&aacute;via Barros da Silva Lima    ^cY#aop0411.htm##
00280000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704003600086002001200122#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#172#168#article#172#<br>   Ru
a Mariante, 288/407    ^cY#aop0411.htm##
00294000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704005000086002001200136#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#173#169#article#172#<br>   90
430-180 Porto Alegre, RS, Brazil     ^cY#aop0411.htm##
00321000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704007700086002001200163#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#174#170#article#172#<br>   Ph
one: (+55 51) 3222-4566 Fax: (+55 51) 3378-9899 </font></p>     ^cY#aop0411.htm#
#
00342000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704009800086002001200184#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#175#171#article#172#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">Submitted: August 30, 2009
     ^cY#aop0411.htm##
00294000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704005000086002001200136#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#p#176#172#article#172#<br>   Ac
cepted: July 20, 2010</font></p>     ^cY#aop0411.htm##
00661000000000301000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100016000850100021001010100
01700122012012300139030002000262065000900282064000500291031000300296032000200299
014000700301865000900308002001200317035001000329801002000339#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop0411.htm#S#c#177#1#article#42#1#^rND^sWells^nK
B#^rND^sManning Jr^nWG#^rND^sValdez^nRB#The effects of insurance generosity on t
he psychological distress and psychological well-being of a general population^l
en#Arch Gen Psychiatry#19890000#1989#46#4#315-20#20110000#aop0411.htm#0003-990X#
Arch Gen Psychiatry##
00635000000000301000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100016000850100018001010100
01700119012010700136030001600243065000900259064000500268031000400273032000200277
014000700279865000900286002001200295035001000307801001600317#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop0411.htm#S#c#178#2#article#42#2#^rND^sWells^nK
B#^rND^sGolding^nJM#^rND^sBurnam^nMA#Psychiatric disorder in a sample of the gen
eral population with and without chronic medical conditions^len#Am J Psychiatry#
19880000#1988#145#8#976-81#20110000#aop0411.htm#0002-953X#Am J Psychiatry##
00651000000000313000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100018000850100016001030100
01700119010001900136012009500155030001600250065000900266064000500275031000300280
032000200283014000500285865000900290002001200299035001000311801001600321#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#c#179#3#article#42#3#^r
ND^sMcQuaid^nJR#^rND^sStein^nMB#^rND^sLaffaye^nC#^rND^sMcCahill^nME#Depression i
n a primary care clinic: the prevalence and impact of an unrecognized disorder^l
en#J Affect Disord#19990000#1999#55#1#1-10#20110000#aop0411.htm#0165-0327#J Affe
ct Disord##
00651000000000289000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100016000850100021001010120
14000122030002000262065000900282064000500291031000300296032000300299014000800302
865000900310002001200319035001000331801002000341#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop0411.htm#S#c#180#4#article#42#4#^rND^sWells^nKB#^rND^sSher
bourne^nCD#Functioning and utility for current health of patients with depressio
n or chronic medical conditions in managed, primary care practices^len#Arch Gen 
Psychiatry#19990000#1999#56#10#897-904#20110000#aop0411.htm#0003-990X#Arch Gen P
sychiatry##
00728000000000337000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100018000850100017001030100
01600120010001500136010001900151011003100170012012000201030000500321065000900326
06400050033503100040034003200030034401400070034786500090035400200120036303500100
0375801000500385#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S
#c#181#5#article#42#5#^rND^sSpitzer^nRL#^rND^sKroenke^nK#^rND^sLinzer^nM#^rND^sH
ahn^nSR#^rND^sWilliams^nJB#deGruy FV 3rd.Brody D.Davies M#Health-related quality
 of life in primary care patients with mental disorders: Results from the PRIME-
MD 1000 Study^len#JAMA#19950000#1995#274#19#1511-7#20110000#aop0411.htm#0098-748
4#JAMA##
00691000000000325000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100020000850100014001050100
02000119010001700139010001600156012011300172030001200285065000900297064000500306
03100030031103200020031401400060031686500090032200200120033103500100034380100120
0353#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#c#182#6#art
icle#42#6#^rND^sBonicatto^nSC#^rND^sDew^nMA#^rND^sZaratiegui^nR#^rND^sLorenzo^nL
#^rND^sPecina^nP#Adult outpatients with depression: worse quality of life than i
n other chronic medical diseases in Argentina^len#Soc Sci Med#20010000#2001#52#6
#911-9#20110000#aop0411.htm#0037-7856#Soc Sci Med##
00705000000000325000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100020000850100018001050100
01900123010001600142010001700158012011300175030001600288065000900304064000500313
03100030031803200040032101400070032586500090033200200120034103500100035380100160
0363#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#c#183#7#art
icle#42#7#^rND^sRavindran^nAV#^rND^sMatheson^nK#^rND^sGriffiths^nJ#^rND^sMerali^
nZ#^rND^sAnisman^nH#Stress, coping, uplifts, and quality of life in subtypes of 
depression: a conceptual frame and emerging data^len#J Affect Disord#20020000#20
02#71#1-3#121-30#20110000#aop0411.htm#0165-0327#J Affect Disord##
00589000000000301000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100017000850100015001020100
01900117010001600136012007100152030001400223710000200237065000900239064000500248
031000300253032000300256014000700259865000900266002001200275#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop0411.htm#S#c#184#8#article#42#8#^rND^sMcCall^n
WV#^rND^sCohen^nW#^rND^sReboussin^nB#^rND^sLawton^nP#Effects of mood and age on 
quality of life in depressed inpatients^len#Affect Disord#2#19990000#1999#55#23#
107-14#20110000#aop0411.htm##
00685000000000301000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100030000850100017001150110
04500132012012300177030001200300065000900312064000500321031000300326032000300329
014000800332865000900340002001200349035001000361801001200371#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop0411.htm#S#c#185#9#article#42#9#^rND^sVan Weel
-Baumgarten^nEM#^rND^sSchers^nHJ#van den Bosch WJ.van den Hoogen HJ.Zitman FG#Lo
ng-term follow-up of depression among patients in the community and in family pr
actice settings: A systematic review^len#J Fam Pract#20000000#2000#49#12#1113-20
#20110000#aop0411.htm#0094-3509#J Fam Pract##
00744000000000337000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100022001050100
01700127010001500144010001500159010001700174012012500191030001600316065000900332
06400050034103100030034603200040034901400060035386500090035900200120036803500100
0380801001600390#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S
#c#186#10#article#42#10#^rND^sEzquiaga^nE#^rND^sGarcia-Lopez^nA#^rND^sde Dios^nC
#^rND^sLeiva^nA#^rND^sBravo^nM#^rND^sMontejo^nJ#Clinical and psychosocial factor
s associated with the outcome of unipolar major depression: a one year prospecti
ve study^len#J Affect Disord#20040000#2004#79#1-3#63-70#20110000#aop0411.htm#016
5-0327#J Affect Disord##
00772000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100027000870100018001140100
02000132010001800152010001900170010002000189010001900209012009500228030002100323
06500090034406400050035303100040035803200020036201400060036486500090037000200120
0379035001000391801002100401#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\a
op0411.htm#S#c#187#11#article#42#11#^rND^sKoivumaa-Honkanen^nH#^rND^sHonkanen^nR
#^rND^sAntikainen^nR#^rND^sHintikka^nJ#^rND^sLaukkanen^nE#^rND^sHonkalampi^nK#^r
ND^sViinamäki^nH#Self-reported life satisfaction and recovery from depression in
 a 1-year prospective study^len#Acta Psychiatr Scand#20010000#2001#103#1#38-44#2
0110000#aop0411.htm#0001-690X#Acta Psychiatr Scand##
00771000000000325000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100027000870100015001140100
01700129010001800146010001600164010001700180012016200197030001600359065000900375
06400050038403100040038901400050039386500090039800200120040703500100041980100160
0429#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#c#188#12#ar
ticle#42#12#^rND^sDe Almeida Fleck^nMP#^rND^sSimon^nG#^rND^sHerrman^nH#^rND^sBus
hnell^nD#^rND^sMartin^nM#^rND^sPatrick^nD#Longitudinal Investigation of Depressi
on Outcomes Group: Major depression and its correlates in primary care settings 
in six countries9-month follow-up study^len#Br J Psychiatry#20050000#2005#186#41
-7#20110000#aop0411.htm#0007-1250#Br J Psychiatry##
00721000000000325000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100018001030100
01800121010001700139010001900156010001500175010001800190012011900208030002600327
71000020035306500090035506400050036403100020036902000030037186500090037400200120
0383#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#c#189#13#ar
ticle#42#13#^rND^sDiehr^nPH#^rND^sDerleth^nAM#^rND^sMcKenna^nSP#^rND^sMartin^nML
#^rND^sBushnell^nDM#^rND^sSimon^nG#^rND^sPatrick^nDL#Synchrony of change in depr
essive symptoms, health status, and quality of life in persons with clinical dep
ression^len#Health Qual Life Outcomes#2#20060000#2006#4#27#20110000#aop0411.htm#
#
00703000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100016001040120
08300120016001800203016001400221018012000235066000700355062000900362014000700371
065000900378064000500387865000900392002001200401#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop0411.htm#S#c#190#14#article#42#14#^rND^sBerlim^nMT#^rND^sF
leck^nMP#Quality of life and major depression: current findings and future persp
ectives^len#^rED^sRitsner^nMS#^rED^sAwad^nG#Quality of life impairment in schizo
phrenia, mood and anxiety disorders: New perspectives on research and treatment^
len#Berlim#Springer#241-52#20070000#2007#20110000#aop0411.htm##
00718000000000337000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100021000870100018001080100
01500126010002000141010002100161010001400182012008900196030002000285065000900305
06400050031403100030031903200020032201400050032486500090032900200120033803500100
0350801002000360#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S
#c#191#15#article#42#15#^rND^sPapakostas^nGI#^rND^sPetersen^nT#^rND^sMahal^nY#^r
ND^sMischoulon^nD#^rND^sNierenberg^nAA#^rND^sFava^nM#Quality of life assessments
 in major depressive disorder: a review of the literature^len#Gen Hosp Psychiatr
y#20040000#2004#26#1#13-7#20110000#aop0411.htm#0163-8343#Gen Hosp Psychiatry##
00553000000000265000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870120091001050300
01800196065000900214064000500223031000200228014000800230865000900238002001200247
035001000259801001800269#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop04
11.htm#S#c#192#16#article#42#16#^rND^sRadloff^nLS#The CES-D scale: a self-report
 depression scale for research in the general population^len#Appl Psychol Meas#1
9770000#1977#1#385-401#20110000#aop0411.htm#0146-6216#Appl Psychol Meas##
00570000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100015000870100018001020120
07500120030001400195065000900209064000500218031000300223032000200226014000700228
865000900235002001200244035001000256801001400266#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop0411.htm#S#c#193#17#article#42#17#^rND^sHunt^nSM#^rND^sMcK
enna^nSP#The QLDS: a scale for the measurement of quality of life in depression^
len#Health Policy#19920000#1992#22#3#307-19#20110000#aop0411.htm#0168-8510#HEALT
H POLICY##
00763000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100019001040100
01500123010001600138012017000154030003400324065000900358064000500367031000400372
032000200376014000600378865000900384002001200393035001000405801003400415#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#c#194#18#article#42#18#
^rND^sWeiller^nE#^rND^sLecrubier^nY#^rND^sMaier^nW#^rND^sUstun^nTB#The relevance
 of recurrent brief depression in primary care: A report from the WHO project on
 Psychological Problems in General Health Care conducted in 14 countries^len#Eur
 Arch Psychiatry Clin Neurosci#19940000#1994#244#4#182-9#20110000#aop0411.htm#09
40-1334#Eur Arch Psychiatry Clin Neurosci##
00752000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100017001030100
01600120010002200136010001600158010001600174010001600190012010300206030001800309
06500090032706400050033603100030034103200020034401400070034686500090035300200120
0362035001000374801001800384#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\a
op0411.htm#S#c#195#19#article#42#19#^rND^sFleck^nMP#^rND^sLouzada^nS#^rND^sXavie
r^nM#^rND^sChachamovich^nE#^rND^sVieira^nG#^rND^sSantos^nL#^rND^sPinzon^nV#Appli
cation of the Portuguese version of the abbreviated instrument of quality of lif
e WHOQOL-bref^len#Rev Saude Publica#20000000#2000#34#2#178-83#20110000#aop0411.h
tm#0034-8910#Rev Saude Publica##
00549000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840110016000870120088001030300
01200191065000900203064000500212031000300217032000200220014000600222865000900228
002001200237035001000249801001200259#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop0411.htm#S#c#196#20#article#42#20#The WHOQOLGROUP#Development of the W
orld Health Organization WHOQOL-BREF quality of life assessment^len#Psychol Med#
19980000#1998#28#3#551-8#20110000#aop0411.htm#0033-2917#Psychol Med##
00588000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100021001050120
09700126030000900223065000900232064000500241031000300246032000200249014000700251
865000900258002001200267035001000279801000900289#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop0411.htm#S#c#197#21#article#42#21#^rND^sWare Jr^nJE#^rND^s
Sherbourne^nCD#The MOS 36-item short-form health survey (SF-36): I. Conceptual f
ramework and item selection^len#Med Care#19920000#1992#30#6#473-83#20110000#aop0
411.htm#0025-7079#Med Care##
00571000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100017001060160
01400123016002100137016001600158018006900174066000700243062000800250065000900258
064000500267865000900272002001200281#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop0411.htm#S#c#198#22#article#42#22#^rND^sBeechmam^nJK#^rND^sKnapp^nMRJ#
^rED^sWing^nJ#^rED^sThornicroft^nG#^rED^sBrewin^nC#Costing psychiatric intervent
ions: Measuring mental health needs^len#London#Gaskell#19920000#1992#20110000#ao
p0411.htm##
00614000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100017001040100
01600121010001900137012009300156030001500249710000200264065000900266064000500275
031000300280032000200283014000600285865000900291002001200300#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop0411.htm#S#c#199#23#article#42#23#^rND^sPaykel
^nES#^rND^sWatters^nL#^rND^sAbbott^nR#^rND^sWadsworth^nM#Do treated psychiatric 
patients become later community cases: A prospective cohort study^len#Eur Psychi
atry#2#20060000#2006#21#5#315-8#20110000#aop0411.htm##
00618000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100021000870100016001080120
12900124030001600253065000900269064000500278031000400283014000600287865000900293
002001200302035001000314801001600324#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop0411.htm#S#c#200#24#article#42#24#^rND^sSkevington^nSM#^rND^sWright^nA
#Changes in the quality of life of patients receiving antidepressant medication 
in primary care: validation of the WHOQOL-100^len#Br J Psychiatry#20010000#2001#
178#261-7#20110000#aop0411.htm#0007-1250#Br J Psychiatry##
00628000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100022000870100019001090100
01900128010001800147010001800165012006700183030001500250710000200265065000900267
064000500276031000300281032000200284014000700286865000900293002001200302#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#c#201#25#article#42#25#
^rND^svon Knorring^nL#^rND^sAkerblad^nAC#^rND^sBengtsson^nF#^rND^sCarlsson^nA#^r
ND^sEkselius^nL#Cost of depression: effect of adherence and treatment response^l
en#Eur Psychiatry#2#20060000#2006#21#6#349-54#20110000#aop0411.htm##
00765000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100019001060100
02000125010002700145010002000172010001900192010001800211012008800229030002100317
06500090033806400050034703100030035203200020035501400060035786500090036300200120
0372035001000384801002100394#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\a
op0411.htm#S#c#202#26#article#42#26#^rND^sViinamäki^nH#^rND^sTanskanen^nA#^rND^s
Honkalampi^nK#^rND^sKoivumaa-Honkanen^nH#^rND^sAntikainen^nR#^rND^sHaatainen^nK#
^rND^sHintikka^nJ#Recovery from depression: a two-year follow-up study of genera
l population subjects^len#Int J Soc Psychiatry#20060000#2006#52#1#19-28#20110000
#aop0411.htm#0020-7640#Int J Soc Psychiatry##
00614000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100016001060120
11300122030001600235065000900251064000500260031000300265032000200268014000700270
865000900277002001200286035001000298801001600308#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop0411.htm#S#c#203#27#article#42#27#^rND^sGoldberg^nJF#^rND^
sHarrow^nM#Consistency of remission and outcome in bipolar and unipolar mood dis
orders: a 10-year prospective follow-up^len#J Affect Disord#20040000#2004#81#2#1
23-31#20110000#aop0411.htm#0165-0327#J Affect Disord##
00633000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100017001040120
13100121030001600252065000900268064000500277031000300282032000400285014000700289
865000900296002001200305035001000317801001600327#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop0411.htm#S#c#204#28#article#42#28#^rND^sKuehner^nC#^rND^sB
uerger^nC#Determinants of subjective quality of life in depressed patients: the 
role of self-esteem, response styles, and social support^len#J Affect Disord#200
50000#2005#86#2-3#205-13#20110000#aop0411.htm#0165-0327#J Affect Disord##
00645000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100015001060100
01700121012009000138030002900228065000900257064000500266031000300271032000200274
014000700276865000900283002001200292035001000304801002900314#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop0411.htm#S#c#205#29#article#42#29#^rND^sSkãrsã
ter^nI#^rND^sBaigi^nA#^rND^sHaglund^nL#Functional status and quality of life in 
patients with first-episode major depression^len#J Psychiatr Ment Health Nurs#20
060000#2006#13#2#205-13#20110000#aop0411.htm#1351-0126#J Psychiatr Ment Health N
urs##
00661000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100015001030100
01500118010001900133012010400152030001600256065000900272064000500281031000400286
032000200290014000800292865000900300002001200309035001000321801001600331#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#c#206#30#article#42#30#
^rND^sSimon^nGE#^rND^sFleck^nM#^rND^sLucas^nR#^rND^sBushnell^nDM#LIDO Group Prev
alence and predictors of depression treatment in an international primary care s
tudy^len#Am J Psychiatry#20040000#2004#161#9#1626-34#20110000#aop0411.htm#0002-9
53X#Am J Psychiatry##
00660000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100018001030100
01800121010001600139012009400155030002000249065000900269064000500278031000300283
032000200286014000700288865000900295002001200304035001000316801002000326#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#c#207#31#article#42#31#
^rND^sSimon^nGE#^rND^sGoldberg^nD#^rND^sTiemens^nBG#^rND^sUstun^nTB#Outcomes of 
recognized and unrecognized depression in an international primary care study^le
n#Gen Hosp Psychiatry#19990000#1999#21#2#97-105#20110000#aop0411.htm#0163-8343#G
en Hosp Psychiatry##
00608000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100015000870100016001020100
01400118010001800132012006200150030001200212065000900224064000500233031000300238
032000200241014000800243865000900251002001200260035001000272801001200282#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#c#208#32#article#42#32#
^rND^sWeich^nS#^rND^sMorgan^nL#^rND^sKing^nM#^rND^sNazareth^nI#Attitudes to depr
ession and its treatment in primary care^len#Psychol Med#20040000#2004#37#9#1239
-48#20110000#aop0411.htm#0033-2917#Psychol Med##
00634000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100014001050100
01600119010001600135012008300151030001400234065000900248064000500257031000300262
032000200265014000800267865000900275002001200284035001000296801001400306#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#c#209#33#article#42#33#
^rND^sHeinonen^nH#^rND^sAro^nAR#^rND^sAalto^nAM#^rND^sUutela^nA#Is the evaluatio
n of the global quality of life determined by emotional status^len#Qual Life Res
#20040000#2004#13#8#1347-56#20110000#aop0411.htm#0962-9343#Qual Life Res##
00776000000000337000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100015001040100
02100119010001700140010001800157010001800175012011900193030003400312065000900346
06400050035503100040036003200020036401400070036686500090037300200120038203500100
0394801003400404#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S
#c#210#34#article#42#34#^rND^sPicardi^nA#^rND^sRucci^nP#^rND^sde Girolamo^nG#^rN
D^sSantone^nG#^rND^sBorsetti^nG#^rND^sMorosini^nP#The quality of life of the men
tally ill living in residential facilities: findings from a national survey in I
taly^len#Eur Arch Psychiatry Clin Neurosci#20060000#2006#256#6#372-81#20110000#a
op0411.htm#0940-1334#Eur Arch Psychiatry Clin Neurosci##
00626000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100015001060100
01600121010001800137012006700155030001600222065000900238064000500247031000400252
032000200256014000700258865000900265002001200274035001000286801001600296#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#c#211#35#article#42#35#
^rND^sRapaport^nMK#^rND^sClary^nC#^rND^sFayard^nR#^rND^sEndicort^nJ#Quality of l
ife impairment in depressive and anxiety disorders^len#Am J Psychiatry#20050000#
2005#162#6#1171-8#20110000#aop0411.htm#0002-953X#Am J Psychiatry##
00638000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100017001050100
01900122010001600141012007600157030001600233065000900249064000500258031000400263
032000200267014000800269865000900277002001200286035001000298801001600308#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#c#212#36#article#42#36#
^rND^sKessler^nRC#^rND^sFoster^nCL#^rND^sSaunders^nWB#^rND^sStang^nPE#Social con
sequences of psychiatric disorders: I: Educational attainment^len#Am J Psychiatr
y#19950000#1995#152#7#1026-32#20110000#aop0411.htm#0002-953X#Am J Psychiatry##
00627000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100018001050100
02000123012009200143030001600235065000900251064000500260031000400265032000200269
014000700271865000900278002001200287035001000299801001600309#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop0411.htm#S#c#213#37#article#42#37#^rND^sKessle
r^nRC#^rND^sWalters^nEE#^rND^sForthofer^nMS#The social consequences of psychiatr
ic disorders: III: probability of marital stability^len#Am J Psychiatry#19980000
#1998#155#8#1092-6#20110000#aop0411.htm#0002-953X#Am J Psychiatry##
00730000000000337000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100017001050100
01600122010001500138010001900153011003100172012012000203030000500323065000900328
06400050033703100040034203200030034601400070034986500090035600200120036503500100
0377801000500387#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S
#c#214#38#article#42#38#^rND^sSpitzer^nRL#^rND^sKroenke^nK#^rND^sLinzer^nM#^rND^
sHahn^nSR#^rND^sWilliams^nJB#deGruy FV 3rd.Brody D.Davies M#Health-related quali
ty of life in primary care patients with mental disorders: Results from the PRIM
E-MD 1000 Study^len#JAMA#19950000#1995#274#19#1511-7#20110000#aop0411.htm#0098-7
484#JAMA##
00686000000000337000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100015000870100018001020100
02100120010001500141010001800156010001600174012007700190030001200267065000900279
06400050028803100030029303200020029601400070029886500090030500200120031403500100
0326801001200336#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S
#c#215#39#article#42#39#^rND^sOrmel^nJ#^rND^sVonkorff^nM#^rND^sOldehinkel^nAJ#^r
ND^sSimon^nG#^rND^sTiemens^nBG#^rND^sUstun^nTB#Onset of disability in depressed 
and non-depressed primary care patients^len#Psychol Med#19990000#1999#29#4#847-5
3#20110000#aop0411.htm#0033-2917#Psychol Med##
00715000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100020001050100
01700125010002500142010001800167010001700185010001600202010002000218012006100238
03000190029971000020031806500090032006400050032903100030033403200020033701400050
0339865000900344002001200353#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\a
op0411.htm#S#c#216#40#article#42#40#^rND^sGazalle^nFK#^rND^sAndreazza^nAC#^rND^s
Hallal^nPC#^rND^sKauer-Sant'anna^nM#^rND^sCeresér^nKM#^rND^sSoares^nJC#^rND^sSan
tin^nA#^rND^sKapczinski^nF#Bipolar depression: the importance of being on remiss
ion^len#Rev Bras Psiquiatr#2#20060000#2006#28#2#93-6#20110000#aop0411.htm##
00666000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100020001040100
02100124010001600145012010700161030001400268065000900282064000500291031000300296
032000200299014000600301865000900307002001200316035001000328801001400338#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop0411.htm#S#c#217#41#article#42#41#
^rND^sBerlim^nMT#^rND^sPavanello^nDP#^rND^sCaldieraro^nMA#^rND^sFleck^nMP#Reliab
ility and validity of the WHOQOL BREF in a sample of Brazilian outpatients with 
major depression^len#Qual Life Res#20050000#2005#14#2#561-4#20110000#aop0411.htm
#0962-9343#Qual Life Res##
00624000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100016001030100
01600119012008700135030002200222065000900244064000500253031000300258032000200261
014000600263865000900269002001200278035001000290801002200300#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop0411.htm#S#c#218#42#article#42#42#^rND^sBagby^
nRM#^rND^sRyder^nAG#^rND^sCristi^nC#Psychosocial and clinical predictors of resp
onse to pharmacotherapy for depression^len#J Psychiatry Neurosci#20020000#2002#2
7#4#250-7#20110000#aop0411.htm#1180-4882#J Psychiatry Neurosci##
00282000000000169000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780910009000800920007000890020012000967030
00400108#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#o#1#1#a
rticle#1#20110311#101417#aop0511.htm#206##
06220000000000817000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780710003000800400003000830010006000860420
00200092120000400094038000400098038000400102121000300106049000300109158000300112
03000220011503200060013706500090014301400070015203500100015922300090016901201500
01780120148003280100034004760100040005100100040005500100046005900100027006360100
04300663010004600706010004300752010003800795010004700833070009400880070014700974
07000730112107001350119407001380132907000910146708316590155808500100321708500290
32270850026032560850026032820850027033080850040033350831762033750850010051370850
03105147085002605178085002705204085002805231085004205259058000505301060001405306
06000140532011700080533407200030534211200090534511100130535411400090536711300140
5376002001205390#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S
#h#2#1#article#1#oa#en#br1.1#1#4.0#GRA#TAB#09#nd#nd#Rev. Bras. Psiquiatr.#ahead#
20110000#^f0^l0#1516-4446#20110318#Serum levels of IL-6, IL-10 and TNF-&#945; in
 patients with bipolar disorder and schizophrenia: differences in pro- and anti-
inflammatory balance^len#Níveis séricos de IL-6, IL-10 e TNF-&#945; em pacientes
 com transtorno bipolar e esquizofrenia: diferenças no equilíbrio pró e antiinfl
amatório^lpt#^rND^1A01 A02 A03^nMauricio^sKunz#^rND^1A01 A02 A03^nKeila Maria^sC
eresér#^rND^1A01 A02 A03^nPedro Domingues^sGoi#^rND^1A01 A02 A03 A04^nGabriel Ro
drigo^sFries#^rND^nAntonio L.^sTeixeira#^rND^1A01 A02 A03^nBrisa Simões^sFernand
es#^rND^1A04 A06^nPaulo Silva^sBelmonte-de-Abreu#^rND^1A01 A02 A03^nMárcia^sKaue
r-Sant'Anna#^rND^1A01 A02 A03^nFlavio^sKapczinski#^rND^1A01 A02 A03 A06^nClariss
a Severino^sGama#Hospital de Clínicas de Porto Alegre^iA01^1Bipolar Disorder Pro
gram^cPorto Alegre^sRS^pBrazil#Universidade Federal do Rio Grande do Sul^iA02^1H
ospital de Clínicas de Porto Alegre^2Laboratory of Molecular Psychiatry^cPorto A
legre^sRS^pBrazil#Universidade Federal do Rio Grande do Sul^iA03^cPorto Alegre^s
RS^pBrazil#Universidade Federal do Rio Grande do Sul^iA04^1Post-Graduation Progr
am in Biological Sciences: Biochemystry^cPorto Alegre^sRS^pBrazil#Universidade F
ederal de Minas Gerais^iA05^1Institute of Biological Sciences^2Laboratory of Imm
unopharmacology^cBelo Horizonte^sMG^pBrazil#Hospital de Clínicas de Porto Alegre
^iA06^1Schizophrenia Program^cPorto Alegre^sRS^pBrazil#^len^aOBJECTIVE: Previous
 reports suggest that cytokines act as potential mediators of the interaction be
tween the immune and neuroendocrine systems, and that a proinflammatory state ma
y be associated with bipolar disorder and schizophrenia. The aim is to compare c
ytokine levels in both disorders. METHOD: Twenty euthymic bipolar disorder patie
nts, 53 chronic stabilized schizophrenia patients and 80 healthy controls were r
ecruited. Subjects were all non-smokers and non-obese. Cytokines TNF-&#945;, IL-
6, and IL-10 were examined by sandwich ELISA. RESULTS: IL-6 levels were increase
d in schizophrenia patients when compared to controls (p < 0.0001) and euthymic 
bipolar disorder patients (p < 0.0001). IL-6 levels were no different in control
s compared to euthymic bipolar disorder patients (p = 0.357). IL-10 was lower in
 controls compared to schizophrenia patients (p = 0.001) or to bipolar disorder 
patients (p = 0.004). There was no significant difference in TNF-&#945; serum le
vels among the groups (p = 0.284). Gender-based classification did not significa
ntly alter these findings, and no correlation was found between the antipsychoti
c dose administered and cytokine levels in patients with schizophrenia. DISCUSSI
ON: These findings evidence a chronic immune activation in schizophrenia. Bipola
r disorder seems to present an episode-related inflammatory syndrome. Increased 
anti-inflammatory factor IL-10 in bipolar disorder and schizophrenia suggests di
fferent patterns of inflammatory balance between these two disorders. Results fu
rther support the need to investigate cytokines as possible biomarkers of diseas
e activity or treatment response.#^ddecs^i1#^tm^len^kBipolar disorder^i1#^tm^len
^kSchizophrenia^i1#^tm^len^kInterleukin-6^i1#^tm^len^kInterleukin-10^i1#^tm^len^
kTumor necrosis factor-alpha^i1#^lpt^aOBJETIVO: Pesquisas sugerem as citocinas c
omo potenciais mediadores da interação entre os sistemas imune e neuroendócrino,
 e que existe um estado pró-inflamatório associado com transtorno bipolar e esqu
izofrenia. O objetivo deste estudo é comparar os níveis de citocinas entre os do
is distúrbios. MÉTODO: Vinte pacientes com transtorno bipolar eutímicos, 53 paci
entes com esquizofrenia cronicamente estabilizados e 80 controles saudáveis fora
m recrutados. Todos os indivíduos são não-fumantes e não-obesos. As citocinas TN
F-&#945;, IL-6 e IL-10 foram examinadas por ELISA sanduíche. RESULTADOS: A IL-6 
estava aumentada nos pacientes com esquizofrenia quando comparados aos controles
 (p < 0,0001) e aos pacientes bipolares eutímicos (p < 0,0001). Os níveis de IL-
6 não foram diferentes nos controles em comparação com pacientes com transtorno 
bipolar eutímicos (p = 0,357). Os níveis de IL-10 foram menores nos controles qu
ando comparados aos esquizofrenia (p = 0,001) ou aos bipolares (p = 0,004). Não 
houve diferença significativa nos níveis séricos de TNF-&#945; entre os grupos (
p = 0,284). A separação por sexo não mostrou diferenças significativas e não hou
ve correlação entre a dose de antipsicóticos e os níveis de citocinas em pacient
es com esquizofrenia. DISCUSSÃO: Estes resultados evidenciam uma ativação imune 
crônica na esquizofrenia. O transtorno bipolar parece apresentar um aumento da a
tividade inflamatória relacionado ao episódio de humor. Níveis maiores de IL-10 
no transtorno bipolar e esquizofrenia sugerem diferentes padrões de equilíbrio i
nflamatório entre esses dois transtornos. Resultados fornecem apoio adicional pa
ra a investigação de citocinas como possíveis biomarcadores para a atividade da 
doença ou resposta ao tratamento.#^ddecs^i2#^tm^lpt^kTranstorno bipolar^i2#^tm^l
pt^kEsquizofrenia^i2#^tm^lpt^kInterleucina-6^i2#^tm^lpt^kInterleucina-10^i2#^tm^
lpt^kFator de necrose tumoral alfa^i2#CNPq#477974/2009-0#305967/2008-8#vancouv#4
0#20100607#June 7, 2010#20100722#July 22, 2010#aop0511.htm##
06477000000000817000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780710003000800400003000830010006000860420
00200092120000400094038000400098038000400102121000300106049000300109158000300112
03000220011503200060013706500090014301400070015203500100015922300090016901201780
01780120169003560100034005250100040005590100040005990100046006390100027006850100
04300712010004600755010004300801010003800844010004700882070009400929070014701023
07000730117007001350124307001380137807000910151608316930160708500100330008500290
33100850026033390850026033650850027033910850040034180831798034580850010052560850
03105266085002605297085002705323085002805350085004205378058000505420060008305425
06000830550811700080559107200030559911200090560211100130561111400090562411300140
5633002001205647#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S
#f#3#1#article#1#oa#en#br1.1#1#4.0#GRA#TAB#09#nd#nd#Rev. Bras. Psiquiatr.#ahead#
20110000#^f0^l0#1516-4446#20110318#<b>Serum levels of IL-6, IL-10 and TNF-</b><b
>&#945;</b><b> in patients with bipolar disorder and schizophrenia</b>: <b>diffe
rences in pro- and anti-inflammatory balance</b>^len#<b>Níveis séricos de IL-6, 
IL-10 e TNF-&#945;</b><b> em pacientes com transtorno bipolar e esquizofrenia</b
>: <b>diferenças no equilíbrio pró e antiinflamatório</b>^lpt#^rND^1A01 A02 A03^
nMauricio^sKunz#^rND^1A01 A02 A03^nKeila Maria^sCeresér#^rND^1A01 A02 A03^nPedro
 Domingues^sGoi#^rND^1A01 A02 A03 A04^nGabriel Rodrigo^sFries#^rND^nAntonio L.^s
Teixeira#^rND^1A01 A02 A03^nBrisa Simões^sFernandes#^rND^1A04 A06^nPaulo Silva^s
Belmonte-de-Abreu#^rND^1A01 A02 A03^nMárcia^sKauer-Sant'Anna#^rND^1A01 A02 A03^n
Flavio^sKapczinski#^rND^1A01 A02 A03 A06^nClarissa Severino^sGama#Hospital de Cl
ínicas de Porto Alegre^iA01^1Bipolar Disorder Program^cPorto Alegre^sRS^pBrazil#
Universidade Federal do Rio Grande do Sul^iA02^1Hospital de Clínicas de Porto Al
egre^2Laboratory of Molecular Psychiatry^cPorto Alegre^sRS^pBrazil#Universidade 
Federal do Rio Grande do Sul^iA03^cPorto Alegre^sRS^pBrazil#Universidade Federal
 do Rio Grande do Sul^iA04^1Post-Graduation Program in Biological Sciences: Bioc
hemystry^cPorto Alegre^sRS^pBrazil#Universidade Federal de Minas Gerais^iA05^1In
stitute of Biological Sciences^2Laboratory of Immunopharmacology^cBelo Horizonte
^sMG^pBrazil#Hospital de Clínicas de Porto Alegre^iA06^1Schizophrenia Program^cP
orto Alegre^sRS^pBrazil#^len^a<b>OBJECTIVE:</b> Previous reports suggest that cy
tokines act as potential mediators of the interaction between the immune and neu
roendocrine systems, and that a proinflammatory state may be associated with bip
olar disorder and schizophrenia. The aim is to compare cytokine levels in both d
isorders. <b>METHOD:</b> Twenty euthymic bipolar disorder patients, 53 chronic s
tabilized schizophrenia patients and 80 healthy controls were recruited. Subject
s were all non-smokers and non-obese. Cytokines TNF-&#945;, IL-6, and IL-10 were
 examined by sandwich ELISA. <b>RESULTS:</b> IL-6 levels were increased in schiz
ophrenia patients when compared to controls (p &lt; 0.0001) and euthymic bipolar
 disorder patients (p &lt; 0.0001). IL-6 levels were no different in controls co
mpared to euthymic bipolar disorder patients (p = 0.357). IL-10 was lower in con
trols compared to schizophrenia patients (p = 0.001) or to bipolar disorder pati
ents (p = 0.004). There was no significant difference in TNF-&#945; serum levels
 among the groups (p = 0.284). Gender-based classification did not significantly
 alter these findings, and no correlation was found between the antipsychotic do
se administered and cytokine levels in patients with schizophrenia. <b>DISCUSSIO
N:</b> These findings evidence a chronic immune activation in schizophrenia. Bip
olar disorder seems to present an episode-related inflammatory syndrome. Increas
ed anti-inflammatory factor IL-10 in bipolar disorder and schizophrenia suggests
 different patterns of inflammatory balance between these two disorders. Results
 further support the need to investigate cytokines as possible biomarkers of dis
ease activity or treatment response.#^ddecs^i1#^tm^len^kBipolar disorder^i1#^tm^
len^kSchizophrenia^i1#^tm^len^kInterleukin-6^i1#^tm^len^kInterleukin-10^i1#^tm^l
en^kTumor necrosis factor-alpha^i1#^lpt^a<b>OBJETIVO:</b> Pesquisas sugerem as c
itocinas como potenciais mediadores da interação entre os sistemas imune e neuro
endócrino, e que existe um estado pró-inflamatório associado com transtorno bipo
lar e esquizofrenia. O objetivo deste estudo é comparar os níveis de citocinas e
ntre os dois distúrbios. <b> MÉTODO:</b> Vinte pacientes com transtorno bipolar 
eutímicos, 53 pacientes com esquizofrenia cronicamente estabilizados e 80 contro
les saudáveis foram recrutados. Todos os indivíduos são não-fumantes e não-obeso
s. As citocinas TNF-&#945;, IL-6 e IL-10 foram examinadas por ELISA sanduíche. <
b>RESULTADOS:</b> A IL-6 estava aumentada nos pacientes com esquizofrenia quando
 comparados aos controles (p &lt; 0,0001) e aos pacientes bipolares eutímicos (p
 &lt; 0,0001). Os níveis de IL-6 não foram diferentes nos controles em comparaçã
o com pacientes com transtorno bipolar eutímicos (p = 0,357). Os níveis de IL-10
 foram menores nos controles quando comparados aos esquizofrenia (p = 0,001) ou 
aos bipolares (p = 0,004). Não houve diferença significativa nos níveis séricos 
de TNF-&#945; entre os grupos (p = 0,284). A separação por sexo não mostrou dife
renças significativas e não houve correlação entre a dose de antipsicóticos e os
 níveis de citocinas em pacientes com esquizofrenia. <b> DISCUSSÃO:</b> Estes re
sultados evidenciam uma ativação imune crônica na esquizofrenia. O transtorno bi
polar parece apresentar um aumento da atividade inflamatória relacionado ao epis
ódio de humor. Níveis maiores de IL-10 no transtorno bipolar e esquizofrenia sug
erem diferentes padrões de equilíbrio inflamatório entre esses dois transtornos.
 Resultados fornecem apoio adicional para a investigação de citocinas como possí
veis biomarcadores para a atividade da doença ou resposta ao tratamento.#^ddecs^
i2#^tm^lpt^kTranstorno bipolar^i2#^tm^lpt^kEsquizofrenia^i2#^tm^lpt^kInterleucin
a-6^i2#^tm^lpt^kInterleucina-10^i2#^tm^lpt^kFator de necrose tumoral alfa^i2#CNP
q#<span lang=EN-US style='font-size:10.0pt;font-family:Verdana'>477974/2009-0</s
pan>#<span lang=EN-US style='font-size:10.0pt;font-family:Verdana'>305967/2008-8
</span>#vancouv#40#20100607#June 7, 2010#20100722#July 22, 2010#aop0511.htm##
06350000000000841000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780640007000800710003000870400003000900010
00600093042000200099120000400101038000400105038000400109121000300113049000300116
15800030011903000210012203200060014306500090014901400070015803500100016522300090
01750120150001840120148003340100034004820100040005160100040005560100046005960100
02600642010004300668010004600711010004300757010003800800010004700838070009600885
07001490098107000750113007001370120507001400134207000930148208316590157508500100
32340850029032440850026032730850026032990850027033250850040033520831762033920850
01005154085003105164085002605195085002705221085002805248085004205276058000505318
06000140532306000140533711700080535107200030535911200090536211100130537111400090
5384113001405393002001205407008008905419#2011nahead#V:\SciELO\serial\rbp\2011nah
ead\markup\aop0511.htm#S#l#4#1#article#1#^a2011#oa#en#br1.1#1#4.0#gra#tab#09#nd#
nd#Rev. bras. psiquiatr#ahead#20110000#^f0^l0#1516-4446#20110318#Serum levels of
 IL-6, IL-10 and TNF-&#945; in patients with bipolar disorder and schizophrenia:
 differences in pro- and anti-inflammatory balance^len#Níveis séricos de IL-6, I
L-10 e TNF-&#945; em pacientes com transtorno bipolar e esquizofrenia: diferença
s no equilíbrio pró e antiinflamatório^lpt#^rND^1A01 A02 A03^nMauricio^sKunz#^rN
D^1A01 A02 A03^nKeila Maria^sCeresér#^rND^1A01 A02 A03^nPedro Domingues^sGoi#^rN
D^1A01 A02 A03 A04^nGabriel Rodrigo^sFries#^rND^nAntonio L^sTeixeira#^rND^1A01 A
02 A03^nBrisa Simões^sFernandes#^rND^1A04 A06^nPaulo Silva^sBelmonte-de-Abreu#^r
ND^1A01 A02 A03^nMárcia^sKauer-Sant'Anna#^rND^1A01 A02 A03^nFlavio^sKapczinski#^
rND^1A01 A02 A03 A06^nClarissa Severino^sGama#^iA01^1Hospital de Clínicas de Por
to Alegre^2Bipolar Disorder Program^cPorto Alegre^sRS^pBrazil#^iA02^1Universidad
e Federal do Rio Grande do Sul^2Hospital de Clínicas de Porto Alegre^3Laboratory
 of Molecular Psychiatry^cPorto Alegre^sRS^pBrazil#^iA03^1Universidade Federal d
o Rio Grande do Sul^cPorto Alegre^sRS^pBrazil#^iA04^1Universidade Federal do Rio
 Grande do Sul^2Post-Graduation Program in Biological Sciences: Biochemystry^cPo
rto Alegre^sRS^pBrazil#^iA05^1Universidade Federal de Minas Gerais^2Institute of
 Biological Sciences^3Laboratory of Immunopharmacology^cBelo Horizonte^sMG^pBraz
il#^iA06^1Hospital de Clínicas de Porto Alegre^2Schizophrenia Program^cPorto Ale
gre^sRS^pBrazil#^len^aOBJECTIVE: Previous reports suggest that cytokines act as 
potential mediators of the interaction between the immune and neuroendocrine sys
tems, and that a proinflammatory state may be associated with bipolar disorder a
nd schizophrenia. The aim is to compare cytokine levels in both disorders. METHO
D: Twenty euthymic bipolar disorder patients, 53 chronic stabilized schizophreni
a patients and 80 healthy controls were recruited. Subjects were all non-smokers
 and non-obese. Cytokines TNF-&#945;, IL-6, and IL-10 were examined by sandwich 
ELISA. RESULTS: IL-6 levels were increased in schizophrenia patients when compar
ed to controls (p < 0.0001) and euthymic bipolar disorder patients (p < 0.0001).
 IL-6 levels were no different in controls compared to euthymic bipolar disorder
 patients (p = 0.357). IL-10 was lower in controls compared to schizophrenia pat
ients (p = 0.001) or to bipolar disorder patients (p = 0.004). There was no sign
ificant difference in TNF-&#945; serum levels among the groups (p = 0.284). Gend
er-based classification did not significantly alter these findings, and no corre
lation was found between the antipsychotic dose administered and cytokine levels
 in patients with schizophrenia. DISCUSSION: These findings evidence a chronic i
mmune activation in schizophrenia. Bipolar disorder seems to present an episode-
related inflammatory syndrome. Increased anti-inflammatory factor IL-10 in bipol
ar disorder and schizophrenia suggests different patterns of inflammatory balanc
e between these two disorders. Results further support the need to investigate c
ytokines as possible biomarkers of disease activity or treatment response.#^ddec
s^i1#^tm^len^kBipolar disorder^i1#^tm^len^kSchizophrenia^i1#^tm^len^kInterleukin
-6^i1#^tm^len^kInterleukin-10^i1#^tm^len^kTumor necrosis factor-alpha^i1#^lpt^aO
BJETIVO: Pesquisas sugerem as citocinas como potenciais mediadores da interação 
entre os sistemas imune e neuroendócrino, e que existe um estado pró-inflamatóri
o associado com transtorno bipolar e esquizofrenia. O objetivo deste estudo é co
mparar os níveis de citocinas entre os dois distúrbios. MÉTODO: Vinte pacientes 
com transtorno bipolar eutímicos, 53 pacientes com esquizofrenia cronicamente es
tabilizados e 80 controles saudáveis foram recrutados. Todos os indivíduos são n
ão-fumantes e não-obesos. As citocinas TNF-&#945;, IL-6 e IL-10 foram examinadas
 por ELISA sanduíche. RESULTADOS: A IL-6 estava aumentada nos pacientes com esqu
izofrenia quando comparados aos controles (p < 0,0001) e aos pacientes bipolares
 eutímicos (p < 0,0001). Os níveis de IL-6 não foram diferentes nos controles em
 comparação com pacientes com transtorno bipolar eutímicos (p = 0,357). Os nívei
s de IL-10 foram menores nos controles quando comparados aos esquizofrenia (p = 
0,001) ou aos bipolares (p = 0,004). Não houve diferença significativa nos nívei
s séricos de TNF-&#945; entre os grupos (p = 0,284). A separação por sexo não mo
strou diferenças significativas e não houve correlação entre a dose de antipsicó
ticos e os níveis de citocinas em pacientes com esquizofrenia. DISCUSSÃO: Estes 
resultados evidenciam uma ativação imune crônica na esquizofrenia. O transtorno 
bipolar parece apresentar um aumento da atividade inflamatória relacionado ao ep
isódio de humor. Níveis maiores de IL-10 no transtorno bipolar e esquizofrenia s
ugerem diferentes padrões de equilíbrio inflamatório entre esses dois transtorno
s. Resultados fornecem apoio adicional para a investigação de citocinas como pos
síveis biomarcadores para a atividade da doença ou resposta ao tratamento.#^ddec
s^i2#^tm^lpt^kTranstorno bipolar^i2#^tm^lpt^kEsquizofrenia^i2#^tm^lpt^kInterleuc
ina-6^i2#^tm^lpt^kInterleucina-10^i2#^tm^lpt^kFator de necrose tumoral alfa^i2#C
NPq#477974/2009-0#305967/2008-8#vancouv#40#20100607#June 7, 2010#20100722#July 2
2, 2010#aop0511.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext
&pid=S1516-44462011005000009##
00598000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704035800082002001200440#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#5#1#article#162#<p><a name="t
op"></a><font face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Serum    
levels of IL-6, IL-10 and TNF-</b></font><b><font size="4">&#945;</font><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="4">    in patients with bipolar
 disorder and schizophrenia: differences in pro- and    anti-inflammatory balanc
e</font></b></p>     ^cY#aop0511.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#6#2#article#162#<p>&nbsp;</p>
     ^cY#aop0511.htm##
00620000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704038000082002001200462#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#7#3#article#162#<p><font face
="Verdana, Arial, Helvetica, sans-serif" size="3"><b>N&iacute;veis    s&eacute;r
icos de IL-6, IL-10 e TNF-</b></font><b><font size="3">&#945;</font><font face="
Verdana, Arial, Helvetica, sans-serif" size="3">    em pacientes com transtorno 
bipolar e esquizofrenia: diferen&ccedil;as no equil&iacute;brio    pr&oacute; e 
antiinflamat&oacute;rio</font></b></p>     ^cY#aop0511.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#8#4#article#162#<p>&nbsp;</p>
     ^cY#aop0511.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#9#5#article#162#<p>&nbsp;</p>
     ^cY#aop0511.htm##
00832000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704059100083002001200674#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#10#6#article#162#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Mauricio Kunz<sup>I,    II
, III, IV</sup>; Keila Maria Ceres&eacute;r<sup>I , II, III, IV</sup>; Pedro    
Domingues Goi<sup>I, II, III, IV</sup>; Gabriel Rodrigo Fries<sup>I, II, III,   
 V</sup>; Antonio L. Teixeira<sup>VI</sup>; Brisa Sim&otilde;es Fernandes<sup>I,
    II, III, IV</sup>; Paulo Silva Belmonte-de-Abreu<sup>III, IV, VII</sup>; M&a
acute;rcia    Kauer-Sant'Anna<sup>I, II, III, IV</sup>; Flavio Kapczinski<sup>I,
 II, III,    IV</sup>; Clarissa Severino Gama<sup>I, II, III, IV, VII</sup></b><
/font></p>     ^cY#aop0511.htm##
00432000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704019100083002001200274#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#11#7#article#162#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2"><sup>I</sup>Bipolar    Disord
er Program, Hospital de Cl&iacute;nicas de Porto Alegre (HCPA), Porto    Alegre,
 RS, Brazil    ^cY#aop0511.htm##
00438000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704019700083002001200280#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#12#8#article#162#<br>   <sup>
II</sup>Laboratory of Molecular Psychiatry, Hospital de Cl&iacute;nicas    de Po
rto Alegre (HCPA), Universidade Federal do Rio Grande do Sul (UFRGS), Porto    A
legre, RS, Brazil    ^cY#aop0511.htm##
00309000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704006800083002001200151#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#13#9#article#162#<br>   <sup>
III</sup>INCT for Translational Medicine, Brazil    ^cY#aop0511.htm##
00397000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704015500084002001200239#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#14#10#article#162#<br>   <sup
>IV</sup>Post-Graduation Program in Medicine: Psychiatry, Universidade Federal  
  do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil    ^cY#aop0511.htm##
00409000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704016700084002001200251#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#15#11#article#162#<br>   <sup
>V</sup>Post-Graduation Program in Biological Sciences: Biochemystry, Universida
de    Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil    ^cY#aop0
511.htm##
00412000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704017000084002001200254#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#16#12#article#162#<br>   <sup
>VI</sup>Laboratory of Immunopharmacology, Institute of Biological Sciences,    
Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil    ^cY#a
op0511.htm##
00385000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704014300084002001200227#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#17#13#article#162#<br>   <sup
>VII</sup>Schizophrenia Program, Hospital de Cl&iacute;nicas de Porto Alegre    
(HCPA), Porto Alegre, RS, Brazil</font></p>     ^cY#aop0511.htm##
00359000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704011700084002001200201#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#18#14#article#162#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><a href="#back">Corresponden
ce</a></font></p>     ^cY#aop0511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#19#15#article#162#<p>&nbsp;</
p>     ^cY#aop0511.htm##
00286000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704004400084002001200128#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#20#16#article#162#<p>&nbsp;</
p> <hr size="1" noshade>     ^cY#aop0511.htm##
00340000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009800084002001200182#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#21#17#article#162#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>ABSTRACT</b></font></p>  
   ^cY#aop0511.htm##
00624000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704038200084002001200466#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#22#18#article#162#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>OBJECTIVE:</b>    Previou
s reports suggest that cytokines act as potential mediators of the interaction  
  between the immune and neuroendocrine systems, and that a proinflammatory stat
e    may be associated with bipolar disorder and schizophrenia. The aim is to co
mpare    cytokine levels in both disorders.    ^cY#aop0511.htm##
00613000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704037100084002001200455#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#23#19#article#162#<br>   <b>M
ETHOD:</b> Twenty euthymic bipolar disorder patients, 53 chronic stabilized    s
chizophrenia patients and 80 healthy controls were recruited. Subjects were    a
ll non-smokers and non-obese. Cytokines TNF-</font><font size="2">&#945;</font><
font face="Verdana, Arial, Helvetica, sans-serif" size="2">,    IL-6, and IL-10 
were examined by sandwich ELISA.    ^cY#aop0511.htm##
01048000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704080600084002001200890#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#24#20#article#162#<br>   <b>R
ESULTS:</b> IL-6 levels were increased in schizophrenia patients when compared  
  to controls (p &lt; 0.0001) and euthymic bipolar disorder patients (p &lt; 0.0
001).    IL-6 levels were no different in controls compared to euthymic bipolar 
disorder    patients (p = 0.357). IL-10 was lower in controls compared to schizo
phrenia    patients (p = 0.001) or to bipolar disorder patients (p = 0.004). The
re was    no significant difference in TNF-</font><font size="2">&#945;</font><f
ont face="Verdana, Arial, Helvetica, sans-serif" size="2">    serum levels among
 the groups (p = 0.284). Gender-based classification did not    significantly al
ter these findings, and no correlation was found between the    antipsychotic do
se administered and cytokine levels in patients with schizophrenia.    ^cY#aop05
11.htm##
00732000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704049000084002001200574#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#25#21#article#162#<br>   <b>D
ISCUSSION:</b> These findings evidence a chronic immune activation in schizophre
nia.    Bipolar disorder seems to present an episode-related inflammatory syndro
me.    Increased anti-inflammatory factor IL-10 in bipolar disorder and schizoph
renia    suggests different patterns of inflammatory balance between these two d
isorders.    Results further support the need to investigate cytokines as possib
le biomarkers    of disease activity or treatment response.</font></p>     ^cY#a
op0511.htm##
00464000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704022200084002001200306#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#26#22#article#162#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Descriptors</b>:    Bipol
ar disorder; Schizophrenia; Interleukin-6; Interleukin-10; Tumor necrosis    fac
tor-alpha</font></p> <hr size="1" noshade>     ^cY#aop0511.htm##
00338000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009600084002001200180#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#27#23#article#162#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>    
 ^cY#aop0511.htm##
00688000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704044600084002001200530#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#28#24#article#162#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>OBJETIVO:</b>    Pesquisa
s sugerem as citocinas como potenciais mediadores da intera&ccedil;&atilde;o    
entre os sistemas imune e neuroend&oacute;crino, e que existe um estado pr&oacut
e;-inflamat&oacute;rio    associado com transtorno bipolar e esquizofrenia. O ob
jetivo deste estudo &eacute;    comparar os n&iacute;veis de citocinas entre os 
dois dist&uacute;rbios. <b>    ^cY#aop0511.htm##
00703000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704046100084002001200545#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#29#25#article#162#<br>   M&Ea
cute;TODO:</b> Vinte pacientes com transtorno bipolar eut&iacute;micos,    53 pa
cientes com esquizofrenia cronicamente estabilizados e 80 controles saud&aacute;
veis    foram recrutados. Todos os indiv&iacute;duos s&atilde;o n&atilde;o-fuman
tes    e n&atilde;o-obesos. As citocinas TNF-</font><font size="2">&#945;</font>
<font face="Verdana, Arial, Helvetica, sans-serif" size="2">,    IL-6 e IL-10 fo
ram examinadas por ELISA sandu&iacute;che.    ^cY#aop0511.htm##
01213000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704097100084002001201055#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#30#26#article#162#<br>   <b>R
ESULTADOS:</b> A IL-6 estava aumentada nos pacientes com esquizofrenia quando   
 comparados aos controles (p &lt; 0,0001) e aos pacientes bipolares eut&iacute;m
icos    (p &lt; 0,0001). Os n&iacute;veis de IL-6 n&atilde;o foram diferentes no
s controles    em compara&ccedil;&atilde;o com pacientes com transtorno bipolar 
eut&iacute;micos    (p = 0,357). Os n&iacute;veis de IL-10 foram menores nos con
troles quando comparados    aos esquizofrenia (p = 0,001) ou aos bipolares (p = 
0,004). N&atilde;o houve    diferen&ccedil;a significativa nos n&iacute;veis s&e
acute;ricos de TNF-</font><font size="2">&#945;</font><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">    entre os grupos (p = 0,284). A separa&cced
il;&atilde;o por sexo n&atilde;o mostrou    diferen&ccedil;as significativas e n
&atilde;o houve correla&ccedil;&atilde;o    entre a dose de antipsic&oacute;tico
s e os n&iacute;veis de citocinas em pacientes    com esquizofrenia. <b>    ^cY#
aop0511.htm##
00882000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704064000084002001200724#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#31#27#article#162#<br>   DISC
USS&Atilde;O:</b> Estes resultados evidenciam uma ativa&ccedil;&atilde;o    imun
e cr&ocirc;nica na esquizofrenia. O transtorno bipolar parece apresentar    um a
umento da atividade inflamat&oacute;ria relacionado ao epis&oacute;dio de    hum
or. N&iacute;veis maiores de IL-10 no transtorno bipolar e esquizofrenia    suge
rem diferentes padr&otilde;es de equil&iacute;brio inflamat&oacute;rio entre    
esses dois transtornos. Resultados fornecem apoio adicional para a investiga&cce
dil;&atilde;o    de citocinas como poss&iacute;veis biomarcadores para a ativida
de da doen&ccedil;a    ou resposta ao tratamento.</font></p>     ^cY#aop0511.htm
##
00470000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704022800084002001200312#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#32#28#article#162#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Descritores:</b>    Trans
torno bipolar; Esquizofrenia; Interleucina-6; Interleucina-10; Fator de    necro
se tumoral alfa</font></p> <hr size="1" noshade>     ^cY#aop0511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#33#29#article#162#<p>&nbsp;</
p>     ^cY#aop0511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#34#30#article#162#<p>&nbsp;</
p>     ^cY#aop0511.htm##
00344000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010200084002001200186#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#35#31#article#162#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Introduction</b></font></
p>     ^cY#aop0511.htm##
00772000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704053000084002001200614#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#36#32#article#162#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Bipolar disorder    and schi
zophrenia share many epidemiologic and clinical features.<sup>1</sup>    Increas
ing data suggest an overlap in genetic susceptibility across the two    diagnose
s.<sup>2</sup> Although their pathophysiology remains unclear, mechanisms    suc
h as oxidative stress and neuroplasticity have recently been implicated.<sup>3-6
</sup>    However, these mechanisms seem to be differently involved in each diso
rder.<sup>7,8</sup></font></p>     ^cY#aop0511.htm##
01234000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704099200084002001201076#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#37#33#article#162#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">It is well recognized    tha
t people with severe mental illnesses, such as schizophrenia (SZ) or bipolar    
disorder, (BD) have worse physical health outcomes and reduced life expectancy  
  compared to the general population.<sup>9</sup> The excessive cardiovascular  
  mortality associated with SZ and BD is attributed in part to an increased risk
    of the modifiable atherosclerotic risk factors: obesity, smoking, diabetes, 
   hypertension and dyslipidaemia.<sup>10-12</sup> Inflammation is a mechanism  
  that plays a part not only in atherosclerosis but also in different neuropsych
iatric    disorders, where it is involved in complex and reciprocal interactions
 with    neurotrophins and oxidative stress. Considering these interactions, a S
ystemic    Toxicity Index for mood episodes has recently been proposed to study 
neurotrophins,    oxidative stress markers and inflammatory markers.<sup>13</sup
></font></p>     ^cY#aop0511.htm##
01196000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704095400084002001201038#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#38#34#article#162#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">The action of cytokines    o
n brain cells has been shown to be an important component of the neuroimmunologi
cal    and neuroinflammatory response. Cytokines and related secretory products 
from    immune cells communicate with the endocrine and central nervous system t
o modulate    their collective functions.<sup>14</sup> In the field of mood diso
rders, the    immune system seems to play a particularly important role. Over th
e years, a    significant body of accumulated evidence suggests that major depre
ssion is associated    with dysfunction of inflammatory mediators.<sup>15</sup> 
Patients with unipolar    depression who are otherwise clinically healthy have b
een shown to present activated    inflammatory pathways, with increased pro-infl
ammatory cytokines, acute-phase    proteins, and increased expression of chemoki
nes and adhesion molecules.<sup>16-18</sup></font></p>     ^cY#aop0511.htm##
01124000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704088200084002001200966#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#39#35#article#162#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">More recently,    available 
evidence indicates that BD and inflammation are linked through shared    genetic
 polymorphisms and gene expression, as well as altered cytokine levels<sup>19</s
up>    during acute episodes<sup>20</sup> and euthymia.<sup>21</sup> It has been
 suggested    that inflammatory cytokines, particularly TNF-</font><font size="2
">&#945;</font><font face="Verdana, Arial, Helvetica, sans-serif" size="2">,    
may play a critical role in changes in neuroplasticity, cell resilience and    n
euronal survival.<sup>22,23</sup> Additionally, the combination of brain-derived
    neurotrophic factor (BDNF) and TNF-</font><font size="2">&#945;</font><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">    serum levels has been 
proposed as staging biomarkers for BD.<sup>24</sup></font></p>     ^cY#aop0511.h
tm##
01019000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704077700084002001200861#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#40#36#article#162#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Inflammatory processes    ha
ve also been implicated in the pathophysiology of SZ, and different studies    h
ave focused on the role of inflammation in SZ.<sup>25</sup> Many observations   
 of immune deregulation in SZ overlap with central pathophysiological mechanisms
    as well as with clinical manifestations of the illness. This is supported by
    a growing database of investigations, some of which even suggest that a subg
roup    of patients with SZ present the features of an autoimmune process.<sup>2
6</sup>    Although this is a concept that has not yet been fully grasped, the g
eneral    evidence of the existence of a pro-inflammatory state in SZ is, indeed
, consistent.<sup>23</sup></font></p>     ^cY#aop0511.htm##
00853000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704061100084002001200695#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#41#37#article#162#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">So far, no other    study ha
s compared the levels of inflammatory markers present in BD and SZ.    The exami
nation of the different expression of physiopathological mechanisms    may provi
de a better understanding of the etiological processes underlying both    disord
ers, as well as new possibilities for treatment. Therefore, this study    was de
signed to examine the levels of both euthymic patients with BD and chronic    st
abilized patients with SZ by comparing their cytokine levels against those    fr
om healthy controls.</font></p>     ^cY#aop0511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#42#38#article#162#<p>&nbsp;</
p>     ^cY#aop0511.htm##
00338000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009600084002001200180#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#43#39#article#162#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Method</b></font></p>    
 ^cY#aop0511.htm##
00343000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010100084002001200185#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#44#40#article#162#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>1. Subjects</b></font></p
>     ^cY#aop0511.htm##
00563000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704032100084002001200405#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#45#41#article#162#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">This study protocol    was a
pproved by the ethics committee of the Hospital de Cl&iacute;nicas de Porto    A
legre (HCPA), in Rio Grande do Sul, Brazil. All subjects provided their written 
   informed consent before inclusion in the study.</font></p>     ^cY#aop0511.ht
m##
02063000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704182100084002001201905#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#46#42#article#162#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">We selected 53    chronicall
y medicated and stabilized outpatients with SZ from the HCPA Schizophrenia    Pr
ogram, and 20 euthymic outpatients with BD from the HCPA Bipolar Disorders    Pr
ogram. All subjects were clinically interviewed by a trained psychiatrist.    On
ly those patients and controls who were non-smokers and non-obese, and who    di
d not present any major medical condition, such as atherosclerotic heart disease
    or diabetes, were included in the study. Obesity was defined as a body mass 
   index (weight in kilograms/height<sup>2</sup> in meters) of 30 or higher. The
    diagnosis of BD and SZ were confirmed according to the Diagnostic and Statis
tical    Manual of Mental Disorders, fourth Edition (DSM-IV).<sup>27</sup> The p
sychiatric    status of patients with SZ was assessed using the Brief Psychiatri
c Rating (BPRS)<sup>28</sup>    and the Clinical Global Impression (CGI).<sup>29
</sup> Only patients with BPRS    scores <u>&lt;</u> 25 and no history of a psyc
hiatric hospitalization over the    last two years were included in the study. M
ood symptoms in patients with BD    were identified using the Young Mania Rating
 Scale (YMRS)<sup>30</sup> and the    Hamilton Depression Rating Scale (HAMD-21)
.<sup>31</sup> Patients were considered    euthymic and, therefore, able to part
icipate in the study if both the YMRS and    the HAMD scores were lower than sev
en. The control group consisted of 80 medication-free    healthy volunteers who 
had no current or previous history, as well as no first-degree    family member 
with a history of a major psychiatric disorder, including dementia    or mental 
retardation as evaluated by the non-patient version of the Structured    Clinica
l Interview for DSM-IV (SCID).</font></p>     ^cY#aop0511.htm##
00365000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704012300084002001200207#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#47#43#article#162#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>2. Serum cytokines    mea
surement</b></font></p>     ^cY#aop0511.htm##
00596000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704035400084002001200438#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#48#44#article#162#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Five milliliters    of antic
oagulant-free blood were drawn by venipuncture from each subject on    the day o
f clinical interview. Serum was obtained by centrifugation at 3,000xg    for 5 m
inutes and then kept frozen at -70&deg;C until the assay i.e., six months    lat
er.</font></p>     ^cY#aop0511.htm##
01868000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704162600084002001201710#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#49#45#article#162#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Serum cytokines    were meas
ured as instructed by the manufacturer, using sandwich ELISA kits for    TNF-</f
ont><font size="2">&#945;</font><font face="Verdana, Arial, Helvetica, sans-seri
f" size="2">,    IL-6 and IL-10 (DuoSet, R&amp;D Systems, Minneapolis, Minn., US
A). All samples    were assayed in duplicates and the same plate was used. Detec
tion limits for    these assays were set at 5pg/ml. In brief, the capture antibo
dy (concentration    provided by the manufacturer) was diluted in PBS, added to 
each well and left    overnight at 4&deg;C. The plate was washed 4 times in PBS 
with 0.05% Tween-20    (Sigma, St. Louis, Mo., USA). The plate was blocked with 
1% bovine serum albumin    and incubated for 1 hour at room temperature before b
eing washed four times    with PBS and 0.05% Tween-20. The samples and standards
 were added, and the plate    incubated overnight at 4&deg;C. After the plate ha
d been washed, detection antibody    (concentration provided by the manufacturer
) diluted in PBS was added. The plate    was incubated for 2 hours at room tempe
rature. After the plate had been washed,    streptavidin (DuoSet, R&amp;D System
s) was added and the plate incubated for    30 minutes. Finally, color reagent <
i>o</i>-phenylenediamine (Sigma) was added    to each well, and the reaction was
 allowed to develop in the dark for 15 minutes.    The reaction was interrupted 
for the addition of 1 M H 2 SO 4 to each well.    The absorbance was read on a p
late reader at 492nm (Emax, Molecular Devices,    Minneapolis, Minn., USA).</fon
t></p>     ^cY#aop0511.htm##
00358000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704011600084002001200200#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#50#46#article#162#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>3. Statistical    analysi
s</b></font></p>     ^cY#aop0511.htm##
00894000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704065200084002001200736#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#51#47#article#162#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">As indicated, demographic   
 and clinical characteristics were analyzed using chi-square and ANOVA tests.   
 Descriptive analyses are presented as mean (standard deviation, SD) or median  
  (interquartile range), and p-values &lt; 0.05 were considered significant. Cyt
okine    levels showed a non-Gaussian distribution and were analyzed by applying
 the    appropriate tests: the Kruskal-Wallis test and the Mann-Whitney test. Re
lationships    between variables were assessed with Spearman rank correlation co
efficient.    Analysis was performed using SPSS Version 16.0.</font></p>     ^cY
#aop0511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#52#48#article#162#<p>&nbsp;</
p>     ^cY#aop0511.htm##
00339000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009700084002001200181#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#53#49#article#162#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Results</b></font></p>   
  ^cY#aop0511.htm##
01049000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704080700084002001200891#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#54#50#article#162#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">The subjects' demographics  
  and clinical characteristics are summarized in <a href="#t1">Table 1</a>. The 
   three groups were not significantly different in terms of age (p = 0.115). Le
ngth    of illness was longer in the group with SZ than in the group with BD (18
.0,    SD = 16.7 vs. 12.0, SD = 16.3, p = 0.026). Patients with SZ were predomin
antly    male (76%), while the BD and control groups had a lower frequency of ma
le subjects    (40% in both groups). In the SZ group, 12 patients were on atypic
al antipsychotics,    13 on typical antipsychotics and 28 on clozapine. The BD g
roup had 15 patients    on lithium, 8 on other mood stabilizers, 10 on antipsych
otics, 3 on antidepressants    and 6 on benzodiazepines.</font></p>     ^cY#aop0
511.htm##
00275000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704003300084002001200117#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#55#51#article#162#<p><a name=
"t1"></a></p>     ^cY#aop0511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#56#52#article#162#<p>&nbsp;</
p>     ^cY#aop0511.htm##
00328000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008600084002001200170#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#57#53#article#162#<p align="c
enter"><img src="/img/revistas/rbp/2011nahead/aop0511t01.jpg"></p>     ^cY#aop05
11.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#58#54#article#162#<p>&nbsp;</
p>     ^cY#aop0511.htm##
01587000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704134500084002001201429#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#59#55#article#162#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">IL-6 was significantly    in
creased in patients with SZ when compared to either the controls (p &lt; 0.0001)
    or the euthymic patients with BD (p &lt; 0.0001). IL-6 levels were no differ
ent    in controls compared to euthymic BD patients (p = 0.357). IL-10 was signi
ficantly    lower in controls compared to SZ (p = 0.001) or BD (p = 0.004). Ther
e was no    significant difference in TNF-</font><font size="2">&#945;</font><fo
nt face="Verdana, Arial, Helvetica, sans-serif" size="2">    serum levels among 
the three groups (p = 0.284) - <a href="/img/revistas/rbp/2011nahead/aop0511f01.
jpg">Figure    1</a>. The significance did not change when patients were classif
ied by gender    (p &lt; 0.001 and p = 0.008 for IL-6, p = 0.003 and p = 0.048 f
or IL-10 and    p = 0.165 and p = 0.159 for TNF-</font><font size="2">&#945;</fo
nt><font face="Verdana, Arial, Helvetica, sans-serif" size="2">,    for males an
d females, respectively). In patients with SZ, no correlation was    found betwe
en the antipsychotic dose (in milligrams of chlorpromazine equivalents)    and I
L-6 (rho = -0.267, p = 0.084), IL-10 (rho = 0.031, p = 0.845) or TNF-</font><fon
t size="2">&#945;</font><font face="Verdana, Arial, Helvetica, sans-serif" size=
"2">    (rho = -0.145, p = 0.363).</font></p>     ^cY#aop0511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#60#56#article#162#<p>&nbsp;</
p>     ^cY#aop0511.htm##
00342000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010000084002001200184#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#61#57#article#162#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Discussion</b></font></p>
     ^cY#aop0511.htm##
01248000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704100600084002001201090#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#62#58#article#162#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Our results are    in line w
ith those from previous reports on the presence of increased inflammatory    mar
kers in BD and SZ. However, we found significantly higher levels of pro-inflamma
tory    cytokine IL-6 in patients with SZ compared to either patients with BD or
 healthy    controls. Previous reports have found an association with IL-6 and a
cute symptomatology    in BD<sup>20</sup> and SZ.<sup>32</sup> Considering that 
our comparison involved    patients in non-acute phases of illness (euthymic BD 
vs. chronic SZ), our finding    that there is an increased presence of IL-6 in S
Z provides further evidence    of a chronic immune activation and inflammatory s
yndrome in SZ.<sup>23</sup>    While increased IL-6 seems to be state-dependent 
in BD, it seems to be a trait    in patients with SZ. Nevertheless, this finding
 could also be explained by the    longer duration of the illness in the SZ grou
p.<sup>33</sup></font></p>     ^cY#aop0511.htm##
00858000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704061600084002001200700#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#63#59#article#162#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Increased levels    of TNF-<
/font><font size="2">&#945;</font><font face="Verdana, Arial, Helvetica, sans-se
rif" size="2">    have also been previously reported in BD and SZ, and have been
 shown to be associated    with the symptomatology of both disorders.<sup>20,34<
/sup> Therefore, the fact    that TNF-</font><font size="2">&#945;</font><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">    levels were not differe
nt from those of the controls in our sample can be explained    by the non-acute
 profile of our subjects.</font></p>     ^cY#aop0511.htm##
01052000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704081000084002001200894#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#64#60#article#162#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Even though inflammation    
plays a role in both disorders, the overall balance of pro- and anti-inflammator
y    components is differently expressed. With this in mind, the increased level
s    of anti-inflammatory IL-10 found in both the SZ and BD groups, when compare
d    to controls, should not be easily dismissed. While this could be attributed
    to a direct response to the elevation of IL-6 in SZ, this phenomenon could a
lso    reflect a compensatory mechanism derived from previous episodes in BD. As
 levels    of IL-10 seem to decline with the progression of the disease,<sup>35<
/sup> the    general pro-inflammatory balance in BD worsens in the later stages 
of the illness    as the anti-inflammatory response abates.</font></p>     ^cY#a
op0511.htm##
01366000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704112400084002001201208#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#65#61#article#162#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">We believe that    a compara
tive assessment of the pathophysiological mechanisms at play in BD    and SZ may
 provide interesting insights into the different roles played by such    mechani
sms in each disorder. Past comparisons have suggested that different    profiles
 of oxidative stress,<sup>8</sup> neurotrophins<sup>7</sup> and different    pat
terns of correlation between oxidative stress markers and neurotrophins are    a
t play in SZ<sup>36</sup> and BD.<sup>37</sup> While different lines of evidence
    suggest that, in BD, we can see an episode-related deterioration pattern, it
    appears that, in SZ, this deterioration pattern seems to be of a chronic nat
ure,    starting at the onset of the illness. This observation brings us back to
 the    classic differentiation between the two diagnoses based on either an epi
sodic    or a chronic-deteriorating course. In SZ, however, difficulties in defi
ning    remission in a chronically ill and stable population may not allow for a
 clear    differentiation of state and trait effects.</font></p>     ^cY#aop0511
.htm##
01065000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704082300084002001200907#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#66#62#article#162#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">The interpretation    of thi
s report and its results must take into consideration certain limitations,    wh
ich include a lack of control for potential confounders. Factors such as diet   
 and level of physical activity can substantially contribute to alterations in  
  inflammatory markers<sup>11,38,39</sup> The excessive incidence of medical con
ditions    in both BD and SZ is increasingly recognized.<sup>9</sup> The majorit
y of these    conditions are related to inflammation, especially cardiovascular 
illness, obesity    and insulin resistance. Even though patients with significan
t medical problems    were excluded from our study, controlling for medical cond
itions, metabolic    alterations and lifestyle factors was not possible.</font><
/p>     ^cY#aop0511.htm##
00862000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704062000084002001200704#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#67#63#article#162#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Another potential    confoun
der is related to the different medications used by patients with BP    and SZ. 
It appears that mood stabilizers in general (and lithium more specifically)    a
ttenuate the pro-inflammatory milieu in BD.<sup>19</sup> Similarly, antipsychoti
cs    may also impact the production of cytokines.<sup>40</sup> Therefore, even 
in    the absence of any correlation between cytokine levels and the dose of ant
ipsychotic    medications taken by our subjects, the confounder effect of medica
tions cannot    be ruled out.</font></p>     ^cY#aop0511.htm##
00786000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704054400084002001200628#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#68#64#article#162#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Our findings point    to the
 involvement of inflammatory mechanisms as a component of the pathophysiology   
 of both BD and SZ, and provide insight into the different patterns seen in this
    association. We believe that studies aimed at performing a comparative analy
sis    among disorders may provide a more thorough understanding of the inflamma
tory    component at play in psychiatric illnesses, thus providing a basis for i
mproved    forms of intervention.</font></p>     ^cY#aop0511.htm##
00348000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010600084002001200190#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#69#65#article#162#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Acknowledgements</b></fon
t></p>     ^cY#aop0511.htm##
00448000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704020600084002001200290#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#70#66#article#162#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Clarissa Severino    Gama is
 funded by research grants from CNPq (Universal 477974/2009-0 and PQ    305967/2
008-8), Brazil.</font></p>     ^cY#aop0511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#71#67#article#162#<p>&nbsp;</
p>     ^cY#aop0511.htm##
00393000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704015100084002001200235#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#72#68#article#162#<p align="c
enter"><a href="/img/revistas/rbp/2011nahead/aop0511q01.jpg"><img src="/img/revi
stas/rbp/2011nahead/aop0511q01thumb.jpg" border="0">    ^cY#aop0511.htm##
00349000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010700084002001200191#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#73#69#article#162#<br>   <fon
t face="Verdana, Arial, Helvetica, sans-serif" size="2">Click to enlarge</font><
/a></p>     ^cY#aop0511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#74#70#article#162#<p>&nbsp;</
p>     ^cY#aop0511.htm##
00342000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010000084002001200184#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#75#71#article#162#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="3"><b>References</b></font></p>
     ^cY#aop0511.htm##
00483000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704022700086002001200313#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#76#72#article#162
#1#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">1. Berrettini 
WH.    Are schizophrenic and bipolar disorders related? A review of family and m
olecular    studies. <i>Biol Psychiatry.</i> 2000;48(6):531-8.    ^cY#aop0511.ht
m##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#77#73#article#162#</font></p>
     ^cY#aop0511.htm##
00495000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704023900086002001200325#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#78#74#article#162
#2#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2. Craddock N,
    O'Donovan MC, Owen MJ. Genes for schizophrenia and bipolar disorder? Implica
tions    for psychiatric nosology. <i>Schizophr Bull.</i> 2006;32(1):9-16.    ^c
Y#aop0511.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#79#75#article#162#</font></p>
     ^cY#aop0511.htm##
00533000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704027700086002001200363#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#80#76#article#162
#3#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">3. Andreazza A
C,    Kauer-Sant'anna M, Frey BN, Bond DJ, Kapczinski F, Young LT, Yatham LN. Ox
idative    stress markers in bipolar disorder: a meta-analysis. <i>J Affect Diso
rd.</i>    2008;111(2-3):135-44.    ^cY#aop0511.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#81#77#article#162#</font></p>
     ^cY#aop0511.htm##
00642000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704038600086002001200472#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#82#78#article#162
#4#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">4. Gama CS, Sa
lvador    M, Andreazza AC, Kapczinski F, Silva Belmonte-de-Abreu P. Elevated ser
um superoxide    dismutase and thiobarbituric acid reactive substances in schizo
phrenia: a study    of patients treated with haloperidol or clozapine. <i>Prog N
europsychopharmacol    Biol Psychiatry.</i> 2006;30(3):512-5.    ^cY#aop0511.htm
##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#83#79#article#162#</font></p>
     ^cY#aop0511.htm##
00571000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704031500086002001200401#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#84#80#article#162
#5#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">5. Gama CS, Sa
lvador    M, Andreazza AC, Lobato MI, Berk M, Kapczinski F, Belmonte-de-Abreu PS
. Elevated    serum thiobarbituric acid reactive substances in clinically sympto
matic schizophrenic    males. <i>Neurosci Lett.</i> 2008;433(3):270-3.    ^cY#ao
p0511.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#85#81#article#162#</font></p>
     ^cY#aop0511.htm##
00588000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704033200086002001200418#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#86#82#article#162
#6#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">6. Vargas HE, 
Gama    CS, Andreazza AC, Medeiros D, Stertz L, Fries G, Palha J, Cereser KM, Be
rk M,    Kapczinski F, Belmonte-de-Abreu PS. Decreased serum neurotrophin 3 in c
hronically    medicated schizophrenic males. <i>Neurosci Lett.</i> 2008;440(3):1
97-201.    ^cY#aop0511.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#87#83#article#162#</font></p>
     ^cY#aop0511.htm##
00556000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704030000086002001200386#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#88#84#article#162
#7#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">7. Gama CS, An
dreazza    AC, Kunz M, Berk M, Belmonte-de-Abreu PS, Kapczinski F. Serum levels 
of brain-derived    neurotrophic factor in patients with schizophrenia and bipol
ar disorder. <i>Neurosci    Lett.</i> 2007;420(1):45-8.    ^cY#aop0511.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#89#85#article#162#</font></p>
     ^cY#aop0511.htm##
00662000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704040600086002001200492#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#90#86#article#162
#8#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">8. Kunz M, Gam
a    CS, Andreazza AC, Salvador M, Cereser KM, Gomes FA, Belmonte-de-Abreu PS, B
erk    M, Kapczinski F. Elevated serum superoxide dismutase and thiobarbituric a
cid    reactive substances in different phases of bipolar disorder and in schizo
phrenia.    <i>Prog Neuropsychopharmacol Biol Psychiatry.</i> 2008;32(7):1677-81
.    ^cY#aop0511.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#91#87#article#162#</font></p>
     ^cY#aop0511.htm##
00507000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704025100086002001200337#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#92#88#article#162
#9#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">9. Roshanaei-M
oghaddam    B, Katon W. Premature mortality from general medical illnesses among
 persons    with bipolar disorder: a review. <i>Psychiatr Serv.</i> 2009;60(2):1
47-56.    ^cY#aop0511.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#93#89#article#162#</font></p>
     ^cY#aop0511.htm##
00553000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000300084704029600087002001200383#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#94#90#article#162
#10#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Elkis H, 
Gama    C, Suplicy H, Tambascia M, Bressan R, Lyra R, Cavalcante S, Minicucci W.
 Brazilian    Consensus on second-generation antipsychotics and metabolic disord
ers. <i>Rev    Bras Psiquiatr.</i> 2008;30(1):77-85.    ^cY#aop0511.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#95#91#article#162#</font></p>
     ^cY#aop0511.htm##
00656000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000300084704039900087002001200486#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#96#92#article#162
#11#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Guimaraes
 LR,    Jacka FN, Gama CS, Berk M, Leitao-Azevedo CL, Belmonte de Abreu MG, Loba
to MI,    Andreazza AC, Cereser KM, Kapczinski F, Belmonte-de-Abreu P. Serum lev
els of    brain-derived neurotrophic factor in schizophrenia on a hypocaloric di
et. <i>Prog    Neuropsychopharmacol Biol Psychiatry.</i> 2008;32(6):1595-8.    ^
cY#aop0511.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#97#93#article#162#</font></p>
     ^cY#aop0511.htm##
00562000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000300084704030500087002001200392#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#98#94#article#162
#12#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Leitao-Az
evedo    CL, Guimaraes LR, de Abreu MG, Gama CS, Lobato MI, Belmonte-de-Abreu PS
. Increased    dyslipidemia in schizophrenic outpatients using new generation an
tipsychotics.    <i>Rev Bras Psiquiatr.</i> 2006;28(4):301-4.    ^cY#aop0511.htm
##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#99#95#article#162#</font></p>
     ^cY#aop0511.htm##
00604000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081888000300085704034600088002001200434#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#100#96#article#16
2#13#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Kapczins
ki    F, Dal-Pizzol F, Teixeira AL, Magalhaes PV, Kauer-Sant'anna M, Klamt F, de
 Bittencourt    Pasquali MA, Quevedo J, Gama CS, Post R. A systemic toxicity ind
ex developed    to assess peripheral changes in mood episodes. <i>Mol Psychiatry
.</i> 2010;15(8):784-6.    ^cY#aop0511.htm##
00263000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081704002000085002001200105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#101#97#article#162#</font></p
>     ^cY#aop0511.htm##
00446000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081888000300085704018800088002001200276#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#102#98#article#16
2#14#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Turnbull
 AV,    Rivier C. Regulation of the HPA axis by cytokines. <i>Brain Behav Immun.
</i>    1995;9(4):253-75.    ^cY#aop0511.htm##
00263000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081704002000085002001200105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#103#99#article#162#</font></p
>     ^cY#aop0511.htm##
00657000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704039800089002001200487#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#104#100#article#1
62#15#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Licinio
 J,    Wong ML. The role of inflammatory mediators in the biology of major depre
ssion:    central nervous system cytokines modulate the biological substrate of 
depressive    symptoms, regulate stress-responsive systems, and contribute to ne
urotoxicity    and neuroprotection. <i>Mol Psychiatry.</i> 1999;4(4):317-27.    
^cY#aop0511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#105#101#article#162#</font></
p>     ^cY#aop0511.htm##
00534000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704027500089002001200364#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#106#102#article#1
62#16#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Kim YK,
 Na    KS, Shin KH, Jung HY, Choi SH, Kim JB. Cytokine imbalance in the pathophy
siology    of major depressive disorder. <i>Prog Neuropsychopharmacol Biol Psych
iatry.</i>    2007;31(5):1044-53.    ^cY#aop0511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#107#103#article#162#</font></
p>     ^cY#aop0511.htm##
00488000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704022900089002001200318#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#108#104#article#1
62#17#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Raison 
CL,    Capuron L, Miller AH. Cytokines sing the blues: inflammation and the path
ogenesis    of depression. <i>Trends Immunol.</i> 2006;27(1):24-31.    ^cY#aop05
11.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#109#105#article#162#</font></
p>     ^cY#aop0511.htm##
00568000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704030900089002001200398#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#110#106#article#1
62#18#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Yang K,
 Xie    G, Zhang Z, Wang C, Li W, Zhou W, Tang Y. Levels of serum interleukin (I
L)-6,    IL-1beta, tumour necrosis factor-alpha and leptin and their correlation
 in depression.    <i>Aust N Z J Psychiatry.</i> 2007;41(3):266-73.    ^cY#aop05
11.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#111#107#article#162#</font></
p>     ^cY#aop0511.htm##
00578000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704031900089002001200408#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#112#108#article#1
62#19#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Goldste
in BI,    Kemp DE, Soczynska JK, McIntyre RS. Inflammation and the phenomenology
, pathophysiology,    comorbidity, and treatment of bipolar disorder: a systemat
ic review of the literature.    <i>J Clin Psychiatry.</i> 2009;70(8):1078-90.   
 ^cY#aop0511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#113#109#article#162#</font></
p>     ^cY#aop0511.htm##
00595000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704033600089002001200425#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#114#110#article#1
62#20#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Brietzk
e E,    Stertz L, Fernandes BS, Kauer-Sant'anna M, Mascarenhas M, Escosteguy Var
gas    A, Chies JA, Kapczinski F. Comparison of cytokine levels in depressed, ma
nic    and euthymic patients with bipolar disorder. <i>J Affect Disord.</i> 2009
;116(3):214-7.    ^cY#aop0511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#115#111#article#162#</font></
p>     ^cY#aop0511.htm##
00530000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704027100089002001200360#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#116#112#article#1
62#21#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Brietzk
e E,    Kauer-Sant'anna M, Teixeira AL, Kapczinski F. Abnormalities in serum che
mokine    levels in euthymic patients with bipolar disorder. <i>Brain Behav Immu
n.</i>    2009;23(8):1079-82.    ^cY#aop0511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#117#113#article#162#</font></
p>     ^cY#aop0511.htm##
00488000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704022900089002001200318#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#118#114#article#1
62#22#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">22. Brietzk
e E,    Kapczinski F. TNF-alpha as a molecular target in bipolar disorder. <i>Pr
og Neuropsychopharmacol    Biol Psychiatry.</i> 2008;32(6):1355-61.    ^cY#aop05
11.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#119#115#article#162#</font></
p>     ^cY#aop0511.htm##
00529000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704027000089002001200359#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#120#116#article#1
62#23#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">23. Potvin 
S, Stip    E, Sepehry AA, Gendron A, Bah R, Kouassi E. Inflammatory cytokine alt
erations    in schizophrenia: a systematic quantitative review. <i>Biol Psychiat
ry.</i>    2008;63(8):801-8.    ^cY#aop0511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#121#117#article#162#</font></
p>     ^cY#aop0511.htm##
00579000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704032000089002001200409#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#122#118#article#1
62#24#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">24. Kapczin
ski    F, Dias VV, Kauer-Sant'Anna M, Brietzke E, Vazquez GH, Vieta E, Berk M. T
he    potential use of biomarkers as an adjunctive tool for staging bipolar diso
rder.    <i>Prog Neuropsychopharmacol Biol Psychiatry.</i> 2009;33(8):1366-71.  
  ^cY#aop0511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#123#119#article#162#</font></
p>     ^cY#aop0511.htm##
00492000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704023300089002001200322#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#124#120#article#1
62#25#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">25. Rotherm
undt    M, Arolt V, Bayer TA. Review of immunological and immunopathological fin
dings    in schizophrenia. <i>Brain Behav Immun.</i> 2001;15(4):319-39.    ^cY#a
op0511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#125#121#article#162#</font></
p>     ^cY#aop0511.htm##
00507000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704024800089002001200337#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#126#122#article#1
62#26#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">26. Strous 
RD,    Shoenfeld Y. Schizophrenia, autoimmunity and immune system dysregulation:
 a    comprehensive model updated and revisited. <i>J Autoimmun.</i> 2006;27(2):
71-80.    ^cY#aop0511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#127#123#article#162#</font></
p>     ^cY#aop0511.htm##
00495000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704023600089002001200325#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#128#124#article#1
62#27#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">27. APA - A
merican    Psychiatry Association. D<i>iagnostic and statistical manual of menta
l disorders.</i>    Washington, DC: American Psychiatry Association; 2000.    ^c
Y#aop0511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#129#125#article#162#</font></
p>     ^cY#aop0511.htm##
00637000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704037800089002001200467#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#130#126#article#1
62#28#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">28. Romano 
F, Elkis    H. <i>Tradu&ccedil;&atilde;o e adapta&ccedil;&atilde;o de um instrum
ento de    avalia&ccedil;&atilde;o psicopatol&oacute;gica das psicoses: a escala
 breve    de avalia&ccedil;&atilde;o psiqui&aacute;trica.</i> Vers&atilde;o Anco
rada (BPRS-A).    <i>J Bras Psiquiatr.</i> 1996;45:43-9.    ^cY#aop0511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#131#127#article#162#</font></
p>     ^cY#aop0511.htm##
00593000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704033400089002001200423#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#132#128#article#1
62#29#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">29. Lima MS
, Soares    BG, Paoliello G, Machado Vieira R, Martins CM, Mota Neto JI, Ferrao 
Y, Schirmer    DA, Volpe FM. The Portuguese version of the Clinical Global Impre
ssion-Schizophrenia    Scale: validation study. <i>Rev Bras Psiquiatr.</i> 2007;
29(3):246-9.    ^cY#aop0511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#133#129#article#162#</font></
p>     ^cY#aop0511.htm##
00487000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704022800089002001200317#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#134#130#article#1
62#30#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">30. Young R
C, Biggs    JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, val
idity and    sensitivity. <i>Br J Psychiatry.</i> 1978;133:429-35.    ^cY#aop051
1.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#135#131#article#162#</font></
p>     ^cY#aop0511.htm##
00432000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704017300089002001200262#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#136#132#article#1
62#31#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">31. Hamilto
n M.    A rating scale for depression. <i>J Neurol Neurosurg Psychiatry.</i> 196
0;23:56-62.    ^cY#aop0511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#137#133#article#162#</font></
p>     ^cY#aop0511.htm##
00473000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704021400089002001200303#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#138#134#article#1
62#32#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">32. Naudin 
J, Mege    JL, Azorin JM, Dassa D. Elevated circulating levels of IL-6 in schizo
phrenia.    <i>Schizophr Res.</i> 1996;20(3):269-73.    ^cY#aop0511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#139#135#article#162#</font></
p>     ^cY#aop0511.htm##
00553000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704029400089002001200383#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#140#136#article#1
62#33#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">33. Ganguli
 R,    Yang Z, Shurin G, Chengappa KN, Brar JS, Gubbi AV, Rabin BS. Serum interl
eukin-6    concentration in schizophrenia: elevation associated with duration of
 illness.    <i>Psychiatry Res.</i> 1994;51(1):1-10.    ^cY#aop0511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#141#137#article#162#</font></
p>     ^cY#aop0511.htm##
00597000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704033800089002001200427#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#142#138#article#1
62#34#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">34. Erbagci
 AB,    Herken H, Koyluoglu O, Yilmaz N, Tarakcioglu M. Serum IL-1beta, sIL-2R, 
IL-6,    IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatol
ogy and    responsiveness to risperidone treatment. <i>Mediators Inflamm.</i> 20
01;10(3):109-15.    ^cY#aop0511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#143#139#article#162#</font></
p>     ^cY#aop0511.htm##
00597000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704033800089002001200427#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#144#140#article#1
62#35#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">35. Kauer-S
ant'Anna    M, Kapczinski F, Andreazza AC, Bond DJ, Lam RW, Young LT, Yatham LN.
 Brain-derived    neurotrophic factor and inflammatory markers in patients with 
early- vs. late-stage    bipolar disorder. <i>Int J Neuropsychopharmacol.</i> 20
09;12(4):447-58.    ^cY#aop0511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#145#141#article#162#</font></
p>     ^cY#aop0511.htm##
00624000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704036500089002001200454#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#146#142#article#1
62#36#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">36. Gama CS
, Berk    M, Andreazza AC, Kapczinski F, Belmonte-de-Abreu P. Serum levels of br
ain-derived    neurotrophic factor and thiobarbituric acid reactive substances i
n chronically    medicated schizophrenic patients: a positive correlation. <i>Re
v Bras Psiquiatr.</i>    2008;30(4):337-40.    ^cY#aop0511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#147#143#article#162#</font></
p>     ^cY#aop0511.htm##
00555000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704029600089002001200385#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#148#144#article#1
62#37#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">37. Kapczin
ski    F, Frey BN, Andreazza AC, Kauer-Sant'Anna M, Cunha AB, Post RM. Increased
 oxidative    stress as a mechanism for decreased BDNF levels in acute manic epi
sodes. <i>Rev    Bras Psiquiatr.</i> 2008;30(3):243-5.    ^cY#aop0511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#149#145#article#162#</font></
p>     ^cY#aop0511.htm##
00579000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704032000089002001200409#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#150#146#article#1
62#38#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">38. Jacka F
N, Gama    CS, Berk M. Brain-derived neurotrophic factor: a modifiable common me
diator    in both the pathophysiology of psychiatric illness and in successful p
harmacological    treatments. <i>Acta Neuropsychiatrica.</i> 2008;20(4):223-5.  
  ^cY#aop0511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#151#147#article#162#</font></
p>     ^cY#aop0511.htm##
00564000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704030500089002001200394#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#152#148#article#1
62#39#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">39. Molteni
 R,    Barnard RJ, Ying Z, Roberts CK, Gomez-Pinilla F. A high-fat, refined suga
r diet    reduces hippocampal brain-derived neurotrophic factor, neuronal plasti
city,    and learning. <i>Neuroscience.</i> 2002;112(4):803-14.    ^cY#aop0511.h
tm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#153#149#article#162#</font></
p>     ^cY#aop0511.htm##
00502000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704024300089002001200332#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#154#150#article#1
62#40#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">40. Drzyzga
 L,    Obuchowicz E, Marcinowska A, Herman ZS. Cytokines in schizophrenia and th
e effects    of antipsychotic drugs. <i>Brain Behav Immun.</i> 2006;20(6):532-45
.    ^cY#aop0511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#155#151#article#162#</font></
p>     ^cY#aop0511.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#156#152#article#162#<p>&nbsp;
</p>     ^cY#aop0511.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#157#153#article#162#<p>&nbsp;
</p>     ^cY#aop0511.htm##
00435000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704019100086002001200277#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#158#154#article#162#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2"><a name="back"></a><b><a h
ref="#top"><img src="/img/revistas/rbp/2011nahead/seta.jpg" border="0"></a>    C
orrespondence:    ^cY#aop0511.htm##
00286000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704004200086002001200128#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#159#155#article#162#<br>   </
b> Clarissa Severino Gama    ^cY#aop0511.htm##
00336000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704009200086002001200178#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#160#156#article#162#<br>   Ho
spital de Cl&iacute;nicas de Porto Alegre - Molecular Psychiatry Laboratory    ^
cY#aop0511.htm##
00306000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704006200086002001200148#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#161#157#article#162#<br>   Ru
a Ramiro Barcelos, 2350 - Pr&eacute;dio Anexo    ^cY#aop0511.htm##
00293000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704004900086002001200135#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#162#158#article#162#<br>   90
035-903 Porto Alegre, RS, Brasil    ^cY#aop0511.htm##
00308000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704006400086002001200150#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#163#159#article#162#<br>   Ph
one: (+55 51) 3359-8845 FAX: (+55 51) 3359-8846    ^cY#aop0511.htm##
00332000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704008800086002001200174#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#164#160#article#162#<br>   Em
ail: <a href="mailto:csgama@yahoo.com">csgama@yahoo.com</a></font></p>     ^cY#a
op0511.htm##
00341000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704009700086002001200183#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#165#161#article#162#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">Submitted: June    7, 2010
    ^cY#aop0511.htm##
00294000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704005000086002001200136#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#p#166#162#article#162#<br>   Ac
cepted: July 22, 2010</font></p>     ^cY#aop0511.htm##
00532000000000265000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100021000850120095001060300
01700201710000200218065000900220064000500229031000300234032000200237014000600239
865000900245002001200254#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop05
11.htm#S#c#167#1#article#40#1#^rND^sBerrettini^nWH#Are schizophrenic and bipolar
 disorders related?: A review of family and molecular studies^len#Biol Psychiatr
y.#2#20000000#2000#48#6#531-8#20110000#aop0511.htm##
00580000000000289000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100018000850100020001030100
01500123012008900138030001600227710000200243065000900245064000500254031000300259
032000200262014000500264865000900269002001200278#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop0511.htm#S#c#168#2#article#40#2#^rND^sCraddock^nN#^rND^sO'
Donovan^nMC#^rND^sOwen^nMJ#Genes for schizophrenia and bipolar disorder?: Implic
ations for psychiatric nosology^len#Schizophr Bull.#2#20060000#2006#32#1#9-16#20
110000#aop0511.htm##
00686000000000337000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100020000850100025001050100
01500130010001500145010002000160010001600180010001700196012006600213030001700279
71000020029606500090029806400050030703100040031203200040031601400070032086500090
0327002001200336#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S
#c#169#3#article#40#3#^rND^sAndreazza^nAC#^rND^sKauer-Sant'anna^nM#^rND^sFrey^nB
N#^rND^sBond^nDJ#^rND^sKapczinski^nF#^rND^sYoung^nLT#^rND^sYatham^nLN#Oxidative 
stress markers in bipolar disorder: a meta-analysis^len#J Affect Disord.#2#20080
000#2008#111#2-3#135-44#20110000#aop0511.htm##
00756000000000313000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100015000850100018001000100
02000118010002000138010003300158012016000191030004300351710000200394065000900396
064000500405031000300410032000200413014000600415865000900421002001200430#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#c#170#4#article#40#4#^r
ND^sGama^nCS#^rND^sSalvador^nM#^rND^sAndreazza^nAC#^rND^sKapczinski^nF#^rND^sSil
va Belmonte-de-Abreu^nP#Elevated serum superoxide dismutase and thiobarbituric a
cid reactive substances in schizophrenia: a study of patients treated with halop
eridol or clozapine^len#Prog Neuropsychopharmacol Biol Psychiatry.#2#20060000#20
06#30#3#512-5#20110000#aop0511.htm##
00724000000000337000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100015000850100018001000100
02000118010001700138010001400155010002000169010002800189012010500217030001500322
71000020033706500090033906400050034803100040035303200020035701400060035986500090
0365002001200374#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S
#c#171#5#article#40#5#^rND^sGama^nCS#^rND^sSalvador^nM#^rND^sAndreazza^nAC#^rND^
sLobato^nMI#^rND^sBerk^nM#^rND^sKapczinski^nF#^rND^sBelmonte-de-Abreu^nPS#Elevat
ed serum thiobarbituric acid reactive substances in clinically symptomatic schiz
ophrenic males^len#Neurosci Lett.#2#20080000#2008#433#3#270-3#20110000#aop0511.h
tm##
00813000000000385000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100017000850100015001020100
02000117010001800137010001600155010001500171010001500186010001800201010001400219
01000200023301000280025301200800028103000150036171000020037606500090037806400050
0387031000400392032000200396014000800398865000900406002001200415#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#c#172#6#article#40#6#^rND^sVarg
as^nHE#^rND^sGama^nCS#^rND^sAndreazza^nAC#^rND^sMedeiros^nD#^rND^sStertz^nL#^rND
^sFries^nG#^rND^sPalha^nJ#^rND^sCereser^nKM#^rND^sBerk^nM#^rND^sKapczinski^nF#^r
ND^sBelmonte-de-Abreu^nPS#Decreased serum neurotrophin 3 in chronically medicate
d schizophrenic males^len#Neurosci Lett.#2#20080000#2008#440#3#197-201#20110000#
aop0511.htm##
00691000000000325000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100015000850100020001000100
01400120010001400134010002800148010002000176012010600196030001500302710000200317
06500090031906400050032803100040033303200020033701400050033986500090034400200120
0353#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#c#173#7#art
icle#40#7#^rND^sGama^nCS#^rND^sAndreazza^nAC#^rND^sKunz^nM#^rND^sBerk^nM#^rND^sB
elmonte-de-Abreu^nPS#^rND^sKapczinski^nF#Serum levels of brain-derived neurotrop
hic factor in patients with schizophrenia and bipolar disorder^len#Neurosci Lett
.#2#20070000#2007#420#1#45-8#20110000#aop0511.htm##
00848000000000361000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100014000850100015000990100
02000114010001800134010001800152010001600170010002800186010001400214010002000228
01201450024803000430039371000020043606500090043806400050044703100030045203200020
0455014000800457865000900465002001200474#2011nahead#V:\SciELO\serial\rbp\2011nah
ead\markup\aop0511.htm#S#c#174#8#article#40#8#^rND^sKunz^nM#^rND^sGama^nCS#^rND^
sAndreazza^nAC#^rND^sSalvador^nM#^rND^sCereser^nKM#^rND^sGomes^nFA#^rND^sBelmont
e-de-Abreu^nPS#^rND^sBerk^nM#^rND^sKapczinski^nF#Elevated serum superoxide dismu
tase and thiobarbituric acid reactive substances in different phases of bipolar 
disorder and in schizophrenia^len#Prog Neuropsychopharmacol Biol Psychiatry.#2#2
0080000#2008#32#7#1677-81#20110000#aop0511.htm##
00573000000000277000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100029000850100015001140120
10100129030001600230710000200246065000900248064000500257031000300262032000200265
014000700267865000900274002001200283#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop0511.htm#S#c#175#9#article#40#9#^rND^sRoshanaei-Moghaddam^nB#^rND^sKat
on^nW#Premature mortality from general medical illnesses among persons with bipo
lar disorder: a review^len#Psychiatr Serv.#2#20090000#2009#60#2#147-56#20110000#
aop0511.htm##
00724000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100015000870100014001020100
01700116010001900133010001700152010001400169010002000183010001900203012008400222
03000200030671000020032606500090032806400050033703100030034203200020034501400060
0347865000900353002001200362#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\a
op0511.htm#S#c#176#10#article#40#10#^rND^sElkis^nH#^rND^sGama^nC#^rND^sSuplicy^n
H#^rND^sTambascia^nM#^rND^sBressan^nR#^rND^sLyra^nR#^rND^sCavalcante^nS#^rND^sMi
nicucci^nW#Brazilian Consensus on second-generation antipsychotics and metabolic
 disorders^len#Rev Bras Psiquiatr.#2#20080000#2008#30#1#77-85#20110000#aop0511.h
tm##
00878000000000385000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100020000870100016001070100
01500123010001400138010002500152010002800177010001700205010002000222010001800242
01000200026001000270028001200930030703000430040071000020044306500090044506400050
0454031000300459032000200462014000700464865000900471002001200480#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#c#177#11#article#40#11#^rND^sGu
imaraes^nLR#^rND^sJacka^nFN#^rND^sGama^nCS#^rND^sBerk^nM#^rND^sLeitao-Azevedo^nC
L#^rND^sBelmonte de Abreu^nMG#^rND^sLobato^nMI#^rND^sAndreazza^nAC#^rND^sCereser
^nKM#^rND^sKapczinski^nF#^rND^sBelmonte-de-Abreu^nP#Serum levels of brain-derive
d neurotrophic factor in schizophrenia on a hypocaloric diet^len#Prog Neuropsych
opharmacol Biol Psychiatry.#2#20080000#2008#32#6#1595-8#20110000#aop0511.htm##
00697000000000325000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100025000870100020001120100
01900132010001500151010001700166010002800183012009200211030002000303710000200323
06500090032506400050033403100030033903200020034201400060034486500090035000200120
0359#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#c#178#12#ar
ticle#40#12#^rND^sLeitao-Azevedo^nCL#^rND^sGuimaraes^nLR#^rND^sde Abreu^nMG#^rND
^sGama^nCS#^rND^sLobato^nMI#^rND^sBelmonte-de-Abreu^nPS#Increased dyslipidemia i
n schizophrenic outpatients using new generation antipsychotics^len#Rev Bras Psi
quiatr.#2#20060000#2006#28#4#301-4#20110000#aop0511.htm##
00810000000000373000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100020000870100020001070100
01900127010002000146010002500166010001500191010003400206010001700240010001500257
01000140027201200860028603000160037271000020038806500090039006400050039903100030
0404032000200407014000600409865000900415002001200424#2011nahead#V:\SciELO\serial
\rbp\2011nahead\markup\aop0511.htm#S#c#179#13#article#40#13#^rND^sKapczinski^nF#
^rND^sDal-Pizzol^nF#^rND^sTeixeira^nAL#^rND^sMagalhaes^nPV#^rND^sKauer-Sant'anna
^nM#^rND^sKlamt^nF#^rND^sde Bittencourt Pasquali^nMA#^rND^sQuevedo^nJ#^rND^sGama
^nCS#^rND^sPost^nR#A systemic toxicity index developed to assess peripheral chan
ges in mood episodes^len#Mol Psychiatry.#2#20100000#2010#15#8#784-6#20110000#aop
0511.htm##
00511000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100016001060120
04400122030001900166710000200185065000900187064000500196031000200201032000200203
014000700205865000900212002001200221#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop0511.htm#S#c#180#14#article#40#14#^rND^sTurnbull^nAV#^rND^sRivier^nC#R
egulation of the HPA axis by cytokines^len#Brain Behav Immun.#2#19950000#1995#9#
4#253-75#20110000#aop0511.htm##
00715000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100015001040120
25400119030001600373710000200389065000900391064000500400031000200405032000200407
014000700409865000900416002001200425#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop0511.htm#S#c#181#15#article#40#15#^rND^sLicinio^nJ#^rND^sWong^nML#The 
role of inflammatory mediators in the biology of major depression: central nervo
us system cytokines modulate the biological substrate of depressive symptoms, re
gulate stress-responsive systems, and contribute to neurotoxicity and neuroprote
ction^len#Mol Psychiatry.#2#19990000#1999#4#4#317-27#20110000#aop0511.htm##
00667000000000325000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100014000870100013001010100
01500114010001500129010001500144010001400159012007500173030004300248710000200291
06500090029306400050030203100030030703200020031001400080031286500090032000200120
0329#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#c#182#16#ar
ticle#40#16#^rND^sKim^nYK#^rND^sNa^nKS#^rND^sShin^nKH#^rND^sJung^nHY#^rND^sChoi^
nSH#^rND^sKim^nJB#Cytokine imbalance in the pathophysiology of major depressive 
disorder^len#Prog Neuropsychopharmacol Biol Psychiatry.#2#20070000#2007#31#5#104
4-53#20110000#aop0511.htm##
00570000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100017001040100
01700121012007800138030001600216710000200232065000900234064000500243031000300248
032000200251014000600253865000900259002001200268#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop0511.htm#S#c#183#17#article#40#17#^rND^sRaison^nCL#^rND^sC
apuron^nL#^rND^sMiller^nAH#Cytokines sing the blues: inflammation and the pathog
enesis of depression^len#Trends Immunol.#2#20060000#2006#27#1#24-31#20110000#aop
0511.htm##
00719000000000337000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100014000870100013001010100
01500114010001400129010001200143010001400155010001400169012012600183030002300309
71000020033206500090033406400050034303100030034803200020035101400070035386500090
0360002001200369#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S
#c#184#18#article#40#18#^rND^sYang^nK#^rND^sXie^nG#^rND^sZhang^nZ#^rND^sWang^nC#
^rND^sLi^nW#^rND^sZhou^nW#^rND^sTang^nY#Levels of serum interleukin (IL)-6, IL-1
beta, tumour necrosis factor-alpha and leptin and their correlation in depressio
n^len#Aust N Z J Psychiatry.#2#20070000#2007#41#3#266-73#20110000#aop0511.htm##
00675000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100020000870100015001070100
02000122010001900142012014300161030001900304710000200323065000900325064000500334
031000300339032000200342014000800344865000900352002001200361#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop0511.htm#S#c#185#19#article#40#19#^rND^sGoldst
ein^nBI#^rND^sKemp^nDE#^rND^sSoczynska^nJK#^rND^sMcIntyre^nRS#Inflammation and t
he phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorde
r: a systematic review of the literature^len#J Clin Psychiatry.#2#20090000#2009#
70#8#1078-90#20110000#aop0511.htm##
00764000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100016001050100
02000121010002500141010002100166010002700187010001600214010002000230012009800250
03000170034871000020036506500090036706400050037603100040038103200020038501400060
0387865000900393002001200402#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\a
op0511.htm#S#c#186#20#article#40#20#^rND^sBrietzke^nE#^rND^sStertz^nL#^rND^sFern
andes^nBS#^rND^sKauer-Sant'anna^nM#^rND^sMascarenhas^nM#^rND^sEscosteguy Vargas^
nA#^rND^sChies^nJA#^rND^sKapczinski^nF#Comparison of cytokine levels in depresse
d, manic and euthymic patients with bipolar disorder^len#J Affect Disord.#2#2009
0000#2009#116#3#214-7#20110000#aop0511.htm##
00627000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100025001050100
01900130010002000149012008700169030001900256710000200275065000900277064000500286
031000300291032000200294014000800296865000900304002001200313#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop0511.htm#S#c#187#21#article#40#21#^rND^sBrietz
ke^nE#^rND^sKauer-Sant'anna^nM#^rND^sTeixeira^nAL#^rND^sKapczinski^nF#Abnormalit
ies in serum chemokine levels in euthymic patients with bipolar disorder^len#Bra
in Behav Immun.#2#20090000#2009#23#8#1079-82#20110000#aop0511.htm##
00552000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100020001050120
05600125030004300181710000200224065000900226064000500235031000300240032000200243
014000800245865000900253002001200262#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop0511.htm#S#c#188#22#article#40#22#^rND^sBrietzke^nE#^rND^sKapczinski^n
F#TNF-alpha as a molecular target in bipolar disorder^len#Prog Neuropsychopharma
col Biol Psychiatry.#2#20080000#2008#32#6#1355-61#20110000#aop0511.htm##
00662000000000325000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100014001030100
01800117010001700135010001300152010001700165012008900182030001700271710000200288
06500090029006400050029903100030030403200020030701400060030986500090031500200120
0324#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#c#189#23#ar
ticle#40#23#^rND^sPotvin^nS#^rND^sStip^nE#^rND^sSepehry^nAA#^rND^sGendron^nA#^rN
D^sBah^nR#^rND^sKouassi^nE#Inflammatory cytokine alterations in schizophrenia: a
 systematic quantitative review^len#Biol Psychiatry.#2#20080000#2008#63#8#801-8#
20110000#aop0511.htm##
00730000000000337000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100020000870100015001070100
02500122010001800147010001800165010001500183010001400198012008700212030004300299
71000020034206500090034406400050035303100030035803200020036101400080036386500090
0371002001200380#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S
#c#190#24#article#40#24#^rND^sKapczinski^nF#^rND^sDias^nVV#^rND^sKauer-Sant'Anna
^nM#^rND^sBrietzke^nE#^rND^sVazquez^nGH#^rND^sVieta^nE#^rND^sBerk^nM#The potenti
al use of biomarkers as an adjunctive tool for staging bipolar disorder^len#Prog
 Neuropsychopharmacol Biol Psychiatry.#2#20090000#2009#33#8#1366-71#20110000#aop
0511.htm##
00574000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100021000870100015001080100
01600123012007700139030001900216710000200235065000900237064000500246031000300251
032000200254014000700256865000900263002001200272#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop0511.htm#S#c#191#25#article#40#25#^rND^sRothermundt^nM#^rN
D^sArolt^nV#^rND^sBayer^nTA#Review of immunological and immunopathological findi
ngs in schizophrenia^len#Brain Behav Immun.#2#20010000#2001#15#4#319-39#20110000
#aop0511.htm##
00571000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100019001040120
10900123030001300232710000200245065000900247064000500256031000300261032000200264
014000600266865000900272002001200281#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop0511.htm#S#c#192#26#article#40#26#^rND^sStrous^nRD#^rND^sShoenfeld^nY#
Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive mod
el updated and revisited^len#J Autoimmun.#2#20060000#2006#27#2#71-80#20110000#ao
p0511.htm##
00489000000000229000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840170032000870180058001190660
01500177062003200192065000900224064000500233865000900238002001200247#2011nahead#
V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#c#193#27#article#40#27#Amer
ican Psychiatry Association#Diagnostic and statistical manual of mental disorder
s^len#Washington^eDC#American Psychiatry Association#20000000#2000#20110000#aop0
511.htm##
00600000000000265000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100015001030120
15300118030001800271710000200289065000900291064000500300031000300305014000500308
865000900313002001200322#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop05
11.htm#S#c#194#28#article#40#28#^rND^sRomano^nF#^rND^sElkis^nH#Tradução e adapta
ção de um instrumento de avaliação psicopatológica das psicoses: a escala breve 
de avaliação psiquiátrica. Versão Ancorada (BPRS-A)^lpt#J Bras Psiquiatr.#2#1996
0000#1996#45#43-9#20110000#aop0511.htm##
00780000000000361000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100015000870100017001020100
01900119010002400138010001800162010002000180010001600200010001900216010001600235
01200990025103000200035071000020037006500090037206400050038103100030038603200020
0389014000600391865000900397002001200406#2011nahead#V:\SciELO\serial\rbp\2011nah
ead\markup\aop0511.htm#S#c#195#29#article#40#29#^rND^sLima^nMS#^rND^sSoares^nBG#
^rND^sPaoliello^nG#^rND^sMachado Vieira^nR#^rND^sMartins^nCM#^rND^sMota Neto^nJI
#^rND^sFerrao^nY#^rND^sSchirmer^nDA#^rND^sVolpe^nFM#The Portuguese version of th
e Clinical Global Impression-Schizophrenia Scale: validation study^len#Rev Bras 
Psiquiatr.#2#20070000#2007#29#3#246-9#20110000#aop0511.htm##
00576000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100016001030100
01800119010001600137012006800153030001700221710000200238065000900240064000500249
031000400254014000700258865000900265002001200274#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop0511.htm#S#c#196#30#article#40#30#^rND^sYoung^nRC#^rND^sBi
ggs^nJT#^rND^sZiegler^nVE#^rND^sMeyer^nDA#A rating scale for mania: reliability,
 validity and sensitivity^len#Br J Psychiatry.#2#19780000#1978#133#429-35#201100
00#aop0511.htm##
00470000000000253000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870120034001050300
03100139710000200170065000900172064000500181031000300186014000600189865000900195
002001200204#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#c#1
97#31#article#40#31#^rND^sHamilton^nM#A rating scale for depression^len#J Neurol
 Neurosurg Psychiatry.#2#19600000#1960#23#56-62#20110000#aop0511.htm##
00573000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100015001030100
01700118010001500135012005700150030001500207710000200222065000900224064000500233
031000300238032000200241014000700243865000900250002001200259#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop0511.htm#S#c#198#32#article#40#32#^rND^sNaudin
^nJ#^rND^sMege^nJL#^rND^sAzorin^nJM#^rND^sDassa^nD#Elevated circulating levels o
f IL-6 in schizophrenia^len#Schizophr Res.#2#19960000#1996#20#3#269-73#20110000#
aop0511.htm##
00704000000000337000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100014001040100
01600118010002000134010001500154010001600169010001600185012010200201030001600303
71000020031906500090032106400050033003100030033503200020033801400050034086500090
0345002001200354#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S
#c#199#33#article#40#33#^rND^sGanguli^nR#^rND^sYang^nZ#^rND^sShurin^nG#^rND^sChe
ngappa^nKN#^rND^sBrar^nJS#^rND^sGubbi^nAV#^rND^sRabin^nBS#Serum interleukin-6 co
ncentration in schizophrenia: elevation associated with duration of illness^len#
Psychiatry Res.#2#19940000#1994#51#1#1-10#20110000#aop0511.htm##
00712000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100016001050100
01900121010001600140010002100156012015300177030001900330710000200349065000900351
064000500360031000300365032000200368014000700370865000900377002001200386#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#c#200#34#article#40#34#
^rND^sErbagci^nAB#^rND^sHerken^nH#^rND^sKoyluoglu^nO#^rND^sYilmaz^nN#^rND^sTarak
cioglu^nM#Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic pati
ents, relation with symptomatology and responsiveness to risperidone treatment^l
en#Mediators Inflamm.#2#20010000#2001#10#3#109-15#20110000#aop0511.htm##
00748000000000337000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100025000870100020001120100
02000132010001500152010001400167010001600181010001700197012011900214030002800333
71000020036106500090036306400050037203100030037703200020038001400070038286500090
0389002001200398#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S
#c#201#35#article#40#35#^rND^sKauer-Sant'Anna^nM#^rND^sKapczinski^nF#^rND^sAndre
azza^nAC#^rND^sBond^nDJ#^rND^sLam^nRW#^rND^sYoung^nLT#^rND^sYatham^nLN#Brain-der
ived neurotrophic factor and inflammatory markers in patients with early- vs: la
te-stage bipolar disorder^len#Int J Neuropsychopharmacol.#2#20090000#2009#12#4#4
47-58#20110000#aop0511.htm##
00736000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100015000870100014001020100
02000116010002000136010002700156012017000183030002000353710000200373065000900375
064000500384031000300389032000200392014000700394865000900401002001200410#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#c#202#36#article#40#36#
^rND^sGama^nCS#^rND^sBerk^nM#^rND^sAndreazza^nAC#^rND^sKapczinski^nF#^rND^sBelmo
nte-de-Abreu^nP#Serum levels of brain-derived neurotrophic factor and thiobarbit
uric acid reactive substances in chronically medicated schizophrenic patients: a
 positive correlation^len#Rev Bras Psiquiatr.#2#20080000#2008#30#4#337-40#201100
00#aop0511.htm##
00688000000000325000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100020000870100015001070100
02000122010002500142010001600167010001500183012009600198030002000294710000200314
06500090031606400050032503100030033003200020033301400060033586500090034100200120
0350#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#c#203#37#ar
ticle#40#37#^rND^sKapczinski^nF#^rND^sFrey^nBN#^rND^sAndreazza^nAC#^rND^sKauer-S
ant'Anna^nM#^rND^sCunha^nAB#^rND^sPost^nRM#Increased oxidative stress as a mecha
nism for decreased BDNF levels in acute manic episodes^len#Rev Bras Psiquiatr.#2
#20080000#2008#30#3#243-5#20110000#aop0511.htm##
00658000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100015001030100
01400118012016400132030002400296710000200320065000900322064000500331031000300336
032000200339014000600341865000900347002001200356#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop0511.htm#S#c#204#38#article#40#38#^rND^sJacka^nFN#^rND^sGa
ma^nCS#^rND^sBerk^nM#Brain-derived neurotrophic factor: a modifiable common medi
ator in both the pathophysiology of psychiatric illness and in successful pharma
cological treatments^len#Acta Neuropsychiatrica.#2#20080000#2008#20#4#223-5#2011
0000#aop0511.htm##
00679000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100018001040100
01400122010001800136010002300154012012400177030001400301710000200315065000900317
064000500326031000400331032000200335014000700337865000900344002001200353#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop0511.htm#S#c#205#39#article#40#39#
^rND^sMolteni^nR#^rND^sBarnard^nRJ#^rND^sYing^nZ#^rND^sRoberts^nCK#^rND^sGomez-P
inilla^nF#A high-fat, refined sugar diet reduces hippocampal brain-derived neuro
trophic factor, neuronal plasticity, and learning^len#Neuroscience.#2#20020000#2
002#112#4#803-14#20110000#aop0511.htm##
00602000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100020001040100
02100124010001700145012007000162030001900232710000200251065000900253064000500262
031000300267032000200270014000700272865000900279002001200288#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop0511.htm#S#c#206#40#article#40#40#^rND^sDrzyzg
a^nL#^rND^sObuchowicz^nE#^rND^sMarcinowska^nA#^rND^sHerman^nZS#Cytokines in schi
zophrenia and the effects of antipsychotic drugs^len#Brain Behav Immun.#2#200600
00#2006#20#6#532-45#20110000#aop0511.htm##
00282000000000169000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780910009000800920007000890020012000967030
00400108#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#o#1#1#a
rticle#1#20110311#101419#aop0611.htm#203##
05035000000000721000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780710003000800400003000830010006000860420
00200092120000400094038000400098038000400102121000300106049000300109158000300112
03000220011503200060013706500090014301400070015203500100015922300090016901201200
01780120127002980100035004250100026004600100041004860100039005270100046005660100
02800612010003500640010003300675070010400708070009700812083153400909085001002443
08500290245308500300248208500230251208500260253508500300256108314450259108500100
40360850031040460850030040770850022041070850025041290850036041540580053041901170
00804243072000304251112000904254111001404263114000904277113001504286002001204301
#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#h#2#1#article#1
#oa#en#br1.1#1#4.0#GRA#TAB#08#nd#nd#Rev. Bras. Psiquiatr.#ahead#20110000#^f0^l0#
1516-4446#20110318#The effectiveness of cognitive behavioral group therapy in tr
eating bipolar disorder: a randomized controlled study^len#A eficácia da terapia
 cognitivo-comportamental para o tratamento do transtorno bipolar: um estudo con
trolado e randomizado^lpt#^rND^1A01^nRafael Thomaz da^sCosta#^rND^1A01^nElie^sCh
eniaux#^rND^1A01^nPedro Augusto Legnani^sRosaes#^rND^1A01^nMarcele Regine de^sCa
rvalho#^rND^1A01^nRafael Christophe da Rocha^sFreire#^rND^1A01^nMárcio^sVersiani
#^rND^1A02^nBernard Pimentel^sRangé#^rND^1A01^nAntonio Egidio^sNardi#Universidad
e Federal do Rio de Janeiro (UFRJ)^iA01^1Institute of Psychiatry^cRio de Janeiro
^sRJ^pBrazil#Universidade Federal do Rio de Janeiro^iA02^1Institute of Psycholog
y^cRio de Janeiro^sRJ^pBrazil#^len^aOBJECTIVE: Recent studies suggest that, when
 combined with pharmacotherapy, structured psychotherapy may modify the course o
f bipolar disorder. However, there are few studies that have examined the effect
s of cognitive behavioral group therapy on the course of this disorder. The aim 
of the present study was to evaluate the effectiveness of 14 sessions of cogniti
ve behavioral group therapy, combined with pharmacotherapy, on the treatment of 
patients with bipolar disorder, and to compare our results against those from th
e use of pharmacotherapy alone. METHOD: Forty-one patients with bipolar I and II
 disorder participated in the study and were randomly allocated to one of two tr
eatment groups; thirty-seven patients remained in the study until its completion
. Mood and anxiety symptoms were measured in all subjects. Statistical analysis 
was used to investigate if the groups differed with respect to demographic chara
cteristics and the scores recorded in the pre- and post-treatment stages, as wel
l as during treatment (intra/inter groups). RESULTS: Patients showed statistical
ly similar population characteristics. The association of cognitive behavioral g
roup therapy and pharmacological treatment proved to be effective. Patients who 
had undergone cognitive behavioral group therapy presented fewer symptoms of man
ia, depression and anxiety, as well as fewer and shorter mood change episodes. C
ONCLUSION: Cognitive behavioral group therapy sessions substantially contributed
 to the improvement of depression symptoms.#^ddecs^i1#^tm^len^kBipolar disorder^
i1#^tm^len^kCognitive therapy^i1#^tm^len^kDepression^i1#^tm^len^kPsychotherapy^i
1#^tm^len^kTreatment outcome^i1#^lpt^aOBJETIVO: Estudos recentes sugerem que uma
 psicoterapia estruturada aplicada junto com a farmacoterapia pode alterar o cur
so do transtorno afetivo bipolar. Entretanto, poucos estudos investigam os resul
tados da terapia cognitivo-comportamental em grupo sobre este transtorno psiquiá
trico. O objetivo desta pesquisa foi avaliar a eficácia de 14 sessões de terapia
 cognitivo-comportamental em grupo concomitante à farmacoterapia para bipolares 
e comparar com a farmacoterapia sozinha. MÉTODO: Quarenta e um pacientes com tra
nstorno bipolar I e II participaram do estudo e foram alocados aleatoriamente pa
ra um dos dois grupos; trinta e sete preencheram todas as escalas. Os sintomas d
e humor e ansiedade de todos os participantes foram acessados. A análise estatís
tica foi utilizada para investigar se os grupos diferiam com relação aos dados d
emográficos e entre os escores pré-, durante e pós-tratamento (intra/intergrupos
). RESULTADOS: Os participantes dos dois grupos mostraram-se similares nas carac
terísticas demográficas. A adição da terapia cognitivo-comportamental em grupo a
o tratamento farmacológico foi efetiva. O grupo da terapia cognitivo-comportamen
tal em grupo apresentou menos sintomas de mania, depressão e ansiedade, bem como
 uma redução na frequência e duração dos episódios de humor. CONCLUSÃO: As sessõ
es de terapia cognitivo-comportamental em grupo foram especialmente importantes 
na melhora dos sintomas depressivos.#^ddecs^i2#^tm^lpt^kTranstorno bipolar^i2#^t
m^lpt^kTerapia cognitiva^i2#^tm^lpt^kDepressão^i2#^tm^lpt^kPsicoterapia^i2#^tm^l
pt^kResultado de tratamento^i2#Council for Scientific and Technological Developm
ent#vancouv#29#20100303#March 3, 2010#20100413#April 13, 2010#aop0611.htm##
05120000000000721000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780710003000800400003000830010006000860420
00200092120000400094038000400098038000400102121000300106049000300109158000300112
03000220011503200060013706500090014301400070015203500100015922300090016901201340
01780120141003120100035004530100026004880100041005140100039005550100046005940100
02800640010003500668010003300703070010400736070009700840083156300937085001002500
08500290251008500300253908500230256908500260259208500300261808314730264808500100
41210850031041310850030041620850022041920850025042140850036042390580053042751170
00804328072000304336112000904339111001404348114000904362113001504371002001204386
#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#f#3#1#article#1
#oa#en#br1.1#1#4.0#GRA#TAB#08#nd#nd#Rev. Bras. Psiquiatr.#ahead#20110000#^f0^l0#
1516-4446#20110318#<b>The effectiveness of cognitive behavioral group therapy in
 treating bipolar disorder</b>: <b>a randomized controlled study</b>^len#<b>A ef
icácia da terapia cognitivo-comportamental para o tratamento do transtorno bipol
ar</b>: <b>um estudo controlado e randomizado</b>^lpt#^rND^1A01^nRafael Thomaz d
a^sCosta#^rND^1A01^nElie^sCheniaux#^rND^1A01^nPedro Augusto Legnani^sRosaes#^rND
^1A01^nMarcele Regine de^sCarvalho#^rND^1A01^nRafael Christophe da Rocha^sFreire
#^rND^1A01^nMárcio^sVersiani#^rND^1A02^nBernard Pimentel^sRangé#^rND^1A01^nAnton
io Egidio^sNardi#Universidade Federal do Rio de Janeiro (UFRJ)^iA01^1Institute o
f Psychiatry^cRio de Janeiro^sRJ^pBrazil#Universidade Federal do Rio de Janeiro^
iA02^1Institute of Psychology^cRio de Janeiro^sRJ^pBrazil#^len^a<b>OBJECTIVE</b>
: Recent studies suggest that, when combined with pharmacotherapy, structured ps
ychotherapy may modify the course of bipolar disorder. However, there are few st
udies that have examined the effects of cognitive behavioral group therapy on th
e course of this disorder. The aim of the present study was to evaluate the effe
ctiveness of 14 sessions of cognitive behavioral group therapy, combined with ph
armacotherapy, on the treatment of patients with bipolar disorder, and to compar
e our results against those from the use of pharmacotherapy alone. <b> METHOD:</
b> Forty-one patients with bipolar I and II disorder participated in the study a
nd were randomly allocated to one of two treatment groups; thirty-seven patients
 remained in the study until its completion. Mood and anxiety symptoms were meas
ured in all subjects. Statistical analysis was used to investigate if the groups
 differed with respect to demographic characteristics and the scores recorded in
 the pre- and post-treatment stages, as well as during treatment (intra/inter gr
oups). <b>RESULTS:</b> Patients showed statistically similar population characte
ristics. The association of cognitive behavioral group therapy and pharmacologic
al treatment proved to be effective. Patients who had undergone cognitive behavi
oral group therapy presented fewer symptoms of mania, depression and anxiety, as
 well as fewer and shorter mood change episodes. <b>CONCLUSION:</b> Cognitive be
havioral group therapy sessions substantially contributed to the improvement of 
depression symptoms.#^ddecs^i1#^tm^len^kBipolar disorder^i1#^tm^len^kCognitive t
herapy^i1#^tm^len^kDepression^i1#^tm^len^kPsychotherapy^i1#^tm^len^kTreatment ou
tcome^i1#^lpt^a<b>OBJETIVO:</b> Estudos recentes sugerem que uma psicoterapia es
truturada aplicada junto com a farmacoterapia pode alterar o curso do transtorno
 afetivo bipolar. Entretanto, poucos estudos investigam os resultados da terapia
 cognitivo-comportamental em grupo sobre este transtorno psiquiátrico. O objetiv
o desta pesquisa foi avaliar a eficácia de 14 sessões de terapia cognitivo-compo
rtamental em grupo concomitante à farmacoterapia para bipolares e comparar com a
 farmacoterapia sozinha. <b>MÉTODO:</b> Quarenta e um pacientes com transtorno b
ipolar I e II participaram do estudo e foram alocados aleatoriamente para um dos
 dois grupos; trinta e sete preencheram todas as escalas. Os sintomas de humor e
 ansiedade de todos os participantes foram acessados. A análise estatística foi 
utilizada para investigar se os grupos diferiam com relação aos dados demográfic
os e entre os escores pré-, durante e pós-tratamento (intra/intergrupos). <b>RES
ULTADOS:</b> Os participantes dos dois grupos mostraram-se similares nas caracte
rísticas demográficas. A adição da terapia cognitivo-comportamental em grupo ao 
tratamento farmacológico foi efetiva. O grupo da terapia cognitivo-comportamenta
l em grupo apresentou menos sintomas de mania, depressão e ansiedade, bem como u
ma redução na frequência e duração dos episódios de humor. <b>CONCLUSÃO:</b> As 
sessões de terapia cognitivo-comportamental em grupo foram especialmente importa
ntes na melhora dos sintomas depressivos.#^ddecs^i2#^tm^lpt^kTranstorno bipolar^
i2#^tm^lpt^kTerapia cognitiva^i2#^tm^lpt^kDepressão^i2#^tm^lpt^kPsicoterapia^i2#
^tm^lpt^kResultado de tratamento^i2#Council for Scientific and Technological Dev
elopment#vancouv#29#20100303#March 3, 2010#20100413#April 13, 2010#aop0611.htm##
05158000000000745000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780640007000800710003000870400003000900010
00600093042000200099120000400101038000400105038000400109121000300113049000300116
15800030011903000210012203200060014306500090014901400070015803500100016522300090
01750120120001840120127003040100035004310100026004660100041004920100039005330100
04600572010002800618010003500646010003300681070010600714070009900820083153400919
08500100245308500290246308500300249208500230252208500260254508500300257108314450
26010850010040460850031040560850030040870850022041170850025041390850036041640580
05304200117000804253072000304261112000904264111001404273114000904287113001504296
002001204311008008904323#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop06
11.htm#S#l#4#1#article#1#^a2011#oa#en#br1.1#1#4.0#gra#tab#08#nd#nd#Rev. bras. ps
iquiatr#ahead#20110000#^f0^l0#1516-4446#20110318#The effectiveness of cognitive 
behavioral group therapy in treating bipolar disorder: a randomized controlled s
tudy^len#A eficácia da terapia cognitivo-comportamental para o tratamento do tra
nstorno bipolar: um estudo controlado e randomizado^lpt#^rND^1A01^nRafael Thomaz
 da^sCosta#^rND^1A01^nElie^sCheniaux#^rND^1A01^nPedro Augusto Legnani^sRosaes#^r
ND^1A01^nMarcele Regine de^sCarvalho#^rND^1A01^nRafael Christophe da Rocha^sFrei
re#^rND^1A01^nMárcio^sVersiani#^rND^1A02^nBernard Pimentel^sRangé#^rND^1A01^nAnt
onio Egidio^sNardi#^iA01^1Universidade Federal do Rio de Janeiro (UFRJ)^2Institu
te of Psychiatry^cRio de Janeiro^sRJ^pBrazil#^iA02^1Universidade Federal do Rio 
de Janeiro^2Institute of Psychology^cRio de Janeiro^sRJ^pBrazil#^len^aOBJECTIVE:
 Recent studies suggest that, when combined with pharmacotherapy, structured psy
chotherapy may modify the course of bipolar disorder. However, there are few stu
dies that have examined the effects of cognitive behavioral group therapy on the
 course of this disorder. The aim of the present study was to evaluate the effec
tiveness of 14 sessions of cognitive behavioral group therapy, combined with pha
rmacotherapy, on the treatment of patients with bipolar disorder, and to compare
 our results against those from the use of pharmacotherapy alone. METHOD: Forty-
one patients with bipolar I and II disorder participated in the study and were r
andomly allocated to one of two treatment groups; thirty-seven patients remained
 in the study until its completion. Mood and anxiety symptoms were measured in a
ll subjects. Statistical analysis was used to investigate if the groups differed
 with respect to demographic characteristics and the scores recorded in the pre-
 and post-treatment stages, as well as during treatment (intra/inter groups). RE
SULTS: Patients showed statistically similar population characteristics. The ass
ociation of cognitive behavioral group therapy and pharmacological treatment pro
ved to be effective. Patients who had undergone cognitive behavioral group thera
py presented fewer symptoms of mania, depression and anxiety, as well as fewer a
nd shorter mood change episodes. CONCLUSION: Cognitive behavioral group therapy 
sessions substantially contributed to the improvement of depression symptoms.#^d
decs^i1#^tm^len^kBipolar disorder^i1#^tm^len^kCognitive therapy^i1#^tm^len^kDepr
ession^i1#^tm^len^kPsychotherapy^i1#^tm^len^kTreatment outcome^i1#^lpt^aOBJETIVO
: Estudos recentes sugerem que uma psicoterapia estruturada aplicada junto com a
 farmacoterapia pode alterar o curso do transtorno afetivo bipolar. Entretanto, 
poucos estudos investigam os resultados da terapia cognitivo-comportamental em g
rupo sobre este transtorno psiquiátrico. O objetivo desta pesquisa foi avaliar a
 eficácia de 14 sessões de terapia cognitivo-comportamental em grupo concomitant
e à farmacoterapia para bipolares e comparar com a farmacoterapia sozinha. MÉTOD
O: Quarenta e um pacientes com transtorno bipolar I e II participaram do estudo 
e foram alocados aleatoriamente para um dos dois grupos; trinta e sete preencher
am todas as escalas. Os sintomas de humor e ansiedade de todos os participantes 
foram acessados. A análise estatística foi utilizada para investigar se os grupo
s diferiam com relação aos dados demográficos e entre os escores pré-, durante e
 pós-tratamento (intra/intergrupos). RESULTADOS: Os participantes dos dois grupo
s mostraram-se similares nas características demográficas. A adição da terapia c
ognitivo-comportamental em grupo ao tratamento farmacológico foi efetiva. O grup
o da terapia cognitivo-comportamental em grupo apresentou menos sintomas de mani
a, depressão e ansiedade, bem como uma redução na frequência e duração dos episó
dios de humor. CONCLUSÃO: As sessões de terapia cognitivo-comportamental em grup
o foram especialmente importantes na melhora dos sintomas depressivos.#^ddecs^i2
#^tm^lpt^kTranstorno bipolar^i2#^tm^lpt^kTerapia cognitiva^i2#^tm^lpt^kDepressão
^i2#^tm^lpt^kPsicoterapia^i2#^tm^lpt^kResultado de tratamento^i2#Council for Sci
entific and Technological Development#vancouv#29#20100303#March 3, 2010#20100413
#April 13, 2010#aop0611.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci
_arttext&pid=S1516-44462011005000008##
00469000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704022900082002001200311#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#5#1#article#170#<p><a name="t
op"></a><font face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>The    ef
fectiveness of cognitive behavioral group therapy in treating bipolar disorder: 
   a randomized controlled study</b></font></p>     ^cY#aop0611.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#6#2#article#170#<p>&nbsp;</p>
     ^cY#aop0611.htm##
00465000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704022500082002001200307#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#7#3#article#170#<p><font face
="Verdana, Arial, Helvetica, sans-serif" size="3"><b>A efic&aacute;cia    da ter
apia cognitivo-comportamental para o tratamento do transtorno bipolar:    um est
udo controlado e randomizado</b></font></p>     ^cY#aop0611.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#8#4#article#170#<p>&nbsp;</p>
     ^cY#aop0611.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#9#5#article#170#<p>&nbsp;</p>
     ^cY#aop0611.htm##
00647000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704040600083002001200489#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#10#6#article#170#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Rafael Thomaz    da Costa<
sup>I</sup>; Elie Cheniaux<sup>I</sup>; Pedro Augusto Legnani Rosaes<sup>I</sup>
;    Marcele Regine de Carvalho<sup>I</sup>; Rafael Christophe da Rocha Freire<s
up>I</sup>;    M&aacute;rcio Versiani<sup>I</sup>; Bernard Pimentel Rang&eacute;
<sup>II</sup>;    Antonio Egidio Nardi<sup>I</sup></b></font></p>     ^cY#aop061
1.htm##
00428000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704018700083002001200270#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#11#7#article#170#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2"><sup>I</sup>Institute    of P
sychiatry, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro,    RJ,
 Brazil    ^cY#aop0611.htm##
00382000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704014100083002001200224#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#12#8#article#170#<br>   <sup>
II</sup>Institute of Psychology, Universidade Federal do Rio de Janeiro    (UFRJ
), Rio de Janeiro, RJ, Brazil</font></p>     ^cY#aop0611.htm##
00358000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704011700083002001200200#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#13#9#article#170#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2"><a href="#back">Correspondenc
e</a></font></p>     ^cY#aop0611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#14#10#article#170#<p>&nbsp;</
p>     ^cY#aop0611.htm##
00286000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704004400084002001200128#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#15#11#article#170#<p>&nbsp;</
p> <hr size="1" noshade>     ^cY#aop0611.htm##
00340000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009800084002001200182#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#16#12#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>ABSTRACT</b></font></p>  
   ^cY#aop0611.htm##
00903000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704066100084002001200745#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#17#13#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>OBJECTIVE</b>:    Recent 
studies suggest that, when combined with pharmacotherapy, structured    psychoth
erapy may modify the course of bipolar disorder. However, there are    few studi
es that have examined the effects of cognitive behavioral group therapy    on th
e course of this disorder. The aim of the present study was to evaluate    the e
ffectiveness of 14 sessions of cognitive behavioral group therapy, combined    w
ith pharmacotherapy, on the treatment of patients with bipolar disorder, and    
to compare our results against those from the use of pharmacotherapy alone.    <
b>    ^cY#aop0611.htm##
00770000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704052800084002001200612#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#18#14#article#170#<br>   METH
OD:</b> Forty-one patients with bipolar I and II disorder participated in    the
 study and were randomly allocated to one of two treatment groups; thirty-seven 
   patients remained in the study until its completion. Mood and anxiety symptom
s    were measured in all subjects. Statistical analysis was used to investigate
    if the groups differed with respect to demographic characteristics and the s
cores    recorded in the pre- and post-treatment stages, as well as during treat
ment    (intra/inter groups).    ^cY#aop0611.htm##
00630000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704038800084002001200472#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#19#15#article#170#<br>   <b>R
ESULTS:</b> Patients showed statistically similar population characteristics.   
 The association of cognitive behavioral group therapy and pharmacological treat
ment    proved to be effective. Patients who had undergone cognitive behavioral 
group    therapy presented fewer symptoms of mania, depression and anxiety, as w
ell as    fewer and shorter mood change episodes.    ^cY#aop0611.htm##
00403000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704016100084002001200245#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#20#16#article#170#<br>   <b>C
ONCLUSION:</b> Cognitive behavioral group therapy sessions substantially    cont
ributed to the improvement of depression symptoms.</font></p>     ^cY#aop0611.ht
m##
00451000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704020900084002001200293#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#21#17#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Descriptors:</b>    Bipol
ar disorder; Cognitive therapy; Depression; Psychotherapy; Treatment outcome</fo
nt></p> <hr size="1" noshade>     ^cY#aop0611.htm##
00338000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009600084002001200180#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#22#18#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>    
 ^cY#aop0611.htm##
00851000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704060900084002001200693#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#23#19#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>OBJETIVO:</b>    Estudos 
recentes sugerem que uma psicoterapia estruturada aplicada junto com    a farmac
oterapia pode alterar o curso do transtorno afetivo bipolar. Entretanto,    pouc
os estudos investigam os resultados da terapia cognitivo-comportamental    em gr
upo sobre este transtorno psiqui&aacute;trico. O objetivo desta pesquisa    foi 
avaliar a efic&aacute;cia de 14 sess&otilde;es de terapia cognitivo-comportament
al    em grupo concomitante &agrave; farmacoterapia para bipolares e comparar co
m    a farmacoterapia sozinha.    ^cY#aop0611.htm##
00779000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704053700084002001200621#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#24#20#article#170#<br>   <b>M
&Eacute;TODO:</b> Quarenta e um pacientes com transtorno bipolar I e II    parti
ciparam do estudo e foram alocados aleatoriamente para um dos dois grupos;    tr
inta e sete preencheram todas as escalas. Os sintomas de humor e ansiedade    de
 todos os participantes foram acessados. A an&aacute;lise estat&iacute;stica    
foi utilizada para investigar se os grupos diferiam com rela&ccedil;&atilde;o   
 aos dados demogr&aacute;ficos e entre os escores pr&eacute;-, durante e p&oacut
e;s-tratamento    (intra/intergrupos).    ^cY#aop0611.htm##
00739000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704049700084002001200581#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#25#21#article#170#<br>   <b>R
ESULTADOS:</b> Os participantes dos dois grupos mostraram-se similares nas    ca
racter&iacute;sticas demogr&aacute;ficas. A adi&ccedil;&atilde;o da terapia    c
ognitivo-comportamental em grupo ao tratamento farmacol&oacute;gico foi efetiva.
    O grupo da terapia cognitivo-comportamental em grupo apresentou menos sintom
as    de mania, depress&atilde;o e ansiedade, bem como uma redu&ccedil;&atilde;o
 na    frequ&ecirc;ncia e dura&ccedil;&atilde;o dos epis&oacute;dios de humor.  
  ^cY#aop0611.htm##
00428000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704018600084002001200270#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#26#22#article#170#<br>   <b>C
ONCLUS&Atilde;O:</b> As sess&otilde;es de terapia cognitivo-comportamental    em
 grupo foram especialmente importantes na melhora dos sintomas depressivos.</fon
t></p>     ^cY#aop0611.htm##
00467000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704022500084002001200309#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#27#23#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Descritores:</b>    Trans
torno bipolar; Terapia cognitiva; Depress&atilde;o; Psicoterapia; Resultado    d
e tratamento</font></p> <hr size="1" noshade>     ^cY#aop0611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#28#24#article#170#<p>&nbsp;</
p>     ^cY#aop0611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#29#25#article#170#<p>&nbsp;</
p>     ^cY#aop0611.htm##
00344000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010200084002001200186#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#30#26#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Introduction</b></font></
p>     ^cY#aop0611.htm##
00734000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704049200084002001200576#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#31#27#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Bipolar disorder    (BD) is 
one of the most prevalent and serious psychiatric disorders globally,    affecti
ng 1% to 3% of the world's population.<sup>1</sup> Accordingly, it has    been t
he object of increased attention in the past few years.<sup>2-4</sup>    Individ
uals suffering from BD often experience impairments in both their personal    li
ves i.e., marital, family and professional lives.<sup>1</sup></font></p>     ^cY
#aop0611.htm##
00894000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704065200084002001200736#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#32#28#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Even when the genetic,    bi
ological and psychopharmacological aspects involved in the treatment of symptoms
    of BD are considered, about 40% of bipolar patients do not respond well to l
ithium    or other mood stabilizers.<sup>5-7</sup> In spite of receiving the req
uired    medication dose, these patients remain free of relapses for a maximum o
f only    two- to three-year follow up periods.<sup>5,8</sup> Moreover, growing 
evidence    suggests that structured psychotherapy used in combination with phar
macotherapy    may modify the course of the BD.<sup>4,9</sup></font></p>     ^cY
#aop0611.htm##
00853000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704061100084002001200695#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#33#29#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Until a few years    ago, it
 was widely believed that psychosocial approaches only served the purpose    of 
improving pharmacologic adherence given that BD has a strong biological componen
t.    Nonetheless, the efficacy of psychotherapy in the treatment of this disord
er    is considerable.<sup>3</sup> More recently, it has been demonstrated that 
psychosocial    approaches also improve patients' quality of life, and that bett
er results can    be attained in the treatment of depression compared to that of
 mania.<sup>10</sup></font></p>     ^cY#aop0611.htm##
01043000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704080100084002001200885#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#34#30#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Cognitive behavioral    ther
apy (CBT) used in conjunction with pharmacotherapy in BD patients can modify    
the course of the disease. Certain studies on the association between individual
    or group CBT and BD have reported improvements in mood and social functionin
g.    Upon further investigation, it was discovered that such improvements were 
maintained    at follow-up.<sup>11-13</sup> However, a recent study concluded th
at CBT is    not likely to be an effective adjunctive therapy for the general po
pulation    with recurrent non-rapid cycling BD,<sup>13</sup> while other studie
s emphasize    that CBT generated better results in the treatment of depression 
when compared    to that of mania.<sup>14-17</sup></font></p>     ^cY#aop0611.ht
m##
00773000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704053100084002001200615#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#35#31#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">CBT strategies    aim at man
aging and preventing cognitive, affective and behavioral symptoms    associated 
with depressive or manic phases, and are conducted with the patient,    as well 
as, sometimes, with his or her family's active cooperation.<sup>18</sup>    Such
 strategies intend to reduce the negative impacts of BD in the psychosocial    a
nd interpersonal domains, thus improving the quality of life of individuals    w
ith BD.<sup>19</sup></font></p>     ^cY#aop0611.htm##
01216000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704097400084002001201058#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#36#32#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">CBT interventions    for BD 
are intended to achieve the following: (1) educate the patient and his/her    fa
mily about the treatment, as well as about the common difficulties associated   
 with the disease (2) teach them how to monitor manic or depressive symptoms    
using, for example, a mood chart, and to assess their severity (3) promote compl
iance    with pharmacological treatment (i.e., psycho-education and reality test
 of thoughts    and beliefs (4) provide subjects with psychological strategies, 
especially in    terms of cognitive-behavioral skills, that will allow them to m
anage stress    factors which, in turn, can interfere with treatment or bring on
 manic and/or    depressive episodes (e.g., circadian rhythm control, daily thou
ght records,    social skills training, problem solving) and (5) reduce the trau
ma and stigma    associated with the diagnosis.<sup>19,20</sup></font></p>     ^
cY#aop0611.htm##
00533000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704029100084002001200375#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#37#33#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">The objective of    this stu
dy is to evaluate the effectiveness of CBGT in BD cases. We tried to    assess t
he effectiveness of 14 sessions of CBGT as a combined intervention used    to co
ntrol mood symptoms.</font></p>     ^cY#aop0611.htm##
00455000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704021300084002001200297#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#38#34#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">The study was approved    by
 the Research Ethics Committee (Brazilian National Research Ethics Committee    
- protocol no. 07/06).</font></p>     ^cY#aop0611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#39#35#article#170#<p>&nbsp;</
p>     ^cY#aop0611.htm##
00338000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009600084002001200180#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#40#36#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Method</b></font></p>    
 ^cY#aop0611.htm##
00370000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704012800084002001200212#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#41#37#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>1. Inclusion    and exclu
sion criteria</b></font></p>     ^cY#aop0611.htm##
00797000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704055500084002001200639#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#42#38#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Subjects were recruited    f
rom the Institute of Psychiatry of the Universidade Federal do Rio de Janeiro   
 (Anxiety and Depression Program Outpatient Clinic). Their age ranged between   
 18 and 60 years, they met the DSM-IV criteria for BD I or II, and had experienc
ed    at least one hypomanic, manic or depressive episode in the previous 12 mon
ths.    Subjects had been taking mood-stabilizing medication for a minimum of on
e month    before the therapy was initiated.</font></p>     ^cY#aop0611.htm##
00991000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704074900084002001200833#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#43#39#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Patients were eligible    fo
r inclusion if they were euthymic, mildly depressed or mildly hypomanic at    th
e time of the initial assessment. They were excluded if they had a Beck Depressi
on    Inventory score <u>&gt;</u> 35 (BDI)<sup>21</sup> and a Young Mania Rating
 Scale    score <u>&gt;</u> 20 (YMS)<sup>22</sup> or presented a comorbid person
ality    disorder and/or any other axis I severe psychiatric disorder. This was 
established    using the Structured Clinical Interview for DSM-IV-TR (SCID- I an
d II).<sup>23</sup>    Patients suffering from any severe physical illness and/o
r using alcohol or    illicit drugs were referred to individual psychotherapy.</
font></p>     ^cY#aop0611.htm##
00490000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704024800084002001200332#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#44#40#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Patients who required    the
 administration of a new mood stabilizer and/or a new antidepressant during    t
he course of treatment were also excluded from the study.</font></p>     ^cY#aop
0611.htm##
00343000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010100084002001200185#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#45#41#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>2. Subjects</b></font></p
>     ^cY#aop0611.htm##
00869000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704062700084002001200711#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#46#42#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Forty-one subjects    with B
ipolar I (</font><font size="2">&#8773;</font><font face="Verdana, Arial, Helvet
ica, sans-serif" size="2">    84% in each group) or II disorder participated in 
the study. The number of subjects    from each therapy group varied from 5 to 6.
 Only two subjects from each group    did not answer any of the instruments of t
he scales. Two subjects from the control    group and one from the CBGT group re
quired hospitalization, and one from the    CBGT group walked away because he pr
eferred to go on individual therapy.</font></p>     ^cY#aop0611.htm##
00346000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010400084002001200188#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#47#43#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>3. Instruments</b></font>
</p>     ^cY#aop0611.htm##
00435000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704019300084002001200277#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#48#44#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Subjects were interviewed   
 using the Structured Clinical Interview for DSM-IV (SCID- I and II).<sup>23</su
p></font></p>     ^cY#aop0611.htm##
00638000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704039600084002001200480#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#49#45#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Mood and anxiety    symptoms
 were assessed in all subjects using the Beck Depression Inventory (BDI),<sup>21
</sup>    the Young Mania Rating Scale (YMRS)<sup>22</sup> and the Beck Anxiety 
Inventory    (BAI).<sup>24</sup> The Beck Hopelessness Scale (BHS)<sup>25</sup> 
was used    for predicting suicidal ideation.</font></p>     ^cY#aop0611.htm##
00606000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704036400084002001200448#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#50#46#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Weekly scores on    the BDI 
and BAI were obtained for both groups. The YMRS was applied at three    differen
t moments in time i.e., at the beginning, the middle and at the end    of treatm
ent, whereas the BHS was applied only at the beginning and at the end    of the 
study period.</font></p>     ^cY#aop0611.htm##
00358000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704011600084002001200200#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#51#47#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>4. Treatment    procedure
s</b></font></p>     ^cY#aop0611.htm##
00593000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704035100084002001200435#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#52#48#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Patients were randomly    al
located to CBGT (n = 27) and to treatment as usual (TAU, n = 14). They were    a
ssessed before, during and after treatment, and up to 6 months post-treatment   
 in terms of their levels of depression, mania and their quality of life scores.
</font></p>     ^cY#aop0611.htm##
00355000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704011300084002001200197#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#53#49#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">1) Treatment as    usual (TA
U)</font></p>     ^cY#aop0611.htm##
00603000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704036100084002001200445#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#54#50#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">The TAU group attended    se
ssions as prescribed by their respective psychiatrists, and did not attend    an
y psychotherapy session. Doctors who had been trained on how to apply the    tes
ts assessed mood symptoms throughout the 14 weeks and at the 6-month follow    u
p session.</font></p>     ^cY#aop0611.htm##
00332000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009000084002001200174#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#55#51#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">2) CBGT</font></p>     ^cY#a
op0611.htm##
00924000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704068200084002001200766#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#56#52#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">The protocol was    administ
ered by an experienced clinical psychologist. It consisted of 14 two-hour    CBG
T sessions which were divided into two stages: the first consisted of three    s
essions during which the therapist provided psychoeducation on BD, symptoms    a
nd medications to the patients and their families. In the second stage, patients
    learned CBT skills by means of specific behavioral and cognitive interventio
ns.    The CBGT protocol used in the present study was based on the treatment ma
nual    'Cognitive Behavioral Therapy for Bipolar Disorder' by Basco and Rush.<s
up>18</sup></font></p>     ^cY#aop0611.htm##
00358000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704011600084002001200200#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#57#53#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>5. Statistical    analysi
s</b></font></p>     ^cY#aop0611.htm##
01115000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704087300084002001200957#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#58#54#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Pearson Chi-Square    Tests 
and ANOVA were performed to investigate if the control group and the CBGT    gro
up differed with respect to demographic characteristics and comorbid diagnoses. 
   Paried-Sample T Test and regression were used to test for differences among  
  scores recorded at the pre-, during- and post-treatment stages, both within   
 the same group and between groups. ANOVA was used to compare mean differences  
  found in both groups at two moments in time i.e., pre and post-treatment, and 
   a multiple regression analysis was performed so that we could understand how 
   the value of the dependent variable changed when any of the independent varia
bles    changed while the other independent variables remained the same. The sig
nificance    level was set at p &lt; 0.05.</font></p>     ^cY#aop0611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#59#55#article#170#<p>&nbsp;</
p>     ^cY#aop0611.htm##
00339000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009700084002001200181#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#60#56#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Results</b></font></p>   
  ^cY#aop0611.htm##
00484000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704024200084002001200326#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#61#57#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Statistically speaking,    p
atients shared similar population characteristics as seen in the demographic    
information presented in <a href="#t1">Table 1</a>.</font></p>     ^cY#aop0611.h
tm##
00275000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704003300084002001200117#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#62#58#article#170#<p><a name=
"t1"></a></p>     ^cY#aop0611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#63#59#article#170#<p>&nbsp;</
p>     ^cY#aop0611.htm##
00328000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008600084002001200170#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#64#60#article#170#<p align="c
enter"><img src="/img/revistas/rbp/2011nahead/aop0611t01.jpg"></p>     ^cY#aop06
11.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#65#61#article#170#<p>&nbsp;</
p>     ^cY#aop0611.htm##
00723000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704048100084002001200565#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#66#62#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Both groups did    not prese
nt any significant difference in terms of their baseline scores on    the BDI, B
AI and YMRS scales. <a href="#t2">Table 2</a> shows the correlations    between 
the clinical scores and the two groups before the first session. The    clinical
 scores were categorized as subclinical, mild, moderate and severe depression/an
xiety,    and as subclinical, hypomania and mania.</font></p>     ^cY#aop0611.ht
m##
00275000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704003300084002001200117#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#67#63#article#170#<p><a name=
"t2"></a></p>     ^cY#aop0611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#68#64#article#170#<p>&nbsp;</
p>     ^cY#aop0611.htm##
00328000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008600084002001200170#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#69#65#article#170#<p align="c
enter"><img src="/img/revistas/rbp/2011nahead/aop0611t02.jpg"></p>     ^cY#aop06
11.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#70#66#article#170#<p>&nbsp;</
p>     ^cY#aop0611.htm##
00895000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704065300084002001200737#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#71#67#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">On one hand, it    is import
ant to note that the average depression scores indicated the presence    of mild
 depression in both groups. On the other hand, the scores on the YMRS    pointed
 towards the presence of sub-clinical hypomanic/manic symptoms in the    two gro
ups. With respect to anxiety, subjects from the CBGT group presented    average 
mild anxiety, whereas subjects from the TAU group presented sub-clinical    anxi
ety. However, the number of patients with subclinical, mild, moderate or    seve
re anxiety was not statistically different between the groups.</font></p>     ^c
Y#aop0611.htm##
00493000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704025100084002001200335#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#72#68#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">The scores of both    groups
 at the beginning, middle and at the end of the treatment are shown in    <a hre
f="/img/revistas/rbp/2011nahead/aop0611t03.jpg">Table 3</a>.</font></p>     ^cY#
aop0611.htm##
00435000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704019300084002001200277#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#73#69#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">The graphs below    indicate
 the variations in the anxiety and depression scores over a period of    14 week
s.</font></p>     ^cY#aop0611.htm##
01091000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704084900084002001200933#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#74#70#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">By initially examining    th
e within-group results, one can say that there were no significant differences  
  in the depression (BDI; p = 0.210) and anxiety scores (BAI; p = 0.234) among  
  control group subjects over the fourteen weeks. The same was true for this gro
up's    scores on manic symptoms (YMRS; p = 0.243) and hopelessness (BHS; p = 0.
312).    However, in the CBGT group, there was a significant difference over tim
e in    the depression (BDI; p = 0.000) and anxiety (BAI; p = 0.000) scores, whi
ch means    that, in the course of those fourteen weeks, scores fell. A signific
ant fall    was seen over the fourteen weeks in the manic symptoms index scores 
(YMRS; p    = 0.000) and between the initial and final scores on hopelessness (B
HS; p =    0.000).</font></p>     ^cY#aop0611.htm##
01353000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704111100084002001201195#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#75#71#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Regression analyses    also 
showed favorable results for the CBGT group. Of all the variables included    in
 the study, the only one that appeared to be significantly associated with    re
duced depression scores was the treatment group, thus favoring CBGT (R square   
 = 0.909 / p = 0.002). Time point during the course of the study significantly  
  predicted a change in anxiety scores for the CBGT group. Specifically, the ele
venth    session represented a key moment in terms of reduced anxiety (R square 
= 0.904    / p = 0.027). Mania scores were not particularly associated with any 
variable    (R square = 0.355 / p = 0.151); this indicates that the model did no
t function    well. Finally, the BHS, which regression analysis indicated as bei
ng part of    the CBGT, was associated with reduced hopelessness (R square = 0.5
51 / 0.002).    However, using the same scale, the higher the BHS score recorded
 in the first    week, the higher this same score was recorded in the last treat
ment week (R    square = 0.355 / 0.000).</font></p>     ^cY#aop0611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#76#72#article#170#<p>&nbsp;</
p>     ^cY#aop0611.htm##
00342000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010000084002001200184#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#77#73#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Discussion</b></font></p>
     ^cY#aop0611.htm##
00662000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704042000084002001200504#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#78#74#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Unfortunately,    to this da
te, only a few studies have investigated the efficacy of CBGT in BD    patients.
 One such study compared results before and after CBT plus pharmacotherapy,<sup>
11</sup>    and another study compared CBT plus pharmacotherapy versus pharmacot
herapy alone.<sup>12</sup>    Neither study included a control group.</font></p>
     ^cY#aop0611.htm##
01147000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704090500084002001200989#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#79#75#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Palmer et al. evaluated    t
he effectiveness of 17 weekly sessions of CGGT in six bipolar patients who    we
re on maintenance mood stabilizers.<sup>11</sup> Results showed that two patient
s    experienced a significant improvement and that a third one showed a trend t
owards    improved well-being. All patients showed improvements in social adjust
ment in    pre- to post-test.<sup>11</sup> In another study, Patelis et al. show
ed that    the inclusion of 14 sessions of CBGT to promote pharmacotherapy adher
ence had    improved the functioning and quality of life of 38 bipolar patients.
 By the    end of the treatment, scores had changed significantly in favour of t
he CBGT    group.<sup>12</sup> The group protocol derived from a combination of 
sources,    including Basco and Rush<sup>18</sup> and Newman.<sup>26</sup></font
></p>     ^cY#aop0611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#80#76#article#170#<p>&nbsp;</
p>     ^cY#aop0611.htm##
00328000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008600084002001200170#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#81#77#article#170#<p align="c
enter"><img src="/img/revistas/rbp/2011nahead/aop0611f01.jpg"></p>     ^cY#aop06
11.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#82#78#article#170#<p>&nbsp;</
p>     ^cY#aop0611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#83#79#article#170#<p>&nbsp;</
p>     ^cY#aop0611.htm##
00328000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008600084002001200170#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#84#80#article#170#<p align="c
enter"><img src="/img/revistas/rbp/2011nahead/aop0611f02.jpg"></p>     ^cY#aop06
11.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#85#81#article#170#<p>&nbsp;</
p>     ^cY#aop0611.htm##
00943000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704070100084002001200785#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#86#82#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">In spite of the    number of
 treatment sessions mentioned above, we are unable to compare results    since s
ubjective measures and follow up varied widely between studies. Considering    t
hat the authors have acknowledged some of the limitations of their respective   
 studies, our ability to interpret their results is rather limited. These limita
tions,    which include the absence a control group against which to compare the
 results    from the experimental group and possible individual changes in medic
ation that    may account for the improvements seen in patients, can however be 
overcome in    future studies.</font></p>     ^cY#aop0611.htm##
00545000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704030300084002001200387#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#87#83#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Group therapy was    well to
lerated by all subjects, as evidenced by the fact that 92.59% of them    remaine
d in the program from beginning to end, thus corroborating the findings    of Pa
telis-Siotis et al.<sup>12</sup></font></p>     ^cY#aop0611.htm##
00567000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704032500084002001200409#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#88#84#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">The inclusion of    CBGT as 
part of the pharmacological treatment was effective. After treatment,    partici
pants presented fewer manic, depressive and anxiety symptoms and a reduction    
in the frequency and duration of mood change episodes.</font></p>     ^cY#aop061
1.htm##
00582000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704034000084002001200424#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#89#85#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">CBGT sessions were    essent
ial for the improvement of depressive symptoms, which supports the findings    o
f Scott et al.,<sup>27</sup> Ball et al.,<sup>28</sup> and Reilly-Harrington    
et al.,<sup>29</sup> who investigated the efficacy of individual CBT.</font></p>
     ^cY#aop0611.htm##
00674000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704043200084002001200516#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#90#86#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Although the mania    index 
scores did fall, in regression, the model did not prove to be functional.    It 
is particularly important to note that subjects from both groups had low    YMRS
 scores in the first assessment (i.e., pre-treatment) and were all medicated    
with mood stabilizers. This explains why we were less likely to see lower scores
.</font></p>     ^cY#aop0611.htm##
01047000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704080500084002001200889#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#91#87#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">A limitation of    this stud
y is the exclusion of patients with severe mania or severe depression.    Althou
gh there were no significant differences in baseline scores, subjects    from th
e CBGT group had slightly higher mean raw anxiety, depression and mania    score
s after treatment compared to before treatment. This could lead to a less    app
arent reduction in symptoms in subjects from the control group. Furthermore,    
we did not conduct a reassessment to evaluate whether the patients had sustained
    the gains made during therapy. Another limitation of this study is its small
    sample size, especially that of the control group (n = 12). Nevertheless, we
    see the presence of a control group as a strength.</font></p>     ^cY#aop061
1.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#92#88#article#170#<p>&nbsp;</
p>     ^cY#aop0611.htm##
00342000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010000084002001200184#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#93#89#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Conclusion</b></font></p>
     ^cY#aop0611.htm##
00667000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704042500084002001200509#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#94#90#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">The inclusion of    CBGT as 
part of the pharmacological treatment was effective. Patients receiving    CBGT 
presented fewer symptoms of mania, depression and anxiety. Subjects from    the 
CBGT group also experienced fewer and shorter mood change episodes. CBGT    sess
ions were especially important for the improvement of depression symptoms.</font
></p>     ^cY#aop0611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#95#91#article#170#<p>&nbsp;</
p>     ^cY#aop0611.htm##
00348000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010600084002001200190#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#96#92#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Acknowledgements</b></fon
t></p>     ^cY#aop0611.htm##
00543000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704030100084002001200385#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#97#93#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">This study was    conducted 
at the Panic and Respiration Laboratory and at the INCT Translational    Medicin
e, Institute of Psychiatry, Universidade Federal do Rio de Janeiro (IPUB-UFRJ), 
   Rio de Janeiro, RJ, Brazil.</font></p>     ^cY#aop0611.htm##
00438000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704019600084002001200280#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#98#94#article#170#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">This study received    a gra
nt from the Brazilian Council for Scientific and Technological Development    (C
NPq).</font></p>     ^cY#aop0611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#99#95#article#170#<p>&nbsp;</
p>     ^cY#aop0611.htm##
00394000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081704015100085002001200236#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#100#96#article#170#<p align="
center"><a href="/img/revistas/rbp/2011nahead/aop0611q03.jpg"><img src="/img/rev
istas/rbp/2011nahead/aop0611q03thumb.jpg" border="0">    ^cY#aop0611.htm##
00350000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081704010700085002001200192#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#101#97#article#170#<br>   <fo
nt face="Verdana, Arial, Helvetica, sans-serif" size="2">Click to enlarge</font>
</a></p>     ^cY#aop0611.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081704002200085002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#102#98#article#170#<p>&nbsp;<
/p>     ^cY#aop0611.htm##
00343000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081704010000085002001200185#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#103#99#article#170#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>References</b></font></p
>     ^cY#aop0611.htm##
00560000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704030200088002001200390#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#104#100#article#1
70#1#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">1. Judd LL, 
Akiskal    HS. The prevalence and disability of bipolar spectrum disorders in th
e USA population:    re-analysis of the ECA atabase taking into account subthres
hold cases. <i>J    Affect Disord.</i> 2003;73(1-2):123-31.    ^cY#aop0611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#105#101#article#170#</font></
p>     ^cY#aop0611.htm##
00433000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704017500088002001200263#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#106#102#article#1
70#2#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2. Jones S. 
Psychotherapy    of bipolar disorder: a review. <i>J Affect Disord.</i> 2004;80(
2-3):101-14.    ^cY#aop0611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#107#103#article#170#</font></
p>     ^cY#aop0611.htm##
00591000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704033300088002001200421#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#108#104#article#1
70#3#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">3. Miklowitz
 DJ,    Otto MW, Frank E, Reilly-Harrington NA, Wisniewski SR, Kogan JN. Psychos
ocial    treatments for bipolar depression: a 1-year randomized trial from the S
ystematic    Treatment Enhancement Program. <i>Arch Gen Psychiatry.</i> 2007;64(
4):419-42.    ^cY#aop0611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#109#105#article#170#</font></
p>     ^cY#aop0611.htm##
00467000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704020900088002001200297#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#110#106#article#1
70#4#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">4. Miklowitz
 DJ.    Adjunctive psychotherapy for bipolar disorder: state of the evidence. <i
>Am    J Psychiatry.</i> 2008;165(11):1408-19.    ^cY#aop0611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#111#107#article#170#</font></
p>     ^cY#aop0611.htm##
00466000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704020800088002001200296#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#112#108#article#1
70#5#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">5. Keck PE, 
McElroy    S. Outcome in the pharmacologic treatment of bipolar disorder. <i>J C
lin Psychopharmacol</i>.    1996;16(1):15-23.    ^cY#aop0611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#113#109#article#170#</font></
p>     ^cY#aop0611.htm##
00541000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704028300088002001200371#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#114#110#article#1
70#6#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">6. Swann AC,
 Bowden    CL, Morris D, Calabrese JR, Petty F, Small J, Dilsaver SC, Davis JM.D
epression    during mania. Treatment response to lithium or divalproex. <i>Arch 
Gen Psychiatry.</i>    1997;54(1):37-42.    ^cY#aop0611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#115#111#article#170#</font></
p>     ^cY#aop0611.htm##
00684000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704042600088002001200514#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#116#112#article#1
70#7#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">7. Bowden CL
, Calabrese    JR, Sachs G, Yatham LN, Asghar SA, Hompland M, Montgomery P, Earl
 N, Smoot TM,    DeVeaugh-Geiss J; Lamictal 606 Study Group.A placebo-controlled
 18-month trial    of lamotrigine and lithium maintenance treatment in recently 
manic or hypomanic    patients with bipolar I disorder. <i>Arch Gen Psychiatry.<
/i> 2003;60(4):392-400.    ^cY#aop0611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#117#113#article#170#</font></
p>     ^cY#aop0611.htm##
00516000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704025800088002001200346#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#118#114#article#1
70#8#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">8. Solomon D
A,    Keitner GI, Miller IW, Shea MT, Keller MB. Course of illness and maintenan
ce    treatments for patients with bipolar disorder. <i>J Clin</i> Psychiatry. 1
995;56(1):5-13.    ^cY#aop0611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#119#115#article#170#</font></
p>     ^cY#aop0611.htm##
00578000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704032000088002001200408#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#120#116#article#1
70#9#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">9. Vieta E, 
Pacchiarotti    I, Scott J, S&aacute;nchez-Moreno J, Di Marzo S, Colom F. Eviden
ce-based research    on the efficacy of psychological interventions in bipolar d
isorders: a critical    review. <i>Curr Psychiatry Rep.</i> 2005;7(6):449-55.   
 ^cY#aop0611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#121#117#article#170#</font></
p>     ^cY#aop0611.htm##
00434000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704017500089002001200264#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#122#118#article#1
70#10#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Sachs G
S. Unmet    clinical needs in bipolar disorder. <i>J Clin Psychopharmacol.</i> 2
003;3(1):2-8.    ^cY#aop0611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#123#119#article#170#</font></
p>     ^cY#aop0611.htm##
00485000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704022600089002001200315#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#124#120#article#1
70#11#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Palmer 
AG,    Williams H, Gorsefield D, Adams M. CBT in a group format for bipolar affe
ctive    disorder. <i>Behav Cogn Psychother.</i> 1995;23:153-68.    ^cY#aop0611.
htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#125#121#article#170#</font></
p>     ^cY#aop0611.htm##
00515000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704025600089002001200345#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#126#122#article#1
70#12#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Patelis
-Siotis    I, Young LT, Robb JC. Group cognitive behavioral therapy for bipolar 
disorder:    a feasibility and effectiveness study. <i>J Affect Disord.</i> 2001
;65(2):145-53.    ^cY#aop0611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#127#123#article#170#</font></
p>     ^cY#aop0611.htm##
00559000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704030000089002001200389#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#128#124#article#1
70#13#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Scott J
, Colom    F, Vieta E. A meta-analysis of relapse rates with adjunctive psycholo
gical therapies    compared to usual psychiatric treatment for bipolar disorders
. <i>Int J Neuropsychopharmachol</i>.    2006;10(1):123-9.    ^cY#aop0611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#129#125#article#170#</font></
p>     ^cY#aop0611.htm##
00477000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704021800089002001200307#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#130#126#article#1
70#14#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Miklowi
tz DJ,    Johnson SL. On the role of goal dysregulation in the treatment of bipo
lar disorder.    <i>Clin Psychol</i>. 2009;16(4):470-75.    ^cY#aop0611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#131#127#article#170#</font></
p>     ^cY#aop0611.htm##
00527000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704026800089002001200357#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#132#128#article#1
70#15#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Zaretsk
y A,    Lancee W, Miller C, Harris A, Parikh SV. Is cognitive-behavioral therapy
 more    effective than psychoeducation in bipolar disorder? <i>Can J Psychiatry
</i>.    2008;53(7):441-8.    ^cY#aop0611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#133#129#article#170#</font></
p>     ^cY#aop0611.htm##
00623000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704036400089002001200453#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#134#130#article#1
70#16#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Parikh 
S, Zaretsky    A, Beaulieu S. <i>Psycho-education versus cognitive behavioral th
erapy for bipolar    disorder: A multi-site national RCT.</i> Paper presented at
 the Annual Meeting    of the American Psychiatric Association. Washington, DC: 
American Psychiatric    Association; 2007.    ^cY#aop0611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#135#131#article#170#</font></
p>     ^cY#aop0611.htm##
00526000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704026700089002001200356#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#136#132#article#1
70#17#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Lam DH,
 Hayward    P, Watkins ER, Wright K, Sham P. Relapse prevention in patients with
 bipolar    disorder: cognitive therapy outcome after 2 years. <i>Am J Psychiatr
y</i>. 2005;162(2):324-9.    ^cY#aop0611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#137#133#article#170#</font></
p>     ^cY#aop0611.htm##
00448000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704018900089002001200278#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#138#134#article#1
70#18#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Basco M
R, Rush    AJ. <i>Cognitive-behavioral therapy for bipolar disorder</i>. New Yor
k: Guilford    Press; 1996.    ^cY#aop0611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#139#135#article#170#</font></
p>     ^cY#aop0611.htm##
00525000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704026600089002001200355#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#140#136#article#1
70#19#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Lam DH,
 Jones    SH, Hayward P, Bright JA. <i>Cognitive Therapy for Bipolar Disorder: A
 Therapist's    Guide to Concepts, Methods and Practice.</i> New York, NY: John 
Wiley and Sons;    1999.    ^cY#aop0611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#141#137#article#170#</font></
p>     ^cY#aop0611.htm##
00462000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704020300089002001200292#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#142#138#article#1
70#20#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Newman 
C. <i>Bipolar    disorder: a cognitive therapy approach</i>. Washington, DC: Ame
rican Psychological    Association; 2002.    ^cY#aop0611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#143#139#article#170#</font></
p>     ^cY#aop0611.htm##
00463000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704020400089002001200293#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#144#140#article#1
70#21#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Beck AT
, Ward    CH, Mendelson M, Erbaugh J. An inventory for measuring depression. <i>
Arch Gen    Psychiatry.</i> 1961;4:561-71.    ^cY#aop0611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#145#141#article#170#</font></
p>     ^cY#aop0611.htm##
00477000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704021800089002001200307#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#146#142#article#1
70#22#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">22. Young R
C, Biggs    JT, Ziegler VE. A rating scale for mania: reliability, validity and 
sensitivity.    <i>Br J Psychiatry.</i> 1978;133:429-35.    ^cY#aop0611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#147#143#article#170#</font></
p>     ^cY#aop0611.htm##
00529000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704027000089002001200359#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#148#144#article#1
70#23#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">23. First M
B, Gibbon    M, Spitzer RL, Williams JBW. <i>User guide for the structured clini
cal interview    for DSM-IV Axis 1 disorders.</i> Washington, DC: American Psych
iatric Association;    1996.    ^cY#aop0611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#149#145#article#170#</font></
p>     ^cY#aop0611.htm##
00497000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704023800089002001200327#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#150#146#article#1
70#24#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">24. Beck AT
, Epstein    N, Brown G, Steer RA. An inventory for measuring clinical anxiety: 
psychometric    properties. <i>J Consult Clin Psychol.</i> 1988;56(6):893-7.    
^cY#aop0611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#151#147#article#170#</font></
p>     ^cY#aop0611.htm##
00444000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704018500089002001200274#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#152#148#article#1
70#25#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">25. Beck AT
, Kouacs    M, Weissman A. Hopelessness and suicidal behaviour. <i>J Am Med Asso
c.</i> 1975;234:1146-9.    ^cY#aop0611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#153#149#article#170#</font></
p>     ^cY#aop0611.htm##
00478000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704021900089002001200308#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#154#150#article#1
70#26#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">26. Otto MW
, Miklovitz    DJ. The Role and Impact of Psychotherapy in the Management of Bip
olar Disorder.    <i>CNS Spectrums.</i> 2004;9(11):27-32.    ^cY#aop0611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#155#151#article#170#</font></
p>     ^cY#aop0611.htm##
00466000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704020700089002001200296#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#156#152#article#1
70#27#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">27. Scott J
, Garland    A, Morhead S. A pilot study of cognitive therapy in bipolar disorde
rs. <i>Psychol    Med</i>. 2001;31(3):459-67.    ^cY#aop0611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#157#153#article#170#</font></
p>     ^cY#aop0611.htm##
00552000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704029300089002001200382#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#158#154#article#1
70#28#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">28. Ball JR
, Mitchell    PB, Corry JC, Skillecorn A, Smith M, Malhi GS. A randomized contro
lled trial    of cognitive therapy for bipolar disorder: focus on long-term chan
ge. <i>J Clin    Psychiatry.</i> 2006;67(2):277-86.    ^cY#aop0611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#159#155#article#170#</font></
p>     ^cY#aop0611.htm##
00571000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704031200089002001200401#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#160#156#article#1
70#29#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">29. Reilly-
Harrington    NA, Deckersbach T, Knauz R, Wu Y, Tran T, Eidelman P, Lund HG, Sac
hs G, Nierenberg    AA. Cognitive behavioral therapy for rapid-cycling bipolar d
isorder: a pilot    study. <i>J Psychiatr Pract.</i> 2007;13(5):291-7.    ^cY#ao
p0611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#161#157#article#170#</font></
p>     ^cY#aop0611.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#162#158#article#170#<p>&nbsp;
</p>     ^cY#aop0611.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#163#159#article#170#<p>&nbsp;
</p>     ^cY#aop0611.htm##
00436000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704019200086002001200278#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#164#160#article#170#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a href
="#top"><img src="/img/revistas/rbp/2011nahead/seta.jpg" border="0"></a>    <b> 
Correspondence:    ^cY#aop0611.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704008200086002001200168#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#165#161#article#170#<br>   </
b> Institute of Psychiatry - Federal University of Rio de Janeiro    ^cY#aop0611
.htm##
00295000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704005100086002001200137#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#166#162#article#170#<br>   IN
CT - Translational Medicine (CNPq)    ^cY#aop0611.htm##
00303000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704005900086002001200145#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#167#163#article#170#<br>   R.
 Piau&iacute;, 413 / 203 - Todos os Santos    ^cY#aop0611.htm##
00285000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704004100086002001200127#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#168#164#article#170#<br>   Ri
o de Janeiro, RJ, Brasil    ^cY#aop0611.htm##
00304000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704006000086002001200146#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#169#165#article#170#<br>   Te
l.: (+55 21) 3649-6965 / (+55 21) 9509-4461    ^cY#aop0611.htm##
00320000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704007600086002001200162#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#170#166#article#170#<br>   La
borat&oacute;rio de P&acirc;nico e Respira&ccedil;&atilde;o    ^cY#aop0611.htm##
00307000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704006300086002001200149#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#171#167#article#170#<br>   Te
l.: (+55 21) 2521-6147 Fax: (+55 21) 2523-6839    ^cY#aop0611.htm##
00340000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704009600086002001200182#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#172#168#article#170#<br>   Em
ail: <a href="mailto:faelthomaz@ig.com.br">faelthomaz@ig.com.br</a></font></p>  
   ^cY#aop0611.htm##
00342000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704009800086002001200184#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#173#169#article#170#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">Submitted: March    3, 201
0    ^cY#aop0611.htm##
00295000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704005100086002001200137#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#p#174#170#article#170#<br>   Ac
cepted: April 13, 2010</font></p>     ^cY#aop0611.htm##
00621000000000277000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100015000850100018001000120
15700118030001700275710000200292065000900294064000500303031000300308032000400311
014000700315865000900322002001200331#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop0611.htm#S#c#175#1#article#29#1#^rND^sJudd^nLL#^rND^sAkiskal^nHS#The p
revalence and disability of bipolar spectrum disorders in the USA population: re
-analysis of the ECA atabase taking into account subthreshold cases^len#J Affect
 Disord.#2#20030000#2003#73#1-2#123-31#20110000#aop0611.htm##
00482000000000265000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100015000850120048001000300
01700148710000200165065000900167064000500176031000300181032000400184014000700188
865000900195002001200204#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop06
11.htm#S#c#176#2#article#29#2#^rND^sJones^nS#Psychotherapy of bipolar disorder: 
a review^len#J Affect Disord.#2#20040000#2004#80#2-3#101-14#20110000#aop0611.htm
##
00724000000000325000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100020000850100015001050100
01500120010002800135010002100163010001600184012012800200030002100328710000200349
06500090035106400050036003100030036503200020036801400070037086500090037700200120
0386#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#c#177#3#art
icle#29#3#^rND^sMiklowitz^nDJ#^rND^sOtto^nMW#^rND^sFrank^nE#^rND^sReilly-Harring
ton^nNA#^rND^sWisniewski^nSR#^rND^sKogan^nJN#Psychosocial treatments for bipolar
 depression: a 1-year randomized trial from the Systematic Treatment Enhancement
 Program^len#Arch Gen Psychiatry.#2#20070000#2007#64#4#419-42#20110000#aop0611.h
tm##
00513000000000265000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100020000850120073001050300
01700178710000200195065000900197064000500206031000400211032000300215014000800218
865000900226002001200235#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop06
11.htm#S#c#178#4#article#29#4#^rND^sMiklowitz^nDJ#Adjunctive psychotherapy for b
ipolar disorder: state of the evidence^len#Am J Psychiatry.#2#20080000#2008#165#
11#1408-19#20110000#aop0611.htm##
00572000000000289000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100015000850100017001000120
06300117030002300180065000900203064000500212031000300217032000200220014000600222
865000900228002001200237035001000249801002300259#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop0611.htm#S#c#179#5#article#29#5#^rND^sKeck^nPE#^rND^sMcElr
oy^nS#Outcome in the pharmacologic treatment of bipolar disorder^len#J Clin Psyc
hopharmacol#19960000#1996#16#1#15-23#20110000#aop0611.htm#0271-0749#J Clin Psych
opharmacol##
00711000000000349000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100016000850100017001010100
01600118010002000134010001500154010001500169010001900184010001600203012007300219
03000210029271000020031306500090031506400050032403100030032903200020033201400060
0334865000900340002001200349#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\a
op0611.htm#S#c#180#6#article#29#6#^rND^sSwann^nAC#^rND^sBowden^nCL#^rND^sMorris^
nD#^rND^sCalabrese^nJR#^rND^sPetty^nF#^rND^sSmall^nJ#^rND^sDilsaver^nSC#^rND^sDa
vis^nJM#Depression during mania: Treatment response to lithium or divalproex^len
#Arch Gen Psychiatry.#2#19970000#1997#54#1#37-42#20110000#aop0611.htm##
00887000000000373000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100017000850100020001020100
01500122010001700137010001700154010001800171010002000189010001400209010001600223
01000240023901201790026303000210044271000020046306500090046506400050047403100030
0479032000200482014000800484865000900492002001200501#2011nahead#V:\SciELO\serial
\rbp\2011nahead\markup\aop0611.htm#S#c#181#7#article#29#7#^rND^sBowden^nCL#^rND^
sCalabrese^nJR#^rND^sSachs^nG#^rND^sYatham^nLN#^rND^sAsghar^nSA#^rND^sHompland^n
M#^rND^sMontgomery^nP#^rND^sEarl^nN#^rND^sSmoot^nTM#^rND^sDeVeaugh-Geiss^nJ#Lami
ctal 606 Study Group: A placebo-controlled 18-month trial of lamotrigine and lit
hium maintenance treatment in recently manic or hypomanic patients with bipolar 
I disorder^len#Arch Gen Psychiatry.#2#20030000#2003#60#4#392-400#20110000#aop061
1.htm##
00671000000000325000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100018000850100018001030100
01700121010001500138010001700153012008400170030001800254065000900272064000500281
03100030028603200020028901400050029186500090029600200120030503500100031780100180
0327#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#c#182#8#art
icle#29#8#^rND^sSolomon^nDA#^rND^sKeitner^nGI#^rND^sMiller^nIW#^rND^sShea^nMT#^r
ND^sKeller^nMB#Course of illness and maintenance treatments for patients with bi
polar disorder^len#J Clin Psychiatry#19950000#1995#56#1#5-13#20110000#aop0611.ht
m#0160-6689#J Clin Psychiatry##
00704000000000325000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100015000850100022001000100
01500122010002400137010001800161010001500179012011500194030002100309710000200330
06500090033206400050034103100020034603200020034801400070035086500090035700200120
0366#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#c#183#9#art
icle#29#9#^rND^sVieta^nE#^rND^sPacchiarotti^nI#^rND^sScott^nJ#^rND^sSánchez-More
no^nJ#^rND^sDi Marzo^nS#^rND^sColom^nF#Evidence-based research on the efficacy o
f psychological interventions in bipolar disorders: a critical review^len#Curr P
sychiatry Rep.#2#20050000#2005#7#6#449-55#20110000#aop0611.htm##
00483000000000265000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870120045001030300
02400148710000200172065000900174064000500183031000200188032000200190014000400192
865000900196002001200205#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop06
11.htm#S#c#184#10#article#29#10#^rND^sSachs^nGS#Unmet clinical needs in bipolar 
disorder^len#J Clin Psychopharmacol.#2#20030000#2003#3#1#2-8#20110000#aop0611.ht
m##
00574000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100018001040100
02000122010001500142012005700157030002300214710000200237065000900239064000500248
031000300253014000700256865000900263002001200272#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop0611.htm#S#c#185#11#article#29#11#^rND^sPalmer^nAG#^rND^sW
illiams^nH#^rND^sGorsefield^nD#^rND^sAdams^nM#CBT in a group format for bipolar 
affective disorder^len#Behav Cogn Psychother.#2#19950000#1995#23#153-68#20110000
#aop0611.htm##
00597000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100024000870100016001110100
01500127012009900142030001700241710000200258065000900260064000500269031000300274
032000200277014000700279865000900286002001200295#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop0611.htm#S#c#186#12#article#29#12#^rND^sPatelis-Siotis^nI#
^rND^sYoung^nLT#^rND^sRobb^nJC#Group cognitive behavioral therapy for bipolar di
sorder: a feasibility and effectiveness study^len#J Affect Disord.#2#20010000#20
01#65#2#145-53#20110000#aop0611.htm##
00637000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100015000870100015001020100
01500117012013900132030002800271710000200299065000900301064000500310031000300315
032000200318014000600320865000900326002001200335#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop0611.htm#S#c#187#13#article#29#13#^rND^sScott^nJ#^rND^sCol
om^nF#^rND^sVieta^nE#A meta-analysis of relapse rates with adjunctive psychologi
cal therapies compared to usual psychiatric treatment for bipolar disorders^len#
Int J Neuropsychopharmachol#2#20060000#2006#10#1#123-9#20110000#aop0611.htm##
00573000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100020000870100018001070120
07500125030001300200065000900213064000500222031000300227032000200230014000700232
865000900239002001200248035001000260801001300270#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop0611.htm#S#c#188#14#article#29#14#^rND^sMiklowitz^nDJ#^rND
^sJohnson^nSL#On the role of goal dysregulation in the treatment of bipolar diso
rder^len#Clin Psychol#20090000#2009#16#4#470-75#20110000#aop0611.htm#0009-9244#C
lin Psychol##
00679000000000325000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100016001050100
01600121010001600137010001700153012009300170030001700263065000900280064000500289
03100030029403200020029701400060029986500090030500200120031403500100032680100170
0336#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#c#189#15#ar
ticle#29#15#^rND^sZaretsky^nA#^rND^sLancee^nW#^rND^sMiller^nC#^rND^sHarris^nA#^r
ND^sParikh^nSV#Is cognitive-behavioral therapy more effective than psychoeducati
on in bipolar disorder?^len#Can J Psychiatry#20080000#2008#53#7#441-8#20110000#a
op0611.htm#0706-7437#Can J Psychiatry##
00689000000000265000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840160016000870160018001030160
01800121018010500139053008100244056002100325052003600346055001200382054000800394
865000900402002001200411#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop06
11.htm#S#c#190#16#article#29#16#^rND^sParikh^nS#^rND^sZaretsky^nA#^rND^sBeaulieu
^nS#Psycho-education versus cognitive behavioral therapy for bipolar disorder: A
 multi-site national RCT^len#Paper presented at the Annual Meeting of the Americ
an Psychiatric Association^i1#Washington^i1^eDC^i1#American Psychiatric Associat
ion^i1#20070000^i1#2007^i1#20110000#aop0611.htm##
00679000000000325000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100014000870100017001010100
01800118010001600136010001400152012009800166030001600264065000900280064000500289
03100040029403200020029801400060030086500090030600200120031503500100032780100160
0337#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#c#191#17#ar
ticle#29#17#^rND^sLam^nDH#^rND^sHayward^nP#^rND^sWatkins^nER#^rND^sWright^nK#^rN
D^sSham^nP#Relapse prevention in patients with bipolar disorder: cognitive thera
py outcome after 2 years^len#Am J Psychiatry#20050000#2005#162#2#324-9#20110000#
aop0611.htm#0002-953X#Am J Psychiatry##
00473000000000241000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840160016000870160015001030180
05400118066000900172062001500181065000900196064000500205865000900210002001200219
#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#c#192#18#articl
e#29#18#^rND^sBasco^nMR#^rND^sRush^nAJ#Cognitive-behavioral therapy for bipolar 
disorder^len#New York#Guilford Press#19960000#1996#20110000#aop0611.htm##
00583000000000265000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840160014000870160016001010160
01700117016001700134018009800151066001300249062002000262065000900282064000500291
865000900296002001200305#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop06
11.htm#S#c#193#19#article#29#19#^rND^sLam^nDH#^rND^sJones^nSH#^rND^sHayward^nP#^
rND^sBright^nJA#Cognitive Therapy for Bipolar Disorder: A Therapist's Guide to C
oncepts, Methods and Practice^len#New York^eNY#John Wiley and Sons#19990000#1999
#20110000#aop0611.htm##
00469000000000229000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840160016000870180051001030660
01500154062003500169065000900204064000500213865000900218002001200227#2011nahead#
V:\SciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#c#194#20#article#29#20#^rND
^sNewman^nC#Bipolar disorder: a cognitive therapy approach^len#Washington^eDC#Am
erican Psychological Association#20020000#2002#20110000#aop0611.htm##
00552000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100015000870100015001020100
01900117010001700136012004200153030002100195710000200216065000900218064000500227
031000200232014000700234865000900241002001200250#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop0611.htm#S#c#195#21#article#29#21#^rND^sBeck^nAT#^rND^sWar
d^nCH#^rND^sMendelson^nM#^rND^sErbaugh^nJ#An inventory for measuring depression^
len#Arch Gen Psychiatry.#2#19610000#1961#4#561-71#20110000#aop0611.htm##
00548000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100016001030100
01800119012006800137030001700205710000200222065000900224064000500233031000400238
014000700242865000900249002001200258#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop0611.htm#S#c#196#22#article#29#22#^rND^sYoung^nRC#^rND^sBiggs^nJT#^rND
^sZiegler^nVE#A rating scale for mania: reliability, validity and sensitivity^le
n#Br J Psychiatry.#2#19780000#1978#133#429-35#20110000#aop0611.htm##
00587000000000265000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840160016000870160016001030160
01800119016002000137018008100157066001500238062003300253065000900286064000500295
865000900300002001200309#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop06
11.htm#S#c#197#23#article#29#23#^rND^sFirst^nMB#^rND^sGibbon^nM#^rND^sSpitzer^nR
L#^rND^sWilliams^nJBW#User guide for the structured clinical interview for DSM-I
V Axis 1 disorders^len#Washington^eDC#American Psychiatric Association#19960000#
1996#20110000#aop0611.htm##
00597000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100015000870100017001020100
01500119010001600134012007300150030002400223710000200247065000900249064000500258
031000300263032000200266014000600268865000900274002001200283#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop0611.htm#S#c#198#24#article#29#24#^rND^sBeck^n
AT#^rND^sEpstein^nN#^rND^sBrown^nG#^rND^sSteer^nRA#An inventory for measuring cl
inical anxiety: psychometric properties^len#J Consult Clin Psychol.#2#19880000#1
988#56#6#893-7#20110000#aop0611.htm##
00518000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100015000870100016001020100
01800118012004000136030001600176710000200192065000900194064000500203031000400208
014000700212865000900219002001200228#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop0611.htm#S#c#199#25#article#29#25#^rND^sBeck^nAT#^rND^sKouacs^nM#^rND^
sWeissman^nA#Hopelessness and suicidal behaviour^len#J Am Med Assoc.#2#19750000#
1975#234#1146-9#20110000#aop0611.htm##
00542000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100015000870100020001020120
07900122030001500201710000200216065000900218064000500227031000200232032000300234
014000600237865000900243002001200252#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop0611.htm#S#c#200#26#article#29#26#^rND^sOtto^nMW#^rND^sMiklovitz^nDJ#T
he Role and Impact of Psychotherapy in the Management of Bipolar Disorder^len#CN
S Spectrums.#2#20040000#2004#9#11#27-32#20110000#aop0611.htm##
00579000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100015000870100017001020100
01700119012006000136030001200196065000900208064000500217031000300222032000200225
014000700227865000900234002001200243035001000255801001200265#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop0611.htm#S#c#201#27#article#29#27#^rND^sScott^
nJ#^rND^sGarland^nA#^rND^sMorhead^nS#A pilot study of cognitive therapy in bipol
ar disorders^len#Psychol Med#20010000#2001#31#3#459-67#20110000#aop0611.htm#0033
-2917#Psychol Med##
00685000000000325000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100015000870100019001020100
01600121010002000137010001500157010001600172012010300188030001900291710000200310
06500090031206400050032103100030032603200020032901400070033186500090033800200120
0347#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0611.htm#S#c#202#28#ar
ticle#29#28#^rND^sBall^nJR#^rND^sMitchell^nPB#^rND^sCorry^nJC#^rND^sSkillecorn^n
A#^rND^sSmith^nM#^rND^sMalhi^nGS#A randomized controlled trial of cognitive ther
apy for bipolar disorder: focus on long-term change^len#J Clin Psychiatry.#2#200
60000#2006#67#2#277-86#20110000#aop0611.htm##
00758000000000361000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100028000870100021001150100
01500136010001200151010001400163010001800177010001500195010001500210010002100225
01200830024603000190032971000020034806500090035006400050035903100030036403200020
0367014000600369865000900375002001200384#2011nahead#V:\SciELO\serial\rbp\2011nah
ead\markup\aop0611.htm#S#c#203#29#article#29#29#^rND^sReilly-Harrington^nNA#^rND
^sDeckersbach^nT#^rND^sKnauz^nR#^rND^sWu^nY#^rND^sTran^nT#^rND^sEidelman^nP#^rND
^sLund^nHG#^rND^sSachs^nG#^rND^sNierenberg^nAA#Cognitive behavioral therapy for 
rapid-cycling bipolar disorder: a pilot study^len#J Psychiatr Pract.#2#20070000#
2007#13#5#291-7#20110000#aop0611.htm##
00282000000000169000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780910009000800920007000890020012000967030
00400108#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#o#1#1#a
rticle#1#20110311#101421#aop0711.htm#130##
05389000000000769000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780710003000800400003000830010006000860420
00200092120000400094038000400098121000300102049000300105158000300108030002200111
03200060013306500090013901400070014803500100015522300090016501200880017401201070
02620100042003690100055004110100040004660100033005060100046005390100028005850100
03800613010002400651010003100675070013000706070007400836070011700910070011201027
07001170113907001140125607001260137008314060149608500100290208500190291208500320
29310850021029630850037029840850018030210831367030390850010044060850020044160850
03104436085002504467085003704492085001904529117000804548072000304556112000904559
111001404568114000904582113001604591002001204607#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop0711.htm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#TAB#07#nd#nd#
Rev. Bras. Psiquiatr.#ahead#20110000#^f0^l0#1516-4446#20110318#Applicability of 
the Rey Auditory-Verbal Learning Test to an adult sample in Brazil^len#O Teste d
e Aprendizagem Auditivo-Verbal de Rey: aplicabilidade para uma amostra de adulto
s brasileiros^lpt#^rND^1A01 A02 A04^nJoão Vinícius^sSalgado#^rND^1A03 A04 A05 A0
6^nLeandro Fernandes^sMalloy-Diniz#^rND^1A06^nSuzana Silva Costa^sAbrantes#^rND^
1A05 A06^nLafaiete^sMoreira#^rND^1A04 A06^nCarlos Guilherme^sSchlottfeldt#^rND^n
Wanderlane^sGuimarães#^rND^nDjeane Marcely Ugoline^sFreitas#^rND^nJuliana^sOlive
ira#^rND^1A06 A07^nDaniel^sFuentes#Universidade Federal de Minas Gerais^iA01^1In
stituto de Ciências Biológicas^2Department of Morphology^cBelo Horizonte^sMG^pBr
azil#Hospital de Ensino Instituto Raul Soares^iA02^cBelo Horizonte^sMG^pBrazil#U
niversidade Federal de Minas Gerai^iA03^1School of Medicine^2INCT de Medicina Mo
lecular^cBelo Horizonte^sMG^pBrazil#Universidade Federal de Minas Gerais^iA04^1P
ost-Graduation Program in Neurosciences^cBelo Horizonte^sMG^pBrazil#Universidade
 Federal de Minas Gerais^iA05^1Post-Graduation Program in Molecular Medicine^cBe
lo Horizonte^sMG^pBrazil#Universidade Federal de Minas Gerais^iA06^1Laboratórios
 Integrados de Neuropsicologia^cBelo Horizonte^sMG^pBrazil#Universidade de São P
aulo^iA07^1Faculdade de Medicina^2Hospital das Clínicas^3Instituto de Psiquiatri
a^cSão Paulo^sSP^pBrazil#^len^aOBJECTIVE: The Rey Auditory-Verbal Learning Test,
 which is used to evaluate learning and memory, is a widely recognized tool in t
he general literature on neuropsychology. This paper aims at presenting the perf
ormance of Brazilian adult subjects on the Rey Auditory-Verbal Learning Test, an
d was written after we published a previous study on the performance of Brazilia
n elderly subjects on this same test. METHOD: A version of the test, featuring a
 list of high-frequency one-syllable and two-syllable concrete Portuguese substa
ntives, was developed. Two hundred and forty-three (243) subjects from both gend
ers were allocated to 6 different age groups (20-24; 25-29; 30-34; 35-44; 45-54 
and 55-60 years old). They were then tested using the Rey Auditory-Verbal Learni
ng Test. RESULTS: Performance on the Rey Auditory-Verbal Learning Test showed a 
positive correlation with educational level and a negative correlation with age.
 Women performed significantly better than men. When applied across similar age 
ranges, our results were similar to those recorded for the English version of th
e Rey Auditory-Verbal Learning Test. CONCLUSION: Our results suggest that the ad
aptation of the Rey Auditory-Verbal Learning Test to Brazilian Portuguese is app
ropriate and that it is applicable to Brazilian subjects for memory capacity eva
luation purposes and across similar age groups and educational levels.#^ddecs^i1
#^tm^len^kMemory^i1#^tm^len^kAuditory perception^i1#^tm^len^kLearning^i1#^tm^len
^kNeuropsychological tests^i1#^tm^len^kAdult^i1#^lpt^aOBJETIVO: O Rey Auditory-V
erbal Learning Test é um teste mundialmente reconhecido na literatura neuropsico
lógica que avalia o aprendizado e a memória. Na sequência de um estudo anterior,
 que apresentou o desempenho dos idosos brasileiros no Rey Auditory-Verbal Learn
ing Test, este trabalho apresenta o desempenho dos adultos brasileiros no Rey Au
ditory-Verbal Learning Test. MÉTODO: Uma versão do teste foi desenvolvida com um
a lista de alta frequência, com uma ou duas sílabas de substantivos concretos do
 português do Brasil. Duzentos e quarenta e três (243) indivíduos de ambos os se
xos foram alocados para seis faixas etárias (20-24, 25-29, 30-34, 35-44, 45-54 e
 55-60 anos) e avaliados com o Rey Auditory-Verbal Learning Test. RESULTADOS: O 
grau de escolaridade e idade mostrou correlação positiva e negativa, respectivam
ente, com o desempenho no Rey Auditory-Verbal Learning Test. As mulheres tiveram
 um desempenho significativamente melhor que os homens. Os resultados foram seme
lhantes aos encontrados para a versão em inglês do Rey Auditory-Verbal Learning 
Test, por meio de faixas etárias semelhantes. CONCLUSÃO: Nossos resultados suger
em que a adaptação do Rey Auditory-Verbal Learning Test para o português brasile
iro é adequada e aplicável para avaliação da capacidade de memória de indivíduos
 brasileiros, com idade similar e educacionais níveis.#^ddecs^i2#^tm^lpt^kMemóri
a^i2#^tm^lpt^kPercepção auditiva^i2#^tm^lpt^kAprendizagem^i2#^tm^lpt^kTestes neu
ropsicológicos^i2#^tm^lpt^kAdulto^i2#vancouv#16#20100401#April 1, 2010#20100825#
August 25, 2010#aop0711.htm##
05513000000000769000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780710003000800400003000830010006000860420
00200092120000400094038000400098121000300102049000300105158000300108030002200111
03200060013306500090013901400070014803500100015522300090016501200950017401201140
02690100042003830100055004250100040004800100033005200100046005530100028005990100
03800627010002400665010003100689070013000720070007400850070012200924070011201046
07001170115807001140127507001260138908314340151508500100294908500190295908500320
29780850021030100850037030310850018030680831444030860850010045300850020045400850
03104560085002504591085003704616085001904653117000804672072000304680112000904683
111001404692114000904706113001604715002001204731#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop0711.htm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#TAB#07#nd#nd#
Rev. Bras. Psiquiatr.#ahead#20110000#^f0^l0#1516-4446#20110318#<b>Applicability 
of the Rey Auditory-Verbal Learning Test to an adult sample in Brazil</b>^len#<b
>O Teste de Aprendizagem Auditivo-Verbal de Rey: aplicabilidade para uma amostra
 de adultos brasileiros</b>^lpt#^rND^1A01 A02 A04^nJoão Vinícius^sSalgado#^rND^1
A03 A04 A05 A06^nLeandro Fernandes^sMalloy-Diniz#^rND^1A06^nSuzana Silva Costa^s
Abrantes#^rND^1A05 A06^nLafaiete^sMoreira#^rND^1A04 A06^nCarlos Guilherme^sSchlo
ttfeldt#^rND^nWanderlane^sGuimarães#^rND^nDjeane Marcely Ugoline^sFreitas#^rND^n
Juliana^sOliveira#^rND^1A06 A07^nDaniel^sFuentes#Universidade Federal de Minas G
erais^iA01^1Instituto de Ciências Biológicas^2Department of Morphology^cBelo Hor
izonte^sMG^pBrazil#Hospital de Ensino Instituto Raul Soares^iA02^cBelo Horizonte
^sMG^pBrazil#Universidade Federal de Minas Gerai^iA03^1School of Medicine^2INCT&
nbsp;de Medicina Molecular^cBelo Horizonte^sMG^pBrazil#Universidade Federal de M
inas Gerais^iA04^1Post-Graduation Program in Neurosciences^cBelo Horizonte^sMG^p
Brazil#Universidade Federal de Minas Gerais^iA05^1Post-Graduation Program in Mol
ecular Medicine^cBelo Horizonte^sMG^pBrazil#Universidade Federal de Minas Gerais
^iA06^1Laboratórios Integrados de Neuropsicologia^cBelo Horizonte^sMG^pBrazil#Un
iversidade de São Paulo^iA07^1Faculdade de Medicina^2Hospital das Clínicas^3Inst
ituto de Psiquiatria^cSão Paulo^sSP^pBrazil#^len^a<b>OBJECTIVE:</b> The Rey Audi
tory-Verbal Learning Test, which is used to evaluate learning and memory, is a w
idely recognized tool in the general literature on neuropsychology. This paper a
ims at presenting the performance of Brazilian adult subjects on the Rey Auditor
y-Verbal Learning Test, and was written after we published a previous study on t
he performance of Brazilian elderly subjects on this same test. <b>METHOD:</b> A
 version of the test, featuring a list of high-frequency one-syllable and two-sy
llable concrete Portuguese substantives, was developed. Two hundred and forty-th
ree (243) subjects from both genders were allocated to 6 different age groups (2
0-24; 25-29; 30-34; 35-44; 45-54 and 55-60 years old). They were then tested usi
ng the Rey Auditory-Verbal Learning Test. <b>RESULTS:</b> Performance on the Rey
 Auditory-Verbal Learning Test showed a positive correlation with educational le
vel and a negative correlation with age. Women performed significantly better th
an men. When applied across similar age ranges, our results were similar to thos
e recorded for the English version of the Rey Auditory-Verbal Learning Test. <b>
CONCLUSION:</b> Our results suggest that the adaptation of the Rey Auditory-Verb
al Learning Test to Brazilian Portuguese is appropriate and that it is applicabl
e to Brazilian subjects for memory capacity evaluation purposes and across simil
ar age groups and educational levels.#^ddecs^i1#^tm^len^kMemory^i1#^tm^len^kAudi
tory perception^i1#^tm^len^kLearning^i1#^tm^len^kNeuropsychological tests^i1#^tm
^len^kAdult^i1#^lpt^a<b>OBJETIVO:</b> O <i>Rey Auditory-Verbal Learning Test</i>
 é um teste mundialmente reconhecido na literatura neuropsicológica que avalia o
 aprendizado e a memória. Na sequência de um estudo anterior, que apresentou o d
esempenho dos idosos brasileiros no <i>Rey Auditory-Verbal Learning Test</i>, es
te trabalho apresenta o desempenho dos adultos brasileiros no <i>Rey Auditory-Ve
rbal Learning Test</i>. <b>MÉTODO:</b> Uma versão do teste foi desenvolvida com 
uma lista de alta frequência, com uma ou duas sílabas de substantivos concretos 
do português do Brasil. Duzentos e quarenta e três (243) indivíduos de ambos os 
sexos foram alocados para seis faixas etárias (20-24, 25-29, 30-34, 35-44, 45-54
 e 55-60 anos) e avaliados com o <i>Rey Auditory-Verbal Learning Test</i>. <b>RE
SULTADOS:</b> O grau de escolaridade e idade mostrou correlação positiva e negat
iva, respectivamente, com o desempenho no <i>Rey Auditory-Verbal Learning Test</
i>. As mulheres tiveram um desempenho significativamente melhor que os homens. O
s resultados foram semelhantes aos encontrados para a versão em inglês do <i>Rey
 Auditory-Verbal Learning Test</i>, por meio de faixas etárias semelhantes. <b>C
ONCLUSÃO:</b> Nossos resultados sugerem que a adaptação do <i>Rey Auditory-Verba
l Learning Test</i> para o português brasileiro é adequada e aplicável para aval
iação da capacidade de memória de indivíduos brasileiros, com idade similar e ed
ucacionais níveis.#^ddecs^i2#^tm^lpt^kMemória^i2#^tm^lpt^kPercepção auditiva^i2#
^tm^lpt^kAprendizagem^i2#^tm^lpt^kTestes neuropsicológicos^i2#^tm^lpt^kAdulto^i2
#vancouv#16#20100401#April 1, 2010#20100825#August 25, 2010#aop0711.htm##
05522000000000793000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780640007000800710003000870400003000900010
00600093042000200099120000400101038000400105121000300109049000300112158000300115
03000210011803200060013906500090014501400070015403500100016122300090017101200880
01800120107002680100042003750100055004170100040004720100033005120100046005450100
02800591010003800619010002400657010003100681070013200712070007600844070011900920
07001140103907001190115307001160127207001280138808314060151608500100292208500190
29320850032029510850021029830850037030040850018030410831367030590850010044260850
02004436085003104456085002504487085003704512085001904549117000804568072000304576
112000904579111001404588114000904602113001604611002001204627008008904639#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#l#4#1#article#1#^a2011#
oa#en#br1.1#1#4.0#tab#07#nd#nd#Rev. bras. psiquiatr#ahead#20110000#^f0^l0#1516-4
446#20110318#Applicability of the Rey Auditory-Verbal Learning Test to an adult 
sample in Brazil^len#O Teste de Aprendizagem Auditivo-Verbal de Rey: aplicabilid
ade para uma amostra de adultos brasileiros^lpt#^rND^1A01 A02 A04^nJoão Vinícius
^sSalgado#^rND^1A03 A04 A05 A06^nLeandro Fernandes^sMalloy-Diniz#^rND^1A06^nSuza
na Silva Costa^sAbrantes#^rND^1A05 A06^nLafaiete^sMoreira#^rND^1A04 A06^nCarlos 
Guilherme^sSchlottfeldt#^rND^nWanderlane^sGuimarães#^rND^nDjeane Marcely Ugoline
^sFreitas#^rND^nJuliana^sOliveira#^rND^1A06 A07^nDaniel^sFuentes#^iA01^1Universi
dade Federal de Minas Gerais^2Instituto de Ciências Biológicas^3Department of Mo
rphology^cBelo Horizonte^sMG^pBrazil#^iA02^1Hospital de Ensino Instituto Raul So
ares^cBelo Horizonte^sMG^pBrazil#^iA03^1Universidade Federal de Minas Gerai^2Sch
ool of Medicine^3INCT de Medicina Molecular^cBelo Horizonte^sMG^pBrazil#^iA04^1U
niversidade Federal de Minas Gerais^2Post-Graduation Program in Neurosciences^cB
elo Horizonte^sMG^pBrazil#^iA05^1Universidade Federal de Minas Gerais^2Post-Grad
uation Program in Molecular Medicine^cBelo Horizonte^sMG^pBrazil#^iA06^1Universi
dade Federal de Minas Gerais^2Laboratórios Integrados de Neuropsicologia^cBelo H
orizonte^sMG^pBrazil#^iA07^1Universidade de São Paulo^2Faculdade de Medicina^3Ho
spital das Clínicas. Instituto de Psiquiatria^cSão Paulo^sSP^pBrazil#^len^aOBJEC
TIVE: The Rey Auditory-Verbal Learning Test, which is used to evaluate learning 
and memory, is a widely recognized tool in the general literature on neuropsycho
logy. This paper aims at presenting the performance of Brazilian adult subjects 
on the Rey Auditory-Verbal Learning Test, and was written after we published a p
revious study on the performance of Brazilian elderly subjects on this same test
. METHOD: A version of the test, featuring a list of high-frequency one-syllable
 and two-syllable concrete Portuguese substantives, was developed. Two hundred a
nd forty-three (243) subjects from both genders were allocated to 6 different ag
e groups (20-24; 25-29; 30-34; 35-44; 45-54 and 55-60 years old). They were then
 tested using the Rey Auditory-Verbal Learning Test. RESULTS: Performance on the
 Rey Auditory-Verbal Learning Test showed a positive correlation with educationa
l level and a negative correlation with age. Women performed significantly bette
r than men. When applied across similar age ranges, our results were similar to 
those recorded for the English version of the Rey Auditory-Verbal Learning Test.
 CONCLUSION: Our results suggest that the adaptation of the Rey Auditory-Verbal 
Learning Test to Brazilian Portuguese is appropriate and that it is applicable t
o Brazilian subjects for memory capacity evaluation purposes and across similar 
age groups and educational levels.#^ddecs^i1#^tm^len^kMemory^i1#^tm^len^kAuditor
y perception^i1#^tm^len^kLearning^i1#^tm^len^kNeuropsychological tests^i1#^tm^le
n^kAdult^i1#^lpt^aOBJETIVO: O Rey Auditory-Verbal Learning Test é um teste mundi
almente reconhecido na literatura neuropsicológica que avalia o aprendizado e a 
memória. Na sequência de um estudo anterior, que apresentou o desempenho dos ido
sos brasileiros no Rey Auditory-Verbal Learning Test, este trabalho apresenta o 
desempenho dos adultos brasileiros no Rey Auditory-Verbal Learning Test. MÉTODO:
 Uma versão do teste foi desenvolvida com uma lista de alta frequência, com uma 
ou duas sílabas de substantivos concretos do português do Brasil. Duzentos e qua
renta e três (243) indivíduos de ambos os sexos foram alocados para seis faixas 
etárias (20-24, 25-29, 30-34, 35-44, 45-54 e 55-60 anos) e avaliados com o Rey A
uditory-Verbal Learning Test. RESULTADOS: O grau de escolaridade e idade mostrou
 correlação positiva e negativa, respectivamente, com o desempenho no Rey Audito
ry-Verbal Learning Test. As mulheres tiveram um desempenho significativamente me
lhor que os homens. Os resultados foram semelhantes aos encontrados para a versã
o em inglês do Rey Auditory-Verbal Learning Test, por meio de faixas etárias sem
elhantes. CONCLUSÃO: Nossos resultados sugerem que a adaptação do Rey Auditory-V
erbal Learning Test para o português brasileiro é adequada e aplicável para aval
iação da capacidade de memória de indivíduos brasileiros, com idade similar e ed
ucacionais níveis.#^ddecs^i2#^tm^lpt^kMemória^i2#^tm^lpt^kPercepção auditiva^i2#
^tm^lpt^kAprendizagem^i2#^tm^lpt^kTestes neuropsicológicos^i2#^tm^lpt^kAdulto^i2
#vancouv#16#20100401#April 1, 2010#20100825#August 25, 2010#aop0711.htm#Internet
^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462011005000007
##
00434000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704019400082002001200276#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#5#1#article#110#<p><a name="t
op"></a><font face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Applicabi
lity    of the Rey Auditory-Verbal Learning Test to an adult sample in Brazil</b
></font></p>     ^cY#aop0711.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#6#2#article#110#<p>&nbsp;</p>
     ^cY#aop0711.htm##
00435000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704019500082002001200277#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#7#3#article#110#<p><font face
="Verdana, Arial, Helvetica, sans-serif" size="3"><b>O Teste de Aprendizagem    
Auditivo-Verbal de Rey: aplicabilidade para uma amostra de adultos brasileiros</
b></font></p>     ^cY#aop0711.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#8#4#article#110#<p>&nbsp;</p>
     ^cY#aop0711.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#9#5#article#110#<p>&nbsp;</p>
     ^cY#aop0711.htm##
00737000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704049600083002001200579#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#10#6#article#110#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Jo&atilde;o    Vin&iacute;
cius Salgado<sup>I, II, IV</sup>; Leandro Fernandes Malloy-Diniz<sup>III,    IV,
 V, VI</sup>; Suzana Silva Costa Abrantes<sup>VI</sup>; Lafaiete Moreira<sup>V, 
   VI</sup>; Carlos Guilherme Schlottfeldt<sup>IV, VI</sup>; Wanderlane Guimar&a
tilde;es<sup>VII</sup>;    Djeane Marcely Ugoline Freitas<sup>VII</sup>; Juliana
 Oliveira<sup>VII</sup>    Daniel Fuentes<sup>VI, VIII</sup></b></font></p>     
^cY#aop0711.htm##
00480000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704023900083002001200322#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#11#7#article#110#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2"><sup>I</sup>Department    of 
Morphology, Instituto de Ci&ecirc;ncias Biol&oacute;gicas (ICB), Universidade   
 Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil    ^cY#aop0711.htm##
00337000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704009600083002001200179#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#12#8#article#110#<br>   <sup>
II</sup>Hospital de Ensino Instituto Raul Soares, Belo Horizonte, MG, Brazil    
^cY#aop0711.htm##
00397000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704015600083002001200239#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#13#9#article#110#<br>   <sup>
III</sup>INCT&nbsp;de Medicina Molecular, School of Medicine, Universidade    Fe
deral de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil    ^cY#aop0711.htm##
00386000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704014400084002001200228#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#14#10#article#110#<br>   <sup
>IV</sup>Post-Graduation Program in Neurosciences, Universidade Federal    de Mi
nas Gerais (UFMG), Belo Horizonte, MG, Brazil    ^cY#aop0711.htm##
00390000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704014800084002001200232#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#15#11#article#110#<br>   <sup
>V</sup>Post-Graduation Program in Molecular Medicine, Universidade Federal    d
e Minas Gerais (UFMG), Belo Horizonte, MG, Brazil    ^cY#aop0711.htm##
00403000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704016100084002001200245#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#16#12#article#110#<br>   <sup
>VI</sup>Laborat&oacute;rios Integrados de Neuropsicologia (LINEU), Universidade
    Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil    ^cY#aop0711.ht
m##
00293000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704005100084002001200135#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#17#13#article#110#<br>   <sup
>VII</sup>Occupational therapist    ^cY#aop0711.htm##
00477000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704023500084002001200319#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#18#14#article#110#<br>   <sup
>VIII</sup>Psychology and Neuropsychology Service, Instituto de Psiquiatria,    
Hospital das Cl&iacute;nicas, Faculdade de Medicina, Universidade de S&atilde;o 
   Paulo (USP), S&atilde;o Paulo, SP, Brazil</font></p>     ^cY#aop0711.htm##
00359000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704011700084002001200201#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#19#15#article#110#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><a href="#back">Corresponden
ce</a></font></p>     ^cY#aop0711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#20#16#article#110#<p>&nbsp;</
p>     ^cY#aop0711.htm##
00286000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704004400084002001200128#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#21#17#article#110#<p>&nbsp;</
p> <hr size="1" noshade>     ^cY#aop0711.htm##
00340000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009800084002001200182#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#22#18#article#110#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>ABSTRACT</b></font></p>  
   ^cY#aop0711.htm##
00744000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704050200084002001200586#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#23#19#article#110#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>OBJECTIVE:</b>    The Rey
 Auditory-Verbal Learning Test, which is used to evaluate learning and    memory
, is a widely recognized tool in the general literature on neuropsychology.    T
his paper aims at presenting the performance of Brazilian adult subjects on    t
he Rey Auditory-Verbal Learning Test, and was written after we published a    pr
evious study on the performance of Brazilian elderly subjects on this same    te
st.    ^cY#aop0711.htm##
00646000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704040400084002001200488#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#24#20#article#110#<br>   <b>M
ETHOD:</b> A version of the test, featuring a list of high-frequency one-syllabl
e    and two-syllable concrete Portuguese substantives, was developed. Two hundr
ed    and forty-three (243) subjects from both genders were allocated to 6 diffe
rent    age groups (20-24; 25-29; 30-34; 35-44; 45-54 and 55-60 years old). They
 were    then tested using the Rey Auditory-Verbal Learning Test.    ^cY#aop0711
.htm##
00623000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704038100084002001200465#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#25#21#article#110#<br>   <b>R
ESULTS:</b> Performance on the Rey Auditory-Verbal Learning Test showed    a pos
itive correlation with educational level and a negative correlation with    age.
 Women performed significantly better than men. When applied across similar    a
ge ranges, our results were similar to those recorded for the English version   
 of the Rey Auditory-Verbal Learning Test.    ^cY#aop0711.htm##
00558000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704031600084002001200400#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#26#22#article#110#<br>   <b>C
ONCLUSION:</b> Our results suggest that the adaptation of the Rey Auditory-Verba
l    Learning Test to Brazilian Portuguese is appropriate and that it is applica
ble    to Brazilian subjects for memory capacity evaluation purposes and across 
similar    age groups and educational levels.</font></p>     ^cY#aop0711.htm##
00440000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704019800084002001200282#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#27#23#article#110#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Descriptors:</b>    Memor
y; Auditory perception; Learning; Neuropsychological tests; Adult</font></p> <hr
 size="1" noshade>     ^cY#aop0711.htm##
00338000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009600084002001200180#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#28#24#article#110#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>    
 ^cY#aop0711.htm##
00757000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704051500084002001200599#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#29#25#article#110#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>OBJETIVO:</b>    O <i>Rey
 Auditory-Verbal Learning Test</i> &eacute; um teste mundialmente reconhecido   
 na literatura neuropsicol&oacute;gica que avalia o aprendizado e a mem&oacute;r
ia.    Na sequ&ecirc;ncia de um estudo anterior, que apresentou o desempenho dos
 idosos    brasileiros no <i>Rey Auditory-Verbal Learning Test</i>, este trabalh
o apresenta    o desempenho dos adultos brasileiros no <i>Rey Auditory-Verbal Le
arning Test</i>.    ^cY#aop0711.htm##
00695000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704045300084002001200537#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#30#26#article#110#<br>   <b>M
&Eacute;TODO:</b> Uma vers&atilde;o do teste foi desenvolvida com uma lista    d
e alta frequ&ecirc;ncia, com uma ou duas s&iacute;labas de substantivos concreto
s    do portugu&ecirc;s do Brasil. Duzentos e quarenta e tr&ecirc;s (243) indiv&
iacute;duos    de ambos os sexos foram alocados para seis faixas et&aacute;rias 
(20-24, 25-29,    30-34, 35-44, 45-54 e 55-60 anos) e avaliados com o <i>Rey Aud
itory-Verbal Learning    Test</i>.    ^cY#aop0711.htm##
00706000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704046400084002001200548#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#31#27#article#110#<br>   <b>R
ESULTADOS:</b> O grau de escolaridade e idade mostrou correla&ccedil;&atilde;o  
  positiva e negativa, respectivamente, com o desempenho no <i>Rey Auditory-Verb
al    Learning Test</i>. As mulheres tiveram um desempenho significativamente me
lhor    que os homens. Os resultados foram semelhantes aos encontrados para a ve
rs&atilde;o    em ingl&ecirc;s do <i>Rey Auditory-Verbal Learning Test</i>, por 
meio de faixas    et&aacute;rias semelhantes.    ^cY#aop0711.htm##
00619000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704037700084002001200461#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#32#28#article#110#<br>   <b>C
ONCLUS&Atilde;O:</b> Nossos resultados sugerem que a adapta&ccedil;&atilde;o    
do <i>Rey Auditory-Verbal Learning Test</i> para o portugu&ecirc;s brasileiro   
 &eacute; adequada e aplic&aacute;vel para avalia&ccedil;&atilde;o da capacidade
    de mem&oacute;ria de indiv&iacute;duos brasileiros, com idade similar e educ
acionais    n&iacute;veis.</font></p>     ^cY#aop0711.htm##
00476000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704023400084002001200318#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#33#29#article#110#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Descritores:</b>    Mem&o
acute;ria; Percep&ccedil;&atilde;o auditiva; Aprendizagem; Testes neuropsicol&oa
cute;gicos;    Adulto</font></p> <hr size="1" noshade>     ^cY#aop0711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#34#30#article#110#<p>&nbsp;</
p>     ^cY#aop0711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#35#31#article#110#<p>&nbsp;</
p>     ^cY#aop0711.htm##
00344000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010200084002001200186#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#36#32#article#110#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Introduction</b></font></
p>     ^cY#aop0711.htm##
00774000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704053200084002001200616#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#37#33#article#110#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">The Rey Auditory-Verbal    L
earning Test (RAVLT) is a useful and easy to perform neuropsychological task    
based on a wordlist-based learning paradigm. The test measures several component
s    of verbal memory such as immediate recall, verbal learning, susceptibility 
to    both proactive and retroactive interference, retention of information afte
r    a certain period of time during which other activities are performed, and r
ecognition    memory.</font></p>     ^cY#aop0711.htm##
00536000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704029400084002001200378#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#38#34#article#110#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">RAVLT was originally    deve
loped by Rey<sup>1</sup> and later modified by authors from several countries,  
  where the test has been recognized as a useful tool for diagnosing memory dist
urbances.<sup>2,3</sup></font></p>     ^cY#aop0711.htm##
01441000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704119900084002001201283#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#39#35#article#110#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">In countries where    Englis
h is the main spoken language, there are several studies providing parameters   
 for result interpretation<sup>4-7</sup> when the test is applied to different  
  age groups. In Brazil, normative standards have been developed for the 16 to  
  89 year-old age bracket.<sup>8</sup> Nonetheless, the cited study adopted a   
 translated version of the wordlist originally used in English speaking countrie
s,    without considering both the frequency at which these translated words are
 used    in Brazilian Portuguese and the number of syllables of each word from t
he lists.    Another version used a list of high-frequency, one or two-syllable 
Portuguese    substantives<sup>9</sup> as stimuli to assess the performance of B
razilian senior    citizens aged 60 to 89 years.<sup>10</sup> The rationale behi
nd the inclusion    of words that frequently appear in Portuguese was that the t
est would be used    to evaluate individuals from all social groups and educatio
nal levels. This    study aims at assessing how well adults aged 20 to 59 years 
can perform on this    new version of the RAVLT.</font></p>     ^cY#aop0711.htm#
#
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#40#36#article#110#<p>&nbsp;</
p>     ^cY#aop0711.htm##
00338000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009600084002001200180#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#41#37#article#110#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Method</b></font></p>    
 ^cY#aop0711.htm##
00364000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704012200084002001200206#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#42#38#article#110#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>1. Participants    and pr
ocedure</b></font></p>     ^cY#aop0711.htm##
00695000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704045300084002001200537#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#43#39#article#110#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Two hundred and    forty-thr
ee individuals from both genders whose ages varied between 20 and 59    years-ol
d were evaluated. Enrollment in the study was made possible through    local adv
ertisements placed at two university campuses and one social club.    Subjects w
ere distributed into seven age-based groups: 20-24; 25-29; 30-34;    35-44; 45-5
4 and 55-59 years old.</font></p>     ^cY#aop0711.htm##
00693000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704045100084002001200535#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#44#40#article#110#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Participants did    not refe
r any cognitive impairment, psychiatric or neurological disturbances,    and had
 not been on any psychotropic medication for at least three weeks. This    infor
mation was obtained using a semi-structured interview, which was carried    out 
before the memory assessment. All subjects had received at least eight years    
of formal education.</font></p>     ^cY#aop0711.htm##
00453000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704021100084002001200295#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#45#41#article#110#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">The RAVLT was applied    and
 corrected according to the same process previously described in Malloy-Diniz   
 et al.<sup>10</sup></font></p>     ^cY#aop0711.htm##
00370000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704012800084002001200212#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#46#42#article#110#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>2. Approval    by the Eth
ics Committee</b></font></p>     ^cY#aop0711.htm##
00587000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704034500084002001200429#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#47#43#article#110#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">This study was    approved b
y the Research Ethics Committee of Hospital Fel&iacute;cio Rocho,    state of Mi
nas Gerais, Brazil (CEP/FR 129/05). All participants signed a consent    form de
claring that they had been properly informed of the purposes of the study.</font
></p>     ^cY#aop0711.htm##
00373000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704013100084002001200215#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#48#44#article#110#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>3. Statistical    analysi
s of the results</b></font></p>     ^cY#aop0711.htm##
01036000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704079400084002001200878#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#49#45#article#110#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">After calculating    the res
pective mean and standard deviations, a descriptive statistical analysis    was 
carried out for each measure. A General Linear Model (UNIANOVA) was developed   
 using gender, age group and educational level i.e., elementary school, secondar
y    school (incomplete), secondary school (complete), undergraduate or graduate
    studies (incomplete) and undergraduate or graduate studies (complete) as fac
tors,    and each RALVT measure as the dependent variable. The performance of ea
ch age    group was compared to that of another group to look for differences fo
und for    each RAVLT cognitive variable. A value of p &lt; 0.05 was considered 
statistically    significant for all tests.</font></p>     ^cY#aop0711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#50#46#article#110#<p>&nbsp;</
p>     ^cY#aop0711.htm##
00339000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009700084002001200181#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#51#47#article#110#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Results</b></font></p>   
  ^cY#aop0711.htm##
01247000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704100500084002001201089#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#52#48#article#110#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">The parametric    distributi
on nature was confirmed based on the interpretation of the Skewness    and Kurto
sis indices for the data's descriptive analysis. The analysis of the    age-grou
p factor showed significant differences in the following RAVLT measures:    A1 &
#91;F = 3,022 (p = 0.007)&#93;; A3 &#91;F = 2.310 (p = 0.034)&#93;; A6 &#91;F   
 = 2.317 (p = 0.034)&#93;; B1 &#91;F = 5.943 (p &lt; 0.001)&#93;; A7 &#91;F =   
 2.539 (p = 0.021)&#93;; recognition &#91;F = 2.571 (p = 0.019)&#93; and learnin
g    during the attempts &#91;F = 2.197 (p = 0.044)&#93;. The other measures did
n't    show significant differences, as follow: A2 &#91;F = 1.919 (p = 0.078)&#9
3;;    A4 &#91;F = 1.157 (p = 0.330)&#93;; A5 &#91;F = 0.938 (p = 0.468)&#93;; p
roactive    interference &#91;F = 0.750 (p = 0.610)&#93;; retroactive interferen
ce &#91;F    = 1.682 (p &lt; 0.126)&#93; and forgetting speed &#91;F = 0.904 (p 
= 0.492)&#93;.</font></p>     ^cY#aop0711.htm##
01086000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704084400084002001200928#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#53#49#article#110#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Fisher LSD post-hoc    analy
sis revealed that, for the A1 variable, the 20-24 and the 25-29 age groups    ou
tperformed the 35-44, 45-54 and 55-59 age groups. The same occurred for B1,    b
ut the 30-34 age group performed significantly worse than the younger groups    
in this variable. For variables A3, A6 and recognition, only the group aged    5
5-59 presented different results compared to that of other groups. For A7,    wi
th the exception of the 45-54 age group, all groups presented different results 
   compared to the 55-59 and 35-44 age group was also different from the 45-54  
  group. As far as the earning during the attempts measure, the 35-44 group outp
erformed    the 25-29 and 55-59 age groups, and the 45-54 group outperformed the
 25-29 group.</font></p>     ^cY#aop0711.htm##
00633000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704039100084002001200475#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#54#50#article#110#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">In all age groups,    men pe
rformed significantly worse in A6 &#91;F = 6.451 (p = 0.012)&#93;, retroactive  
  interference &#91;F = 5.176 (p = 0.024)&#93; and learning during the attempts 
   &#91;F = 3.930 (p = 0.048)&#93;. With respect to the other measures, no diffe
rence    was seen between men and women.</font></p>     ^cY#aop0711.htm##
00441000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704019900084002001200283#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#55#51#article#110#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">We found only an    interact
ion between age group and gender in forgetting speed &#91;F = 2,292    (p = 0.03
6)&#93;.</font></p>     ^cY#aop0711.htm##
01045000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704080300084002001200887#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#56#52#article#110#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">The analysis of    the educa
tional-level factor showed significant differences in A1 &#91;F = 2.581    (p &l
t; 0.038)&#93; and B1 &#91;F = 4.281(p = 0.002)&#93;. Considering the A1    tria
l, Fisher LSD post-hoc analysis revealed that subjects with incomplete undergrad
uate    or graduate studies performed better than subjects from both the complet
e and    incomplete elementary and secondary school groups. Considering the B1 t
rial,    subjects who had completed their undergraduate studies performed better
 than    those who had either fully or partially attended only elementary and se
condary    schools. We found interaction between age group and educational level
 in the    B1 trial &#91;F = 1,540 (p = 0.038)&#93;.</font></p>     ^cY#aop0711.
htm##
00485000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704024300084002001200327#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#57#53#article#110#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">The results for    the diffe
rent age groups, according to gender and age, are described in <a href="/img/rev
istas/rbp/2011nahead/aop0711t01.jpg">Table    1</a>.</font></p>     ^cY#aop0711.
htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#58#54#article#110#<p>&nbsp;</
p>     ^cY#aop0711.htm##
00342000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010000084002001200184#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#59#55#article#110#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Discussion</b></font></p>
     ^cY#aop0711.htm##
01444000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704120200084002001201286#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#60#56#article#110#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">In general, our    results a
re consistent with reports that age is the most influential demographic    featu
re in RAVLT performance. However, this influence is weaker in the groups    aged
 20-39 and stronger in the groups aged 40-59.<sup>2,11</sup> In our study,    mo
st measures (A3, A6, A7, recognition) showed differences only between the    old
est group (55-59) and the other groups, except in the case of A7, where the    p
erformance of the 50-55 group was different from that of the 35-54 group. In    
A1 and B1, however, the two youngest groups outperformed the groups above 35    
years of age, and in B1, the group aged 25-29 also outperformed the 30-34 age   
 group. Our results, therefore, suggest that age has a different impact on memor
y    variables depending on one's stage in life. The variable learning during th
e    attempts showed interesting results since the best performance was seen in 
the    groups aged 35-44 and 45-54. These findings suggest that these groups per
formed    worse than the younger groups in A1, however, it seems that their perf
ormance    in trials does compensate this handicap.</font></p>     ^cY#aop0711.h
tm##
00735000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704049300084002001200577#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#61#57#article#110#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">As recommended    by Geffen 
et al.,<sup>5</sup> proactive and retroactive interference, as well    as forget
ting speed, were calculated using quotients rather than differences.    No diffe
rences in results were seen among age groups regarding these quotients,    which
 is consistent with the results reported by other authors,<sup>5,12</sup>    thu
s indicating that age has little influence on these abilities.</font></p>     ^c
Y#aop0711.htm##
01362000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704112000084002001201204#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#62#58#article#110#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">The influence of    the educ
ational level was limited to A1 and B1 trials. A recent study conducted    with 
a Brazilian adult sample suggesting that the articulatory loop of the working   
 memory could be particularly affected by educational level found similar result
s    for A1.<sup>13</sup> This study also found a relationship between education
al    level and performance in A1, but not in B1. These discrepancies could be j
ustified    by the use of different age groups, as well as different ranges of e
ducational    level in relation to our sample. Another study identified a certai
n connection    between educational level and performance in all RAVLT' measures
 analyzed, except    learning.<sup>14</sup> Nonetheless, in a recent meta-analys
is carried out by    Mitrushina et al., educational level didn't substantially c
ontribute to test    performance.<sup>15</sup> The relationship between educatio
nal level and other    variables, such as age and intelligence, should be contem
plated by future studies    on RAVLT performance.</font></p>     ^cY#aop0711.htm
##
01036000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704079400084002001200878#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#63#59#article#110#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">According to our    results,
 gender also influenced performance in the RAVLT. Women outperformed    men in A
6, retroactive interference and learning during the attempts. In the    literatu
re, there are reports that woman either outperformed men in recall trials    but
 not in the recognition trial,<sup>2,5,12,16</sup> or that woman outperformed   
 men in recall and recognition.<sup>13</sup> There is also a study that fails   
 to show female superiority.<sup>3</sup> Our results are consistent with the    
notion that, in general, women perform better in recall trials, but not in the  
  recognition trial. Nevertheless, it appears that, in the RAVLT, influence of  
  gender is weaker compared to that of age.</font></p>     ^cY#aop0711.htm##
00957000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704071500084002001200799#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#64#60#article#110#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Our findings point    out to
 the existence of certain discrepancies between our study and that of    Malloy-
Diniz et al.<sup>8</sup> Since we divided our subjects aged between 18    and 59
 into seven different age groups, this study's sample was better characterized  
  compared to the previous study. Furthermore, differently from the previous stu
dy,    women performed better in this study than men in certain test sets (A6, r
etroactive    interference and learning during the attempts). Considering that M
alloy-Diniz    et al. used a smaller sample, this difference could be explained 
on the basis    of this study's sample size.</font></p>     ^cY#aop0711.htm##
00622000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704038000084002001200464#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#65#61#article#110#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">A limitation of    this stud
y is that our subjects have a high level of formal education, and that    subjec
ts with psychiatric and neurological symptoms were excluded. As a result,    we 
could expect our sample to have a better cognitive performance compared to    th
at of the overall population.</font></p>     ^cY#aop0711.htm##
00518000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704027600084002001200360#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#66#62#article#110#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Studies using subjects    fr
om different socio-economic backgrounds, as well as other clinical populations  
  are being performed to contribute with more information about this test's vali
dity.</font></p>     ^cY#aop0711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#67#63#article#110#<p>&nbsp;</
p>     ^cY#aop0711.htm##
00393000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704015100084002001200235#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#68#64#article#110#<p align="c
enter"><a href="/img/revistas/rbp/2011nahead/aop0711q01.jpg"><img src="/img/revi
stas/rbp/2011nahead/aop0711q01thumb.jpg" border="0">    ^cY#aop0711.htm##
00349000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010700084002001200191#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#69#65#article#110#<br>   <fon
t face="Verdana, Arial, Helvetica, sans-serif" size="2">Click to enlarge</font><
/a></p>     ^cY#aop0711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#70#66#article#110#<p>&nbsp;</
p>     ^cY#aop0711.htm##
00342000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010000084002001200184#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#71#67#article#110#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="3"><b>References</b></font></p>
     ^cY#aop0711.htm##
00424000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704016800086002001200254#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#72#68#article#110
#1#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">1. Rey A. <i>L
'Examen    clinique en psychologie</i>. Paris: Press Universitaire de France; 19
58.    ^cY#aop0711.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#73#69#article#110#</font></p>
     ^cY#aop0711.htm##
00548000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704029200086002001200378#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#74#70#article#110
#2#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2. Messinis L,
    Tsakona I, Malefaki S, Papathanasopoulos P. Normative data and discriminant 
   validity of Rey's Verbal Learning Test for the Greek adult population. <i>Arc
h    Clin Neuropsychol</i>. 2007; 22(6):739-52.    ^cY#aop0711.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#75#71#article#110#</font></p>
     ^cY#aop0711.htm##
00571000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704031500086002001200401#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#76#72#article#110
#3#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">3. Schoenberg 
MR,    Dawson KA, Duff K, Patton D, Scott JG, Adams RL.Test performance and clas
sification    statistics for the Rey Auditory Verbal Learning Test in selected c
linical samples.    <i>Arch Clin Neuropsychol</i>. 2006;21(7):693-703.    ^cY#ao
p0711.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#77#73#article#110#</font></p>
     ^cY#aop0711.htm##
00490000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704023400086002001200320#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#78#74#article#110
#4#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">4. Wiens NA, M
cMinn    MR, Crossen JR. Rey auditory-verbal learning test: development of norms
 for    healthy young adults. <i>Clin Neuropsychol.</i> 1988;2:67-87.    ^cY#aop
0711.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#79#75#article#110#</font></p>
     ^cY#aop0711.htm##
00529000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704027300086002001200359#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#80#76#article#110
#5#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">5. Geffen G, M
oar    KJ, O'Hanlon AP, Clark CR, Geffen LB. Performance measures of 16 to 86-ye
ar-old    males and females on the auditory verbal learning test. <i>Clin Neurop
sychol.</i>    1990;4:45-63.    ^cY#aop0711.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#81#77#article#110#</font></p>
     ^cY#aop0711.htm##
00513000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704025700086002001200343#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#82#78#article#110
#6#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">6. Mitrushina 
M,    Satz P, Chervinsky A, D'Elia L. Performance of four age groups of normal e
lderly    on the Rey auditory-verbal learning test. <i>J Clin Psychol.</i> 1991;
47(3):351-7.    ^cY#aop0711.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#83#79#article#110#</font></p>
     ^cY#aop0711.htm##
00594000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704033800086002001200424#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#84#80#article#110
#7#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">7. Gale SD, Ba
xter    L, Connor DJ, Herring A, Comer J. Sex differences on the Rey Auditory Ve
rbal    Learning Test and the Brief Visuospatial Memory Test-Revised in the elde
rly:    normative data in 172 participants. <i>J Clin Exp Neuropsychol</i>. 2007
;29(5):561-7.    ^cY#aop0711.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#85#81#article#110#</font></p>
     ^cY#aop0711.htm##
00530000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704027400086002001200360#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#86#82#article#110
#8#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">8. Malloy-Dini
z    LF, da Cruz MF, Torres V, Cosenza R. O teste de aprendizagem auditivo-verba
l    de Rey: normas para uma popula&ccedil;&atilde;o brasileira. <i>Rev Bras Neu
rol</i>.    2000;36(3):79-83.    ^cY#aop0711.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#87#83#article#110#</font></p>
     ^cY#aop0711.htm##
00574000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704031800086002001200404#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#88#84#article#110
#9#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">9. Malloy-Dini
z    LF, Fuentes D, Abrantes S, Lasmar V, Salgado JV. O teste de aprendizagem au
ditivo    verbal de Rey. In: Malloy-Diniz LF, Fuentes D, Mattos P, Abreu N. <i>A
val Neuropsicol&oacute;gica</i>.    Porto Alegre: ARTMED; 2010. p.337-43.    ^cY
#aop0711.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#89#85#article#110#</font></p>
     ^cY#aop0711.htm##
00544000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000300084704028700087002001200374#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#90#86#article#110
#10#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Malloy-Di
niz    LF, Lasmar VA, Gazinelli Lde S, Fuentes D, Salgado JV. The Rey auditory-v
erbal    learning test: applicability for the Brazilian elderly population. <i>R
ev Bras    Psiquiatr</i>. 2007;29(4):324-9.    ^cY#aop0711.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#91#87#article#110#</font></p>
     ^cY#aop0711.htm##
00522000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000300084704026500087002001200352#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#92#88#article#110
#11#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Vakil E, 
Blachstien    H. Rey auditory verbal learning test: developmental norms for adul
ts, and sensitivity    of different memory measures to age. <i>Clin Neuropsychol
</i>. 1997;11:356-69.    ^cY#aop0711.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#93#89#article#110#</font></p>
     ^cY#aop0711.htm##
00508000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000300084704025100087002001200338#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#94#90#article#110
#12#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Bolla-Wil
son    K, Blecker ML. Influence of verbal intelligence, sex, age, and education 
on    the Rey Auditory Verbal Learning Test. <i>Dev Neuropsychol</i>. 1986;2(3):
203-11.    ^cY#aop0711.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#95#91#article#110#</font></p>
     ^cY#aop0711.htm##
00617000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000300084704036000087002001200447#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#96#92#article#110
#13#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">13. van der E
lst    W, van Boxtel MPJ, van Breukelen GJP, Jolles J. Rey's verbal learning tes
t:    Normative data for 1855 healthy participants aged 24-81 years and the infl
uence    of age, sex, education, and mode of presentation. <i>J Int Neuropsychol
 Society</i>.    2005;11(3):290-302.    ^cY#aop0711.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#97#93#article#110#</font></p>
     ^cY#aop0711.htm##
00491000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000300084704023400087002001200321#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#98#94#article#110
#14#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Teruya LC
,    Ortiz KZ, Minett TSC. Performance of normal adults on Rey auditory learning
    test: a pilot study. <i>Arq NeuroPsiquiatr</i>. 2009;67(2A):224-8.    ^cY#ao
p0711.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#99#95#article#110#</font></p>
     ^cY#aop0711.htm##
00480000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081888000300085704022200088002001200310#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#100#96#article#11
0#15#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Mitrushi
na    M, Bone K, D'Elia L. <i>Handbook of normative data for neuropsychological 
assessment.</i>    New York: Oxford University Press; 2005.    ^cY#aop0711.htm##
00263000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081704002000085002001200105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#101#97#article#110#</font></p
>     ^cY#aop0711.htm##
00505000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081888000300085704024700088002001200335#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#102#98#article#11
0#16#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Lannoo E
, Vingerhoets    G. Flemish nomative data on common neuropsychological tests: In
fluence of age,    education, and gender. <i>Psychol Belgica</i>. 1997;37(3):141
-56.    ^cY#aop0711.htm##
00263000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081704002000085002001200105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#103#99#article#110#</font></p
>     ^cY#aop0711.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#104#100#article#110#<p>&nbsp;
</p>     ^cY#aop0711.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#105#101#article#110#<p>&nbsp;
</p>     ^cY#aop0711.htm##
00436000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704019200086002001200278#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#106#102#article#110#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a href
="#top"><img src="/img/revistas/rbp/2011nahead/seta.jpg" border="0"></a>    <b> 
Correspondence:    ^cY#aop0711.htm##
00294000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704005000086002001200136#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#107#103#article#110#<br>   </
b> Leandro Fernandes Malloy-Diniz    ^cY#aop0711.htm##
00306000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704006200086002001200148#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#108#104#article#110#<br>   Fa
culdade de Filosofia e Ci&ecirc;ncias Humanas    ^cY#aop0711.htm##
00323000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704007900086002001200165#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#109#105#article#110#<br>   De
partamento de Psicologia, Universidade Federal de Minas Gerais    ^cY#aop0711.ht
m##
00289000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704004500086002001200131#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#110#106#article#110#<br>   Av
. Ant&ocirc;nio Carlos, 6627    ^cY#aop0711.htm##
00295000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704005100086002001200137#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#111#107#article#110#<br>   31
270-901 Belo Horizonte, MG, Brasil    ^cY#aop0711.htm##
00344000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704010000086002001200186#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#112#108#article#110#<br>   Em
ail: <a href="mailto:malloy.diniz@gmail.com">malloy.diniz@gmail.com</a></font></
p>     ^cY#aop0711.htm##
00342000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704009800086002001200184#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#113#109#article#110#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">Submitted: April    1, 201
0    ^cY#aop0711.htm##
00296000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704005200086002001200138#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#p#114#110#article#110#<br>   Ac
cepted: August 25, 2010</font></p>     ^cY#aop0711.htm##
00436000000000229000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830160013000850180037000980660
00600135062003000141065000900171064000500180865000900185002001200194#2011nahead#
V:\SciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#c#115#1#article#16#1#^rND^s
Rey^nA#L'Examen clinique en psychologie^lfr#Paris#Press Universitaire de France#
19580000#1958#20110000#aop0711.htm##
00645000000000301000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100018000850100017001030100
01800120010002700138012010600165030002300271710000200294065000900296064000500305
031000300310032000200313014000700315865000900322002001200331#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop0711.htm#S#c#116#2#article#16#2#^rND^sMessinis
^nL#^rND^sTsakona^nI#^rND^sMalefaki^nS#^rND^sPapathanasopoulos^nP#Normative data
 and discriminant validity of Rey's Verbal Learning Test for the Greek adult pop
ulation^len#Arch Clin Neuropsychol#2#20070000#2007#22#6#739-52#20110000#aop0711.
htm##
00706000000000325000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100021000850100017001060100
01400123010001600137010001600153010001600169012012200185030002300307710000200330
06500090033206400050034103100030034603200020034901400080035186500090035900200120
0368#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#c#117#3#art
icle#16#3#^rND^sSchoenberg^nMR#^rND^sDawson^nKA#^rND^sDuff^nK#^rND^sPatton^nD#^r
ND^sScott^nJG#^rND^sAdams^nRL#Test performance and classification statistics for
 the Rey Auditory Verbal Learning Test in selected clinical samples^len#Arch Cli
n Neuropsychol#2#20060000#2006#21#7#693-703#20110000#aop0711.htm##
00563000000000277000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100016000850100017001010100
01800118012008500136030001900221710000200240065000900242064000500251031000200256
014000600258865000900264002001200273#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop0711.htm#S#c#118#4#article#16#4#^rND^sWiens^nNA#^rND^sMcMinn^nMR#^rND^
sCrossen^nJR#Rey auditory-verbal learning test: development of norms for healthy
 young adults^len#Clin Neuropsychol.#2#19880000#1988#2#67-87#20110000#aop0711.ht
m##
00635000000000301000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100016000850100015001010100
01900116010001600135010001700151012010100168030001900269710000200288065000900290
064000500299031000200304014000600306865000900312002001200321#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop0711.htm#S#c#119#5#article#16#5#^rND^sGeffen^n
G#^rND^sMoar^nKJ#^rND^sO'Hanlon^nAP#^rND^sClark^nCR#^rND^sGeffen^nLB#Performance
 measures of 16 to 86-year-old males and females on the auditory verbal learning
 test^len#Clin Neuropsychol.#2#19900000#1990#4#45-63#20110000#aop0711.htm##
00615000000000301000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100020000850100014001050100
02000119010001600139012009400155030001600249710000200265065000900267064000500276
031000300281032000200284014000600286865000900292002001200301#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop0711.htm#S#c#120#6#article#16#6#^rND^sMitrushi
na^nM#^rND^sSatz^nP#^rND^sChervinsky^nA#^rND^sD'Elia^nL#Performance of four age 
groups of normal elderly on the Rey auditory-verbal learning test^len#J Clin Psy
chol.#2#19910000#1991#47#3#351-7#20110000#aop0711.htm##
00754000000000325000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100015000850100016001000100
01700116010001700133010001500150012015900165030002400324065000900348064000500357
03100030036203200020036501400060036786500090037300200120038203500100039480100240
0404#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#c#121#7#art
icle#16#7#^rND^sGale^nSD#^rND^sBaxter^nL#^rND^sConnor^nDJ#^rND^sHerring^nA#^rND^
sComer^nJ#Sex differences on the Rey Auditory Verbal Learning Test and the Brief
 Visuospatial Memory Test-Revised in the elderly: normative data in 172 particip
ants^len#J Clin Exp Neuropsychol#20070000#2007#29#5#561-7#20110000#aop0711.htm#0
168-8634#J Clin Exp Neuropsychol##
00614000000000301000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100023000850100018001080100
01600126010001700142012008900159030001600248710000200264065000900266064000500275
031000300280032000200283014000600285865000900291002001200300#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop0711.htm#S#c#122#8#article#16#8#^rND^sMalloy-D
iniz^nLF#^rND^sda Cruz^nMF#^rND^sTorres^nV#^rND^sCosenza^nR#O teste de aprendiza
gem auditivo-verbal de Rey: normas para uma população brasileira^lpt#Rev Bras Ne
urol#2#20000000#2000#36#3#79-83#20110000#aop0711.htm##
00737000000000349000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100023000850100017001080100
01800125010001600143010001800159012005100177016002300228016001700251016001600268
01600150028401800260029906600130032506200070033806500090034506400050035401400070
0359865000900366002001200375#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\a
op0711.htm#S#c#123#9#article#16#9#^rND^sMalloy-Diniz^nLF#^rND^sFuentes^nD#^rND^s
Abrantes^nS#^rND^sLasmar^nV#^rND^sSalgado^nJV#O teste de aprendizagem auditivo v
erbal de Rey^les#^rND^sMalloy-Diniz^nLF#^rND^sFuentes^nD#^rND^sMattos^nP#^rND^sA
breu^nN#Aval Neuropsicológica^lpt#Porto Alegre#ARTMED#20100000#2010#337-43#20110
000#aop0711.htm##
00660000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100023000870100017001100100
02300127010001700150010001800167012009400185030001900279710000200298065000900300
064000500309031000300314032000200317014000600319865000900325002001200334#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#c#124#10#article#16#10#
^rND^sMalloy-Diniz^nLF#^rND^sLasmar^nVA#^rND^sGazinelli Lde^nS#^rND^sFuentes^nD#
^rND^sSalgado^nJV#The Rey auditory-verbal learning test: applicability for the B
razilian elderly population^len#Rev Bras Psiquiatr#2#20070000#2007#29#4#324-9#20
110000#aop0711.htm##
00614000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100015000870100020001020120
12300122030001800245065000900263064000500272031000300277014000700280865000900287
002001200296035001000308801001800318#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop0711.htm#S#c#125#11#article#16#11#^rND^sVakil^nE#^rND^sBlachstien^nH#R
ey auditory verbal learning test: developmental norms for adults, and sensitivit
y of different memory measures to age^len#Clin Neuropsychol#19970000#1997#11#356
-69#20110000#aop0711.htm#0197-3681#Clin Neuropsychol##
00573000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100022000870100018001090120
10300127030001700230710000200247065000900249064000500258031000200263032000200265
014000700267865000900274002001200283#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop0711.htm#S#c#126#12#article#16#12#^rND^sBolla-Wilson^nK#^rND^sBlecker^
nML#Influence of verbal intelligence, sex, age, and education on the Rey Auditor
y Verbal Learning Test^len#Dev Neuropsychol#2#19860000#1986#2#3#203-11#20110000#
aop0711.htm##
00712000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100022000870100022001090100
02500131010001600156012016100172030002700333710000200360065000900362064000500371
031000300376032000200379014000800381865000900389002001200398#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop0711.htm#S#c#127#13#article#16#13#^rND^svan de
r Elst^nW#^rND^svan Boxtel^nMPJ#^rND^svan Breukelen^nGJP#^rND^sJolles^nJ#Rey's v
erbal learning test: Normative data for 1855 healthy participants aged 24-81 yea
rs and the influence of age, sex, education, and mode of presentation^len#J Int 
Neuropsychol Society#2#20050000#2005#11#3#290-302#20110000#aop0711.htm##
00613000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100016001040100
01800120012007800138030001900216065000900235064000500244031000300249032000300252
014000600255865000900261002001200270035001000282801001900292#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop0711.htm#S#c#128#14#article#16#14#^rND^sTeruya
^nLC#^rND^sOrtiz^nKZ#^rND^sMinett^nTSC#Performance of normal adults on Rey audit
ory learning test: a pilot study^len#Arq NeuroPsiquiatr#20090000#2009#67#2A#224-
8#20110000#aop0711.htm#0004-282X#Arq Neuropsiquiatr##
00524000000000253000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840160020000870160014001070160
01600121018006500137066000900202062002400211065000900235064000500244865000900249
002001200258#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0711.htm#S#c#1
29#15#article#16#15#^rND^sMitrushina^nM#^rND^sBone^nK#^rND^sD'Elia^nL#Handbook o
f normative data for neuropsychological assessment^len#New York#Oxford Universit
y Press#20050000#2005#20110000#aop0711.htm##
00569000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100021001030120
10200124030001600226710000200242065000900244064000500253031000300258032000200261
014000700263865000900270002001200279#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop0711.htm#S#c#130#16#article#16#16#^rND^sLannoo^nE#^rND^sVingerhoets^nG
#Flemish nomative data on common neuropsychological tests: Influence of age, edu
cation, and gender^len#Psychol Belgica#2#19970000#1997#37#3#141-56#20110000#aop0
711.htm##
00282000000000169000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780910009000800920007000890020012000967030
00400108#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#o#1#1#a
rticle#1#20110311#101423#aop0811.htm#156##
05885000000000721000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780710003000800400003000830010006000860420
00200092120000400094038000400098038000400102121000300106049000300109158000300112
03000220011503200060013706500090014301400070015203500100015922300090016901201010
01780120114002790100026003930100033004190100030004520100026004820100029005080100
03000537010002500567070013300592070017600725083167600901085001002577085003302587
08500290262008500530264908500280270208500230273008320120275308500100476508500410
47750850031048160850048048470850029048950850022049240580062049460580082050081170
00805090072000305098112000905101111001705110114000905127113001505136002001205151
#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#h#2#1#article#1
#oa#en#br1.1#1#4.0#GRA#TAB#05#nd#nd#Rev. Bras. Psiquiatr.#ahead#20110000#^f0^l0#
1516-4446#20110318#Creatine kinase levels in patients with bipolar disorder: dep
ressive, manic, and euthymic phases^len#Comparação das fases de depressão, mania
 e eutimia sobre os níveis de creatina quinase em pacientes bipolares^lpt#^rND^1
A01^nGustavo^sFeier#^rND^1A01^nSamira S.^sValvassori#^rND^1A01^nGislaine T.^sRez
in#^rND^1A01^nMárcio^sBúrigo#^rND^1A01^nEmilio L.^sStreck#^rND^1A02^nFlávio^sKap
czinski#^rND^1A01^nJoão^sQuevedo#Universidade do Extremo Sul Catarinense^iA01^1N
ational Institute for Translational Medicine^2Laboratory of Neurosciences^sSC^pB
razil#Universidade Federal do Rio Grande do Sul^iA02^1Hospital de Clínicas de Po
rto Alegre^2Institute for Translational Medicine^3Bipolar Disorders Program^cPor
to Alegre^sRS^pBrazil#^len^aOBJECTIVE: Bipolar disorder is a severe, recurrent, 
and often chronic psychiatric illness associated with significant functional imp
airment, morbidity, and mortality. Creatine kinase is an important enzyme, parti
cularly for cells with high and fluctuating energy requirements, such as neurons
, and is a potential marker of brain injury. The aim of the present study was to
 compare serum creatine kinase levels between bipolar disorder patients, in the 
various phases (depressive, manic, and euthymic), and healthy volunteers. METHOD
: Forty-eight bipolar patients were recruited: 18 in the euthymic phase; 17 in t
he manic phase; and 13 in the depressive phase. The control group comprised 41 h
ealthy volunteers. The phases of bipolar disorder were defined as follows: euthy
mic-not meeting the DSM-IV criteria for a mood episode and scoring < 8 on the Ha
milton Depression Rating Scale (HDRS) and Young Mania Rating Scale (YMRS); manic
-scoring < 7 on the HDRS and &gt; 7 on the YMRS; depressive-scoring &gt; 7 on th
e HDRS and < 7 on the YMRS. Patients in mixed phases were excluded. Blood sample
s were collected from all participants. RESULTS: Creatine kinase levels were hig
her in the manic patients than in the controls. However, we observed no signific
ant difference between euthymic and depressive patients in terms of the creatine
 kinase level. CONCLUSION: Our results suggest that the clinical differences amo
ng the depressive, manic, and euthymic phases of bipolar disorder are paralleled
 by contrasting levels of creatine kinase. However, further studies are needed i
n order to understand the state-dependent differences observed in serum creatine
 kinase activity.#^ddecs^i1#^tm^len^kCase-control studies^i1#^tm^len^kBipolar di
sorder^i1#^tm^len^kWater level measurement^i1^sadverse effects#^tm^len^kCreatine
 kinase^i1#^tm^len^kDepression^i1#^lpt^aOBJETIVO: O transtorno do humor bipolar 
é uma doença psiquiátrica grave, recorrente e crônica associada a significativo 
prejuízo funcional, morbidade e mortalidade. A creatina quinase tem sido propost
a como um marcador de dano cerebral. A creatina quinase é uma enzima importante 
principalmente para células que necessitam de uma grande quantidade de energia, 
como os neurônios. O objetivo do presente estudo foi comparar os níveis de creat
ina quinase entre as fases depressiva, maníaca e eutímica de pacientes com trans
torno do humor bipolar. MÉTODO: Para avaliação dos níveis de creatina quinase no
 soro, 48 pacientes bipolares foram recrutados; 18 estavam eutímicos, 17 estavam
 em mania e 13 em episódio depressivo. Foi feita também uma comparação com um gr
upo controle que incluiu 41 voluntários saudáveis. Grupo eutimia: foram incluído
s os pacientes que não cumpriam os critérios do DSM-IV para episódios de humor e
 deveriam ter a pontuação inferior a oito nas escalas de avaliação de mania (YMR
S) e depressão (HDRS); grupo mania: foram incluídos os pacientes que apresentava
m YMRS &gt; 7 e HDRS < 7; grupo depressão: foram incluídos os pacientes que apre
sentavam HDRS &gt; 7 e YMRS < 7. Os pacientes em episódios mistos não foram incl
uídos no estudo. Amostras de sangue foram coletadas de todos os participantes. R
ESULTADOS: Durante a mania, os níveis de creatina quinase foram aumentados em co
mparação com voluntários saudáveis. Entretanto, não houve diferença significativ
a nos níveis de creatina quinase em pacientes eutímicos e depressivos, quando co
mparados com o grupo controle. CONCLUSÃO: Nossos resultados sugerem que as fases
 maníaca, depressiva e eutímica do transtorno do humor bipolar, além de apresent
arem sintomatologia distinta, também podem ser diferenciadas pelo nível de creat
ina quinase presente no sangue do paciente. Entretanto, mais estudos são necessá
rios para entender as diferenças observadas na atividade da creatina quinase dur
ante as fases do transtorno do humor bipolar.#^ddecs^i2#^tm^lpt^kEstudos de caso
s e controles^i2#^tm^lpt^kTranstorno bipolar^i2#^tm^lpt^kMedição de níveis^i2^se
feitos adversos#^tm^lpt^kCreatina quinase^i2#^tm^lpt^kDepressão^i2#Conselho Naci
onal de Desenvolvimento Científico e Tecnológico#Fundação de Apoio à Pesquisa Ci
entífica e Tecnológica do Estado de Santa Catarina#vancouv#26#20091109#November 
9, 2009#20100809#August 9, 2010#aop0811.htm##
05970000000000721000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780710003000800400003000830010006000860420
00200092120000400094038000400098038000400102121000300106049000300109158000300112
03000220011503200060013706500090014301400070015203500100015922300090016901201080
01780120121002860100026004070100033004330100030004660100026004960100029005220100
03000551010002500581070013300606070017600739083171300915085001002628085003302638
08500290267108500530270008500280275308500230278108320460280408500100485008500410
48600850031049010850048049320850029049800850022050090580062050310580082050931170
00805175072000305183112000905186111001705195114000905212113001505221002001205236
#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#f#3#1#article#1
#oa#en#br1.1#1#4.0#GRA#TAB#05#nd#nd#Rev. Bras. Psiquiatr.#ahead#20110000#^f0^l0#
1516-4446#20110318#<b>Creatine kinase levels in patients with bipolar disorder: 
depressive, manic, and euthymic phases</b>^len#<b>Comparação das fases de depres
são, mania e eutimia sobre os níveis de creatina quinase em pacientes bipolares<
/b>^lpt#^rND^1A01^nGustavo^sFeier#^rND^1A01^nSamira S.^sValvassori#^rND^1A01^nGi
slaine T.^sRezin#^rND^1A01^nMárcio^sBúrigo#^rND^1A01^nEmilio L.^sStreck#^rND^1A0
2^nFlávio^sKapczinski#^rND^1A01^nJoão^sQuevedo#Universidade do Extremo Sul Catar
inense^iA01^1National Institute for Translational Medicine^2Laboratory of Neuros
ciences^sSC^pBrazil#Universidade Federal do Rio Grande do Sul^iA02^1Hospital de 
Clínicas de Porto Alegre^2Institute for Translational Medicine^3Bipolar Disorder
s Program^cPorto Alegre^sRS^pBrazil#^len^a<b>OBJECTIVE:</b> Bipolar disorder is 
a severe, recurrent, and often chronic psychiatric illness associated with signi
ficant functional impairment, morbidity, and mortality. Creatine kinase is an im
portant enzyme, particularly for cells with high and fluctuating energy requirem
ents, such as neurons, and is a potential marker of brain injury. The aim of the
 present study was to compare serum creatine kinase levels between bipolar disor
der patients, in the various phases (depressive, manic, and euthymic), and healt
hy volunteers. <b>METHOD:</b> Forty-eight bipolar patients were recruited: 18 in
 the euthymic phase; 17 in the manic phase; and 13 in the depressive phase. The 
control group comprised 41 healthy volunteers. The phases of bipolar disorder we
re defined as follows: euthymic-not meeting the DSM-IV criteria for a mood episo
de and scoring &lt; 8 on the Hamilton Depression Rating Scale (HDRS) and Young M
ania Rating Scale (YMRS); manic-scoring &lt; 7 on the HDRS and &gt; 7 on the YMR
S; depressive-scoring &gt; 7 on the HDRS and &lt; 7 on the YMRS. Patients in mix
ed phases were excluded. Blood samples were collected from all participants. <b>
RESULTS:</b> Creatine kinase levels were higher in the manic patients than in th
e controls. However, we observed no significant difference between euthymic and 
depressive patients in terms of the creatine kinase level. <b>CONCLUSION:</b> Ou
r results suggest that the clinical differences among the depressive, manic, and
 euthymic phases of bipolar disorder are paralleled by contrasting levels of cre
atine kinase. However, further studies are needed in order to understand the sta
te-dependent differences observed in serum creatine kinase activity.#^ddecs^i1#^
tm^len^kCase-control studies^i1#^tm^len^kBipolar disorder^i1#^tm^len^kWater leve
l measurement^i1^sadverse effects#^tm^len^kCreatine kinase^i1#^tm^len^kDepressio
n^i1#^lpt^a<b>OBJETIVO:</b> O transtorno do humor bipolar é uma doença psiquiátr
ica grave, recorrente e crônica associada a significativo prejuízo funcional, mo
rbidade e mortalidade. A creatina quinase tem sido proposta como um marcador de 
dano cerebral. A creatina quinase é uma enzima importante principalmente para cé
lulas que necessitam de uma grande quantidade de energia, como os neurônios. O o
bjetivo do presente estudo foi comparar os níveis de creatina quinase entre as f
ases depressiva, maníaca e eutímica de pacientes com transtorno do humor bipolar
. <b>MÉTODO:</b> Para avaliação dos níveis de creatina quinase no soro, 48 pacie
ntes bipolares foram recrutados; 18 estavam eutímicos, 17 estavam em mania e 13 
em episódio depressivo. Foi feita também uma comparação com um grupo controle qu
e incluiu 41 voluntários saudáveis. Grupo eutimia: foram incluídos os pacientes 
que não cumpriam os critérios do DSM-IV para episódios de humor e deveriam ter a
 pontuação inferior a oito nas escalas de avaliação de mania (YMRS) e depressão 
(HDRS); grupo mania: foram incluídos os pacientes que apresentavam YMRS &gt; 7 e
 HDRS &lt; 7; grupo depressão: foram incluídos os pacientes que apresentavam HDR
S &gt; 7 e YMRS &lt; 7. Os pacientes em episódios mistos não foram incluídos no 
estudo. Amostras de sangue foram coletadas de todos os participantes. <b>RESULTA
DOS:</b> Durante a mania, os níveis de creatina quinase foram aumentados em comp
aração com voluntários saudáveis. Entretanto, não houve diferença significativa 
nos níveis de creatina quinase em pacientes eutímicos e depressivos, quando comp
arados com o grupo controle. <b>CONCLUSÃO:</b> Nossos resultados sugerem que as 
fases maníaca, depressiva e eutímica do transtorno do humor bipolar, além de apr
esentarem sintomatologia distinta, também podem ser diferenciadas pelo nível de 
creatina quinase presente no sangue do paciente. Entretanto, mais estudos são ne
cessários para entender as diferenças observadas na atividade da creatina quinas
e durante as fases do transtorno do humor bipolar.#^ddecs^i2#^tm^lpt^kEstudos de
 casos e controles^i2#^tm^lpt^kTranstorno bipolar^i2#^tm^lpt^kMedição de níveis^
i2^sefeitos adversos#^tm^lpt^kCreatina quinase^i2#^tm^lpt^kDepressão^i2#Conselho
 Nacional de Desenvolvimento Científico e Tecnológico#Fundação de Apoio à Pesqui
sa Científica e Tecnológica do Estado de Santa Catarina#vancouv#26#20091109#Nove
mber 9, 2009#20100809#August 9, 2010#aop0811.htm##
06005000000000745000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780640007000800710003000870400003000900010
00600093042000200099120000400101038000400105038000400109121000300113049000300116
15800030011903000210012203200060014306500090014901400070015803500100016522300090
01750120101001840120114002850100026003990100032004250100029004570100026004860100
02800512010003000540010002500570070013500595070017800730083167600908085001002584
08500330259408500290262708500530265608500280270908500230273708320120276008500100
47720850041047820850031048230850048048540850029049020850022049310580062049530580
08205015117000805097072000305105112000905108111001705117114000905134113001505143
002001205158008008905170#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop08
11.htm#S#l#4#1#article#1#^a2011#oa#en#br1.1#1#4.0#gra#tab#05#nd#nd#Rev. bras. ps
iquiatr#ahead#20110000#^f0^l0#1516-4446#20110318#Creatine kinase levels in patie
nts with bipolar disorder: depressive, manic, and euthymic phases^len#Comparação
 das fases de depressão, mania e eutimia sobre os níveis de creatina quinase em 
pacientes bipolares^lpt#^rND^1A01^nGustavo^sFeier#^rND^1A01^nSamira S^sValvassor
i#^rND^1A01^nGislaine T^sRezin#^rND^1A01^nMárcio^sBúrigo#^rND^1A01^nEmilio L^sSt
reck#^rND^1A02^nFlávio^sKapczinski#^rND^1A01^nJoão^sQuevedo#^iA01^1Universidade 
do Extremo Sul Catarinense^2National Institute for Translational Medicine^3Labor
atory of Neurosciences^sSC^pBrazil#^iA02^1Universidade Federal do Rio Grande do 
Sul^2Hospital de Clínicas de Porto Alegre^3Institute for Translational Medicine.
 Bipolar Disorders Program^cPorto Alegre^sRS^pBrazil#^len^aOBJECTIVE: Bipolar di
sorder is a severe, recurrent, and often chronic psychiatric illness associated 
with significant functional impairment, morbidity, and mortality. Creatine kinas
e is an important enzyme, particularly for cells with high and fluctuating energ
y requirements, such as neurons, and is a potential marker of brain injury. The 
aim of the present study was to compare serum creatine kinase levels between bip
olar disorder patients, in the various phases (depressive, manic, and euthymic),
 and healthy volunteers. METHOD: Forty-eight bipolar patients were recruited: 18
 in the euthymic phase; 17 in the manic phase; and 13 in the depressive phase. T
he control group comprised 41 healthy volunteers. The phases of bipolar disorder
 were defined as follows: euthymic-not meeting the DSM-IV criteria for a mood ep
isode and scoring < 8 on the Hamilton Depression Rating Scale (HDRS) and Young M
ania Rating Scale (YMRS); manic-scoring < 7 on the HDRS and &gt; 7 on the YMRS; 
depressive-scoring &gt; 7 on the HDRS and < 7 on the YMRS. Patients in mixed pha
ses were excluded. Blood samples were collected from all participants. RESULTS: 
Creatine kinase levels were higher in the manic patients than in the controls. H
owever, we observed no significant difference between euthymic and depressive pa
tients in terms of the creatine kinase level. CONCLUSION: Our results suggest th
at the clinical differences among the depressive, manic, and euthymic phases of 
bipolar disorder are paralleled by contrasting levels of creatine kinase. Howeve
r, further studies are needed in order to understand the state-dependent differe
nces observed in serum creatine kinase activity.#^ddecs^i1#^tm^len^kCase-control
 studies^i1#^tm^len^kBipolar disorder^i1#^tm^len^kWater level measurement^i1^sad
verse effects#^tm^len^kCreatine kinase^i1#^tm^len^kDepression^i1#^lpt^aOBJETIVO:
 O transtorno do humor bipolar é uma doença psiquiátrica grave, recorrente e crô
nica associada a significativo prejuízo funcional, morbidade e mortalidade. A cr
eatina quinase tem sido proposta como um marcador de dano cerebral. A creatina q
uinase é uma enzima importante principalmente para células que necessitam de uma
 grande quantidade de energia, como os neurônios. O objetivo do presente estudo 
foi comparar os níveis de creatina quinase entre as fases depressiva, maníaca e 
eutímica de pacientes com transtorno do humor bipolar. MÉTODO: Para avaliação do
s níveis de creatina quinase no soro, 48 pacientes bipolares foram recrutados; 1
8 estavam eutímicos, 17 estavam em mania e 13 em episódio depressivo. Foi feita 
também uma comparação com um grupo controle que incluiu 41 voluntários saudáveis
. Grupo eutimia: foram incluídos os pacientes que não cumpriam os critérios do D
SM-IV para episódios de humor e deveriam ter a pontuação inferior a oito nas esc
alas de avaliação de mania (YMRS) e depressão (HDRS); grupo mania: foram incluíd
os os pacientes que apresentavam YMRS &gt; 7 e HDRS < 7; grupo depressão: foram 
incluídos os pacientes que apresentavam HDRS &gt; 7 e YMRS < 7. Os pacientes em 
episódios mistos não foram incluídos no estudo. Amostras de sangue foram coletad
as de todos os participantes. RESULTADOS: Durante a mania, os níveis de creatina
 quinase foram aumentados em comparação com voluntários saudáveis. Entretanto, n
ão houve diferença significativa nos níveis de creatina quinase em pacientes eut
ímicos e depressivos, quando comparados com o grupo controle. CONCLUSÃO: Nossos 
resultados sugerem que as fases maníaca, depressiva e eutímica do transtorno do 
humor bipolar, além de apresentarem sintomatologia distinta, também podem ser di
ferenciadas pelo nível de creatina quinase presente no sangue do paciente. Entre
tanto, mais estudos são necessários para entender as diferenças observadas na at
ividade da creatina quinase durante as fases do transtorno do humor bipolar.#^dd
ecs^i2#^tm^lpt^kEstudos de casos e controles^i2#^tm^lpt^kTranstorno bipolar^i2#^
tm^lpt^kMedição de níveis^i2^sefeitos adversos#^tm^lpt^kCreatina quinase^i2#^tm^
lpt^kDepressão^i2#Conselho Nacional de Desenvolvimento Científico e Tecnológico#
Fundação de Apoio à Pesquisa Científica e Tecnológica do Estado de Santa Catarin
a#vancouv#26#20091109#November 9, 2009#20100809#August 9, 2010#aop0811.htm#Inter
net^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462011005000
005##
00450000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704021000082002001200292#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#5#1#article#126#<p><a name="t
op"></a><font face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Creatine 
   kinase levels in patients with bipolar disorder: depressive, manic, and euthy
mic    phases</b></font></p>     ^cY#aop0811.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#6#2#article#126#<p>&nbsp;</p>
     ^cY#aop0811.htm##
00473000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704023300082002001200315#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#7#3#article#126#<p><font face
="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Compara&ccedil;&atilde;o   
 das fases de depress&atilde;o, mania e eutimia sobre os n&iacute;veis de creati
na    quinase em pacientes bipolares</b></font></p>     ^cY#aop0811.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#8#4#article#126#<p>&nbsp;</p>
     ^cY#aop0811.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#9#5#article#126#<p>&nbsp;</p>
     ^cY#aop0811.htm##
00577000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704033600083002001200419#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#10#6#article#126#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Gustavo Feier<sup>I</sup>;
    Samira S. Valvassori<sup>I</sup>; Gislaine T. Rezin<sup>II</sup>; M&aacute;r
cio    B&uacute;rigo<sup>II</sup>; Emilio L. Streck<sup>II</sup>; Fl&aacute;vio 
Kapczinski<sup>III</sup>;    Jo&atilde;o Quevedo<sup>I</sup></b></font></p>     
^cY#aop0811.htm##
00539000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704029800083002001200381#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#11#7#article#126#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2"><sup>I</sup>Laboratory    of 
Neurosciences and National Institute for Translational Medicine, Postgraduate   
 Program in Health Sciences, Health Sciences&nbsp;Unit, Universidade do Extremo 
   Sul Catarinense (UNESC), SC, Brazil    ^cY#aop0811.htm##
00497000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704025600083002001200339#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#12#8#article#126#<br>   <sup>
II</sup>Laboratory of Experimental Pathophysiology and National Institute    for
 Translational Medicine, Postgraduate Program in Health Sciences, Health    Scie
nces Unit, Universidade do Extremo Sul de Santa Catarina (UNESC), SC, Brazil    
^cY#aop0811.htm##
00485000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704024400083002001200327#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#13#9#article#126#<br>   <sup>
III</sup>Bipolar Disorders Program and National Institute for Translational    M
edicine, Hospital de Cl&iacute;nicas de Porto Alegre, Universidade Federal    do
 Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil</font></p>     ^cY#aop0811.
htm##
00359000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704011700084002001200201#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#14#10#article#126#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><a href="#back">Corresponden
ce</a></font></p>     ^cY#aop0811.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#15#11#article#126#<p>&nbsp;</
p>     ^cY#aop0811.htm##
00286000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704004400084002001200128#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#16#12#article#126#<p>&nbsp;</
p> <hr size="1" noshade>     ^cY#aop0811.htm##
00340000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009800084002001200182#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#17#13#article#126#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>ABSTRACT</b></font></p>  
   ^cY#aop0811.htm##
00866000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704062400084002001200708#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#18#14#article#126#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>OBJECTIVE:</b>    Bipolar
 disorder is a severe, recurrent, and often chronic psychiatric illness    assoc
iated with significant functional impairment, morbidity, and mortality.    Creat
ine kinase is an important enzyme, particularly for cells with high and    fluct
uating energy requirements, such as neurons, and is a potential marker    of bra
in injury. The aim of the present study was to compare serum creatine    kinase 
levels between bipolar disorder patients, in the various phases (depressive,    
manic, and euthymic), and healthy volunteers.    ^cY#aop0811.htm##
00899000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704065700084002001200741#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#19#15#article#126#<br>   <b>M
ETHOD:</b> Forty-eight bipolar patients were recruited: 18 in the euthymic    ph
ase; 17 in the manic phase; and 13 in the depressive phase. The control group   
 comprised 41 healthy volunteers. The phases of bipolar disorder were defined   
 as follows: euthymic-not meeting the DSM-IV criteria for a mood episode and    
scoring &lt; 8 on the Hamilton Depression Rating Scale (HDRS) and Young Mania   
 Rating Scale (YMRS); manic-scoring &lt; 7 on the HDRS and &gt; 7 on the YMRS;  
  depressive-scoring &gt; 7 on the HDRS and &lt; 7 on the YMRS. Patients in mixe
d    phases were excluded. Blood samples were collected from all participants.  
  ^cY#aop0811.htm##
00484000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704024200084002001200326#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#20#16#article#126#<br>   <b>R
ESULTS:</b> Creatine kinase levels were higher in the manic patients than    in 
the controls. However, we observed no significant difference between euthymic   
 and depressive patients in terms of the creatine kinase level.    ^cY#aop0811.h
tm##
00610000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704036800084002001200452#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#21#17#article#126#<br>   <b>C
ONCLUSION:</b> Our results suggest that the clinical differences among the    de
pressive, manic, and euthymic phases of bipolar disorder are paralleled by    co
ntrasting levels of creatine kinase. However, further studies are needed in    o
rder to understand the state-dependent differences observed in serum creatine   
 kinase activity.</font></p>     ^cY#aop0811.htm##
00481000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704023900084002001200323#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#22#18#article#126#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Descriptors</b>:    Case-
control studies; Bipolar disorder; Water level measurement/adverse effects;    C
reatine kinase; Depression</font></p> <hr size="1" noshade>     ^cY#aop0811.htm#
#
00338000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009600084002001200180#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#23#19#article#126#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>    
 ^cY#aop0811.htm##
00962000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704072000084002001200804#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#24#20#article#126#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>OBJETIVO:</b>    O transt
orno do humor bipolar &eacute; uma doen&ccedil;a psiqui&aacute;trica    grave, r
ecorrente e cr&ocirc;nica associada a significativo preju&iacute;zo    funcional
, morbidade e mortalidade. A creatina quinase tem sido proposta como    um marca
dor de dano cerebral. A creatina quinase &eacute; uma enzima importante    princ
ipalmente para c&eacute;lulas que necessitam de uma grande quantidade de    ener
gia, como os neur&ocirc;nios. O objetivo do presente estudo foi comparar    os n
&iacute;veis de creatina quinase entre as fases depressiva, man&iacute;aca    e 
eut&iacute;mica de pacientes com transtorno do humor bipolar.    ^cY#aop0811.htm
##
01259000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704101700084002001201101#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#25#21#article#126#<br>   <b>M
&Eacute;TODO:</b> Para avalia&ccedil;&atilde;o dos n&iacute;veis de creatina    
quinase no soro, 48 pacientes bipolares foram recrutados; 18 estavam eut&iacute;
micos,    17 estavam em mania e 13 em epis&oacute;dio depressivo. Foi feita tamb
&eacute;m    uma compara&ccedil;&atilde;o com um grupo controle que incluiu 41 v
olunt&aacute;rios    saud&aacute;veis. Grupo eutimia: foram inclu&iacute;dos os 
pacientes que n&atilde;o    cumpriam os crit&eacute;rios do DSM-IV para epis&oac
ute;dios de humor e deveriam    ter a pontua&ccedil;&atilde;o inferior a oito na
s escalas de avalia&ccedil;&atilde;o    de mania (YMRS) e depress&atilde;o (HDRS
); grupo mania: foram inclu&iacute;dos    os pacientes que apresentavam YMRS &gt
; 7 e HDRS &lt; 7; grupo depress&atilde;o:    foram inclu&iacute;dos os paciente
s que apresentavam HDRS &gt; 7 e YMRS &lt;    7. Os pacientes em epis&oacute;dio
s mistos n&atilde;o foram inclu&iacute;dos    no estudo. Amostras de sangue fora
m coletadas de todos os participantes.    ^cY#aop0811.htm##
00610000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704036800084002001200452#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#26#22#article#126#<br>   <b>R
ESULTADOS:</b> Durante a mania, os n&iacute;veis de creatina quinase foram    au
mentados em compara&ccedil;&atilde;o com volunt&aacute;rios saud&aacute;veis.   
 Entretanto, n&atilde;o houve diferen&ccedil;a significativa nos n&iacute;veis  
  de creatina quinase em pacientes eut&iacute;micos e depressivos, quando compar
ados    com o grupo controle.    ^cY#aop0811.htm##
00771000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704052900084002001200613#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#27#23#article#126#<br>   <b>C
ONCLUS&Atilde;O:</b> Nossos resultados sugerem que as fases man&iacute;aca,    d
epressiva e eut&iacute;mica do transtorno do humor bipolar, al&eacute;m de    ap
resentarem sintomatologia distinta, tamb&eacute;m podem ser diferenciadas    pel
o n&iacute;vel de creatina quinase presente no sangue do paciente. Entretanto,  
  mais estudos s&atilde;o necess&aacute;rios para entender as diferen&ccedil;as 
   observadas na atividade da creatina quinase durante as fases do transtorno do
    humor bipolar.</font></p>     ^cY#aop0811.htm##
00514000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704027200084002001200356#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#28#24#article#126#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Descritores:</b>    Estud
os de casos e controles; Transtorno bipolar; Medi&ccedil;&atilde;o de n&iacute;v
eis/efeitos    adversos; Creatina quinase; Depress&atilde;o</font></p> <hr size=
"1" noshade>     ^cY#aop0811.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#29#25#article#126#<p>&nbsp;</
p>     ^cY#aop0811.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#30#26#article#126#<p>&nbsp;</
p>     ^cY#aop0811.htm##
00344000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010200084002001200186#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#31#27#article#126#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Introduction</b></font></
p>     ^cY#aop0811.htm##
00641000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704039900084002001200483#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#32#28#article#126#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Bipolar disorder    (BD) is 
a severe, recurrent, and chronic psychiatric disorder that is associated    with
 suicide, as well as with significant functional impairment and morbidity.    Pa
tients with BD typically experience recurrent changes in mood, including manic, 
   depressive, and mixed episodes.<sup>1-3</sup></font></p>     ^cY#aop0811.htm#
#
01392000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704115000084002001201234#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#33#29#article#126#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Creatine kinase    (CK), an 
enzyme that catalyses the reversible transphosphorylation of creatine    by aden
osine triphosphate, plays a key role in energy buffering and energy transport,  
  particularly in cells with high and fluctuating energy requirements, including
    neurons.<sup>4</sup> CK is found mainly in the skeletal muscle, heart, and b
rain;    substantially elevated serum levels of CK usually indicate damage or st
ress    in one or more of these. Enhanced serum CK activity is found also in a s
ubstantial    proportion of patients hospitalized with acute schizophrenia or af
fective psychosis.<sup>5-10</sup>    A recent study of BD patients demonstrated 
that serum CK levels were higher    in manic patients than in depressive patient
s. Likewise, when tested within    the same patient, serum CK levels were found 
to be higher during the manic phase    than in the depressive phase. In agreemen
t with this, it has been demonstrated    that CK levels increase in the cerebros
pinal fluid and serum of BD patients    after an acute episode.<sup>11,12</sup><
/font></p>     ^cY#aop0811.htm##
00617000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704037500084002001200459#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#34#30#article#126#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Despite recent    data indic
ating that serum CK levels are elevated in BD, we found no studies    evaluating
 CK levels in manic, depressive, and euthymic BD patients. Therefore,    this st
udy was designed to investigate whether changes in serum CK levels are    associ
ated with mood episodes.</font></p>     ^cY#aop0811.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#35#31#article#126#<p>&nbsp;</
p>     ^cY#aop0811.htm##
00338000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009600084002001200180#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#36#32#article#126#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Method</b></font></p>    
 ^cY#aop0811.htm##
00343000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010100084002001200185#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#37#33#article#126#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>1. Subjects</b></font></p
>     ^cY#aop0811.htm##
02153000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704191100084002001201995#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#38#34#article#126#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">The present study    was app
roved by the Ethic Comitee in Human Research of Universidade do Extremo    Sul d
e Santa Catarina (UNESC), protocol number: 42/2008. We evaluated 48 patients    
with BD type I, recruited from among those enrolled in the Bipolar Disorders    
Program of the Hospital de Cl&iacute;nicas de Porto Alegre, located in the city 
   of Porto Alegre, Brazil. Of those 48 patients, 18 were in the euthymic state,
    17 were in the manic state, and 13 were in the depressive state. We also rec
ruited    a comparison group of 41 healthy volunteers. Psychiatric diagnoses wer
e based    on clinical interviews and were confirmed with the structured clinica
l interview    for DSM-IV Axis I personality disorders (SCID-I). Manic and depre
ssive symptoms    were assessed using the Young Mania Rating Scale (YMRS) and th
e Hamilton Depression    Rating Scale (HDRS), respectively. Acute manic or depre
ssive episodes were defined    by DSM-IV-TR criteria. Patients were divided into
 three groups as follows: euthymic-patients    who did not meet the DSM-IV crite
ria for a mood episode and who scored &lt;    8 on the HDRS and YMRS; manic-pati
ents who scored &lt; 7 on the HDRS and &gt;    7 on the YMRS; and depressive-pat
ients who scored &gt; 7 on the HDRS and &lt;    7 on the YMRS. Patients in mixed
 phases were excluded. The healthy volunteers    were screened for psychiatric d
isorders using the SCID-I, non-patient version.    The healthy subjects were not
 on medication and had no history of major psychiatric    disorders, dementia, o
r mental retardation. Any individual (patient or control)    who had a medical c
ondition that could result in elevated CK levels-including    acute kidney injur
y, heart disease and musculoskeletal disorders-was excluded,    as were those wh
o had received intramuscular injections.</font></p>     ^cY#aop0811.htm##
00370000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704012800084002001200212#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#39#35#article#126#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>2. Determination    of se
rum CK levels</b></font></p>     ^cY#aop0811.htm##
01384000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704114200084002001201226#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#40#36#article#126#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">From each subject,    5 mL o
f blood were drawn by venipuncture into an anticoagulant-free vacuum tube.    Th
e blood was immediately centrifuged at 3000 &times; <i>g</i> for 5min, and    th
e serum was stored at "80&deg;C for subsequent assay. The reaction mixture    fo
r CK assay contained 100mmol/L of Tris-HCl buffer, pH 7.5, 30mmol/L of phosphocr
eatine,    20mmol/L of glucose, 12mmol/L of magnesium acetate, 10 &#181;mol/L of
 diadenosine    pentaphosphate, 15mmol/L of sodium azide, 20mmol/L of <i>N</i>-a
cetylcysteine,    2mmol/L of adenosine diphosphate, 5mmol/L of adenosine monopho
sphate, 2mmol/L    of nicotinamide adenine dinucleotide, 3500U/L of hexokinase, 
2000U/L of glucose-6-phosphate    dehydrogenase, and approximately 1.5&#181;g of
 protein, in a final volume of    1200&#181;L. The CK activity was calculated ba
sed on the appearance (formation)    of reduced nicotinamide adenine dinucleotid
e, monitored with a spectrophotometer    at 340nm at 37&deg;C. The upper limit o
f normal for CK is 150U/L for women and    175U/L for men.<sup>13</sup></font></
p>     ^cY#aop0811.htm##
00345000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010300084002001200187#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#41#37#article#126#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>3. Statistics</b></font><
/p>     ^cY#aop0811.htm##
00842000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704060000084002001200684#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#42#38#article#126#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Descriptive analyses    are 
presented as number and percentage. Demographic and clinical characteristics    
were analyzed using the chi-square test and ANOVA, as necessary. Levels of CK   
 were analyzed by one-way ANOVA, followed by Tukey's post hoc test when the F   
 value was significant, and are expressed as mean and standard deviation. All   
 analyses were performed with the Statistical Package for the Social Sciences   
 17.0 (SPSS Inc., Chicago, IL, USA). The level of significance was set at p &lt;
    0.05.</font></p>     ^cY#aop0811.htm##
00341000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009900084002001200183#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#43#39#article#126#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>4. Ethics</b></font></p> 
    ^cY#aop0811.htm##
00452000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704021000084002001200294#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#44#40#article#126#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">The study design    was appr
oved by the local research ethics committee, and all participants gave    writte
n informed consent.</font></p>     ^cY#aop0811.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#45#41#article#126#<p>&nbsp;</
p>     ^cY#aop0811.htm##
00339000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009700084002001200181#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#46#42#article#126#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Results</b></font></p>   
  ^cY#aop0811.htm##
01173000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704093100084002001201015#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#47#43#article#126#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Demographic and    clinical 
characteristics of the patients and controls are presented in <a href="/img/revi
stas/rbp/2011nahead/aop0811t01.jpg">Table    1</a>. All groups were homogeneous 
regarding age and sex. No statistical difference    was found between the BD pha
ses in terms of years since diagnosis or number    of manic or depressive episod
es. Serum CK levels were significantly higher in    the manic patients than in t
he controls (2.12 &plusmn; 0.42 vs. 1.84 &plusmn;    0.26U/&#181;L, p = 0.013; <
a href="#f1">Figure 1</a>). In addition, CK levels    were significantly lower i
n the depressed patients (1.72 &plusmn; 0.16) than    in the manic patients (p =
 0.005). Furthermore, CK levels in the depressive    and euthymic patients (1.89
 &plusmn; 0.33 for the latter) did not differ significantly    from those observ
ed for the controls.</font></p>     ^cY#aop0811.htm##
00275000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704003300084002001200117#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#48#44#article#126#<p><a name=
"f1"></a></p>     ^cY#aop0811.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#49#45#article#126#<p>&nbsp;</
p>     ^cY#aop0811.htm##
00328000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008600084002001200170#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#50#46#article#126#<p align="c
enter"><img src="/img/revistas/rbp/2011nahead/aop0811f01.jpg"></p>     ^cY#aop08
11.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#51#47#article#126#<p>&nbsp;</
p>     ^cY#aop0811.htm##
00342000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010000084002001200184#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#52#48#article#126#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Discussion</b></font></p>
     ^cY#aop0811.htm##
01177000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704093500084002001201019#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#53#49#article#126#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Our results show    that ser
um levels of CK are higher in manic BD patients than in healthy control    subje
cts. Although CK levels were higher in the manic patients than in the depressed 
   patients, the levels observed in the latter group did not differ significantl
y    from those obtained for the controls. One of the most important findings of
    the study is that there was no significant difference between the euthymic p
atients    and the controls in terms of the serum CK levels. In clinical practic
e, serum    CK is measured as a marker of myocardial infarction (heart attack), 
rhabdomyolysis    (severe muscle breakdown), muscular dystrophy, and acute kidne
y injury. In view    of this, it should be borne in mind that the elevated serum
 CK levels seen in    the manic patients evaluated here might simply represent i
ncreased motor activity.</font></p>     ^cY#aop0811.htm##
01260000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704101800084002001201102#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#54#50#article#126#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">In agreement with    our fin
dings, Segal et al. showed that CK levels are higher in manic patients    than i
n those who are depressed.<sup>11</sup> In addition, an increase in the    cereb
rospinal fluid and serum levels of CK have been shown to increase in BD    patie
nts after an acute episode.<sup>12,14,15</sup> Furthermore, there is strong    e
vidence that metabolic impairment and mitochondrial dysfunction are involved    
in the pathophysiology of BD.<sup>16-20</sup> The phosphocreatine/CK energy    c
ircuit, which is important for maintaining normal energy homeostasis,<sup>21,22<
/sup>    has a number of integrated functions, such as temporary energy bufferin
g and    energy transfer, as well as regulating metabolic capacity.<sup>23</sup>
 In view    of these data, we can suggest that the increased CK activity seen in
 manic BD    patients is a compensatory mechanism related to the mitochondrial d
amage that    occurs in BD.</font></p>     ^cY#aop0811.htm##
01844000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704160200084002001201686#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#55#51#article#126#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Soni et al. evaluated    pat
ients suffering from a variety of psychoses and graded those patients on    the 
basis of the degree of psychomotor activity.<sup>24</sup> Serum creatine    phos
phokinase (CPK) levels were found to be related to the degree of psychomotor    
activity, irrespective of the diagnostic category. Retarded patients and withdra
wn    patients had normal serum CPK, but transitory increases in CPK were observ
ed    as those patients returned to normal psychomotor activity, suggesting that
 nonphysiological    motor activity is more directly related to the rise of seru
m CPK than is motor    activity <i>per se</i>. However, a postmortem study<sup>2
5</sup> showed that    expression of CK mRNA is decreased in the hippocampus and
 dorsolateral prefrontal    cortex of BD patients. In addition, decreased CK act
ivity has been reported    in a rat model of d-amphetamine-induced mania.<sup>20
</sup> That finding could    be explained by the fact that increased dopamine ac
tivity inhibits CK. In a    clinical study of patients with bipolar I or II diso
rder (BP I or BP II),<sup>26</sup>    brain phosphorus metabolism was measured b
y phosphorus-31 magnetic resonance    spectroscopy. The authors found that phosp
hocreatine levels were significantly    lower in the BP II patients, regardless 
of the BD phase, than in a group of    normal controls, suggesting that brain hi
gh-energy phosphate metabolism is impaired    in BP II and that there are pathop
hysiological differences between BP I and    BP II.</font></p>     ^cY#aop0811.h
tm##
01454000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704121200084002001201296#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#56#52#article#126#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">To our knowledge,    this is
 the first study of its type to include euthymic patients. The inclusion    of s
uch a group could provide data about the persistence of altered serum CK    leve
ls during remission. However, because our sample was small, the present    study
 did not have sufficient power to detect possible differences between the    gro
ups. Another limitation of our study is that we did not evaluate the effects    
that mood stabilizers or other drugs have on CK activity. However, it is of    n
ote that we compared the BD (phase) subgroups with the control group. The fact  
  that the levels of the CK in the euthymic BD patients were comparable to those
    observed for the controls might indicate that alterations in CK levels are a
ssociated    with acute mood episodes, especially acute mania. Although CK activ
ity does    not explain the entire psychiatric profile, it does shed light on ce
rtain topics    including the potential development of alternative treatments an
d the possibility    that treatment response could be monitored more specificall
y by measuring the    levels of biological markers in plasma.</font></p>     ^cY
#aop0811.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#57#53#article#126#<p>&nbsp;</
p>     ^cY#aop0811.htm##
00342000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010000084002001200184#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#58#54#article#126#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Conclusion</b></font></p>
     ^cY#aop0811.htm##
00622000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704038000084002001200464#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#59#55#article#126#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">In conclusion,    our result
s suggest that the clinical differences among the depressive, manic,    and euth
ymic phases of BD are paralleled by contrasting levels of CK. However,    furthe
r studies are needed in order to understand the state-dependent differences    o
bserved in serum CK activity.</font></p>     ^cY#aop0811.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#60#56#article#126#<p>&nbsp;</
p>     ^cY#aop0811.htm##
00348000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010600084002001200190#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#61#57#article#126#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Acknowledgements</b></fon
t></p>     ^cY#aop0811.htm##
01229000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704098700084002001201071#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#62#58#article#126#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">This research was    support
ed by grants from the Conselho Nacional de Desenvolvimento Cient&iacute;fico    
e Tecnol&oacute;gico (CNPq, National Council for Scientific and Technological   
 Development; FK, ELS, and JQ), Funda&ccedil;&atilde;o de Apoio &agrave; Pesquis
a    Cient&iacute;fica e Tecnol&oacute;gica do Estado de Santa Catarina (FAPESC,
    Santa Catarina State Foundation for the Support of Scientific and Technologi
cal    Research; ELS, and JQ), Instituto C&eacute;rebro e Mente (Brain and Mind 
Institute;    ELS, and JQ) and Universidade do Extremo Sul de Santa Catarina (UN
ESC, University    of the Extreme South of Santa Catarina; ELS, and JQ). ELS, FK
, and JQ are CNPq    Research Fellows. SSV is the recipient of a scholarship fro
m the Coordena&ccedil;&atilde;o    de Aperfei&ccedil;oamento de Pessoal de N&iac
ute;vel Superior (CAPES, Office    for the Advancement of Higher Education).</fo
nt></p>     ^cY#aop0811.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#63#59#article#126#<p>&nbsp;</
p>     ^cY#aop0811.htm##
00394000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704015200084002001200236#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#64#60#article#126#<p align="c
enter"><a href="/img/revistas/rbp/2011nahead/aop0811q01.jpg"><img src="/img/revi
stas/rbp/2011nahead/aop0811qa01thumb.jpg" border="0">    ^cY#aop0811.htm##
00349000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010700084002001200191#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#65#61#article#126#<br>   <fon
t face="Verdana, Arial, Helvetica, sans-serif" size="2">Click to enlarge</font><
/a></p>     ^cY#aop0811.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#66#62#article#126#<p>&nbsp;</
p>     ^cY#aop0811.htm##
00342000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010000084002001200184#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#67#63#article#126#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="3"><b>References</b></font></p>
     ^cY#aop0811.htm##
00496000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704024000086002001200326#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#68#64#article#126
#1#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">1. APA - Ameri
can    Psychiatric Association. DSM-IV: diagnostic and statistical manual of men
tal    disorders. 4th ed. New York: American Psychiatric Association; 1994.    ^
cY#aop0811.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#69#65#article#126#</font></p>
     ^cY#aop0811.htm##
00510000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704025400086002001200340#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#70#66#article#126
#2#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2. Coryell W, 
Scheftner    W, Keller M, Endicott J, Maser J, Lklerman G. The enduring psycholo
gical consequences    of mania and depression. <i>Am J Psychiatry</i>. 1993;150(
5):720-7.    ^cY#aop0811.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#71#67#article#126#</font></p>
     ^cY#aop0811.htm##
00542000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704028600086002001200372#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#72#68#article#126
#3#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">3. Yuan-Who C,
    Dilsaver SC. Lifetime rates of suicide attempts among subjects with bipolar 
   and unipolar disorders relative to subjects with other axis I disorders. <i>B
iol    Psychiatry</i>. 1996;39(10):896-9.    ^cY#aop0811.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#73#69#article#126#</font></p>
     ^cY#aop0811.htm##
00502000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704024600086002001200332#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#74#70#article#126
#4#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">4. Andres RH, 
Ducray    AD, Schlattner U, Wallimann T, Widmer HR. Functions and effects of cre
atine    in the central nervous system. <i>Brain Res Bull</i>. 2008;76(4):329-43
.    ^cY#aop0811.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#75#71#article#126#</font></p>
     ^cY#aop0811.htm##
00429000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704017300086002001200259#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#76#72#article#126
#5#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">5. Meltzer HY.
    Neuromuscular dysfunction in schizophrenia. <i>Schizophr Bull</i>. 1976;2(1)
:106-35.    ^cY#aop0811.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#77#73#article#126#</font></p>
     ^cY#aop0811.htm##
00500000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704024400086002001200330#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#78#74#article#126
#6#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">6. Meltzer HY,
    Ross-Stanton J, Schlessinger S. Mean serum creatine kinase activity in patie
nts    with functional psychoses. <i>Arch Gen Psychiatry</i>. 1980;37(6):650-5. 
   ^cY#aop0811.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#79#75#article#126#</font></p>
     ^cY#aop0811.htm##
00665000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704040900086002001200495#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#80#76#article#126
#7#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">7. Hatta k, Ta
kahashi    T, Nakamura H, Yamashiro H, Endo H, Fujii S, Fukami G, Masui K, Asuka
i N, Yonezawa    Y. Abnormal physiological conditions in acute schizophrenic pat
ients on emergency    admission: dehydration, hypokalemia, leukocytosis and elev
ated muscle enzymes.    <i>Eur Arch Psychiatry Clin Neurosci</i>. 1998;248(4):18
0-8.    ^cY#aop0811.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#81#77#article#126#</font></p>
     ^cY#aop0811.htm##
00545000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704028900086002001200375#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#82#78#article#126
#8#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">8. Hermesh H, 
Manor    I, Shiloh R, Weizman R, Munitz H. Absence of myoglobinuria in acute psy
chosis    with marked elevation in serum creatine phosphokinase level. <i>Eur Ne
uropsychopharmacol</i>.    2001;11(2):111-5.    ^cY#aop0811.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#83#79#article#126#</font></p>
     ^cY#aop0811.htm##
00556000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704030000086002001200386#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#84#80#article#126
#9#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">9. Hermesh H, 
Manor    I, Shiloh R, Aizenberg D, Benjamini Y, Munitz H, Weizmann A. High serum
 creatine    kinase level: possible risk factor for neuroleptic malignant syndro
me. <i>J    Clin Psychopharmacol</i>. 2002;22(3):252-6.    ^cY#aop0811.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#85#81#article#126#</font></p>
     ^cY#aop0811.htm##
00570000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000300084704031300087002001200400#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#86#82#article#126
#10#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">10. MacDonald
 ML,    Naydenov A, Chu M, Matzilevich D, Konradi C. Decrease in creatine kinase
 messenger    RNA expression in the hippocampus and dorsolateral prefrontal cort
ex in bipolar    disorder. <i>Bipolar Disord</i>. 2006;8(3):255A-64A.    ^cY#aop
0811.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#87#83#article#126#</font></p>
     ^cY#aop0811.htm##
00509000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000300084704025200087002001200339#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#88#84#article#126
#11#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Segal M, 
Avital    A, Drobot M, Lukanin A, Derevenski A, Sandbank S, Weizman A. CK levels
 in unmedicated    bipolar patients. <i>Eur Neuropsychopharmacol</i>. 2007;17(12
):763-7.    ^cY#aop0811.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#89#85#article#126#</font></p>
     ^cY#aop0811.htm##
00518000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000300084704026100087002001200348#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#90#86#article#126
#12#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Vale S, E
spejel    MA, Calcaneo F, Ocampo J, Diaz-de-Leon J. Creatine phosphokinase. Incr
eased    activity of the spina fluid in psychotic patients. <i>Arch Neurol</i>. 
1974;30(1):103-4.    ^cY#aop0811.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#91#87#article#126#</font></p>
     ^cY#aop0811.htm##
00462000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000300084704020500087002001200292#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#92#88#article#126
#13#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Rosalki S
B.    An improved procedure for serum creatine phosphokinase determination. <i>J
 Lab    Clin Med</i>. 1967;69(4):696-705.    ^cY#aop0811.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#93#89#article#126#</font></p>
     ^cY#aop0811.htm##
00535000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000300084704027800087002001200365#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#94#90#article#126
#14#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Manor I, 
Hermesh    H, Valevski A, Benjamin Y, Munitz H, Weizman A. Recurrence pattern of
 serum    creatine phosphokinase levels in repeated acute psychosis. <i>Biol Psy
chiatry</i>.    1998;43(4):288-92.    ^cY#aop0811.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#95#91#article#126#</font></p>
     ^cY#aop0811.htm##
00472000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000300084704021500087002001200302#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#96#92#article#126
#15#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Taylor JR
,    Abichandani L. Creatine phosphokinase elevations and psychiatric symptomato
logy.    <i>Biol Psychiatry</i>. 1980;15(6):865-70.    ^cY#aop0811.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#97#93#article#126#</font></p>
     ^cY#aop0811.htm##
00453000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000300084704019600087002001200283#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#98#94#article#126
#16#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Hough CJ,
 Chuang    DM. The mitochondrial hypothesis of bipolar disorder. <i>Bipolar Diso
rd.</i>    2000;2(3 Pt 1):145-7.    ^cY#aop0811.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#99#95#article#126#</font></p>
     ^cY#aop0811.htm##
00447000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081888000300085704018900088002001200277#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#100#96#article#12
6#17#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Kato T, 
Kato    N. Mitochondrial dysfunction in bipolar disorder. <i>Bipolar Disord</i>.
 2000;2(3    Pt 1):180-90.    ^cY#aop0811.htm##
00263000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081704002000085002001200105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#101#97#article#126#</font></p
>     ^cY#aop0811.htm##
00518000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081888000300085704026000088002001200348#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#102#98#article#12
6#18#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Konradi 
C,    Eaton M, MacDonald ML, Walsh J, Benes FM, Heckers S. Molecular evidence fo
r    mitochondrial dysfunction in bipolar disorder. <i>Arch Gen Psychiatry</i>. 
2004;61(3):300-8.    ^cY#aop0811.htm##
00263000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081704002000085002001200105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#103#99#article#126#</font></p
>     ^cY#aop0811.htm##
00485000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704022600089002001200315#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#104#100#article#1
26#19#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Rezin G
T, Amboni    G, Zugno AI, Quevedo J, Streck EL. Mitochondrial dysfunction and ps
ychiatric    disorders. <i>Neurochem Res</i>. 2009;34(6):1021-9.    ^cY#aop0811.
htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#105#101#article#126#</font></
p>     ^cY#aop0811.htm##
00541000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704028200089002001200371#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#106#102#article#1
26#20#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Streck 
EL,    Amboni G, Scaini G, Di-Pietro PB, Rezin GT, Valvassori SS, Luz G, Kapczin
ski    F, Quevedo J. Brain creatine kinase activity in an animal model of mania.
 <i>Life    Sci</i>. 2008;82(7-8):424-9.    ^cY#aop0811.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#107#103#article#126#</font></
p>     ^cY#aop0811.htm##
00580000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704032100089002001200410#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#108#104#article#1
26#21#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Khuchua
 ZA,    Qin W, Boero J, Cheng J, Payne RM, Saks VA, Strauss AW. Octamer formatio
n and    coupling of cardiac sarcomeric mitochondrial creatine kinase are mediat
ed by    charged N-terminal residues. <i>J Biol Chem</i>. 1998;273(36):22990-6. 
   ^cY#aop0811.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#109#105#article#126#</font></
p>     ^cY#aop0811.htm##
00504000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704024500089002001200334#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#110#106#article#1
26#22#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">22. Schlatt
ner    U, Wallimann T. Octamers of mitochondrial creatine kinase isoenzymes diff
er    in stability and membrane binding. <i>J Biol Chem</i>. 2000;275(23):17314-
20.    ^cY#aop0811.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#111#107#article#126#</font></
p>     ^cY#aop0811.htm##
00599000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704034000089002001200429#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#112#108#article#1
26#23#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">23. Saks VA
, Kuznetsov    AV, Kupriyanov VV, Miceli MV, Jacobus WE. Creatine kinase of rat 
heart mitochondria.    The demonstration of functional coupling to oxidative pho
sphorylation in an    inner membrane matrix preparation. <i>J Biol Chem</i>. 198
5;260(12):7757-64.    ^cY#aop0811.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#113#109#article#126#</font></
p>     ^cY#aop0811.htm##
00439000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704018000089002001200269#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#114#110#article#1
26#24#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">24. Soni SD
. Serum    creatine phosphokinase in acute psychosis. <i>Br J Psychiatry</i>. 19
76;128(568):181-3.    ^cY#aop0811.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#115#111#article#126#</font></
p>     ^cY#aop0811.htm##
00591000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704033200089002001200421#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#116#112#article#1
26#25#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">25. Hermesh
 H,    Stein D, Manor I, Shechtmann T, Blumensohn R, Meged S, Shiloh R, Benjamin
i Y,    Weizmann A. Creatine kinase levels in untreated hospitalized adolescents
 during    acute psychosis. <i>J Am Acad Child Adolesc Psychiatry</i>. 2002;41(9
):1045-53.    ^cY#aop0811.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#117#113#article#126#</font></
p>     ^cY#aop0811.htm##
00571000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704031200089002001200401#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#118#114#article#1
26#26#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">26. Kato T,
 Takahashi    S, Shioiri T, Murashita J, Hamakawa H, Inubushi T. Reduction of br
ain phosphocreatine    in bipolar II disorder detected by phosphorus-31 magnetic
 resonance spectroscopy.    <i>J Affect Disord.</i> 1994;31(2):125-33.    ^cY#ao
p0811.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#119#115#article#126#</font></
p>     ^cY#aop0811.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#120#116#article#126#<p>&nbsp;
</p>     ^cY#aop0811.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#121#117#article#126#<p>&nbsp;
</p>     ^cY#aop0811.htm##
00436000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704019200086002001200278#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#122#118#article#126#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a href
="#top"><img src="/img/revistas/rbp/2011nahead/seta.jpg" border="0"></a>    <b> 
Correspondence:    ^cY#aop0811.htm##
00283000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704003900086002001200125#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#123#119#article#126#<br>   </
b> Jo&atilde;o Quevedo    ^cY#aop0811.htm##
00315000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704007100086002001200157#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#124#120#article#126#<br>   La
borat&oacute;rio de Neuroci&ecirc;ncias, PPGCS, UNASAU    ^cY#aop0811.htm##
00298000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704005400086002001200140#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#125#121#article#126#<br>   Un
iversidade do Extremo Sul Catarinense    ^cY#aop0811.htm##
00296000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704005200086002001200138#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#126#122#article#126#<br>   88
806-000 Crici&uacute;ma, SC, Brazil    ^cY#aop0811.htm##
00281000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704003700086002001200123#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#127#123#article#126#<br>   Fa
x (+55 48) 3443-4817    ^cY#aop0811.htm##
00334000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704009000086002001200176#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#128#124#article#126#<br>   Em
ail: <a href="mailto:quevedo@unesc.net">quevedo@unesc.net</a></font></p>     ^cY
#aop0811.htm##
00345000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704010100086002001200187#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#129#125#article#126#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">Submitted: November    9, 
2009    ^cY#aop0811.htm##
00295000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704005100086002001200137#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#p#130#126#article#126#<br>   Ac
cepted: August 9, 2010</font></p>     ^cY#aop0811.htm##
00505000000000241000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830170033000850180066001180630
00200184066000900186062003300195065000900228064000500237865000900242002001200251
#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#c#131#1#article
#26#1#American Psychiatric Association#DSM-IV: diagnostic and statistical manual
 of mental disorders^len#4#New York#American Psychiatric Association#19940000#19
94#20110000#aop0811.htm##
00683000000000337000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100017000850100019001020100
01600121010001800137010001500155010001800170012006800188030001600256065000900272
06400050028103100040028603200020029001400060029286500090029800200120030703500100
0319801001600329#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0811.htm#S
#c#132#2#article#26#2#^rND^sCoryell^nW#^rND^sScheftner^nW#^rND^sKeller^nM#^rND^s
Endicott^nJ#^rND^sMaser^nJ#^rND^sLklerman^nG#The enduring psychological conseque
nces of mania and depression^len#Am J Psychiatry#19930000#1993#150#5#720-7#20110
000#aop0811.htm#0002-953X#Am J Psychiatry##
00640000000000289000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100018000850100019001030120
13900122030001600261065000900277064000500286031000300291032000300294014000600297
865000900303002001200312035001000324801001600334#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop0811.htm#S#c#133#3#article#26#3#^rND^sYuan-Who^nC#^rND^sDi
lsaver^nSC#Lifetime rates of suicide attempts among subjects with bipolar and un
ipolar disorders relative to subjects with other axis I disorders^len#Biol Psych
iatry#19960000#1996#39#10#896-9#20110000#aop0811.htm#0006-3223#Biol Psychiatry##
00656000000000325000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100017000850100017001020100
02000119010001900139010001700158012006800175030001500243065000900258064000500267
03100030027203200020027501400070027786500090028400200120029303500100030580100150
0315#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#c#134#4#art
icle#26#4#^rND^sAndres^nRH#^rND^sDucray^nAD#^rND^sSchlattner^nU#^rND^sWallimann^
nT#^rND^sWidmer^nHR#Functions and effects of creatine in the central nervous sys
tem^len#Brain Res Bull#20080000#2008#76#4#329-43#20110000#aop0811.htm#0361-9230#
Brain Res Bull##
00514000000000277000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100018000850120047001030300
01500150065000900165064000500174031000200179032000200181014000700183865000900190
002001200199035001000211801001500221#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop0811.htm#S#c#135#5#article#26#5#^rND^sMeltzer^nHY#Neuromuscular dysfun
ction in schizophrenia^len#Schizophr Bull#19760000#1976#2#1#106-35#20110000#aop0
811.htm#0586-7614#Schizophr Bull##
00623000000000301000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100018000850100022001030100
02200125012007800147030002000225065000900245064000500254031000300259032000200262
014000600264865000900270002001200279035001000291801002000301#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop0811.htm#S#c#136#6#article#26#6#^rND^sMeltzer^
nHY#^rND^sRoss-Stanton^nJ#^rND^sSchlessinger^nS#Mean serum creatine kinase activ
ity in patients with functional psychoses^len#Arch Gen Psychiatry#19800000#1980#
37#6#650-5#20110000#aop0811.htm#0003-990X#Arch Gen Psychiatry##
00922000000000385000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100015000850100019001000100
01800119010001900137010001400156010001500170010001600185010001500201010001600216
01000180023201201610025003000340041106500090044506400050045403100040045903200020
0463014000600465865000900471002001200480035001000492801003400502#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#c#137#7#article#26#7#^rND^sHatt
a^nk#^rND^sTakahashi^nT#^rND^sNakamura^nH#^rND^sYamashiro^nH#^rND^sEndo^nH#^rND^
sFujii^nS#^rND^sFukami^nG#^rND^sMasui^nK#^rND^sAsukai^nN#^rND^sYonezawa^nY#Abnor
mal physiological conditions in acute schizophrenic patients on emergency admiss
ion: dehydration, hypokalemia, leukocytosis and elevated muscle enzymes^len#Eur 
Arch Psychiatry Clin Neurosci#19980000#1998#248#4#180-8#20110000#aop0811.htm#094
0-1334#Eur Arch Psychiatry Clin Neurosci##
00706000000000325000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100017000850100015001020100
01600117010001700133010001600150012010800166030002500274065000900299064000500308
03100030031303200020031601400060031886500090032400200120033303500100034580100250
0355#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#c#138#8#art
icle#26#8#^rND^sHermesh^nH#^rND^sManor^nI#^rND^sShiloh^nR#^rND^sWeizman^nR#^rND^
sMunitz^nH#Absence of myoglobinuria in acute psychosis with marked elevation in 
serum creatine phosphokinase level^len#Eur Neuropsychopharmacol#20010000#2001#11
#2#111-5#20110000#aop0811.htm#0924-977X#Eur Neuropsychopharmacol##
00751000000000349000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100017000850100015001020100
01600117010001900133010001900152010001600171010001800187012009400205030002300299
06500090032206400050033103100030033603200020033901400060034186500090034700200120
0356035001000368801002300378#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\a
op0811.htm#S#c#139#9#article#26#9#^rND^sHermesh^nH#^rND^sManor^nI#^rND^sShiloh^n
R#^rND^sAizenberg^nD#^rND^sBenjamini^nY#^rND^sMunitz^nH#^rND^sWeizmann^nA#High s
erum creatine kinase level: possible risk factor for neuroleptic malignant syndr
ome^len#J Clin Psychopharmacol#20020000#2002#22#3#252-6#20110000#aop0811.htm#027
1-0749#J Clin Psychopharmacol##
00686000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100020000870100018001070100
01300125010002100138010001700159012013100176030001500307710000200322065000900324
064000500333031000200338032000200340014000900342865000900351002001200360#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#c#140#10#article#26#10#
^rND^sMacDonald^nML#^rND^sNaydenov^nA#^rND^sChu^nM#^rND^sMatzilevich^nD#^rND^sKo
nradi^nC#Decrease in creatine kinase messenger RNA expression in the hippocampus
 and dorsolateral prefrontal cortex in bipolar disorder^len#Bipolar Disord#2#200
60000#2006#8#3#255A-64A#20110000#aop0811.htm##
00709000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100015000870100016001020100
01600118010001700134010002000151010001800171010001700189012004600206030002500252
06500090027706400050028603100030029103200030029401400060029786500090030300200120
0312035001000324801002500334#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\a
op0811.htm#S#c#141#11#article#26#11#^rND^sSegal^nM#^rND^sAvital^nA#^rND^sDrobot^
nM#^rND^sLukanin^nA#^rND^sDerevenski^nA#^rND^sSandbank^nS#^rND^sWeizman^nA#CK le
vels in unmedicated bipolar patients^len#Eur Neuropsychopharmacol#20070000#2007#
17#12#763-7#20110000#aop0811.htm#0924-977X#Eur Neuropsychopharmacol##
00669000000000325000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100014000870100018001010100
01800119010001600137010002200153012008800175030001200263065000900275064000500284
03100030028903200020029201400060029486500090030000200120030903500100032180100120
0331#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#c#142#12#ar
ticle#26#12#^rND^sVale^nS#^rND^sEspejel^nMA#^rND^sCalcaneo^nF#^rND^sOcampo^nJ#^r
ND^sDiaz-de-Leon^nJ#Creatine phosphokinase: Increased activity of the spina flui
d in psychotic patients^len#Arch Neurol#19740000#1974#30#1#103-4#20110000#aop081
1.htm#0003-9942#Arch Neurol##
00544000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870120073001050300
01500178065000900193064000500202031000300207032000200210014000800212865000900220
002001200229035001000241801001500251#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop0811.htm#S#c#143#13#article#26#13#^rND^sRosalki^nSB#An improved proced
ure for serum creatine phosphokinase determination^len#J Lab Clin Med#19670000#1
967#69#4#696-705#20110000#aop0811.htm#0022-2143#J Lab Clin Med##
00705000000000337000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100015000870100017001020100
01800119010001800137010001600155010001700171012009000188030001600278065000900294
06400050030303100030030803200020031101400070031386500090032000200120032903500100
0341801001600351#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0811.htm#S
#c#144#14#article#26#14#^rND^sManor^nI#^rND^sHermesh^nH#^rND^sValevski^nA#^rND^s
Benjamin^nY#^rND^sMunitz^nH#^rND^sWeizman^nA#Recurrence pattern of serum creatin
e phosphokinase levels in repeated acute psychosis^len#Biol Psychiatry#19980000#
1998#43#4#288-92#20110000#aop0811.htm#0006-3223#Biol Psychiatry##
00573000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100021001040120
06900125030001600194065000900210064000500219031000300224032000200227014000700229
865000900236002001200245035001000257801001600267#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop0811.htm#S#c#145#15#article#26#15#^rND^sTaylor^nJR#^rND^sA
bichandani^nL#Creatine phosphokinase elevations and psychiatric symptomatology^l
en#Biol Psychiatry#19800000#1980#15#6#865-70#20110000#aop0811.htm#0006-3223#Biol
 Psychiatry##
00514000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100017001030120
05300120030001600173710000200189065000900191064000500200031000200205032000200207
014000600209865000900215002001200224#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop0811.htm#S#c#146#16#article#26#16#^rND^sHough^nCJ#^rND^sChuang^nDM#The
 mitochondrial hypothesis of bipolar disorder^len#Bipolar Disord.#2#20000000#200
0#2#3#145-7#20110000#aop0811.htm##
00506000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100014000870100014001010120
05000115030001500165710000200180065000900182064000500191031000200196032000200198
014000700200865000900207002001200216#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop0811.htm#S#c#147#17#article#26#17#^rND^sKato^nT#^rND^sKato^nN#Mitochon
drial dysfunction in bipolar disorder^len#Bipolar Disord#2#20000000#2000#2#3#180
-90#20110000#aop0811.htm##
00694000000000337000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100015001040100
02000119010001500139010001600154010001700170012007300187030002000260065000900280
06400050028903100030029403200020029701400060029986500090030500200120031403500100
0326801002000336#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0811.htm#S
#c#148#18#article#26#18#^rND^sKonradi^nC#^rND^sEaton^nM#^rND^sMacDonald^nML#^rND
^sWalsh^nJ#^rND^sBenes^nFM#^rND^sHeckers^nS#Molecular evidence for mitochondrial
 dysfunction in bipolar disorder^len#Arch Gen Psychiatry#20040000#2004#61#3#300-
8#20110000#aop0811.htm#0003-990X#Arch Gen Psychiatry##
00636000000000325000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100016001030100
01600119010001700135010001700152012005600169030001400225065000900239064000500248
03100030025303200020025601400070025886500090026500200120027403500100028680100140
0296#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#c#149#19#ar
ticle#26#19#^rND^sRezin^nGT#^rND^sAmboni^nG#^rND^sZugno^nAI#^rND^sQuevedo^nJ#^rN
D^sStreck^nEL#Mitochondrial dysfunction and psychiatric disorders^len#Neurochem 
Res#20090000#2009#34#6#1021-9#20110000#aop0811.htm#0364-3190#Neurochem Res##
00756000000000373000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100016001040100
01600120010002000136010001600156010002100172010001300193010002000206010001700226
01200630024303000090030606500090031506400050032403100030032903200040033201400060
0336865000900342002001200351035001000363801000900373#2011nahead#V:\SciELO\serial
\rbp\2011nahead\markup\aop0811.htm#S#c#150#20#article#26#20#^rND^sStreck^nEL#^rN
D^sAmboni^nG#^rND^sScaini^nG#^rND^sDi-Pietro^nPB#^rND^sRezin^nGT#^rND^sValvassor
i^nSS#^rND^sLuz^nG#^rND^sKapczinski^nF#^rND^sQuevedo^nJ#Brain creatine kinase ac
tivity in an animal model of mania^len#Life Sci#20080000#2008#82#7-8#424-9#20110
000#aop0811.htm#0024-3205#Life sci##
00762000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100013001050100
01500118010001500133010001600148010001500164010001800179012013100197030001200328
06500090034006400050034903100040035403200030035801400080036186500090036900200120
0378035001000390801001200400#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\a
op0811.htm#S#c#151#21#article#26#21#^rND^sKhuchua^nZA#^rND^sQin^nW#^rND^sBoero^n
J#^rND^sCheng^nJ#^rND^sPayne^nRM#^rND^sSaks^nVA#^rND^sStrauss^nAW#Octamer format
ion and coupling of cardiac sarcomeric mitochondrial creatine kinase are mediate
d by charged N-terminal residues^len#J Biol Chem#19980000#1998#273#36#22990-6#20
110000#aop0811.htm#0021-9258#J Biol Chem##
00599000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100020000870100019001070120
09800126030001200224065000900236064000500245031000400250032000300254014000900257
865000900266002001200275035001000287801001200297#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop0811.htm#S#c#152#22#article#26#22#^rND^sSchlattner^nU#^rND
^sWallimann^nT#Octamers of mitochondrial creatine kinase isoenzymes differ in st
ability and membrane binding^len#J Biol Chem#20000000#2000#275#23#17314-20#20110
000#aop0811.htm#0021-9258#J Biol Chem##
00745000000000325000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100015000870100020001020100
02100122010001700143010001800160012015700178030001200335065000900347064000500356
03100040036103200030036501400080036886500090037600200120038503500100039780100120
0407#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#c#153#23#ar
ticle#26#23#^rND^sSaks^nVA#^rND^sKuznetsov^nAV#^rND^sKupriyanov^nVV#^rND^sMiceli
^nMV#^rND^sJacobus^nWE#Creatine kinase of rat heart mitochondria: The demonstrat
ion of functional coupling to oxidative phosphorylation in an inner membrane mat
rix preparation^len#J Biol Chem#19850000#1985#260#12#7757-64#20110000#aop0811.ht
m#0021-9258#J Biol Chem##
00523000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100015000870120052001020300
01600154065000900170064000500179031000400184032000400188014000600192865000900198
002001200207035001000219801001600229#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop0811.htm#S#c#154#24#article#26#24#^rND^sSoni^nSD#Serum creatine phosph
okinase in acute psychosis^len#Br J Psychiatry#19760000#1976#128#568#181-3#20110
000#aop0811.htm#0007-1250#Br J Psychiatry##
00832000000000373000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100015001040100
01500119010002000134010002000154010001500174010001600189010001900205010001800224
01200880024203000350033006500090036506400050037403100030037903200020038201400080
0384865000900392002001200401035001000413801003500423#2011nahead#V:\SciELO\serial
\rbp\2011nahead\markup\aop0811.htm#S#c#155#25#article#26#25#^rND^sHermesh^nH#^rN
D^sStein^nD#^rND^sManor^nI#^rND^sShechtmann^nT#^rND^sBlumensohn^nR#^rND^sMeged^n
S#^rND^sShiloh^nR#^rND^sBenjamini^nY#^rND^sWeizmann^nA#Creatine kinase levels in
 untreated hospitalized adolescents during acute psychosis^len#J Am Acad Child A
dolesc Psychiatry#20020000#2002#41#9#1045-53#20110000#aop0811.htm#0890-8567#J Am
 Acad Child Adolesc Psychiatry##
00704000000000325000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100014000870100019001010100
01700120010001900137010001800156010001800174012012000192030001700312710000200329
06500090033106400050034003100030034503200020034801400070035086500090035700200120
0366#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0811.htm#S#c#156#26#ar
ticle#26#26#^rND^sKato^nT#^rND^sTakahashi^nS#^rND^sShioiri^nT#^rND^sMurashita^nJ
#^rND^sHamakawa^nH#^rND^sInubushi^nT#Reduction of brain phosphocreatine in bipol
ar II disorder detected by phosphorus-31 magnetic resonance spectroscopy^len#J A
ffect Disord.#2#19940000#1994#31#2#125-33#20110000#aop0811.htm##
00282000000000169000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780910009000800920007000890020012000967030
00400108#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#o#1#1#a
rticle#1#20110311#101426#aop0911.htm#210##
04410000000000673000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780710003000800400003000830010006000860420
00200092120000400094038000400098038000400102121000300106049000300109158000300112
03000220011503200060013706500090014301400070015203500100015922300090016901200960
01780120084002740100030003580100027003880100027004150100033004420700093004750700
12300568070007000691083134700761085001002108085001702118085002702135085003102162
08500230219308500230221608312910223908500100353008500180354008500290355808500300
35870850022036170850022036391170008036610720003036691120009036721110017036811140
00903698113001703707002001203724#2011nahead#V:\SciELO\serial\rbp\2011nahead\mark
up\aop0911.htm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#GRA#TAB#06#nd#nd#Rev. Bras. P
siquiatr.#ahead#20110000#^f0^l0#1516-4446#20110318#Physical activity and depress
ive symptoms in community-dwelling elders from southern Brazil^len#Atividade fís
ica e sintomas depressivos em idosos sul-brasileiros da comunidade^lpt#^rND^1A01
^nCésar L.^sReichert#^rND^1A02^nCésar L.^sDiogo#^rND^1A03^nJosé L.^sVieira#^rND^
1A02^nRoberta R.^sDalacorte#Centro Universitário Feevale^iA01^1Physiology Exerci
se Laboratory^cNovo Hamburgo^sRS^pBrazil#Pontifícia Universidade Católica Rio Gr
ande do Sul^iA02^1Institute of Geriatrics and Gerontology^cPorto Alegre^sRS^pBra
zil#Rio Grande do Sul Cardiology Institute^iA03^cPorto Alegre^sRS^pBrazil#^len^a
OBJECTIVE: To determine the existence of a relationship between physical activit
y and depressive symptoms in community-dwelling elders. METHOD: This is a cross-
sectional, population-based study, which included 379 community-dwelling elders 
from Novo Hamburgo, state of RS, Brazil. The level of physical activity was esti
mated using the International Physical Activity Questionnaire and depressive sym
ptoms were diagnosed according to the Yesavage Geriatric Depression Scale. The a
ssociation between the level of physical activity and depressive symptoms was an
alyzed by logistic regression. RESULTS: A tendency towards a lower prevalence of
 depressive symptoms was observed in individuals with higher levels of physical 
activity, both in the sample as a whole as well as among men, but not among wome
n (p for linear trend 0.04, 0.03 and 0.36, respectively). The odds ratio of the 
presence of depressive symptoms in the very active group, as compared against th
at of the insufficiently active group was 0.32 (95% CI: 0.12-0.86) for men and 0
.76 (95% CI: 0.39-1.46) for women. CONCLUSION: In this population of aged indivi
duals, more intense physical activity is related to a lower prevalence of depres
sive symptoms. As shown by gender stratification, physical activity is inversely
 related to depressive symptoms in men, albeit not in women.#^ddecs^i1#^tm^len^k
Aged^i1#^tm^len^kMotor activity^i1#^tm^len^kSigns and symptoms^i1#^tm^len^kDepre
ssion^i1#^tm^len^kGeriatrics^i1#^lpt^aOBJETIVO: Avaliar a relação entre atividad
e física e sintomas depressivos em idosos da comunidade. MÉTODO: Estudo transver
sal de base populacional que incluiu 379 idosos da comunidade da cidade de Novo 
Hamburgo-RS, Brasil. O nível de atividade física foi estimado pelo Questionário 
Internacional de Atividade Física e os sintomas depressivos foram diagnosticados
 por meio da Escala de Depressão Geriátrica de Yesavage. A associação entre níve
l de atividade física e sintomas depressivos foi analisada por regressão logísti
ca. RESULTADOS: Foi observada uma tendência a menor prevalência de sintomas depr
essivos em indivíduos com níveis mais altos de atividade física na amostra como 
um todo e entre os homens, mas não entre as mulheres (p = 0,04, 0,03 e 0,36, res
pectivamente). O odds ratio para a presença de sintomas depressivos no grupo mui
to ativo, quando comparado com o grupo insuficientemente ativo, foi de 0,32 (IC 
95%: 0,12-0,86) para homens e 0,76 (IC 95%: 0,39-1,46) para mulheres. CONCLUSÃO:
 Nesta população de idosos, a atividade física mais intensa está relacionada com
 uma menor prevalência de sintomas depressivos. Como demonstrado pela estratific
ação por gênero, a atividade física está inversamente relacionada com sintomas d
epressivos em homens, mas não em mulheres.#^ddecs^i2#^tm^lpt^kIdoso^i2#^tm^lpt^k
Atividade motora^i2#^tm^lpt^kSinais e sintomas^i2#^tm^lpt^kDepressão^i2#^tm^lpt^
kGeriatria^i2#vancouv#40#20091109#November 9, 2009#20101018#October 18, 2010#aop
0911.htm##
04487000000000673000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780710003000800400003000830010006000860420
00200092120000400094038000400098038000400102121000300106049000300109158000300112
03000220011503200060013706500090014301400070015203500100015922300090016901201030
01780120091002810100030003720100027004020100027004290100033004560700093004890700
12300582070007000705083137500775085001002150085001702160085002702177085003102204
08500230223508500230225808313260228108500100360708500180361708500290363508500300
36640850022036940850022037161170008037380720003037461120009037491110017037581140
00903775113001703784002001203801#2011nahead#V:\SciELO\serial\rbp\2011nahead\mark
up\aop0911.htm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#GRA#TAB#06#nd#nd#Rev. Bras. P
siquiatr.#ahead#20110000#^f0^l0#1516-4446#20110318#<b>Physical activity and depr
essive symptoms in community-dwelling elders from southern Brazil</b>^len#<b>Ati
vidade física e sintomas depressivos em idosos sul-brasileiros da comunidade</b>
^lpt#^rND^1A01^nCésar L.^sReichert#^rND^1A02^nCésar L.^sDiogo#^rND^1A03^nJosé L.
^sVieira#^rND^1A02^nRoberta R.^sDalacorte#Centro Universitário Feevale^iA01^1Phy
siology Exercise Laboratory^cNovo Hamburgo^sRS^pBrazil#Pontifícia Universidade C
atólica Rio Grande do Sul^iA02^1Institute of Geriatrics and Gerontology^cPorto A
legre^sRS^pBrazil#Rio Grande do Sul Cardiology Institute^iA03^cPorto Alegre^sRS^
pBrazil#^len^a<b>OBJECTIVE:</b> To determine the existence of a relationship bet
ween physical activity and depressive symptoms in community-dwelling elders. <b>
METHOD:</b> This is a cross-sectional, population-based study, which included 37
9 community-dwelling elders from Novo Hamburgo, state of RS, Brazil. The level o
f physical activity was estimated using the International Physical Activity Ques
tionnaire and depressive symptoms were diagnosed according to the Yesavage Geria
tric Depression Scale. The association between the level of physical activity an
d depressive symptoms was analyzed by logistic regression. <b>RESULTS:</b> A ten
dency towards a lower prevalence of depressive symptoms was observed in individu
als with higher levels of physical activity, both in the sample as a whole as we
ll as among men, but not among women (p for linear trend 0.04, 0.03 and 0.36, re
spectively). The odds ratio of the presence of depressive symptoms in the very a
ctive group, as compared against that of the insufficiently active group was 0.3
2 (95% CI: 0.12-0.86) for men and 0.76 (95% CI: 0.39-1.46) for women. <b>CONCLUS
ION:</b> In this population of aged individuals, more intense physical activity 
is related to a lower prevalence of depressive symptoms. As shown by gender stra
tification, physical activity is inversely related to depressive symptoms in men
, albeit not in women.#^ddecs^i1#^tm^len^kAged^i1#^tm^len^kMotor activity^i1#^tm
^len^kSigns and symptoms^i1#^tm^len^kDepression^i1#^tm^len^kGeriatrics^i1#^lpt^a
<b>OBJETIVO:</b> Avaliar a relação entre atividade física e sintomas depressivos
 em idosos da comunidade. <b>MÉTODO:</b> Estudo transversal de base populacional
 que incluiu 379 idosos da comunidade da cidade de Novo Hamburgo-RS, Brasil. O n
ível de atividade física foi estimado pelo Questionário Internacional de Ativida
de Física e os sintomas depressivos foram diagnosticados por meio da Escala de D
epressão Geriátrica de Yesavage. A associação entre nível de atividade física e 
sintomas depressivos foi analisada por regressão logística. <b>RESULTADOS:</b> F
oi observada uma tendência a menor prevalência de sintomas depressivos em indiví
duos com níveis mais altos de atividade física na amostra como um todo e entre o
s homens, mas não entre as mulheres (p = 0,04, 0,03 e 0,36, respectivamente). O 
<i>odds ratio</i> para a presença de sintomas depressivos no grupo muito ativo, 
quando comparado com o grupo insuficientemente ativo, foi de 0,32 (IC 95%: 0,12-
0,86) para homens e 0,76 (IC 95%: 0,39-1,46) para mulheres. <b>CONCLUSÃO:</b> Ne
sta população de idosos, a atividade física mais intensa está relacionada com um
a menor prevalência de sintomas depressivos. Como demonstrado pela estratificaçã
o por gênero, a atividade física está inversamente relacionada com sintomas depr
essivos em homens, mas não em mulheres.#^ddecs^i2#^tm^lpt^kIdoso^i2#^tm^lpt^kAti
vidade motora^i2#^tm^lpt^kSinais e sintomas^i2#^tm^lpt^kDepressão^i2#^tm^lpt^kGe
riatria^i2#vancouv#40#20091109#November 9, 2009#20101018#October 18, 2010#aop091
1.htm##
04563000000000697000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780640007000800710003000870400003000900010
00600093042000200099120000400101038000400105038000400109121000300113049000300116
15800030011903000210012203200060014306500090014901400070015803500100016522300090
01750120096001840120084002800100029003640100026003930100026004190100032004450700
09500477070012500572070007200697083136100769085001002130085001702140085002702157
08500310218408500230221508500230223808313090226108500100357008500180358008500290
35980850030036270850022036570850022036791170008037010720003037091120009037121110
01703721114000903738113001703747002001203764008008903776#2011nahead#V:\SciELO\se
rial\rbp\2011nahead\markup\aop0911.htm#S#l#4#1#article#1#^a2011#oa#en#br1.1#1#4.
0#gra#tab#06#nd#nd#Rev. bras. psiquiatr#ahead#20110000#^f0^l0#1516-4446#20110318
#Physical activity and depressive symptoms in community-dwelling elders from sou
thern Brazil^len#Atividade física e sintomas depressivos em idosos sul-brasileir
os da comunidade^lpt#^rND^1A01^nCésar L^sReichert#^rND^1A02^nCésar L^sDiogo#^rND
^1A03^nJosé L^sVieira#^rND^1A02^nRoberta R^sDalacorte#^iA01^1Centro Universitári
o Feevale^2Physiology Exercise Laboratory^cNovo Hamburgo^sRS^pBrazil#^iA02^1Pont
ifícia Universidade Católica Rio Grande do Sul^2Institute of Geriatrics and Gero
ntology^cPorto Alegre^sRS^pBrazil#^iA03^1Rio Grande do Sul Cardiology Institute^
cPorto Alegre^sRS^pBrazil#^len^aOBJECTIVE: To determine the existence of a relat
ionship between physical activity and depressive symptoms in community-dwelling 
elders. METHOD: This is a cross-sectional, population-based study, which include
d 379 community-dwelling elders from Novo Hamburgo, state of RS, Brazil. The lev
el of physical activity was estimated using the International Physical Activity 
Questionnaire and depressive symptoms were diagnosed according to the Yesavage G
eriatric Depression Scale. The association between the level of physical activit
y and depressive symptoms was analyzed by logistic regression. RESULTS: A tenden
cy towards a lower prevalence of depressive symptoms was observed in individuals
 with higher levels of physical activity, both in the sample as a whole as well 
as among men, but not among women (p for linear trend 0.04, 0.03 and 0.36, respe
ctively). The odds ratio of the presence of depressive symptoms in the very acti
ve group, as compared against that of the insufficiently active group was 0.32 (
95 percent CI: 0.12-0.86) for men and 0.76 (95 percent CI: 0.39-1.46) for women.
 CONCLUSION: In this population of aged individuals, more intense physical activ
ity is related to a lower prevalence of depressive symptoms. As shown by gender 
stratification, physical activity is inversely related to depressive symptoms in
 men, albeit not in women.#^ddecs^i1#^tm^len^kAged^i1#^tm^len^kMotor activity^i1
#^tm^len^kSigns and symptoms^i1#^tm^len^kDepression^i1#^tm^len^kGeriatrics^i1#^l
pt^aOBJETIVO: Avaliar a relação entre atividade física e sintomas depressivos em
 idosos da comunidade. MÉTODO: Estudo transversal de base populacional que inclu
iu 379 idosos da comunidade da cidade de Novo Hamburgo-RS, Brasil. O nível de at
ividade física foi estimado pelo Questionário Internacional de Atividade Física 
e os sintomas depressivos foram diagnosticados por meio da Escala de Depressão G
eriátrica de Yesavage. A associação entre nível de atividade física e sintomas d
epressivos foi analisada por regressão logística. RESULTADOS: Foi observada uma 
tendência a menor prevalência de sintomas depressivos em indivíduos com níveis m
ais altos de atividade física na amostra como um todo e entre os homens, mas não
 entre as mulheres (p = 0,04, 0,03 e 0,36, respectivamente). O odds ratio para a
 presença de sintomas depressivos no grupo muito ativo, quando comparado com o g
rupo insuficientemente ativo, foi de 0,32 (IC 95 por cento: 0,12-0,86) para home
ns e 0,76 (IC 95 por cento: 0,39-1,46) para mulheres. CONCLUSÃO: Nesta população
 de idosos, a atividade física mais intensa está relacionada com uma menor preva
lência de sintomas depressivos. Como demonstrado pela estratificação por gênero,
 a atividade física está inversamente relacionada com sintomas depressivos em ho
mens, mas não em mulheres.#^ddecs^i2#^tm^lpt^kIdoso^i2#^tm^lpt^kAtividade motora
^i2#^tm^lpt^kSinais e sintomas^i2#^tm^lpt^kDepressão^i2#^tm^lpt^kGeriatria^i2#va
ncouv#40#20091109#November 9, 2009#20101018#October 18, 2010#aop0911.htm#Interne
t^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-4446201100500000
6##
00445000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704020500082002001200287#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#5#1#article#166#<p><a name="t
op"></a><font face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Physical 
   activity and depressive symptoms in community-dwelling elders from southern  
  Brazil</b></font></p>     ^cY#aop0911.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#6#2#article#166#<p>&nbsp;</p>
     ^cY#aop0911.htm##
00419000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704017900082002001200261#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#7#3#article#166#<p><font face
="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Atividade f&iacute;sica    
e sintomas depressivos em idosos sul-brasileiros da comunidade</b></font></p>   
  ^cY#aop0911.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#8#4#article#166#<p>&nbsp;</p>
     ^cY#aop0911.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#9#5#article#166#<p>&nbsp;</p>
     ^cY#aop0911.htm##
00481000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704024000083002001200323#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#10#6#article#166#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2"><b>C&eacute;sar    L. Reicher
t<sup>I</sup>; C&eacute;sar L. Diogo<sup>II</sup>; Jos&eacute; L.    Vieira<sup>
III</sup>; Roberta R. Dalacorte<sup>II</sup></b></font></p>     ^cY#aop0911.htm#
#
00424000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704018300083002001200266#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#11#7#article#166#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2"><sup>I</sup>Physiology    Exe
rcise Laboratory, Centro Universit&aacute;rio Feevale, Novo Hamburgo, RS,    Bra
zil    ^cY#aop0911.htm##
00411000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704017000083002001200253#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#12#8#article#166#<br>   <sup>
II</sup>Institute of Geriatrics and Gerontology, Pontif&iacute;cia Universidade 
   Cat&oacute;lica Rio Grande do Sul (PUCRS), Porto Alegre, RS, Brazil    ^cY#ao
p0911.htm##
00346000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704010500083002001200188#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#13#9#article#166#<br>   <sup>
III</sup>Rio Grande do Sul Cardiology Institute, Porto Alegre, RS, Brazil</font>
</p>     ^cY#aop0911.htm##
00359000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704011700084002001200201#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#14#10#article#166#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><a href="#back">Corresponden
ce</a></font></p>     ^cY#aop0911.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#15#11#article#166#<p>&nbsp;</
p>     ^cY#aop0911.htm##
00286000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704004400084002001200128#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#16#12#article#166#<p>&nbsp;</
p> <hr size="1" noshade>     ^cY#aop0911.htm##
00340000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009800084002001200182#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#17#13#article#166#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>ABSTRACT</b></font></p>  
   ^cY#aop0911.htm##
00461000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704021900084002001200303#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#18#14#article#166#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>OBJECTIVE:</b>    To dete
rmine the existence of a relationship between physical activity and depressive  
  symptoms in community-dwelling elders.    ^cY#aop0911.htm##
00733000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704049100084002001200575#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#19#15#article#166#<br>   <b>M
ETHOD:</b> This is a cross-sectional, population-based study, which included    
379 community-dwelling elders from Novo Hamburgo, state of RS, Brazil. The level
    of physical activity was estimated using the International Physical Activity
    Questionnaire and depressive symptoms were diagnosed according to the Yesava
ge    Geriatric Depression Scale. The association between the level of physical 
activity    and depressive symptoms was analyzed by logistic regression.    ^cY#
aop0911.htm##
00765000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704052300084002001200607#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#20#16#article#166#<br>   <b>R
ESULTS:</b> A tendency towards a lower prevalence of depressive symptoms    was 
observed in individuals with higher levels of physical activity, both in    the 
sample as a whole as well as among men, but not among women (p for linear    tre
nd 0.04, 0.03 and 0.36, respectively). The odds ratio of the presence of    depr
essive symptoms in the very active group, as compared against that of the    ins
ufficiently active group was 0.32 (95% CI: 0.12-0.86) for men and 0.76 (95%    C
I: 0.39-1.46) for women.    ^cY#aop0911.htm##
00550000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704030800084002001200392#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#21#17#article#166#<br>   <b>C
ONCLUSION:</b> In this population of aged individuals, more intense physical    
activity is related to a lower prevalence of depressive symptoms. As shown by   
 gender stratification, physical activity is inversely related to depressive    
symptoms in men, albeit not in women.</font></p>     ^cY#aop0911.htm##
00434000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704019200084002001200276#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#22#18#article#166#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Descriptors</b>:    Aged;
 Motor activity; Signs and symptoms; Depression; Geriatrics</font></p> <hr size=
"1" noshade>     ^cY#aop0911.htm##
00338000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009600084002001200180#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#23#19#article#166#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>    
 ^cY#aop0911.htm##
00445000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704020300084002001200287#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#24#20#article#166#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>OBJETIVO:</b>    Avaliar 
a rela&ccedil;&atilde;o entre atividade f&iacute;sica e sintomas depressivos    
em idosos da comunidade.    ^cY#aop0911.htm##
00799000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704055700084002001200641#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#25#21#article#166#<br>   <b>M
&Eacute;TODO:</b> Estudo transversal de base populacional que incluiu 379    ido
sos da comunidade da cidade de Novo Hamburgo-RS, Brasil. O n&iacute;vel de    at
ividade f&iacute;sica foi estimado pelo Question&aacute;rio Internacional    de 
Atividade F&iacute;sica e os sintomas depressivos foram diagnosticados por    me
io da Escala de Depress&atilde;o Geri&aacute;trica de Yesavage. A associa&ccedil
;&atilde;o    entre n&iacute;vel de atividade f&iacute;sica e sintomas depressiv
os foi analisada    por regress&atilde;o log&iacute;stica.    ^cY#aop0911.htm##
00801000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704055900084002001200643#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#26#22#article#166#<br>   <b>R
ESULTADOS:</b> Foi observada uma tend&ecirc;ncia a menor preval&ecirc;ncia    de
 sintomas depressivos em indiv&iacute;duos com n&iacute;veis mais altos de    at
ividade f&iacute;sica na amostra como um todo e entre os homens, mas n&atilde;o 
   entre as mulheres (p = 0,04, 0,03 e 0,36, respectivamente). O <i>odds ratio</
i>    para a presen&ccedil;a de sintomas depressivos no grupo muito ativo, quand
o    comparado com o grupo insuficientemente ativo, foi de 0,32 (IC 95%: 0,12-0,
86)    para homens e 0,76 (IC 95%: 0,39-1,46) para mulheres.    ^cY#aop0911.htm#
#
00662000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704042000084002001200504#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#27#23#article#166#<br>   <b>C
ONCLUS&Atilde;O:</b> Nesta popula&ccedil;&atilde;o de idosos, a atividade    f&i
acute;sica mais intensa est&aacute; relacionada com uma menor preval&ecirc;ncia 
   de sintomas depressivos. Como demonstrado pela estratifica&ccedil;&atilde;o  
  por g&ecirc;nero, a atividade f&iacute;sica est&aacute; inversamente relaciona
da    com sintomas depressivos em homens, mas n&atilde;o em mulheres.</font></p>
     ^cY#aop0911.htm##
00441000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704019900084002001200283#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#28#24#article#166#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Descritores:</b>    Idoso
; Atividade motora; Sinais e sintomas; Depress&atilde;o; Geriatria</font></p> <h
r size="1" noshade>     ^cY#aop0911.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#29#25#article#166#<p>&nbsp;</
p>     ^cY#aop0911.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#30#26#article#166#<p>&nbsp;</
p>     ^cY#aop0911.htm##
00344000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010200084002001200186#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#31#27#article#166#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Introduction</b></font></
p>     ^cY#aop0911.htm##
00775000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704053300084002001200617#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#32#28#article#166#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Population ageing    is a ma
jor human challenge. It results in changes to the epidemiological profile,    wi
th an increase in the prevalence and incidence of chronic illnesses such as    h
eart disease, cancer and depression. The prevalence of communicable diseases    
is decreasing while that of the chronic-degenerative diseases is increasing,    
thus creating different demands in terms of population-oriented health care    p
olicies.<sup>1,2</sup></font></p>     ^cY#aop0911.htm##
00973000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704073100084002001200815#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#33#29#article#166#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Depression, which    is a ch
ronic disorder associated to high levels of strain, requires that a significantl
y    high amount of resources be invested in health care systems. It is currentl
y    considered the fourth cause of disability-adjusted life years for incapacit
y    or premature death. According to World Health Organization (WHO) estimates,
    in 2020, major depressive disorder will be the second most important cause o
f    incapacity in the world.<sup>3</sup> Nevertheless, a high number of patient
s    is still not properly diagnosed and frequently fail to receive adequate tre
atment    once the disorder has been identified.<sup>4</sup></font></p>     ^cY#
aop0911.htm##
00853000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704061100084002001200695#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#34#30#article#166#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Elderly individuals    prese
nt certain characteristics which may frequently lead to symptoms of depression. 
   These characteristics include biological factors, the presence of other chron
ic    diseases and psychosocial factors such as inadequate social support, grief
 and    mourning.<sup>5,6</sup> Studies investigating the prevalence of depressi
on in    elderly populations present variable results, ranging from 4-5% to over
 30%,    depending on the population analyzed and the evaluation instruments emp
loyed.<sup>7-9</sup></font></p>     ^cY#aop0911.htm##
00803000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704056100084002001200645#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#35#31#article#166#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Although around    50% of th
e cases respond well to pharmacological or psychotherapy, resistance    to treat
ment can be attributed to the disorder's chronic course. Older patients    prese
nt higher risks of experiencing an adverse effect of antidepressant drugs    due
 to the pharmacokinetic alterations associated to aging and as a result of    th
e simultaneous use of other drugs for comorbidities, thus increasing the potenti
al    for harmful drug interaction.<sup>4,10</sup></font></p>     ^cY#aop0911.ht
m##
01117000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704087500084002001200959#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#36#32#article#166#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Regular physical    activity
 has been associated not only with a reduction in the risk of certain    chronic
 diseases such as diabetes mellitus, cardiovascular diseases, osteoporosis    an
d certain types of cancer, but also to lower mortality indices.<sup>11-16</sup> 
   Observational and experimental studies have shown an inverse relationship bet
ween    the level of physical activity and depressive symptoms but, in aged indi
viduals,    this phenomenon remains largely unclear. Studies investigating this 
relationship    in elderly populations are scarce and often present methodologic
al flaws.<sup>17-29</sup>    To contribute to this discussion, the present study
 examined the association    between depressive symptoms and the level of physic
al activity in community-dwelling    elders.</font></p>     ^cY#aop0911.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#37#33#article#166#<p>&nbsp;</
p>     ^cY#aop0911.htm##
00338000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009600084002001200180#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#38#34#article#166#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Method</b></font></p>    
 ^cY#aop0911.htm##
01457000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704121500084002001201299#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#39#35#article#166#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">A total of 379    individual
s (127 males and 252 females) were enrolled in the study. Details    on the meth
odology used have been published previously.<sup>30</sup> In brief,    we conduc
ted a study with senior citizens from the town of Novo Hamburgo in    Rio Grande
 do Sul, which is a state located in the southern part Brazil. According    to t
he Brazilian Institute of Geography and Statistics (IBGE), in 2000, the    town 
had a population of 236,000 inhabitants of which about 17,000 were over    the a
ge of 60 and 98% resided in urban areas. Gender distribution was as follows:    
51% female and 49% male. Thanks to a 19<sup>th</sup> century immigration wave   
 from Germany, the population is mainly from a German background. The sample    
was determined with a confidence level of 95% and an error margin of 5%, control
led    for age, sex, location in the city and economic stratum according to the 
population    distribution as reported by IBGE in 2000 and to regional data as r
eported by    the National Association of Research Companies (<i>Associa&ccedil;
&atilde;o    Nacional de Empresas de Pesquisa</i>).<sup>31</sup></font></p>     
^cY#aop0911.htm##
00787000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704054500084002001200629#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#40#36#article#166#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Subjects were contacted    b
y telephone or letter, invited to participate in an interview and undergo a    m
etabolic-functional evaluation at the Feevale University Center. All participant
s    agreed to participate in the study and signed an informed consent form. The
    project was approved by the Ethics Committee of the S&atilde;o Lucas Hospita
l    (docket number 04/02232), Pontif&iacute;cia Universidade Cat&oacute;lica do
    Rio Grande do Sul, RS, Brazil.</font></p>     ^cY#aop0911.htm##
00782000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704054000084002001200624#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#41#37#article#166#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">All data were collected    b
y trained investigators. Height and weight were measured using an anthropometric
    scale (Welmy&reg;, SP, Brazil). Body mass index (BMI) was defined as weight 
   (kg) divided by the square of the height (m). The blood pressure (BP) of subj
ects    who had rested for 10 minutes was measured one time on each arm using a 
standard    mercury sphygmomanometer, and the mean numbers between the two readi
ngs was    used for analyses.</font></p>     ^cY#aop0911.htm##
01341000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704109900084002001201183#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#42#38#article#166#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Participants filled    out t
he short version of the International Physical Activity Questionnaire (IPAQ).<su
p>32</sup>    The weekly energy expenditure was calculated according to internat
ional standards    and was expressed as metabolic equivalent task (MET/week) or 
converted to kcal/wk    using the relationship kcal = MET x weight &divide; 60. 
Depending on the weekly    energy expenditure expressed in MET, individuals were
 classified as insufficiently    active (up to 600 MET/week), sufficiently activ
e (between 601 and 1500 MET/week)    and very active (over 1500 MET/week).<sup>3
3</sup> The short version (15 questions)    of the Yesavage Geriatric Depression
 Scale (GDS) was used.<sup>34</sup> The    presence of depressive symptoms was d
etermined based on the use of antidepressant    medications or a score of five o
r more points in the GDS. Participants also    answered the CAGE questionnaire a
nd two or more positive answers were indicative    of the presence of alcohol-re
lated problems.<sup>35</sup></font></p>     ^cY#aop0911.htm##
00748000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704050600084002001200590#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#43#39#article#166#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Continuous variables    are 
presented as means (standard deviations) and categorical variables as numbers   
 and percentages. Comparisons of the demographic, anthropometric and clinical   
 characteristics of participants with or without depressive symptoms were perfor
med    using the chi-square test for categorical variables while the Student's t
 test    or the Mann-Whitney test were used to compare numerical variables.</fon
t></p>     ^cY#aop0911.htm##
00845000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704060300084002001200687#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#44#40#article#166#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">The prevalence    of depress
ive symptoms at the three levels of physical activity was analyzed    using the 
chi-square test. The odds ratio of the presence of depressive symptoms    in eac
h level of physical activity was calculated by logistic regression based    on a
 model adjusted for age, sex and smoking. An analysis stratified by gender    wa
s performed. The significance level was established at 0.05 (two-tailed).    The
 statistical analyses were performed using version 13 of the SPSS software    (C
hicago, IL).</font></p>     ^cY#aop0911.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#45#41#article#166#<p>&nbsp;</
p>     ^cY#aop0911.htm##
00339000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009700084002001200181#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#46#42#article#166#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Results</b></font></p>   
  ^cY#aop0911.htm##
01331000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704108900084002001201173#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#47#43#article#166#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><a href="/img/revistas/rbp/2
011nahead/aop0911t01.jpg">Table    1</a> summarizes the demographic and clinical
 characteristics of the subjects    according to gender. Females had a body mass
 index of 28.7 and males of 27.1    (p = 0.001). At 68%, hypertension, which was
 higher in females than in males    (74% and 56%, respectively p = 0.001) was hi
ghly prevalent. Smoking was more    frequent in males (20% vs. 7%, p = 0.001). A
nalysis of the alcohol consumption    according to the CAGE questionnaire showed
 a prevalence of 11% among males,    3% among females (p = 0.004) and 6% in the 
sample as a whole. The level of physical    activity was homogeneously distribut
ed in the studied population (34% were insufficiently    active, 35% were suffic
iently active and 31% were very active). The frequency    of activity in very ac
tive individuals was higher among males (37% vs. 28%).    Based on the GDS, arou
nd 30% of the population i.e., 27% of males and 32% of    females experienced de
pressive symptoms.</font></p>     ^cY#aop0911.htm##
00641000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704039900084002001200483#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#48#44#article#166#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Demographic and    clinical 
characteristics of individuals with or without depressive symptoms    are shown 
in <a href="/img/revistas/rbp/2011nahead/aop0911t02.jpg">Table 2</a>.    Smoking
 was the only variable whose prevalence in both groups was significantly    diff
erent i.e., 17% and 9%, respectively (p = 0.03).</font></p>     ^cY#aop0911.htm#
#
00696000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704045400084002001200538#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#49#45#article#166#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">When analyzing    the preval
ence of depressive symptoms, we verified a substantial linear trend    across th
e different levels of physical activity, having found a lower prevalence    in t
he group with the highest level of physical activity (<a href="#f1">Figure    1<
/a>). This linear trend was present in the population as a whole and among    me
n, albeit not in women.</font></p>     ^cY#aop0911.htm##
00275000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704003300084002001200117#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#50#46#article#166#<p><a name=
"f1"></a></p>     ^cY#aop0911.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#51#47#article#166#<p>&nbsp;</
p>     ^cY#aop0911.htm##
00328000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008600084002001200170#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#52#48#article#166#<p align="c
enter"><img src="/img/revistas/rbp/2011nahead/aop0911f01.jpg"></p>     ^cY#aop09
11.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#53#49#article#166#<p>&nbsp;</
p>     ^cY#aop0911.htm##
00840000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704059800084002001200682#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#54#50#article#166#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Considering both    genders,
 the group with the highest level of physical activity (very active)    was 42% 
less likely to have depressive symptoms (95% IC 1% to 66%) than the    group con
sisting of insufficiently active individuals. A gender-specific analysis    show
ed that this association was seen only among males, and that very active    male
s were 68% less likely to present depressive symptoms when compared to males    
from the insufficiently active group (95% IC 14% to 88%); <a href="#t3">Table   
 3</a>.</font></p>     ^cY#aop0911.htm##
00275000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704003300084002001200117#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#55#51#article#166#<p><a name=
"t3"></a></p>     ^cY#aop0911.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#56#52#article#166#<p>&nbsp;</
p>     ^cY#aop0911.htm##
00328000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008600084002001200170#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#57#53#article#166#<p align="c
enter"><img src="/img/revistas/rbp/2011nahead/aop0911t03.jpg"></p>     ^cY#aop09
11.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#58#54#article#166#<p>&nbsp;</
p>     ^cY#aop0911.htm##
00342000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010000084002001200184#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#59#55#article#166#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Discussion</b></font></p>
     ^cY#aop0911.htm##
00794000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704055200084002001200636#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#60#56#article#166#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">This study showed    that mo
re intense levels of physical activity were related to a lower prevalence    of 
depressive symptoms among a population of elderly individuals, and that the    a
ssociation occurred among men but not among women. The probability of having    
symptoms of depression was 42% lower in elders classified as very physically    
active compared those who were insufficiently active. When men were analyzed    
separately, this probability rose to 68%.</font></p>     ^cY#aop0911.htm##
01509000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704126700084002001201351#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#61#57#article#166#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Other studies report    simi
lar results where there is an inverse relationship between physical activity    
and depressive symptoms. Population-based observational studies such as the    A
lameda County Study, which included 1,900 subjects between the ages of 25 and   
 77 showed that a low level of physical or recreational activity was an independ
ent    predictor of depressive symptoms.<sup>28</sup> The Rancho Bernardo Study 
reported    similar results after evaluating a cohort of 2,375 individuals betwe
en 1984    and 1987. An additional follow-up evaluation of the 1,180 surviving m
embers    was conducted between 1992 e 1995.<sup>17,27</sup> In certain cohort s
tudies,    however, no relationship has been observed between the level of physi
cal activity    and depressive symptoms. In another study, performed in Germany,
 the association    between risk for depression and physical inactivity initiall
y detected among    1,536 individuals was not observed when the same population 
was analyzed again    after 5 years.<sup>29</sup> Similarly, a cohort study with
 a follow-up of 973    physicians for 15 years found no association of exercise 
and risk of depression.<sup>22</sup></font></p>     ^cY#aop0911.htm##
01922000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704168000084002001201764#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#62#58#article#166#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Experimental studies    have
 also shown decreased depressive symptoms among individuals with high physical  
  activity, although different types of methodological flaws have not allowed   
 an accurate definition of the issue. In a clinical study of 43 individuals aged
    between 17 and 60 years, Martinsen and colleagues observed a reduction in de
pression    scores among subjects performing systematic aerobic exercise, but th
e impossibility    of performing blind analyses of the results was seen as a pot
ential source of    bias.<sup>20</sup> Blumenthal and colleagues have randomly a
ssigned 156 depressive    patients over 50 years of age to a program of aerobic 
exercise, antidepressant    drugs or a combination of both. At the final evaluat
ion, the groups did not    differ statistically on the Hamilton Rating Scale for
 Depression and the Beck    Depression Inventory scores, although patients recei
ving medication alone exhibited    the fastest initial response.<sup>21</sup> Th
e results of a meta-regression    analysis of 14 clinical trials showed importan
t methodological weaknesses that    make the assessment of the effectiveness of 
exercise in reducing symptoms of    depression unfeasible.<sup>19</sup> The most
 frequent problems observed were    absence of a control group, inadequate rando
mization process and lack of intention    to treat analysis. Other problems obse
rved refer to the follow up, which should    be longer for a chronic disease, an
d to the fact that participants in most studies    were community volunteers, wh
ich could result in an overestimation of results.</font></p>     ^cY#aop0911.htm
##
01308000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704106600084002001201150#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#63#59#article#166#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">The prevalence    of depress
ive symptoms in the present study ranged from 17% (in very active    males) to 4
0% (in insufficiently active females). Although such large variation    has alre
ady been described in other studies, the prevalence observed is higher    compar
ed to the prevalence found in other investigations. An epidemiologic study    th
at included 18,571 participants from five different states in the US showed    a
 prevalence of 3% for major depression and 15% for depressive symptoms among    
community elders.<sup>36</sup> As stressed by Snowdon, different countries prese
nt    a highly variable prevalence of depression and depressive symptoms, with o
ver    a ten-fold difference among them.<sup>9</sup> In Brazil, Veras and Murphy
 have    observed a prevalence of up to 37% of symptoms of depression in poorer 
communities.<sup>37</sup>    In northeastern Brazil, the analysis of a populatio
n of 1,120 elders showed    a prevalence of 23% for depression.<sup>6</sup></fon
t></p>     ^cY#aop0911.htm##
01163000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704092100084002001201005#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#64#60#article#166#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">The higher prevalence    of 
depressive symptoms observed in Brazilian elders may be explained by the    coun
try&acute;s poor social and health system structures. The fact that, in    the p
resent study, the sample was composed of individuals who agreed to participate  
  may also have influenced the rates observed since they may be patients who are
    more used to receiving medical care. Because the sample selection was perfor
med    by telephone and a large number of males declined to participate, we can'
t rule    out the possibility that they failed to agree to participate because o
f their    depressive symptoms, which could, in theory, make them less prone to 
accepting    to take on tasks such as participating in medical research. This fa
ct may have    influenced the results and doesn't allow a generalization of thes
e results.</font></p>     ^cY#aop0911.htm##
01432000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704119000084002001201274#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#65#61#article#166#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Another consideration    rel
ates to the sample's proportion of females, which, numerically, were twice    as
 numerous as men, possibly bearing an influence on the results. Similar results,
    however, have been reported in other populations with a higher frequency of 
   females, which, in turn, may be explained by their higher life expectancy or 
   predisposition to participate as volunteers in studies involving medical cons
ultation    and clinical and laboratory evaluations.<sup>38</sup> Another import
ant point    that needs mentioning concerns a bias, which may have affected our 
results,    and is related to the social interaction that results from physical 
activity,    which has already been shown to be associated to a lower prevalence
 of symptoms    of depression.<sup>39</sup> It is thus possible that elders iden
tified as more    active and with fewer depressive symptoms are actually benefit
ed by social interaction.    A further possible bias may be related to the quest
ionnaires used to evaluate    the level of physical activity, which tend to over
estimate these activities.<sup>40</sup></font></p>     ^cY#aop0911.htm##
00967000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704072500084002001200809#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#66#62#article#166#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">Finally, cross-sectional    
studies represent an appropriate approach to raise a hypothesis about the relati
onship    between physical activity and depressive symptoms, as well as to searc
h for    other factors that may be associated to these symptoms in the elderly. 
The inverse    association between physical activity and symptoms of depression 
observed should,    however, be analyzed within the context of this type of desi
gn, where a positive    association does not necessarily mean a causal relations
hip. Therefore, this    study should be interpreted as a hypothesis-generating s
tudy, thus suggesting    the need for further studies.</font></p>     ^cY#aop091
1.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#67#63#article#166#<p>&nbsp;</
p>     ^cY#aop0911.htm##
00342000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010000084002001200184#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#68#64#article#166#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Conclusion</b></font></p>
     ^cY#aop0911.htm##
00726000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704048400084002001200568#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#69#65#article#166#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">The present population-based
    study showed an inverse relationship between the level of physical activity 
   and the prevalence of symptoms of depression in elderly individuals. The resu
lts    indicate the need for studies with different designs to identify a causal
 relationship,    affording the opportunity to establish physical activity as a 
therapeutic alternative    for a depressive disorder.</font></p>     ^cY#aop0911
.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#70#66#article#166#<p>&nbsp;</
p>     ^cY#aop0911.htm##
00347000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010500084002001200189#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#71#67#article#166#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Acknowledgement</b></font
></p>     ^cY#aop0911.htm##
00380000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704013800084002001200222#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#72#68#article#166#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">There was no outside    fund
ing/support for this study.</font></p>     ^cY#aop0911.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#73#69#article#166#<p>&nbsp;</
p>     ^cY#aop0911.htm##
00353000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704011100084002001200195#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#74#70#article#166#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Authors' contribution</b>
</font></p>     ^cY#aop0911.htm##
00768000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704052600084002001200610#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#75#71#article#166#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">CLR: search for    subjects 
and data, analysis and interpretation of data and preparation of the    manuscri
pt. CLD: study's concept and design and preparation of the manuscript.    JLV: s
tudy's concept and design, statistical analysis and interpretation of    data, a
nd critical review of the manuscript for important intellectual content.    RRD:
 study's concept and design, search for subjects and data and preparation    of 
the manuscript.</font></p>     ^cY#aop0911.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#76#72#article#166#<p>&nbsp;</
p>     ^cY#aop0911.htm##
00393000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704015100084002001200235#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#77#73#article#166#<p align="c
enter"><a href="/img/revistas/rbp/2011nahead/aop0911q01.jpg"><img src="/img/revi
stas/rbp/2011nahead/aop0911q01thumb.jpg" border="0">    ^cY#aop0911.htm##
00349000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010700084002001200191#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#78#74#article#166#<br>   <fon
t face="Verdana, Arial, Helvetica, sans-serif" size="2">Click to enlarge</font><
/a></p>     ^cY#aop0911.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#79#75#article#166#<p>&nbsp;</
p>     ^cY#aop0911.htm##
00342000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010000084002001200184#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#80#76#article#166#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="3"><b>References</b></font></p>
     ^cY#aop0911.htm##
00735000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704047900086002001200565#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#81#77#article#166
#1#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">1. Active agei
ng:    a policy framework. Noncommunicable Diseases and Mental Health Cluster, N
oncommunicable    Disease Prevention and Health Promotion Department, Ageing and
 Life Course.    World Health Organization, 2002.&#91;cited 2009 Aug 24&#93;.Ava
ilable from:    <a href="http://whqlibdoc.who.int/hq/2002/WHO_NMH_NPH_02.8.pdf" 
target="_blank">http://whqlibdoc.who.int/hq/2002/WHO_NMH_NPH_02.8.pdf</a>.    ^c
Y#aop0911.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#82#78#article#166#</font></p>
     ^cY#aop0911.htm##
00629000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704037300086002001200459#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#83#79#article#166
#2#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2. Brundtland 
GH.    Ageing: Exploding the myths. In: Ageing and Health Programme, World Healt
h Organization,    1999. &#91;cited 2009 Aug 24&#93;. Available from: <a href="h
ttp://whqlibdoc.who.int/hq/1999/WHO_HSC_AHE_99.1.pdf" target="_blank">http://whq
libdoc.who.int/hq/1999/WHO_HSC_AHE_99.1.pdf</a>.    ^cY#aop0911.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#84#80#article#166#</font></p>
     ^cY#aop0911.htm##
00519000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704026300086002001200349#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#85#81#article#166
#3#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">3. Rodgers A, 
Ezzati    M, Vander Hoorn S, Lopez AD, Lin RB, Murray CJ. Distribution of major 
health    risks: findings from the Global Burden of Disease study. <i>PLoS Med</
i>. 2004;1(1):e27.    ^cY#aop0911.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#86#82#article#166#</font></p>
     ^cY#aop0911.htm##
00551000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704029500086002001200381#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#87#83#article#166
#4#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">4. Fleck MP, L
afer    B, Sougey EB, Del Porto JA, Brasil MA, Juruena MF. Guidelines of the Bra
zilian    Medical Association for the treatment of depression (complete version)
. <i>Rev    Bras Psiquiatr</i>. 2003;25(2):114-22.    ^cY#aop0911.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#88#84#article#166#</font></p>
     ^cY#aop0911.htm##
00497000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704024100086002001200327#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#89#85#article#166
#5#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">5. Alexopoulos
    GS, Borson S, Cuthbert BN, Devanand DP, Mulsant BH, Olin JT, Oslin DW. Asses
sment    of late life depression. <i>Biol Psychiatry</i>. 2002;52(3):164-74.    
^cY#aop0911.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#90#86#article#166#</font></p>
     ^cY#aop0911.htm##
00480000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704022400086002001200310#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#91#87#article#166
#6#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">6. Duarte MB, 
Rego    MA. Depression and clinical illness: comorbidity in a geriatric outpatie
nt clinic.    <i>Cad Saude Publica</i>. 2007;23(3):691-700.    ^cY#aop0911.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#92#88#article#166#</font></p>
     ^cY#aop0911.htm##
00541000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704028500086002001200371#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#93#89#article#166
#7#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">7. Barry KL, F
leming    MF, Manwell LB, Copeland LA, Appel S. Prevalence of and factors associ
ated with    current and lifetime depression in older adult primary care patient
s. <i>Fam    Med</i>. 1998;30(5):366-71.    ^cY#aop0911.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#94#90#article#166#</font></p>
     ^cY#aop0911.htm##
00574000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704031800086002001200404#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#95#91#article#166
#8#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">8. Almeida-Fil
ho    N, Mari Jde J, Coutinho E, Franca JF, Fernandes J, Andreoli SB, Busnello E
D.    Brazilian multicentric study of psychiatric morbidity. Methodological feat
ures    and prevalence estimates. <i>Br J Psychiatry</i>. 1997;171:524-9.    ^cY
#aop0911.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#96#92#article#166#</font></p>
     ^cY#aop0911.htm##
00443000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704018700086002001200273#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#97#93#article#166
#9#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">9. Snowdon J. 
How    high is the prevalence of depression in old age? <i>Rev Bras Psiquiatr</i
>.    2002;24(1):42-7.    ^cY#aop0911.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#98#94#article#166#</font></p>
     ^cY#aop0911.htm##
00511000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000300084704025400087002001200341#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#99#95#article#166
#10#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Blazer DG
,    Hybels CF, Fillenbaum GG, Pieper CF. Predictors of antidepressant use among
    older adults: have they changed over time? <i>Am J Psychiatry</i>. 2005;162(
4):705-10.    ^cY#aop0911.htm##
00263000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081704002000085002001200105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#100#96#article#166#</font></p
>     ^cY#aop0911.htm##
00559000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081888000300085704030100088002001200389#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#101#97#article#16
6#11#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Manini T
M,    Everhart JE, Patel KV, Schoeller DA, Colbert LH, Visser M, Tylavsky F, Bau
er    DC, Goodpaster BH, Harris TB. Daily activity energy expenditure and mortal
ity    among older adults. <i>JAMA</i>. 2006;296(2):171-9.    ^cY#aop0911.htm##
00263000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081704002000085002001200105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#102#98#article#166#</font></p
>     ^cY#aop0911.htm##
00457000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081888000300085704019900088002001200287#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#103#99#article#16
6#12#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Pescatel
lo    LS. Exercising for health: the merits of lifestyle physical activity. <i>W
est    J Med</i>. 2001;174(2):114-8.    ^cY#aop0911.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#104#100#article#166#</font></
p>     ^cY#aop0911.htm##
00524000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704026500089002001200354#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#105#101#article#1
66#13#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Wanname
thee    SG, Shaper AG, Whincup PH. Modifiable lifestyle factors and the metaboli
c syndrome    in older men: Effects of lifestyle changes. <i>J Am Geriatr Soc</i
>. 2006;54(12):1909-14.    ^cY#aop0911.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#106#102#article#166#</font></
p>     ^cY#aop0911.htm##
00504000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704024500089002001200334#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#107#103#article#1
66#14#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Paffenb
arger    RS, Jr., Hyde RT, Wing AL, Hsieh CC. Physical activity, all-cause morta
lity,    and longevity of college alumni. <i>N Engl J Med</i>. 1986;314(10):605-
13.    ^cY#aop0911.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#108#104#article#166#</font></
p>     ^cY#aop0911.htm##
00513000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704025400089002001200343#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#109#105#article#1
66#15#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Stampfe
r MJ,    Hu FB, Manson JE, Rimm EB, Willett WC. Primary prevention of coronary h
eart    disease in women through diet and lifestyle. <i>N Engl J Med</i>. 2000;3
43(1):16-22.    ^cY#aop0911.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#110#106#article#166#</font></
p>     ^cY#aop0911.htm##
00529000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704027000089002001200359#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#111#107#article#1
66#16#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Gregg E
W, Cauley    JA, Stone K, Thompson TJ, Bauer DC, Cummings SR, Ensrud KE. Relatio
nship of    changes in physical activity and mortality among older women. <i>JAM
A</i>. 2003;289(18):2379-86.    ^cY#aop0911.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#112#108#article#166#</font></
p>     ^cY#aop0911.htm##
00548000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704028900089002001200378#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#113#109#article#1
66#17#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Kritz-S
ilverstein    D, Barrett-Connor E, Corbeau C. Cross-sectional and prospective st
udy of exercise    and depressed mood in the elderly: the Rancho Bernardo study.
 <i>Am J Epidemiol</i>.    2001;153(6):596-603.    ^cY#aop0911.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#114#110#article#166#</font></
p>     ^cY#aop0911.htm##
00540000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704028100089002001200370#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#115#111#article#1
66#18#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Antunes
 HK,    Stella SG, Santos RF, Bueno OF, de Mello MT. Depression, anxiety and qua
lity    of life scores in seniors after an endurance exercise program. <i>Rev Br
as Psiquiatr</i>.    2005;27(4):266-71.    ^cY#aop0911.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#116#112#article#166#</font></
p>     ^cY#aop0911.htm##
00565000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704030600089002001200395#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#117#113#article#1
66#19#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Lawlor 
DA,    Hopker SW. The effectiveness of exercise as an intervention in the manage
ment    of depression: systematic review and meta-regression analysis of randomi
sed    controlled trials. <i>Br Med J</i>. 2001;322(7289):763-7.    ^cY#aop0911.
htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#118#114#article#166#</font></
p>     ^cY#aop0911.htm##
00483000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704022400089002001200313#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#119#115#article#1
66#20#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Martins
en EW,    Medhus A, Sandvik L. Effects of aerobic exercise on depression: a cont
rolled    study. <i>BMJ (Clin Res Ed).</i> 1985;291(6488):109.    ^cY#aop0911.ht
m##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#120#116#article#166#</font></
p>     ^cY#aop0911.htm##
00604000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704034500089002001200434#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#121#117#article#1
66#21#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Blument
hal    JA, Babyak MA, Moore KA, Craighead WE, Herman S, Khatri P, Waugh R, Napol
itano    MA, Forman LM, Appelbaum M, Doraiswamy PM, Krishnan KR. Effects of exer
cise    training on older patients with major depression. <i>Arch Intern Med</i>
. 1999;159(19):2349-56.    ^cY#aop0911.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#122#118#article#166#</font></
p>     ^cY#aop0911.htm##
00496000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704023700089002001200326#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#123#119#article#1
66#22#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">22. Cooper-
Patrick    L, Ford DE, Mead LA, Chang PP, Klag MJ. Exercise and depression in mi
dlife:    a prospective study. <i>Am J Public Health</i>. 1997;87(4):670-3.    ^
cY#aop0911.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#124#120#article#166#</font></
p>     ^cY#aop0911.htm##
00497000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704023800089002001200327#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#125#121#article#1
66#23#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">23. Dunn AL
, Trivedi    MH, Kampert JB, Clark CG, Chambliss HO. Exercise treatment for depr
ession: efficacy    and dose response. <i>Am J Prev Med</i>. 2005;28(1):1-8.    
^cY#aop0911.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#126#122#article#166#</font></
p>     ^cY#aop0911.htm##
00581000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704032200089002001200411#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#127#123#article#1
66#24#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">24. Babyak 
M, Blumenthal    JA, Herman S, Kathri P, Doraiswamy M, Moore K, Craighead WE, Ba
ldewicz TT, Krishnan    KR. Exercise treatment for major depression: maintenance
 of therapeutic benefit    at 10 months. <i>Psychosom Med</i>. 2000;62(5):633-8.
    ^cY#aop0911.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#128#124#article#166#</font></
p>     ^cY#aop0911.htm##
00545000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704028600089002001200375#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#129#125#article#1
66#25#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">25. Guimar&
atilde;es    MNJ, Caldas CP. A influ&ecirc;ncia da atividade f&iacute;sica nos q
uadros depressivos    de pessoas idosas: uma revis&atilde;o sistem&aacute;tica. 
<i>Rev Bras Epidemiol</i>.    2006;9:481-92.    ^cY#aop0911.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#130#126#article#166#</font></
p>     ^cY#aop0911.htm##
00513000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704025400089002001200343#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#131#127#article#1
66#26#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">26. Camacho
 TC,    Roberts RE, Lazarus NB, Kaplan GA, Cohen RD. Physical activity and depre
ssion:    evidence from the Alameda County Study. <i>Am J Epidemiol</i>. 1991;13
4(2):220-31.    ^cY#aop0911.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#132#128#article#166#</font></
p>     ^cY#aop0911.htm##
00545000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704028600089002001200375#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#133#129#article#1
66#27#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">27. Farmer 
ME,    Locke BZ, Moscicki EK, Dannenberg AL, Larson DB, Radloff LS. Physical act
ivity    and depressive symptoms: the NHANES I Epidemiologic Follow-up Study. <i
>Am J    Epidemiol</i>. 1988;128(6):1340-51.    ^cY#aop0911.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#134#130#article#166#</font></
p>     ^cY#aop0911.htm##
00510000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704025100089002001200340#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#135#131#article#1
66#28#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">28. Strawbr
idge    WJ, Deleger S, Roberts RE, Kaplan GA. Physical activity reduces the risk
 of    subsequent depression for older adults. <i>Am J Epidemiol</i>. 2002;156(4
):328-34.    ^cY#aop0911.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#136#132#article#166#</font></
p>     ^cY#aop0911.htm##
00492000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704023300089002001200322#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#137#133#article#1
66#29#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">29. Weyerer
 S.    Physical inactivity and depression in the community. Evidence from the Up
per    Bavarian Field Study. <i>Int J Sports Med</i>. 1992;13(6):492-6.    ^cY#a
op0911.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#138#134#article#166#</font></
p>     ^cY#aop0911.htm##
00550000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704029100089002001200380#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#139#135#article#1
66#30#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">30. Dalacor
te RR,    Reichert CL, Vieira JL. Metabolic syndrome and physical activity in so
uthern    Brazilian community-dwelling elders: a population-based, cross-section
al study.    <i>BMC Public Health</i>. 2009;9:25.    ^cY#aop0911.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#140#136#article#166#</font></
p>     ^cY#aop0911.htm##
00572000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704031300089002001200402#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#141#137#article#1
66#31#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">31. Institu
to Brasileiro    de Geografia e Estat&iacute;sitca (IBGE). Censo 2000 com divis&
atilde;o territorial    2001. &#91;cited 2009 Aug 24&#93;. Available from: <a hr
ef="http://www.ibge.gov.br" target="_blank">http://www.ibge.gov.br</a>.    ^cY#a
op0911.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#142#138#article#166#</font></
p>     ^cY#aop0911.htm##
00592000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704033300089002001200422#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#143#139#article#1
66#32#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">32. Craig C
L, Marshall    AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelu
nd U, Yngve    A, Sallis JF, Oja P. International physical activity questionnair
e: 12-country    reliability and validity. <i>Med Sci Sports Exerc</i>. 2003;35(
8):1381-95.    ^cY#aop0911.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#144#140#article#166#</font></
p>     ^cY#aop0911.htm##
00506000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704024700089002001200336#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#145#141#article#1
66#33#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">33. Interna
tional    Physical Activity Questionnaire. &#91;cited 2009 Aug 24&#93;. Availabl
e from:    <a href="http://www.ipaq.ki.se" target="_blank">http://www.ipaq.ki.se
</a>.    ^cY#aop0911.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#146#142#article#166#</font></
p>     ^cY#aop0911.htm##
00533000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704027400089002001200363#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#147#143#article#1
66#34#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">34. Almeida
 OP,    Almeida SA. &#91;Reliability of the Brazilian version of the ++abbreviat
ed form    of Geriatric Depression Scale (GDS) short form&#93;. <i>Arq Neuropsiq
uiatr</i>.    1999;57(2B):421-6.    ^cY#aop0911.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#148#144#article#166#</font></
p>     ^cY#aop0911.htm##
00426000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704016700089002001200256#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#149#145#article#1
66#35#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">35. Ewing J
A. Detecting    alcoholism. The CAGE questionnaire. <i>JAMA</i>. 1984;252(14):19
05-7.    ^cY#aop0911.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#150#146#article#166#</font></
p>     ^cY#aop0911.htm##
00623000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704036400089002001200453#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#151#147#article#1
66#36#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">36. Regier 
DA,    Farmer ME, Rae DS, Myers JK, Kramer M, Robins LN, George LK, Karno M, Loc
ke    BZ. One-month prevalence of mental disorders in the United States and soci
odemographic    characteristics: the Epidemiologic Catchment Area study. <i>Acta
 Psychiatr Scand</i>.    1993;88(1):35-47.    ^cY#aop0911.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#152#148#article#166#</font></
p>     ^cY#aop0911.htm##
00460000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704020100089002001200290#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#153#149#article#1
66#37#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">37. Veras R
P, Murphy    E. The mental health of older people in Rio de Janeiro. <i>Int J Ge
riatr Psychiatry</i>.    1994;9:285-95.    ^cY#aop0911.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#154#150#article#166#</font></
p>     ^cY#aop0911.htm##
00503000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704024400089002001200333#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#155#151#article#1
66#38#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">38. Barreto
 SM,    Kalache A, Giatti L. Does health status explain gender dissimilarity in 
healthcare    use among older adults? <i>Cad Saude Publica</i>. 2006;22(2):347-5
5.    ^cY#aop0911.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#156#152#article#166#</font></
p>     ^cY#aop0911.htm##
00494000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704023500089002001200324#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#157#153#article#1
66#39#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">39. McNeil 
JK,    LeBlanc EM, Joyner M. The effect of exercise on depressive symptoms in th
e moderately    depressed elderly. <i>Psychol Aging</i>. 1991;6(3):487-8.    ^cY
#aop0911.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#158#154#article#166#</font></
p>     ^cY#aop0911.htm##
00543000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704028400089002001200373#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#159#155#article#1
66#40#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">40. Fogelho
lm M,    Malmberg J, Suni J, Santtila M, Kyrolainen H, Mantysaari M, Oja P. Inte
rnational    Physical Activity Questionnaire: validity against fitness. <i>Med S
ci Sports    Exerc</i>. 2006;38(4):753-60.    ^cY#aop0911.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#160#156#article#166#</font></
p>     ^cY#aop0911.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#161#157#article#166#<p>&nbsp;
</p>     ^cY#aop0911.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#162#158#article#166#<p>&nbsp;
</p>     ^cY#aop0911.htm##
00436000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704019200086002001200278#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#163#159#article#166#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a href
="#top"><img src="/img/revistas/rbp/2011nahead/seta.jpg" border="0"></a>    <b> 
Correspondence:    ^cY#aop0911.htm##
00284000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704004000086002001200126#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#164#160#article#166#<br>   </
b> Roberta R. Dalacorte    ^cY#aop0911.htm##
00315000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704007100086002001200157#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#165#161#article#166#<br>   Av
enida Ipiranga, 6690 - Instituto de Geriatria da PUCRS    ^cY#aop0911.htm##
00293000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704004900086002001200135#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#166#162#article#166#<br>   91
530-001 Porto Alegre, RS, Brasil    ^cY#aop0911.htm##
00284000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704004000086002001200126#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#167#163#article#166#<br>   Ph
one: (+55 51) 3336-8153    ^cY#aop0911.htm##
00344000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704010000086002001200186#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#168#164#article#166#<br>   Em
ail: <a href="mailto:robertarigod@gmail.com">robertarigod@gmail.com</a></font></
p>     ^cY#aop0911.htm##
00345000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704010100086002001200187#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#169#165#article#166#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">Submitted: November    9, 
2009    ^cY#aop0911.htm##
00297000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704005300086002001200139#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#p#170#166#article#166#<br>   Ac
cepted: October 18, 2010</font></p>     ^cY#aop0911.htm##
00501000000000241000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830180038000850620026001230650
00900149064000500158110000900163109001200172037005400184865000900238002001200247
#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#c#171#1#article
#40#1#Active ageing: a policy framework^len#World Health Organization#20020000#2
002#20090824#2009 Aug 24#http://whqlibdoc.who.int/hq/2002/WHO_NMH_NPH_02.8.pdf#2
0110000#aop0911.htm##
00572000000000265000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100021000850120032001060180
03200138062002600170065000900196064000500205110000900210109001200219037005400231
865000900285002001200294#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop09
11.htm#S#c#172#2#article#40#2#^rND^sBrundtland^nGH#Ageing: Exploding the myths^l
en#Ageing and Health Programme^len#World Health Organization#19990000#1999#20090
824#2009 Aug 24#http://whqlibdoc.who.int/hq/1999/WHO_HSC_AHE_99.1.pdf#20110000#a
op0911.htm##
00656000000000325000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100017000850100016001020100
02200118010001600140010001400156010001700170012008900187030000900276710000200285
06500090028706400050029603100020030103200020030301400040030586500090030900200120
0318#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#c#173#3#art
icle#40#3#^rND^sRodgers^nA#^rND^sEzzati^nM#^rND^sVander Hoorn^nS#^rND^sLopez^nAD
#^rND^sLin^nRB#^rND^sMurray^nCJ#Distribution of major health risks: findings fro
m the Global Burden of Disease study^len#PLoS Med#2#20040000#2004#1#1#e27#201100
00#aop0911.htm##
00685000000000325000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100016000850100015001010100
01700116010002000133010001700153010001800170012010300188030001900291710000200310
06500090031206400050032103100030032603200020032901400070033186500090033800200120
0347#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#c#174#4#art
icle#40#4#^rND^sFleck^nMP#^rND^sLafer^nB#^rND^sSougey^nEB#^rND^sDel Porto^nJA#^r
ND^sBrasil^nMA#^rND^sJuruena^nMF#Guidelines of the Brazilian Medical Association
 for the treatment of depression (complete version)^len#Rev Bras Psiquiatr#2#200
30000#2003#25#2#114-22#20110000#aop0911.htm##
00688000000000349000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100022000850100016001070100
01900123010001900142010001800161010001500179010001600194012003900210030001600249
06500090026506400050027403100030027903200020028201400070028486500090029100200120
0300035001000312801001600322#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\a
op0911.htm#S#c#175#5#article#40#5#^rND^sAlexopoulos^nGS#^rND^sBorson^nS#^rND^sCu
thbert^nBN#^rND^sDevanand^nDP#^rND^sMulsant^nBH#^rND^sOlin^nJT#^rND^sOslin^nDW#A
ssessment of late life depression^len#Biol Psychiatry#20020000#2002#52#3#164-74#
20110000#aop0911.htm#0006-3223#Biol Psychiatry##
00583000000000289000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100017000850100015001020120
08200117030001800199065000900217064000500226031000300231032000200234014000800236
865000900244002001200253035001000265801001800275#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop0911.htm#S#c#176#6#article#40#6#^rND^sDuarte^nMB#^rND^sReg
o^nMA#Depression and clinical illness: comorbidity in a geriatric outpatient cli
nic^len#Cad Saude Publica#20070000#2007#23#3#691-700#20110000#aop0911.htm#0102-3
11X#Cad Saude Publica##
00685000000000325000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100016000850100018001010100
01800119010001900137010001500156012011500171030000800286065000900294064000500303
03100030030803200020031101400070031386500090032000200120032903500100034180100080
0351#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#c#177#7#art
icle#40#7#^rND^sBarry^nKL#^rND^sFleming^nMF#^rND^sManwell^nLB#^rND^sCopeland^nLA
#^rND^sAppel^nS#Prevalence of and factors associated with current and lifetime d
epression in older adult primary care patients^len#Fam Med#19980000#1998#30#5#36
6-71#20110000#aop0911.htm#0742-3225#Fam Med##
00751000000000337000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100023000850100018001080100
01800126010001700144010001900161010001900180010001900199012010800218030001600326
06500090034206400050035103100040035601400060036086500090036600200120037503500100
0387801001600397#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S
#c#178#8#article#40#8#^rND^sAlmeida-Filho^nN#^rND^sMari Jde^nJ#^rND^sCoutinho^nE
#^rND^sFranca^nJF#^rND^sFernandes^nJ#^rND^sAndreoli^nSB#^rND^sBusnello^nED#Brazi
lian multicentric study of psychiatric morbidity: Methodological features and pr
evalence estimates^len#Br J Psychiatry#19970000#1997#171#524-9#20110000#aop0911.
htm#0007-1250#Br J Psychiatry##
00491000000000265000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100017000850120057001020300
01900159710000200178065000900180064000500189031000300194032000200197014000500199
865000900204002001200213#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop09
11.htm#S#c#179#9#article#40#9#^rND^sSnowdon^nJ#How high is the prevalence of dep
ression in old age?^len#Rev Bras Psiquiatr#2#20020000#2002#24#1#42-7#20110000#ao
p0911.htm##
00649000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100017001040100
02100121010001700142012008600159030001600245065000900261064000500270031000400275
032000200279014000700281865000900288002001200297035001000309801001600319#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#c#180#10#article#40#10#
^rND^sBlazer^nDG#^rND^sHybels^nCF#^rND^sFillenbaum^nGG#^rND^sPieper^nCF#Predicto
rs of antidepressant use among older adults: have they changed over time?^len#Am
 J Psychiatry#20050000#2005#162#4#705-10#20110000#aop0911.htm#0002-953X#Am J Psy
chiatry##
00789000000000385000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100019001040100
01600123010002000139010001800159010001600177010001800193010001600211010002100227
01000170024801200710026503000050033606500090034106400050035003100040035503200020
0359014000600361865000900367002001200376035001000388801000500398#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#c#181#11#article#40#11#^rND^sMa
nini^nTM#^rND^sEverhart^nJE#^rND^sPatel^nKV#^rND^sSchoeller^nDA#^rND^sColbert^nL
H#^rND^sVisser^nM#^rND^sTylavsky^nF#^rND^sBauer^nDC#^rND^sGoodpaster^nBH#^rND^sH
arris^nTB#Daily activity energy expenditure and mortality among older adults^len
#JAMA#20060000#2006#296#2#171-9#20110000#aop0911.htm#0098-7484#JAMA##
00534000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100021000870120069001080300
01100177065000900188064000500197031000400202032000200206014000600208865000900214
002001200223035001000235801001100245#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop0911.htm#S#c#182#12#article#40#12#^rND^sPescatello^nLS#Exercising for 
health: the merits of lifestyle physical activity^len#West J Med#20010000#2001#1
74#2#114-8#20110000#aop0911.htm#0093-0415#West J Med##
00642000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100022000870100017001090100
01800126012010300144030001700247065000900264064000500273031000300278032000300281
014000800284865000900292002001200301035001000313801001700323#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop0911.htm#S#c#183#13#article#40#13#^rND^sWannam
ethee^nSG#^rND^sShaper^nAG#^rND^sWhincup^nPH#Modifiable lifestyle factors and th
e metabolic syndrome in older men: Effects of lifestyle changes^len#J Am Geriatr
 Soc#20060000#2006#54#12#1909-14#20110000#aop0911.htm#0002-8614#J Am Geriatr Soc
##
00635000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100027000870100015001140100
01500129010001600144012007600160030001300236065000900249064000500258031000400263
032000300267014000700270865000900277002001200286035001000298801001300308#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#c#184#14#article#40#14#
^rND^sPaffenbarger RS^nJr.#^rND^sHyde^nRT#^rND^sWing^nAL#^rND^sHsieh^nCC#Physica
l activity, all-cause mortality, and longevity of college alumni^len#N Engl J Me
d#19860000#1986#314#10#605-13#20110000#aop0911.htm#0028-4793#N Engl J Med##
00663000000000325000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100013001060100
01700119010001500136010001800151012008500169030001300254065000900267064000500276
03100040028103200020028501400060028786500090029300200120030203500100031480100130
0324#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#c#185#15#ar
ticle#40#15#^rND^sStampfer^nMJ#^rND^sHu^nFB#^rND^sManson^nJE#^rND^sRimm^nEB#^rND
^sWillett^nWC#Primary prevention of coronary heart disease in women through diet
 and lifestyle^len#N Engl J Med#20000000#2000#343#1#16-22#20110000#aop0911.htm#0
028-4793#N Engl J Med##
00707000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100017001030100
01500120010001900135010001600154010001900170010001700189012008100206030000500287
06500090029206400050030103100040030603200030031001400080031386500090032100200120
0330035001000342801000500352#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\a
op0911.htm#S#c#186#16#article#40#16#^rND^sGregg^nEW#^rND^sCauley^nJA#^rND^sStone
^nK#^rND^sThompson^nTJ#^rND^sBauer^nDC#^rND^sCummings^nSR#^rND^sEnsrud^nKE#Relat
ionship of changes in physical activity and mortality among older women^len#JAMA
#20030000#2003#289#18#2379-86#20110000#aop0911.htm#0098-7484#JAMA##
00661000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100027000870100024001140100
01700138012011500155030001500270065000900285064000500294031000400299032000200303
014000800305865000900313002001200322035001000334801001500344#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop0911.htm#S#c#187#17#article#40#17#^rND^sKritz-
Silverstein^nD#^rND^sBarrett-Connor^nE#^rND^sCorbeau^nC#Cross-sectional and pros
pective study of exercise and depressed mood in the elderly: the Rancho Bernardo
 study^len#Am J Epidemiol#20010000#2001#153#6#596-603#20110000#aop0911.htm#0002-
9262#Am J Epidemiol##
00654000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100017001050100
01700122010001600139010001900155012009800174030001900272710000200291065000900293
064000500302031000300307032000200310014000700312865000900319002001200328#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#c#188#18#article#40#18#
^rND^sAntunes^nHK#^rND^sStella^nSG#^rND^sSantos^nRF#^rND^sBueno^nOF#^rND^sde Mel
lo^nMT#Depression, anxiety and quality of life scores in seniors after an endura
nce exercise program^len#Rev Bras Psiquiatr#2#20050000#2005#27#4#266-71#20110000
#aop0911.htm##
00654000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100017001040120
16500121030000900286065000900295064000500304031000400309032000500313014000600318
865000900324002001200333035001000345801000900355#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop0911.htm#S#c#189#19#article#40#19#^rND^sLawlor^nDA#^rND^sH
opker^nSW#The effectiveness of exercise as an intervention in the management of 
depression: systematic review and meta-regression analysis of randomised control
led trials^len#Br Med J#20010000#2001#322#7289#763-7#20110000#aop0911.htm#0007-1
447#Br Med J##
00565000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100020000870100016001070100
01700123012006600140030001900206710000200225065000900227064000500236031000400241
032000500245014000400250865000900254002001200263#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop0911.htm#S#c#190#20#article#40#20#^rND^sMartinsen^nEW#^rND
^sMedhus^nA#^rND^sSandvik^nL#Effects of aerobic exercise on depression: a contro
lled study^len#BMJ (Clin Res Ed).#2#19850000#1985#291#6488#109#20110000#aop0911.
htm##
00880000000000409000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100021000870100017001080100
01600125010002000141010001600161010001600177010001500193010002100208010001700229
01000190024601000210026501000190028601200730030503000160037806500090039406400050
04030310004004080320003004120140008004158650009004230020012004320350010004448010
01600454#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#c#191#2
1#article#40#21#^rND^sBlumenthal^nJA#^rND^sBabyak^nMA#^rND^sMoore^nKA#^rND^sCrai
ghead^nWE#^rND^sHerman^nS#^rND^sKhatri^nP#^rND^sWaugh^nR#^rND^sNapolitano^nMA#^r
ND^sForman^nLM#^rND^sAppelbaum^nM#^rND^sDoraiswamy^nPM#^rND^sKrishnan^nKR#Effect
s of exercise training on older patients with major depression^len#Arch Intern M
ed#19990000#1999#159#19#2349-56#20110000#aop0911.htm#0003-9926#Arch Intern Med##
00652000000000325000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100024000870100015001110100
01500126010001600141010001500157012006000172030001900232065000900251064000500260
03100030026503200020026801400060027086500090027600200120028503500100029780100190
0307#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#c#192#22#ar
ticle#40#22#^rND^sCooper-Patrick^nL#^rND^sFord^nDE#^rND^sMead^nLA#^rND^sChang^nP
P#^rND^sKlag^nMJ#Exercise and depression in midlife: a prospective study^len#Am 
J Public Health#19970000#1997#87#4#670-3#20110000#aop0911.htm#0090-0036#Am J Pub
lic Health##
00648000000000325000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100015000870100018001020100
01800120010001600138010002000154012006600174030001400240065000900254064000500263
03100030026803200020027101400040027386500090027700200120028603500100029880100140
0308#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#c#193#23#ar
ticle#40#23#^rND^sDunn^nAL#^rND^sTrivedi^nMH#^rND^sKampert^nJB#^rND^sClark^nCG#^
rND^sChambliss^nHO#Exercise treatment for depression: efficacy and dose response
^len#Am J Prev Med#20050000#2005#28#1#1-8#20110000#aop0911.htm#0749-3797#Am J Pr
ev Med##
00801000000000373000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100021001030100
01600124010001600140010002000156010001500176010002000191010002000211010001900231
01200930025003000140034306500090035706400050036603100030037103200020037401400060
0376865000900382002001200391035001000403801001400413#2011nahead#V:\SciELO\serial
\rbp\2011nahead\markup\aop0911.htm#S#c#194#24#article#40#24#^rND^sBabyak^nM#^rND
^sBlumenthal^nJA#^rND^sHerman^nS#^rND^sKathri^nP#^rND^sDoraiswamy^nM#^rND^sMoore
^nK#^rND^sCraighead^nWE#^rND^sBaldewicz^nTT#^rND^sKrishnan^nKR#Exercise treatmen
t for major depression: maintenance of therapeutic benefit at 10 months^len#Psyc
hosom Med#20000000#2000#62#5#633-8#20110000#aop0911.htm#0033-3174#Psychosom Med#
#
00560000000000265000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100021000870100017001080120
10400125030001900229710000200248065000900250064000500259031000200264014000700266
865000900273002001200282#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop09
11.htm#S#c#195#25#article#40#25#^rND^sGuimarães^nMNJ#^rND^sCaldas^nCP#A influênc
ia da atividade física nos quadros depressivos de pessoas idosas: uma revisão si
stemática^lpt#Rev Bras Epidemiol#2#20060000#2006#9#481-92#20110000#aop0911.htm##
00665000000000325000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100018001050100
01800123010001700141010001600158012007700174030001500251065000900266064000500275
03100040028003200020028401400070028686500090029300200120030203500100031480100150
0324#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#c#196#26#ar
ticle#40#26#^rND^sCamacho^nTC#^rND^sRoberts^nRE#^rND^sLazarus^nNB#^rND^sKaplan^n
GA#^rND^sCohen^nRD#Physical activity and depression: evidence from the Alameda C
ounty Study^len#Am J Epidemiol#19910000#1991#134#2#220-31#20110000#aop0911.htm#0
002-9262#Am J Epidemiol##
00712000000000337000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100016001040100
01900120010002100139010001700160010001800177012009000195030001500285065000900300
06400050030903100040031403200020031801400080032086500090032800200120033703500100
0349801001500359#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S
#c#197#27#article#40#27#^rND^sFarmer^nME#^rND^sLocke^nBZ#^rND^sMoscicki^nEK#^rND
^sDannenberg^nAL#^rND^sLarson^nDB#^rND^sRadloff^nLS#Physical activity and depres
sive symptoms: the NHANES I Epidemiologic Follow-up Study^len#Am J Epidemiol#198
80000#1988#128#6#1340-51#20110000#aop0911.htm#0002-9262#Am J Epidemiol##
00644000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100022000870100017001090100
01800126010001700144012008100161030001500242065000900257064000500266031000400271
032000200275014000700277865000900284002001200293035001000305801001500315#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#c#198#28#article#40#28#
^rND^sStrawbridge^nWJ#^rND^sDeleger^nS#^rND^sRoberts^nRE#^rND^sKaplan^nGA#Physic
al activity reduces the risk of subsequent depression for older adults^len#Am J 
Epidemiol#20020000#2002#156#4#328-34#20110000#aop0911.htm#0002-9262#Am J Epidemi
ol##
00574000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870120102001040300
01700206065000900223064000500232031000300237032000200240014000600242865000900248
002001200257035001000269801001700279#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop0911.htm#S#c#199#29#article#40#29#^rND^sWeyerer^nS#Physical inactivity
 and depression in the community: Evidence from the Upper Bavarian Field Study^l
en#Int J Sports Med#19920000#1992#13#6#492-6#20110000#aop0911.htm#0172-4622#Int 
J sports Med##
00617000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100020000870100019001070100
01700126012013600143030001800279710000200297065000900299064000500308031000200313
014000300315865000900318002001200327#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop0911.htm#S#c#200#30#article#40#30#^rND^sDalacorte^nRR#^rND^sReichert^n
CL#^rND^sVieira^nJL#Metabolic syndrome and physical activity in southern Brazili
an community-dwelling elders: a population-based, cross-sectional study^len#BMC 
Public Health#2#20090000#2009#9#25#20110000#aop0911.htm##
00476000000000217000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840160062000870180044001491100
00900193109001200202037002300214865000900237002001200246#2011nahead#V:\SciELO\se
rial\rbp\2011nahead\markup\aop0911.htm#S#c#201#31#article#40#31#^rND^sInstituto 
Brasileiro de Geografia e Estatísitca^n(IBGE)#Censo 2000 com divisão territorial
 2001^lpt#20090824#2009 Aug 24#http://www.ibge.gov.br#20110000#aop0911.htm##
00855000000000397000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100019001030100
01800122010001700140010001600157010002000173010001500193010001700208010001500225
01000170024001000130025701200870027003000210035706500090037806400050038703100030
0392032000200395014000800397865000900405002001200414035001000426801002100436#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop0911.htm#S#c#202#32#article#40
#32#^rND^sCraig^nCL#^rND^sMarshall^nAL#^rND^sSjostrom^nM#^rND^sBauman^nAE#^rND^s
Booth^nML#^rND^sAinsworth^nBE#^rND^sPratt^nM#^rND^sEkelund^nU#^rND^sYngve^nA#^rN
D^sSallis^nJF#^rND^sOja^nP#International physical activity questionnaire: 12-cou
ntry reliability and validity^len#Med Sci Sports Exerc#20030000#2003#35#8#1381-9
5#20110000#aop0911.htm#0195-9131#Med Sci Sports Exerc##
00403000000000205000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840170046000871100009001331090
01200142037002200154865000900176002001200185#2011nahead#V:\SciELO\serial\rbp\201
1nahead\markup\aop0911.htm#S#c#203#33#article#40#33#International Physical Activ
ity Questionnaire#20090824#2009 Aug 24#http://www.ipaq.ki.se#20110000#aop0911.ht
m##
00624000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100018001050120
11600123030001900239065000900258064000500267031000300272032000300275014000600278
865000900284002001200293035001000305801001900315#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop0911.htm#S#c#204#34#article#40#34#^rND^sAlmeida^nOP#^rND^s
Almeida^nSA#[Reliability of the Brazilian version of the ++abbreviated form of G
eriatric Depression Scale (GDS) short form]^len#Arq Neuropsiquiatr#19990000#1999
#57#2B#421-6#20110000#aop0911.htm#0004-282X#Arq Neuropsiquiatr##
00499000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870120049001030300
00500152065000900157064000500166031000400171032000300175014000700178865000900185
002001200194035001000206801000500216#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop0911.htm#S#c#205#35#article#40#35#^rND^sEwing^nJA#Detecting alcoholism
: The CAGE questionnaire^len#JAMA#19840000#1984#252#14#1905-7#20110000#aop0911.h
tm#0098-7484#JAMA##
00847000000000373000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100017001040100
01400121010001600135010001600151010001700167010001700184010001500201010001600216
01201430023203000210037506500090039606400050040503100030041003200020041301400060
0415865000900421002001200430035001000442801002100452#2011nahead#V:\SciELO\serial
\rbp\2011nahead\markup\aop0911.htm#S#c#206#36#article#40#36#^rND^sRegier^nDA#^rN
D^sFarmer^nME#^rND^sRae^nDS#^rND^sMyers^nJK#^rND^sKramer^nM#^rND^sRobins^nLN#^rN
D^sGeorge^nLK#^rND^sKarno^nM#^rND^sLocke^nBZ#One-month prevalence of mental diso
rders in the United States and sociodemographic characteristics: the Epidemiolog
ic Catchment Area study^len#Acta Psychiatr Scand#19930000#1993#88#1#35-47#201100
00#aop0911.htm#0001-690X#Acta Psychiatr Scand##
00557000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100016001030120
05600119030002500175065000900200064000500209031000200214014000700216865000900223
002001200232035001000244801002500254#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop0911.htm#S#c#207#37#article#40#37#^rND^sVeras^nRP#^rND^sMurphy^nE#The 
mental health of older people in Rio de Janeiro^len#Int J Geriatr Psychiatry#199
40000#1994#9#285-95#20110000#aop0911.htm#0885-6230#Int J Geriatr Psychiatry##
00623000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100017001050100
01600122012009000138030001800228065000900246064000500255031000300260032000200263
014000700265865000900272002001200281035001000293801001800303#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop0911.htm#S#c#208#38#article#40#38#^rND^sBarret
o^nSM#^rND^sKalache^nA#^rND^sGiatti^nL#Does health status explain gender dissimi
larity in healthcare use among older adults?^len#Cad Saude Publica#20060000#2006
#22#2#347-55#20110000#aop0911.htm#0102-311X#Cad Saude Publica##
00609000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100018001040100
01600122012008600138030001400224065000900238064000500247031000200252032000200254
014000600256865000900262002001200271035001000283801001400293#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop0911.htm#S#c#209#39#article#40#39#^rND^sMcNeil
^nJK#^rND^sLeBlanc^nEM#^rND^sJoyner^nM#The effect of exercise on depressive symp
toms in the moderately depressed elderly^len#Psychol Aging#19910000#1991#6#3#487
-8#20110000#aop0911.htm#0882-7974#Psychol Aging##
00734000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100018001060100
01400124010001800138010002000156010002000176010001300196012007600209030002100285
06500090030606400050031503100030032003200020032301400070032586500090033200200120
0341035001000353801002100363#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\a
op0911.htm#S#c#210#40#article#40#40#^rND^sFogelholm^nM#^rND^sMalmberg^nJ#^rND^sS
uni^nJ#^rND^sSanttila^nM#^rND^sKyrolainen^nH#^rND^sMantysaari^nM#^rND^sOja^nP#In
ternational Physical Activity Questionnaire: validity against fitness^len#Med Sc
i Sports Exerc#20060000#2006#38#4#753-60#20110000#aop0911.htm#0195-9131#Med Sci 
Sports Exerc##
00282000000000169000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780910009000800920007000890020012000967030
00400108#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#o#1#1#a
rticle#1#20110408#161708#aop1011.htm#225##
04639000000000649000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780710003000800400003000830010006000860420
00200092120000400094038000400098121000300102049000300105158000300108030002200111
03200060013306500090013901400070014803500100015522300090016501200740017401200870
02480100026003350100029003610100032003900700115004220700143005370700091006800831
40400771085001002175085002102185085002302206085003302229085001902262085002502281
08314700230608500100377608500220378608500250380808500330383308500190386608500290
38851170008039140720003039221120009039251110015039341140009039491130019039580020
01203977#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#h#2#1#a
rticle#1#tr#en#br1.1#1#4.0#TAB#11#nd#nd#Rev. Bras. Psiquiatr.#ahead#20110000#^f0
^l0#1516-4446#20110415#Exposure to violence in incarcerated youth from the city 
of São Paulo^len#Exposição à violência entre jovens da cidade de São Paulo em pr
ivação de liberdade^lpt#^rND^1A01^nSusan^sHuculak#^rND^1A02^nJohn D.^sMcLennan#^
rND^1A03^nIsabel A. S.^sBordin#University of Calgary^iA01^1Faculty of Medicine^2
Department of Community Health Sciences^cCalgary^sAlberta^pCanada#University of 
Calgary^iA02^1Faculty of Medicine^2Departments of Community Health Sciences, Psy
chiatry and Pediatrics^cCalgary^sAlberta^pCanada#Universidade Federal de São Pau
lo^iA03^1Departamento de Psiquiatria^cSão Paulo^sSP^pBrazil#^len^aOBJECTIVE: Thi
s study aimed to determine the extent of exposure to community violence among de
linquent Brazilian youth in the 12-month period prior to their incarceration and
 to identify factors associated with this exposure. METHOD: With an oversampling
 of girls, a cross-section of youth under 18 years of age from juvenile detentio
n units in the city of São Paulo, Brazil completed a structured interview. Key i
tems related to exposure to violence (witnessed and experienced) were drawn from
 the Social and Health Assessment questionnaire to cover the 12-month period pri
or to incarceration. RESULTS: Participants (n = 325, 89% boys) reported high rat
es of exposure to violence with largely similar levels for boys and girls. Being
 threatened with physical harm, being beaten or mugged and/ or shot at were the 
most common forms of violence experienced. After controlling for demographic and
 family variables, the fact of having peers involved in risk behavior, easy acce
ss to guns and previous involvement with the justice system were associated with
 witnessed violence; whereas having slept on the street was the only variable as
sociated with experienced violence. CONCLUSION: This group of youth was exposed 
to high levels of violence and other adverse experiences. Future research should
 examine the effectiveness of strategies aimed at reducing the exposure to viole
nce of high-risk youth.#^ddecs^i1#^tm^len^kViolence^i1#^tm^len^kAdolescent^i1#^t
m^len^kJuvenile delinquency^i1#^tm^len^kBrazil^i1#^tm^len^kHuman rights^i1#^lpt^
aOBJETIVO: Esse estudo procurou determinar a extensão da exposição à violência n
a comunidade entre jovens brasileiros delinquentes nos 12 meses que antecederam 
sua privação de liberdade e identificar fatores associados a essa exposição. MÉT
ODO: Um corte transversal de menores de 18 anos internados em unidades da Fundaç
ão Casa/ex-FEBEM na cidade de São Paulo, Brasil (com meninas superamostradas) pa
rticipou de entrevista estruturada. Itens-chave sobre exposição à violência (tes
temunhada e vivenciada) foram retirados do questionário Social and Health Assess
ment para cobrir o período de 12 meses anterior à internação. RESULTADOS: Os par
ticipantes (n = 325, 89% meninos) referiram altas taxas de exposição à violência
, taxas estas muito similares entre meninos e meninas. Ter sofrido ameaças de le
são física, ter sido espancado ou assaltado e/ou baleado foram as formas mais co
muns de violência vivenciada. Após controlar por fatores sociodemográficos e fam
iliares, o relacionamento com jovens envolvidos em comportamentos de risco, o fá
cil acesso a armas de fogo e a passagem prévia pela Justiça estiveram associados
 à violência testemunhada, enquanto ter dormido na rua foi o único fator associa
do à violência vivenciada. CONCLUSÃO: Esse grupo de jovens foi exposto a altos n
íveis de violência e a outras experiências adversas. Pesquisas futuras devem exa
minar a efetividade de estratégias que visem reduzir a exposição à violência ent
re jovens de alto risco.#^ddecs^i2#^tm^lpt^kViolência^i2#^tm^lpt^kAdolescência^i
2#^tm^lpt^kDelinquência juvenil^i2#^tm^lpt^kBrasil^i2#^tm^lpt^kDireitos humanos^
i2#vancouv#39#20100427#April 27, 2010#20100927#September 27, 2010#aop1011.htm##
04717000000000649000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780710003000800400003000830010006000860420
00200092120000400094038000400098121000300102049000300105158000300108030002200111
03200060013306500090013901400070014803500100015522300090016501200810017401200940
02550100026003490100029003750100032004040700115004360700143005510700091006940831
43200785085001002217085002102227085002302248085003302271085001902304085002502323
08315060234808500100385408500220386408500250388608500330391108500190394408500290
39631170008039920720003040001120009040031110015040121140009040271130019040360020
01204055#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#f#3#1#a
rticle#1#tr#en#br1.1#1#4.0#TAB#11#nd#nd#Rev. Bras. Psiquiatr.#ahead#20110000#^f0
^l0#1516-4446#20110415#<b>Exposure to violence in incarcerated youth from the ci
ty of São Paulo</b>^len#<b>Exposição à violência entre jovens da cidade de São P
aulo em privação de liberdade</b>^lpt#^rND^1A01^nSusan^sHuculak#^rND^1A02^nJohn 
D.^sMcLennan#^rND^1A03^nIsabel A. S.^sBordin#University of Calgary^iA01^1Faculty
 of Medicine^2Department of Community Health Sciences^cCalgary^sAlberta^pCanada#
University of Calgary^iA02^1Faculty of Medicine^2Departments of Community Health
 Sciences, Psychiatry and Pediatrics^cCalgary^sAlberta^pCanada#Universidade Fede
ral de São Paulo^iA03^1Departamento de Psiquiatria^cSão Paulo^sSP^pBrazil#^len^a
<b>OBJECTIVE: </b>This study aimed to determine the extent of exposure to commun
ity violence among delinquent Brazilian youth in the 12-month period prior to th
eir incarceration and to identify factors associated with this exposure. <b>METH
OD: </b>With an oversampling of girls, a cross-section of youth under 18 years o
f age from juvenile detention units in the city of São Paulo, Brazil completed a
 structured interview. Key items related to exposure to violence (witnessed and 
experienced) were drawn from the Social and Health Assessment questionnaire to c
over the 12-month period prior to incarceration. <b>RESULTS: </b>Participants (n
 = 325, 89% boys) reported high rates of exposure to violence with largely simil
ar levels for boys and girls. Being threatened with physical harm, being beaten 
or mugged and/ or shot at were the most common forms of violence experienced. Af
ter controlling for demographic and family variables, the fact of having peers i
nvolved in risk behavior, easy access to guns and previous involvement with the 
justice system were associated with witnessed violence; whereas having slept on 
the street was the only variable associated with experienced violence. <b>CONCLU
SION: </b>This group of youth was exposed to high levels of violence and other a
dverse experiences. Future research should examine the effectiveness of strategi
es aimed at reducing the exposure to violence of high-risk youth.#^ddecs^i1#^tm^
len^kViolence^i1#^tm^len^kAdolescent^i1#^tm^len^kJuvenile delinquency^i1#^tm^len
^kBrazil^i1#^tm^len^kHuman rights^i1#^lpt^a<b>OBJETIVO: </b>Esse estudo procurou
 determinar a extensão da exposição à violência na comunidade entre jovens brasi
leiros delinquentes nos 12 meses que antecederam sua privação de liberdade e ide
ntificar fatores associados a essa exposição. <b>MÉTODO: </b>Um corte transversa
l de menores de 18 anos internados em unidades da Fundação Casa/ex-FEBEM na cida
de de São Paulo, Brasil (com meninas superamostradas) participou de entrevista e
struturada. Itens-chave sobre exposição à violência (testemunhada e vivenciada) 
foram retirados do questionário<i> Social and Health Assessment</i> para cobrir 
o período de 12 meses anterior à internação. <b>RESULTADOS: </b>Os participantes
 (n = 325, 89% meninos) referiram altas taxas de exposição à violência, taxas es
tas muito similares entre meninos e meninas. Ter sofrido ameaças de lesão física
, ter sido espancado ou assaltado e/ou baleado foram as formas mais comuns de vi
olência vivenciada. Após controlar por fatores sociodemográficos e familiares, o
 relacionamento com jovens envolvidos em comportamentos de risco, o fácil acesso
 a armas de fogo e a passagem prévia pela Justiça estiveram associados à violênc
ia testemunhada, enquanto ter dormido na rua foi o único fator associado à violê
ncia vivenciada. <b> CONCLUSÃO: </b>Esse grupo de jovens foi exposto a altos nív
eis de violência e a outras experiências adversas. Pesquisas futuras devem exami
nar a efetividade de estratégias que visem reduzir a exposição à violência entre
 jovens de alto risco.#^ddecs^i2#^tm^lpt^kViolência^i2#^tm^lpt^kAdolescência^i2#
^tm^lpt^kDelinquência juvenil^i2#^tm^lpt^kBrasil^i2#^tm^lpt^kDireitos humanos^i2
#vancouv#39#20100427#April 27, 2010#20100927#September 27, 2010#aop1011.htm##
04778000000000673000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780640007000800710003000870400003000900010
00600093042000200099120000400101038000400105121000300109049000300112158000300115
03000210011803200060013906500090014501400070015403500100016122300090017101200740
01800120087002540100026003410100028003670100031003950700117004260700145005430700
09300688083141100781085001002192085002102202085002302223085003302246085001902279
08500250229808314790232308500100380208500220381208500250383408500330385908500190
38920850029039111170008039400720003039481120009039511110015039601140009039751130
01903984002001204003008008904015#2011nahead#V:\SciELO\serial\rbp\2011nahead\mark
up\aop1011.htm#S#l#4#1#article#1#^a2011#tr#en#br1.1#1#4.0#tab#11#nd#nd#Rev. bras
. psiquiatr#ahead#20110000#^f0^l0#1516-4446#20110415#Exposure to violence in inc
arcerated youth from the city of São Paulo^len#Exposição à violência entre joven
s da cidade de São Paulo em privação de liberdade^lpt#^rND^1A01^nSusan^sHuculak#
^rND^1A02^nJohn D^sMcLennan#^rND^1A03^nIsabel A. S^sBordin#^iA01^1University of 
Calgary^2Faculty of Medicine^3Department of Community Health Sciences^cCalgary^s
Alberta^pCanada#^iA02^1University of Calgary^2Faculty of Medicine^3Departments o
f Community Health Sciences, Psychiatry and Pediatrics^cCalgary^sAlberta^pCanada
#^iA03^1Universidade Federal de São Paulo^2Departamento de Psiquiatria^cSão Paul
o^sSP^pBrazil#^len^aOBJECTIVE: This study aimed to determine the extent of expos
ure to community violence among delinquent Brazilian youth in the 12-month perio
d prior to their incarceration and to identify factors associated with this expo
sure. METHOD: With an oversampling of girls, a cross-section of youth under 18 y
ears of age from juvenile detention units in the city of São Paulo, Brazil compl
eted a structured interview. Key items related to exposure to violence (witnesse
d and experienced) were drawn from the Social and Health Assessment questionnair
e to cover the 12-month period prior to incarceration. RESULTS: Participants (n 
= 325, 89 percent boys) reported high rates of exposure to violence with largely
 similar levels for boys and girls. Being threatened with physical harm, being b
eaten or mugged and/ or shot at were the most common forms of violence experienc
ed. After controlling for demographic and family variables, the fact of having p
eers involved in risk behavior, easy access to guns and previous involvement wit
h the justice system were associated with witnessed violence; whereas having sle
pt on the street was the only variable associated with experienced violence. CON
CLUSION: This group of youth was exposed to high levels of violence and other ad
verse experiences. Future research should examine the effectiveness of strategie
s aimed at reducing the exposure to violence of high-risk youth.#^ddecs^i1#^tm^l
en^kViolence^i1#^tm^len^kAdolescent^i1#^tm^len^kJuvenile delinquency^i1#^tm^len^
kBrazil^i1#^tm^len^kHuman rights^i1#^lpt^aOBJETIVO: Esse estudo procurou determi
nar a extensão da exposição à violência na comunidade entre jovens brasileiros d
elinquentes nos 12 meses que antecederam sua privação de liberdade e identificar
 fatores associados a essa exposição. MÉTODO: Um corte transversal de menores de
 18 anos internados em unidades da Fundação Casa/ex-FEBEM na cidade de São Paulo
, Brasil (com meninas superamostradas) participou de entrevista estruturada. Ite
ns-chave sobre exposição à violência (testemunhada e vivenciada) foram retirados
 do questionário Social and Health Assessment para cobrir o período de 12 meses 
anterior à internação. RESULTADOS: Os participantes (n = 325, 89 por cento menin
os) referiram altas taxas de exposição à violência, taxas estas muito similares 
entre meninos e meninas. Ter sofrido ameaças de lesão física, ter sido espancado
 ou assaltado e/ou baleado foram as formas mais comuns de violência vivenciada. 
Após controlar por fatores sociodemográficos e familiares, o relacionamento com 
jovens envolvidos em comportamentos de risco, o fácil acesso a armas de fogo e a
 passagem prévia pela Justiça estiveram associados à violência testemunhada, enq
uanto ter dormido na rua foi o único fator associado à violência vivenciada. CON
CLUSÃO: Esse grupo de jovens foi exposto a altos níveis de violência e a outras 
experiências adversas. Pesquisas futuras devem examinar a efetividade de estraté
gias que visem reduzir a exposição à violência entre jovens de alto risco.#^ddec
s^i2#^tm^lpt^kViolência^i2#^tm^lpt^kAdolescência^i2#^tm^lpt^kDelinquência juveni
l^i2#^tm^lpt^kBrasil^i2#^tm^lpt^kDireitos humanos^i2#vancouv#39#20100427#April 2
7, 2010#20100927#September 27, 2010#aop1011.htm#Internet^ihttp://www.scielo.br/s
cielo.php?script=sci_arttext&pid=S1516-44462011005000011##
00403000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704016300082002001200245#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#5#1#article#182#<p><font size
="4" face="verdana"><b><a name="title"></a>Exposure to violence       in incarce
rated youth from the city of S&atilde;o Paulo </b></font></p>     ^cY#aop1011.ht
m##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#6#2#article#182#<p>&nbsp;</p>
     ^cY#aop1011.htm##
00443000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704020300082002001200285#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#7#3#article#182#<p><font size
="3" face="verdana"><b>Exposi&ccedil;&atilde;o &agrave; viol&ecirc;ncia       en
tre jovens da cidade de S&atilde;o Paulo em priva&ccedil;&atilde;o de       libe
rdade </b></font></p>     ^cY#aop1011.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#8#4#article#182#<p>&nbsp;</p>
     ^cY#aop1011.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#9#5#article#182#<p>&nbsp;</p>
     ^cY#aop1011.htm##
00398000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704015700083002001200240#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#10#6#article#182#<p><font siz
e="2" face="Verdana"><b>Susan Huculak<Sup>I</Sup>; John D. McLennan<Sup>II</Sup>
;       Isabel A. S. Bordin<Sup>III</Sup></b></font></p>     ^cY#aop1011.htm##
00407000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704016600083002001200249#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#11#7#article#182#<p><font siz
e="2" face="Verdana"><Sup>I</Sup>Department of Community Health Sciences,     Fa
culty of Medicine, University of Calgary, Calgary, Alberta, Canada    ^cY#aop101
1.htm##
00408000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704016700083002001200250#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#12#8#article#182#<br>   <Sup>
II</Sup>Departments of Community Health Sciences, Psychiatry and Pediatrics,   F
aculty of Medicine, University of Calgary, Calgary, Alberta, Canada    ^cY#aop10
11.htm##
00394000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704015300083002001200236#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#13#9#article#182#<br>   <Sup>
III</Sup>Departamento de Psiquiatria, Universidade Federal de S&atilde;o   Paulo
 (UNIFESP), S&atilde;o Paulo, SP, Brazil </font></p>     ^cY#aop1011.htm##
00328000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008600084002001200170#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#14#10#article#182#<p><font si
ze="2" face="Verdana"><a href="#end">Correspondence</a></font></p>     ^cY#aop10
11.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#15#11#article#182#<p>&nbsp;</
p>     ^cY#aop1011.htm##
00286000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704004400084002001200128#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#16#12#article#182#<p>&nbsp;</
p> <hr size="1" noshade>     ^cY#aop1011.htm##
00311000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704006900084002001200153#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#17#13#article#182#<p><font si
ze="2" face="Verdana"><b>ABSTRACT</b></font> </p>     ^cY#aop1011.htm##
00532000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704029000084002001200374#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#18#14#article#182#<p><font si
ze="2" face="Verdana"><B>OBJECTIVE: </B>This study aimed to determine     the ex
tent of exposure to community violence among delinquent Brazilian youth     in t
he 12&#45;month period prior to their incarceration and to identify factors     
associated with this exposure.     ^cY#aop1011.htm##
00655000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704041300084002001200497#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#19#15#article#182#<br>   <B>M
ETHOD: </B>With an oversampling of girls, a cross&#45;section of youth under   1
8 years of age from juvenile detention units in the city of S&atilde;o Paulo,   
Brazil completed a structured interview. Key items related to exposure to violen
ce   (witnessed and experienced) were drawn from the Social and Health Assessmen
t   questionnaire to cover the 12&#45;month period prior to incarceration.    ^c
Y#aop1011.htm##
00853000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704061100084002001200695#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#20#16#article#182#<br>   <B>R
ESULTS: </B>Participants (n = 325, 89% boys) reported high rates of exposure   t
o violence with largely similar levels for boys and girls. Being threatened   wi
th physical harm, being beaten or mugged and/ or shot at were the most common   
forms of violence experienced. After controlling for demographic and family   va
riables, the fact of having peers involved in risk behavior, easy access   to gu
ns and previous involvement with the justice system were associated with   witne
ssed violence; whereas having slept on the street was the only variable   associ
ated with experienced violence.     ^cY#aop1011.htm##
00512000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704027000084002001200354#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#21#17#article#182#<br>   <B>C
ONCLUSION: </B>This group of youth was exposed to high levels of violence   and 
other adverse experiences. Future research should examine the effectiveness   of
 strategies aimed at reducing the exposure to violence of high&#45;risk youth. <
/font></p>     ^cY#aop1011.htm##
00457000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704021500084002001200299#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#22#18#article#182#<p><font si
ze="2" face="Verdana"><B>Descriptors: </B>Violence; Adolescent; Juvenile     del
inquency; Brazil; Human rights </font></p> <hr size="1" noshade> <b><font size="
2" face="VERDANA">RESUMO</font></b>     ^cY#aop1011.htm##
00604000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704036200084002001200446#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#23#19#article#182#<p><font si
ze="2" face="Verdana"><B>OBJETIVO: </B>Esse estudo procurou determinar     a ext
ens&atilde;o da exposi&ccedil;&atilde;o &agrave; viol&ecirc;ncia na     comunida
de entre jovens brasileiros delinquentes nos 12 meses que antecederam     sua pr
iva&ccedil;&atilde;o de liberdade e identificar fatores associados     a essa ex
posi&ccedil;&atilde;o.     ^cY#aop1011.htm##
00764000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704052200084002001200606#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#24#20#article#182#<br>   <B>M
&Eacute;TODO: </B>Um corte transversal de menores de 18 anos internados   em uni
dades da Funda&ccedil;&atilde;o Casa/ex&#45;FEBEM na cidade de S&atilde;o   Paul
o, Brasil (com meninas superamostradas) participou de entrevista estruturada.   
Itens&#45;chave sobre exposi&ccedil;&atilde;o &agrave; viol&ecirc;ncia (testemun
hada   e vivenciada) foram retirados do question&aacute;rio<I> Social and Health
 Assessment</I> para   cobrir o per&iacute;odo de 12 meses anterior &agrave; int
erna&ccedil;&atilde;o.     ^cY#aop1011.htm##
01012000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704077000084002001200854#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#25#21#article#182#<br>   <B>R
ESULTADOS: </B>Os participantes (n = 325, 89% meninos) referiram altas   taxas d
e exposi&ccedil;&atilde;o &agrave; viol&ecirc;ncia, taxas estas muito   similare
s entre meninos e meninas. Ter sofrido amea&ccedil;as de les&atilde;o   f&iacute
;sica, ter sido espancado ou assaltado e/ou baleado foram as formas   mais comun
s de viol&ecirc;ncia vivenciada. Ap&oacute;s controlar por fatores   sociodemogr
&aacute;ficos e familiares, o relacionamento com jovens envolvidos   em comporta
mentos de risco, o f&aacute;cil acesso a armas de fogo e a passagem   pr&eacute;
via pela Justi&ccedil;a estiveram associados &agrave; viol&ecirc;ncia   testemun
hada, enquanto ter dormido na rua foi o &uacute;nico fator associado &agrave; vi
ol&ecirc;ncia   vivenciada. <B>    ^cY#aop1011.htm##
00577000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704033500084002001200419#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#26#22#article#182#<br>   CONC
LUS&Atilde;O: </B>Esse grupo de jovens foi exposto a altos n&iacute;veis   de vi
ol&ecirc;ncia e a outras experi&ecirc;ncias adversas. Pesquisas futuras   devem 
examinar a efetividade de estrat&eacute;gias que visem reduzir a exposi&ccedil;&
atilde;o &agrave; viol&ecirc;ncia   entre jovens de alto risco. </font></p>     
^cY#aop1011.htm##
00431000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704018900084002001200273#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#27#23#article#182#<p><font si
ze="2" face="Verdana"><B>Descritores: </B>Viol&ecirc;ncia; Adolesc&ecirc;ncia;  
   Delinqu&ecirc;ncia juvenil; Brasil; Direitos humanos </font></p> <hr size="1"
 noshade>     ^cY#aop1011.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#28#24#article#182#<p>&nbsp;</
p>     ^cY#aop1011.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#29#25#article#182#<p>&nbsp;</
p>     ^cY#aop1011.htm##
00314000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007200084002001200156#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#30#26#article#182#<p><font si
ze="3" face="Verdana"><B>Introduction</B></font></p>     ^cY#aop1011.htm##
01158000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704091600084002001201000#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#31#27#article#182#<p><font si
ze="2" face="Verdana">Exposure to violence represents a violation     under the 
United Nations Convention on the Rights of the Child.<Sup>1 </Sup>In     additio
n to identifying protection and care factors for the well&#45;being of     child
ren and youth in the Convention, there are explicit articles addressing     viol
ence both at home and in the general society. In addition to acknowledging     t
he violation of these rights, studies show that children and youth exposed     t
o violence are at a heightened risk for several negative outcomes including     
violent or aggressive behavior and delinquency,<Sup>2&#45;4 </Sup>mental health 
    problems such as post&#45;traumatic stress disorder, substance use, anxiety 
and     depression,<Sup>2,5&#45;7 </Sup>academic problems,<Sup>8 </Sup>cognitive
 impairments,<Sup>9 </Sup>and     criminal offenses in early adulthood.<Sup>10 <
/Sup></font></p>     ^cY#aop1011.htm##
01491000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704124900084002001201333#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#32#28#article#182#<p><font si
ze="2" face="Verdana">There are a number of reports on exposure to     violence 
of typical and high&#45;risk youth in high&#45;income countries, particularly   
  the United States,<Sup>11&#45;16 </Sup>however, much less information is avail
able     on the extent and predictors of youth exposure to community violence in
 low&#45;and     middle&#45;income countries. Recently, a retrospective report o
f child sexual     abuse in El Salvador has flagged the importance of coordinati
ng efforts at     the state and community levels to strengthen the realization o
f the rights     of these children and youth.<Sup>17 </Sup>High&#45;risk youth (
e.g., delinquent     youth) should be afforded particular priority as they may b
e exposed to higher     rates of violence than other youth.<Sup>18 </Sup>For exa
mple, one study in     the United States found delinquent youth to have signific
antly higher levels     of witnessed and directly experienced community violence
 as compared to inner&#45;city     youth attending high school.<Sup>18 </Sup>Lik
ewise, at least in the United     States, delinquent youth may also experience h
igher rates of traumatic violence     as compared with their community counterpa
rts.<Sup>19 </Sup></font></p>     ^cY#aop1011.htm##
01525000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704128300084002001201367#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#33#29#article#182#<p><font si
ze="2" face="Verdana">Among the first countries to ratify the Convention     on 
the Rights of the Child and home to one of the most progressive legislations    
 on the rights of children,<Sup>20 </Sup>Brazil may be posited to be among     t
he leaders in protecting the rights of its children and youth. However,     ther
e have been several reports on the violation of the rights of youth in     Brazi
l, and particularly of those who are especially marginalized.<Sup>21 </Sup>For  
   example, among incarcerated youth in the S&atilde;o Paulo detention system,  
   an Amnesty International report<Sup>22 </Sup>highlighted concerns of overcrow
ding,     physical abuse, understaffing and lack of staff training, unsanitary c
onditions,     and inappropriate transfers to adult prison facilities. Even in t
he general     community, Brazilian youth can be exposed to particularly high le
vels of     violence. In a sample of 1,193 young people attending the eighth gra
de in     Porto Alegre, Brazil, 28% reported having been mugged, 25% chased by g
angs,     and 20% threatened with physical harm. In the city of S&atilde;o Paulo
, eight&#45;graders     reported having used knives (5.3%) and guns (3.8%) in fi
ghts occurred in     the last 30 days.<Sup>23 </Sup></font></p>     ^cY#aop1011.
htm##
00821000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704057900084002001200663#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#34#30#article#182#<p><font si
ze="2" face="Verdana">Despite these patterns, little systematic information     
can be found on exposure to violence of youth who have been incarcerated     in 
Brazil, a potentially very high&#45;risk group. The aims of this study were     
(1) to determine the prevalence of witnessed and experienced violence in     inc
arcerated youth from the city of S&atilde;o Paulo, Brazil; (2) to examine     wh
ether this prevalence varies according to gender; and (3) to determine     wheth
er potential risk factors are associated with exposure to violence. </font></p> 
    ^cY#aop1011.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#35#31#article#182#<p>&nbsp;</
p>     ^cY#aop1011.htm##
00309000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704006700084002001200151#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#36#32#article#182#<p><font si
ze="3" face="Verdana"><B>Method </B></font></p>     ^cY#aop1011.htm##
00324000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008200084002001200166#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#37#33#article#182#<p><font si
ze="2" face="Verdana"><b>1. Setting and sample </b></font></p>     ^cY#aop1011.h
tm##
01857000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704161500084002001201699#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#38#34#article#182#<p><font si
ze="2" face="Verdana">At the planning stage of the study's sampling,     the age
ncy that manages juvenile detention units in the state of S&atilde;o     Paulo <
I>(Funda&ccedil;&atilde;o do Bem&#45;Estar do Menor &#45;FEBEM, </I>now <I>Funda
&ccedil;&atilde;o     Casa) </I>provided information on the number of units oper
ating within the     greater metropolitan area of the city of S&atilde;o Paulo. 
All girls were     housed within two free&#45;standing units, both of which were
 included in the     sample. Boys were housed in either free&#45;standing units 
or units within large     compounds. Sampling for boys was stratified across the
se two unit types to     ensure the inclusion of freestanding units. Two of the 
five free&#45;standing     units for boys were randomly selected. The compound u
nits for boys each contained     multiple individual units. Of the five total co
mpounds, two were not eligible     for inclusion as they were deemed unsafe for 
the research staff to enter     given their history of violent riots. Two of the
 remaining three compounds     were selected randomly, within which seven indivi
dual units were selected     randomly. An eighth individual unit, which housed t
he youngest boys, was     added to ensure the inclusion of a full range of youth
. Additional details     on the sampling methods used are reported elsewhere.<Su
p>24 </Sup>It was     not possible to reweight the sample to generate findings t
hat would estimate     violence prevalence for the full source population given 
the lack of information     on the number of youth in each unit </font></p>     
^cY#aop1011.htm##
00767000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704052500084002001200609#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#39#35#article#182#<p><font si
ze="2" face="Verdana">Youth within the selected units had to fulfill     the fol
lowing inclusion criteria to be eligible: (1) age between 12 and 17     years, (
2) reside in the city of S&atilde;o Paulo immediately before incarceration,     
(3) being placed in a locked facility on a full&#45;time basis at the time of   
  recruitment, and (4) 'Awaiting Judicial Decision' status (a report     filed w
ith the judge that commences the process for deciding on the release     date fo
r the youth). </font></p>     ^cY#aop1011.htm##
00316000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007400084002001200158#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#40#36#article#182#<p><font si
ze="2" face="Verdana"><B>2. Procedures</B> </font></p>     ^cY#aop1011.htm##
00766000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704052400084002001200608#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#41#37#article#182#<p><font si
ze="2" face="Verdana">Youth were interviewed face&#45;to&#45;face using a     st
ructured questionnaire between April and October, 2004. The study was approved  
   by the ethics committee of the Universidade Federal de S&atilde;o Paulo.     
In addition, the study was approved by FEBEM officers and by a judge responsible
     for the incarcerated youth. The youth were informed of the voluntary nature
     of the study and only those who assented to participate were included in   
  the study. </font></p>     ^cY#aop1011.htm##
00314000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007200084002001200156#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#42#38#article#182#<p><font si
ze="2" face="Verdana"><B>3. Measures</B> </font></p>     ^cY#aop1011.htm##
00341000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009900084002001200183#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#43#39#article#182#<p><font si
ze="2" face="Verdana">1) Exposure to violence (dependent variables) </font></p> 
    ^cY#aop1011.htm##
01621000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704137900084002001201463#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#44#40#article#182#<p><font si
ze="2" face="Verdana">The full questionnaire contained several sections     take
n from the Social and Health Assessment (SAHA) questionnaire.<Sup>25 </Sup>These
     included the section on witnessed and experienced violence for which findin
gs     have been reported in other populations.<Sup>3,26 </Sup>Six items evaluat
ing     several types of exposure to violence (being beaten/mugged, threatened w
ith     serious physical harm, seriously wounded by violence, shot at with a gun
,     chased by gangs/ individuals, attacked/stabbed with a knife) were asked tw
ice     (witnessed and experienced). The scale included five Likert&#45;type res
ponses: 'none' (0), '1&#45;2     times' (1), '3&#45;5 times' (2), '6&#45;9 times
' (3), '10     or more times' (4). The youth were asked to report on the 12&#45;
month     period prior to their current incarceration. Total index scores for wi
tnessed     violence and experienced violence were produced through summation of
 the     values assigned to each individual item (i.e., 0 to 4). Cronbach's     
alpha (&alpha;) for the witnessed violence and experienced violence scales     w
ere 0.80 and 0.63, respectively. For reporting on exposure to violence,     indi
vidual items were dichotomized between 0 and <U>&gt;</u> 1 exposures.     Furthe
r detail about these variables is available elsewhere.<Sup>27 </Sup></font></p> 
    ^cY#aop1011.htm##
00320000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007800084002001200162#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#45#41#article#182#<p><font si
ze="2" face="Verdana">2) Independent variables </font></p>     ^cY#aop1011.htm##
00776000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704053400084002001200618#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#46#42#article#182#<p><font si
ze="2" face="Verdana">The Brazilian Economic Classification Criteria<Sup>28 </Su
p>was     used to classify the participants' economic status. The instrument    
 is based on the quantity of household goods, the educational level of the     h
ead of the household, and the number of home employees working at least     five
 days a week. The total score is associated with one of five categories     betw
een 'A' (high) and 'E' (low). A/B and D/E were     collapsed to increase the sam
ple size per category. </font></p>     ^cY#aop1011.htm##
01487000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704124500084002001201329#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#47#43#article#182#<p><font si
ze="2" face="Verdana">Several questions were drawn from the Drug Use     Screeni
ng Inventory &#150; Revised (DUSI&#45;R), an instrument for youth that     inqui
res about the types and extent of involvement with substance use and     consequ
ences of drug or alcohol problems, such as family dysfunctions or     academic p
roblems.<Sup>29 </Sup>A Brazilian Portuguese version of this instrument,     whi
ch was shown to be psychometrically sound,<Sup>30 </Sup>was used. From     the d
rug use frequency section of this instrument, a report of use of any     illicit
 drug for 10 or more times in the month preceding incarceration was     coded as
 'heavy drug use'. The response pattern to 14 questions     on family adjustment
 from the DUSI&#45;R (e.g., 'Were your parents or guardians     unaware of your 
likes and dislikes?', 'Has a member of your family     ever been arrested?') was
 used to create the Family Adjustment Problem     Index (FAPI). The scale had an
 internal consistency of 0.63 (Cronbach's     alpha). Single items on past invol
vement with gangs and alcohol use by a     family member 'causing problems at ho
me, at work, or with friends' were     also extracted from other sections of thi
s instrument. </font></p>     ^cY#aop1011.htm##
00878000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704063600084002001200720#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#48#44#article#182#<p><font si
ze="2" face="Verdana">The extent to which the youth's peers     engaged in risk 
behaviors was assessed with items drawn from the SAHA. The     resulting scale (
Peers Engaged in Risk Behaviors &#45; PERB) includes nine items     describing a
 variety of behaviors (e.g. dropping out of school, involvement     in drug traf
fic) scored from one (no friends engaged in the behavior) to     four (most or a
ll friends engaged). A 10<Sup>th </Sup>item from the original     scale related 
to smoking was excluded to improve the psychometric performance     of the scale
. Cronbach's alpha was 0.85 for this sample. </font></p>     ^cY#aop1011.htm##
00633000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704039100084002001200475#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#49#45#article#182#<p><font si
ze="2" face="Verdana">Several questions were specifically developed     for the 
study, including whether the youth had (1) slept on the street, (2)     had prev
iously been under a juvenile justice measure, and (3) whether the     youth perc
eived that obtaining a gun in theirneighborhood was easy. The number     of year
s behind in school was also determined. </font></p>     ^cY#aop1011.htm##
00314000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007200084002001200156#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#50#46#article#182#<p><font si
ze="2" face="Verdana"><B>4. Analysis</B> </font></p>     ^cY#aop1011.htm##
01604000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704136200084002001201446#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#51#47#article#182#<p><font si
ze="2" face="Verdana">Chi&#45;square and Fisher's exact tests were     used to d
etermine the relationship between exposure to violence and gender.     Spearman 
correlations, Student's <I>t</I>&#45;tests, and analyses of variance     (ANOVA)
 were used to determine the bivariate relationship between exposure     to viole
nce and variables hypothesized to be associated with witnessed and     experienc
ed violence. Multiple hierarchical regression analyses were run     to determine
 whether any of the hypothesized variables were associated with     community vi
olence scores within the sample. Hypothesized risk factors with     significant 
bivariate relationships (p &lt; 0.05) with either witnessed or     experienced c
ommunity violence were used in the multivariate analysis. Potential     associat
ed variables that were conceptually similar were grouped in hierarchical     blo
ck entries to estimate their relationship with exposure to violence. This     ap
proach allows the evaluation of the extent of the contribution, if any,     acco
unted for by each block (e.g. family variables) as well as any unique     contri
butions accounted for by individual variables. Separate regression     analyses 
were completed for witnessed and experienced violence to determine     if there 
were any unique associated variables in each case. </font></p>     ^cY#aop1011.h
tm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#52#48#article#182#<p>&nbsp;</
p>     ^cY#aop1011.htm##
00310000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704006800084002001200152#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#53#49#article#182#<p><font si
ze="3" face="Verdana"><B>Results</B> </font></p>     ^cY#aop1011.htm##
00850000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704060800084002001200692#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#54#50#article#182#<p><font si
ze="2" face="Verdana">Participants (n = 325, 89% boys) were aged 12&#45;17     y
ears (mean = 15.9, SD = 1.1). Boys and girls were similar across a variety     o
f demographic and risk factors hypothesized to be linked with exposure to     vi
olence in this population (<a href="#tab01">Table 1</a>). Significantly     more
 girls than boys reported having slept on the street (</font><font>&#967;</font>
<font size="2" face="verdana"><Sup>2 </Sup>=     7.1, p &lt; 0.01) and were more
 frequently connected with peers engaged in     risk behaviors (t = 2.0, df = 29
4, p &lt; 0.05). </font></p>     ^cY#aop1011.htm##
00278000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704003600084002001200120#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#55#51#article#182#<p><a name=
"tab01"></a></p>     ^cY#aop1011.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#56#52#article#182#<p>&nbsp;</
p>     ^cY#aop1011.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#57#53#article#182#<p align="c
enter"><img src="/img/revistas/rbp/2011nahead/a10tab01.jpg"></p>     ^cY#aop1011
.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#58#54#article#182#<p>&nbsp;</
p>     ^cY#aop1011.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#59#55#article#182#<p><font si
ze="2" face="Verdana"><B>1. Exposure to violence</B> </font></p>     ^cY#aop1011
.htm##
01096000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704085400084002001200938#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#60#56#article#182#<p><font si
ze="2" face="Verdana">In this sample, 94% of the girls and 96% of     the boys w
itnessed and 61% of the girls and 60% of the boys experienced at     least one t
ype of violence identified in the SAHA in the year prior to incarceration     (<
a href="#tab02">Table 2</a>). Seeing or being a beating or mugging victim     or
 being threatened with serious harm were the violence types that received     th
e most endorsements from both boys and girls. In addition, 14% of girls     and 
10% of boys reported having witnessed at least three different types     of viol
ence at a 'high frequency' level (defined here as six     or more incidences), a
nd 17% of girls and 6% of boys reported having experienced     one or more types
 of violence at a 'high frequency' level. Sexual     abuse was more common among
 girls (p &lt; 0.005). </font></p>     ^cY#aop1011.htm##
00278000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704003600084002001200120#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#61#57#article#182#<p><a name=
"tab02"></a></p>     ^cY#aop1011.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#62#58#article#182#<p>&nbsp;</
p>     ^cY#aop1011.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#63#59#article#182#<p align="c
enter"><img src="/img/revistas/rbp/2011nahead/a10tab02.jpg"></p>     ^cY#aop1011
.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#64#60#article#182#<p>&nbsp;</
p>     ^cY#aop1011.htm##
00350000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010800084002001200192#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#65#61#article#182#<p><font si
ze="2" face="Verdana"><B>2. Correlates of exposure to community violence</B> </f
ont></p>     ^cY#aop1011.htm##
00801000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704055900084002001200643#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#66#62#article#182#<p><font si
ze="2" face="Verdana">Results of the bivariate analysis are summarized     in <a
 href="#tab03">Table 3</a>. Given the bivariate association between     age and 
both witnessed and experienced violence, age was entered into the     first bloc
k for the multivariate analysis as the single demographic control.     Most of t
he measured risk factors demonstrated statistically significant     bivariate re
lationships with both witnessed and experienced violence exposure     in the exp
ected direction (<a href="#tab03">Table 3</a>). </font></p>     ^cY#aop1011.htm#
#
00278000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704003600084002001200120#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#67#63#article#182#<p><a name=
"tab03"></a></p>     ^cY#aop1011.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#68#64#article#182#<p>&nbsp;</
p>     ^cY#aop1011.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#69#65#article#182#<p align="c
enter"><img src="/img/revistas/rbp/2011nahead/a10tab03.jpg"></p>     ^cY#aop1011
.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#70#66#article#182#<p>&nbsp;</
p>     ^cY#aop1011.htm##
00324000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008200084002001200166#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#71#67#article#182#<p><font si
ze="2" face="Verdana"><B>3. Witnessed violence</B> </font></p>     ^cY#aop1011.h
tm##
01719000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704147700084002001201561#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#72#68#article#182#<p><font si
ze="2" face="Verdana">Upon examining the possible independent associations     o
f witnessed violence, the demographic control variable (age) explained a     sma
ll but significant amount of the variance in the criterion (F<sub>(1,280)</sub> 
=     5.64, p &lt; 0.05). After controlling for age, the risk factors as a group
     explained an additional 30.6% of the variability in witnessed violence outc
ome     scores. The block comprising variables associated with family adjustment
     problems made the greatest overall contribution among the various risk fact
or     blocks, explaining 16.2% of the variance (F<sub>(3,278)</sub> = 20.55, p 
&lt; 0.001).     The remaining blocks made significant, although more modest, co
ntributions,     including peer group/neighborhood variables, adverse experience
s (having     slept on the street) and youth behavior problems. Additional risk 
factors     that made unique contributions to the variance in witnessed violence
 within     the final model were involvement with high&#45;risk peers (t = 4.0, 
p &lt; 0.001),     easy access to guns (t = 2.5, p &lt; 0.05), and having had pr
evious involvement     with the juvenile justice system (t = 2.3, p &lt; 0.05). 
Gang involvement,     alcohol&#45;related problems in the family, and heavy drug
 use by the youth,     despite having a bivariate relationship with witnessed vi
olence, proved redundant     with other variables that were added to the final m
odel. </font></p>     ^cY#aop1011.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#73#69#article#182#<p><font si
ze="2" face="Verdana"><B>4. Experienced violence</B> </font></p>     ^cY#aop1011
.htm##
01159000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704091700084002001201001#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#74#70#article#182#<p><font si
ze="2" face="Verdana">Using experienced violence as the dependent     variable, 
the various risk factors as a group accounted for 18.6% of the     variance in o
utcome scores.The block including family difficulties contributed     to the lar
gest gain in variance, with 11.5% (F<sub>(2,278)</sub> = 19.93,     p &lt; 0.001
). The blocks with peer group/neighborhood and adverse experience     variables 
also made significant, although less substantial, contributions     to the varia
nce (4.5%, F<sub>(5,275)</sub> = 11.28, p &lt; 0.001, and 2.6%,     F<sub>(6,274
)</sub> = 11.15, p &lt; 0.001, respectively). Having slept on     the street was
 also a modestly significant contributor (t = 2.3, p &lt; 0.05).     Age, high&#
45;risk peers, easy access to guns, behaviorrelated variables, and     number of
 years behind in school were only redundant explanatory factors     within the m
odel. </font></p>     ^cY#aop1011.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#75#71#article#182#<p>&nbsp;</
p>     ^cY#aop1011.htm##
00313000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007100084002001200155#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#76#72#article#182#<p><font si
ze="3" face="Verdana"><B>Discussion</B> </font></p>     ^cY#aop1011.htm##
02281000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704203900084002001202123#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#77#73#article#182#<p><font si
ze="2" face="Verdana">Nearly all participants had witnessed and over     half ha
d been victimized by violence within their communities. Comparing     these resu
lts to the existing literature is problematic as most studies did     not use th
e same or similar instruments for measuring exposure rates. For     example, one
 study involving a sample of 1,193 eighthgrade public&#45;school     students fr
om Porto Alegre in the south of Brazil noted exceptionally high     rates of bot
h witnessed (98%) and experienced (71%) violence.<Sup>31 </Sup>However,     the 
study used an instrument with a broader coverage of violence types and     also 
inquired about lifetime exposure, in contrast with the current study's     more 
restricted list of items and time frame of 12 months. However, two studies     w
ere identified that did use the same measure reported in the current study.     
Schwab&#45;Stone et al. examined exposure to violence in a large sample (n =    
 2,600) of adolescents in an American urban center with high levels of economic 
    disadvantage. The authors reported that 36% of the sample had suffered at   
  least one of the six types of violence investigated.<Sup>26 </Sup>Ruchkin     
et al. examined the levels of violence in a sample of 370 delinquent youth     w
ithin a juvenile detention center in northern Russia and found violence     expo
sure rates of 50% (witnessed) and 32% (experienced).<Sup>3 </Sup>The     higher 
rates found in the present study in relation to Russia's may     be partly due t
o the difference in the overall level of violence in the two     countries, as i
ndicated by homicide rates. Based on data from the 1990s,     the homicide rate 
in Brazil was 32 deaths per 100,000 inhabitants, whereas     in Russia it was ne
arly half of that, with 18 deaths per 100,000.<Sup>32 </Sup>Furthermore,     the
 study settings were different in these two countries, with S&atilde;o     Paulo
 being a large urban centre in contrast with the northern Russian district     s
tudied. </font></p>     ^cY#aop1011.htm##
01505000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704126300084002001201347#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#78#74#article#182#<p><font si
ze="2" face="Verdana">Few gender differences were found in this study,     speci
fically in the areas of exposure to violence and physical abuse. Although     so
me studies have obtained similar findings &#45; for example, in the case of     
youth recruited from a poor, urban community in the United States with high     
crime rates<Sup>33 </Sup>&#45; most investigations found boys to be more exposed
     to community violence as compared with girls.<Sup>14,33,34 </Sup>As these  
   studies covered a number of community and higher risk samples, thus implying 
    the robustness of this gender&#45;related pattern, the question is raised ab
out     why a similar pattern was not observed in the current findings. Conduct 
disorder,     which substantially overlaps with the construct of delinquency, is
 much less     frequent in girls than in boys.<Sup>35 </Sup>Girls with conduct d
isorder     may represent a more extreme subset within this gender group in cont
rast     with boys.This more extreme group may then have similar or even more ex
treme     experiences than their male counterparts. Supporting this is the findi
ng     that more girls than boys in this sample had slept on the street, a parti
cularly     extreme experience. </font></p>     ^cY#aop1011.htm##
00768000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704052600084002001200610#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#79#75#article#182#<p><font si
ze="2" face="Verdana">The current study found higher rates of sexual     abuse a
mong girls compared with boys. This is consistent with findings from     both co
mmunity and incarcerated samples of girls.<Sup>14,16,18 </Sup>Although     small
er in number, the extent of exposures and the higher rates of sexual     abuse r
equire that policies and interventions aimed at reducing the exposure     to vio
lence of youth at risk for delinquency and incarceration give special     attent
ions to girls. </font></p>     ^cY#aop1011.htm##
01544000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704130200084002001201386#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#80#76#article#182#<p><font si
ze="2" face="Verdana">Family adjustment problems figured prominently     among t
he correlates of both witnessed and experienced violence in the final     regres
sion models of the analysis. This was partially consistent with findings     by 
Salzinger et al., which found that family problems mediated the risk of     expo
sure to community violence in a sample from New York City.<Sup>11 </Sup>Similarl
y,     a separate investigation examined the rates of exposure to community viol
ence     among youth across different community settings and found the highest r
ates     among youth from families that are economically struggling to survive (
characterized,     for example, by little cohesion and monitoring by parents) li
ving in inner&#45;city     dwellings.<Sup>12 </Sup>Although the related variable
 'living arrangement' (e.g.,     not living with both parents) has been previous
ly reported to be a predictor     of exposure to violence,<Sup>36 </Sup>it was n
ot a significant correlate     in this study. A possible explanation for this is
 that not living with both     parents is also frequent among the general popula
tion in Brazil. For instance,     only 62.7% of eighth&#45;graders in the city o
f S&atilde;o Paulo live with both     biological parents.<Sup>23 </Sup></font></
p>     ^cY#aop1011.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#81#77#article#182#<p>&nbsp;</
p>     ^cY#aop1011.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#82#78#article#182#<p align="c
enter"><img src="/img/revistas/rbp/2011nahead/a10tab04.jpg"></p>     ^cY#aop1011
.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#83#79#article#182#<p>&nbsp;</
p>     ^cY#aop1011.htm##
03077000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704283500084002001202919#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#84#80#article#182#<p><font si
ze="2" face="Verdana">The correlates of violence include the household     but e
xtend beyond, into the neighborhood and broader social milieu. Among     these a
dditional risk factors, the variables peer group and neighborhood     problems w
ere among the most robust variables associated with exposure to     violence; in
 particular, connection with high&#45;risk peers was found to be     strongly as
sociated with witnessed violence. In a longitudinal study on the     exposure of
 young adolescents to violence in high&#45;risk neighborhoods, deviant     behav
ior of friends, in conjunction with other risk factors, made an important     co
ntribution to the total exposure to violence one year later.<Sup>11 </Sup>Gun   
  access by the youth may incorporate an additional dimension of risk, when     
combined with other contextual factors, to the prediction of exposure to     vio
lence. Though easy gun access by the youth uniquely contributed to witnessed    
 violence levels, it proved redundant in the final model for experienced violenc
e.     Some reports suggest that weapon carrying may be associated with higher l
evels     of witnessed violence, at least among high&#45;risk youth.<Sup>37 </Su
p>Likewise,     the role of perpetration of violence or other criminal acts shou
ld be considered.     Variables associated with behavior problems, particularly 
previous involvement     with the juvenile justice system, were associated with 
witnessed violence     in the multiple regression analysis, but not with experie
nced violence. This     pattern was consistent with that found by Albus, Weist, 
and Perez&#45;Smith in     a cross&#45;section of inner&#45;city youth.<Sup>38 <
/Sup>Another study found the     youth's own deviant behavior acts along with pe
er deviance to mediate     the effects of problematic parenting on exposure to v
iolence one year later.<Sup>11 </Sup>In     general, the combination of these ty
pes of variables in the prediction of     exposure to violence, i.e., involvemen
t with high&#45;risk peers, access to guns,     and some direct involvement in c
riminal activities, is akin to the findings     of Halliday&#45;Boykins and Grah
am.<Sup>39 </Sup>These investigators describe     how youth's general involvemen
t with violence might underlie the associations     between exposure to and perp
etration of violence, as well as contribute to     other undesirable outcomes su
ch as connection with deviant peers. Violent     crimes, predominantly robbery, 
were by far the most frequently self&#45;reported     index crime precipitating 
incarceration in this sample.<Sup>24 </Sup>Unfortunately,     details concerning
 the perpetration of violent acts by the participants and     the temporal relat
ionship between this and exposure to violence were not     available in this stu
dy. </font></p>     ^cY#aop1011.htm##
00958000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704071600084002001200800#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#85#81#article#182#<p><font si
ze="2" face="Verdana">The experience of sleeping on the street was     also a si
gnificant correlate on both witnessed and experienced violence.     Sleeping on 
the street alone may increase exposure to violence by virtue     of the increase
d time spent on the street, where violence occurs. In addition,     sleeping on 
the street is likely to be associated with other risk factors     that may contr
ibute to the youth's exposure to community violence (e.g.,     domestic violence
, limited social networks). This finding strengthens the     importance of prior
itizing policies and interventions aimed at supporting     youth at risk of livi
ng on the street or currently on the street. </font></p>     ^cY#aop1011.htm##
01097000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704085500084002001200939#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#86#82#article#182#<p><font si
ze="2" face="Verdana">Unexpected was the finding that younger youth     (aged 12
 to14 years) reported higher exposure rates to witnessed and experienced     vio
lence, and this remained true in the multivariate model for witnessed     violen
ce. One possible explanation for this pattern is a sampling limitation,     i.e.
, two of the male compounds were excluded from the sampling due to the     heigh
tened risk to staff. These compounds tended to house older and more     recidivi
stic youth, who may in turn have had more exposure to violence. Therefore,     o
lder male youth included in this study may have had less extreme experiences    
 than older male youth excluded from this study. Additionally, being incarcerate
d     at a younger age may be indicative of a particular group exposed to extrem
e     life experiences. </font></p>     ^cY#aop1011.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#87#83#article#182#<p>&nbsp;</
p>     ^cY#aop1011.htm##
00314000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007200084002001200156#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#88#84#article#182#<p><font si
ze="3" face="Verdana"><B>Limitations</B> </font></p>     ^cY#aop1011.htm##
01310000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704106800084002001201152#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#89#85#article#182#<p><font si
ze="2" face="Verdana">First, these data are cross&#45;sectional and sequencing  
   of risks and exposure to violence cannot be determined from these data, nor  
   can causality. Second, the examination of gender differences may have been   
  limited by the relatively small size of the sample of girls. Third, sampling  
   limitations, in particular the lack of sampling of some compounds that were  
   more likely to house older and more recidivistic male youth may have resulted
     in a failure to sample a more representative range of the incarcerated popu
lation.     It is not known whether the findings presented here can be generaliz
ed to     populations other than incarcerated youth from the city of S&atilde;o 
Paulo;     however, we are not aware of any peculiarities of this population tha
t could     prevent the generalization of the findings to other incarcerated pop
ulations     in Brazil. Lastly, this study was not able to investigate the relat
ionship     between exposure to violence and violence perpetration by youth. </f
ont></p>     ^cY#aop1011.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#90#86#article#182#<p>&nbsp;</
p>     ^cY#aop1011.htm##
00313000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007100084002001200155#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#91#87#article#182#<p><font si
ze="3" face="Verdana"><B>Conclusion</B> </font></p>     ^cY#aop1011.htm##
00972000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704073000084002001200814#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#92#88#article#182#<p><font si
ze="2" face="Verdana">This study contributes to the growing recognition     that
 delinquent youth are frequently exposed to very high rates of violence.     Alt
hough most research has focused on youth from high&#45;income countries, there  
   is growing evidence that youth in low&#45;and middle&#45;income countries exp
erience     similar, if not more extreme, situations. These reports clearly iden
tify     a failure in the realization of the rights for protection of vulnerable
 youth     under the UN Convention. Future research should investigate the effec
tiveness     of strategies aimed at reducing high&#45;risk youth's exposure to v
iolence     and improving the realization of their rights. </font></p>     ^cY#a
op1011.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#93#89#article#182#<p>&nbsp;</
p>     ^cY#aop1011.htm##
00310000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704006800084002001200152#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#94#90#article#182#<p><font si
ze="3" face="Verdana"><B>Funding</B> </font></p>     ^cY#aop1011.htm##
00529000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704028700084002001200371#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#95#91#article#182#<p><font si
ze="2" face="Verdana">Dr. McLennan and Dr. Bordin received funding     for the f
ull study, including all aspects of data collection for the original     study b
y the Canadian International Development Agency through the Child     Protection
 Research Fund. </font></p>     ^cY#aop1011.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#96#92#article#182#<p>&nbsp;</
p>     ^cY#aop1011.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#97#93#article#182#<p align="c
enter"><img src="/img/revistas/rbp/2011nahead/a11img01.jpg"></p>     ^cY#aop1011
.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#98#94#article#182#<p>&nbsp;</
p>     ^cY#aop1011.htm##
00313000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007100084002001200155#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#99#95#article#182#<p><font si
ze="3" face="Verdana"><B>References</B> </font></p>     ^cY#aop1011.htm##
00602000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081888000200085704034500087002001200432#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#100#96#article#18
2#1#<p><font size="2" face="Verdana">1. UN General Assembly. <I>Convention on th
e       Rights of the Child</I>, United Nations, Treaty Series. 1989;1577: 3. &#
91;cited       2010 aug 22&#93;. Available from: <a href="http://www.unhcr.org/r
efworld/docid/3ae6b38f0.html" target="_blank">http://www.unhcr.org/refworld/doci
d/3ae6b38f0.html</a>.    ^cY#aop1011.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081704002100085002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#101#97#article#182# </font></
p>     ^cY#aop1011.htm##
00483000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081888000200085704022600087002001200313#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#102#98#article#18
2#2#<p><font size="2" face="Verdana">2. Gorman&#45;Smith D, Tolan P. The role of
 exposure     to community violence and developmental problems among inner&#45;c
ity youth. <I>Dev     Psychopathol. </I>1998;10(1):101&#45;16.    ^cY#aop1011.ht
m##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081704002100085002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#103#99#article#182# </font></
p>     ^cY#aop1011.htm##
00523000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704026500088002001200353#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#104#100#article#1
82#3#<p><font size="2" face="Verdana">3. Ruchkin VV, Schwab&#45;Stone M, Koposov
 R, Vermeiren     R, Steiner H. Violence exposure, posttraumatic stress, and per
sonality in     juvenile delinquents. <I>J Am Acad Child Adolesc Psychiatry</I>.
 2002;41(3):322&#45;9.    ^cY#aop1011.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#105#101#article#182# </font><
/p>     ^cY#aop1011.htm##
00463000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704020500088002001200293#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#106#102#article#1
82#4#<p><font size="2" face="Verdana">4. O'Keefe M. Adolescents' exposure     to
 community and school violence: prevalence and behavioural correlates. <I>J     
Adolesc Health</I>. 1997;20(5):368&#45;76.    ^cY#aop1011.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#107#103#article#182# </font><
/p>     ^cY#aop1011.htm##
00471000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704021300088002001200301#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#108#104#article#1
82#5#<p><font size="2" face="Verdana">5. Buka SL,Stichick TL, Birdthistle I. Ear
ls     FJ. Youth exposure toviolence:Prevalence, risks, and consequences. <I>Am 
    J Orthopsychiatry</I>. 2001;71(3):298&#45;310.    ^cY#aop1011.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#109#105#article#182# </font><
/p>     ^cY#aop1011.htm##
00431000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704017300088002001200261#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#110#106#article#1
82#6#<p><font size="2" face="Verdana">6. Aisenberg E, Herrenkohl T. Risk and res
ilience     in children and families. <I>J Interpers Violence</I>. 2008;23(3):29
6&#45;315.    ^cY#aop1011.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#111#107#article#182# </font><
/p>     ^cY#aop1011.htm##
00539000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704028100088002001200369#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#112#108#article#1
82#7#<p><font size="2" face="Verdana">7. Paula CS, Vedovato MS, Bordin IAS, Barr
os     MG, D'Antino ME, Mercadante MT. Mental health and violence among sixth   
  grade students from a city in the state of S&atilde;o Paulo State. <I>Rev     
Saude Publica. </I>2008;42(3):1&#45;4.    ^cY#aop1011.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#113#109#article#182# </font><
/p>     ^cY#aop1011.htm##
00412000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704015400088002001200242#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#114#110#article#1
82#8#<p><font size="2" face="Verdana">8. Bailey S, Whittle N. Young people: vict
ims     of violence. <I>Curr Opin Psychiatry</I>. 2004;17(4):263&#45;8.    ^cY#a
op1011.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#115#111#article#182# </font><
/p>     ^cY#aop1011.htm##
00586000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704032800088002001200416#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#116#112#article#1
82#9#<p><font size="2" face="Verdana">9. Saltzman W, Pynoos R, Layne C, Steinber
g     A, Aisenberg E.Trauma/grief&#45;focused intervention for adolescents expos
ed     to community violence: Results of a school&#45;based screening and group 
treatment     protocol. <I>Group Dyn&#45;Theory Res Pract</I>. 2001;5(4):291&#45
;303.    ^cY#aop1011.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#117#113#article#182# </font><
/p>     ^cY#aop1011.htm##
00533000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704027400089002001200363#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#118#114#article#1
82#10#<p><font size="2" face="Verdana">10. Eitle D, Turner RJ. Exposure to commu
nity     violence and young adult crime: The effects of witnessing violence, tra
umatic     victimization, and other stressful life events. <I>J Res Crime Delinq
</I>.     2002;39(2):214&#45;37.    ^cY#aop1011.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#119#115#article#182# </font><
/p>     ^cY#aop1011.htm##
00524000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704026500089002001200354#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#120#116#article#1
82#11#<p><font size="2" face="Verdana">11. Salzinger S, Ng&#45;Mak DS, Feldman R
S, Kam     C, Rosario M. Exposure to community violence: Processes that increase
 the     risk for inner&#45;city middle school children. <I>J Early Adolesc</I>.
 2006;26(2):232&#45;66.    ^cY#aop1011.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#121#117#article#182# </font><
/p>     ^cY#aop1011.htm##
00515000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704025600089002001200345#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#122#118#article#1
82#12#<p><font size="2" face="Verdana">12. Sheidow AJ, Gorman&#45;Smith D, Tolan
 PH, Henry     DB. Family and community characteristics: Risk factors for violen
ce exposure     in inner&#45;city youth<I>. Am J Community Psychol. </I>2001;29(
3):345&#45;60.    ^cY#aop1011.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#123#119#article#182# </font><
/p>     ^cY#aop1011.htm##
00456000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704019700089002001200286#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#124#120#article#1
82#13#<p><font size="2" face="Verdana">13. Weist MD, Acosta, OM, Youngstrom EA. 
Predictors     of violence exposure among inner&#45;city youth. <I>J Clin Child 
Psychol. 2001;30(1)</I>:187&#45;98.    ^cY#aop1011.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#125#121#article#182# </font><
/p>     ^cY#aop1011.htm##
00569000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704031000089002001200399#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#126#122#article#1
82#14#<p><font size="2" face="Verdana">14. Hanson RF, Self&#45;Brown S, Fricker&
#45;Elhai A,     Kilpatrick DG, Saunders BE, Resnick HS. Relations among family 
environment     and violence exposure among youth: findings from the National Su
rvey of Adolescents. <I>Child     Maltreat</I>. 2006;11(1):3&#45;15.    ^cY#aop1
011.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#127#123#article#182# </font><
/p>     ^cY#aop1011.htm##
00473000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704021400089002001200303#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#128#124#article#1
82#15#<p><font size="2" face="Verdana">15. Nofziger S, Kurtz D. Violent lives: A
 lifestyle     model linking exposure to violence to juvenile violent offending.
 <I>J Res     Crime Delinq</I>. 2005;42(1):3&#45;26.    ^cY#aop1011.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#129#125#article#182# </font><
/p>     ^cY#aop1011.htm##
00511000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704025200089002001200341#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#130#126#article#1
82#16#<p><font size="2" face="Verdana">16. Rosario M, Salzinger S, Feldman RS, N
g&#45;Mak     DS. Community violence exposure and delinquent behaviors among you
th: The     moderating role of coping<I>. J Community Psychol. 2003;</I>31(5):48
9&#45;512.    ^cY#aop1011.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#131#127#article#182# </font><
/p>     ^cY#aop1011.htm##
00456000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704019700089002001200286#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#132#128#article#1
82#17#<p><font size="2" face="Verdana">17. Pallitto CC, Murillo V. Childhood abu
se     as a risk factor for adolescent pregnancy in El Salvador. <I>J Adolesc He
alth</I>.     2008;42(6):580&#45;6.    ^cY#aop1011.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#133#129#article#182# </font><
/p>     ^cY#aop1011.htm##
00634000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704037500089002001200464#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#134#130#article#1
82#18#<p><font size="2" face="Verdana">18. Wood J, Foy DW, Layne C, Pynoos R, Ja
mes     CB. An examination of the relationships between violence exposure, postt
raumatic     stress symptomatology, and delinquent activity: An 'ecopathological
' model     of delinquent behavior among incarcerated adolescents. <I>J Aggressi
on Maltreatment     Trauma</I>. 2002;6(1):127&#45;47.    ^cY#aop1011.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#135#131#article#182# </font><
/p>     ^cY#aop1011.htm##
00508000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704024900089002001200338#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#136#132#article#1
82#19#<p><font size="2" face="Verdana">19. Abram KM, Teplin LA, Charles DR, Long
worth     SL, McClelland GM, Dulcan MK. Posttraumatic stress disorder and trauma
 in     youth in juvenile detention. <I>Arch Gen Psychiatry</I>. 2004;61(4):403&
#45;10.    ^cY#aop1011.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#137#133#article#182# </font><
/p>     ^cY#aop1011.htm##
00532000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704027300089002001200362#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#138#134#article#1
82#20#<p><font size="2" face="Verdana">20. UNICEF. <I>Making child rights consti
tutional       in Brazil</I>; 2001. &#91;cited 2010 aug 23&#93;. Available from:
 <a href="http://www.unicef.org/sowc96/lbrzil.htm" target="_blank">http://www.un
icef.org/sowc96/lbrzil.htm</a>.    ^cY#aop1011.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#139#135#article#182# </font><
/p>     ^cY#aop1011.htm##
00402000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704014300089002001200232#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#140#136#article#1
82#21#<p><font size="2" face="Verdana">21. Bochenek M, Delgado F. Children in cu
stody     in Brazil. <I>Lancet</I>. 2006;367(9511):696&#45;7.    ^cY#aop1011.htm
##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#141#137#article#182# </font><
/p>     ^cY#aop1011.htm##
00507000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704024800089002001200337#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#142#138#article#1
82#22#<p><font size="2" face="Verdana">22. Amnesty International. <I>Brazil A wa
ste       of lives: FEBEM juvenile detention centres, S&atilde;o Paulo. A human 
rights       crisis, not a public security issue</I>; 2000. AI Index: AMR 19/014
/2000.    ^cY#aop1011.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#143#139#article#182# </font><
/p>     ^cY#aop1011.htm##
00663000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704040400089002001200493#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#144#140#article#1
82#23#<p><font size="2" face="Verdana">23. Instituto Brasileiro de Geografia e E
stat&iacute;stica     &#45; IBGE. <I>Pesquisa nacional de sa&uacute;de do escola
r</I>. 2009. &#91;citado     23 ago 2010&#93;. Available from: <a href="http://w
ww.ibge.gov.br/home/estatistica/populacao/pense/pense.pdf" target="_blank">http:
//www.ibge.     gov.br/home/estatistica/populacao/pense/pense.pdf</a> </font></p
>     ^cY#aop1011.htm##
00503000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704024400089002001200333#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#145#141#article#1
82#24#<p><font size="2" face="Verdana">24. McLennan J, Bordin I, Bennett K, Riga
to     F, Brinkerhoff M. Trafficking among youth in conflict with the law in S&a
tilde;o     Paulo, Brazil. <I>Social Psych Psych Epid.</I> 2008;43(10):816&#45;2
3.    ^cY#aop1011.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#146#142#article#182# </font><
/p>     ^cY#aop1011.htm##
00427000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704016800089002001200257#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#147#143#article#1
82#25#<p><font size="2" face="Verdana">25. Weissberg RP, Voyce CK, Kasprow WJ, A
rthur     M, Shriver T. <I>The social and health assessment.</I> New Haven (CT);
 1991.    ^cY#aop1011.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#148#144#article#182# </font><
/p>     ^cY#aop1011.htm##
00519000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704026000089002001200349#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#149#145#article#1
82#26#<p><font size="2" face="Verdana">26. Schwab&#45;Stone M, Chen C, Greenberg
er E, Silver     D, Lichtman J, Voyce C. No safe haven. II: The effects of viole
nce exposure     on urban youth. <I>J Am Acad Child Adolesc Psychiatry</I>. 1999
;38(4):359&#45;67.    ^cY#aop1011.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#150#146#article#182# </font><
/p>     ^cY#aop1011.htm##
00536000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704027700089002001200366#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#151#147#article#1
82#27#<p><font size="2" face="Verdana">27. Huculak S, McLennan JD. "The     Lord
 is my Shepherd": Examining spirituality as a protection     against mental heal
th problems in youth exposed to violence in Brazil. <I>Ment     Health Religion 
Culture</I>. 2010;13(5):467&#45;84.    ^cY#aop1011.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#152#148#article#182# </font><
/p>     ^cY#aop1011.htm##
00648000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704038900089002001200478#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#153#149#article#1
82#28#<p><font size="2" face="Verdana">28. Associa&ccedil;&atilde;o Brasileira d
e Empresas     de Pesquisa &#45; ABEP. <I>Crit&eacute;rio de classifica&ccedil;&
atilde;o econ&ocirc;mica     Brasil</I>; 2003. &#91;citado 23 ago 2010&#93;. Ava
ilable from: <a href="http://www.abep.org/codigosguias/ABEP_CCEB_2003.pdf" targe
t="_blank">http://www.abep.org/codigosguias/ABEP_CCEB_2003.pdf</a>.    ^cY#aop10
11.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#154#150#article#182# </font><
/p>     ^cY#aop1011.htm##
00486000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704022700089002001200316#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#155#151#article#1
82#29#<p><font size="2" face="Verdana">29. Tarter RE, Kirisci L. Validity of the
 drug     use screening inventory for predicting DSM&#45;III&#45;R substance use
 disorder. <I>J     Child Adoles Subst. </I>2001;10(4):45&#45;53.    ^cY#aop1011
.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#156#152#article#182# </font><
/p>     ^cY#aop1011.htm##
00477000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704021800089002001200307#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#157#153#article#1
82#30#<p><font size="2" face="Verdana">30. De Micheli D, Formigoni M. Psychometr
ic     properties of the Brazilian version of the drug use screening inventory. 
<I>Alcohol     Clin Exp Res</I>. 2002;26(10):1523&#45;8.    ^cY#aop1011.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#158#154#article#182# </font><
/p>     ^cY#aop1011.htm##
00524000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704026500089002001200354#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#159#155#article#1
82#31#<p><font size="2" face="Verdana">31. Zavaschi ML, Benetti S, Polanczyk GV,
 Soles     N, Sanchotene ML. Adolescents exposed to physical violence in the com
munity:     a survey in Brazilian public schools.<I>Rev Panam Salud Publica</I>.
 2002;12(5):327&#45;32.    ^cY#aop1011.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#160#156#article#182# </font><
/p>     ^cY#aop1011.htm##
00467000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704020800089002001200297#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#161#157#article#1
82#32#<p><font size="2" face="Verdana">32. Krug E, Dahlberg LL, Mercy JA, Zwi AB
, Lozano     R, editors. <I>World report on violence and health</I>. Geneva, Swi
tzerland:     World Health Organization; 2002.    ^cY#aop1011.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#162#158#article#182# </font><
/p>     ^cY#aop1011.htm##
00520000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704026100089002001200350#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#163#159#article#1
82#33#<p><font size="2" face="Verdana">33. Foster JD, Kuperminc GP, Price AW. Ge
nder     differences in posttraumatic stress and related symptoms among inner&#4
5;city     minority youth exposed to community violence. <I>J Youth Adolesc</I>.
 2004;33:59&#45;70.    ^cY#aop1011.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#164#160#article#182# </font><
/p>     ^cY#aop1011.htm##
00534000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704027500089002001200364#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#165#161#article#1
82#34#<p><font size="2" face="Verdana">34. Ruchkin VV, Henrich CC, Jones SM, Ver
meiren     R, Schwab&#45;Stone M. Violence exposure and psychopathology in urban
 youth:     the mediating role of posttraumatic stress. <I>J Abnorm Child Psycho
l</I>.     2007;35(4):578&#45;93.    ^cY#aop1011.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#166#162#article#182# </font><
/p>     ^cY#aop1011.htm##
00513000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704025400089002001200343#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#167#163#article#1
82#35#<p><font size="2" face="Verdana">35. Nock MK, Kazdin AE, Hiripi E, Kessler
 RC.     Prevalence, subtypes, and correlates of DSM&#45;IV conduct disorder in 
the National     Comorbidity Survey Replication. <I>Psychol Med</I>. 2006;36(5):
699&#45;710.    ^cY#aop1011.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#168#164#article#182# </font><
/p>     ^cY#aop1011.htm##
00403000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704014400089002001200233#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#169#165#article#1
82#36#<p><font size="2" face="Verdana">36. Esbensen F, Huizinga D. Victimization
 and     Delinquency. <I>Youth Soc</I>. 1991;23(2):202&#45;28.    ^cY#aop1011.ht
m##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#170#166#article#182# </font><
/p>     ^cY#aop1011.htm##
00473000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704021400089002001200303#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#171#167#article#1
82#37#<p><font size="2" face="Verdana">37. Patchin JW, Huebner McCluskey JD, Var
ano     SP, Bynum TS. Exposure to community violence and childhood delinquency. 
<I>Crime     Delinquency</I>. 2006;52(2):307&#45;32.    ^cY#aop1011.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#172#168#article#182# </font><
/p>     ^cY#aop1011.htm##
00540000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704028100089002001200370#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#173#169#article#1
82#38#<p><font size="2" face="Verdana">38. Albus KE, Weist MD, Perez&#45;Smith A
M. Associations     between youth risk behavior and exposure to violence: implic
ations for the     provision of mental health services in urban schools. <I>Beha
v Modif</I>.     2004;28(4):548&#45;64.    ^cY#aop1011.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#174#170#article#182# </font><
/p>     ^cY#aop1011.htm##
00517000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704025800089002001200347#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#175#171#article#1
82#39#<p><font size="2" face="Verdana">39. Halliday&#45;Boykins CA, Grahman S. A
t both     ends of the gun: testing the relationship between community violence 
exposure     and youth violent behaviour. <I>J Abnorm Child Psychol</I>. 2001;29
(5):383&#45;402.    ^cY#aop1011.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#176#172#article#182# </font><
/p>     ^cY#aop1011.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#177#173#article#182#<p>&nbsp;
</p>     ^cY#aop1011.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#178#174#article#182#<p>&nbsp;
</p>     ^cY#aop1011.htm##
00406000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704016200086002001200248#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#179#175#article#182#<p><font 
size="2" face="Verdana"><b><a name="end"></a><a href="#title"><img src="/img/rev
istas/rbp/2011nahead/seta.jpg" border="0"></a> Correspondence</b>    ^cY#aop1011
.htm##
00272000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002800086002001200114#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#180#176#article#182#<br>   Su
san Huculak    ^cY#aop1011.htm##
00288000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704004400086002001200130#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#181#177#article#182#<br>   3r
d Floor, TRW Building, 3280    ^cY#aop1011.htm##
00310000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704006600086002001200152#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#182#178#article#182#<br>   Ho
spital Drive NW, Calgary, Alberta, CANADA T2N 4Z6    ^cY#aop1011.htm##
00307000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704006300086002001200149#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#183#179#article#182#<br>   Ph
one: (403) 220&#45;4295 Fax (403) 270&#45;7307    ^cY#aop1011.htm##
00340000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704009600086002001200182#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#184#180#article#182#<br>   Em
ail: <a href="mailto:huculaks@ucalgary.ca">huculaks@ucalgary.ca</a></font></p>  
   ^cY#aop1011.htm##
00310000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704006600086002001200152#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#185#181#article#182#<p><font 
size="2" face="Verdana">Submitted: April 27, 2010    ^cY#aop1011.htm##
00299000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704005500086002001200141#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#p#186#182#article#182#<br>   Ac
cepted: September 27, 2010</font></p>     ^cY#aop1011.htm##
00478000000000229000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830170020000850180042001050620
01500147065000900162064000500171037005100176865000900227002001200236#2011nahead#
V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#c#187#1#article#39#1#UN Gen
eral Assembly#Convention on the Rights of the Child^len#United Nations#19890000#
1989#http://www.unhcr.org/refworld/docid/3ae6b38f0.html#20110000#aop1011.htm##
00600000000000289000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100022000850100015001070120
09700122030001700219065000900236064000500245031000300250032000200253014000700255
865000900262002001200271035001000283801001700293#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop1011.htm#S#c#188#2#article#39#2#^rND^sGorman-Smith^nD#^rND
^sTolan^nP#The role of exposure to community violence and developmental problems
 among inner-city youth^len#Dev Psychopathol#19980000#1998#10#1#101-16#20110000#
aop1011.htm#0954-5794#Dev Psychopathol##
00715000000000325000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100018000850100022001030100
01700125010001900142010001700161012008500178030003500263065000900298064000500307
03100030031203200020031501400060031786500090032300200120033203500100034480100350
0354#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#c#189#3#art
icle#39#3#^rND^sRuchkin^nVV#^rND^sSchwab-Stone^nM#^rND^sKoposov^nR#^rND^sVermeir
en^nR#^rND^sSteiner^nH#Violence exposure, posttraumatic stress, and personality 
in juvenile delinquents^len#J Am Acad Child Adolesc Psychiatry#20020000#2002#41#
3#322-9#20110000#aop1011.htm#0890-8567#J Am Acad Child Adolesc Psychiatry##
00569000000000277000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100017000850120098001020300
01700200065000900217064000500226031000300231032000200234014000700236865000900243
002001200252035001000264801001700274#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop1011.htm#S#c#190#4#article#39#4#^rND^sO'Keefe^nM#Adolescents' exposure
 to community and school violence: prevalence and behavioural correlates^len#J A
dolesc Health#19970000#1997#20#5#368-76#20110000#aop1011.htm#1054-139X#J Adolesc
 Health##
00618000000000301000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100015000850100019001000100
02100119012007600140030002100216065000900237064000500246031000300251032000200254
014000800256865000900264002001200273035001000285801002100295#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop1011.htm#S#c#191#5#article#39#5#^rND^sBuka^nSL
#^rND^sStichick^nTL#^rND^sBirdthistle^nI#Earls FJ: Youth exposure toviolence:Pre
valence, risks, and consequences^len#Am J Orthopsychiatry#20010000#2001#71#3#298
-310#20110000#aop1011.htm#0002-9432#Am J Orthopsychiatry##
00522000000000277000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100019000850100020001040120
04900124030002100173710000200194065000900196064000500205031000300210032000200213
014000800215865000900223002001200232#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop1011.htm#S#c#192#6#article#39#6#^rND^sAisenberg^nE#^rND^sHerrenkohl^nT
#Risk and resilience in children and families^len#J Interpers Violence#2#2008000
0#2008#23#3#296-315#20110000#aop1011.htm##
00724000000000337000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100016000850100019001010100
01800120010001700138010001800155010002100173012010200194030001800296065000900314
06400050032303100030032803200020033101400040033386500090033700200120034603500100
0358801001800368#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S
#c#193#7#article#39#7#^rND^sPaula^nCS#^rND^sVedovato^nMS#^rND^sBordin^nIAS#^rND^
sBarros^nMG#^rND^sD'Antino ME#^rND^sMercadante^nMT#Mental health and violence am
ong sixth grade students from a city in the state of São Paulo State^len#Rev Sau
de Publica#20080000#2008#42#3#1-4#20110000#aop1011.htm#0034-8910#Rev Saude Publi
ca##
00503000000000277000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100016000850100017001010120
03800118030002100156710000200177065000900179064000500188031000300193032000200196
014000600198865000900204002001200213#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop1011.htm#S#c#194#8#article#39#8#^rND^sBailey^nS#^rND^sWhittle^nN#Young
 people: victims of violence^len#Curr Opin Psychiatry#2#20040000#2004#17#4#263-8
#20110000#aop1011.htm##
00712000000000313000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100018000850100016001030100
01500119010001900134010001900153012015000172030002700322710000200349065000900351
064000500360031000200365032000200367014000800369865000900377002001200386#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#c#195#9#article#39#9#^r
ND^sSaltzman^nW#^rND^sPynoos^nR#^rND^sLayne^nC#^rND^sSteinberg^nA#^rND^sAisenber
g^nE#Trauma/grief-focused intervention for adolescents exposed to community viol
ence: Results of a school-based screening and group treatment protocol^len#Group
 Dyn-Theory Res Pract#2#20010000#2001#5#4#291-303#20110000#aop1011.htm##
00655000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100015000870100017001020120
15100119030001900270065000900289064000500298031000300303032000200306014000700308
865000900315002001200324035001000336801001900346#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop1011.htm#S#c#196#10#article#39#10#^rND^sEitle^nD#^rND^sTur
ner^nRJ#Exposure to community violence and young adult crime: The effects of wit
nessing violence, traumatic victimization, and other stressful life events^len#J
 Res Crime Delinq#20020000#2002#39#2#214-37#20110000#aop1011.htm#0022-4278#J Res
 Crime Delinq##
00693000000000325000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100017001060100
01800123010001300141010001700154012010700171030001600278065000900294064000500303
03100030030803200020031101400070031386500090032000200120032903500100034180100160
0351#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#c#197#11#ar
ticle#39#11#^rND^sSalzinger^nS#^rND^sNg-Mak^nDS#^rND^sFeldman^nRS#^rND^sKam^nC#^
rND^sRosario^nM#Exposure to community violence: Processes that increase the risk
 for inner-city middle school children^len#J Early Adolesc#20060000#2006#26#2#23
2-66#20110000#aop1011.htm#0272-4316#J Early Adolesc##
00673000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100022001050100
01600127010001600143012009700159030002300256065000900279064000500288031000300293
032000200296014000700298865000900305002001200314035001000326801002300336#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#c#198#12#article#39#12#
^rND^sSheidow^nAJ#^rND^sGorman-Smith^nD#^rND^sTolan^nPH#^rND^sHenry^nDB#Family a
nd community characteristics: Risk factors for violence exposure in inner-city y
outh^len#Am J Community Psychol#20010000#2001#29#3#345-60#20110000#aop1011.htm#0
091-0562#Am J Community Psychol##
00618000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100013001030100
00900116010002100125012005900146030002100205065000900226064000500235031000300240
032000200243014000700245865000900252002001200261035001000273801002100283#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#c#199#13#article#39#13#
^rND^sWeist^nMD#^rND^sAcosta#^rND^sOM#^rND^sYoungstrom^nEA#Predictors of violenc
e exposure among inner-city youth^len#J Clin Child Psychol#20010000#2001#30#1#18
7-98#20110000#aop1011.htm#0047-228X#J Clin Child Psychol##
00716000000000325000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100020001040100
02300124010002100147010001900168010001800187012012300205030001500328710000200343
06500090034506400050035403100030035903200020036201400050036486500090036900200120
0378#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#c#200#14#ar
ticle#39#14#^rND^sHanson^nRF#^rND^sSelf-Brown^nS#^rND^sFricker-Elhai^nA#^rND^sKi
lpatrick^nDG#^rND^sSaunders^nBE#^rND^sResnick^nHS#Relations among family environ
ment and violence exposure among youth: findings from the National Survey of Ado
lescents^len#Child Maltreat#2#20060000#2006#11#1#3-15#20110000#aop1011.htm##
00599000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100015001050120
09600120030001900216065000900235064000500244031000300249032000200252014000500254
865000900259002001200268035001000280801001900290#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop1011.htm#S#c#201#15#article#39#15#^rND^sNofziger^nS#^rND^s
Kurtz^nD#Violent lives: A lifestyle model linking exposure to violence to juveni
le violent offending^len#J Res Crime Delinq#20050000#2005#42#1#3-26#20110000#aop
1011.htm#0022-4278#J Res Crime Delinq##
00670000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100019001040100
01800123010001700141012010000158030002000258065000900278064000500287031000300292
032000200295014000800297865000900305002001200314035001000326801002000336#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#c#202#16#article#39#16#
^rND^sRosario^nM#^rND^sSalzinger^nS#^rND^sFeldman^nRS#^rND^sNg-Mak^nDS#Community
 violence exposure and delinquent behaviors among youth: The moderating role of 
coping^len#J Community Psychol#20030000#2003#31#5#489-512#20110000#aop1011.htm#0
090-4392#J Community Psychol##
00580000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100017001060120
07700123030001700200065000900217064000500226031000300231032000200234014000600236
865000900242002001200251035001000263801001700273#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop1011.htm#S#c#203#17#article#39#17#^rND^sPallitto^nCC#^rND^
sMurillo^nV#Childhood abuse as a risk factor for adolescent pregnancy in El Salv
ador^len#J Adolesc Health#20080000#2008#42#6#580-6#20110000#aop1011.htm#1054-139
X#J Adolesc Health##
00767000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100014000870100014001010100
01500115010001600130010001600146012021000162030003300372710000200405065000900407
064000500416031000200421032000200423014000700425865000900432002001200441#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#c#204#18#article#39#18#
^rND^sWood^nJ#^rND^sFoy^nDW#^rND^sLayne^nC#^rND^sPynoos^nR#^rND^sJames^nCB#An ex
amination of the relationships between violence exposure, posttraumatic stress s
ymptomatology, and delinquent activity: An 'ecopathological' model of delinquent
 behavior among incarcerated adolescents^len#J Aggression Maltreatment Trauma#2#
20020000#2002#6#1#127-47#20110000#aop1011.htm##
00707000000000337000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100017001030100
01800120010002000138010002100158010001700179012007600196030002000272065000900292
06400050030103100030030603200020030901400070031186500090031800200120032703500100
0339801002000349#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S
#c#205#19#article#39#19#^rND^sAbram^nKM#^rND^sTeplin^nLA#^rND^sCharles^nDR#^rND^
sLongworth^nSL#^rND^sMcClelland^nGM#^rND^sDulcan^nMK#Posttraumatic stress disord
er and trauma in youth in juvenile detention^len#Arch Gen Psychiatry#20040000#20
04#61#4#403-10#20110000#aop1011.htm#0003-990X#Arch Gen Psychiatry##
00481000000000241000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840170007000870180049000940650
00900143064000500152110000900157109001200166037004000178865000900218002001200227
#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#c#206#20#articl
e#39#20#UNICEF#Making child rights constitutional in Brazil^len#20010000#2001#20
100823#2010 aug 23#http://www.unicef.org/sowc96/lbrzil.htm#20110000#aop1011.htm#
#
00520000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100017001050120
03400122030000700156065000900163064000500172031000400177032000500181014000600186
865000900192002001200201035001000213801000700223#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop1011.htm#S#c#207#21#article#39#21#^rND^sBochenek^nM#^rND^s
Delgado^nF#Children in custody in Brazil^len#Lancet#20060000#2006#367#9511#696-7
#20110000#aop1011.htm#0099-5355#Lancet##
00439000000000217000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840170022000870180073001090650
00900182064000500191062000400196865000900200002001200209#2011nahead#V:\SciELO\se
rial\rbp\2011nahead\markup\aop1011.htm#S#c#208#22#article#39#22#Amnesty Internat
ional#Brazil A waste of lives: FEBEM juvenile detention centres, São Paulo^len#2
0000000#2000#AMR#20110000#aop1011.htm##
00542000000000241000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840170048000870180042001350650
00900177064000500186110000900191109001200200037006700212865000900279002001200288
#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#c#209#23#articl
e#39#23#Instituto Brasileiro de Geografia e Estatística#Pesquisa nacional de saú
de do escolar^lpt#20090000#2009#20100823#23 ago 2010#http://www.ibge. gov.br/hom
e/estatistica/populacao/pense/pense.pdf#20110000#aop1011.htm##
00637000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100016001050100
01700121010001600138010002100154012007400175030002400249710000200273065000900275
064000500284031000300289032000300292014000700295865000900302002001200311#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#c#210#24#article#39#24#
^rND^sMcLennan^nJ#^rND^sBordin^nI#^rND^sBennett^nK#^rND^sRigato^nF#^rND^sBrinker
hoff^nM#Trafficking among youth in conflict with the law in São Paulo, Brazil^le
n#Social Psych Psych Epid#2#20080000#2008#43#10#816-23#20110000#aop1011.htm##
00526000000000265000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840160020000870160016001070160
01800123016001600141016001700157018003700174066001400211065000900225064000500234
865000900239002001200248#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop10
11.htm#S#c#211#25#article#39#25#^rND^sWeissberg^nRP#^rND^sVoyce^nCK#^rND^sKaspro
w^nWJ#^rND^sArthur^nM#^rND^sShriver^nT#The social and health assessment^len#New 
Haven^eCT#19910000#1991#20110000#aop1011.htm##
00729000000000337000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100022000870100014001090100
02100123010001600144010001800160010001500178012007100193030003500264065000900299
06400050030803100030031303200020031601400070031886500090032500200120033403500100
0346801003500356#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S
#c#212#26#article#39#26#^rND^sSchwab-Stone^nM#^rND^sChen^nC#^rND^sGreenberger^nE
#^rND^sSilver^nD#^rND^sLichtman^nJ#^rND^sVoyce^nC#No safe haven: II: The effects
 of violence exposure on urban youth^len#J Am Acad Child Adolesc Psychiatry#1999
0000#1999#38#4#359-67#20110000#aop1011.htm#0890-8567#J Am Acad Child Adolesc Psy
chiatry##
00619000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100019001040120
14000123030002900263710000200292065000900294064000500303031000300308032000200311
014000700313865000900320002001200329#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop1011.htm#S#c#213#27#article#39#27#^rND^sHuculak^nS#^rND^sMcLennan^nJD#
"The Lord is my Shepherd": Examining spirituality as a protection against mental
 health problems in youth exposed to violence in Brazil^len#Ment Health Religion
 Culture#2#20100000#2010#13#5#467-84#20110000#aop1011.htm##
00530000000000241000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840170046000870180047001330650
00900180064000500189110000900194109001200203037005200215865000900267002001200276
#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#c#214#28#articl
e#39#28#Associação Brasileira de Empresas de Pesquisa#Critério de classificação 
econômica Brasil^lpt#20030000#2003#20100823#23 ago 2010#http://www.abep.org/codi
gosguias/ABEP_CCEB_2003.pdf#20110000#aop1011.htm##
00565000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100017001040120
09700121030002100218710000200239065000900241064000500250031000300255032000200258
014000600260865000900266002001200275#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop1011.htm#S#c#215#29#article#39#29#^rND^sTarter^nRE#^rND^sKirisci^nL#Va
lidity of the drug use screening inventory for predicting DSM-III-R substance us
e disorder^len#J Child Adoles Subst#2#20010000#2001#10#4#45-53#20110000#aop1011.
htm##
00605000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100020000870100019001070120
08900126030002100215065000900236064000500245031000300250032000300253014000700256
865000900263002001200272035001000284801002100294#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop1011.htm#S#c#216#30#article#39#30#^rND^sDe Micheli^nD#^rND
^sFormigoni^nM#Psychometric properties of the Brazilian version of the drug use 
screening inventory^len#Alcohol Clin Exp Res#20020000#2002#26#10#1523-8#20110000
#aop1011.htm#0145-6008#Alcohol Clin Exp Res##
00666000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100017001060100
02000123010001500143010002100158012011600179030000800295710000200303065000900305
064000500314031000300319032000200322014000700324865000900331002001200340#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#c#217#31#article#39#31#
^rND^sZavaschi^nML#^rND^sBenetti^nS#^rND^sPolanczyk^nGV#^rND^sSoles^nN#^rND^sSan
chotene^nML#Adolescents exposed to physical violence in the community: a survey 
in Brazilian public schools.Rev Panam Salud^les#Publica#2#20020000#2002#12#5#327
-32#20110000#aop1011.htm##
00565000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840160014000870160019001010160
01600120016001400136016001600150018004800166066001200214062002600226065000900252
064000500261865000900266002001200275#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop1011.htm#S#c#218#32#article#39#32#^rED^sKrug^nE#^rED^sDahlberg^nLL#^rE
D^sMercy^nJA#^rED^sZwi^nAB#^rED^sLozano^nR#World report on violence and health.G
eneva,^len#Switzerland#World Health Organization#20020000#2002#20110000#aop1011.
htm##
00646000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100020001040100
01600124012013000140030001600270065000900286064000500295031000300300014000600303
865000900309002001200318035001000330801001600340#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop1011.htm#S#c#219#33#article#39#33#^rND^sFoster^nJD#^rND^sK
uperminc^nGP#^rND^sPrice^nAW#Gender differences in posttraumatic stress and rela
ted symptoms among inner-city minority youth exposed to community violence^len#J
 Youth Adolesc#20040000#2004#33#59-70#20110000#aop1011.htm#0047-2891#J Youth Ado
lesc##
00710000000000325000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100018001050100
01600123010001900139010002200158012010100180030002300281065000900304064000500313
03100030031803200020032101400070032386500090033000200120033903500100035180100230
0361#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#c#220#34#ar
ticle#39#34#^rND^sRuchkin^nVV#^rND^sHenrich^nCC#^rND^sJones^nSM#^rND^sVermeiren^
nR#^rND^sSchwab-Stone^nM#Violence exposure and psychopathology in urban youth: t
he mediating role of posttraumatic stress^len#J Abnorm Child Psychol#20070000#20
07#35#4#578-93#20110000#aop1011.htm#0091-0627#J Abnorm Child Psychol##
00664000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100015000870100017001020100
01600119010001800135012011500153030001200268065000900280064000500289031000300294
032000200297014000800299865000900307002001200316035001000328801001200338#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop1011.htm#S#c#221#35#article#39#35#
^rND^sNock^nMK#^rND^sKazdin^nAE#^rND^sHiripi^nE#^rND^sKessler^nRC#Prevalence, su
btypes, and correlates of DSM-IV conduct disorder in the National Comorbidity Su
rvey Replication^len#Psychol Med#20060000#2006#36#5#699-710#20110000#aop1011.htm
#0033-2917#Psychol Med##
00524000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100018001050120
03400123030001000157065000900167064000500176031000300181032000200184014000700186
865000900193002001200202035001000214801001000224#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop1011.htm#S#c#222#36#article#39#36#^rND^sEsbensen^nF#^rND^s
Huizinga^nD#Victimization and Delinquency^len#Youth Soc#19910000#1991#23#2#202-2
8#20110000#aop1011.htm#0044-118X#Youth Soc##
00596000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100028001050100
01700133010001600150012006100166030001800227710000200245065000900247064000500256
031000300261032000200264014000700266865000900273002001200282#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop1011.htm#S#c#223#37#article#39#37#^rND^sPatchi
n^nJW#^rND^sHuebner McCluskey^nJD#^rND^sVarano^nSP#^rND^sBynum^nTS#Exposure to c
ommunity violence and childhood delinquency^len#Crime Delinquency#2#20060000#200
6#52#2#307-32#20110000#aop1011.htm##
00669000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100016001030100
02200119012014500141030001200286065000900298064000500307031000300312032000200315
014000700317865000900324002001200333035001000345801001200355#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop1011.htm#S#c#224#38#article#39#38#^rND^sAlbus^
nKE#^rND^sWeist^nMD#^rND^sPerez-Smith^nAM#Associations between youth risk behavi
or and exposure to violence: implications for the provision of mental health ser
vices in urban schools^len#Behav Modif#20040000#2004#28#4#548-64#20110000#aop101
1.htm#0145-4455#Behav Modif##
00643000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100027000870100017001140120
11800131030002300249065000900272064000500281031000300286032000200289014000800291
865000900299002001200308035001000320801002300330#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop1011.htm#S#c#225#39#article#39#39#^rND^sHalliday-Boykins^n
CA#^rND^sGrahman^nS#At both ends of the gun: testing the relationship between co
mmunity violence exposure and youth violent behaviour^len#J Abnorm Child Psychol
#20010000#2001#29#5#383-402#20110000#aop1011.htm#0091-0627#J Abnorm Child Psycho
l##
00282000000000169000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780910009000800920007000890020012000967030
00400108#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#o#1#1#a
rticle#1#20110408#161713#aop1111.htm#187##
04476000000000637000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780710003000800400003000830010006000860420
00200092120000400094038000400098121000300102049000300105158000300108030002200111
03200060013306500090013901400070014803500100015522300090016501200920017401201360
02660100033004020100033004350100033004680700099005010700094006000831326006940850
01002020085002902030085002902059085002802088085002202116085006302138083136802201
08500100356908500320357908500360361108500310364708500240367808500640370211700080
3766072000303774112000903777111001303786114000903799113001803808002001203826#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#h#2#1#article#1#oa#
en#br1.1#1#4.0#TAB#13#nd#nd#Rev. Bras. Psiquiatr.#ahead#20110000#^f0^l0#1516-444
6#20110415#Concession of sickness benefit to social security beneficiaries due t
o mental disorders^len#Chance de deferimento de requerimentos de auxílio-doença 
a segurados do Instituto Nacional do Seguro Social com transtornos mentais^lpt#^
rND^1A01^nAdriana Kelmer^sSiano#^rND^1A02^nLuiz Cláudio^sRibeiro#^rND^1A01^nMári
o Sérgio^sRibeiro#Universidade Federal de Juiz de Fora^iA01^1Department of Medic
al Clinics^cJuiz de Fora^sMG^pBrazil#Universidade Federal de Juiz de Fora^iA02^1
Department of Statistics^cJuiz de Fora^sMG^pBrazil#^len^aOBJECTIVE: Assess the o
dds of having an initial claim for statutory sickness benefit awarded (ascribed 
to mental disorder as the main registered diagnosis), in relation to institution
al, clinical, sociodemographic and welfare factors in Juiz de Fora-MG, Brazil. M
ETHOD: Two models of logistic regression, taking into account the categories of 
the medical examiners, were built with the aim of characterizing the relative we
ight of several variables affecting the medical conclusion. RESULTS: The factors
 more strongly related to an award of benefit were a claimant assessed by a phys
ician without a specialization in psychiatry; with a diagnosis of psychosis; up 
to 29 years of age; with other non-psychiatric (musculoskeletal and cardiovascul
ar) co-morbidities; registered with the national insurance system as employed; a
nd male. DISCUSSION: In both models, examiners with a specialization in psychiat
ry were associated with a lower likelihood of award of benefit. This suggests th
at examinations undertaken by doctors having a specialty related to the diagnosi
s supporting the sickness benefit claim are stricter than those undertaken by no
n-specialists. CONCLUSION: The results suggest that benefit award odds were asso
ciated with the specialty of the examiner, medical diagnosis, age, gender and cl
aimant category.#^ddecs^i1#^tm^len^kMental disorders^i1#^tm^len^kDisabled person
s^i1#^tm^len^kSocial security^i1#^tm^len^kDiagnosis^i1#^tm^len^kEvaluation of re
sults of therapeutic interventions^i1#^lpt^aOBJETIVO: Avaliar a chance de deferi
mento em relação a fatores institucionais, clínicos, sociodemográficos e previde
nciários em exames periciais iniciais de requerentes de auxílio-doença com regis
tro de algum transtorno mental como diagnóstico principal em Juiz de Fora-MG. MÉ
TODO: Considerando as categorias de peritos médicos avaliadores, foram construíd
os dois modelos de regressão logística buscando caracterizar o peso relativo de 
diversas variáveis sobre a conclusão médico-pericial. RESULTADOS: Os fatores que
 se mostraram fortemente associados a maior chance de deferimento foram: segurad
o avaliado por perito médico sem especialidade em psiquiatria; com diagnóstico d
e psicoses; na faixa etária de até 29 anos de idade; com outras comorbidades clí
nicas que não as psiquiátricas, osteomusculares e cardiovasculares; vinculado ao
 INSS como empregado; e do sexo masculino. DISCUSSÃO: Nos dois modelos estudados
, os peritos médicos especialistas em psiquiatria se associaram a menor chance d
e deferimento. Isto sugere que profissionais especializados na área relativa ao 
diagnóstico dos segurados sejam mais rigorosos em suas avaliações periciais que 
os peritos não-especialistas. CONCLUSÃO: Os resultados sugerem que a chance de d
eferimento esteve associada à especialidade do perito médico examinador, ao diag
nóstico, idade, sexo e categoria de segurado.#^ddecs^i2#^tm^lpt^kTranstornos men
tais^i2#^tm^lpt^kPessoas com deficiência^i2#^tm^lpt^kPrevidência social^i2#^tm^l
pt^kDiagnóstico^i2#^tm^lpt^kAvaliação de resultado de intervenções terapêuticas^
i2#vancouv#29#20100511#May 11, 2010#20101121#November 21, 2010#aop1111.htm##
04560000000000637000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780710003000800400003000830010006000860420
00200092120000400094038000400098121000300102049000300105158000300108030002200111
03200060013306500090013901400070014803500100015522300090016501200990017401201430
02730100033004160100033004490100033004820700099005150700094006140831361007080850
01002069085002902079085002902108085002802137085002202165085006302187083140302250
08500100365308500320366308500360369508500310373108500240376208500640378611700080
3850072000303858112000903861111001303870114000903883113001803892002001203910#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#f#3#1#article#1#oa#
en#br1.1#1#4.0#TAB#13#nd#nd#Rev. Bras. Psiquiatr.#ahead#20110000#^f0^l0#1516-444
6#20110415#<b>Concession of sickness benefit to social security beneficiaries du
e to mental disorders</b>^len#<b>Chance de deferimento de requerimentos de auxíl
io-doença a segurados do Instituto Nacional do Seguro Social com transtornos men
tais</b>^lpt#^rND^1A01^nAdriana Kelmer^sSiano#^rND^1A02^nLuiz Cláudio^sRibeiro#^
rND^1A01^nMário Sérgio^sRibeiro#Universidade Federal de Juiz de Fora^iA01^1Depar
tment of Medical Clinics^cJuiz de Fora^sMG^pBrazil#Universidade Federal de Juiz 
de Fora^iA02^1Department of Statistics^cJuiz de Fora^sMG^pBrazil#^len^a<b>OBJECT
IVE: </b>Assess the odds of having an initial claim for statutory sickness benef
it awarded (ascribed to mental disorder as the main registered diagnosis), in re
lation to institutional, clinical, sociodemographic and welfare factors in Juiz 
de Fora-MG, Brazil. <b>METHOD: </b>Two models of logistic regression, taking int
o account the categories of the medical examiners, were built with the aim of ch
aracterizing the relative weight of several variables affecting the medical conc
lusion. <b>RESULTS: </b>The factors more strongly related to an award of benefit
 were a claimant assessed by a physician without a specialization in psychiatry;
 with a diagnosis of psychosis; up to 29 years of age; with other non-psychiatri
c (musculoskeletal and cardiovascular) co-morbidities; registered with the natio
nal insurance system as employed; and male. <b>DISCUSSION: </b>In both models, e
xaminers with a specialization in psychiatry were associated with a lower likeli
hood of award of benefit. This suggests that examinations undertaken by doctors 
having a specialty related to the diagnosis supporting the sickness benefit clai
m are stricter than those undertaken by non-specialists. <b>CONCLUSION: </b>The 
results suggest that benefit award odds were associated with the specialty of th
e examiner, medical diagnosis, age, gender and claimant category.#^ddecs^i1#^tm^
len^kMental disorders^i1#^tm^len^kDisabled persons^i1#^tm^len^kSocial security^i
1#^tm^len^kDiagnosis^i1#^tm^len^kEvaluation of results of therapeutic interventi
ons^i1#^lpt^a<b>OBJETIVO: </b>Avaliar a chance de deferimento em relação a fator
es institucionais, clínicos, sociodemográficos e previdenciários em exames peric
iais iniciais de requerentes de auxílio-doença com registro de algum transtorno 
mental como diagnóstico principal em Juiz de Fora-MG. <b>MÉTODO: </b>Considerand
o as categorias de peritos médicos avaliadores, foram construídos dois modelos d
e regressão logística buscando caracterizar o peso relativo de diversas variávei
s sobre a conclusão médico-pericial. <b>RESULTADOS: </b>Os fatores que se mostra
ram fortemente associados a maior chance de deferimento foram: segurado avaliado
 por perito médico sem especialidade em psiquiatria; com diagnóstico de psicoses
; na faixa etária de até 29 anos de idade; com outras comorbidades clínicas que 
não as psiquiátricas, osteomusculares e cardiovasculares; vinculado ao INSS como
 empregado; e do sexo masculino. <b>DISCUSSÃO: </b>Nos dois modelos estudados, o
s peritos médicos especialistas em psiquiatria se associaram a menor chance de d
eferimento. Isto sugere que profissionais especializados na área relativa ao dia
gnóstico dos segurados sejam mais rigorosos em suas avaliações periciais que os 
peritos não-especialistas. <b>CONCLUSÃO: </b>Os resultados sugerem que a chance 
de deferimento esteve associada à especialidade do perito médico examinador, ao 
diagnóstico, idade, sexo e categoria de segurado.#^ddecs^i2#^tm^lpt^kTranstornos
 mentais^i2#^tm^lpt^kPessoas com deficiência^i2#^tm^lpt^kPrevidência social^i2#^
tm^lpt^kDiagnóstico^i2#^tm^lpt^kAvaliação de resultado de intervenções terapêuti
cas^i2#vancouv#29#20100511#May 11, 2010#20101121#November 21, 2010#aop1111.htm##
04599000000000661000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780640007000800710003000870400003000900010
00600093042000200099120000400101038000400105121000300109049000300112158000300115
03000210011803200060013906500090014501400070015403500100016122300090017101200920
01800120136002720100033004080100033004410100033004740700101005070700096006080831
32600704085001002030085002902040085002902069085002802098085002202126085006302148
08313680221108500100357908500320358908500360362108500310365708500240368808500640
37121170008037760720003037841120009037871110013037961140009038091130018038180020
01203836008008903848#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.h
tm#S#l#4#1#article#1#^a2011#oa#en#br1.1#1#4.0#tab#13#nd#nd#Rev. bras. psiquiatr#
ahead#20110000#^f0^l0#1516-4446#20110415#Concession of sickness benefit to socia
l security beneficiaries due to mental disorders^len#Chance de deferimento de re
querimentos de auxílio-doença a segurados do Instituto Nacional do Seguro Social
 com transtornos mentais^lpt#^rND^1A01^nAdriana Kelmer^sSiano#^rND^1A02^nLuiz Cl
áudio^sRibeiro#^rND^1A01^nMário Sérgio^sRibeiro#^iA01^1Universidade Federal de J
uiz de Fora^2Department of Medical Clinics^cJuiz de Fora^sMG^pBrazil#^iA02^1Univ
ersidade Federal de Juiz de Fora^2Department of Statistics^cJuiz de Fora^sMG^pBr
azil#^len^aOBJECTIVE: Assess the odds of having an initial claim for statutory s
ickness benefit awarded (ascribed to mental disorder as the main registered diag
nosis), in relation to institutional, clinical, sociodemographic and welfare fac
tors in Juiz de Fora-MG, Brazil. METHOD: Two models of logistic regression, taki
ng into account the categories of the medical examiners, were built with the aim
 of characterizing the relative weight of several variables affecting the medica
l conclusion. RESULTS: The factors more strongly related to an award of benefit 
were a claimant assessed by a physician without a specialization in psychiatry; 
with a diagnosis of psychosis; up to 29 years of age; with other non-psychiatric
 (musculoskeletal and cardiovascular) co-morbidities; registered with the nation
al insurance system as employed; and male. DISCUSSION: In both models, examiners
 with a specialization in psychiatry were associated with a lower likelihood of 
award of benefit. This suggests that examinations undertaken by doctors having a
 specialty related to the diagnosis supporting the sickness benefit claim are st
ricter than those undertaken by non-specialists. CONCLUSION: The results suggest
 that benefit award odds were associated with the specialty of the examiner, med
ical diagnosis, age, gender and claimant category.#^ddecs^i1#^tm^len^kMental dis
orders^i1#^tm^len^kDisabled persons^i1#^tm^len^kSocial security^i1#^tm^len^kDiag
nosis^i1#^tm^len^kEvaluation of results of therapeutic interventions^i1#^lpt^aOB
JETIVO: Avaliar a chance de deferimento em relação a fatores institucionais, clí
nicos, sociodemográficos e previdenciários em exames periciais iniciais de reque
rentes de auxílio-doença com registro de algum transtorno mental como diagnóstic
o principal em Juiz de Fora-MG. MÉTODO: Considerando as categorias de peritos mé
dicos avaliadores, foram construídos dois modelos de regressão logística buscand
o caracterizar o peso relativo de diversas variáveis sobre a conclusão médico-pe
ricial. RESULTADOS: Os fatores que se mostraram fortemente associados a maior ch
ance de deferimento foram: segurado avaliado por perito médico sem especialidade
 em psiquiatria; com diagnóstico de psicoses; na faixa etária de até 29 anos de 
idade; com outras comorbidades clínicas que não as psiquiátricas, osteomusculare
s e cardiovasculares; vinculado ao INSS como empregado; e do sexo masculino. DIS
CUSSÃO: Nos dois modelos estudados, os peritos médicos especialistas em psiquiat
ria se associaram a menor chance de deferimento. Isto sugere que profissionais e
specializados na área relativa ao diagnóstico dos segurados sejam mais rigorosos
 em suas avaliações periciais que os peritos não-especialistas. CONCLUSÃO: Os re
sultados sugerem que a chance de deferimento esteve associada à especialidade do
 perito médico examinador, ao diagnóstico, idade, sexo e categoria de segurado.#
^ddecs^i2#^tm^lpt^kTranstornos mentais^i2#^tm^lpt^kPessoas com deficiência^i2#^t
m^lpt^kPrevidência social^i2#^tm^lpt^kDiagnóstico^i2#^tm^lpt^kAvaliação de resul
tado de intervenções terapêuticas^i2#vancouv#29#20100511#May 11, 2010#20101121#N
ovember 21, 2010#aop1111.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sc
i_arttext&pid=S1516-44462011005000013##
00445000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704020500082002001200287#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#5#1#article#154#<p><font size
="4" face="Verdana"><B><a name="title"></a>Concession of sickness       benefit 
to social security beneficiaries due to mental disorders<a href="#end"><sup>*</s
up></a> </B></font></p>     ^cY#aop1111.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#6#2#article#154#<p>&nbsp;</p>
     ^cY#aop1111.htm##
00493000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704025300082002001200335#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#7#3#article#154#<p><font size
="3" face="Verdana"><b>Chance de deferimento de requerimentos de       aux&iacut
e;lio&#45;doen&ccedil;a a segurados do Instituto Nacional do Seguro       Social
 com transtornos mentais<a href="#end"><sup>*</sup></a> </b></font></p>     ^cY#
aop1111.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#8#4#article#154#<p>&nbsp;</p>
     ^cY#aop1111.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#9#5#article#154#<p>&nbsp;</p>
     ^cY#aop1111.htm##
00429000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704018800083002001200271#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#10#6#article#154#<p><font siz
e="2" face="Verdana"><b>Adriana Kelmer Siano<Sup>I</Sup>; Luiz Cl&aacute;udio   
    Ribeiro<Sup>II</Sup>; M&aacute;rio S&eacute;rgio Ribeiro<Sup>I</Sup></b></fo
nt></p>     ^cY#aop1111.htm##
00399000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704015800083002001200241#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#11#7#article#154#<p><font siz
e="2" face="Verdana"><Sup>I</Sup>Department of Medical Clinics, Universidade    
 Federal de Juiz de Fora (UFJF), Juiz de Fora, MG, Brazil     ^cY#aop1111.htm##
00379000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704013800083002001200221#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#12#8#article#154#<BR>   <Sup>
II</Sup>Department of Statistics, Universidade Federal de Juiz de Fora   (UFJF),
 Juiz de Fora, MG, Brazil </font></p>     ^cY#aop1111.htm##
00327000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704008600083002001200169#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#13#9#article#154#<p><font siz
e="2" face="Verdana"><a href="#end">Correspondence</a></font></p>     ^cY#aop111
1.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#14#10#article#154#<p>&nbsp;</
p>     ^cY#aop1111.htm##
00286000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704004400084002001200128#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#15#11#article#154#<p>&nbsp;</
p> <hr size="1" noshade>     ^cY#aop1111.htm##
00310000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704006800084002001200152#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#16#12#article#154#<p><font si
ze="2" face="Verdana"><b>ABSTRACT</b></font></p>     ^cY#aop1111.htm##
00568000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704032600084002001200410#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#17#13#article#154#<p><font si
ze="2" face="Verdana"><B>OBJECTIVE: </B>Assess the odds of having     an initial
 claim for statutory sickness benefit awarded (ascribed to mental     disorder a
s the main registered diagnosis), in relation to institutional,     clinical, so
ciodemographic and welfare factors in Juiz de Fora&#45;MG, Brazil.     ^cY#aop11
11.htm##
00489000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704024700084002001200331#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#18#14#article#154#<BR>   <B>M
ETHOD: </B>Two models of logistic regression, taking into account the categories
   of the medical examiners, were built with the aim of characterizing the relat
ive   weight of several variables affecting the medical conclusion.     ^cY#aop1
111.htm##
00628000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704038600084002001200470#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#19#15#article#154#<BR>   <B>R
ESULTS: </B>The factors more strongly related to an award of benefit were   a cl
aimant assessed by a physician without a specialization in psychiatry;   with a 
diagnosis of psychosis; up to 29 years of age; with other non&#45;psychiatric   
(musculoskeletal and cardiovascular) co&#45;morbidities; registered with the nat
ional   insurance system as employed; and male.    ^cY#aop1111.htm##
00602000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704036000084002001200444#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#20#16#article#154#<BR>   <B>D
ISCUSSION: </B>In both models, examiners with a specialization in psychiatry   w
ere associated with a lower likelihood of award of benefit. This suggests   that
 examinations undertaken by doctors having a specialty related to the diagnosis 
  supporting the sickness benefit claim are stricter than those undertaken by   
non&#45;specialists.     ^cY#aop1111.htm##
00442000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704020000084002001200284#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#21#17#article#154#<BR>   <B>C
ONCLUSION: </B>The results suggest that benefit award odds were associated   wit
h the specialty of the examiner, medical diagnosis, age, gender and claimant   c
ategory. </font></p>     ^cY#aop1111.htm##
00511000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704026900084002001200353#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#22#18#article#154#<p><font si
ze="2" face="Verdana"><B>Descriptors: </B>Mental disorders; Disabled     persons
; Social security; Diagnosis; Evaluation of results of therapeutic     intervent
ions </font></p> <hr size="1" noshade> <b><font size="2" face="VERDANA">RESUMO</
font></b>     ^cY#aop1111.htm##
00644000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704040200084002001200486#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#23#19#article#154#<p><font si
ze="2" face="Verdana"><B>OBJETIVO: </B>Avaliar a chance de deferimento     em re
la&ccedil;&atilde;o a fatores institucionais, cl&iacute;nicos, sociodemogr&aacut
e;ficos     e previdenci&aacute;rios em exames periciais iniciais de requerentes
 de aux&iacute;lio&#45;doen&ccedil;a     com registro de algum transtorno mental
 como diagn&oacute;stico principal     em Juiz de Fora&#45;MG.     ^cY#aop1111.h
tm##
00546000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704030400084002001200388#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#24#20#article#154#<BR>   <B>M
&Eacute;TODO: </B>Considerando as categorias de peritos m&eacute;dicos   avaliad
ores, foram constru&iacute;dos dois modelos de regress&atilde;o log&iacute;stica
   buscando caracterizar o peso relativo de diversas vari&aacute;veis sobre a   
conclus&atilde;o m&eacute;dico&#45;pericial.     ^cY#aop1111.htm##
00712000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704047000084002001200554#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#25#21#article#154#<BR>   <B>R
ESULTADOS: </B>Os fatores que se mostraram fortemente associados a maior   chanc
e de deferimento foram: segurado avaliado por perito m&eacute;dico sem   especia
lidade em psiquiatria; com diagn&oacute;stico de psicoses; na faixa   et&aacute;
ria de at&eacute; 29 anos de idade; com outras comorbidades cl&iacute;nicas   qu
e n&atilde;o as psiqui&aacute;tricas, osteomusculares e cardiovasculares;   vinc
ulado ao INSS como empregado; e do sexo masculino.     ^cY#aop1111.htm##
00632000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704039000084002001200474#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#26#22#article#154#<BR>   <B>D
ISCUSS&Atilde;O: </B>Nos dois modelos estudados, os peritos m&eacute;dicos   esp
ecialistas em psiquiatria se associaram a menor chance de deferimento. Isto   su
gere que profissionais especializados na &aacute;rea relativa ao diagn&oacute;st
ico   dos segurados sejam mais rigorosos em suas avalia&ccedil;&otilde;es perici
ais   que os peritos n&atilde;o&#45;especialistas.     ^cY#aop1111.htm##
00484000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704024200084002001200326#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#27#23#article#154#<BR>   <B>C
ONCLUS&Atilde;O: </B>Os resultados sugerem que a chance de deferimento   esteve 
associada &agrave; especialidade do perito m&eacute;dico examinador,   ao diagn&
oacute;stico, idade, sexo e categoria de segurado. </font></p>     ^cY#aop1111.h
tm##
00529000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704028700084002001200371#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#28#24#article#154#<p><font si
ze="2" face="Verdana"><B>Descritores: </B>Transtornos mentais; Pessoas     com d
efici&ecirc;ncia; Previd&ecirc;ncia social; Diagn&oacute;stico; Avalia&ccedil;&a
tilde;o     de resultado de interven&ccedil;&otilde;es terap&ecirc;uticas </font
></p> <hr size="1" noshade>     ^cY#aop1111.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#29#25#article#154#<p>&nbsp;</
p>     ^cY#aop1111.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#30#26#article#154#<p>&nbsp;</
p>     ^cY#aop1111.htm##
00315000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007300084002001200157#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#31#27#article#154#<p><font si
ze="3" face="Verdana"><B>Introduction</B> </font></p>     ^cY#aop1111.htm##
01215000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704097300084002001201057#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#32#28#article#154#<p><font si
ze="2" face="Verdana">Clearly conceived to act as an insurance system,<Sup>1 </S
up>sickness     benefit is a welfare/cash benefit paid by the Brazilian National
 Insurance     Institute (<I>Instituto Nacional do Seguro Social, </I>INSS) to t
hose who,     because of a health problem, are temporarily incapable of performi
ng their     work activities <B>&#150; </B><I>sine qua non </I>this being the de
ciding     condition for claimants to have their benefit claim awarded.<Sup>1&#4
5;3 </Sup>The     last few decades have witnessed a significant rise in the numb
er of work     disability&#45;related sickness benefits awarded, with the conseq
uent economic     impact on the country.<Sup>4,5 </Sup>Although not one quantita
tive study     on this problem has been found, according to INSS data, 575,742 i
nstances     of sickness benefit were awarded in 1988, a figure which increased 
to 1,860,695     in 2005 and 2,188,671 in 2006.<Sup>6,7 </Sup></font></p>     ^c
Y#aop1111.htm##
01361000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704111900084002001201203#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#33#29#article#154#<p><font si
ze="2" face="Verdana">As from 2005, the INSS implemented administrative     chan
ges that should reduce the awarding of sickness benefits<Sup>8</Sup>:     (1) im
plementation of the office of career INSS medical examiner, with the     public 
selection of three thousand doctors, aiming to replace provisional, <I>ad     ho
c </I>and fee&#45;for&#45;services examiners; (2) creation of the Estimated Insu
rance     Coverage (<I>Cobertura Previdenci&aacute;ria Estimada, </I>COPES), whi
ch     aims to reduce waiting lists by elimination of intermediate medical exami
nations     and through the establishment of deadlines for payment of benefits, 
according     to the expected length of time necessary for the claimant to be de
emed fit     to work again; (3) the creation of the Postponement Request (<I>Ped
ido de     Prorroga&ccedil;&atilde;o, </I>PP), which allows the claimant to requ
est     longer recovery periods. In spite of all these changes, the number of in
stances     of sickness benefit awarded in 2007 and 2008 was still high: 1,825,5
08 and     1,806,727, respectively.<Sup>7 </Sup></font></p>     ^cY#aop1111.htm#
#
00811000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704056900084002001200653#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#34#30#article#154#<p><font si
ze="2" face="Verdana">Research on the number and cost of work disability&#45;rel
ated     benefits is not an exclusively Brazilian phenomenon,<Sup>9&#45;13 </Sup
>and studies     seeking associated factors can be found in the international li
terature.<Sup>3&#45;5,14&#45;17 </Sup>As     for the clinical implications that 
may justify classification as 'unfit     for work', some studies have pointed to
 the relevance of the following     diagnostic categories: musculoskeletal, card
iovascular and mental disorders.<Sup>3,11,15&#45;18 </Sup></font></p>     ^cY#ao
p1111.htm##
00768000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704052600084002001200610#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#35#31#article#154#<p><font si
ze="2" face="Verdana">The World Health Organization (WHO) has highlighted     th
e economic impact of mental disorders, and the need for more research into     t
heir high indirect costs, which are due to the fall in productivity resulting   
  from the prolonged spells of disability that these disorders entail.<Sup>19 </
Sup>Prince     et al. reported some 2005 WHO data, which showed that neurologica
l/psychiatric     disorders account for 31.7% of all years lived with disability
.<Sup>20 </Sup></font></p>     ^cY#aop1111.htm##
01159000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704091700084002001201001#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#36#32#article#154#<p><font si
ze="2" face="Verdana">Other studies have highlighted that, because     of the su
bjective aspects involved, mental disorders represent one of the     most comple
x situations dealt with by experts working with incapacity claims.<Sup>2,21&#45;
23 </Sup>This     situation may not only accentuate conflicts as a result of a d
iversity of     interpretation, but final decisions on work disability may be eq
uivocal too.     The increase in the number of claimants with a registered menta
l disorder     as their main diagnosis at the initial medical examination,<Sup>3
 </Sup>may     lead to the possibility of inadequate granting of benefits. The d
irect costs     (related to the payment of the benefits) and the indirect ones (
due to the     individual's having to withdraw from the labor market) justify th
e     need to assess factors associated with inequalities in the awarding of ben
efit. </font></p>     ^cY#aop1111.htm##
00735000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704049300084002001200577#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#37#33#article#154#<p><font si
ze="2" face="Verdana">The aim of this study was to assess the odds     of having
 an initial claim for statutory sickness benefit awarded (where     a mental dis
order was registered as the main diagnosis at the initial medical     examinatio
n), in relation to institutional, clinical, sociodemographic and     welfare fac
tors. Establishing these factors is likely to make a substantial     contributio
n to the possibility of reducing excessive grants of benefit. </font></p>     ^c
Y#aop1111.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#38#34#article#154#<p>&nbsp;</
p>     ^cY#aop1111.htm##
00309000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704006700084002001200151#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#39#35#article#154#<p><font si
ze="3" face="Verdana"><B>Method</B> </font></p>     ^cY#aop1111.htm##
01113000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704087100084002001200955#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#40#36#article#154#<p><font si
ze="2" face="Verdana">This retrospective study searched a databank     provided 
by the Brazilian National Insurance Information and Technology Administration   
  (<I>Empresa de Tecnologia e Informa&ccedil;&otilde;es da Previd&ecirc;ncia    
 Social, </I>DATAPREV), which contains institutional, sociodemographic, clinical
     and welfare variables concerning the sickness benefits granted after initia
l     medical examinations undertaken in two agencies of the Juiz de Fora INSS  
   Executive Management (<I>Ger&ecirc;ncia Executiva de Juiz de Fora, </I>Gex/JF
),     between July 2004 and December 2006. The Largo do Riachuelo and S&atilde;
o     Dimas agencies may be considered representative of Brazilian agencies of  
   medium&#45;sized cities; besides, they have the advantage of having been digi
talized     before the period analyzed. </font></p>     ^cY#aop1111.htm##
00581000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704033900084002001200423#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#41#37#article#154#<p><font si
ze="2" face="Verdana">As described elsewhere,<Sup>8,24 </Sup>all medical     exa
minations having, as their main diagnosis, a group F condition (mental     and b
ehavioral disorders) as listed in the tenth edition of the International     Cla
ssification of Diseases (ICD&#45;X), were considered in this study. </font></p> 
    ^cY#aop1111.htm##
01368000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704112600084002001201210#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#42#38#article#154#<p><font si
ze="2" face="Verdana">Taking into account the changes in welfare legislation    
 and the categories of the medical examiners &#150; related to their professiona
l     links to the INSS &#150; the assessed period was subdivided thus: (1) from
     July 2004 to July 2005, comprising the 13 study months prior to the impleme
ntation     of COPES, involving INSS examiners admitted before 2005 ('old examin
ers'),     those admitted after 2005 ('recent examiners')<a name="tx01"></a><a h
ref="#nt01"><sup>1</sup></a> and <I>ad     hoc</I>/fee&#45;for&#45;services exam
iners; (2) from August 2005 to November 2005,     the first four months after im
plementation of COPES, including 'old     examiners', 'recent examiners' and <I>
ad hoc</I>/fee&#45;for&#45;services     examiners; (3) from December 2005 to Apr
il 2006, the final five months of     COPES, prior to the implementation of PP, 
involving 'old examiners' and 'recent     examiners'; and (4) from May 2006 to D
ecember 2006, encompassing the     eight study months after the implementation o
f PP, with 'old examiners' and 'recent     examiners'. </font></p>     ^cY#aop11
11.htm##
00905000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704066300084002001200747#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#43#39#article#154#<p><font si
ze="2" face="Verdana">For comparison of the three core institutional     variabl
es of this study &#151; medical examiner category, INSS agency and     study per
iod &#151; 'old examiners' were considered as the typical     examiner group, be
cause it was the only one undertaking examinations throughout     the study peri
od. The Largo do Riachuelo INSS agency, whose clientele is     composed of Juiz 
de Fora residents, was chosen as the typical INSS agency.     Because it antedat
ed changes in the legislation and in the composition of     the INSS examiner st
aff, the first period studied was considered to be the     typical one. </font><
/p>     ^cY#aop1111.htm##
01332000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704109000084002001201174#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#44#40#article#154#<p><font si
ze="2" face="Verdana">The 11,236 registers of the databank were statistically   
  analyzed with SPSS 14.0 software (series number 9656438). Descriptive and     
exploratory analyses, bivariate analyses<Sup>8,24 </Sup>and result stratificatio
n     showed an interactive effect among the three core institutional variables.
     These interactions were considered in the logistic regression models used  
   to show the relative weight of the institutional, sociodemographic, clinical 
    and welfare variables on the outcome variable, that is, 'the outcome     of 
the benefit&#45;related medical examination'. Once the <I>ad hoc</I>/fee&#45;for
&#45;services     examiners were present, only during the first and second perio
ds, two models     were defined in order to represent each of the realities iden
tified: Model     1, to represent the first two study periods and the three cate
gories of medical     examiners; and Model 2, applicable to all four periods but
 excluding the     examinations performed by the <I>ad hoc</I>/fee&#45;for&#45;s
ervices examiners. </font></p>     ^cY#aop1111.htm##
00812000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704057000084002001200654#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#45#41#article#154#<p><font si
ze="2" face="Verdana">The logistic regression models were built by     the Enter
 method, including: (1) the core institutional variables (medical     examiner c
ategory, INSS agency and study period); (2) the medical examiner's     specialty
; (3) sociodemographic variables (age range and gender); (4) clinical     variab
les (main and secondary diagnoses); and (5) welfare&#45;related variables     (c
laimant category and the median<a name="tx02"></a><a href="#nt02"><sup>2</sup></
a> of     their INSS affiliation and contribution period). </font></p>     ^cY#a
op1111.htm##
00891000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704064900084002001200733#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#46#42#article#154#<p><font si
ze="2" face="Verdana">Each variable used in the two models was included     in a
n <I>a priori </I>order related to the expected weight of its influence     on '
the outcome of the benefit&#45;related medical examination',     according to th
e work experience of the main author of this study on welfarerelated     medical
 examinations: category of medical examiner &rarr; INSS agency &rarr; study     
period &rarr; specialty of the medical examiner &rarr; main diagnosis &rarr; age
     range &rarr; secondary diagnosis &rarr; category of claimant &rarr; gender 
&rarr; contribution     period &rarr; affiliation period. </font></p>     ^cY#ao
p1111.htm##
00836000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704059400084002001200678#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#47#43#article#154#<p><font si
ze="2" face="Verdana">In an attempt to represent the reality observed     in the
 results of the stratified analyses concerning the benefit&#45;related     medic
al conclusion and regarding the variables, three interactions among     the inst
itutional variables were included in the models: 'examiner     category versus I
NSS agency', 'examiner category versus period',     and 'INSS agency versus peri
od'. These interactions were included     in the models immediately after the is
olated institutional variables<a name="tx03"></a><a href="#nt03"><sup>3</sup></a
>. </font></p>     ^cY#aop1111.htm##
00805000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704056300084002001200647#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#48#44#article#154#<p><font si
ze="2" face="Verdana">It was previously established that the institutional     v
ariables would be included and considered in the models, regardless of their    
 statistical significance on bivariate analyses and on the final models. For    
 the other variables, we used, as the entry criterion in each model, the classic
al     statistical significance on bivariate analyses (p <u>&lt;</u> 0.05 on Pea
rson's     chi&#45;square test); and their retention in the final models require
d a p&#45;value <u>&lt;</u> 0.05     in each model. </font></p>     ^cY#aop1111.
htm##
01104000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704086200084002001200946#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#49#45#article#154#<p><font si
ze="2" face="Verdana">For the institutional variables, the categories     consid
ered typical (the 'old examiners', the Largo do Riachuelo     INSS agency, and t
he 'first period') were taken as reference     categories in each model. For the
 variable 'specialization of the medical     examiner', the reference category w
as 'psychiatry', as     the medical specialty best trained to deal with mental d
isorders. For the     other variables, the reference category was considered tha
t which a higher     awarding rate on bivariate analysis, that is: (1) giving 'p
sychoses' as     the main diagnosis; (2) age range 'up to 29 years' ; (3) 'other
     clinical pictures' as secondary diagnosis; (4) 'employed' as     claimant c
ategory; (5) 'male' gender; (6) 'above median' contribution     time; and (7) 'a
bove median' affiliation time. </font></p>     ^cY#aop1111.htm##
00530000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704028800084002001200372#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#50#46#article#154#<p><font si
ze="2" face="Verdana">The study was submitted to and approved by the     Researc
h Ethics Committee of the Universidade Federal de Juiz de Fora (CEP/UFJF,     pr
otocol number 041/2007). There was no conflict of interest in the development   
  of this study. </font></p>     ^cY#aop1111.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#51#47#article#154#<p>&nbsp;</
p>     ^cY#aop1111.htm##
00310000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704006800084002001200152#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#52#48#article#154#<p><font si
ze="3" face="Verdana"><B>Results </B></font></p>     ^cY#aop1111.htm##
00699000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704045700084002001200541#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#53#49#article#154#<p><font si
ze="2" face="Verdana"><a href="/img/revistas/rbp/2011nahead/a11tab01.jpg">Table 
1</a> presents     a description of the group of medical examinations included i
n this study     and the results of bivariate analysis in relation to the three 
core institutional     variables considered (medical examiner category, INSS age
ncy and study period),     showing only the six variables that met inclusion cri
teria for the two models. </font></p>     ^cY#aop1111.htm##
00630000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704038800084002001200472#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#54#50#article#154#<p><font si
ze="2" face="Verdana">The final models (1 and 2) were composed of     the follow
ing variables and interactions: examiner category, INSS agency,     study period
, examiner category vs. INSS agency, examiner category vs. period,     INSS agen
cy vs. period, examiner specialty, main diagnosis, age range, secondary     diag
nosis, claimant category and gender. </font></p>     ^cY#aop1111.htm##
01103000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704086100084002001200945#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#55#51#article#154#<p><font si
ze="2" face="Verdana"><a href="#tab02">Table 2</a> shows     claimants seen at t
he S&atilde;o Dimas INSS agency by <I>ad hoc </I>/fee&#45;for&#45;services     e
xaminers during the second study period; by examiners from non&#45;psychiatric  
   specialties; and by examiners not registered as specialists in the Disability
     Benefit Management System (<I>Sistema de Administra&ccedil;&atilde;o de Ben
ef&iacute;cios     por Incapacidade, </I>SABI) were significantly more likely to
 be awarded     a benefit (OR ranging from 1.82 to 4.58). The other variable cat
egories included     in this model, which resulted in significant difference wer
e associated with     lower odds of benefit concession, with OR ranging from 0.0
4 (with anxiety     disorders as main diagnosis) and 0.68 (<I>ad hoc</I>/fee&#45
;for&#45;services examiners). </font></p>     ^cY#aop1111.htm##
00278000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704003600084002001200120#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#56#52#article#154#<p><a name=
"tab02"></a></p>     ^cY#aop1111.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#57#53#article#154#<p>&nbsp;</
p>     ^cY#aop1111.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#58#54#article#154#<p align="c
enter"><img src="/img/revistas/rbp/2011nahead/a11tab02.jpg"></p>     ^cY#aop1111
.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#59#55#article#154#<p>&nbsp;</
p>     ^cY#aop1111.htm##
00907000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704066500084002001200749#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#60#56#article#154#<p><font si
ze="2" face="Verdana">Likewise, in Model 2 (<a href="#tab03">Table       3</a>),
 the circumstances associated with a higher likelihood of award       of benefit
, with OR ranging from and 4.95, were nearly the same: S&atilde;o       Dimas IN
SS agency; second study period; examiners from other specialties       different
 from psychiatry; and examiners without a specialty register.       The other va
riable categories showing a significant difference on Model       2 were associa
ted with a lower likelihood of award, with OR ranging from       0.13 (anxiety d
isorders as main diagnosis) to 0.82 (age range of 30&#45;49       years). </font
></p>     ^cY#aop1111.htm##
00278000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704003600084002001200120#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#61#57#article#154#<p><a name=
"tab03"></a></p>     ^cY#aop1111.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#62#58#article#154#<p>&nbsp;</
p>     ^cY#aop1111.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#63#59#article#154#<p align="c
enter"><img src="/img/revistas/rbp/2011nahead/a11tab03.jpg"></p>     ^cY#aop1111
.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#64#60#article#154#<p>&nbsp;</
p>     ^cY#aop1111.htm##
00313000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007100084002001200155#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#65#61#article#154#<p><font si
ze="3" face="Verdana"><B>Discussion </B></font></p>     ^cY#aop1111.htm##
00767000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704052500084002001200609#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#66#62#article#154#<p><font si
ze="2" face="Verdana">The likelihood of benefits being awarded was     significa
ntly higher for males and for the 'up to 29 years' age     range. Although no ev
idence for an association between gender and the awarding     of mental disorder
&#45;related sickness benefit has been found in the literature,     the results 
for age are in accordance with Mycletun et al.,<Sup>12 </Sup>who     identified 
an interaction between younger age and awarding of benefits ascribed     to ment
al disorders. </font></p>     ^cY#aop1111.htm##
01828000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704158600084002001201670#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#67#63#article#154#<p><font si
ze="2" face="Verdana">The 'employed' claimant category     was strongly predicti
ve of the awarding of sickness benefit, with higher     odds than for the other 
INSS claimant categories. Actually, the legislation     on benefitrelated medica
l examinations for the awarding of sickness benefit     does not distinguish cla
imants based on their links to the INSS &#151; neither     by their period of af
filiation nor by their contribution record &#151; once     the probation period 
is over. Otherwise, these results point to the possibility     that the work sta
tus of sickness benefit claimants did influence the examiners' conclusions:     
medical complaints from claimants in other categories may not be valued as     h
ighly by the examiners as those manifested by traditionally employed claimants. 
    On one hand, it is usually supposed by the medical INSS examiners that many 
    claimants in other categories do not actually carry out the occupation state
d,     which could indicate that such claimants would be seeking alternative inc
ome     sources, without being actually unfit for work. On the other hand, it is
     possible that the subjectivity involved in the examiners' conclusions<Sup>2
2 </Sup>may     be penalizing these claimants working in the informal labor mark
et. The same     dynamics may be occuring in the case of the significantly lower
 benefits     granted to women: it is noteworthy that even though it is expected
 that women     constitute the majority of 'home workers', since this difference
     was sustained in both models. </font></p>     ^cY#aop1111.htm##
01188000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704094600084002001201030#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#68#64#article#154#<p><font si
ze="2" face="Verdana">Taking the diagnosis of psychoses as reference,     the od
ds in favour of granting benefit decreased in the following order:     disorders
 due to the use of psychoactive drugs, minor mood disorders, other     mental di
sorders and anxiety disorders. Okpaku et al. have reported that     sickness ben
efit claimants diagnosed with psychoses or mood disorders were     more likely t
o receive a benefit compared with those diagnosed with anxiety.<Sup>23 </Sup>Sco
tt     et al. showed that mood disorders were more closely associated with disab
ility     than anxiety disorders and disorders related to the use of psychoactiv
e substances,     with even milder mood disorders being more disabling than anxi
ety disorders.<Sup>25 </Sup>Such     results indicate that the examiners are cor
rectly acting as gatekeepers,<Sup>1 </Sup>prioritizing     access for claimants 
with more severe mental disorders. </font></p>     ^cY#aop1111.htm##
01404000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704116200084002001201246#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#69#65#article#154#<p><font si
ze="2" face="Verdana">As for comorbidities, Prince et al. highlighted     the im
portance of mental disorders as risk factors for the development of     transmis
sible and non&#45;transmissible diseases, and as contributors to accidental     
and non&#45;accidental damage; on the other hand, those authors stated that seve
ral     clinical pathologies could increase the risk of mental disorders or prol
ong     their episodes.<Sup>20 </Sup>Moussavi et al. found significantly higher 
prevalence     rates of depression among patients with chronic clinical diseases
 such as     arthritis, angina and diabetes, with depression being associated wi
th clinical     deterioration.<Sup>26 </Sup>Other studies have emphasized that c
o&#45;ocurring     clinical comorbidities and psychiatric comorbidities are more
 disabling than     any clinical or psychiatric disease in without any comorbidi
ty.<Sup>25,27,28 </Sup>In     accordance with this observation, our results show
ed that the absence of     a comorbidity was significantly associated with a low
er likelihood of benefit     being granted, compared with the presence of any co
morbidity. </font></p>     ^cY#aop1111.htm##
01044000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704080200084002001200886#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#70#66#article#154#<p><font si
ze="2" face="Verdana">Throughout its history, the performance of the     INSS ex
aminers has been influenced by sociopolitical factors that resulted     in more 
or less severe tightening of the benefit award process. In the last     few year
s, however, the progressive decrease in the number of awards suggests     that m
ore stringent criteria for the assessment of work disability have prevailed.    
 Considering that in both models examiners with a specialization in psychiatry  
   were responsible for granting a significantly lower number of benefits, our  
   results suggest that examinations undertaken by doctors with a specialization
     related to the diagnosis supporting the sickness benefit claim are stricter
     than those undertaken by non&#45;specialists. </font></p>     ^cY#aop1111.h
tm##
00827000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704058500084002001200669#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#71#67#article#154#<p><font si
ze="2" face="Verdana">The results indicate that the fall in awarding     rates f
rom the first to the fourth period (see <a href="/img/revistas/rbp/2011nahead/a1
1tab01.jpg">Table     1</a>) cannot be solely attributed to the taking on of the
 'recent     examiners' or to the introduction of normative changes. It' is     
possible that changes which have occurred in the past few years in the INSS     
disability&#45;related medical examinations sector have resulted in concrete    
 changes in a practice hitherto consolidated, one that lasted until 2005. </font
></p>     ^cY#aop1111.htm##
02071000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704182900084002001201913#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#72#68#article#154#<p><font si
ze="2" face="Verdana">In spite of the impact of these changes on the     Welfare
 State &#151; a reduction in disability benefit concessions, after     years of 
progressive increases &#151; such changes challenge the conceptions     of claim
ants, who still file a sickness benefit claim for reasons that more     often th
an not extrapolate the relationship between disease and ability to     work. Alt
hough the medical examiner is frequently seen by claimants as a     professional
 whose job is to deny a benefit, it is necessary to acknowledge     that, once t
he legal requirements for an award of sickness benefit are met,     awarding the
 benefit is less complex than denying it, since: (1) in denying     the claim, t
he examiner is exposed to the various consequences of the claimant's     non&#45
;conformism; (2) the examiner, as a fellow human being, is fully aware     of th
e difficulties that may arise because of the absence of an expected     income s
ource,<Sup>29 </Sup>more often than not the only income source for     that citi
zen and their family; and (3) undoubtedly &#150; often through personal     expe
rience &#150; the examiners recognize that in some cases, working conditions    
 exact a toll, and may threaten the workers' health. Notwithstanding,     accord
ing to the welfare legislation, such considerations are not the subject     of t
he medical examination, the latter focusing on the analysis of the work     disa
bility, based on technical, administrative and legal norms.<Sup>3,8,24 </Sup>Suc
h     aspects grow in complexity in an environment in which fraud is potentially
     present. Examiners try to deal with their doubts every day, faced with a   
  succession of painstaking assessments that require immediate decisions to     
be reached, in a short space of time. </font></p>     ^cY#aop1111.htm##
01387000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704114500084002001201229#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#73#69#article#154#<p><font si
ze="2" face="Verdana">Because the national insurance system frequently     faces
 labor and social demands, and is held responsible for ills of different     ori
gins, we consider that this institution should: (1) liaise with competent     or
gans to remedy the shortage of specialized care and/or the inadequacy of     wor
king conditions, thus reducing the demand for welfare benefits; and (2)     prop
ose discussions concerning a labor and welfare legislation review, particularly 
    of instruments that unjustly favor a minority, while failing to benefit citi
zens     in need. Leaving the burden of rejecting those who do not meet the crit
eria     which would grant access on medical grounds to the benefit sought on th
e     shoulders of the medical examinations sector of the national insurance sys
tem     is not appropriate, since it unduly favors some who are dishonest and fa
ils     to differentiate these from the others who believe that they are merely 
seeking     their rights. Such rights, however, demand the observance of certain
 duties,     which, in turn, must be the target of institutional control. </font
></p>     ^cY#aop1111.htm##
01015000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704077300084002001200857#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#74#70#article#154#<p><font si
ze="2" face="Verdana">The main limitation of this study is the use     of a seco
ndary data bank. Even though a primary analysis of its consistence     was perfo
rmed, it is not possible to guarantee the thoroughness of its quality.     The v
ariables selected for the study were chosen by the authors, based on     the wor
k experience of the main author as a medical expert with the INSS.     However, 
some of them (e.g. the indicators of previous benefit) had not been     recorded
 for a large percentage of the registrations, which rendered their     analysis 
unfeasible. The chosen method and the high number of registrations     evaluated
 were adequate for an exploratory assessment of the factors associated     with 
awarding of benefits. </font></p>     ^cY#aop1111.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#75#71#article#154#<p>&nbsp;</
p>     ^cY#aop1111.htm##
00313000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007100084002001200155#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#76#72#article#154#<p><font si
ze="3" face="Verdana"><B>Conclusion </B></font></p>     ^cY#aop1111.htm##
00730000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704048800084002001200572#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#77#73#article#154#<p><font si
ze="2" face="Verdana">The aim of this study was to assess the odds     of having
 an initial claim for statutory sickness benefit awarded (ascribed     to mental
 disorder as the main registered diagnosis on the initial medical     examinatio
n), in relation to institutional, clinical, sociodemographic and     welfare fac
tors. Finding these factors is, in itself, a substantial contribution     to the
 possibility of reducing the unduly granting of benefit. </font></p>     ^cY#aop
1111.htm##
00870000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704062800084002001200712#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#78#74#article#154#<p><font si
ze="2" face="Verdana">The results of this study indicate that the     odds in fa
vour of the awarding of benefit were associated with the specialty     of the ex
aminer, medical diagnosis, age, gender and claimant category. As     for the thr
ee core institutional variables evaluated here, the results suggest     that the
y cannot be independently taken as predictors of different patterns     of medic
al conclusion. Considering these results and the limitations exposed     above, 
the authors suggest the undertaking of follow&#45;up studies to further     expl
ore these findings in greater depth. </font></p>     ^cY#aop1111.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#79#75#article#154#<p>&nbsp;</
p>     ^cY#aop1111.htm##
00319000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007700084002001200161#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#80#76#article#154#<p><font si
ze="3" face="Verdana"><B>Acknowledgements </B></font></p>     ^cY#aop1111.htm##
00498000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704025600084002001200340#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#81#77#article#154#<p><font si
ze="2" face="Verdana">We thank our colleagues Marco Ant&ocirc;nio     Aguirre de
 Souza and Aline Evangelista Santiago for their invaluable collaboration     dur
ing the initial stages of the work that originated this article. </font></p>    
 ^cY#aop1111.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#82#78#article#154#<p>&nbsp;</
p>     ^cY#aop1111.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#83#79#article#154#<p align="c
enter"><img src="/img/revistas/rbp/2011nahead/a11img01.jpg"></p>     ^cY#aop1111
.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#84#80#article#154#<p>&nbsp;</
p>     ^cY#aop1111.htm##
00313000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007100084002001200155#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#85#81#article#154#<p><font si
ze="3" face="Verdana"><B>References </B></font></p>     ^cY#aop1111.htm##
00553000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704029700086002001200383#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#86#82#article#154
#1#<p><font size="2" face="Verdana">1. Marasciulo ACE. Avalia&ccedil;&atilde;o d
e     desempenho do programa de benef&iacute;cios por incapacidade do Instituto 
    Nacional do Seguro Social, ger&ecirc;ncia de Florian&oacute;polis, SC, 2000&
#45;2002     &#91;tese&#93;. S&atilde;o Paulo; 2004.    ^cY#aop1111.htm##
00263000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002100084002001200105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#87#83#article#154# </font></p
>     ^cY#aop1111.htm##
00419000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704016300086002001200249#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#88#84#article#154
#2#<p><font size="2" face="Verdana"> 2. Gonzaga P. <I>Per&iacute;cia m&eacute;di
ca       da previd&ecirc;ncia social</I>. 4a. ed. S&atilde;o Paulo: LTr; 2006.  
  ^cY#aop1111.htm##
00263000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002100084002001200105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#89#85#article#154# </font></p
>     ^cY#aop1111.htm##
00651000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704039500086002001200481#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#90#86#article#154
#3#<p><font size="2" face="Verdana">3. Siano AK, Ribeiro LC, Santiago AE, Souza 
    MAA, Ribeiro MS. Relev&acirc;ncia dos transtornos mentais entre as per&iacut
e;cias     m&eacute;dicas de requerentes de Aux&iacute;lio&#45;doen&ccedil;a na 
Ger&ecirc;ncia     Executiva do Instituto Nacional do Seguro Social de Juiz de F
ora &#45; Minas     Gerais. <I>HU Revista</I>. 2008;34(04):235&#45;42.    ^cY#ao
p1111.htm##
00263000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002100084002001200105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#91#87#article#154# </font></p
>     ^cY#aop1111.htm##
00484000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704022800086002001200314#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#92#88#article#154
#4#<p><font size="2" face="Verdana">4. Cechin J, Giambiagi F. <I>O aumento das d
espesas       do INSS com o Aux&iacute;lio&#45;doen&ccedil;a</I>. Boletim de Con
juntura do       IPEA. Rio de Janeiro: IPEA; 2004. p.81&#45;90.    ^cY#aop1111.h
tm##
00263000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002100084002001200105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#93#89#article#154# </font></p
>     ^cY#aop1111.htm##
00488000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704023200086002001200318#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#94#90#article#154
#5#<p><font size="2" face="Verdana">5. Mora M. <I>Aux&iacute;lio&#45;doen&ccedil
;a:       contribui&ccedil;&atilde;o para um diagn&oacute;stico</I>. Boletim de 
Conjuntura       do IPEA. Rio de Janeiro: IPEA; 2007. p.89&#45;100.    ^cY#aop11
11.htm##
00263000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002100084002001200105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#95#91#article#154# </font></p
>     ^cY#aop1111.htm##
00542000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704028600086002001200372#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#96#92#article#154
#6#<p><font size="2" face="Verdana">6. Brasil. <I>Anu&aacute;rio Estat&iacute;st
ico       da Previd&ecirc;ncia Social 2005 &#45;Suplemento Hist&oacute;rico (198
0&#45;2005)</I>.       Bras&iacute;lia: Minist&eacute;rio da Previd&ecirc;ncia S
ocial / DATAPREV;       2005. p.56&#45;8.    ^cY#aop1111.htm##
00263000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002100084002001200105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#97#93#article#154# </font></p
>     ^cY#aop1111.htm##
00481000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704022500086002001200311#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#98#94#article#154
#7#<p><font size="2" face="Verdana">7. <I>Brasil. Anu&aacute;rio Estat&iacute;st
ico       da Previd&ecirc;ncia Social 2008</I>. Bras&iacute;lia: Minist&eacute;r
io       da Previd&ecirc;ncia Social / DATAPREV; 2008. p.19.    ^cY#aop1111.htm#
#
00263000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002100084002001200105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#99#95#article#154# </font></p
>     ^cY#aop1111.htm##
00889000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081888000200085704063200087002001200719#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#100#96#article#15
4#8#<p><font size="2" face="Verdana">8. Siano AK, Ribeiro LC, Santiago AE, Ribei
ro     MS. Influ&ecirc;ncia de Altera&ccedil;&otilde;es Normativas da Previd&eci
rc;ncia     Social Sobre o Perfil de Concess&atilde;o de Aux&iacute;lio&#45;doen
&ccedil;a     Relativo a Transtornos Mentais. <I>Aprovado para publica&ccedil;&a
tilde;o     na Revista Ci&ecirc;nc sa&uacute;de coletiva</I>. 2009. Available fr
om: URL: <a href="http://www.abrasco.org.br/cienciaesaudecoletiva/artigos/artigo
_int.php?id_artigo=2878" target="_blank">http://www.abrasco.org.br/cienciaesaude
coletiva/artigos/artigo_int.     php?id_artigo=2878</a> </font></p>     ^cY#aop1
111.htm##
00460000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081888000200085704020300087002001200290#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#101#97#article#15
4#9#<p><font size="2" face="Verdana">9. Elders LA, Burdorf A, Ory FG. Ethnic dif
ferences     in disability risk between Dutch and Turkish scaffolders. <I>J Occu
p Health</I>.     2004;46(5):391&#45;7.    ^cY#aop1111.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081704002100085002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#102#98#article#154# </font></
p>     ^cY#aop1111.htm##
00476000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081888000300085704021800088002001200306#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#103#99#article#15
4#10#<p><font size="2" face="Verdana">10. Ford FM, Ford J. Non&#45;attendance fo
r Social     Security medical examination: patients who cannot afford to get bet
ter? <I>Occup     Med </I>(Lond). 2000;50(7):504&#45;7.    ^cY#aop1111.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#104#100#article#154# </font><
/p>     ^cY#aop1111.htm##
00474000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704021500089002001200304#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#105#101#article#1
54#11#<p><font size="2" face="Verdana">11. Moncrieff J, Pomerleau J. Trends in s
ickness     benefits in Great Britain and the contribution of mental disorders. 
<I>J     Public Health Med</I>. 2000;22(1):59&#45;67.    ^cY#aop1111.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#106#102#article#154# </font><
/p>     ^cY#aop1111.htm##
00565000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704030600089002001200395#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#107#103#article#1
54#12#<p><font size="2" face="Verdana">12. Mykletun A, Overland S, Dahl AA, Krok
stad     S, Bjerkeset O, Glozier N, Aar&oslash; LE, Prince M. A population&#45;b
ased cohort     study of the effect of common mental disorders on disability pen
sion awards. <I>Am     J Psychiatry</I>. 2006;163(8):1412&#45;8.    ^cY#aop1111.
htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#108#104#article#154# </font><
/p>     ^cY#aop1111.htm##
00503000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704024400089002001200333#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#109#105#article#1
54#13#<p><font size="2" face="Verdana">13. Shiels C, Gabbay MB, Ford FM. Patient
 factors     associated with duration of certified sickness absence and transiti
on to     long&#45;term incapacity. <I>Br J Gen Pract</I>. 2004;54(499):86&#45;9
1.    ^cY#aop1111.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#110#106#article#154# </font><
/p>     ^cY#aop1111.htm##
00464000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704020500089002001200294#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#111#107#article#1
54#14#<p><font size="2" face="Verdana">14. Quadagno J. Incentives to disability 
in     federal disability insurance and supplemental security income. <I>Clin Or
thop     Relat Res</I>. 1997(336):11&#45;7.    ^cY#aop1111.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#112#108#article#154# </font><
/p>     ^cY#aop1111.htm##
00511000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704025200089002001200341#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#113#109#article#1
54#15#<p><font size="2" face="Verdana">15. Boff BM, Leite DF, Azambuja MI. Morbi
dade     subjacente &agrave; concess&atilde;o de benef&iacute;cio por incapacida
de     tempor&aacute;ria para o trabalho. <I>Rev Saude Publica</I>. 2002;36(3):3
37&#45;42.    ^cY#aop1111.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#114#110#article#154# </font><
/p>     ^cY#aop1111.htm##
00581000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704032200089002001200411#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#115#111#article#1
54#16#<p><font size="2" face="Verdana">16. Sampaio RF, Silveira AM, Parreira VF,
 Makino     AT, Mateo MM. An&aacute;lise das aposentadorias por incapacidade per
manente     entre os trabalhadores da Universidade Federal de Minas Gerais no pe
r&iacute;odo     de 1966 a 1999. <I>Rev Assoc Med Bras. </I>2003;49(1):60&#45;6.
    ^cY#aop1111.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#116#112#article#154# </font><
/p>     ^cY#aop1111.htm##
00470000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704021100089002001200300#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#117#113#article#1
54#17#<p><font size="2" face="Verdana">17. Silveira DBB, Monteiro MS. Morbidade 
entre     trabalhadores de uma institui&ccedil;&atilde;o de sa&uacute;de. <I>Sa&
uacute;de     debate</I>. 2004;28(68):206&#45;11.    ^cY#aop1111.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#118#114#article#154# </font><
/p>     ^cY#aop1111.htm##
00566000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704030700089002001200396#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#119#115#article#1
54#18#<p><font size="2" face="Verdana">18. Moura AAG, Carvalho EF, Silva NJC. Re
percuss&atilde;o     das doen&ccedil;as cr&ocirc;nicas n&atilde;otransmiss&iacut
e;veis na concess&atilde;o     de benef&iacute;cios pela previd&ecirc;ncia socia
l. <I>Ci&ecirc;nc Saude     Coletiva</I>. 2007;12(6):1661&#45;72.    ^cY#aop1111
.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#120#116#article#154# </font><
/p>     ^cY#aop1111.htm##
00530000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704027100089002001200360#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#121#117#article#1
54#19#<p><font size="2" face="Verdana">19. Organiza&ccedil;&atilde;o Mundial da 
Sa&uacute;de     &#45; OMS. Relat&oacute;rio sobre a sa&uacute;de no mundo &#45;
 2001: <I>Sa&uacute;de     Mental: nova concep&ccedil;&atilde;o, nova esperan&cc
edil;a.</I> Geneva;     2001.    ^cY#aop1111.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#122#118#article#154# </font><
/p>     ^cY#aop1111.htm##
00456000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704019700089002001200286#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#123#119#article#1
54#20#<p><font size="2" face="Verdana">20. Prince M, Patel V, Saxena S, Maj M, M
aselko     J, Phillips MR, Rahman A. No health without mental health. <I>Lancet<
/I>.     2007;370(9590):859&#45;77.    ^cY#aop1111.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#124#120#article#154# </font><
/p>     ^cY#aop1111.htm##
00521000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704026200089002001200351#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#125#121#article#1
54#21#<p><font size="2" face="Verdana">21. Leo RJ, Del Regno P. Social security 
claims     of psychiatric disability: Elements of case adjudication and the role
 of     primary care physicians. <I>Prim Care Companion J Clin Psychiatry</I>. 2
001;3(6):255&#45;62.    ^cY#aop1111.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#126#122#article#154# </font><
/p>     ^cY#aop1111.htm##
00472000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704021300089002001200302#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#127#123#article#1
54#22#<p><font size="2" face="Verdana">22. Melo MPP, Assun&ccedil;&atilde;o A&Aa
cute;.     A decis&atilde;o pericial no &acirc;mbito da previd&ecirc;ncia social
. <I>Physis </I>(Rio     J). 2003;13(2):343&#45;65.    ^cY#aop1111.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#128#124#article#154# </font><
/p>     ^cY#aop1111.htm##
00516000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704025700089002001200346#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#129#125#article#1
54#23#<p><font size="2" face="Verdana">23. Okpaku SO, Sibulkin AE, Schenzler C. 
Disability     determinations for adults with mental disorders: Social Security 
Administration     vs independent judgments. <I>Am J Public Health</I>. 1994;84(
11):1791&#45;5.    ^cY#aop1111.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#130#126#article#154# </font><
/p>     ^cY#aop1111.htm##
00545000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704028600089002001200375#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#131#127#article#1
54#24#<p><font size="2" face="Verdana">24. Siano AK, Ribeiro LC, Santiago AE, Ri
beiro     MS. An&aacute;lise descritiva de exames periciais iniciais de segurado
s do     Instituto Nacional do Seguro Social apresentando transtornos mentais. <
I>HU     Revista</I>. 2009;35(01):25&#45;34.    ^cY#aop1111.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#132#128#article#154# </font><
/p>     ^cY#aop1111.htm##
00483000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704022400089002001200313#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#133#129#article#1
54#25#<p><font size="2" face="Verdana">25. Scott KM, McGee MA, Wells JE, Oakley 
Browne     MA. Disability in Te Rau Hinengaro: the New Zealand Mental Health Sur
vey. <I>Aust     N Z J Psychiatry</I>. 2006;40(10):889&#45;95.    ^cY#aop1111.ht
m##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#134#130#article#154# </font><
/p>     ^cY#aop1111.htm##
00510000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704025100089002001200340#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#135#131#article#1
54#26#<p><font size="2" face="Verdana">26. Moussavi S, Chatterji S, Verdes E, Ta
ndon     A, Patel V, Ustun B. Depression, chronic diseases, and decrements in he
alth:     results from the World Health Surveys. <I>Lancet</I>. 2007;370(9590):8
51&#45;8.    ^cY#aop1111.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#136#132#article#154# </font><
/p>     ^cY#aop1111.htm##
00408000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704014900089002001200238#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#137#133#article#1
54#27#<p><font size="2" face="Verdana">27. Glozier N. Mental ill health and fitn
ess     for work. <I>Occup Environ Med</I>. 2002;59(10):714&#45;20.    ^cY#aop11
11.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#138#134#article#154# </font><
/p>     ^cY#aop1111.htm##
00489000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704023000089002001200319#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#139#135#article#1
54#28#<p><font size="2" face="Verdana">28. Watkins KE, Wells KB, McLellan AT. Te
rmination     of social security benefits among Los Angeles recipients disabled 
by substance     abuse. <I>Psychiatr Serv</I>. 1999;50(7):914&#45;8.    ^cY#aop1
111.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#140#136#article#154# </font><
/p>     ^cY#aop1111.htm##
00486000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704022700089002001200316#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#141#137#article#1
54#29#<p><font size="2" face="Verdana">29. Cassis I, Dupriez K, Burnand B, Vader
 JP.     Quality of work incapacity assessment in the Swiss disability insurance
 system. <I>Int     J Qual Health Care</I>. 1996;8(6):567&#45;75.    ^cY#aop1111
.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#142#138#article#154# </font><
/p>     ^cY#aop1111.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#143#139#article#154#<p>&nbsp;
</p>     ^cY#aop1111.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#144#140#article#154#<p>&nbsp;
</p>     ^cY#aop1111.htm##
00406000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704016200086002001200248#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#145#141#article#154#<p><font 
size="2" face="Verdana"><b><a name="end"></a><a href="#title"><img src="/img/rev
istas/rbp/2011nahead/seta.jpg" border="0"></a> Correspondence</b>    ^cY#aop1111
.htm##
00293000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704004900086002001200135#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#146#142#article#154#<br>   M&
aacute;rio S&eacute;rgio Ribeiro    ^cY#aop1111.htm##
00289000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704004500086002001200131#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#147#143#article#154#<br>   Ru
a Severino Meireles, 325/902    ^cY#aop1111.htm##
00297000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704005300086002001200139#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#148#144#article#154#<br>   36
025&#45;040 Juiz de Fora, MG, Brazil    ^cY#aop1111.htm##
00288000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704004400086002001200130#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#149#145#article#154#<br>   Ph
one: (+55 32) 3211&#45;3833    ^cY#aop1111.htm##
00349000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704010500086002001200191#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#150#146#article#154#<br>   Em
ail: <a href="mailto:mariosribeiro@acessa.com">mariosribeiro@acessa.com</a> </fo
nt></p>     ^cY#aop1111.htm##
00308000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704006400086002001200150#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#151#147#article#154#<p><font 
size="2" face="Verdana">Submitted: May 11, 2010    ^cY#aop1111.htm##
00299000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704005500086002001200141#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#152#148#article#154#<br>   Ac
cepted: November 21, 2010 </font></p>     ^cY#aop1111.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#153#149#article#154#<p>&nbsp;
</p>     ^cY#aop1111.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#154#150#article#154#<p>&nbsp;
</p>     ^cY#aop1111.htm##
00788000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704054400086002001200630#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#155#151#article#154#<p><font 
size="2" face="Verdana"><a name="end"></a><a href="#title">*</a> This     articl
e is derived from the Master Degree dissertation entitled: 'Influence     of soc
iodemographic, clinical and institutional factors on the concession     of benef
its due to work disability, to claimants with mental disorders, by     the medic
al examinations sector of the national insurance system (INSS) in     Juiz de Fo
ra&#45;MG. The work was awarded the 'Profesor Ulysses Vianna     Filho Prize' by
 the Brazilian Psychiatry Association, in 2009.    ^cY#aop1111.htm##
00416000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704017200086002001200258#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#156#152#article#154#<br>   <a
 name="nt01"></a><a href="#tx01">1</a> Some of the 'new examiners' started   the
ir activities in the Gex/JF in July 2005, just before COPES implementation.    ^
cY#aop1111.htm##
00529000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704028500086002001200371#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#157#153#article#154#<br>   <a
 name="nt02"></a><a href="#tx02">2</a> Once the analysis of these variables   sh
owed a positive asymmetric distribution of its values, we opted for the use   of
 the median as reference, because it better represented the trends for affiliati
on   and contribution times.    ^cY#aop1111.htm##
00945000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704070100086002001200787#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#p#158#154#article#154#<br>   <a
 name="nt03"></a><a href="#tx03">3</a> If these interactions among the instituti
onal   variables had not been added to the models, we would have lost the opport
unity   of assessing the weight of the observed results on the stratifications F
or   example: had we taken only the variables 'examiner category' and 'place   o
f examination' into account, we would have been limited to assessing   the inter
action between the S&atilde;o Dimas INSS agency and 'old examiners' (reference  
 category) but not the interaction with the other examiners, who, in turn, would
   have been assessed only in their interaction with the Largo do Riachuelo INSS
   agency (reference category). </font></p>     ^cY#aop1111.htm##
00522000000000217000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830160022000850180152001070460
01000259045000900269044000500278865000900283002001200292#2011nahead#V:\SciELO\se
rial\rbp\2011nahead\markup\aop1111.htm#S#c#159#1#article#29#1#^rND^sMarasciulo^n
ACE#Avaliação de desempenho do programa de benefícios por incapacidade do Instit
uto Nacional do Seguro Social, gerência de Florianópolis, SC, 2000-2002^lpt#São 
Paulo#20040000#2004#20110000#aop1111.htm##
00436000000000241000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830160017000850180041001020630
00200143066001000145062000400155065000900159064000500168865000900173002001200182
#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#c#160#2#article
#29#2#^rND^sGonzaga^nP#Perícia médica da previdência social^lpt#4#São Paulo#LTr#
20060000#2006#20110000#aop1111.htm##
00769000000000325000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100016000850100018001010100
01900119010001700138010001800155012019000173030001100363065000900374064000500383
03100030038803200030039101400070039486500090040100200120041003500100042280100110
0432#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#c#161#3#art
icle#29#3#^rND^sSiano^nAK#^rND^sRibeiro^nLC#^rND^sSantiago^nAE#^rND^sSouza^nMAA#
^rND^sRibeiro^nMS#Relevância dos transtornos mentais entre as perícias médicas d
e requerentes de Auxílio-doença na Gerência Executiva do Instituto Nacional do S
eguro Social de Juiz de Fora - Minas Gerais^lpt#HU Revista#20080000#2008#34#04#2
35-42#20110000#aop1111.htm#0103-3123#HU revista##
00503000000000241000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830160016000850160019001010180
08600120066001500206062000500221065000900226064000500235865000900240002001200249
#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#c#162#4#article
#29#4#^rND^sCechin^nJ#^rND^sGiambiagi^nF#O aumento das despesas do INSS com o Au
xílio-doença.Boletim de Conjuntura do IPEA^lpt#Rio de Janeiro#IPEA#20040000#2004
#20110000#aop1111.htm##
00468000000000229000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830160014000850180084000990660
01500183062000500198065000900203064000500212865000900217002001200226#2011nahead#
V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#c#163#5#article#29#5#^rND^s
Mora^nM#Auxílio-doença: contribuição para um diagnóstico. Boletim de Conjuntura 
do IPEA^lpt#Rio de Janeiro#IPEA#20070000#2007#20110000#aop1111.htm##
00495000000000229000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830170007000850180085000920660
00900177062004400186065000900230064000500239865000900244002001200253#2011nahead#
V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#c#164#6#article#29#6#Brasil
#Anuário Estatístico da Previdência Social 2005 -Suplemento Histórico (1980-2005
)^lpt#Brasília#Ministério da Previdência Social / DATAPREV#20050000#2005#2011000
0#aop1111.htm##
00467000000000229000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830160013000850180051000980660
00900149062004400158065000900202064000500211865000900216002001200225#2011nahead#
V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#c#165#7#article#29#7#^rND^s
Brasil#Anuário Estatístico da Previdência Social 2008^lpt#Brasília#Ministério da
 Previdência Social / DATAPREV#20080000#2008#20110000#aop1111.htm##
00712000000000265000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830160016000850160018001010160
01900119016001800138018013900156062002900295065000900324064000500333037008700338
865000900425002001200434#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop11
11.htm#S#c#166#8#article#29#8#^rND^sSiano^nAK#^rND^sRibeiro^nLC#^rND^sSantiago^n
AE#^rND^sRibeiro^nMS#Influência de Alterações Normativas da Previdência Social S
obre o Perfil de Concessão de Auxílio-doença Relativo a Transtornos Mentais^lpt#
Revista Ciênc saúde coletiva#20090000#2009#http://www.abrasco.org.br/cienciaesau
decoletiva/artigos/artigo_int. php?id_artigo=2878#20110000#aop1111.htm##
00566000000000289000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100017000850100017001020100
01400119012008000133030001500213710000200228065000900230064000500239031000300244
032000200247014000600249865000900255002001200264#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop1111.htm#S#c#167#9#article#29#9#^rND^sElders^nLA#^rND^sBur
dorf^nA#^rND^sOry^nFG#Ethnic differences in disability risk between Dutch and Tu
rkish scaffolders^len#J Occup Health#2#20040000#2004#46#5#391-7#20110000#aop1111
.htm##
00561000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100015000870100014001020120
10200116030001700218710000200235065000900237064000500246031000300251032000200254
014000600256865000900262002001200271#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop1111.htm#S#c#168#10#article#29#10#^rND^sFord^nFM#^rND^sFord^nJ#Non-att
endance for Social Security medical examination: patients who cannot afford to g
et better?^len#Occup Med (Lond)#2#20000000#2000#50#7#504-7#20110000#aop1111.htm#
#
00601000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100019001060120
09000125030002000215065000900235064000500244031000300249032000200252014000600254
865000900260002001200269035001000281801002000291#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop1111.htm#S#c#169#11#article#29#11#^rND^sMoncrieff^nJ#^rND^
sPomerleau^nJ#Trends in sickness benefits in Great Britain and the contribution 
of mental disorders^len#J Public Health Med#20000000#2000#22#1#59-67#20110000#ao
p1111.htm#0957-4832#J Public Health Med##
00781000000000361000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100018001050100
01500123010001800138010001900156010001700175010001500192010001600207012010600223
03000160032906500090034506400050035403100040035903200020036301400070036586500090
0372002001200381035001000393801001600403#2011nahead#V:\SciELO\serial\rbp\2011nah
ead\markup\aop1111.htm#S#c#170#12#article#29#12#^rND^sMykletun^nA#^rND^sOverland
^nS#^rND^sDahl^nAA#^rND^sKrokstad^nS#^rND^sBjerkeset^nO#^rND^sGlozier^nN#^rND^sA
arø^nLE#^rND^sPrince^nM#A population-based cohort study of the effect of common 
mental disorders on disability pension awards^len#Am J Psychiatry#20060000#2006#
163#8#1412-8#20110000#aop1111.htm#0002-953X#Am J Psychiatry##
00639000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100017001030100
01500120012011400135030001500249065000900264064000500273031000300278032000400281
014000600285865000900291002001200300035001000312801001500322#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop1111.htm#S#c#171#13#article#29#13#^rND^sShiels
^nC#^rND^sGabbay^nMB#^rND^sFord^nFM#Patient factors associated with duration of 
certified sickness absence and transition to long-term incapacity^len#Br J Gen P
ract#20040000#2004#54#499#86-91#20110000#aop1111.htm#0960-1643#Br J Gen Pract##
00521000000000253000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870120094001050300
02200199710000200221065000900223064000500232032000400237014000500241865000900246
002001200255#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#c#1
72#14#article#29#14#^rND^sQuadagno^nJ#Incentives to disability in federal disabi
lity insurance and supplemental security income^len#Clin Orthop Relat Res#2#1997
0000#1997#336#11-7#20110000#aop1111.htm##
00626000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100015000870100016001020100
01900118012009400137030001800231065000900249064000500258031000300263032000200266
014000700268865000900275002001200284035001000296801001800306#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop1111.htm#S#c#173#15#article#29#15#^rND^sBoff^n
BM#^rND^sLeite^nDF#^rND^sAzambuja^nMI#Morbidade subjacente à concessão de benefí
cio por incapacidade temporária para o trabalho^lpt#Rev Saude Publica#20020000#2
002#36#3#337-42#20110000#aop1111.htm#0034-8910#Rev Saude Publica##
00743000000000325000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100019001050100
01900124010001700143010001600160012014800176030001900324065000900343064000500352
03100030035703200020036001400050036286500090036700200120037603500100038880100190
0398#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#c#174#16#ar
ticle#29#16#^rND^sSampaio^nRF#^rND^sSilveira^nAM#^rND^sParreira^nVF#^rND^sMakino
^nAT#^rND^sMateo^nMM#Análise das aposentadorias por incapacidade permanente entr
e os trabalhadores da Universidade Federal de Minas Gerais no período de 1966 a 
1999^lpt#Rev Assoc Med Bras#20030000#2003#49#1#60-6#20110000#aop1111.htm#0004-52
41#Rev Assoc Med Bras##
00529000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100020000870100019001070120
06200126030001300188710000200201065000900203064000500212031000300217032000300220
014000700223865000900230002001200239#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop1111.htm#S#c#175#17#article#29#17#^rND^sSilveira^nDBB#^rND^sMonteiro^n
MS#Morbidade entre trabalhadores de uma instituição de saúde^lpt#Saúde debate#2#
20040000#2004#28#68#206-11#20110000#aop1111.htm##
00607000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100019001040100
01700123012010600140030002100246710000200267065000900269064000500278031000300283
032000200286014000800288865000900296002001200305#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop1111.htm#S#c#176#18#article#29#18#^rND^sMoura^nAAG#^rND^sC
arvalho^nEF#^rND^sSilva^nNJC#Repercussão das doenças crônicas nãotransmissíveis 
na concessão de benefícios pela previdência social^lpt#Ciênc Saude Coletiva#2#20
070000#2007#12#6#1661-72#20110000#aop1111.htm##
00466000000000217000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840170029000870180090001160660
00700206065000900213064000500222865000900227002001200236#2011nahead#V:\SciELO\se
rial\rbp\2011nahead\markup\aop1111.htm#S#c#177#19#article#29#19#Organização Mund
ial da Saúde#Relatório sobre a saúde no mundo - 2001: Saúde Mental: nova concepç
ão, nova esperança^lpt#Geneva#20010000#2001#20110000#aop1111.htm##
00660000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100015001030100
01600118010001300134010001700147010001900164010001600183012003600199030000700235
06500090024206400050025103100040025603200050026001400070026586500090027200200120
0281035001000293801000700303#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\a
op1111.htm#S#c#178#20#article#29#20#^rND^sPrince^nM#^rND^sPatel^nV#^rND^sSaxena^
nS#^rND^sMaj^nM#^rND^sMaselko^nJ#^rND^sPhillips^nMR#^rND^sRahman^nA#No health wi
thout mental health^len#Lancet#20070000#2007#370#9590#859-77#20110000#aop1111.ht
m#0099-5355#Lancet##
00608000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100014000870100019001010120
12400120030003800244710000200282065000900284064000500293031000200298032000200300
014000700302865000900309002001200318#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop1111.htm#S#c#179#21#article#29#21#^rND^sLeo^nRJ#^rND^sDel Regno^nP#Soc
ial security claims of psychiatric disability: Elements of case adjudication and
 the role of primary care physicians^len#Prim Care Companion J Clin Psychiatry#2
#20010000#2001#3#6#255-62#20110000#aop1111.htm##
00519000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100019001030120
05500122030001500177710000200192065000900194064000500203031000300208032000200211
014000700213865000900220002001200229#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop1111.htm#S#c#180#22#article#29#22#^rND^sMelo^nMPP#^rND^sAssunção^nAÁ#A
 decisão pericial no âmbito da previdência social^lpt#Physis (Rio J)#2#20030000#
2003#13#2#343-65#20110000#aop1111.htm##
00660000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100019001040100
01900123012012000142030001900262065000900281064000500290031000300295032000300298
014000700301865000900308002001200317035001000329801001900339#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop1111.htm#S#c#181#23#article#29#23#^rND^sOkpaku
^nSO#^rND^sSibulkin^nAE#^rND^sSchenzler^nC#Disability determinations for adults 
with mental disorders: Social Security Administration vs independent judgments^l
en#Am J Public Health#19940000#1994#84#11#1791-5#20110000#aop1111.htm#0090-0036#
Am J Public Health##
00688000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100018001030100
01900121010001800140012013700158030001100295065000900306064000500315031000300320
032000300323014000600326865000900332002001200341035001000353801001100363#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#c#182#24#article#29#24#
^rND^sSiano^nAK#^rND^sRibeiro^nLC#^rND^sSantiago^nAE#^rND^sRibeiro^nMS#Análise d
escritiva de exames periciais iniciais de segurados do Instituto Nacional do Seg
uro Social apresentando transtornos mentais^lpt#HU Revista#20090000#2009#35#01#2
5-34#20110000#aop1111.htm#0103-3123#HU revista##
00648000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100016001030100
01600119010002400135012007300159030002200232065000900254064000500263031000300268
032000300271014000700274865000900281002001200290035001000302801002200312#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#c#183#25#article#29#25#
^rND^sScott^nKM#^rND^sMcGee^nMA#^rND^sWells^nJE#^rND^sOakley Browne^nMA#Disabili
ty in Te Rau Hinengaro: the New Zealand Mental Health Survey^len#Aust N Z J Psyc
hiatry#20060000#2006#40#10#889-95#20110000#aop1111.htm#0004-8674#Aust N Z J Psyc
hiatry##
00696000000000337000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100019001050100
01600124010001600140010001500156010001500171012009800186030000700284065000900291
06400050030003100040030503200050030901400060031486500090032000200120032903500100
0341801000700351#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S
#c#184#26#article#29#26#^rND^sMoussavi^nS#^rND^sChatterji^nS#^rND^sVerdes^nE#^rN
D^sTandon^nA#^rND^sPatel^nV#^rND^sUstun^nB#Depression, chronic diseases, and dec
rements in health: results from the World Health Surveys^len#Lancet#20070000#200
7#370#9590#851-8#20110000#aop1111.htm#0099-5355#Lancet##
00519000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870120043001040300
01800147065000900165064000500174031000300179032000300182014000700185865000900192
002001200201035001000213801001800223#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop1111.htm#S#c#185#27#article#29#27#^rND^sGlozier^nN#Mental ill health a
nd fitness for work^len#Occup Environ Med#20020000#2002#59#10#714-20#20110000#ao
p1111.htm#1351-0711#Occup Environ Med##
00629000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100016001050100
01900121012010100140030001500241065000900256064000500265031000300270032000200273
014000600275865000900281002001200290035001000302801001500312#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop1111.htm#S#c#186#28#article#29#28#^rND^sWatkin
s^nKE#^rND^sWells^nKB#^rND^sMcLellan^nAT#Termination of social security benefits
 among Los Angeles recipients disabled by substance abuse^len#Psychiatr Serv#199
90000#1999#50#7#914-8#20110000#aop1111.htm#1075-2730#Psychiatr Serv##
00652000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100017001030100
01700120010001600137012008300153030002300236065000900259064000500268031000200273
032000200275014000700277865000900284002001200293035001000305801002300315#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop1111.htm#S#c#187#29#article#29#29#
^rND^sCassis^nI#^rND^sDupriez^nK#^rND^sBurnand^nB#^rND^sVader^nJP#Quality of wor
k incapacity assessment in the Swiss disability insurance system^len#Int J Qual 
Health Care#19960000#1996#8#6#567-75#20110000#aop1111.htm#1353-4505#Int J Qual H
ealth Care##
00282000000000169000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780910009000800920007000890020012000967030
00400108#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#o#1#1#a
rticle#1#20110408#161723#aop1211.htm#270##
05328000000000745000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780710003000800400003000830010006000860420
00200092120000400094038000400098121000300102049000300105158000300108030002200111
03200060013306500090013901400070014803500100015522300090016501200480017401200470
02220100035002690100042003040100043003460100044003890100051004330100025004840100
03800509010003100547010003700578070008800615070005900703070006800762070007100830
07000970090108316300099808500100262808500230263808500360266108500210269708500300
27180850032027480831575027800850010043550850021043650850036043860850021044220850
03204443085002904475117000804504072000304512112000904515111001804524114000904542
113001904551002001204570#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop12
11.htm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#TAB#12#nd#nd#Rev. Bras. Psiquiatr.#ah
ead#20110000#^f0^l0#1516-4446#20110408#Cerebellar volume in patients with dement
ia^len#Volume cerebelar em pacientes com demência^lpt#^rND^1A01 A02^nLeonardo^sB
aldaçara#^rND^1A01^nJoão Guilherme Fiorani^sBorgio#^rND^1A03^nWalter André dos S
antos^sMoraes#^rND^1A01 A04^nAcioly Luiz Tavares^sLacerda#^rND^1A05^nMaria Beatr
iz Marcondes Macedo^sMontaño#^rND^1A03^nSérgio^sTufik#^rND^1A01^nRodrigo Affonse
ca^sBressan#^rND^1A05^nLuiz Roberto^sRamos#^rND^1A01^nAndrea Parolin^sJackowski#
Universidade Federal de São Paulo^iA01^1Department of Psychiatry^cSão Paulo^sSP^
pBrazil#Universidade Federal do Tocantins^iA02^cPalmas^sTO^pBrazil#Universidade 
Federal de São Paulo^iA03^1Department of Psychobiology#Instituto Sinapse de Neur
ociências Clínicas^iA04^cCampinas^sSP^pBrazil#Universidade Federal de São Paulo^
iA05^1Department of Preventive Medicine^cSão Paulo^sSP^pBrazil#^len^aOBJECTIVE: 
The aim of this study was to examine the cerebellar volume of subjects at differ
ent stages of Alzheimer's disease and to investigate whether volume reductions i
n this structure are related to cognitive decline. METHOD: Ninety-six subjects f
rom an epidemiological study were submitted to a magnetic resonance imaging scan
 and evaluated using the Mini-Mental State Examination and the Functional Activi
ties Questionnaire. Subjects were divided into five groups according to the Clin
ical Dementia Rating scale. Twenty-six subjects from the original group who had 
no dementia diagnosis at baseline were re-evaluated for the onset of dementia af
ter two years. RESULTS: The volumes of the cerebellar hemispheres, posterior cer
ebellar lobe, vermis and temporal lobe were found to be reduced as a function of
 the severity of the disease. There were significant positive correlations betwe
en the volume of the temporal lobe and cerebellum and the language, attention, a
nd total scores in the Mini-Mental State Examination and the Functional Activiti
es Questionnaire. A logistic regression analysis demonstrated that reduced tempo
ral lobe, posterior cerebellar lobe and vermal volume at baseline is a risk fact
or for the onset of dementia. CONCLUSION: This is the first study demonstrating 
that reduced cerebellar volume is already apparent at the predementia stage. The
 results of this study support the involvement of the cerebellum in the progress
ion of dementia. Whereas the cerebellum might not be directly associated with th
e origin of Alzheimer's disease, it may provide useful information related to it
s prognosis.#^ddecs^i1#^tm^len^kCerebellum^i1#^tm^len^kEpidemiological studies^i
1#^tm^len^kDementia^i1#^tm^len^kAlzheimer disease^i1#^tm^len^kDisease progressio
n^i1#^lpt^aOBJETIVO: O objetivo deste estudo foi examinar o volume cerebelar em 
indivíduos em diferentes fases da doença de Alzheimer e investigar se sua reduçã
o estaria relacionada com o declínio cognitivo. MÉTODO: Noventa e seis indivíduo
s de um estudo epidemiológico foram submetidos à ressonância magnética e avaliad
os por meio do Mini Exame do Estado Mental e do Questionário de Atividades Funci
onais. Os sujeitos foram divididos em cinco grupos de acordo com a Escala de Gra
vidade da Demência. Vinte e seis indivíduos do grupo original que não tinham o d
iagnóstico de demência no início do estudo foram reavaliados após dois anos para
 detectar o desenvolvimento da doença. RESULTADOS: Os volumes dos hemisférios ce
rebelares, lobo cerebelar posterior, vermis e lobo temporal estavam diminuídos p
roporcionalmente à gravidade da doença. Houve correlações positivas e significat
ivas entre o Questionário de Atividades Funcionais, Mini Exame do Estado Mental 
e seus respectivos subtestes para linguagem e atenção com os volumes do lobo tem
poral e cerebelar. A análise de regressão logística demonstrou que o volume redu
zido do lobo temporal, lobo cerebelar posterior e vermis pode ser um fator de ri
sco para o futuro desenvolvimento de demência. CONCLUSÃO: Este é o primeiro estu
do que demonstrou que o volume do cerebelo pode estar reduzido na fase pré-demên
cia e reforça o papel dessa estrutura na progressão da doença de Alzheimer. Cons
iderando que o cerebelo pode não estar diretamente associado com a origem da doe
nça de Alzheimer, este achado tem valor para o prognóstico.#^ddecs^i2#^tm^lpt^kC
erebelo^i2#^tm^lpt^kEstudos epidemiológicos^i2#^tm^lpt^kDemência^i2#^tm^lpt^kDoe
nça de Alzheimer^i2#^tm^lpt^kAvanço da doença^i2#vancouv#48#20100222#February 22
, 1010#20100924#September 24, 2010#aop1211.htm##
05398000000000745000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780710003000800400003000830010006000860420
00200092120000400094038000400098121000300102049000300105158000300108030002200111
03200060013306500090013901400070014803500100015522300090016501200550017401200540
02290100035002830100042003180100043003600100044004030100051004470100025004980100
03800523010003100561010003700592070008800629070005900717070006800776070007100844
07000970091508316580101208500100267008500230268008500360270308500210273908500300
27600850032027900831603028220850010044250850021044350850036044560850021044920850
03204513085002904545117000804574072000304582112000904585111001804594114000904612
113001904621002001204640#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop12
11.htm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#TAB#12#nd#nd#Rev. Bras. Psiquiatr.#ah
ead#20110000#^f0^l0#1516-4446#20110408#<b>Cerebellar volume in patients with dem
entia</b>^len#<b>Volume cerebelar em pacientes com demência</b>^lpt#^rND^1A01 A0
2^nLeonardo^sBaldaçara#^rND^1A01^nJoão Guilherme Fiorani^sBorgio#^rND^1A03^nWalt
er André dos Santos^sMoraes#^rND^1A01 A04^nAcioly Luiz Tavares^sLacerda#^rND^1A0
5^nMaria Beatriz Marcondes Macedo^sMontaño#^rND^1A03^nSérgio^sTufik#^rND^1A01^nR
odrigo Affonseca^sBressan#^rND^1A05^nLuiz Roberto^sRamos#^rND^1A01^nAndrea Parol
in^sJackowski#Universidade Federal de São Paulo^iA01^1Department of Psychiatry^c
São Paulo^sSP^pBrazil#Universidade Federal do Tocantins^iA02^cPalmas^sTO^pBrazil
#Universidade Federal de São Paulo^iA03^1Department of Psychobiology#Instituto S
inapse de Neurociências Clínicas^iA04^cCampinas^sSP^pBrazil#Universidade Federal
 de São Paulo^iA05^1Department of Preventive Medicine^cSão Paulo^sSP^pBrazil#^le
n^a<b>OBJECTIVE: </b>The aim of this study was to examine the cerebellar volume 
of subjects at different stages of Alzheimer's disease and to investigate whethe
r volume reductions in this structure are related to cognitive decline. <b>METHO
D: </b>Ninety-six subjects from an epidemiological study were submitted to a mag
netic resonance imaging scan and evaluated using the Mini-Mental State Examinati
on and the Functional Activities Questionnaire. Subjects were divided into five 
groups according to the Clinical Dementia Rating scale. Twenty-six subjects from
 the original group who had no dementia diagnosis at baseline were re-evaluated 
for the onset of dementia after two years. <b>RESULTS: </b>The volumes of the ce
rebellar hemispheres, posterior cerebellar lobe, vermis and temporal lobe were f
ound to be reduced as a function of the severity of the disease. There were sign
ificant positive correlations between the volume of the temporal lobe and cerebe
llum and the language, attention, and total scores in the Mini-Mental State Exam
ination and the Functional Activities Questionnaire. A logistic regression analy
sis demonstrated that reduced temporal lobe, posterior cerebellar lobe and verma
l volume at baseline is a risk factor for the onset of dementia. <b>CONCLUSION: 
</b>This is the first study demonstrating that reduced cerebellar volume is alre
ady apparent at the predementia stage. The results of this study support the inv
olvement of the cerebellum in the progression of dementia. Whereas the cerebellu
m might not be directly associated with the origin of Alzheimer's disease, it ma
y provide useful information related to its prognosis.#^ddecs^i1#^tm^len^kCerebe
llum^i1#^tm^len^kEpidemiological studies^i1#^tm^len^kDementia^i1#^tm^len^kAlzhei
mer disease^i1#^tm^len^kDisease progression^i1#^lpt^a<b>OBJETIVO: </b>O objetivo
 deste estudo foi examinar o volume cerebelar em indivíduos em diferentes fases 
da doença de Alzheimer e investigar se sua redução estaria relacionada com o dec
línio cognitivo. <b>MÉTODO: </b>Noventa e seis indivíduos de um estudo epidemiol
ógico foram submetidos à ressonância magnética e avaliados por meio do Mini Exam
e do Estado Mental e do Questionário de Atividades Funcionais. Os sujeitos foram
 divididos em cinco grupos de acordo com a Escala de Gravidade da Demência. Vint
e e seis indivíduos do grupo original que não tinham o diagnóstico de demência n
o início do estudo foram reavaliados após dois anos para detectar o desenvolvime
nto da doença. <b>RESULTADOS: </b>Os volumes dos hemisférios cerebelares, lobo c
erebelar posterior, vermis e lobo temporal estavam diminuídos proporcionalmente 
à gravidade da doença. Houve correlações positivas e significativas entre o Ques
tionário de Atividades Funcionais, Mini Exame do Estado Mental e seus respectivo
s subtestes para linguagem e atenção com os volumes do lobo temporal e cerebelar
. A análise de regressão logística demonstrou que o volume reduzido do lobo temp
oral, lobo cerebelar posterior e vermis pode ser um fator de risco para o futuro
 desenvolvimento de demência. <b>CONCLUSÃO: </b>Este é o primeiro estudo que dem
onstrou que o volume do cerebelo pode estar reduzido na fase pré-demência e refo
rça o papel dessa estrutura na progressão da doença de Alzheimer. Considerando q
ue o cerebelo pode não estar diretamente associado com a origem da doença de Alz
heimer, este achado tem valor para o prognóstico.#^ddecs^i2#^tm^lpt^kCerebelo^i2
#^tm^lpt^kEstudos epidemiológicos^i2#^tm^lpt^kDemência^i2#^tm^lpt^kDoença de Alz
heimer^i2#^tm^lpt^kAvanço da doença^i2#vancouv#48#20100222#February 22, 1010#201
00924#September 24, 2010#aop1211.htm##
05480000000000769000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780640007000800710003000870400003000900010
00600093042000200099120000400101038000400105121000300109049000300112158000300115
03000210011803200060013906500090014501400070015403500100016122300090017101200480
01800120047002280100035002750100042003100100043003520100044003950100051004390100
02500490010003800515010003100553010003700584070009000621070006100711070009300772
07000730086507000990093808316300103708500100266708500230267708500360270008500210
27360850030027570850032027870831575028190850010043940850021044040850036044250850
02104461085003204482085002904514117000804543072000304551112000904554111001804563
114000904581113001904590002001204609008008904621#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop1211.htm#S#l#4#1#article#1#^a2011#oa#en#br1.1#1#4.0#tab#12
#nd#nd#Rev. bras. psiquiatr#ahead#20110000#^f0^l0#1516-4446#20110408#Cerebellar 
volume in patients with dementia^len#Volume cerebelar em pacientes com demência^
lpt#^rND^1A01 A02^nLeonardo^sBaldaçara#^rND^1A01^nJoão Guilherme Fiorani^sBorgio
#^rND^1A03^nWalter André dos Santos^sMoraes#^rND^1A01 A04^nAcioly Luiz Tavares^s
Lacerda#^rND^1A05^nMaria Beatriz Marcondes Macedo^sMontaño#^rND^1A03^nSérgio^sTu
fik#^rND^1A01^nRodrigo Affonseca^sBressan#^rND^1A05^nLuiz Roberto^sRamos#^rND^1A
01^nAndrea Parolin^sJackowski#^iA01^1Universidade Federal de São Paulo^2Departme
nt of Psychiatry^cSão Paulo^sSP^pBrazil#^iA02^1Universidade Federal do Tocantins
^cPalmas^sTO^pBrazil#^iA03^1Universidade Federal de São Paulo^2Department of Psy
chobiology^cSão Paulo^sSP^pBrazil#^iA04^1Instituto Sinapse de Neurociências Clín
icas^cCampinas^sSP^pBrazil#^iA05^1Universidade Federal de São Paulo^2Department 
of Preventive Medicine^cSão Paulo^sSP^pBrazil#^len^aOBJECTIVE: The aim of this s
tudy was to examine the cerebellar volume of subjects at different stages of Alz
heimer's disease and to investigate whether volume reductions in this structure 
are related to cognitive decline. METHOD: Ninety-six subjects from an epidemiolo
gical study were submitted to a magnetic resonance imaging scan and evaluated us
ing the Mini-Mental State Examination and the Functional Activities Questionnair
e. Subjects were divided into five groups according to the Clinical Dementia Rat
ing scale. Twenty-six subjects from the original group who had no dementia diagn
osis at baseline were re-evaluated for the onset of dementia after two years. RE
SULTS: The volumes of the cerebellar hemispheres, posterior cerebellar lobe, ver
mis and temporal lobe were found to be reduced as a function of the severity of 
the disease. There were significant positive correlations between the volume of 
the temporal lobe and cerebellum and the language, attention, and total scores i
n the Mini-Mental State Examination and the Functional Activities Questionnaire.
 A logistic regression analysis demonstrated that reduced temporal lobe, posteri
or cerebellar lobe and vermal volume at baseline is a risk factor for the onset 
of dementia. CONCLUSION: This is the first study demonstrating that reduced cere
bellar volume is already apparent at the predementia stage. The results of this 
study support the involvement of the cerebellum in the progression of dementia. 
Whereas the cerebellum might not be directly associated with the origin of Alzhe
imer's disease, it may provide useful information related to its prognosis.#^dde
cs^i1#^tm^len^kCerebellum^i1#^tm^len^kEpidemiological studies^i1#^tm^len^kDement
ia^i1#^tm^len^kAlzheimer disease^i1#^tm^len^kDisease progression^i1#^lpt^aOBJETI
VO: O objetivo deste estudo foi examinar o volume cerebelar em indivíduos em dif
erentes fases da doença de Alzheimer e investigar se sua redução estaria relacio
nada com o declínio cognitivo. MÉTODO: Noventa e seis indivíduos de um estudo ep
idemiológico foram submetidos à ressonância magnética e avaliados por meio do Mi
ni Exame do Estado Mental e do Questionário de Atividades Funcionais. Os sujeito
s foram divididos em cinco grupos de acordo com a Escala de Gravidade da Demênci
a. Vinte e seis indivíduos do grupo original que não tinham o diagnóstico de dem
ência no início do estudo foram reavaliados após dois anos para detectar o desen
volvimento da doença. RESULTADOS: Os volumes dos hemisférios cerebelares, lobo c
erebelar posterior, vermis e lobo temporal estavam diminuídos proporcionalmente 
à gravidade da doença. Houve correlações positivas e significativas entre o Ques
tionário de Atividades Funcionais, Mini Exame do Estado Mental e seus respectivo
s subtestes para linguagem e atenção com os volumes do lobo temporal e cerebelar
. A análise de regressão logística demonstrou que o volume reduzido do lobo temp
oral, lobo cerebelar posterior e vermis pode ser um fator de risco para o futuro
 desenvolvimento de demência. CONCLUSÃO: Este é o primeiro estudo que demonstrou
 que o volume do cerebelo pode estar reduzido na fase pré-demência e reforça o p
apel dessa estrutura na progressão da doença de Alzheimer. Considerando que o ce
rebelo pode não estar diretamente associado com a origem da doença de Alzheimer,
 este achado tem valor para o prognóstico.#^ddecs^i2#^tm^lpt^kCerebelo^i2#^tm^lp
t^kEstudos epidemiológicos^i2#^tm^lpt^kDemência^i2#^tm^lpt^kDoença de Alzheimer^
i2#^tm^lpt^kAvanço da doença^i2#vancouv#48#20100222#February 22, 1010#20100924#S
eptember 24, 2010#aop1211.htm#Internet^ihttp://www.scielo.br/scielo.php?script=s
ci_arttext&pid=S1516-44462011005000012##
00369000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704012900082002001200211#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#5#1#article#218#<p><font size
="4" face="verdana"><b><a name="title"></a>Cerebellar volume in       patients w
ith dementia</b></font></p>     ^cY#aop1211.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#6#2#article#218#<p>&nbsp;</p>
     ^cY#aop1211.htm##
00349000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704010900082002001200191#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#7#3#article#218#<p><font size
="3" face="verdana"><b>Volume cerebelar em pacientes com dem&ecirc;ncia </b></fo
nt></p>     ^cY#aop1211.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#8#4#article#218#<p>&nbsp;</p>
     ^cY#aop1211.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#9#5#article#218#<p>&nbsp;</p>
     ^cY#aop1211.htm##
00794000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704055300083002001200636#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#10#6#article#218#<p><font siz
e="2" face="Verdana"><b>Leonardo Balda&ccedil;ara<Sup>I, II</Sup>; Jo&atilde;o  
     Guilherme Fiorani Borgio<Sup>I</Sup>;<Sup></Sup> Walter Andr&eacute; dos Sa
ntos Moraes<Sup>III</Sup>;<Sup></Sup> Acioly       Luiz Tavares Lacerda<Sup>I, I
V</Sup>;<Sup></Sup> Maria Beatriz Marcondes Macedo Monta&ntilde;o<Sup>V</Sup>;<S
up></Sup> S&eacute;rgio       Tufik<Sup>III</Sup>;<Sup></Sup> Rodrigo Affonseca 
Bressan<Sup>I</Sup>;<Sup></Sup> Luiz Roberto       Ramos<Sup>V</Sup>;<Sup></Sup>
 Andrea Parolin Jackowski<Sup>I</Sup></b></font></p>     ^cY#aop1211.htm##
00495000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704025400083002001200337#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#11#7#article#218#<p><font siz
e="2" face="Verdana"><Sup>I</Sup>Laborat&oacute;rio Interdisciplinar     de Neur
oci&ecirc;ncias Cl&iacute;nicas (Linc), Department of Psychiatry,     Universida
de Federal de S&atilde;o Paulo (UNIFESP), S&atilde;o Paulo, SP,     Brazil    ^c
Y#aop1211.htm##
00328000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704008700083002001200170#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#12#8#article#218#<br>   <Sup>
II</Sup>Universidade Federal do Tocantins (UFT), Palmas, TO, Brazil    ^cY#aop12
11.htm##
00381000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704014000083002001200223#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#13#9#article#218#<br>   <Sup>
III</Sup>Department of Psychobiology, Universidade Federal de S&atilde;o   Paulo
 (UNIFESP), S&atilde;o Paulo, SP, Brazil    ^cY#aop1211.htm##
00350000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010800084002001200192#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#14#10#article#218#<br>   <Sup
>IV</Sup>Instituto Sinapse de Neuroci&ecirc;ncias Cl&iacute;nicas, Campinas,   S
P, Brazil    ^cY#aop1211.htm##
00399000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704015700084002001200241#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#15#11#article#218#<br>   <Sup
>V</Sup>Department of Preventive Medicine, Universidade Federal de S&atilde;o   
Paulo (UNIFESP), S&atilde;o Paulo, SP, Brazil </font></p>     ^cY#aop1211.htm##
00328000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008600084002001200170#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#16#12#article#218#<p><font si
ze="2" face="Verdana"><a href="#end">Correspondence</a></font></p>     ^cY#aop12
11.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#17#13#article#218#<p>&nbsp;</
p>     ^cY#aop1211.htm##
00286000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704004400084002001200128#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#18#14#article#218#<p>&nbsp;</
p> <hr size="1" noshade>     ^cY#aop1211.htm##
00311000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704006900084002001200153#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#19#15#article#218#<p><font si
ze="2" face="Verdana"><B>ABSTRACT </B></font></p>     ^cY#aop1211.htm##
00524000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704028200084002001200366#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#20#16#article#218#<p><font si
ze="2" face="Verdana"><B>OBJECTIVE: </B>The aim of this study was     to examine
 the cerebellar volume of subjects at different stages of Alzheimer's     diseas
e and to investigate whether volume reductions in this structure are     related
 to cognitive decline.     ^cY#aop1211.htm##
00734000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704049200084002001200576#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#21#17#article#218#<br>   <B>M
ETHOD: </B>Ninety&#45;six subjects from an epidemiological study were submitted 
  to a magnetic resonance imaging scan and evaluated using the Mini&#45;Mental S
tate   Examination and the Functional Activities Questionnaire. Subjects were di
vided   into five groups according to the Clinical Dementia Rating scale. Twenty
&#45;six   subjects from the original group who had no dementia diagnosis at bas
eline   were re&#45;evaluated for the onset of dementia after two years.     ^cY
#aop1211.htm##
00857000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704061500084002001200699#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#22#18#article#218#<br>   <B>R
ESULTS: </B>The volumes of the cerebellar hemispheres, posterior cerebellar   lo
be, vermis and temporal lobe were found to be reduced as a function of the   sev
erity of the disease. There were significant positive correlations between   the
 volume of the temporal lobe and cerebellum and the language, attention,   and t
otal scores in the Mini&#45;Mental State Examination and the Functional Activiti
es   Questionnaire. A logistic regression analysis demonstrated that reduced tem
poral   lobe, posterior cerebellar lobe and vermal volume at baseline is a risk 
factor   for the onset of dementia.     ^cY#aop1211.htm##
00667000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704042500084002001200509#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#23#19#article#218#<br>   <B>C
ONCLUSION: </B>This is the first study demonstrating that reduced cerebellar   v
olume is already apparent at the predementia stage. The results of this study   
support the involvement of the cerebellum in the progression of dementia. Wherea
s   the cerebellum might not be directly associated with the origin of Alzheimer
's   disease, it may provide useful information related to its prognosis. </font
></p>     ^cY#aop1211.htm##
00478000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704023600084002001200320#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#24#20#article#218#<p><font si
ze="2" face="Verdana"><B>Descriptors: </B>Cerebellum; Epidemiological     studie
s; Dementia; Alzheimer disease; Disease progression </font></p> <hr size="1" nos
hade> <b><font size="2" face="VERDANA">RESUMO</font></b>     ^cY#aop1211.htm##
00534000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704029200084002001200376#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#25#21#article#218#<p><font si
ze="2" face="Verdana"><B>OBJETIVO: </B>O objetivo deste estudo foi     examinar 
o volume cerebelar em indiv&iacute;duos em diferentes fases da doen&ccedil;a    
 de Alzheimer e investigar se sua redu&ccedil;&atilde;o estaria relacionada     
com o decl&iacute;nio cognitivo.     ^cY#aop1211.htm##
00851000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704060900084002001200693#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#26#22#article#218#<br>   <B>M
&Eacute;TODO: </B>Noventa e seis indiv&iacute;duos de um estudo epidemiol&oacute
;gico   foram submetidos &agrave; resson&acirc;ncia magn&eacute;tica e avaliados
 por   meio do Mini Exame do Estado Mental e do Question&aacute;rio de Atividade
s   Funcionais. Os sujeitos foram divididos em cinco grupos de acordo com a Esca
la   de Gravidade da Dem&ecirc;ncia. Vinte e seis indiv&iacute;duos do grupo ori
ginal   que n&atilde;o tinham o diagn&oacute;stico de dem&ecirc;ncia no in&iacut
e;cio   do estudo foram reavaliados ap&oacute;s dois anos para detectar o desenv
olvimento   da doen&ccedil;a.     ^cY#aop1211.htm##
00938000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704069600084002001200780#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#27#23#article#218#<br>   <B>R
ESULTADOS: </B>Os volumes dos hemisf&eacute;rios cerebelares, lobo cerebelar   p
osterior, vermis e lobo temporal estavam diminu&iacute;dos proporcionalmente &ag
rave; gravidade   da doen&ccedil;a. Houve correla&ccedil;&otilde;es positivas e 
significativas   entre o Question&aacute;rio de Atividades Funcionais, Mini Exam
e do Estado   Mental e seus respectivos subtestes para linguagem e aten&ccedil;&
atilde;o   com os volumes do lobo temporal e cerebelar. A an&aacute;lise de regr
ess&atilde;o   log&iacute;stica demonstrou que o volume reduzido do lobo tempora
l, lobo cerebelar   posterior e vermis pode ser um fator de risco para o futuro 
desenvolvimento   de dem&ecirc;ncia.     ^cY#aop1211.htm##
00692000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704045000084002001200534#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#28#24#article#218#<br>   <B>C
ONCLUS&Atilde;O: </B>Este &eacute; o primeiro estudo que demonstrou que   o volu
me do cerebelo pode estar reduzido na fase pr&eacute;&#45;dem&ecirc;ncia   e ref
or&ccedil;a o papel dessa estrutura na progress&atilde;o da doen&ccedil;a   de A
lzheimer. Considerando que o cerebelo pode n&atilde;o estar diretamente   associ
ado com a origem da doen&ccedil;a de Alzheimer, este achado tem valor   para o p
rogn&oacute;stico. </font></p>     ^cY#aop1211.htm##
00458000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704021600084002001200300#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#29#25#article#218#<p><font si
ze="2" face="Verdana"><B>Descritores: </B>Cerebelo; Estudos epidemiol&oacute;gic
os;     Dem&ecirc;ncia; Doen&ccedil;a de Alzheimer; Avan&ccedil;o da doen&ccedil
;a </font></p> <hr size="1" noshade>     ^cY#aop1211.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#30#26#article#218#<p>&nbsp;</
p>     ^cY#aop1211.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#31#27#article#218#<p>&nbsp;</
p>     ^cY#aop1211.htm##
00315000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007300084002001200157#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#32#28#article#218#<p><font si
ze="3" face="Verdana"><b>Introduction</b> </font></p>     ^cY#aop1211.htm##
00678000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704043600084002001200520#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#33#29#article#218#<p><font si
ze="2" face="Verdana">The occurrence of dementia is rising substantially     wor
ldwide. There is currently no cure for dementia; therefore, extensive     effort
s for the prevention of the disease have mounted.<Sup>1 </Sup>The proper     ide
ntification of individuals at increased risk for dementia will allow for     a m
ore efficient implementation of preventive measures currently available.<sup>1 <
/sup></font></p>     ^cY#aop1211.htm##
00835000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704059300084002001200677#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#34#30#article#218#<p><font si
ze="2" face="Verdana">There is a growing interest in magnetic resonance     imag
ing (MRI)&#45;based measures and associated standard cognitive assessments     a
s methods allowing for the optimal prediction of future clinical decline.<Sup>2 
</Sup>MRI     is widely used as a noninvasive method to assess gray and white ma
tter volumes,     with highly reproducible results.<Sup>3 </Sup>Gray and white m
atter volumes     were shown to correlate with confirmed pathological neuronal l
oss and with     the molecular hallmarks of Alzheimer's disease (AD).<Sup>4 </Su
p></font></p>     ^cY#aop1211.htm##
01060000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704081800084002001200902#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#35#31#article#218#<p><font si
ze="2" face="Verdana">Recently, the possibility of an early diagnosis     of AD 
has brought attention to the importance of neuroimaging investigations     in pr
edementia patients.<Sup>5 </Sup>Several studies using region&#45;of&#45;interest
     (ROI) and voxel&#45;based analyses have reported reduced volumes in the hip
pocampus,     parahippocampal gyrus, cingulate and other brain regions in patien
ts with     mild cognitive impairment (MCI) and AD.<Sup>2,6&#45;8 </Sup>The spat
ial pattern     of brain atrophy in MCI is complex and highly variable and does 
not always     progress in a linear manner. Characterizing these inter&#45;indiv
idual variations     in the manifestation of these diseases through the developm
ent of biomarkers     poses even greater challenges.<Sup>8,9 </Sup></font></p>  
   ^cY#aop1211.htm##
01289000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704104700084002001201131#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#36#32#article#218#<p><font si
ze="2" face="Verdana">There is strong evidence that the cerebellum     not only 
modulates important motor functions, but also plays a significant     role in th
e operation of cognitive functions, emotional processing, and behavior.<Sup>10,1
1 </Sup>From     this perspective, the cerebellum exerts a regulatory function t
hat enhances     and supplements other brain functions, throughout direct and in
direct circuits.<Sup>10,11 </Sup>In     AD, diffuse plaques are commonly found i
n fibrillar and thioflavin positive     cells of the granular layer and Purkinje
 cells in the molecular layer of     the cerebellar cortex.<Sup>12,13 </Sup>It h
as been suggested that neuronal     loss in the cerebellum, such as decreases in
 granule cell numbers and volumetric     loss in the molecular layer, may be the
 result of primary pathologic changes     in the cerebral cortex, a process call
ed <I>diaschisis.</I><Sup>14 </Sup><I>Diaschisis </I>is     the mechanism sugges
ted for cerebellar impairment in dementia.<Sup>10 </Sup></font></p>     ^cY#aop1
211.htm##
00805000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704056300084002001200647#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#37#33#article#218#<p><font si
ze="2" face="Verdana">There is a lack of studies examining the cerebellar     vo
lume in patients with AD. In this study, we analyzed the volume of the     cereb
ellum and its subregions in subjects with AD, MCI, and in healthy control     su
bjects. We hypothesized that the cerebellar volume would be proportionally     r
educed at different stages of dementia. We also investigated whether cerebellar 
    reductions are related to cognitive impairment including orientation, memory
,     attention, language, and executive functions. </font></p>     ^cY#aop1211.
htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#38#34#article#218#<p>&nbsp;</
p>     ^cY#aop1211.htm##
00309000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704006700084002001200151#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#39#35#article#218#<p><font si
ze="3" face="Verdana"><b>Method</b> </font></p>     ^cY#aop1211.htm##
00314000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007200084002001200156#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#40#36#article#218#<p><font si
ze="2" face="Verdana"><b>1. Database </b></font></p>     ^cY#aop1211.htm##
00764000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704052200084002001200606#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#41#37#article#218#<p><font si
ze="2" face="Verdana">All data used in this study were obtained from     the Eld
erly Epidemiology Study (EPIDOSO) database. The EPIDOSO study was     the first 
community&#45;based cohort study examining the elderly in Brazil.<Sup>15 </Sup>T
his     epidemiological study evaluated 1,667 individuals aged 65 years and olde
r     living in an urban district of the city of S&atilde;o Paulo. The main goal
     of the EPIDOSO was to identify predictors of good health in the elderly.<Su
p>15 </Sup></font></p>     ^cY#aop1211.htm##
00314000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007200084002001200156#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#42#38#article#218#<p><font si
ze="2" face="Verdana"><b>2. Subjects </b></font></p>     ^cY#aop1211.htm##
00677000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704043500084002001200519#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#43#39#article#218#<p><font si
ze="2" face="Verdana">We selected 96 subjects from the outpatient     clinic of 
EPIDOSO with AD (n = 70) and cognitive impairment without dementia     (n = 16),
 in addition to 10 subjects without cognitive complaints or functional     impai
rment and with a Mini&#45;Mental State Examination (MMSE) score of 30. All     s
ubjects were classified with the Clinical Dementia Rating scale (CDR).<Sup>15 </
Sup></font></p>     ^cY#aop1211.htm##
00802000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704056000084002001200644#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#44#40#article#218#<p><font si
ze="2" face="Verdana">Subjects were divided into five groups according     to de
mentia severity (CDR score) as follows: 0 = controls, 0.5 = questionable     or 
very mild impairment, 1 = mild impairment, 2 = moderate impairment, and     3 = 
severe impairment. We classified all the subjects without cognitive complaints  
   or functional impairment and with an MMSE equal to 30 as CDR = 0. The patient
s     who met the diagnostic criteria proposed by Petersen et al. for MCI were  
   included in the CDR = 0.5 group.<Sup>16 </Sup></font></p>     ^cY#aop1211.htm
##
01458000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704121600084002001201300#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#45#41#article#218#<p><font si
ze="2" face="Verdana">Alzheimer's diagnosis was made according     to the criter
ia of the National Institute of Neurological and Communicative     Disorders and
 Stroke and the Alzheimer's Disease and Related Disorders     Association (NINCD
S&#45;ADRDA).<Sup>17 </Sup>A clinical and sociodemographic     questionnaire inc
luding questions about age, gender, education, neurological     and psychiatric 
family history, previous psychiatric treatment, and drug     treatment was admin
istered to each patient. Subjects were excluded if they     had any neurological
, psychiatric or medical conditions that could potentially     affect the centra
l nervous system, such as substance abuse or dependence,     atypical headache, 
head trauma with loss of consciousness, asymptomatic or     symptomatic cerebral
 infarction detected on T2weighted MRI, hypertension,     chronic lung disease, 
kidney disease, chronic hepatic disease, cancer or     diabetes mellitus. Subjec
ts were also excluded if the cause of dementia was     not AD (8 cases). We used
 the Structured Clinical Interview for DSM&#45;IV (SCID)<Sup>18 </Sup>to     exc
lude psychiatric disorders as the cause of cognitive impairment. </font></p>    
 ^cY#aop1211.htm##
00561000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704031900084002001200403#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#46#42#article#218#<p><font si
ze="2" face="Verdana">The cognitive evaluation was performed with     the MMSE<S
up>19 </Sup>and adjusted for years of education based on information     provide
d by Bruck et al.<Sup>20 </Sup>Functionality was evaluated with the     Function
al Activities Questionnaire (FAQ).<Sup>21 </Sup></font></p>     ^cY#aop1211.htm#
#
00511000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704026900084002001200353#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#47#43#article#218#<p><font si
ze="2" face="Verdana">All participants signed informed consent forms     before 
participation in this study, which was approved by the Institutional     Review 
Board (IRB) of the Universidade Federal de S&atilde;o Paulo (CEP n° 0258/08). </
font></p>     ^cY#aop1211.htm##
00313000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007100084002001200155#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#48#44#article#218#<p><font si
ze="2" face="Verdana"><b>3. Outcome </b></font></p>     ^cY#aop1211.htm##
00555000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704031300084002001200397#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#49#45#article#218#<p><font si
ze="2" face="Verdana">Twenty&#45;six subjects without dementia at baseline     (
CDR = 0 and CDR = 0.5) were re&#45;evaluated after two years. MR images were    
 analyzed to evaluate whether cerebellar volume alterations at baseline could   
  be related to future cognitive decline. </font></p>     ^cY#aop1211.htm##
00336000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009400084002001200178#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#50#46#article#218#<p><font si
ze="2" face="Verdana"><b>4. Image acquisition and analysis </b></font></p>     ^
cY#aop1211.htm##
01404000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704116200084002001201246#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#51#47#article#218#<p><font si
ze="2" face="Verdana">MRI scans were performed immediately or up to     15 days 
after the neuropsychological evaluation. Images were collected using     a GE Si
gma 1.5T scanner (General Electric Medical Systems, Milwaukee, Wisconsin)     wi
th a coronal 3D SPGR acquisition sequence (TE = 5msec, TR = 33.3msec, flip     a
ngle = 45 degrees, acquisition matrix = 256x256, NEX = 1, FOV = 34cm, slice     
thickness = 1.3mm, 124 slices). Data were analyzed using the software Brains    
 2.<Sup>22 </Sup>Two raters, blind in regard to the subjects' diagnoses,     per
formed ROI analyses. All brain structures, except the cerebellar vermis,     wer
e measured using the Brains 2 semiautomated method.<Sup>22 </Sup>Brain     segme
ntation was performed for all patients and manually checked and edited     to en
sure accuracy.<Sup>23,24 </Sup>Volumes were output in cm<Sup>3</Sup>.     To eva
luate whether cerebellar volume reductions were secondary to superior     struct
ure atrophy, the cerebral and temporal lobes were also segmented. All     cerebr
al and cerebellar measurements were corrected for the total intracranial     vol
ume (TIV). </font></p>     ^cY#aop1211.htm##
00339000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009700084002001200181#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#52#48#article#218#<p><font si
ze="2" face="Verdana">1) TIV, cerebral, and temporal lobe volumes </font></p>   
  ^cY#aop1211.htm##
00753000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704051100084002001200595#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#53#49#article#218#<p><font si
ze="2" face="Verdana">Total intracranial volumes were calculated by     manually
 tracing the intracranial volume of each coronal slice after exclusion     of th
e skull and dura, summing these areas across successive coronal slices     inclu
ding gray and white matter and CSF volumes, and multiplying the sum     by the s
lice thickness. These measures included the frontal, parietal, temporal,     and
 occipital cortices, subcortical structures, the cerebellum, and the brainstem. 
</font></p>     ^cY#aop1211.htm##
00717000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704047500084002001200559#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#54#50#article#218#<p><font si
ze="2" face="Verdana">The cerebral volume was obtained from T1&#45;weighted     
volumetric imaging using a semi&#45;automated, iterative 3D morphologic techniqu
e.     This technique includes a consistent CSF&#45;brain intensity threshold se
t at     60% of mean brain intensity. Every slice between the superior point of 
the     cortex and the inferior limit of segmentation, set at the lowest point o
f     the brain, was measured.<Sup>25 </Sup></font></p>     ^cY#aop1211.htm##
00767000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704052500084002001200609#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#55#51#article#218#<p><font si
ze="2" face="Verdana">The temporal lobes were segmented on cerebral     images, 
which required detecting their boundaries as determined by the upper     plane o
f the cerebellum, the Sylvian fissure, the upper plane of the medial     tempora
l lobe, and the posterior plane of the temporal lobe. The posterior     plane of
 the temporal lobe was determined manually. The posterior border     was defined
 as the point at which the posterior horn of the lateral ventricle     appeared.
<Sup>26 </Sup></font></p>     ^cY#aop1211.htm##
00317000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007500084002001200159#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#56#52#article#218#<p><font si
ze="2" face="Verdana">2) Cerebellar volumes </font></p>     ^cY#aop1211.htm##
01415000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704117300084002001201257#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#57#53#article#218#<p><font si
ze="2" face="Verdana">The cerebellar hemispheres and vermis volumes     were cal
culated by summing up the areas of successive coronal slices after     ROI traci
ng. Tracing of the cerebellum was also performed using the Brains     2 semi&#45
;automated model and manually corrected based on descriptions from     previous 
studies.<Sup>23,24 </Sup>The left and right cerebellar hemispheres     and the v
ermis were manually traced using protocols described elsewhere (De     Bellis an
d Kuchibhatla<Sup>27 </Sup>and Luft<Sup>23</Sup>). The measurement     of the ce
rebellum started as it appeared laterally to the pons. The tentorium     cerebel
li acted as the superior limit and the base of the cerebellum itself     as the 
inferior limit. The cisterna magna and transverse sinus were excluded.<Sup>27 </
Sup>The     last slice included was the one at which the cerebellum was no longe
r distinguishable     from the transverse sinus or had disappeared. The measurem
ent of the vermis     began at the slice where the anterior and/or inferior post
erior lobes appeared.     Measurements were made until the vermis was no longer 
visible.<Sup>27 </Sup></font></p>     ^cY#aop1211.htm##
00314000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007200084002001200156#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#58#54#article#218#<p><font si
ze="2" face="Verdana">3) Reproducibility </font></p>     ^cY#aop1211.htm##
00807000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704056500084002001200649#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#59#55#article#218#<p><font si
ze="2" face="Verdana">To evaluate the intra&#45;rater reproducibility,     the s
ame rater repeated the TIV, brain, temporal lobe, and cerebellar measurements   
  twice, at least a week apart, for 10 randomly selected subjects. Inter&#45;rat
er     reproducibility was assessed by two investigators, blinded in regard to t
he     patient's details, who measured TIV and brain volumes for five randomly  
   selected subjects. Inter&#45; and intra&#45;rater reliability tests were cons
idered     excellent (ICC &gt; 0.96) for all regions. </font></p>     ^cY#aop121
1.htm##
00319000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007700084002001200161#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#60#56#article#218#<p><font si
ze="2" face="Verdana"><b>5. Data analyses </b></font></p>     ^cY#aop1211.htm##
00594000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704035200084002001200436#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#61#57#article#218#<p><font si
ze="2" face="Verdana">All statistical analyses were conducted using     the Stat
istical Package for the Social Sciences (SPSS) 15.0 for Windows.<Sup>28 </Sup>Be
fore     analysis, the measures were examined for normality using the Shapiro&#4
5;Wilk     test. The level of significance was set at p &lt; 0.05, 2&#45;tailed.
 </font></p>     ^cY#aop1211.htm##
00695000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704045300084002001200537#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#62#58#article#218#<p><font si
ze="2" face="Verdana">A Chi&#45;square test was used to assess gender     differ
ences, whereas age, years of education, MMSE scores, and FAQ differences     bet
ween groups were assessed using analyses of variance (ANOVAs). To account     fo
r inter&#45;individual differences in head size, cerebellar volumes were correct
ed     by dividing them by each subject's intracranial volume and multiplying   
  this ratio by 1000. </font></p>     ^cY#aop1211.htm##
00831000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704058900084002001200673#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#63#59#article#218#<p><font si
ze="2" face="Verdana">By employing the General Linear Model, analyses     of cov
ariance (ANCOVAs) were performed to investigate volume differences     in the br
ain and cerebellar subregions across CDR groups, followed by Duncan's     post h
oc test. Age and years of education were used as covariates. We examined     the
 relationship between the cerebellar volume, MMSE total score, MMSE sub&#45;test
s     scores, and FAQ score by employing a multivariable regression model contro
lled     for age, years of education, and cerebral and temporal lobe volumes. </
font></p>     ^cY#aop1211.htm##
01128000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704088600084002001200970#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#64#60#article#218#<p><font si
ze="2" face="Verdana">Student's <I>t</I>&#45;test was used to assess     differe
nces in cerebral, temporal lobe, and cerebellar volumes between patients     tha
t developed dementia and patients that did not develop dementia two years     af
ter baseline. Logistic regression analysis was used to calculate odds ratios    
 (ORs) of association with 95% confidence intervals (CIs) of dementia onset     
with possible predictive variables. The left and right cerebellum and the     ve
rmis at baseline were used as main variables in each analysis and compared     i
n a full multivariate model for potentially confounding effects of age,     year
s of education, and left temporal lobe, right temporal lobe, and cerebral     vo
lume. Given the disproportionate stratified sampling, weighted analyses     were
 performed. The level of alpha was set at p &lt; 0.10. </font></p>     ^cY#aop12
11.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#65#61#article#218#<p>&nbsp;</
p>     ^cY#aop1211.htm##
00310000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704006800084002001200152#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#66#62#article#218#<p><font si
ze="3" face="Verdana"><b>Results</b> </font></p>     ^cY#aop1211.htm##
00335000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009300084002001200177#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#67#63#article#218#<p><font si
ze="2" face="Verdana"><b>1. Demographic and clinical data </b></font></p>     ^c
Y#aop1211.htm##
00682000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704044000084002001200524#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#68#64#article#218#<p><font si
ze="2" face="Verdana">The general demographic characteristics of the     groups 
are displayed in <a href="#tab01">Table 1</a>. No significant     gender differe
nces were observed between groups (</font><font>&#967;</font><font size="2" face
="verdana"><Sup>2 </Sup>=     1.635, p = 0.802), but there were significant diff
erences in age (F = 1.787,     p = 0.138) and years of education (F = 1.733, p =
 0.150). </font></p>     ^cY#aop1211.htm##
00278000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704003600084002001200120#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#69#65#article#218#<p><a name=
"tab01"></a></p>     ^cY#aop1211.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#70#66#article#218#<p>&nbsp;</
p>     ^cY#aop1211.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#71#67#article#218#<p align="c
enter"><img src="/img/revistas/rbp/2011nahead/a12tab01.jpg"></p>     ^cY#aop1211
.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#72#68#article#218#<p>&nbsp;</
p>     ^cY#aop1211.htm##
00339000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009700084002001200181#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#73#69#article#218#<p><font si
ze="2" face="Verdana"><b>2. Brain and cerebellar measurements </b></font></p>   
  ^cY#aop1211.htm##
00599000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704035700084002001200441#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#74#70#article#218#<p><FONT si
ze="2" face="Verdana">Cerebellar hemispheres were progressively reduced     in C
DR groups 1, 2, and 3. The volume of the vermis, however, was found to     be al
ready reduced in the CDR 0.5 group, and this reduction trended progressively    
 along with increasing CDR scores (see <a href="#tab02">Table 2</a> for     deta
ils). </font></p>     ^cY#aop1211.htm##
00278000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704003600084002001200120#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#75#71#article#218#<p><a name=
"tab02"></a></p>     ^cY#aop1211.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#76#72#article#218#<p>&nbsp;</
p>     ^cY#aop1211.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#77#73#article#218#<p align="c
enter"><img src="/img/revistas/rbp/2011nahead/a12tab02.jpg"></p>     ^cY#aop1211
.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#78#74#article#218#<p>&nbsp;</
p>     ^cY#aop1211.htm##
02175000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704193300084002001202017#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#79#75#article#218#<p><FONT si
ze="2" face="Verdana">There were significant correlations between     all cerebe
llar regions and the MMSE total scores and sub&#45;tests, and the FAQ.     Howev
er, when controlling for brain and temporal lobe volumes, few correlations     r
emained significant. MMSE total scores correlated positively with the volumes   
  of the left temporal lobe (</font><font>&#946;</font><font size="2" face="verd
ana"> =     0.492, t = 1.876, p = 0.064), right cerebellum (</font><font>&#946;<
/font><font size="2" face="verdana"> =     0.0543, t = 1.263, p &lt; 0.080), and
 posterior cerebellar lobe (</font><font>&#946;</font><font size="2" face="verda
na"> =     0.0627, t = 1.774, p = 0.058). The MMSE language sub&#45;test correla
ted positively     with the left temporal lobe (</font><font>&#946;</font><font 
size="2" face="verdana"> =     0.452, t = 1.642, p = 0.052), right cerebellar he
misphere (</font><font>&#946;</font><font size="2" face="verdana"> =     0.442, 
t = 9.542, p &lt; 0.020), posterior cerebellar lobe (</font><font>&#946;</font><
font size="2" face="verdana"> =     0.422, t = 1.284, p = 0.062) and vermis (</f
ont><font>&#946;</font><font size="2" face="verdana"> =     0.380, t = 4.520, p 
&lt; 0.018). Attention correlated positively with the     posterior cerebellar l
obe (</font><font>&#946;</font><font size="2" face="verdana"> =     0.365, t = 2
.252, p = 0.044) and vermis volumes (</font><font>&#946;</font><font size="2" fa
ce="verdana"> =     0.260, t = 2.747, p = 0.007). FAQ scores correlated negative
ly with the left     temporal lobe (</font><font>&#946;</font><font size="2" fac
e="verdana"> =     &#45;0.666, t = &#45;3.196, p = 0.002), right cerebellum (</f
ont><font>&#946;</font><font size="2" face="verdana"> =     &#45;0.111, t = &#45
;1.736, p = 0.086) and vermis volumes (</font><font>&#946;</font><font size="2" 
face="verdana"> =     &#45;0.809, t = &#45;2.884, p = 0.005). </font></p>     ^c
Y#aop1211.htm##
00313000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007100084002001200155#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#80#76#article#218#<p><font si
ze="2" face="Verdana"><b>3. Outcome </b></font></p>     ^cY#aop1211.htm##
00582000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704034000084002001200424#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#81#77#article#218#<p><font si
ze="2" face="Verdana">Of the 26 subjects without dementia at baseline,     10 su
bjects (1 with CDR = 0 and 4 with CDR = 0.5) developed dementia after     two ye
ars. There were no differences in intracranial volume, cerebral volume,     temp
oral lobes, and right cerebellum between the two groups at baseline. </font></p>
     ^cY#aop1211.htm##
00595000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704035300084002001200437#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#82#78#article#218#<p><font si
ze="2" face="Verdana">In a logistic regression analysis, reduced left     tempor
al lobe (OR = 2.002, C.I.: 1.102&#45;3.123, p = 0.058), posterior cerebellar    
 lobe (OR = 1.402, C.I.: 1.004&#45;2.903, p = 0.068), and vermal volume (OR =   
  1.480, C.I.: 1.024&#45;2.803, p = 0.042) were related to future dementia onset
. </font></p>     ^cY#aop1211.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#83#79#article#218#<p>&nbsp;</
p>     ^cY#aop1211.htm##
00313000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007100084002001200155#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#84#80#article#218#<p><font si
ze="3" face="Verdana"><b>Discussion</b> </font></p>     ^cY#aop1211.htm##
01031000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704078900084002001200873#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#85#81#article#218#<p><font si
ze="2" face="Verdana">We determined the volumes of cerebellar substructures     
on MRI scans of healthy controls and subjects with cognitive impairment as     c
lassified with the CDR. Our study yielded three major findings: (1) the     volu
mes of the cerebellum and its subregions were significantly smaller in     subje
cts with cognitive impairment when compared to healthy controls; (2)     the rig
ht cerebellar hemisphere, posterior cerebellar lobe, and vermis volumes     were
 associated with poor cognitive performance as determined by the MMSE;     and (
3) the posterior cerebellar lobe and vermis volumes, together with the     volum
e of the left temporal lobe, were associated with future dementia onset     in t
he MCI group as compared to controls. </font></p>     ^cY#aop1211.htm##
00339000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009700084002001200181#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#86#82#article#218#<p><font si
ze="2" face="Verdana"><b>1. Cerebellar morphology in dementia </b></font></p>   
  ^cY#aop1211.htm##
00962000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704072000084002001200804#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#87#83#article#218#<p><font si
ze="2" face="Verdana">Dementias constitute a heterogeneous group of     diseases
 that share a common cognitive impairment of organic etiology. Although     seve
ral causes and pathophysiological mechanisms underlie the clinical presentation 
    of different types of dementia, neuroimaging studies have confirmed some    
 common findings such as atrophy of certain brain structures or even global     
brain atrophy and progressive impairment of different cognitive domains.<Sup>10 
</Sup>In     AD, for example, temporal lobe volume reduction is observed even at
 early     stages of the disease, and hippocampal reduction can be observed befo
re the     first symptoms manifest.<Sup>29 </Sup></font></p>     ^cY#aop1211.htm
##
01319000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704107700084002001201161#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#88#84#article#218#<p><font si
ze="2" face="Verdana">Previous studies have reported cerebellar abnormalities   
  in dementia.<Sup>13,30,31 </Sup>In neuropathological studies, neuronal shrinka
ge     and loss are well known changes that accompany AD and are most notable in
     the temporoparietal neocortex, limbic system, and some neuronal groups such
     as the locus coeruleus of the brain stem and the basal nucleus of Meynert  
   in the basal forebrain.<Sup>30 </Sup>Morphological studies, conversely, have 
    focused on the traditional neuropathological hallmarks of AD, such as amyloi
d     plaques, neurofibrillary tangles, and amyloid angiopathy,<Sup>30 </Sup>and
     little has been reported on neuronal loss and other structural changes in  
   AD.<Sup>13 </Sup>There is only one structural MRI study that has previously  
   demonstrated that the posterior cerebellar lobes are smaller in AD patients  
   when compared to healthy controls, and that this atrophy is associated with  
   poorer cognitive performance in AD subjects, but not in MCI patients.<Sup>31 
</Sup></font></p>     ^cY#aop1211.htm##
01065000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704082300084002001200907#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#89#85#article#218#<p><font si
ze="2" face="Verdana">The most relevant pathological features of AD     in the c
erebellum are diffuse A</font><font>&#946;</font><font size="2" face="verdana"> 
deposits     and neurofibrillary tangles, but these are not associated with neur
onal loss.<Sup>32 </Sup>However,     in many neurodegenerative diseases, when a 
relatively large central nervous     system region is affected by neuronal loss,
 other regions are not always     completely spared in terms of morphology due t
o their direct and indirect     connections with the primarily affected region.<
Sup>32 </Sup>Therefore, in     these 'secondarily' affected regions, despite the
 presence of     mild atrophy, there is evidence that no relevant histopathologi
cal changes     are visible under microscopic examination.<Sup>33 </Sup></font><
/p>     ^cY#aop1211.htm##
01087000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704084500084002001200929#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#90#86#article#218#<p><font si
ze="2" face="Verdana"><I>Diaschisis </I>is the cerebellar reduction     related 
to the atrophy of superior structures and is commonly observed at     late stage
s of dementia.<Sup>13 </Sup>The main hypothesis suggesting the     implication o
f the cerebellum in dementia invokes a possible role for <I>diaschisis,</I><Sup>
13,23,30 </Sup>but     our results show that cerebellar volume reductions can be
 observed even at     early stages of the disease. Moreover, there are reports t
hat secondarily     affected regions could present mild atrophy and no histopath
ological changes,<Sup>33 </Sup>and     this is what we investigated here. Possib
le reasons for cerebellar volume     reductions in dementia include vascular fac
tors, toxins (e.g. alcoholic dementia),<Sup>13,23,30 </Sup>and     normal aging.
<Sup>30 </Sup></font></p>     ^cY#aop1211.htm##
01274000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704103200084002001201116#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#91#87#article#218#<p><font si
ze="2" face="Verdana">In this study, we observed correlations between     cerebe
llar volume reduction and cognitive decline in AD patients. Although     the cer
ebellum is virtually free of neurofibrillary pathology, the magnitude     of cer
ebellar atrophy strongly correlates with the duration and stage of     illness.<
Sup>13,30 </Sup>In previous studies, cerebellar atrophy was only     evident at 
late stages of the disease,<Sup>13,30 </Sup>and a correlation     was observed b
etween the loss of granule cells and the duration of AD.<Sup>13,30 </Sup>Importa
ntly,     ascending fibers originating from the inferior olivary nucleus act as 
a powerful     excitatory pathway on Purkinje cells in the cerebellar cortex tha
t may play     a substantial role in motor performance and learning of new motor
 skills.<Sup>34 </Sup>Therefore,     even cerebellar changes that are present du
e to superior structure atrophy     can lead to the impairment of these connecti
ons and may have important consequences. </font></p>     ^cY#aop1211.htm##
00341000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009900084002001200183#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#92#88#article#218#<p><font si
ze="2" face="Verdana"><b>2. Cerebellum and cognitive impairment </b></font></p> 
    ^cY#aop1211.htm##
00849000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704060700084002001200691#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#93#89#article#218#<p><font si
ze="2" face="Verdana">In our study, cerebellar volume correlated with     MMSE t
otal scores and sub&#45;scores for language and attention, in addition     to ha
ving a negative correlation with the FAQ. In past studies, the cerebellum     ha
s only been implicated in movement, gait, posture, and balance.<Sup>10,11 </Sup>
However,     recent studies suggest a possible involvement of the cerebellum in 
cognition,     emotional processing, and behavior due to its connections with co
rtical areas     and associated areas involved in superior mental functions.<Sup
>10,11,35 </Sup></font></p>     ^cY#aop1211.htm##
00808000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704056600084002001200650#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#94#90#article#218#<p><font si
ze="2" face="Verdana">Some studies point to the involvement of the     cerebellu
m in language control, and cerebellar lesions have been related     to language 
impairments such as dysarthria, mutism, aggramatism, difficulty     in naming an
d repetition tasks, verbal working memory, and impairment in     verbal executiv
e functions.<Sup>36&#45;38 </Sup>Apart from speech motor deficits,     aphasic s
yndromes and isolated constellations of agrammatic speech have sporadically     
been observed in cerebellar dysfunctions.<Sup>38 </Sup></font></p>     ^cY#aop12
11.htm##
00728000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704048600084002001200570#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#95#91#article#218#<p><font si
ze="2" face="Verdana">Hassid was the first to provide evidence that     crossed 
cerebral <I>diaschisis </I>might also be associated with extensive     constella
tions of disrupted verbal functions.<Sup>39 </Sup>A recent report     corroborat
es this idea and suggests that dysfunctional cortico&#45;cerebellar     connecti
ons could be related to deficient representations of temporal information     an
d impaired sequencing of linguistic data.<Sup>40 </Sup></font></p>     ^cY#aop12
11.htm##
00717000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704047500084002001200559#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#96#92#article#218#<p><font si
ze="2" face="Verdana">Even ifcerebellar volume reductions weredue     todecrease
d temporal lobe and brain volume, to the best of our knowledge     there are no 
studies demonstrating that vermis atrophy in dementia could     be related to <I
>diaschisis</I>. Although it is possible that reduced vermis     volume could oc
cur in conjunction with similar processes like cerebellar     volume reduction, 
it may be best considered as a risk factor. </font></p>     ^cY#aop1211.htm##
01284000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704104200084002001201126#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#97#93#article#218#<p><font si
ze="2" face="Verdana">The possibility that the cerebellum might be     a part of
 attentional networks was not seriously taken into consideration     until the l
ate 1980s and early 1990s. Since then, two lines of reasoning     have been prop
osed to explain the role of the cerebellum in attention. It     has become clear
 that the projections from the dentate nucleus (the largest     and most phyloge
netically recent of the cerebellar nuclei in humans and higher     primates) to 
the primary motor cortex represent only a fraction of its output.<Sup>41 </Sup>K
elly     and Strick found that other portions of the dentate nucleus innervate o
culomotor,     prefrontal, and posterior parietal areas of the cerebral cortex, 
parts of     the brain that are essential for cognitive functions including atte
ntional     control.<Sup>42 </Sup>Activation has been observed in posterior part
s of     the cerebellum (including the hemispheres and vermis) when assessing sp
atial     shifts in visual attention.<Sup>41 </Sup></font></p>     ^cY#aop1211.h
tm##
01125000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704088300084002001200967#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#98#94#article#218#<p><font si
ze="2" face="Verdana">Classically, the functions of the cerebellar     vermis we
re thought to be related to the vestibular system and to be involved     in bala
nce, coordination, motor activity, tonus, and posture. But there is     clear ev
idence of its involvement in such functions as speech, memory, visuomotor     pr
ocessing, attention, and emotion.<Sup>10,43 </Sup>These functions are mediated  
   by afferent connections of the vermis such as vestibulocerebellum fibers,    
 reticulocerebellum fibers, and spinalcerebellum tracts, and by efferent connect
ions     with the pons, medulla oblonga and reticular formation.<Sup>11,44 </Sup
>Some     studies reported connections between the cerebellar vermis and the flo
cculonodular     lobe to the midbrain and the limbic system that have led to the
 idea of a 'limbic     cerebellum'.<Sup>11,45 </Sup></font></p>     ^cY#aop1211.
htm##
01170000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704092800084002001201012#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#99#95#article#218#<p><font si
ze="2" face="Verdana">The fact that visual information conveyed by     the mossy
 and climbing fibers is integrated in Purkinje cells of the cerebellar     vermi
s (lobules V, VI, VII) involved with oculomotor control has been firmly     esta
blished from classical neurophysiological studies.<Sup>46,47 </Sup>The     flocc
ulonodular lobe and the vermis modulate the position and velocity of     the eye
s with respect to the orientation of the head and the body, enabling     the sub
ject to fixate clearly on a new target, reposition the gaze in saccadic     eye 
movements, and fixate on points while moving, besides being involved     in the 
refinement of motor commands before they reach the eye muscles.<Sup>47 </Sup>If 
    the motor control of the eyes is impaired, the results of cognitive tests   
  may also be impaired, because many cognitive tests like the MMSE require     v
isual integrity. </font></p>     ^cY#aop1211.htm##
00329000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081704008600085002001200171#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#100#96#article#218#<p><font s
ize="2" face="Verdana"><b>3. Cerebellum and outcome </b></font></p>     ^cY#aop1
211.htm##
01149000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081704090600085002001200991#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#101#97#article#218#<p><font s
ize="2" face="Verdana">Based on these preliminary findings, reduced     posterio
r cerebellar lobe and vermis volumes could be potential risk factors     for fut
ure dementia onset, suggesting the possible involvement of the cerebellum     in
 AD outcome. Although cerebellar changes accompany similar changes in the     te
mporal lobe, they cannot be considered as an isolated factor. Our study     eval
uated volumes at one point in time, and we have hypothesized two possible     wa
ys in which cerebellar volume may change: (1) cerebellar volume reductions     c
ould be secondary to temporal lobe volume reductions, or; (2) cerebellar     vol
ume reductions could be evident prior to temporal lobe impairment and     could 
be related to other factors not observed here. This suggests that cerebellar    
 volume reductions can be considered as a risk factor later dementia onset. </fo
nt></p>     ^cY#aop1211.htm##
00732000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081704048900085002001200574#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#102#98#article#218#<p><font s
ize="2" face="Verdana">Finally, a significant negative correlation     between t
he volume of the vermis and functionality was observed. Previous     studies hav
e shown that the functioning of the vermis is related to the prognosis     and m
ortality rates in dementia.<Sup>48 </Sup>Since the cerebellum is also     relate
d to motor and executive functions, this finding indicates a new possibility    
 to be explored in the context of dementia rehabilitation. </font></p>     ^cY#a
op1211.htm##
00318000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081704007500085002001200160#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#103#99#article#218#<p><font s
ize="2" face="Verdana"><b>4. Limitations </b></font></p>     ^cY#aop1211.htm##
01000000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704075600086002001200842#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#104#100#article#218#<p><font 
size="2" face="Verdana">The interpretation of our results is currently     limit
ed because we were not able to obtain detailed and extensive neuropsychological 
    data from our subjects, and were thus able to analyze only certain cognitive
     functions. Our control and MCI groups were very small, and we could not cal
culate     ROC curves for cerebellar volumes and dementia onset. Our findings ar
e correlational     and thus cannot imply causality; whether cerebellar structur
al alterations     and their relation to cognitive functioning are due to primar
y cerebellar     impairment in the course of AD or secondary to destructive proc
esses in other     regions more typically associated with AD remains to be deter
mined. </font></p>     ^cY#aop1211.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#105#101#article#218#<p>&nbsp;
</p>     ^cY#aop1211.htm##
00315000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704007100086002001200157#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#106#102#article#218#<p><font 
size="3" face="Verdana"><b>Conclusion</b> </font></p>     ^cY#aop1211.htm##
01167000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704092300086002001201009#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#107#103#article#218#<p><font 
size="2" face="Verdana">To the best of our knowledge, there are no studies     e
valuating cerebellar volume changes in patients with different levels of     dem
entia and predementia. Our results support previous neuropathological     findin
gs of cerebellar involvement in cognition and AD. Moreover, they indicate     th
at cognitive impairment may be at least partly related to structural changes    
 in the cerebellum. Our findings and interpretations are preliminary and need   
  to be confirmed and validated by future longitudinal studies. The cerebellum  
   could be studied in MCI and AD cohorts to further examine the relationship   
  between changes in the cerebellar morphology and cognitive impairment. The    
 cerebellar roles in motor and non&#45;motor functions could also be explored   
  in studies on new therapeutics and rehabilitation for patients suffering     f
rom dementia. </font></p>     ^cY#aop1211.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#108#104#article#218#<p>&nbsp;
</p>     ^cY#aop1211.htm##
00321000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704007700086002001200163#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#109#105#article#218#<p><font 
size="3" face="Verdana"><b>Acknowledgements</b> </font></p>     ^cY#aop1211.htm#
#
00806000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704056200086002001200648#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#110#106#article#218#<p><font 
size="2" face="Verdana">This study was supported by the Conselho Nacional     de
 Desenvolvimento Cient&iacute;fico e Tecnol&oacute;gico (CNPq), Brazil,     and 
the Funda&ccedil;&atilde;o de Apoio &agrave; Pesquisa do Estado de S&atilde;o   
  Paulo (FAPESP), Brazil. AJ is funded by the Programa de Apoio a Projetos     I
nstitucionais com a Participa&ccedil;&atilde;o de Rec&eacute;m&#45;Doutores     
&#45; Coordena&ccedil;&atilde;o de Aperfei&ccedil;oamento de Pessoal de N&iacute
;vel     Superior (PRODOC&#45;CAPES, 0151/08&#45;4). </font></p>     ^cY#aop1211
.htm##
00605000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704036100086002001200447#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#111#107#article#218#<p><font 
size="2" face="Verdana">The funding sources had no role in the study     design,
 data collection, data analysis, data interpretation or writing of     the repor
t. The corresponding author had full access to all of the data in     the study 
and had final responsibility for the decision to submit the manuscript     for p
ublication. </font></p>     ^cY#aop1211.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#112#108#article#218#<p>&nbsp;
</p>     ^cY#aop1211.htm##
00328000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704008400086002001200170#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#113#109#article#218#<p align=
"center"><img src="/img/revistas/rbp/2011nahead/a12img01.jpg"></p>     ^cY#aop12
11.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#114#110#article#218#<p>&nbsp;
</p>     ^cY#aop1211.htm##
00314000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704007000086002001200156#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#115#111#article#218#<p><font 
size="3" face="Verdana"><b>References</b></font></p>     ^cY#aop1211.htm##
00561000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704030300088002001200391#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#116#112#article#2
18#1#<p><font size="2" face="Verdana">1. Coelho FGM, Santos&#45;Galduroz RF, Gob
bi S,     Stella F. Atividade f&iacute;sica sistematizada e desempenho cognitivo
 em     idosos com dem&ecirc;ncia de Alzheimer: uma revis&atilde;o sistem&aacute
;tica. <i>Rev     Bras Psiquiatr</i>. 2009;31(2):163&#45;70.    ^cY#aop1211.htm#
#
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#117#113#article#218# </font><
/p>     ^cY#aop1211.htm##
00814000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704055600088002001200644#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#118#114#article#2
18#2#<p><font size="2" face="Verdana">2. Leow AD, Yanovsky I, Parikshak N, Hua X
,     Lee S, Toga AW, Jack CR Jr, Bernstein MA, Britson PJ, Gunter JL, Ward CP, 
    Borowski B, Shaw LM, Trojanowski JQ, Fleisher AS, Harvey D, Kornak J, Schuff
     N, Alexander GE, Weiner MW, Thompson PM; Alzheimer's Disease Neuroimaging  
   Initiative. Alzheimer's disease neuroimaging initiative: a one&#45;year     f
ollow up study using tensor&#45;based morphometry correlating degenerative rates
,     biomarkers and cognition. <I>NeuroImage</I>. 2009;45(3):645&#45;55.    ^cY
#aop1211.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#119#115#article#218# </font><
/p>     ^cY#aop1211.htm##
00705000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704044700088002001200535#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#120#116#article#2
18#3#<p><font size="2" face="Verdana">3. Leos AD, Klunder AD, Jack CR Jr., Toga 
AW,     Dale AM, Bernstein MA, Britson PJ, Gunter JL, Ward CP, Whitwell JL, Boro
wski     BJ, Fleisher AS, Fox NC, Harvey D, Kornak J, Schuff N, Studholme C, Ale
xander     GE, Weiner MW, Thompson PM; ADNI Preparatory Phase Study. Longitudina
l stability     of MRI for mapping brain change using tensorbased morphometry. <
I>NeuroImage</I>.     2006;31(2):627&#45;40.    ^cY#aop1211.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#121#117#article#218# </font><
/p>     ^cY#aop1211.htm##
00507000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704024900088002001200337#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#122#118#article#2
18#4#<p><font size="2" face="Verdana">4. Silbert LC, Quinn JF, Moore MM, Corbrid
ge     E, Ball MJ, Murdoch G, Sexton G, Kaye JA. Changes in premorbid brain volu
me     predict Alzheimer's disease pathology. <I>Neurology</I>. 2003;61(4):487&#
45;92.    ^cY#aop1211.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#123#119#article#218# </font><
/p>     ^cY#aop1211.htm##
00434000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704017600088002001200264#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#124#120#article#2
18#5#<p><font size="2" face="Verdana">5. Apostolova LG, Thompson PM. Brain mappi
ng     as a tool to study neurodegeneration. <I>Neurotherapeutics</I>. 2007;4(3)
:387&#45;400.    ^cY#aop1211.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#125#121#article#218#</font></
p>     ^cY#aop1211.htm##
00689000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704043100088002001200519#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#126#122#article#2
18#6#<p><font size="2" face="Verdana">6. Tapiola T, Pennanen C, Tapiola M, Tervo
 S,     Kivipelto M, H&auml;nninen T, Pihlajam&auml;ki M, Laakso MP, Hallikainen
     M, H&auml;m&auml;l&auml;inen A, Vanhanen M, Helkala EL, Vanninen R, Nissine
n     A, Rossi R, Frisoni GB, Soininen H. MRI of hippocampus and entorhinal cort
ex     in mild cognitive impairment: a follow&#45;up study. <I>Neurobiol Aging</
I>.     2008;29(1):31&#45;8.    ^cY#aop1211.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#127#123#article#218# </font><
/p>     ^cY#aop1211.htm##
00561000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704030300088002001200391#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#128#124#article#2
18#7#<p><font size="2" face="Verdana">7. Kivipelto M, Ngandu T, Laatikainen T, W
inblad     B, Soininen H, Tuomilehto J. Risk score for the prediction of dementi
a risk     in 20 years among middle aged people: a longitudinal, population&#45;
based study. <I>Lancet     Neurol</I>. 2006;5(9):735&#45;41.    ^cY#aop1211.htm#
#
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#129#125#article#218# </font><
/p>     ^cY#aop1211.htm##
00507000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704024900088002001200337#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#130#126#article#2
18#8#<p><font size="2" face="Verdana">8. Small GW, Brookheimer SY, Thompston PM,
 Cole     GM, Huang SC, Kepe V, Barrio JR. Currrent and future uses of neuroimag
ing     for cognitively impaired patients. <I>Lancet Neurol</I>. 2008;7(2):161&#
45;72.    ^cY#aop1211.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#131#127#article#218#</font></
p>     ^cY#aop1211.htm##
00538000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704028000088002001200368#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#132#128#article#2
18#9#<p><font size="2" face="Verdana">9. Carrillo MC, Blackwell A, Hampel H, Lin
dborg     J, Sperling R, Schenk D, Sevigny JJ, Ferris S, Bennett DA, Craft S, Hs
u T,     Klunk W. Early risk assessment for Alzheimer's disease. <I>Alzheimer's 
    Dement</I>. 2009;5(2):182&#45;96.    ^cY#aop1211.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#133#129#article#218# </font><
/p>     ^cY#aop1211.htm##
00457000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704019800089002001200287#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#134#130#article#2
18#10#<p><font size="2" face="Verdana">10. Balda&ccedil;ara L, Borgio JGF, Lacer
da     ALT, Jackowski AP. Cerebellum and psychiatric disorders. <I>Rev Bras Psiq
uiatr</I>.     2008;30(3):281&#45;9.    ^cY#aop1211.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#135#131#article#218# </font><
/p>     ^cY#aop1211.htm##
00479000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704022000089002001200309#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#136#132#article#2
18#11#<p><font size="2" face="Verdana">11. Schmahmann JD, Weilburg JB, Sherman J
C.     The neuropsychiatry of the cerebellum &#45;insights from the clinic. <I>C
erebellum </I>(London,     England). 2007;6(3):254&#45;67.    ^cY#aop1211.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#137#133#article#218#</font></
p>     ^cY#aop1211.htm##
00532000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704027300089002001200362#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#138#134#article#2
18#12#<p><font size="2" face="Verdana">12. Yamazaki T, Yamaguchi H, Nakazato Y, 
Ishiguro     K, Kawarabayashi T, Hirai S. Ultrastructural characterization of ce
rebellar     diffuse plaques in Alzheimer's disease. <I>J Neuropathol Exp Neurol
</I>.     1992;51(3):281&#45;6.    ^cY#aop1211.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#139#135#article#218# </font><
/p>     ^cY#aop1211.htm##
00550000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704029100089002001200380#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#140#136#article#2
18#13#<p><font size="2" face="Verdana">13. Wegiel J, Wisniewski HM, Dziewiatkows
ki     J, Badmajew E, Tarnawski M, Reisberg B, Mlodzik B, De Leon MJ, Miller DC.
     Cerebellar atrophy in Alzheimer's disease&#45;clinicopathological correlati
ons. <I>Brain     Res</I>. 1999;818(1):41&#45;50.    ^cY#aop1211.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#141#137#article#218#</font></
p>     ^cY#aop1211.htm##
00400000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704014100089002001200230#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#142#138#article#2
18#14#<p><font size="2" face="Verdana">14. Meyer JS, Obara K, Muramatsu K. Diasc
hisis. <I>Neurological       Res</I>. 1993;15(6):362&#45;6.    ^cY#aop1211.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#143#139#article#218# </font><
/p>     ^cY#aop1211.htm##
00464000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704020500089002001200294#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#144#140#article#2
18#15#<p><font size="2" face="Verdana">15. Monta&ntilde;o MBMM, Ramos LR. Valida
de     da vers&atilde;o em portugu&ecirc;s da Clinical Dementia Rating. <I>Rev S
aude     Publica</I>. 2005;39(6):912&#45;7.    ^cY#aop1211.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#145#141#article#218# </font><
/p>     ^cY#aop1211.htm##
00486000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704022700089002001200316#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#146#142#article#2
18#16#<p><font size="2" face="Verdana">16. Petersen RC, Smith GE, Waring SC, Ivn
ik     RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characteri
zation     and outcome. <I>Arch Neurol</I>. 1999;56(3):303&#45;8.    ^cY#aop1211
.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#147#143#article#218# </font><
/p>     ^cY#aop1211.htm##
00604000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704034500089002001200434#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#148#144#article#2
18#17#<p><font size="2" face="Verdana">17. McKhann G, Drachman D, Folstein M, Ka
tzman     R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease:    
 report of the NINCDSADRDA Work Group under the auspices of Department of     He
alth and Human Services Task Force on Alzheimer's Disease. <I>Neurology</I>.    
 1984;34(7):939&#45;44.    ^cY#aop1211.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#149#145#article#218# </font><
/p>     ^cY#aop1211.htm##
00561000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704030200089002001200391#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#150#146#article#2
18#18#<p><font size="2" face="Verdana">18. Del&#45;Ben CM, Rodrigues CR, Zuardi 
AW. Reliability     of the Portuguese version of the structured clinical intervi
ew for DSM&#45;III&#45;R     (SCID) in a Brazilian sample of psychiatric outpati
ents. <I>Braz Med Biol     Res. </I>1996;29(12):1675&#45;82.    ^cY#aop1211.htm#
#
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#151#147#article#218# </font><
/p>     ^cY#aop1211.htm##
00500000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704024100089002001200330#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#152#148#article#2
18#19#<p><font size="2" face="Verdana">19. Folstein MF, Folstein SE, McHugh PR. 
Mini&#45;mental     state: a practical method for grading the cognitive state of
 patients for     the clinician. <I>J Psychiatr Res</I>. 1975;12(3):189&#45;98. 
   ^cY#aop1211.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#153#149#article#218# </font><
/p>     ^cY#aop1211.htm##
00504000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704024500089002001200334#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#154#150#article#2
18#20#<p><font size="2" face="Verdana">20. Brucki SM, Nitrini R, Caramelli P, Be
rtolucci     PH, Okamoto IH. Suggestions for utilization of the mini&#45;mental 
state examination     in Brazil. <I>Arq Neuropsiquiatr</I>. 2003;61(3B):771&#45;
81.    ^cY#aop1211.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#155#151#article#218# </font><
/p>     ^cY#aop1211.htm##
00483000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704022400089002001200313#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#156#152#article#2
18#21#<p><font size="2" face="Verdana">21. Pfeffer RI, Kurosaki TT, Harrah CH Jr
.,     Chance JM, Filos S. Measurement of functional activities in older adults 
    in the community. <I>J Gerontol</I>. 1982;37(3):323&#45;9.    ^cY#aop1211.ht
m##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#157#153#article#218# </font><
/p>     ^cY#aop1211.htm##
00424000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704016500089002001200254#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#158#154#article#2
18#22#<p><font size="2" face="Verdana">22. Iowa Neuroimaging Center. <I>Imaging 
Lab.       Brains 2</I>. Iowa City: University of Iowa Hospitals and Clinics; 20
06.    ^cY#aop1211.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#159#155#article#218# </font><
/p>     ^cY#aop1211.htm##
00569000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704031000089002001200399#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#160#156#article#2
18#23#<p><font size="2" face="Verdana">23. Luft AR, Skalej M, Schulz JB, Welte D
, Kolb     R, B&uuml;rk K, Klockgether T, Voight K. Patterns of age&#45;related 
shrinkage     in cerebellum and brainstem observed in vivo using three&#45;dimen
sional MRI     volumetry. <I>Cereb Cortex</I>. 1999;9(7):712&#45;21.    ^cY#aop1
211.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#161#157#article#218# </font><
/p>     ^cY#aop1211.htm##
00507000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704024800089002001200337#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#162#158#article#2
18#24#<p><font size="2" face="Verdana">24. Pierson R, Corson PW, Sears LL, Alica
ta     D, Magnotta V, Oleary D, Andreasen NC. Manual and semiautomated measureme
nt     of cerebellar subregions on MR images. <I>NeuroImage</I>. 2002;17(1):61&#
45;76.    ^cY#aop1211.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#163#159#article#218# </font><
/p>     ^cY#aop1211.htm##
00498000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704023900089002001200328#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#164#160#article#2
18#25#<p><font size="2" face="Verdana">25. Jenkins R, Fox NC, Rossor AM, Harvey 
RJ,     Rossor MN. Intracranial volume and Alzheimer disease: evidence against t
he     cerebral reserve hypothesis. <I>Arch Neurol</I>. 2000;57(2):220&#45;4.   
 ^cY#aop1211.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#165#161#article#218# </font><
/p>     ^cY#aop1211.htm##
00508000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704024900089002001200338#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#166#162#article#2
18#26#<p><font size="2" face="Verdana">26. Hayashi N, Sanada S, Suzuki M, Matsuu
ra     Y. Study of automated segmentation of the cerebellum and brainstem on bra
in     MR images. <I>Nippon Hoshasen Gijutsu Gakkai Zasshi</I>. 2005;61(4):499&#
45;505.    ^cY#aop1211.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#167#163#article#218# </font><
/p>     ^cY#aop1211.htm##
00471000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704021200089002001200301#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#168#164#article#2
18#27#<p><font size="2" face="Verdana">27. De Bellis MD, Kuchibhatla M. Cerebell
ar     volumes in pediatric maltreatmentrelated posttraumatic stress disorder. <
I>Biol     Psychiatry</I>. 2006;60(7):697&#45;703.    ^cY#aop1211.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#169#165#article#218# </font><
/p>     ^cY#aop1211.htm##
00356000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704009700089002001200186#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#170#166#article#2
18#28#<p><font size="2" face="Verdana"> 28. SPSS Inc. SPSS for Windows. Chicago;
 1989&#45;2004.    ^cY#aop1211.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#171#167#article#218# </font><
/p>     ^cY#aop1211.htm##
00593000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704033400089002001200423#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#172#168#article#2
18#29#<p><font size="2" face="Verdana">29. Wang H, Golob E, Bert A, Nie K, Chu Y
, Dick     MB, Mandelkern M, Su MY. Alterations in regional brain volume and ind
ividual     MRI&#45;guided perfusion in normal control, stable mild cognitive im
pairment,     and MCIAD converter. <I>J Geriatr Psychiatry Neurol</I>. 2009;22(1
):35&#45;45.    ^cY#aop1211.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#173#169#article#218# </font><
/p>     ^cY#aop1211.htm##
00480000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704022100089002001200310#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#174#170#article#2
18#30#<p><font size="2" face="Verdana">30. Sjobeck M, Englund E. Alzheimer's    
 disease and the cerebellum: a morphologic study on neuronal and glial changes. 
<I>Dement     Geriatr Cog Disord</I>. 2001;12(3):211&#45;8.    ^cY#aop1211.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#175#171#article#218# </font><
/p>     ^cY#aop1211.htm##
00527000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704026800089002001200357#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#176#172#article#2
18#31#<p><font size="2" face="Verdana">31. Thomann PA, Schlafer C, Seidl U, Sant
os     VD, Essig M, Schroder J. The cerebellum in mild cognitive impairment and 
    Alzheimer's disease &#45;a structural MRI study. <I>J Psychiatr Res</I>.    
 2008;42(14):1198&#45;202.    ^cY#aop1211.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#177#173#article#218# </font><
/p>     ^cY#aop1211.htm##
00494000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704023500089002001200324#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#178#174#article#2
18#32#<p><font size="2" face="Verdana">32. Wang HY, D'Andrea MR, Nagele RG. Cere
bellar     diffuse amyloid plaques are derived from dendritic Abeta42 accumulati
ons     in Purkinje cells. <I>Neurobiol Aging</I>. 2002;23(2):213&#45;23.    ^cY
#aop1211.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#179#175#article#218# </font><
/p>     ^cY#aop1211.htm##
00581000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704032200089002001200411#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#180#176#article#2
18#33#<p><font size="2" face="Verdana">33. Ribaut&#45;Barassin C, Dupont JL, Hae
berle AM,     Bombarde G, Huber G, Moussaoui S, Mariani J, Bailly Y. Alzheimer's
     disease proteins in cerebellar and hippocampal synapses during postnatal   
  development and aging of the rat. <I>Neuroscience</I>. 2003;120(2):405&#45;23.
    ^cY#aop1211.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#181#177#article#218# </font><
/p>     ^cY#aop1211.htm##
00502000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704024300089002001200332#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#182#178#article#2
18#34#<p><font size="2" face="Verdana">34. Baloyannis S. Pathological alteration
s of     the climbing fibres of the cerebellum in vascular dementia: a Golgi and
 electron     microscope study. <I>J Neurol Sci</I>. 2007;257(1&#45;2):56&#45;61
.    ^cY#aop1211.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#183#179#article#218# </font><
/p>     ^cY#aop1211.htm##
00487000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704022800089002001200317#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#184#180#article#2
18#35#<p><font size="2" face="Verdana">35. Konarski JZ, McIntyre RS, Grupp LA, K
ennedy     SH. Is the cerebellum relevant in the circuitry of neuropsychiatric d
isorders? <I>J     Psychiatry Neurosci</I>. 2005;30(3):178&#45;86.    ^cY#aop121
1.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#185#181#article#218#</font></
p>     ^cY#aop1211.htm##
00477000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704021800089002001200307#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#186#182#article#2
18#36#<p><font size="2" face="Verdana">36. Im SH, Park ES, Kim DY, Song DH, Lee 
JD.     The neuroradiological findings of children with developmental language d
isorder. <I>Yonsei     Med J</I>. 2007;48(3):405&#45;11.    ^cY#aop1211.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#187#183#article#218# </font><
/p>     ^cY#aop1211.htm##
00449000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704019000089002001200279#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#188#184#article#2
18#37#<p><font size="2" face="Verdana">37. Desmond JE, Fiez JA. Neuroimaging stu
dies     of the cerebellum: language, learning and memory. <I>Trends Cogn Sci</I
>.     1998;2(9):355&#45;62.    ^cY#aop1211.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#189#185#article#218# </font><
/p>     ^cY#aop1211.htm##
00504000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704024500089002001200334#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#190#186#article#2
18#38#<p><font size="2" face="Verdana">38. Ackermann H, Mathiak K, Riecker A. Th
e contribution     of the cerebellum to speech production and speech perception:
 clinical and     functional imaging data. <I>Cerebellum</I>. 2007;6(3):202&#45;
13.    ^cY#aop1211.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#191#187#article#218# </font><
/p>     ^cY#aop1211.htm##
00430000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704017100089002001200260#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#192#188#article#2
18#39#<p><font size="2" face="Verdana">39. Hassid EI. A case of language dysfunc
tion     associated with cerebellar infarction. <I>J Neurol Rehab</I>. 1995;9:15
7&#45;60.    ^cY#aop1211.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#193#189#article#218# </font><
/p>     ^cY#aop1211.htm##
00544000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704028500089002001200374#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#194#190#article#2
18#40#<p><font size="2" face="Verdana">40. Marien P, Saerens J, Nanhoe R, Moens 
E,     Nagels G. Cerebellar induced aphasia: case report of cerebellar induced p
refrontal     aphasic language phenomena supported by SPECT findings. <I>J Neuro
l Sci</I>.     1996;144(1&#45;2):34&#45;43.    ^cY#aop1211.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#195#191#article#218# </font><
/p>     ^cY#aop1211.htm##
00418000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704015900089002001200248#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#196#192#article#2
18#41#<p><font size="2" face="Verdana">41. Haarmeier T, Thier P. The attentive c
erebellum     &#45; myth or reality? <I>Cerebellum</I>. 2007;6(3):177&#45;83.   
 ^cY#aop1211.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#197#193#article#218# </font><
/p>     ^cY#aop1211.htm##
00452000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704019300089002001200282#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#198#194#article#2
18#42#<p><font size="2" face="Verdana">42. Kelly RM, Strick PL. Cerebellar loops
 with     motor cortex and prefrontal cortex of a nonhuman primate. <I>J Neurosc
i.</I> 2003;23(10):8432&#45;44.    ^cY#aop1211.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#199#195#article#218# </font><
/p>     ^cY#aop1211.htm##
00468000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704020900089002001200298#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#200#196#article#2
18#43#<p><font size="2" face="Verdana">43. Schutter DJ, van Honk J. The cerebell
um     in emotion regulation: a repetitive transcranial magnetic stimulation stu
dy. <I>Cerebellum</I>.     2009;8(1):28&#45;34.    ^cY#aop1211.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#201#197#article#218# </font><
/p>     ^cY#aop1211.htm##
00493000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704023400089002001200323#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#202#198#article#2
18#44#<p><font size="2" face="Verdana">44. Schmahmann JD, Pandya DN.The cerebroc
erebellar     system. In: Schmahmann JD, editor. <I>The cerebellum and cognition
</I>. San     Diego, California, USA: Academic Press; 1997. p.31&#45;60.    ^cY#
aop1211.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#203#199#article#218# </font><
/p>     ^cY#aop1211.htm##
00503000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704024400089002001200333#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#204#200#article#2
18#45#<p><font size="2" face="Verdana">45. Bugalho P, Correa B, Viana&#45;Baptis
ta M. Role     of the cerebellum in cognitive and behavioural control: scientifi
c basis     and investigation models. <I>Acta Med Port</I>. 2006;19(3):257&#45;6
7.    ^cY#aop1211.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#205#201#article#218# </font><
/p>     ^cY#aop1211.htm##
00531000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704027200089002001200361#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#206#202#article#2
18#46#<p><font size="2" face="Verdana">46. Crowdy KA, Hollands MA, Ferguson IT, 
Marple&#45;Horvat     DE. Evidence for interactive locomotor and oculomotor defi
cits in cerebellar     patients during visually guided stepping. <I>Exp Brain Re
s.</I> 2000;135(4):437&#45;54.    ^cY#aop1211.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#207#203#article#218# </font><
/p>     ^cY#aop1211.htm##
00463000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704020400089002001200293#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#208#204#article#2
18#47#<p><font size="2" face="Verdana">47. Moretti R, Bava A, Torre P, Antonello
 RM,     Cazzato G. Reading errors in patients with cerebellar vermis lesions. <
I>J     Neurol</I>. 2002;249(4):461&#45;8.    ^cY#aop1211.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#209#205#article#218# </font><
/p>     ^cY#aop1211.htm##
00555000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704029600089002001200385#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#210#206#article#2
18#48#<p><font size="2" face="Verdana">48. Ramos LR, Simoes EJ, Albert MS. Depen
dence     in activities of daily living and cognitive impairment strongly predic
ted     mortality in older urban residents in Brazil: a 2&#45;year follow&#45;up
. <I>J Am     Geriatr Soc</I>. 2001;49(9):1168&#45;75.    ^cY#aop1211.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#211#207#article#218#</font></
p>     ^cY#aop1211.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#212#208#article#218#<p>&nbsp;
</p>     ^cY#aop1211.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#213#209#article#218#<p>&nbsp;
</p>     ^cY#aop1211.htm##
00406000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704016200086002001200248#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#214#210#article#218#<p><font 
size="2" face="Verdana"><b><a name="end"></a><a href="#title"><img src="/img/rev
istas/rbp/2011nahead/seta.jpg" border="0"></a> Correspondence</b>    ^cY#aop1211
.htm##
00284000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704004000086002001200126#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#215#211#article#218#<br>   Le
onardo Balda&ccedil;ara    ^cY#aop1211.htm##
00317000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704007300086002001200159#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#216#212#article#218#<br>   Un
iversidade Federal do Tocantins &#45; CUP &#45; Medicina    ^cY#aop1211.htm##
00324000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704008000086002001200166#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#217#213#article#218#<br>   Av
. NS 15 ALC NO14, 109 Norte, Bloco BALA &#45; Caixa Postal 114     ^cY#aop1211.h
tm##
00291000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704004700086002001200133#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#218#214#article#218#<br>   77
001&#45;090 Palmas, TO, Brazil    ^cY#aop1211.htm##
00319000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704007500086002001200161#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#219#215#article#218#<br>   Ph
one: (+55 63) 3232&#45;8158 / Fax: (+55 63) 3232&#45;8277     ^cY#aop1211.htm##
00357000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704011300086002001200199#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#220#216#article#218#<br>   Em
ail: <a href="mailto:leonardobaldassara@gmail.com">leonardobaldassara@gmail.com<
/a> </font></p>     ^cY#aop1211.htm##
00313000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704006900086002001200155#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#221#217#article#218#<p><font 
size="2" face="Verdana">Submitted: February 22, 1010    ^cY#aop1211.htm##
00300000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704005600086002001200142#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#p#222#218#article#218#<br>   Ac
cepted: September 24, 2010 </font></p>     ^cY#aop1211.htm##
00649000000000301000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100018000850100026001030100
01500129010001600144012011900160030001900279710000200298065000900300064000500309
031000300314032000200317014000700319865000900326002001200335#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop1211.htm#S#c#223#1#article#48#1#^rND^sCoelho^n
FGM#^rND^sSantos-Galduroz^nRF#^rND^sGobbi^nS#^rND^sStella^nF#Atividade física si
stematizada e desempenho cognitivo em idosos com demência de Alzheimer: uma revi
são sistemática^lpt#Rev Bras Psiquiatr#2#20090000#2009#31#2#163-70#20110000#aop1
211.htm##
01261000000000529000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100015000850100018001000100
01900118010001300137010001300150010001500163010001800178010002000196010001800216
01000170023401000150025101000180026601000150028401000220029901000190032101000160
03400100016003560100016003720100020003880100017004080100019004250110044004440120
16400488030001100652065000900663064000500672031000300677032000200680014000700682
865000900689002001200698035001000710801001100720#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop1211.htm#S#c#224#2#article#48#2#^rND^sLeow^nAD#^rND^sYanov
sky^nI#^rND^sParikshak^nN#^rND^sHua^nX#^rND^sLee^nS#^rND^sToga^nAW#^rND^sJack Jr
^nCR#^rND^sBernstein^nMA#^rND^sBritson^nPJ#^rND^sGunter^nJL#^rND^sWard^nCP#^rND^
sBorowski^nB#^rND^sShaw^nLM#^rND^sTrojanowski^nJQ#^rND^sFleisher^nAS#^rND^sHarve
y^nD#^rND^sKornak^nJ#^rND^sSchuff^nN#^rND^sAlexander^nGE#^rND^sWeiner^nMW#^rND^s
Thompson^nPM#Alzheimer's Disease Neuroimaging Initiative#Alzheimer's disease neu
roimaging initiative: a one-year follow up study using tensor-based morphometry 
correlating degenerative rates, biomarkers and cognition^len#NeuroImage#20090000
#2009#45#3#645-55#20110000#aop1211.htm#1053-8119#NEUROIMAGE##
01145000000000517000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100015000850100018001000100
01800118010001500136010001500151010002000166010001800186010001700204010001500221
01000190023601000190025501000190027401000140029301000160030701000160032301000160
03390100019003550100020003740100017003940100019004110110029004300120089004590300
01100548065000900559064000500568031000300573032000200576014000700578865000900585
002001200594035001000606801001100616#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop1211.htm#S#c#225#3#article#48#3#^rND^sLeos^nAD#^rND^sKlunder^nAD#^rND^
sJack Jr^nCR#^rND^sToga^nAW#^rND^sDale^nAM#^rND^sBernstein^nMA#^rND^sBritson^nPJ
#^rND^sGunter^nJL#^rND^sWard^nCP#^rND^sWhitwell^nJL#^rND^sBorowski^nBJ#^rND^sFle
isher^nAS#^rND^sFox^nNC#^rND^sHarvey^nD#^rND^sKornak^nJ#^rND^sSchuff^nN#^rND^sSt
udholme^nC#^rND^sAlexander^nGE#^rND^sWeiner^nMW#^rND^sThompson^nPM#ADNI Preparat
ory Phase Study#Longitudinal stability of MRI for mapping brain change using ten
sorbased morphometry^len#NeuroImage#20060000#2006#31#2#627-40#20110000#aop1211.h
tm#1053-8119#NEUROIMAGE##
00732000000000361000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100018000850100016001030100
01600119010001900135010001500154010001700169010001600186010001500202012007600217
03000100029306500090030306400050031203100030031703200020032001400070032286500090
0329002001200338035001000350801001000360#2011nahead#V:\SciELO\serial\rbp\2011nah
ead\markup\aop1211.htm#S#c#226#4#article#48#4#^rND^sSilbert^nLC#^rND^sQuinn^nJF#
^rND^sMoore^nMM#^rND^sCorbridge^nE#^rND^sBall^nMJ#^rND^sMurdoch^nG#^rND^sSexton^
nG#^rND^sKaye^nJA#Changes in premorbid brain volume predict Alzheimer's disease 
pathology^len#Neurology#20030000#2003#61#4#487-92#20110000#aop1211.htm#0028-3878
#Neurology##
00525000000000277000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100021000850100019001060120
05500125030001800180710000200198065000900200064000500209031000200214032000200216
014000800218865000900226002001200235#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop1211.htm#S#c#227#5#article#48#5#^rND^sApostolova^nLG#^rND^sThompson^nP
M#Brain mapping as a tool to study neurodegeneration^len#Neurotherapeutics#2#200
70000#2007#4#3#387-400#20110000#aop1211.htm##
01041000000000469000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100017000850100018001020100
01700120010001500137010001900152010001800171010002100189010001700210010002100227
01000200024801000180026801000180028601000180030401000180032201000150034001000180
03550100018003730120093003910300016004840650009005000640005005090310003005140320
00200517014000500519865000900524002001200533035001000545801001600555#2011nahead#
V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#c#228#6#article#48#6#^rND^s
Tapiola^nT#^rND^sPennanen^nC#^rND^sTapiola^nM#^rND^sTervo^nS#^rND^sKivipelto^nM#
^rND^sHänninen^nT#^rND^sPihlajamäki^nM#^rND^sLaakso^nMP#^rND^sHallikainen^nM#^rN
D^sHämäläinen^nA#^rND^sVanhanen^nM#^rND^sHelkala^nEL#^rND^sVanninen^nR#^rND^sNis
sinen^nA#^rND^sRossi^nR#^rND^sFrisoni^nGB#^rND^sSoininen^nH#MRI of hippocampus a
nd entorhinal cortex in mild cognitive impairment: a follow-up study^len#Neurobi
ol Aging#20080000#2008#29#1#31-8#20110000#aop1211.htm#0197-4580#Neurobiol Aging#
#
00712000000000325000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100019000850100016001040100
02100120010001700141010001800158010002000176012012800196030001400324710000200338
06500090034006400050034903100020035403200020035601400070035886500090036500200120
0374#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#c#229#7#art
icle#48#7#^rND^sKivipelto^nM#^rND^sNgandu^nT#^rND^sLaatikainen^nT#^rND^sWinblad^
nB#^rND^sSoininen^nH#^rND^sTuomilehto^nJ#Risk score for the prediction of dement
ia risk in 20 years among middle aged people: a longitudinal, population-based s
tudy^len#Lancet Neurol#2#20060000#2006#5#9#735-41#20110000#aop1211.htm##
00684000000000337000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100016000850100022001010100
02000123010001500143010001600158010001400174010001700188012007900205030001400284
71000020029806500090030006400050030903100020031403200020031601400070031886500090
0325002001200334#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S
#c#230#8#article#48#8#^rND^sSmall^nGW#^rND^sBrookheimer^nSY#^rND^sThompston^nPM#
^rND^sCole^nGM#^rND^sHuang^nSC#^rND^sKepe^nV#^rND^sBarrio^nJR#Currrent and futur
e uses of neuroimaging for cognitively impaired patients^len#Lancet Neurol#2#200
80000#2008#7#2#161-72#20110000#aop1211.htm##
00801000000000397000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100019000850100019001040100
01600123010001800139010001800157010001600175010001800191010001600209010001800225
01000150024301000130025801000150027101200500028603000190033671000020035506500090
0357064000500366031000200371032000200373014000700375865000900382002001200391#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#c#231#9#article#48#
9#^rND^sCarrillo^nMC#^rND^sBlackwell^nA#^rND^sHampel^nH#^rND^sLindborg^nJ#^rND^s
Sperling^nR#^rND^sSchenk^nD#^rND^sSevigny^nJJ#^rND^sFerris^nS#^rND^sBennett^nDA#
^rND^sCraft^nS#^rND^sHsu^nT#^rND^sKlunk^nW#Early risk assessment for Alzheimer's
 disease^len#Alzheimer's Dement#2#20090000#2009#5#2#182-96#20110000#aop1211.htm#
#
00573000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100018001060100
01900124010002000143012004100163030001900204710000200223065000900225064000500234
031000300239032000200242014000600244865000900250002001200259#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop1211.htm#S#c#232#10#article#48#10#^rND^sBaldaç
ara^nL#^rND^sBorgio^nJGF#^rND^sLacerda^nALT#^rND^sJackowski^nAP#Cerebellum and p
sychiatric disorders^len#Rev Bras Psiquiatr#2#20080000#2008#30#3#281-9#20110000#
aop1211.htm##
00580000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100021000870100019001080100
01800127012006800145030002900213710000200242065000900244064000500253031000200258
032000200260014000700262865000900269002001200278#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop1211.htm#S#c#233#11#article#48#11#^rND^sSchmahmann^nJD#^rN
D^sWeilburg^nJB#^rND^sSherman^nJC#The neuropsychiatry of the cerebellum -insight
s from the clinic^len#Cerebellum (London, England)#2#20070000#2007#6#3#254-67#20
110000#aop1211.htm##
00732000000000337000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100019001050100
01800124010001800142010002300160010001500183012009000198030002500288065000900313
06400050032203100030032703200020033001400060033286500090033800200120034703500100
0359801002500369#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S
#c#234#12#article#48#12#^rND^sYamazaki^nT#^rND^sYamaguchi^nH#^rND^sNakazato^nY#^
rND^sIshiguro^nK#^rND^sKawarabayashi^nT#^rND^sHirai^nS#Ultrastructural character
ization of cerebellar diffuse plaques in Alzheimer's disease^len#J Neuropathol E
xp Neurol#19920000#1992#51#3#281-6#20110000#aop1211.htm#0022-3069#J Neuropathol 
Exp Neurol##
00785000000000373000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100021001030100
02400124010001800148010001900166010001800185010001700203010001800220010001700238
01200790025503000100033406500090034406400050035303100040035803200020036201400060
0364865000900370002001200379035001000391801001000401#2011nahead#V:\SciELO\serial
\rbp\2011nahead\markup\aop1211.htm#S#c#235#13#article#48#13#^rND^sWegiel^nJ#^rND
^sWisniewski^nHM#^rND^sDziewiatkowski^nJ#^rND^sBadmajew^nE#^rND^sTarnawski^nM#^r
ND^sReisberg^nB#^rND^sMlodzik^nB#^rND^sDe Leon^nMJ#^rND^sMiller^nDC#Cerebellar a
trophy in Alzheimer's disease-clinicopathological correlations^len#Brain Res#199
90000#1999#818#1#41-50#20110000#aop1211.htm#0006-8993#Brain res##
00512000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100015001030100
01900118012002000137030001700157710000200174065000900176064000500185031000300190
032000200193014000600195865000900201002001200210#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop1211.htm#S#c#236#14#article#48#14#^rND^sMeyer^nJS#^rND^sOb
ara^nK#^rND^sMuramatsu^nK#Diaschisis^lunknown#Neurological Res#2#19930000#1993#1
5#6#362-6#20110000#aop1211.htm##
00569000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100020000870100016001070120
06400123030001800187065000900205064000500214031000300219032000200222014000600224
865000900230002001200239035001000251801001800261#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop1211.htm#S#c#237#15#article#48#15#^rND^sMontaño^nMBMM#^rND
^sRamos^nLR#Validade da versão em português da Clinical Dementia Rating^lpt#Rev 
Saude Publica#20050000#2005#39#6#912-7#20110000#aop1211.htm#0034-8910#Rev Saude 
Publica##
00677000000000337000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100016001060100
01700122010001600139010001900155010001600174012006900190030001200259065000900271
06400050028003100030028503200020028801400060029086500090029600200120030503500100
0317801001200327#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S
#c#238#16#article#48#16#^rND^sPetersen^nRC#^rND^sSmith^nGE#^rND^sWaring^nSC#^rND
^sIvnik^nRJ#^rND^sTangalos^nEG#^rND^sKokmen^nE#Mild cognitive impairment: clinic
al characterization and outcome^len#Arch Neurol#19990000#1999#56#3#303-8#2011000
0#aop1211.htm#0003-9942#Arch Neurol##
00785000000000337000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100018001040100
01800122010001700140010001500157010001800172012018000190030001000370065000900380
06400050038903100030039403200020039701400070039986500090040600200120041503500100
0427801001000437#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S
#c#239#17#article#48#17#^rND^sMcKhann^nG#^rND^sDrachman^nD#^rND^sFolstein^nM#^rN
D^sKatzman^nR#^rND^sPrice^nD#^rND^sStadlan^nEM#Clinical diagnosis of Alzheimer's
 disease: report of the NINCDSADRDA Work Group under the auspices of Department 
of Health and Human Services Task Force on Alzheimer's Disease^len#Neurology#198
40000#1984#34#7#939-44#20110000#aop1211.htm#0028-3878#Neurology##
00650000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100020001050100
01700125012014900142030001800291710000200309065000900311064000500320031000300325
032000300328014000800331865000900339002001200348#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop1211.htm#S#c#240#18#article#48#18#^rND^sDel-Ben^nCM#^rND^s
Rodrigues^nCR#^rND^sZuardi^nAW#Reliability of the Portuguese version of the stru
ctured clinical interview for DSM-III-R (SCID) in a Brazilian sample of psychiat
ric outpatients^len#Braz Med Biol Res#2#19960000#1996#29#12#1675-82#20110000#aop
1211.htm##
00637000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100019001060100
01700125012010400142030001600246065000900262064000500271031000300276032000200279
014000700281865000900288002001200297035001000309801001600319#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop1211.htm#S#c#241#19#article#48#19#^rND^sFolste
in^nMF#^rND^sFolstein^nSE#^rND^sMcHugh^nPR#Mini-mental state: a practical method
 for grading the cognitive state of patients for the clinician^len#J Psychiatr R
es#19750000#1975#12#3#189-98#20110000#aop1211.htm#0022-3956#J Psychiatr Res##
00680000000000325000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100017001040100
01900121010002100140010001800161012007900179030001900258065000900277064000500286
03100030029103200030029401400070029786500090030400200120031303500100032580100190
0335#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#c#242#20#ar
ticle#48#20#^rND^sBrucki^nSM#^rND^sNitrini^nR#^rND^sCaramelli^nP#^rND^sBertolucc
i^nPH#^rND^sOkamoto^nIH#Suggestions for utilization of the mini-mental state exa
mination in Brazil^len#Arq Neuropsiquiatr#20030000#2003#61#3B#771-81#20110000#ao
p1211.htm#0004-282X#Arq Neuropsiquiatr##
00654000000000325000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100019001050100
02000124010001700144010001500161012007400176030001100250065000900261064000500270
03100030027503200020027801400060028086500090028600200120029503500100030780100110
0317#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#c#243#21#ar
ticle#48#21#^rND^sPfeffer^nRI#^rND^sKurosaki^nTT#^rND^sHarrah Jr^nCH#^rND^sChanc
e^nJM#^rND^sFilos^nS#Measurement of functional activities in older adults in the
 community^len#J Gerontol#19820000#1982#37#3#323-9#20110000#aop1211.htm#0022-142
2#J Gerontol##
00453000000000229000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840170025000870180025001120660
01000137062004100147065000900188064000500197865000900202002001200211#2011nahead#
V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#c#244#22#article#48#22#Iowa
 Neuroimaging Center#Imaging Lab.Brains 2^len#Iowa City#University of Iowa Hospi
tals and Clinics#20060000#2006#20110000#aop1211.htm##
00780000000000361000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100015000870100016001020100
01700118010001500135010001400150010001400164010002100178010001600199012012100215
03000130033606500090034906400050035803100020036303200020036501400070036786500090
0374002001200383035001000395801001300405#2011nahead#V:\SciELO\serial\rbp\2011nah
ead\markup\aop1211.htm#S#c#245#23#article#48#23#^rND^sLuft^nAR#^rND^sSkalej^nM#^
rND^sSchulz^nJB#^rND^sWelte^nD#^rND^sKolb^nR#^rND^sBürk^nK#^rND^sKlockgether^nT#
^rND^sVoight^nK#Patterns of age-related shrinkage in cerebellum and brainstem ob
served in vivo using three-dimensional MRI volumetry^len#Cereb Cortex#19990000#1
999#9#7#712-21#20110000#aop1211.htm#1047-3211#Cereb Cortex##
00715000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100017001040100
01600121010001700137010001800154010001600172010002000188012007900208030001100287
06500090029806400050030703100030031203200020031501400060031786500090032300200120
0332035001000344801001100354#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\a
op1211.htm#S#c#246#24#article#48#24#^rND^sPierson^nR#^rND^sCorson^nPW#^rND^sSear
s^nLL#^rND^sAlicata^nD#^rND^sMagnotta^nV#^rND^sOleary^nD#^rND^sAndreasen^nNC#Man
ual and semiautomated measurement of cerebellar subregions on MR images^len#Neur
oImage#20020000#2002#17#1#61-76#20110000#aop1211.htm#1053-8119#NEUROIMAGE##
00671000000000325000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100014001040100
01700118010001700135010001700152012009600169030001200265065000900277064000500286
03100030029103200020029401400060029686500090030200200120031103500100032380100120
0333#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#c#247#25#ar
ticle#48#25#^rND^sJenkins^nR#^rND^sFox^nNC#^rND^sRossor^nAM#^rND^sHarvey^nRJ#^rN
D^sRossor^nMN#Intracranial volume and Alzheimer disease: evidence against the ce
rebral reserve hypothesis^len#Arch Neurol#20000000#2000#57#2#220-4#20110000#aop1
211.htm#0003-9942#Arch Neurol##
00689000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100016001040100
01600120010001800136012008700154030003800241065000900279064000500288031000300293
032000200296014000800298865000900306002001200315035001000327801003800337#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#c#248#26#article#48#26#
^rND^sHayashi^nN#^rND^sSanada^nS#^rND^sSuzuki^nM#^rND^sMatsuura^nY#Study of auto
mated segmentation of the cerebellum and brainstem on brain MR images^len#Nippon
 Hoshasen Gijutsu Gakkai Zasshi#20050000#2005#61#4#499-505#20110000#aop1211.htm#
0369-4305#NIPPON HOSHASEN GIJUTSU GAKKAI ZASSHI##
00594000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100020000870100021001070120
08600128030001600214065000900230064000500239031000300244032000200247014000800249
865000900257002001200266035001000278801001600288#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop1211.htm#S#c#249#27#article#48#27#^rND^sDe Bellis^nMD#^rND
^sKuchibhatla^nM#Cerebellar volumes in pediatric maltreatmentrelated posttraumat
ic stress disorder^len#Biol Psychiatry#20060000#2006#60#7#697-703#20110000#aop12
11.htm#0006-3223#Biol Psychiatry##
00383000000000217000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840170009000870180021000960660
00800117065000900125064001000134865000900144002001200153#2011nahead#V:\SciELO\se
rial\rbp\2011nahead\markup\aop1211.htm#S#c#250#28#article#48#28#SPSS Inc#SPSS fo
r Windows^len#Chicago#20040000#1989-2004#20110000#aop1211.htm##
00828000000000361000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100014000870100015001010100
01400116010001300130010001300143010001500156010002000171010001300191012015000204
03000280035406500090038206400050039103100030039603200020039901400060040186500090
0407002001200416035001000428801002800438#2011nahead#V:\SciELO\serial\rbp\2011nah
ead\markup\aop1211.htm#S#c#251#29#article#48#29#^rND^sWang^nH#^rND^sGolob^nE#^rN
D^sBert^nA#^rND^sNie^nK#^rND^sChu^nY#^rND^sDick^nMB#^rND^sMandelkern^nM#^rND^sSu
^nMY#Alterations in regional brain volume and individual MRI-guided perfusion in
 normal control, stable mild cognitive impairment, and MCIAD converter^len#J Ger
iatr Psychiatry Neurol#20090000#2009#22#1#35-45#20110000#aop1211.htm#0891-9887#J
 Geriatr Psychiatry Neurol##
00567000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100017001040120
09400121030002600215710000200241065000900243064000500252031000300257032000200260
014000600262865000900268002001200277#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop1211.htm#S#c#252#30#article#48#30#^rND^sSjobeck^nM#^rND^sEnglund^nE#Al
zheimer's disease and the cerebellum: a morphologic study on neuronal and glial 
changes^len#Dement Geriatr Cog Disord#2#20010000#2001#12#3#211-8#20110000#aop121
1.htm##
00714000000000337000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100018001050100
01500123010001700138010001500155010001800170012009600188030001600284065000900300
06400050030903100030031403200030031701400090032086500090032900200120033803500100
0350801001600360#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S
#c#253#31#article#48#31#^rND^sThomann^nPA#^rND^sSchlafer^nC#^rND^sSeidl^nU#^rND^
sSantos^nVD#^rND^sEssig^nM#^rND^sSchroder^nJ#The cerebellum in mild cognitive im
pairment and Alzheimer's disease -a structural MRI study^len#J Psychiatr Res#200
80000#2008#42#14#1198-202#20110000#aop1211.htm#0022-3956#J Psychiatr Res##
00634000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100015000870100018001020100
01700120012010600137030001600243065000900259064000500268031000300273032000200276
014000700278865000900285002001200294035001000306801001600316#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop1211.htm#S#c#254#32#article#48#32#^rND^sWang^n
HY#^rND^sD'Andrea MR#^rND^sNagele^nRG#Cerebellar diffuse amyloid plaques are der
ived from dendritic Abeta42 accumulations in Purkinje cells^len#Neurobiol Aging#
20020000#2002#23#2#213-23#20110000#aop1211.htm#0197-4580#Neurobiol Aging##
00801000000000361000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100025000870100017001120100
01900129010001800148010001500166010001900181010001700200010001600217012012200233
03000130035506500090036806400050037703100040038203200020038601400070038886500090
0395002001200404035001000416801001300426#2011nahead#V:\SciELO\serial\rbp\2011nah
ead\markup\aop1211.htm#S#c#255#33#article#48#33#^rND^sRibaut-Barassin^nC#^rND^sD
upont^nJL#^rND^sHaeberle^nAM#^rND^sBombarde^nG#^rND^sHuber^nG#^rND^sMoussaoui^nS
#^rND^sMariani^nJ#^rND^sBailly^nY#Alzheimer's disease proteins in cerebellar and
 hippocampal synapses during postnatal development and aging of the rat^len#Neur
oscience#20030000#2003#120#2#405-23#20110000#aop1211.htm#0306-4522#Neuroscience#
#
00600000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100020000870120130001070300
01300237065000900250064000500259031000400264032000400268014000600272865000900278
002001200287035001000299801001300309#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop1211.htm#S#c#256#34#article#48#34#^rND^sBaloyannis^nS#Pathological alt
erations of the climbing fibres of the cerebellum in vascular dementia: a Golgi 
and electron microscope study^len#J Neurol Sci#20070000#2007#257#1-2#56-61#20110
000#aop1211.htm#0022-510X#J Neurol Sci##
00652000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100019001060100
01600125010001800141012007800159030002200237065000900259064000500268031000300273
032000200276014000700278865000900285002001200294035001000306801002200316#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#c#257#35#article#48#35#
^rND^sKonarski^nJZ#^rND^sMcIntyre^nRS#^rND^sGrupp^nLA#^rND^sKennedy^nSH#Is the c
erebellum relevant in the circuitry of neuropsychiatric disorders^len#J Psychiat
ry Neurosci#20050000#2005#30#3#178-86#20110000#aop1211.htm#1180-4882#J Psychiatr
y Neurosci##
00651000000000325000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100013000870100015001000100
01400115010001500129010001400144012008400158030001300242065000900255064000500264
03100030026903200020027201400070027486500090028100200120029003500100030280100130
0312#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#c#258#36#ar
ticle#48#36#^rND^sIm^nSH#^rND^sPark^nES#^rND^sKim^nDY#^rND^sSong^nDH#^rND^sLee^n
JD#The neuroradiological findings of children with developmental language disord
er^len#Yonsei Med J#20070000#2007#48#3#405-11#20110000#aop1211.htm#0513-5796#Yon
sei Med J##
00536000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100015001050120
07400120030001600194710000200210065000900212064000500221031000200226032000200228
014000700230865000900237002001200246#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop1211.htm#S#c#259#37#article#48#37#^rND^sDesmond^nJE#^rND^sFiez^nJA#Neu
roimaging studies of the cerebellum: language, learning and memory^len#Trends Co
gn Sci#2#19980000#1998#2#9#355-62#20110000#aop1211.htm##
00609000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100017001060100
01700123012012000140030001100260710000200271065000900273064000500282031000200287
032000200289014000700291865000900298002001200307#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop1211.htm#S#c#260#38#article#48#38#^rND^sAckermann^nH#^rND^
sMathiak^nK#^rND^sRiecker^nA#The contribution of the cerebellum to speech produc
tion and speech perception: clinical and functional imaging data^len#Cerebellum#
2#20070000#2007#6#3#202-13#20110000#aop1211.htm##
00492000000000253000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870120073001040300
01500177710000200192065000900194064000500203031000200208014000700210865000900217
002001200226#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#c#2
61#39#article#48#39#^rND^sHassid^nEI#A case of language dysfunction associated w
ith cerebellar infarction^len#J Neurol Rehab#2#19950000#1995#9#157-60#20110000#a
op1211.htm##
00710000000000325000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100017001030100
01600120010001500136010001600151012013200167030001300299065000900312064000500321
03100040032603200040033001400060033486500090034000200120034903500100036180100130
0371#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#c#262#40#ar
ticle#48#40#^rND^sMarien^nP#^rND^sSaerens^nJ#^rND^sNanhoe^nR#^rND^sMoens^nE#^rND
^sNagels^nG#Cerebellar induced aphasia: case report of cerebellar induced prefro
ntal aphasic language phenomena supported by SPECT findings^len#J Neurol Sci#199
60000#1996#144#1-2#34-43#20110000#aop1211.htm#0022-510X#J Neurol Sci##
00505000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100015001060120
04700121030001100168710000200179065000900181064000500190031000200195032000200197
014000700199865000900206002001200215#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop1211.htm#S#c#263#41#article#48#41#^rND^sHaarmeier^nT#^rND^sThier^nP#Th
e attentive cerebellum - myth or reality^len#Cerebellum#2#20070000#2007#6#3#177-
83#20110000#aop1211.htm##
00574000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100017001030120
08300120030001100203065000900214064000500223031000300228032000300231014000800234
865000900242002001200251035001000263801001100273#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop1211.htm#S#c#264#42#article#48#42#^rND^sKelly^nRM#^rND^sSt
rick^nPL#Cerebellar loops with motor cortex and prefrontal cortex of a nonhuman 
primate^len#J Neurosci#20030000#2003#23#10#8432-44#20110000#aop1211.htm#0270-647
4#J Neurosci##
00555000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100018001060120
09500124030001100219710000200230065000900232064000500241031000200246032000200248
014000600250865000900256002001200265#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop1211.htm#S#c#265#43#article#48#43#^rND^sSchutter^nDJ#^rND^svan Honk^nJ
#The cerebellum in emotion regulation: a repetitive transcranial magnetic stimul
ation study^len#Cerebellum#2#20090000#2009#8#1#28-34#20110000#aop1211.htm##
00573000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100021000870100017001080120
03300125016002100158018005600179066000400235062001500239014000600254065000900260
064000500269865000900274002001200283#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop1211.htm#S#c#266#44#article#48#44#^rND^sSchmahmann^nJD#^rND^sPandya^nD
N#The cerebrocerebellar system^len#^rED^sSchmahmann^nJD#The cerebellum and cogni
tion.San Diego, California,^len#USA#Academic Press#31-60#19970000#1997#20110000#
aop1211.htm##
00638000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100016001040100
02400120012010700144030001400251065000900265064000500274031000300279032000200282
014000700284865000900291002001200300035001000312801001400322#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop1211.htm#S#c#267#45#article#48#45#^rND^sBugalh
o^nP#^rND^sCorrea^nB#^rND^sViana-Baptista^nM#Role of the cerebellum in cognitive
 and behavioural control: scientific basis and investigation models^len#Acta Med
 Port#20060000#2006#19#3#257-67#20110000#aop1211.htm#0870-399X#Acta Med Port##
00684000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100019001040100
01900123010002400142012011800166030001400284065000900298064000500307031000400312
032000200316014000700318865000900325002001200334035001000346801001400356#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#c#268#46#article#48#46#
^rND^sCrowdy^nKA#^rND^sHollands^nMA#^rND^sFerguson^nIT#^rND^sMarple-Horvat^nDE#E
vidence for interactive locomotor and oculomotor deficits in cerebellar patients
 during visually guided stepping^len#Exp Brain Res#20000000#2000#135#4#437-54#20
110000#aop1211.htm#0014-4819#Exp Brain Res##
00633000000000325000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100014001040100
01500118010002000133010001700153012006200170030000900232065000900241064000500250
03100040025503200020025901400060026186500090026700200120027603500100028880100090
0298#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1211.htm#S#c#269#47#ar
ticle#48#47#^rND^sMoretti^nR#^rND^sBava^nA#^rND^sTorre^nP#^rND^sAntonello^nRM#^r
ND^sCazzato^nG#Reading errors in patients with cerebellar vermis lesions^len#J N
eurol#20020000#2002#249#4#461-8#20110000#aop1211.htm#0340-5354#J Neurol##
00685000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100017001030100
01700120012015400137030001700291065000900308064000500317031000300322032000200325
014000800327865000900335002001200344035001000356801001700366#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop1211.htm#S#c#270#48#article#48#48#^rND^sRamos^
nLR#^rND^sSimoes^nEJ#^rND^sAlbert^nMS#Dependence in activities of daily living a
nd cognitive impairment strongly predicted mortality in older urban residents in
 Brazil: a 2-year follow-up^len#J Am Geriatr Soc#20010000#2001#49#9#1168-75#2011
0000#aop1211.htm#0002-8614#J Am Geriatr Soc##
00282000000000169000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780910009000800920007000890020012000967030
00400108#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#o#1#1#a
rticle#1#20110408#161730#aop1311.htm#228##
04576000000000661000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780710003000800400003000830010006000860420
00200092120000400094038000400098121000300102049000300105158000300108030002200111
03200060013306500090013901400070014803500100015522300090016501201240017401201300
02980100030004280100037004580100034004950100030005290100031005590700079005900700
04500669070003600714070003900750083122300789085001002012085003802022085003102060
08500190209108500270211008315760213708500100371308500460372308500300376908500190
37990850027038181170008038450720003038531120009038561110012038651140009038771130
01603886002001203902#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.h
tm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#TAB#10#nd#nd#Rev. Bras. Psiquiatr.#ahead#
20110000#^f0^l0#1516-4446#20110415#The relationship between perceived social sup
port and severity of body dysmorphic disorder symptoms: the role of gender^len#O
 efeito do gênero sobre a relação entre suporte social apreendido e gravidade do
s sintomas do transtorno dismórfico corporal^lpt#^rND^1A01 A02^nLuana^sMarques#^
rND^1A03 A04^nHilary M.^sWeingarden#^rND^1A03 A04^nNicole J.^sLeBlanc#^rND^1A01 
A02^nJedidiah^sSiev#^rND^1A01 A03^nSabine^sWilhelm#Massachusetts General Hospita
l^iA01^1Department of Psychiatry^cBoston^sMA^pUSA#Harvard Medical School^iA02^cB
oston^sMA^pUSA#Massachusetts General Hospital^iA03#Tufts University^iA04^cBoston
^sMA^pUSA#^len^aOBJECTIVE: Whether social support is associated with severity of
 body dysmorphic symptoms is unknown. To address this gap in the literature, the
 present study aims to examine the association between three domains of perceive
d social support (i.e., family, friends, and significant others) and severity of
 body dysmorphic disorder symptoms. METHOD: Participants (N = 400) with symptoms
 consistent with diagnosis of body dysmorphic disorder completed measures of sym
ptomatology and social support via the internet. RESULTS: More perceived social 
support from friends and significant others was associated with less severe body
 dysmorphic disorder symptoms for males, and more perceived social support from 
family and friends was associated with less severe body dysmorphic disorder symp
toms among females. Additionally, gender moderated the association between perce
ived social support from significant others and symptom severity, such that perc
eived social support from a significant other was significantly negatively assoc
iated with body dysmorphic symptom severity in males, but not females. CONCLUSIO
N: The present study implicates social support as an important area of future bo
dy dysmorphic disorder research.#^ddecs^i1#^tm^len^kBody dysmorphic disorders^i1
#^tm^len^kSigns and symptoms^i1#^tm^len^kGender^i1#^tm^len^kSocial support^i1#^l
pt^aOBJETIVO: Não há informação sobre o impacto do suporte social apreendido sob
re a gravidade dos sintomas do transtorno dismórfico corporal. A fim de investig
ar essa relação, este estudo visa avaliar a associação entre três domínios do su
porte social apreendido (familiares, amigos, e relacionamentos amorosos signific
ativos) e a gravidade dos sintomas do transtorno dismórfico corporal. MÉTODO: Os
 participantes (N = 400) com sintomas compatíveis com o diagnóstico de transtorn
o dismórfico corporal preencheram questionários sobre seus sintomas e suporte so
cial via internet. RESULTADOS: Foi encontrada correlação inversa estatisticament
e significativa entre a apreensão do suporte social por parte de amigos e relaci
onamentos amorosos e a gravidade dos sintomas de transtorno dismórfico corporal 
em homens. Do mesmo modo, foi encontrada correlação inversa e estatisticamente s
ignificativa entre a apreensão do suporte social por parte de familiares e amigo
s e gravidade dos sintomas de transtorno dismórfico corporal em mulheres. Além d
isso, gênero foi um moderador da associação entre apreensão do suporte social po
r parte de relacionamentos amorosos e gravidade dos sintomas de transtorno dismó
rfico corporal. A apreensão de suporte social por parte de relacionamentos amoro
sos mostrou-se inversamente associada à gravidade dos sintomas de transtorno dis
mórfico corporal em homens, mas não em mulheres. CONCLUSÃO: Este estudo demonstr
a a importância da avaliação do suporte social apreendido em estudos futuros env
olvendo pacientes com transtorno dismórfico corporal.#^ddecs^i2#^tm^lpt^kTransto
rnos dismórficos corporais^i2#^tm^lpt^kSinais e sintomas^i2#^tm^lpt^kGênero^i2#^
tm^lpt^kSuporte social^i2#vancouv#44#20100505#May 5, 2010#20100816#August 16, 20
10#aop1311.htm##
04653000000000661000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780710003000800400003000830010006000860420
00200092120000400094038000400098121000300102049000300105158000300108030002200111
03200060013306500090013901400070014803500100015522300090016501201380017401201370
03120100030004490100037004790100034005160100030005500100031005800700079006110700
04500690070003600735070003900771083125100810085001002061085003802071085003102109
08500190214008500270215908316040218608500100379008500460380008500300384608500190
38760850027038951170008039220720003039301120009039331110012039421140009039541130
01603963002001203979#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.h
tm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#TAB#10#nd#nd#Rev. Bras. Psiquiatr.#ahead#
20110000#^f0^l0#1516-4446#20110415#<b>The relationship between perceived social 
support and severity of body dysmorphic disorder symptoms</b>: <b>the role of ge
nder</b>^len#<b>O efeito do gênero sobre a relação entre suporte social apreendi
do e gravidade dos sintomas do transtorno dismórfico corporal</b>^lpt#^rND^1A01 
A02^nLuana^sMarques#^rND^1A03 A04^nHilary M.^sWeingarden#^rND^1A03 A04^nNicole J
.^sLeBlanc#^rND^1A01 A02^nJedidiah^sSiev#^rND^1A01 A03^nSabine^sWilhelm#Massachu
setts General Hospital^iA01^1Department of Psychiatry^cBoston^sMA^pUSA#Harvard M
edical School^iA02^cBoston^sMA^pUSA#Massachusetts General Hospital^iA03#Tufts Un
iversity^iA04^cBoston^sMA^pUSA#^len^a<b>OBJECTIVE:</b> Whether social support is
 associated with severity of body dysmorphic symptoms is unknown. To address thi
s gap in the literature, the present study aims to examine the association betwe
en three domains of perceived social support (i.e., family, friends, and signifi
cant others) and severity of body dysmorphic disorder symptoms. <b>METHOD:</b> P
articipants (N = 400) with symptoms consistent with diagnosis of body dysmorphic
 disorder completed measures of symptomatology and social support via the intern
et. <b>RESULTS:</b> More perceived social support from friends and significant o
thers was associated with less severe body dysmorphic disorder symptoms for male
s, and more perceived social support from family and friends was associated with
 less severe body dysmorphic disorder symptoms among females. Additionally, gend
er moderated the association between perceived social support from significant o
thers and symptom severity, such that perceived social support from a significan
t other was significantly negatively associated with body dysmorphic symptom sev
erity in males, but not females. <b>CONCLUSION:</b> The present study implicates
 social support as an important area of future body dysmorphic disorder research
.#^ddecs^i1#^tm^len^kBody dysmorphic disorders^i1#^tm^len^kSigns and symptoms^i1
#^tm^len^kGender^i1#^tm^len^kSocial support^i1#^lpt^a<b>OBJETIVO: </b>Não há inf
ormação sobre o impacto do suporte social apreendido sobre a gravidade dos sinto
mas do transtorno dismórfico corporal. A fim de investigar essa relação, este es
tudo visa avaliar a associação entre três domínios do suporte social apreendido 
(familiares, amigos, e relacionamentos amorosos significativos) e a gravidade do
s sintomas do transtorno dismórfico corporal. <b>MÉTODO:</b> Os participantes (N
 = 400) com sintomas compatíveis com o diagnóstico de transtorno dismórfico corp
oral preencheram questionários sobre seus sintomas e suporte social via internet
. <b>RESULTADOS: </b>Foi encontrada correlação inversa estatisticamente signific
ativa entre a apreensão do suporte social por parte de amigos e relacionamentos 
amorosos e a gravidade dos sintomas de transtorno dismórfico corporal em homens.
 Do mesmo modo, foi encontrada correlação inversa e estatisticamente significati
va entre a apreensão do suporte social por parte de familiares e amigos e gravid
ade dos sintomas de transtorno dismórfico corporal em mulheres. Além disso, gêne
ro foi um moderador da associação entre apreensão do suporte social por parte de
 relacionamentos amorosos e gravidade dos sintomas de transtorno dismórfico corp
oral. A apreensão de suporte social por parte de relacionamentos amorosos mostro
u-se inversamente associada à gravidade dos sintomas de transtorno dismórfico co
rporal em homens, mas não em mulheres. <b>CONCLUSÃO: </b>Este estudo demonstra a
 importância da avaliação do suporte social apreendido em estudos futuros envolv
endo pacientes com transtorno dismórfico corporal.#^ddecs^i2#^tm^lpt^kTranstorno
s dismórficos corporais^i2#^tm^lpt^kSinais e sintomas^i2#^tm^lpt^kGênero^i2#^tm^
lpt^kSuporte social^i2#vancouv#44#20100505#May 5, 2010#20100816#August 16, 2010#
aop1311.htm##
04718000000000685000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780640007000800710003000870400003000900010
00600093042000200099120000400101038000400105121000300109049000300112158000300115
03000210011803200060013906500090014501400070015403500100016122300090017101201240
01800120130003040100030004340100036004640100033005000100030005330100031005630700
08100594070004700675070005500722070004100777083122300818085001002041085003802051
08500310208908500190212008500270213908315760216608500100374208500460375208500300
37980850019038280850027038471170008038740720003038821120009038851110012038941140
00903906113001603915002001203931008008903943#2011nahead#V:\SciELO\serial\rbp\201
1nahead\markup\aop1311.htm#S#l#4#1#article#1#^a2011#oa#en#br1.1#1#4.0#tab#10#nd#
nd#Rev. bras. psiquiatr#ahead#20110000#^f0^l0#1516-4446#20110415#The relationshi
p between perceived social support and severity of body dysmorphic disorder symp
toms: the role of gender^len#O efeito do gênero sobre a relação entre suporte so
cial apreendido e gravidade dos sintomas do transtorno dismórfico corporal^lpt#^
rND^1A01 A02^nLuana^sMarques#^rND^1A03 A04^nHilary M^sWeingarden#^rND^1A03 A04^n
Nicole J^sLeBlanc#^rND^1A01 A02^nJedidiah^sSiev#^rND^1A01 A03^nSabine^sWilhelm#^
iA01^1Massachusetts General Hospital^2Department of Psychiatry^cBoston^sMA^pUSA#
^iA02^1Harvard Medical School^cBoston^sMA^pUSA#^iA03^1Massachusetts General Hosp
ital^cBoston^sMA^pUSA#^iA04^1Tufts University^cBoston^sMA^pUSA#^len^aOBJECTIVE: 
Whether social support is associated with severity of body dysmorphic symptoms i
s unknown. To address this gap in the literature, the present study aims to exam
ine the association between three domains of perceived social support (i.e., fam
ily, friends, and significant others) and severity of body dysmorphic disorder s
ymptoms. METHOD: Participants (N = 400) with symptoms consistent with diagnosis 
of body dysmorphic disorder completed measures of symptomatology and social supp
ort via the internet. RESULTS: More perceived social support from friends and si
gnificant others was associated with less severe body dysmorphic disorder sympto
ms for males, and more perceived social support from family and friends was asso
ciated with less severe body dysmorphic disorder symptoms among females. Additio
nally, gender moderated the association between perceived social support from si
gnificant others and symptom severity, such that perceived social support from a
 significant other was significantly negatively associated with body dysmorphic 
symptom severity in males, but not females. CONCLUSION: The present study implic
ates social support as an important area of future body dysmorphic disorder rese
arch.#^ddecs^i1#^tm^len^kBody dysmorphic disorders^i1#^tm^len^kSigns and symptom
s^i1#^tm^len^kGender^i1#^tm^len^kSocial support^i1#^lpt^aOBJETIVO: Não há inform
ação sobre o impacto do suporte social apreendido sobre a gravidade dos sintomas
 do transtorno dismórfico corporal. A fim de investigar essa relação, este estud
o visa avaliar a associação entre três domínios do suporte social apreendido (fa
miliares, amigos, e relacionamentos amorosos significativos) e a gravidade dos s
intomas do transtorno dismórfico corporal. MÉTODO: Os participantes (N = 400) co
m sintomas compatíveis com o diagnóstico de transtorno dismórfico corporal preen
cheram questionários sobre seus sintomas e suporte social via internet. RESULTAD
OS: Foi encontrada correlação inversa estatisticamente significativa entre a apr
eensão do suporte social por parte de amigos e relacionamentos amorosos e a grav
idade dos sintomas de transtorno dismórfico corporal em homens. Do mesmo modo, f
oi encontrada correlação inversa e estatisticamente significativa entre a apreen
são do suporte social por parte de familiares e amigos e gravidade dos sintomas 
de transtorno dismórfico corporal em mulheres. Além disso, gênero foi um moderad
or da associação entre apreensão do suporte social por parte de relacionamentos 
amorosos e gravidade dos sintomas de transtorno dismórfico corporal. A apreensão
 de suporte social por parte de relacionamentos amorosos mostrou-se inversamente
 associada à gravidade dos sintomas de transtorno dismórfico corporal em homens,
 mas não em mulheres. CONCLUSÃO: Este estudo demonstra a importância da avaliaçã
o do suporte social apreendido em estudos futuros envolvendo pacientes com trans
torno dismórfico corporal.#^ddecs^i2#^tm^lpt^kTranstornos dismórficos corporais^
i2#^tm^lpt^kSinais e sintomas^i2#^tm^lpt^kGênero^i2#^tm^lpt^kSuporte social^i2#v
ancouv#44#20100505#May 5, 2010#20100816#August 16, 2010#aop1311.htm#Internet^iht
tp://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462011005000010##
00330000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704009000082002001200172#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#5#1#article#180#<p align="rig
ht"><font size="2" face="Verdana"><b>ORIGINAL ARTICLE</b></font></p>     ^cY#aop
1311.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#6#2#article#180#<p>&nbsp;</p>
     ^cY#aop1311.htm##
00452000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704021200082002001200294#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#7#3#article#180#<p><font size
="4" face="verdana"><b><a name="title"></a>The relationship between       percei
ved social support and severity of body dysmorphic disorder symptoms:       the 
role of gender </b></font></p>     ^cY#aop1311.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#8#4#article#180#<p>&nbsp;</p>
     ^cY#aop1311.htm##
00465000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704022500082002001200307#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#9#5#article#180#<p><font size
="3" face="Verdana"><b>O efeito do g&ecirc;nero sobre a rela&ccedil;&atilde;o   
    entre suporte social apreendido e gravidade dos sintomas do transtorno      
 dism&oacute;rfico corporal </b></font></p>     ^cY#aop1311.htm##
00263000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704002200083002001200105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#10#6#article#180#<p>&nbsp;</p
>     ^cY#aop1311.htm##
00263000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704002200083002001200105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#11#7#article#180#<p>&nbsp;</p
>     ^cY#aop1311.htm##
00477000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704023600083002001200319#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#12#8#article#180#<p><font siz
e="2" face="Verdana"><b>Luana Marques<Sup>I, II</Sup>; Hilary M. Weingarden<Sup>
III, IV</Sup>; Nicole       J. LeBlanc<Sup>III, IV</Sup>; Jedidiah Siev<Sup>I, I
I</Sup>; Sabine Wilhelm<Sup>I, III</Sup></b></font></p>     ^cY#aop1311.htm##
00372000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704013100083002001200214#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#13#9#article#180#<p><font siz
e="2" face="Verdana"><Sup>I</Sup>Department of Psychiatry, Massachusetts     Gen
eral Hospital, Boston, MA, USA     ^cY#aop1311.htm##
00310000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704006800084002001200152#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#14#10#article#180#<br>   <Sup
>II</Sup>Harvard Medical School, Boston, MA, USA     ^cY#aop1311.htm##
00376000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704013400084002001200218#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#15#11#article#180#<br>   <Sup
>III</Sup>Obsessive&#45;Compulsive and Related Disorders Clinic, Massachusetts  
 General Hospital, Boston, MA, USA     ^cY#aop1311.htm##
00316000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007400084002001200158#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#16#12#article#180#<br>   <Sup
>IV</Sup>Tufts University, Boston, MA, USA </font></p>     ^cY#aop1311.htm##
00328000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008600084002001200170#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#17#13#article#180#<p><font si
ze="2" face="Verdana"><a href="#end">Correspondence</a></font></p>     ^cY#aop13
11.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#18#14#article#180#<p>&nbsp;</
p>     ^cY#aop1311.htm##
00286000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704004400084002001200128#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#19#15#article#180#<p>&nbsp;</
p> <hr size="1" noshade>     ^cY#aop1311.htm##
00311000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704006900084002001200153#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#20#16#article#180#<p><font si
ze="2" face="Verdana"><b>ABSTRACT</b></font> </p>     ^cY#aop1311.htm##
00646000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704040400084002001200488#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#21#17#article#180#<p><font si
ze="2" face="Verdana"><B>OBJECTIVE:</B> Whether social support is     associated
 with severity of body dysmorphic symptoms is unknown. To address     this gap i
n the literature, the present study aims to examine the association     between 
three domains of perceived social support (i.e., family, friends,     and signif
icant others) and severity of body dysmorphic disorder symptoms.     ^cY#aop1311
.htm##
00441000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704019900084002001200283#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#22#18#article#180#<br>   <B>M
ETHOD:</B> Participants (N = 400) with symptoms consistent with diagnosis   of b
ody dysmorphic disorder completed measures of symptomatology and social   suppor
t via the internet.     ^cY#aop1311.htm##
00860000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704061800084002001200702#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#23#19#article#180#<br>   <B>R
ESULTS:</B> More perceived social support from friends and significant   others 
was associated with less severe body dysmorphic disorder symptoms for   males, a
nd more perceived social support from family and friends was associated   with l
ess severe body dysmorphic disorder symptoms among females. Additionally,   gend
er moderated the association between perceived social support from significant  
 others and symptom severity, such that perceived social support from a signific
ant   other was significantly negatively associated with body dysmorphic symptom
   severity in males, but not females.     ^cY#aop1311.htm##
00400000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704015800084002001200242#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#24#20#article#180#<br>   <B>C
ONCLUSION:</B> The present study implicates social support as an important   are
a of future body dysmorphic disorder research. </font></p>     ^cY#aop1311.htm##
00411000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704016900084002001200253#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#25#21#article#180#<p><font si
ze="2" face="Verdana"><B>Descriptors</B>: Body dysmorphic disorders;     Signs a
nd symptoms; Gender; Social support </font></p> <hr size="1" noshade>     ^cY#ao
p1311.htm##
00308000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704006600084002001200150#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#26#22#article#180#<p><font si
ze="2" face="VERDANA"><b>RESUMO</b></font></p>     ^cY#aop1311.htm##
00783000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704054100084002001200625#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#27#23#article#180#<p><font si
ze="2" face="Verdana"><B>OBJETIVO: </B>N&atilde;o h&aacute; informa&ccedil;&atil
de;o     sobre o impacto do suporte social apreendido sobre a gravidade dos sint
omas     do transtorno dism&oacute;rfico corporal. A fim de investigar essa rela
&ccedil;&atilde;o,     este estudo visa avaliar a associa&ccedil;&atilde;o entre
 tr&ecirc;s dom&iacute;nios     do suporte social apreendido (familiares, amigos
, e relacionamentos amorosos     significativos) e a gravidade dos sintomas do t
ranstorno dism&oacute;rfico     corporal.     ^cY#aop1311.htm##
00492000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704025000084002001200334#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#28#24#article#180#<br>   <b>M
&Eacute;TODO:</b> Os participantes (N = 400) com sintomas compat&iacute;veis   c
om o diagn&oacute;stico de transtorno dism&oacute;rfico corporal preencheram   q
uestion&aacute;rios sobre seus sintomas e suporte social via internet.     ^cY#a
op1311.htm##
01247000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704100500084002001201089#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#29#25#article#180#<br>   <B>R
ESULTADOS: </B>Foi encontrada correla&ccedil;&atilde;o inversa estatisticamente 
  significativa entre a apreens&atilde;o do suporte social por parte de amigos  
 e relacionamentos amorosos e a gravidade dos sintomas de transtorno dism&oacute
;rfico   corporal em homens. Do mesmo modo, foi encontrada correla&ccedil;&atild
e;o   inversa e estatisticamente significativa entre a apreens&atilde;o do supor
te   social por parte de familiares e amigos e gravidade dos sintomas de transto
rno   dism&oacute;rfico corporal em mulheres. Al&eacute;m disso, g&ecirc;nero fo
i   um moderador da associa&ccedil;&atilde;o entre apreens&atilde;o do suporte  
 social por parte de relacionamentos amorosos e gravidade dos sintomas de transt
orno   dism&oacute;rfico corporal. A apreens&atilde;o de suporte social por part
e   de relacionamentos amorosos mostrou&#45;se inversamente associada &agrave; g
ravidade   dos sintomas de transtorno dism&oacute;rfico corporal em homens, mas 
n&atilde;o   em mulheres.     ^cY#aop1311.htm##
00479000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704023700084002001200321#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#30#26#article#180#<br>   <B>C
ONCLUS&Atilde;O: </B>Este estudo demonstra a import&acirc;ncia da avalia&ccedil;
&atilde;o   do suporte social apreendido em estudos futuros envolvendo pacientes
 com transtorno   dism&oacute;rfico corporal. </font></p>     ^cY#aop1311.htm##
00431000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704018900084002001200273#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#31#27#article#180#<p><font si
ze="2" face="Verdana"><B>Descritores: </B>Transtornos dism&oacute;rficos     cor
porais; Sinais e sintomas; G&ecirc;nero; Suporte social </font></p> <hr size="1"
 noshade>     ^cY#aop1311.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#32#28#article#180#<p>&nbsp;</
p>     ^cY#aop1311.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#33#29#article#180#<p>&nbsp;</
p>     ^cY#aop1311.htm##
00315000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007300084002001200157#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#34#30#article#180#<p><font si
ze="3" face="Verdana"><b>Introduction</b> </font></p>     ^cY#aop1311.htm##
01438000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704119600084002001201280#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#35#31#article#180#<p><font si
ze="2" face="Verdana">Body dysmorphic disorder (BDD) is characterized     by an 
excessive and impairing concern with an imagined physical defect. Either     the
 perceived appearance flaw is nonexistent, or the concern is distinctly     exce
ssive.<Sup>1 </Sup>In response to anxiety associated with the appearance     pre
occupation, individuals with BDD typically engage in time&#45;consuming compulsi
ve     behaviors performed to disguise the perceived defect, such as skin pickin
g     and camouflaging body parts with clothing, makeup, hats or wigs, as well  
   as undergoing permanent measures such as plastic surgery.<Sup>2,3 </Sup>BDD  
   usually onsets in adolescence and typically follows a chronic course.<Sup>4 <
/Sup>Studies     documented community and population prevalence rates between 0.
7&#45;2.4%.<Sup>2,5,6 </Sup>and     prevalence rates in psychiatric in&#45;patie
nt facilities between 13&#45;16%,<Sup>7,8 </Sup>making     BDD a relatively comm
on disorder. Some studies found that BDD is equally     common across the gender
s,<Sup>1 </Sup>whereas other studies documented that     it occurs slightly more
 often in women than men.<Sup>1,2,9,10 </Sup></font></p>     ^cY#aop1311.htm##
00813000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704057100084002001200655#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#36#32#article#180#<p><font si
ze="2" face="Verdana">BDD is a severe disorder associated with especially     hi
gh functional impairment. Quality of life is poorer in individuals with     BDD 
than in those with depression or medical illnesses.<Sup>11 </Sup>Moreover,     i
ndividuals with BDD spend an average of three to eight hours daily worrying     
about appearance concerns, and 27&#45;39% are considered to have delusional preo
ccupations.<Sup>4 </Sup>BDD     sufferers have higher rates of unemployment and 
lower incomes than the population     at large.<Sup>2 </Sup></font></p>     ^cY#
aop1311.htm##
00718000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704047600084002001200560#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#37#33#article#180#<p><font si
ze="2" face="Verdana">BDD is also associated with high levels of social     impa
irment. BDD sufferers are frequently socially avoidant, live alone, or     are h
ousebound.<Sup>2,12,13 </Sup>Suicide rates in BDD are amongst the highest     of
 any psychiatric disorder: 80% of BDD sufferers report lifetime suicidal     ide
ation, and suicide attempts were documented in 2428% of adults with BDD     and 
44.4% of adolescents with BDD.<Sup>3,9 </Sup></font></p>     ^cY#aop1311.htm##
01372000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704113000084002001201214#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#38#34#article#180#<p><font si
ze="2" face="Verdana">Considering both the high functional and psychosocial     
impairment in BDD and the accompanying heightened suicide risk, it is important 
    to study variables associated with BDD severity. Social support is one varia
ble     that has been linked to severity of several disorders sharing similar fe
atures     with BDD, such as obsessive&#45;compulsive disorder (OCD; BDD patient
s have appearance&#45;related 'obsessions' and 'compulsions'),     eating disord
ers (ED; BDD sufferers have a disturbed body image) and social     anxiety disor
der (SAD; i.e., BDD sufferers become anxious in social situations     because th
ey are concerned that others might notice their perceived appearance     defect)
.<Sup>14&#45;17 </Sup>Overall, research demonstrated an inverse relationship    
 between social support and treatment outcome in OCD,<Sup>15,18 </Sup>lower     
levels of social support among individuals with ED and SAD compared to healthy  
   controls,<Sup>14,16,17,19,20 </Sup>and an inverse relationship between social
     support and disorder severity in SAD.<Sup>14,19 </Sup></font></p>     ^cY#a
op1311.htm##
02564000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704232200084002001202406#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#39#35#article#180#<p><font si
ze="2" face="Verdana">While a relationship between social support     and sympto
m severity was demonstrated for the disorders most similar to BDD,     this asso
ciation was not examined for BDD. Research examining the relationship     betwee
n social support and BDD symptom severity is merited, as it could ultimately    
 lead to knowledge of correlates of BDD severity, as well as future research    
 aimed to target this factor in treatment. As such, the present study was     de
signed to examine the association between perceived social support and     body 
dysmorphic symptom severity. Drawing from past literature examining     social s
upport, it was hypothesized that lower levels of perceived social     support wo
uld be associated with more severe BDD symptoms. Consistent with     the larger 
social support literature, which documented a three&#45;factor structure     thr
ough exploratory factor analyses of adolescent, college, and older adult     sam
ples,<Sup>21&#45;23 </Sup>the present study sought to separately examine the    
 association between perceived social support from each of these three domains, 
    that is, family, friends, and significant others and body dysmorphic symptom
     severity. Finally, research suggests that gender may moderate the relations
hip     between social support and disorder symptom severity.<Sup>24&#45;27 </Su
p>For     example, some studies found that social support was significantly nega
tively     associated with depression among women but not among men.<Sup>24,27 <
/Sup>However,     opposite findings were also noted.<Sup>25,26,28 </Sup>For inst
ance, another     study demonstrated that social support was more protective aga
inst the incidence     of depressive and anxiety disorders in men than in women.
<Sup>25 </Sup>Thus,     while past literature suggests that gender may moderate 
the association between     social support and disorder severity, it is difficul
t to draw conclusions     across studies. It is therefore important to examine t
he role of gender in     this association in the current study. This study used 
an internet survey     design to examine (1) the association between three domai
ns of perceived     social support and body dysmorphic symptom severity, and (2)
 whether gender     moderates these relationships. </font></p>     ^cY#aop1311.h
tm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#40#36#article#180#<p>&nbsp;</
p>     ^cY#aop1311.htm##
00309000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704006700084002001200151#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#41#37#article#180#<p><font si
ze="3" face="Verdana"><b>Method</b> </font></p>     ^cY#aop1311.htm##
00595000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704035300084002001200437#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#42#38#article#180#<p><font si
ze="2" face="Verdana">All procedures were approved by the Massachusetts     Gene
ral Hospital institutional review board (protocol number 2008P001825).     Data 
for the present study were collected in conjunction with a larger, internet&#45;
based     study of participants with symptoms consistent with a diagnosis of BDD
. </font></p>     ^cY#aop1311.htm##
00333000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009100084002001200175#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#43#39#article#180#<p><font si
ze="2" face="Verdana"><b>1. Participants and procedures </b></font></p>     ^cY#
aop1311.htm##
00814000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704057200084002001200656#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#44#40#article#180#<p><font si
ze="2" face="Verdana">Participants were recruited via online advertisements     
posted on BDD&#45;related web pages, in forums, blogs, and support groups, and  
   through the Massachusetts General Hospital OCD and Related Disorders Clinic  
   website. Flyers advertising the study were also posted around the Boston     
area. Advertisements contained a URL that directed interested participants     t
o the survey website; posted on SurveyMonkey.com.<Sup>29 </Sup>The survey     li
nk was active online between November 2008 and January 2009. </font></p>     ^cY
#aop1311.htm##
00844000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704060200084002001200686#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#45#41#article#180#<p><font si
ze="2" face="Verdana">Once logged into the website, participants first     encou
ntered an informed consent page, which they were required to read and     agree 
to before continuing. Next, participants were presented with a series     of dem
ographic questions, followed by a self&#45;report measure adapted from     the B
DD&#45;YBOCS and a series of questionnaires about BDD symptoms and psychosocial 
    impairment, including the Multidimensional Scale of Perceived Social Support
.<Sup>22 </Sup>Participants     could skip any questions that they did not wish 
to answer. </font></p>     ^cY#aop1311.htm##
00526000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704028400084002001200368#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#46#42#article#180#<p><font si
ze="2" face="Verdana">At the end of the survey, participants were     asked seve
ral questions about the relevance and clarity of the survey. Participants     re
ceived a $10 electronic gift certificate as remuneration for participation     i
n the study. </font></p>     ^cY#aop1311.htm##
01270000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704102800084002001201112#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#47#43#article#180#<p><font si
ze="2" face="Verdana">A total of 782 participants initiated the study     by agr
eeing to the information presented on the informed consent page. Participants   
  who reported primary weight concerns were excluded in order to eliminate     p
articipants with a likely primary diagnosis of an eating disorder. Additionally,
     duplicate responses and data from responders who did not complete any quest
ions     on the primary questionnaire (modified self&#45;report adapted from BDD
&#45;YBOCS)     were excluded. In order to identify participants with symptoms c
onsistent     with a diagnosis of body dysmorphic disorder, the sample was then 
limited     to participants with a 10&#45;item modified self&#45;report BDD&#45;
YBOCS score of 16     or greater, to reflect the Yale&#45;Brown Obsessive Compul
sive Scale's     (Y&#45;BOCS')<Sup>30 </Sup>cutoff score for clinically signific
ant symptoms.     Thus, a final sample of N = 400 participants (310 females, 90 
males) was     included in analyses. </font></p>     ^cY#aop1311.htm##
00314000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007200084002001200156#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#48#44#article#180#<p><font si
ze="2" face="Verdana"><b>2. Measures </b></font></p>     ^cY#aop1311.htm##
00319000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007700084002001200161#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#49#45#article#180#<p><font si
ze="2" face="Verdana">1) Demographic questions</font></p>     ^cY#aop1311.htm##
00346000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010400084002001200188#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#50#46#article#180#<p><font si
ze="2" face="Verdana"> Demographic data were collected for participants. </font>
</p>     ^cY#aop1311.htm##
00331000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008900084002001200173#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#51#47#article#180#<p><font si
ze="2" face="Verdana">2) Body Dysmorphic Symptom Severity </font></p>     ^cY#ao
p1311.htm##
01836000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704159400084002001201678#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#52#48#article#180#<p><font si
ze="2" face="Verdana">We adapted the 10&#45;item version of the clinician&#45;ad
ministered     Yale&#45;Brown Obsessive Compulsive Scale modified for BDD (BDD&#
45;YBOCS)<Sup>31 </Sup>to     create a self&#45;report measure of symptom severi
ty. Modeled after the Y&#45;BOCS,<Sup>30 </Sup>the     BDD&#45;YBOCS is a measur
e of past&#45;week BDD symptom severity. Rather than using     the 12&#45;item v
ersion, which includes an item on insight that cannot be assessed     via self&#
45;report, we used the 10&#45;item version, which excludes this item. The     se
lf&#45;report scale was presented in a Likert&#45;type format from 0 (least extr
eme)     to 4 (most extreme), with higher total scores indicating more severe BD
D     symptomatology. Psychometric properties of the 12&#45;item BDD&#45;YBOCS i
ndicate     good internal consistency (</font><font>&#945;</font><font size="2" 
face="verdana"> =     0.80), convergent validity (r = 0.55 with the Clinical Glo
bal Impression     Scale), test&#45;retest reliability (intra&#45;class correlat
ion for total score     = 0.99 and 0.88, respectively), and sensitivity to chang
e with treatment.<Sup>31 </Sup>The     psychometric properties of the clinician&
#45;administered 10&#45;item version are     comparable for reliability, factor 
structure, convergent and discriminant     validity, and sensitivity to change.<
Sup>31 </Sup>In the present study, the     BDD&#45;YBOCS had good internal consi
stency (</font><font>&#945;</font><font size="2" face="verdana"> =     0.76) des
pite its use as a self&#45;report measure. </font></p>     ^cY#aop1311.htm##
00323000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008100084002001200165#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#53#49#article#180#<p><font si
ze="2" face="Verdana">3) Perceived Social Support </font></p>     ^cY#aop1311.ht
m##
01473000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704123100084002001201315#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#54#50#article#180#<p><font si
ze="2" face="Verdana">PerceivedsocialsupportwasmeasuredusingtheMultidimensional 
    Scale of Perceived Social Support (MSPSS).<Sup>22 </Sup>The MSPSS is a 12&#4
5;item     Likert&#45;type scale containing three subscales: family, friends, an
d significant     other. Items range from one to seven. To calculate total score
s for each     of the subscales, responses for items in the subscales are averag
ed, with     higher scores indicating greater perceived social support. A total 
perceived     social support score can also be calculated by summing up the thre
e subscales.     The MSPSS has strong internal consistency (</font><font>&#945;<
/font><font size="2" face="verdana"> =     0.88) and good construct validity whe
n correlated with the Hopkins Symptom     Checklist (HSCL) Depression and Anxiet
y subscales.<Sup>22 </Sup>In the present     study, the MSPSS also demonstrated 
excellent internal consistency for the     family subscale (</font><font>&#945;<
/font><font size="2" face="verdana"> =     0.93), friends subscale (</font><font
>&#945;</font><font size="2" face="verdana"> =     0.93), and significant other 
subscale (</font><font>&#945;</font><font size="2" face="verdana"> =     0.95). 
</font></p>     ^cY#aop1311.htm##
00321000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007900084002001200163#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#55#51#article#180#<p><font si
ze="2" face="Verdana">4) Depression and anxiety </font></p>     ^cY#aop1311.htm#
#
01215000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704097300084002001201057#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#56#52#article#180#<p><font si
ze="2" face="Verdana">The Depression Anxiety Stress Scale&#45;21 Item     Versio
n (DASS21)<Sup>32 </Sup>was used to measure symptoms of depression,     anxiety,
 and stress by way of three self&#45;report subscales. This information     was 
used to control for depression during analyses. In a large, non&#45;clinical    
 sample, the depression, anxiety, and stress subscales demonstrated strong     i
nternal consistency (</font><font>&#945;</font><font size="2" face="verdana"> = 
    0.88, 0.82, and 0.90, respectively).<Sup>33 </Sup>In a clinical sample, the 
    subscales also demonstrated strong internal consistency (</font><font>&#945;
</font><font size="2" face="verdana"> =     0.96, 0.89, and 0.93, respectively).
<Sup>34 </Sup>Finally, in the present     sample, the three subscales were shown
 to have strong internal consistency     (</font><font>&#945;</font><font size="
2" face="verdana"> = 0.87, 0.83, and     0.82, respectively). </font></p>     ^c
Y#aop1311.htm##
00325000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008300084002001200167#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#57#53#article#180#<p><font si
ze="2" face="Verdana"><b>3. Analytical strategy </b></font></p>     ^cY#aop1311.
htm##
00724000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704048200084002001200566#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#58#54#article#180#<p><font si
ze="2" face="Verdana">Statistical analyses were conducted using SPSS     version
 17.0. Group differences in BDD symptom severity and depression were     tested.
 The first aim was to examine the association between the three domains     of p
erceived social support and body dysmorphic symptom severity. To this     end, t
he family, friends, and significant other subscales of the MSPSS were     correl
ated with the BDDYBOCS for both males and females. </font></p>     ^cY#aop1311.h
tm##
01492000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704125000084002001201334#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#59#55#article#180#<p><font si
ze="2" face="Verdana">The second goal of the current study was to     test wheth
er gender moderated the association between perceived social support     and BDD
 symptom severity. For these analyses, three multiple regressions     were used 
for the three subscales of the MSPSS. Multiple regression was chosen     in part
 because it does not require the sample to have an equal gender distribution.<Su
p>35,36 </Sup>The     predictor variables for the three regressions (MSPSS famil
y, friends, and     significant other subscales) were centered for the purpose o
f interpretation,     and three interaction terms were created with the three pr
edictor variables     and gender. For each of the three models, the BDD&#45;YBOC
S score was then regressed     on the predictor variable and the appropriate int
eraction term. Because depression     is commonly comorbid with BDD and has been
 shown to be associated with social     support, it was entered as a covariate i
n each of the three regressions.     The correlation between depression and anxi
ety was approaching collinearity.     Therefore anxiety was not entered as a cov
ariate. In order to probe significant     interactions, a simple slope test was 
used.<Sup>35 </Sup></font></p>     ^cY#aop1311.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#60#56#article#180#<p>&nbsp;</
p>     ^cY#aop1311.htm##
00310000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704006800084002001200152#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#61#57#article#180#<p><font si
ze="3" face="Verdana"><b>Results</b> </font></p>     ^cY#aop1311.htm##
00692000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704045000084002001200534#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#62#58#article#180#<p><font si
ze="2" face="Verdana">Participants ranged in age from 18 to 62 years,     and ha
d a mean (SD) age of 31.57 (9.79) years. The majority of participants     were C
aucasian (N = 292; 73%) and half of the participants were employed     either fu
ll&#45;time of part&#45;time (N = 230). One hundred and fifty&#45;two of the    
 participants were single (38%), while 220 were either dating, married, or     c
ohabitating (55%). </font></p>     ^cY#aop1311.htm##
00962000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704072000084002001200804#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#63#59#article#180#<p><font si
ze="2" face="Verdana">Sample means and standard deviations for the     BDD&#45;Y
BOCS, DASS&#45;21 depression subscale, and MSPSS are presented in <a href="/img/
revistas/rbp/2011nahead/a13tab01.jpg">Table     1</a>. Prior to conducting our p
rimary analysis, we examined if there were     group differences in our primary 
outcome variable (e.g., BDD&#45;YBOCS) since     such differences would bias the
 proposed moderation analysis. Results suggested     that there were no group di
fferences in BDD&#45;YBOCS scores for males as compared     to females (<I>t</I>
(399) = &#45;1.02, p = 0.31), suggesting that males and females     in the sampl
e had similarly severe body dysmorphic symptoms. </font></p>     ^cY#aop1311.htm
##
01223000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704098100084002001201065#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#64#60#article#180#<p><font si
ze="2" face="Verdana">First&#45;order correlations were run to examine     the a
ssociation between scores on the BDD&#45;YBOCS and the three subscales of     th
e MSPSS for males and females (<a href="/img/revistas/rbp/2011nahead/a13tab01.jp
g">Table 1</a>).     As predicted, there were significant negative associations 
between perceived     social support from friends and significant others and bod
y dysmorphic symptom     severity among males. Perceived social support from fam
ily and friends was     also significantly negatively associated with body dysmo
rphic symptom severity     in females. In other words, the more social support p
articipants had, the     less severe their BDD was. Contrary to hypotheses, perc
eived social support     from family was not significantly associated with sympt
om severity in males,     and perceived social support from significant others w
as not significantly     associated with symptom severity in females. </font></p
>     ^cY#aop1311.htm##
01827000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704158500084002001201669#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#65#61#article#180#<p><font si
ze="2" face="Verdana">In order to examine the role of gender as a     moderator 
of these relationships, three moderation analyses were conducted,     controllin
g for depression in each regression. The regression analyses demonstrated     th
at gender did not moderate the relationship between perceived social support    
 from family and body dysmorphic symptom severity (</font><font>&#946;</font><fo
nt size="2" face="verdana"> =     0.075, t = 1.52, p = 0.13), nor did it moderat
e the relationship between     perceived social support from friends and symptom
 severity, (</font><font>&#946;</font><font size="2" face="verdana"> =     .087,
 t = 1.80, p = 0.07). However, gender did moderate the relationship     between 
perceived social support from significant others and symptom severity,     as sh
own by a significant overall model, F(4, 350) = 24.06, p &lt; 0.001,     and a s
ignificant interaction term between support from significant others     and gend
er, (</font><font>&#946;</font><font size="2" face="verdana"> = 0.13,     t = 2.
75, p = 0.01). A simple slope test revealed that perceived social support     fr
om a significant other was significantly associated with symptom severity     fo
r males (</font><font>&#946;</font><font size="2" face="verdana"> = &#45;0.23,  
   p &lt; 0.01), but not for females (</font><font>&#946;</font><font size="2" f
ace="verdana"> =     0.04, p = 0.58); see <a href="#fig01">Figure 1</a>. For mal
es, perceived     social support from significant others accounted for 21.6% of 
variance in     symptom severity. </font></p>     ^cY#aop1311.htm##
00278000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704003600084002001200120#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#66#62#article#180#<p><a name=
"fig01"></a></p>     ^cY#aop1311.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#67#63#article#180#<p>&nbsp;</
p>     ^cY#aop1311.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#68#64#article#180#<p align="c
enter"><img src="/img/revistas/rbp/2011nahead/a13fig01.jpg"></p>     ^cY#aop1311
.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#69#65#article#180#<p>&nbsp;</
p>     ^cY#aop1311.htm##
00313000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007100084002001200155#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#70#66#article#180#<p><font si
ze="3" face="Verdana"><b>Discussion</b> </font></p>     ^cY#aop1311.htm##
00605000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704036300084002001200447#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#71#67#article#180#<p><font si
ze="2" face="Verdana">The aim of the present study was to examine     the associ
ation between perceived social support and body dysmorphic symptom     severity 
in an internet sample with symptoms consistent with a diagnosis     of BDD. Furt
hermore, the role of gender as a potential moderator of this     relationship wa
s examined. </font></p>     ^cY#aop1311.htm##
00994000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704075200084002001200836#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#72#68#article#180#<p><font si
ze="2" face="Verdana">In males, less perceived social support from     friends a
nd significant others was associated with increased body dysmorphic     symptom 
severity. Given that the current study is adequately powered for     the propose
d analysis, it is unlikely that the nonsignificant association     between perce
ived social support from family and body dysmorphic symptom     severity in male
s is due to lack of power. For females, results revealed     that less perceived
 social support from family and friends was associated     with increased body d
ysmorphic symptom severity, while the association between     perceived social s
upport from significant others and symptom severity was     non&#45;significant.
 </font></p>     ^cY#aop1311.htm##
00792000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704055000084002001200634#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#73#69#article#180#<p><font si
ze="2" face="Verdana">Findings that participants with less perceived     social 
support experienced greater body dysmorphic symptom severity are consistent     
with the broader social support literature.<Sup>19,25 </Sup>Although correlation
s     were weak in magnitude, they were stronger than those reported in studies 
    of other disorders, such as SAD.<Sup>19 </Sup>Considering the high degree   
  of impairment associated with BDD, results implicate social support as an     
important area of future BDD research. </font></p>     ^cY#aop1311.htm##
00635000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704039300084002001200477#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#74#70#article#180#<p><font si
ze="2" face="Verdana">Moderation analyses revealed that gender moderated     the
 relationship between social support from significant others and BDD symptom    
 severity so that this relationship was significant only among males, and     no
t females. Gender did not moderate the relationships between social support     
from family and friends and BDD symptoms. </font></p>     ^cY#aop1311.htm##
01117000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704087500084002001200959#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#75#71#article#180#<p><font si
ze="2" face="Verdana">One way to expand our interpretation of these     results 
is by considering the greater social support literature. The support     gap hyp
othesis postulates that men receive more spousal support than do women,     perh
aps due to women's socialized gender role as caregivers.<Sup>37,38 </Sup>Studies
     have also shown that women benefit less than men from social support provid
ed     by a romantic partner.<Sup>38 </Sup>As such, women in the present sample 
    may receive less social support from romantic partners than men in the prese
nt     sample, therefore benefiting less from this domain of social support. Giv
en     that the length of a romantic relationship might have an impact on social
     support and body dysmorphic symptoms, future studies should consider includ
ing     relationship length as a covariate. </font></p>     ^cY#aop1311.htm##
00720000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704047800084002001200562#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#76#72#article#180#<p><font si
ze="2" face="Verdana">The present study has limitations. First, causality     ca
nnot be inferred from the correlational analyses. Thus, it is impossible     to 
know if perceived social support influenced the severity of body dysmorphic     
symptoms, or if individuals with more severe BDD were too impaired to form     s
ocial relationships in the first place and were, therefore, less likely     to r
eceive social support from others around them. </font></p>     ^cY#aop1311.htm##
00794000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704055200084002001200636#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#77#73#article#180#<p><font si
ze="2" face="Verdana">It is also possible that these two phenomena     had a bid
irectional relationship, in which lower perceived social support     led to more
 severe BDD symptoms, which in turn inhibited the individuals' ability     to mo
bilize social support. Second, although we controlled for the most likely     co
nfounding variable, that is, depression, it is possible that other confounding  
   variables, such as other comorbid psychological disorders (e.g., OCD and     
SAD), might have influenced the results. </font></p>     ^cY#aop1311.htm##
02170000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704192800084002001202012#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#78#74#article#180#<p><font si
ze="2" face="Verdana">Additionally, there are several limitations     associated
 with the use of an internet study design. First, a sampling bias     may have r
esulted from collecting data over the internet given that not all     population
s have equal computer access or skills. However, research suggests     that inte
rnet surveys deliver data that are equally reliable to that of other     study d
esigns.<Sup>39,40 </Sup>It is important to highlight that the current     study 
had a larger proportion of females compared to males. Although this     might se
em unusual given previous studies that have documented that BDD is     similarly
 prevalent in both genders, newer data suggests that BDD appears     to affect s
lightly more females than males.<Sup>41&#45;43 </Sup>Additionally,     these res
ults are consistent with other Internet studies, which seem to draw     more fem
ale than male participants.<Sup>44 </Sup>Future studies might consider     addit
ional recruiting strategies targeting males that might help address     this sam
pling bias. Furthermore, because data were collected through self&#45;report    
 via the internet, formal diagnosis of BDD by a clinician was not possible.     
Thus, it is difficult to know whether the present findings apply to patients    
 with clinically&#45;diagnosed BDD. Future internet studies might want to invite
     a small subset of the sample to a clinical setting to conduct a confirmator
y     diagnostic assessment. This limitation was minimized by the inclusion of  
   participants with symptom severity comparable to a formal diagnosis of BDD,  
   as indicated by scores on the self&#45;report measure adapted from the BDD&#4
5;YBOCS.     Finally, the self&#45;report version of the 10&#45;item BDD&#45;YBO
CS used in the present     sample has never been used before, although its inter
nal consistency in the     current study was acceptable. </font></p>     ^cY#aop
1311.htm##
01008000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704076600084002001200850#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#79#75#article#180#<p><font si
ze="2" face="Verdana">It should also be noted that the use of internet     data 
collection may have increased the external validity of the sample in     several
 important ways. For instance, the sample may have included participants     who
, due to the shame and stigma associated with having BDD, might not have     bee
n willing to come into a clinic to be assessed. It is also possible that     usi
ng an internet survey to collect data may have promoted a larger geographic     
representation of the sample as opposed to collecting data from within a     cli
nical setting. Finally, the use of an internet survey design allowed for     the
 collection of data from both treatment seeking and non&#45;treatment seeking   
  individuals. </font></p>     ^cY#aop1311.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#80#76#article#180#<p>&nbsp;</
p>     ^cY#aop1311.htm##
00313000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007100084002001200155#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#81#77#article#180#<p><font si
ze="3" face="Verdana"><b>Conclusion</b> </font></p>     ^cY#aop1311.htm##
00986000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704074400084002001200828#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#82#78#article#180#<p><font si
ze="2" face="Verdana">Ultimately, in light of the aforementioned limitations,   
  findings from the present study require future examination in participants    
 formally diagnosed with BDD and, if possible, through a longitudinal design.   
  If replicated, future researchers should consider the potential clinical     i
mplications of these results. More specifically, future investigations could    
 examine the effectiveness of cognitive behavioral interventions aimed to     ad
dress low perceived social support by highlighting available support networks   
  and developing or expanding support networks. It could also be helpful to     
involve family members or significant others in therapy for this reason. </font>
</p>     ^cY#aop1311.htm##
00611000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704036900084002001200453#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#83#79#article#180#<p><font si
ze="2" face="Verdana">In summary, the present study addressed a gap     in our u
nderstanding of whether social support is related to BDD symptom     severity an
d whether gender influences this relationship. Findings suggest     that the spe
cific domain of perceived social support may be an important     area of future 
research for BDD. </font></p>     ^cY#aop1311.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#84#80#article#180#<p>&nbsp;</
p>     ^cY#aop1311.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#85#81#article#180#<p align="c
enter"><img src="/img/revistas/rbp/2011nahead/a13img01.jpg"></p>     ^cY#aop1311
.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#86#82#article#180#<p>&nbsp;</
p>     ^cY#aop1311.htm##
00313000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007100084002001200155#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#87#83#article#180#<p><font si
ze="3" face="Verdana"><b>References</b> </font></p>     ^cY#aop1311.htm##
00482000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704022600086002001200312#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#88#84#article#180
#1#<p><font size="2" face="Verdana">1. American Psychiatry Association. Diagnost
ic     and statistical manual of mental disorders. 4th ed., text&#45;revision ed
. Washington,     DC: American Psychiatric Association; 2000.    ^cY#aop1311.htm
##
00263000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002100084002001200105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#89#85#article#180# </font></p
>     ^cY#aop1311.htm##
00487000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704023100086002001200317#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#90#86#article#180
#2#<p><font size="2" face="Verdana">2. Rief W, Buhlmann U, Wilhelm S, Borkenhage
n     A, Br&auml;hler E. The prevalence of body dysmorphic disorder: A populatio
n&#45;based     survey. <I>Psychol Med</I>. 2006;36(6):877&#45;85.    ^cY#aop131
1.htm##
00263000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002100084002001200105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#91#87#article#180# </font></p
>     ^cY#aop1311.htm##
00491000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704023500086002001200321#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#92#88#article#180
#3#<p><font size="2" face="Verdana">3. Phillips KA, Didie ER, Menard W, Pagano M
E,     Fay C, Weisberg RB. Clinical features of body dysmorphic disorder in adol
escents     and adults. <I>Psychiatry Res.</I> 2006;141(3):305&#45;14.    ^cY#ao
p1311.htm##
00263000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002100084002001200105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#93#89#article#180# </font></p
>     ^cY#aop1311.htm##
00464000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704020800086002001200294#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#94#90#article#180
#4#<p><font size="2" face="Verdana">4. Phillips KA, Didie ER, Feusner J, Wilhelm
     S. Body dysmorphic disorder: treating an underrecognized disorder. <I>Am   
  J Psychiatry</I>. 2008;165(9):1111&#45;8.    ^cY#aop1311.htm##
00263000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002100084002001200105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#95#91#article#180# </font></p
>     ^cY#aop1311.htm##
00570000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704031400086002001200400#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#96#92#article#180
#5#<p><font size="2" face="Verdana">5. Bienvenu OJ, Samuels JF, Riddle MA, Hoehn
&#45;Saric     R, Liang KY, Cullen BA, Grados MA, Nestadt G. The relationship of
 obsessive&#45;compulsive     disorder to possible spectrum disorders: Results f
rom a family study. <I>Bio     Psychiatry</I>. 2000;48(4):287&#45;93.    ^cY#aop
1311.htm##
00263000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002100084002001200105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#97#93#article#180# </font></p
>     ^cY#aop1311.htm##
00472000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704021600086002001200302#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#98#94#article#180
#6#<p><font size="2" face="Verdana">6. Phillips KA, Quinn G, Stout RL. Functiona
l     impairment in body dysmorphic disorder: a prospective, follow&#45;up study
. <I>J     Psychiatr Res. </I>2008;42(9):701&#45;7.    ^cY#aop1311.htm##
00263000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002100084002001200105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#99#95#article#180# </font></p
>     ^cY#aop1311.htm##
00534000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081888000200085704027700087002001200364#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#100#96#article#18
0#7#<p><font size="2" face="Verdana">7. Conroy M, Menard W, Fleming&#45;Ives K, 
Modha     P, Cerullo H, Phillips KA. Prevalence and clinical characteristics of 
body     dysmorphic disorder in an adult inpatient setting. <I>Gen Hosp Psychiat
ry</I>.     2008;30(1):67&#45;72.    ^cY#aop1311.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081704002100085002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#101#97#article#180# </font></
p>     ^cY#aop1311.htm##
00493000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081888000200085704023600087002001200323#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#102#98#article#18
0#8#<p><font size="2" face="Verdana">8. Grant JE, Kim SW, Crow SJ. Prevalence an
d     clinical features of body dysmorphic disorder in adolescent and adult psyc
hiatric     inpatients. <I>J Clin Psychiatry</I>. 2001;62(7):517&#45;22.    ^cY#
aop1311.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081704002100085002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#103#99#article#180# </font></
p>     ^cY#aop1311.htm##
00527000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704026900088002001200357#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#104#100#article#1
80#9#<p><font size="2" face="Verdana">9. Phillips KA, Menard W, Fay C, Weisberg 
R.     Demographic characteristics, phenomenology, comorbidity, and family histo
ry     in 200 individuals with body dysmorphic disorder. <I>Psychosomatics</I>. 
    2005;46(4):317&#45;25.    ^cY#aop1311.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#105#101#article#180# </font><
/p>     ^cY#aop1311.htm##
00592000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704033300089002001200422#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#106#102#article#1
80#10#<p><font size="2" face="Verdana">10. Fontenelle LF, Telles LL, Nazar BP, d
e Menezes     GB, do Nascimento AL, Mendlowicz MV, Versiani M. A sociodemographi
c, phenomenological,     and long&#45;term follow&#45;up study of patients with 
body dysmorphic disorder in     Brazil. <I>Int J Psychiatry Med.</I> 2006;36(2):
243&#45;59.    ^cY#aop1311.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#107#103#article#180# </font><
/p>     ^cY#aop1311.htm##
00474000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704021500089002001200304#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#108#104#article#1
80#11#<p><font size="2" face="Verdana">11. Phillips KA, Menard W, Fay C, Pagano 
ME.     Psychosocial functioning and quality of life in body dysmorphic disorder
. <I>Compr     Psychiatry</I>. 2005;46(4):254&#45;60.    ^cY#aop1311.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#109#105#article#180# </font><
/p>     ^cY#aop1311.htm##
00427000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704016800089002001200257#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#110#106#article#1
80#12#<p><font size="2" face="Verdana">12. Phillips KA. Quality of life for pati
ents     with body dysmorphic disorder. <I>J Nerv Ment Dis</I>. 2000;188(3):170&
#45;5.    ^cY#aop1311.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#111#107#article#180# </font><
/p>     ^cY#aop1311.htm##
00455000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704019600089002001200285#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#112#108#article#1
80#13#<p><font size="2" face="Verdana">13. Phillips KA. <I>The broken mirror: un
derstanding       and treating body dysmorphic disorder.</I> New York, NY US: Ox
ford University       Press; 1996.    ^cY#aop1311.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#113#109#article#180# </font><
/p>     ^cY#aop1311.htm##
00466000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704020700089002001200296#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#114#110#article#1
80#14#<p><font size="2" face="Verdana">14. Davidson JR, Hughes DC, George LK, Bl
azer     DG. The boundary of social phobia: Exploring the threshold. <I>Arch Gen
 Psychiatry</I>.     1994;51(12): 975&#45;83.    ^cY#aop1311.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#115#111#article#180# </font><
/p>     ^cY#aop1311.htm##
00470000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704021100089002001200300#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#116#112#article#1
80#15#<p><font size="2" face="Verdana">15. Steketee G. Social support and treatm
ent     outcome of obsessive compulsive disorder at 9&#45;month follow&#45;up. <
I>Behav Psychother</I>.     1993;21(2):81&#45;95.    ^cY#aop1311.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#117#113#article#180# </font><
/p>     ^cY#aop1311.htm##
00469000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704021000089002001200299#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#118#114#article#1
80#16#<p><font size="2" face="Verdana">16. Stice E, Whitenton K. Risk factors fo
r body     dissatisfaction in adolescent girls: a longitudinal investigation. <I
>Develop     Psychol.</I> 2002;38(5):669&#45;78.    ^cY#aop1311.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#119#115#article#180# </font><
/p>     ^cY#aop1311.htm##
00472000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704021300089002001200302#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#120#116#article#1
80#17#<p><font size="2" face="Verdana">17. Tiller JM, Sloane G, Schmidt U, Troop
 N.     Social support in patients with anorexia nervosa and bulimia nervosa. <I
>Int     J Eating Disord. </I>1997;21(1): 31&#45;8.    ^cY#aop1311.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#121#117#article#180# </font><
/p>     ^cY#aop1311.htm##
00469000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704021000089002001200299#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#122#118#article#1
80#18#<p><font size="2" face="Verdana">18. Steketee G, Eisen J, Dyck I, Warshaw 
M,     Rasmussen S. Predictors of course in obsessive&#45;compulsive disorder. <
I>Psychiatry     Res.</I> 1999;89(3):229&#45;38.    ^cY#aop1311.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#123#119#article#180# </font><
/p>     ^cY#aop1311.htm##
00505000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704024600089002001200335#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#124#120#article#1
80#19#<p><font size="2" face="Verdana">19. Torgrud LJ, Walker JR, Murray L, Cox 
BJ,     Chartier M, Kjernisted KD. Deficits in perceived social support associat
ed     with generalized social phobia. <I>Cogn Behav Ther</I>. 2004;33(2):87&#45
;96.    ^cY#aop1311.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#125#121#article#180# </font><
/p>     ^cY#aop1311.htm##
00514000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704025500089002001200344#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#126#122#article#1
80#20#<p><font size="2" face="Verdana">20. Gerner B, Wilson PH. The relationship
 between     friendship factors and adolescent girls' body image concern, body d
issatisfaction,     and restrained eating. <I>Int J Eating Disord</I>. 2005;37(4
):313&#45;20.    ^cY#aop1311.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#127#123#article#180# </font><
/p>     ^cY#aop1311.htm##
00493000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704023400089002001200323#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#128#124#article#1
80#21#<p><font size="2" face="Verdana">21. Kazarian SS, McCabe SB. Dimensions of
 social     support in the MSPSS: factorial structure, reliability, and theoreti
cal implications. <I>J     Community Psychol. </I>1991;19(2):150&#45;60.    ^cY#
aop1311.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#129#125#article#180# </font><
/p>     ^cY#aop1311.htm##
00460000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704020100089002001200290#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#130#126#article#1
80#22#<p><font size="2" face="Verdana">22. Zimet GD, Dahlem NW, Zimet SG, Farley
 GK.     The multidimensional scale of perceived social support. <I>J Personalit
y     Assess</I>. 1988;52(1):30&#45;41.    ^cY#aop1311.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#131#127#article#180# </font><
/p>     ^cY#aop1311.htm##
00439000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704018000089002001200269#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#132#128#article#1
80#23#<p><font size="2" face="Verdana">23. Stanley MA, Beck JG, Zebb BJ. Psychom
etric     properties of the MSPSS in older adults. <I>Aging Ment Health.</I> 199
8;2(3):186&#45;93.    ^cY#aop1311.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#133#129#article#180# </font><
/p>     ^cY#aop1311.htm##
00539000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704028000089002001200369#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#134#130#article#1
80#24#<p><font size="2" face="Verdana">24. Kendler KS, Myers J, Prescott CA. Sex
 differences     in the relationship between social support and risk for major d
epression:     a longitudinal study of opposite&#45;sex twin pairs. <I>Am J Psyc
hiatry</I>.     2005;162(2):250&#45;6.    ^cY#aop1311.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#135#131#article#180# </font><
/p>     ^cY#aop1311.htm##
00572000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704031300089002001200402#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#136#132#article#1
80#25#<p><font size="2" face="Verdana">25. Plaisier I, de Bruijn JG, de Graaf R,
 ten     Have M, Beekman AT, Penninx BW. The contribution of working conditions 
and     social support to the onset of depressive and anxiety disorders among ma
le     and female employees. <I>Soc Sci Med</I>. 2007;64(2):401&#45;10.    ^cY#a
op1311.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#137#133#article#180# </font><
/p>     ^cY#aop1311.htm##
00433000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704017400089002001200263#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#138#134#article#1
80#26#<p><font size="2" face="Verdana">26. Shumaker SA, Hill DR. Gender differen
ces     in social support and physical health. <I>Health Psychol</I>. 1991;10(2)
:102&#45;11.    ^cY#aop1311.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#139#135#article#180# </font><
/p>     ^cY#aop1311.htm##
00517000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704025800089002001200347#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#140#136#article#1
80#27#<p><font size="2" face="Verdana">27. Wareham S, Fowler K, Pike A. Determin
ants     of depression severity and duration in Canadian adults: the moderating 
effects     of gender and social support. <I>J Applied Soc Psychol</I>. 2007;37(
12):2951&#45;79.    ^cY#aop1311.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#141#137#article#180# </font><
/p>     ^cY#aop1311.htm##
00516000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704025700089002001200346#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#142#138#article#1
80#28#<p><font size="2" face="Verdana">28. Berkman LF, Cohen S, Syme SL. <I>The 
relationship       of social networks and social support to morbidity and mortal
ity. Social       support and health. </I>San Diego, CA US: Academic Press; 1985
. p.241&#45;62.    ^cY#aop1311.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#143#139#article#180# </font><
/p>     ^cY#aop1311.htm##
00477000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704021800089002001200307#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#144#140#article#1
80#29#<p><font size="2" face="Verdana">29. Finley R. SurveyMonkey.com. 1999 &#91
;cited     2008 dez 30&#93;; Available from: <a href="http://www.surveymonkey.co
m" target="_blank">www.surveymonkey.com</a> </font></p>     ^cY#aop1311.htm##
00495000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704023600089002001200325#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#145#141#article#1
80#30#<p><font size="2" face="Verdana">30. Goodman WK, Price LH, Rasmussen SA, M
azure     C. The Yale&#45;Brown Obsessive Compulsive Scale: I. Development, use,
 and reliability. <I>Arch     Gen Psychiatry.</I> 1989;46(11):1006&#45;11.    ^c
Y#aop1311.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#146#142#article#180# </font><
/p>     ^cY#aop1311.htm##
00585000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704032600089002001200415#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#147#143#article#1
80#31#<p><font size="2" face="Verdana">31. Phillips KA, Hollander E, Rasmussen S
A,     Aronowitz BR. A severity rating scale for body dysmorphic disorder: Devel
opment,     reliability, and validity of a modified version of the Yale&#45;Brow
n Obsessive     Compulsive Scale. <I>Psychopharmacol Bull</I>. 1997;33(1):17&#45
;22.    ^cY#aop1311.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#148#144#article#180# </font><
/p>     ^cY#aop1311.htm##
00539000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704028000089002001200369#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#149#145#article#1
80#32#<p><font size="2" face="Verdana">32. Lovibond PF, Lovibond SH. The structu
re     of negative emotional states: comparison of the Depression Anxiety Stress
     Scales (DASS) with the Beck Depression and Anxiety Inventories. <I>Behav   
  Res Ther</I>. 1995;33(3):335&#45;43.    ^cY#aop1311.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#150#146#article#180# </font><
/p>     ^cY#aop1311.htm##
00543000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704028400089002001200373#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#151#147#article#1
80#33#<p><font size="2" face="Verdana">33. Henry JD, Crawford JR. The short&#45;
form version     of the Depression Anxiety Stress Scales (DASS&#45;21): Construc
t validity and     normative data in a large non&#45;clinical sample. <I>Br J Cl
in Psychol</I>.     2005;44(2):227&#45;39.    ^cY#aop1311.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#152#148#article#180# </font><
/p>     ^cY#aop1311.htm##
00496000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704023700089002001200326#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#153#149#article#1
80#34#<p><font size="2" face="Verdana">34. Brown TA, Chorpita BF, Korotitsch W, 
Barlow     DH. Psychometric properties of the Depression Anxiety Stress Scales (
DASS)     in clinical samples. <I>Behav Res Ther</I>. 1997;35(1):79&#45;89.    ^
cY#aop1311.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#154#150#article#180# </font><
/p>     ^cY#aop1311.htm##
00453000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704019400089002001200283#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#155#151#article#1
80#35#<p><font size="2" face="Verdana">35. Aiken LS, West SG. <I>Multiple regres
sion:       testing and interpreting interactions. </I>Thousand Oaks, CA US: Sag
e Publications,       Inc; 1991.    ^cY#aop1311.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#156#152#article#180# </font><
/p>     ^cY#aop1311.htm##
00377000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704011800089002001200207#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#157#153#article#1
80#36#<p><font size="2" face="Verdana"> 36. Cohen J. A power primer. <I>Psychol 
Bull</I>.     1992;112(1):155&#45;9.    ^cY#aop1311.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#158#154#article#180# </font><
/p>     ^cY#aop1311.htm##
00510000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704025100089002001200340#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#159#155#article#1
80#37#<p><font size="2" face="Verdana">37. Belle D. The stress of caring: Women 
as     providers of social support. In: Breznitz LGS, editor. <I>Handbook of str
ess:     theoretical and clinical aspects. </I>New York: Free Press; 1982. p.496
&#45;505.    ^cY#aop1311.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#160#156#article#180# </font><
/p>     ^cY#aop1311.htm##
00478000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704021900089002001200308#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#161#157#article#1
80#38#<p><font size="2" face="Verdana">38. Schwarzer R, Gutierrez&#45;Dona B. Mo
re spousal     support for men than for women: a comparison of sources and types
 of support. <I>Sex     Roles</I>. 2005;52(7):523&#45;32.    ^cY#aop1311.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#162#158#article#180# </font><
/p>     ^cY#aop1311.htm##
00527000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704026800089002001200357#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#163#159#article#1
80#39#<p><font size="2" face="Verdana">39. Coles ME, Cook LM, BlakeTR. Assessing
 obsessive     compulsive symptoms and cognitions on the internet: Evidence for 
the comparability     of paper and Internet administration. <I>Behav Res Ther</I
>. 2007;45(9):2232&#45;40.    ^cY#aop1311.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#164#160#article#180# </font><
/p>     ^cY#aop1311.htm##
00546000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704028700089002001200376#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#165#161#article#1
80#40#<p><font size="2" face="Verdana">40. Kongsved SM, Basnov M, Holm&#45;Chris
tensen     K, Hjollund NH. Response rate and completeness of questionnaires: a r
andomized     study of Internet versus paper&#45;and&#45;pencil versions. <I>J M
ed Internet Res</I>.     2007;9(3):39&#45;48.    ^cY#aop1311.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#166#162#article#180# </font><
/p>     ^cY#aop1311.htm##
00424000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704016500089002001200254#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#167#163#article#1
80#41#<p><font size="2" face="Verdana">41. Phillips KA, Diaz SF. Gender differen
ces     in body dysmorphic disorder. <I>J Nerv Ment Dis.</I> 1997;185(9):570&#45
;7.    ^cY#aop1311.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#168#164#article#180# </font><
/p>     ^cY#aop1311.htm##
00474000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704021500089002001200304#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#169#165#article#1
80#42#<p><font size="2" face="Verdana">42. Phillips KA, Menard W, Fay C. Gender 
similarities     and differences in 200 individuals with body dysmorphic disorde
r. <I>Compr     Psychiatry. </I>2006;47(2):77&#45;87.    ^cY#aop1311.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#170#166#article#180# </font><
/p>     ^cY#aop1311.htm##
00499000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704024000089002001200329#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#171#167#article#1
80#43#<p><font size="2" face="Verdana">43. Perugi G, Akiskal HS, Giannotti D, Fr
are     F, Di Vaio S, Cassano GB. Genderrelated differences in body dysmorphic d
isorder     (dysmorphophobia). <I>J Nerv Ment Dis</I>. 1997;185(9):578&#45;82.  
  ^cY#aop1311.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#172#168#article#180# </font><
/p>     ^cY#aop1311.htm##
00634000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704037500089002001200464#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#173#169#article#1
80#44#<p><font size="2" face="Verdana">44. Woods DW, Flessner CA, Franklin ME, K
euthen     NJ, Goodwin RD, Stein DJ, Walther MR; Trichotillomania Learning Cente
r&#45;Scientific     Advisory Board. The trichotillomania impact project (TIP): 
Exploring phenomenology,     functional impairment, and treatment utilization. <
I>J Clin Psychiatry</I>.     2006;67(12):1877&#45;88.    ^cY#aop1311.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#174#170#article#180# </font><
/p>     ^cY#aop1311.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#175#171#article#180#<p>&nbsp;
</p>     ^cY#aop1311.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#176#172#article#180#<p>&nbsp;
</p>     ^cY#aop1311.htm##
00406000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704016200086002001200248#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#177#173#article#180#<p><font 
size="2" face="Verdana"><b><a name="end"></a><a href="#title"><img src="/img/rev
istas/rbp/2011nahead/seta.jpg" border="0"></a> Correspondence</b>    ^cY#aop1311
.htm##
00272000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002800086002001200114#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#178#174#article#180#<br>   Lu
ana Marques    ^cY#aop1311.htm##
00316000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704007200086002001200158#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#179#175#article#180#<br>   De
partment of Psychiatry, Massachusetts General Hospital     ^cY#aop1311.htm##
00277000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704003300086002001200119#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#180#176#article#180#<br>   On
e Bowdoin Square    ^cY#aop1311.htm##
00280000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704003600086002001200122#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#181#177#article#180#<br>   Bo
ston, MA 02114, USA    ^cY#aop1311.htm##
00312000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704006800086002001200154#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#182#178#article#180#<br>   Te
lephone: (617) 726&#45;0776 Fax: (617) 643&#45;3080    ^cY#aop1311.htm##
00343000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704009900086002001200185#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#183#179#article#180#<br>   Em
ail: <a href="mailto:lmarques@partners.org">lmarques@partners.org</a> </font></p
>     ^cY#aop1311.htm##
00350000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704010600086002001200192#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#p#184#180#article#180#<p><font 
size="2" face="Verdana">Submitted: May 5, 2010 Accepted: August 16,     2010 </f
ont></p>     ^cY#aop1311.htm##
00490000000000241000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830170032000850180058001170630
00200175066000300177062003300180065000900213064000500222865000900227002001200236
#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#c#185#1#article
#44#1#American Psychiatry Association#Diagnostic and statistical manual of menta
l disorders^len#4#DC#American Psychiatric Association#20000000#2000#20110000#aop
1311.htm##
00653000000000325000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100014000850100018000990100
01700117010002100134010001700155012007400172030001200246065000900258064000500267
03100030027203200020027501400070027786500090028400200120029303500100030580100120
0315#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#c#186#2#art
icle#44#2#^rND^sRief^nW#^rND^sBuhlmann^nU#^rND^sWilhelm^nS#^rND^sBorkenhagen^nA#
^rND^sBrähler^nE#The prevalence of body dysmorphic disorder: A population-based 
survey^len#Psychol Med#20060000#2006#36#6#877-85#20110000#aop1311.htm#0033-2917#
Psychol Med##
00687000000000337000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100019000850100016001040100
01600120010001700136010001300153010001900166012007600185030001500261065000900276
06400050028503100040029003200020029401400070029686500090030300200120031203500100
0324801001500334#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S
#c#187#3#article#44#3#^rND^sPhillips^nKA#^rND^sDidie^nER#^rND^sMenard^nW#^rND^sP
agano^nME#^rND^sFay^nC#^rND^sWeisberg^nRB#Clinical features of body dysmorphic d
isorder in adolescents and adults^len#Psychiatry Res#20060000#2006#141#3#305-14#
20110000#aop1311.htm#0165-1781#Psychiatry res##
00625000000000313000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100019000850100016001040100
01700120010001700137012006700154030001600221065000900237064000500246031000400251
032000200255014000700257865000900264002001200273035001000285801001600295#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#c#188#4#article#44#4#^r
ND^sPhillips^nKA#^rND^sDidie^nER#^rND^sFeusner^nJ#^rND^sWilhelm^nS#Body dysmorph
ic disorder: treating an underrecognized disorder^len#Am J Psychiatry#20080000#2
008#165#9#1111-8#20110000#aop1311.htm#0002-953X#Am J Psychiatry##
00755000000000349000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100019000850100018001040100
01700122010002100139010001600160010001700176010001700193010001700210012011400227
03000150034171000020035606500090035806400050036703100030037203200020037501400070
0377865000900384002001200393#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\a
op1311.htm#S#c#189#5#article#44#5#^rND^sBienvenu^nOJ#^rND^sSamuels^nJF#^rND^sRid
dle^nMA#^rND^sHoehn-Saric^nR#^rND^sLiang^nKY#^rND^sCullen^nBA#^rND^sGrados^nMA#^
rND^sNestadt^nG#The relationship of obsessive-compulsive disorder to possible sp
ectrum disorders: Results from a family study^len#Bio Psychiatry#2#20000000#2000
#48#4#287-93#20110000#aop1311.htm##
00611000000000301000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100019000850100015001040100
01600119012008600135030001600221065000900237064000500246031000300251032000200254
014000600256865000900262002001200271035001000283801001600293#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop1311.htm#S#c#190#6#article#44#6#^rND^sPhillips
^nKA#^rND^sQuinn^nG#^rND^sStout^nRL#Functional impairment in body dysmorphic dis
order: a prospective, follow-up study^len#J Psychiatr Res#20080000#2008#42#9#701
-7#20110000#aop1311.htm#0022-3956#J Psychiatr Res##
00726000000000337000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100016000850100016001010100
02200117010001500139010001700154010001900171012010200190030002000292065000900312
06400050032103100030032603200020032901400060033186500090033700200120034603500100
0358801002000368#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S
#c#191#7#article#44#7#^rND^sConroy^nM#^rND^sMenard^nW#^rND^sFleming-Ives^nK#^rND
^sModha^nP#^rND^sCerullo^nH#^rND^sPhillips^nKA#Prevalence and clinical character
istics of body dysmorphic disorder in an adult inpatient setting^len#Gen Hosp Ps
ychiatry#20080000#2008#30#1#67-72#20110000#aop1311.htm#0163-8343#Gen Hosp Psychi
atry##
00637000000000301000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100016000850100014001010100
01500115012011200130030001800242065000900260064000500269031000300274032000200277
014000700279865000900286002001200295035001000307801001800317#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop1311.htm#S#c#192#8#article#44#8#^rND^sGrant^nJ
E#^rND^sKim^nSW#^rND^sCrow^nSJ#Prevalence and clinical features of body dysmorph
ic disorder in adolescent and adult psychiatric inpatients^len#J Clin Psychiatry
#20010000#2001#62#7#517-22#20110000#aop1311.htm#0160-6689#J Clin Psychiatry##
00681000000000313000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100019000850100016001040100
01300120010001800133012012900151030001500280065000900295064000500304031000300309
032000200312014000700314865000900321002001200330035001000342801001500352#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#c#193#9#article#44#9#^r
ND^sPhillips^nKA#^rND^sMenard^nW#^rND^sFay^nC#^rND^sWeisberg^nR#Demographic char
acteristics, phenomenology, comorbidity, and family history in 200 individuals w
ith body dysmorphic disorder^len#Psychosomatics#20050000#2005#46#4#317-25#201100
00#aop1311.htm#0033-3182#Psychosomatics##
00798000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100021000870100017001080100
01600125010002100141010002400162010002100186010001800207012012400225030002100349
06500090037006400050037903100030038403200020038701400070038986500090039600200120
0405035001000417801002100427#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\a
op1311.htm#S#c#194#10#article#44#10#^rND^sFontenelle^nLF#^rND^sTelles^nLL#^rND^s
Nazar^nBP#^rND^sde Menezes^nGB#^rND^sdo Nascimento^nAL#^rND^sMendlowicz^nMV#^rND
^sVersiani^nM#A sociodemographic, phenomenological, and long-term follow-up stud
y of patients with body dysmorphic disorder in Brazil^len#Int J Psychiatry Med#2
0060000#2006#36#2#243-59#20110000#aop1311.htm#0091-2174#Int J Psychiatry Med##
00634000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100016001060100
01300122010001700135012007700152030001700229065000900246064000500255031000300260
032000200263014000700265865000900272002001200281035001000293801001700303#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#c#195#11#article#44#11#
^rND^sPhillips^nKA#^rND^sMenard^nW#^rND^sFay^nC#^rND^sPagano^nME#Psychosocial fu
nctioning and quality of life in body dysmorphic disorder^len#Compr Psychiatry#2
0050000#2005#46#4#254-60#20110000#aop1311.htm#0010-440X#Compr Psychiatry##
00536000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870120063001060300
01600169065000900185064000500194031000400199032000200203014000600205865000900211
002001200220035001000232801001600242#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop1311.htm#S#c#196#12#article#44#12#^rND^sPhillips^nKA#Quality of life f
or patients with body dysmorphic disorder^len#J Nerv Ment Dis#20000000#2000#188#
3#170-5#20110000#aop1311.htm#0022-3018#J Nerv Ment Dis##
00487000000000229000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840160019000870180086001060660
00600192062002400198065000900222064000500231865000900236002001200245#2011nahead#
V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#c#197#13#article#44#13#^rND
^sPhillips^nKA#The broken mirror: understanding and treating body dysmorphic dis
order. New York,^len#NY US#Oxford University Press#19960000#1996#20110000#aop131
1.htm##
00628000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100017001060100
01700123010001700140012005900157030002000216065000900236064000500245031000300250
032000300253014000700256865000900263002001200272035001000284801002000294#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#c#198#14#article#44#14#
^rND^sDavidson^nJR#^rND^sHughes^nDC#^rND^sGeorge^nLK#^rND^sBlazer^nDG#The bounda
ry of social phobia: Exploring the threshold^len#Arch Gen Psychiatry#19940000#19
94#51#12#975-83#20110000#aop1311.htm#0003-990X#Arch Gen Psychiatry##
00568000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870120095001050300
01700200065000900217064000500226031000300231032000200234014000600236865000900242
002001200251035001000263801001700273#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop1311.htm#S#c#199#15#article#44#15#^rND^sSteketee^nG#Social support and
 treatment outcome of obsessive compulsive disorder at 9-month follow-up^len#Beh
av Psychother#19930000#1993#21#2#81-95#20110000#aop1311.htm#0141-3473#Behav Psyc
hother##
00556000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100015000870100019001020120
09200121030001600213710000200229065000900231064000500240031000300245032000200248
014000700250865000900257002001200266#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop1311.htm#S#c#200#16#article#44#16#^rND^sStice^nE#^rND^sWhitenton^nK#Ri
sk factors for body dissatisfaction in adolescent girls: a longitudinal investig
ation^len#Develop Psychol#2#20020000#2002#38#5#669-78#20110000#aop1311.htm##
00594000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100016001040100
01700120010001500137012007300152030002000225710000200245065000900247064000500256
031000300261032000200264014000500266865000900271002001200280#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop1311.htm#S#c#201#17#article#44#17#^rND^sTiller
^nJM#^rND^sSloane^nG#^rND^sSchmidt^nU#^rND^sTroop^nN#Social support in patients 
with anorexia nervosa and bulimia nervosa^len#Int J Eating Disord#2#19970000#199
7#21#1#31-8#20110000#aop1311.htm##
00641000000000325000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100015001050100
01400120010001700134010001900151012005800170030001500228065000900243064000500252
03100030025703200020026001400070026286500090026900200120027803500100029080100150
0300#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#c#202#18#ar
ticle#44#18#^rND^sSteketee^nG#^rND^sEisen^nJ#^rND^sDyck^nI#^rND^sWarshaw^nM#^rND
^sRasmussen^nS#Predictors of course in obsessive-compulsive disorder^len#Psychia
try Res#19990000#1999#89#3#229-38#20110000#aop1311.htm#0165-1781#Psychiatry res#
#
00664000000000325000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100017001050100
01600122010001400138010001800152010002100170012008300191030001600274710000200290
06500090029206400050030103100030030603200020030901400060031186500090031700200120
0326#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#c#203#19#ar
ticle#44#19#^rND^sTorgrud^nLJ#^rND^sWalker^nJR#^rND^sMurray^nL#^rND^sCox^nBJ#^rN
D^sChartier^nM#^rND^sKjernisted^nKD#Deficits in perceived social support associa
ted with generalized social phobia^len#Cogn Behav Ther#2#20040000#2004#33#2#87-9
6#20110000#aop1311.htm##
00601000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100017001030120
13400120030002000254710000200274065000900276064000500285031000300290032000200293
014000700295865000900302002001200311#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop1311.htm#S#c#204#20#article#44#20#^rND^sGerner^nB#^rND^sWilson^nPH#The
 relationship between friendship factors and adolescent girls' body image concer
n, body dissatisfaction, and restrained eating^len#Int J Eating Disord#2#2005000
0#2005#37#4#313-20#20110000#aop1311.htm##
00620000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100017001060120
11000123030002000233065000900253064000500262031000300267032000200270014000700272
865000900279002001200288035001000300801002000310#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop1311.htm#S#c#205#21#article#44#21#^rND^sKazarian^nSS#^rND^
sMcCabe^nSB#Dimensions of social support in the MSPSS: factorial structure, reli
ability, and theoretical implications^len#J Community Psychol#19910000#1991#19#2
#150-60#20110000#aop1311.htm#0090-4392#J Community Psychol##
00583000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100017001030100
01600120010001700136012005900153030002100212710000200233065000900235064000500244
031000300249032000200252014000600254865000900260002001200269#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop1311.htm#S#c#206#22#article#44#22#^rND^sZimet^
nGD#^rND^sDahlem^nNW#^rND^sZimet^nSG#^rND^sFarley^nGK#The multidimensional scale
 of perceived social support^len#J Personality Assess#2#19880000#1988#52#1#30-41
#20110000#aop1311.htm##
00548000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100015001050100
01500120012005700135030001800192710000200210065000900212064000500221031000200226
032000200228014000700230865000900237002001200246#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop1311.htm#S#c#207#23#article#44#23#^rND^sStanley^nMA#^rND^s
Beck^nJG#^rND^sZebb^nBJ#Psychometric properties of the MSPSS in older adults^len
#Aging Ment Health#2#19980000#1998#2#3#186-93#20110000#aop1311.htm##
00672000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100015001050100
01900120012014200139030001600281065000900297064000500306031000400311032000200315
014000600317865000900323002001200332035001000344801001600354#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop1311.htm#S#c#208#24#article#44#24#^rND^sKendle
r^nKS#^rND^sMyers^nJ#^rND^sPrescott^nCA#Sex differences in the relationship betw
een social support and risk for major depression: a longitudinal study of opposi
te-sex twin pairs^len#Am J Psychiatry#20050000#2005#162#2#250-6#20110000#aop1311
.htm#0002-953X#Am J Psychiatry##
00759000000000337000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100020001050100
01800125010001800143010001800161010001800179012014300197030001200340065000900352
06400050036103100030036603200020036901400070037186500090037800200120038703500100
0399801001200409#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S
#c#209#25#article#44#25#^rND^sPlaisier^nI#^rND^sde Bruijn^nJG#^rND^sde Graaf^nR#
^rND^sten Have^nM#^rND^sBeekman^nAT#^rND^sPenninx^nBW#The contribution of workin
g conditions and social support to the onset of depressive and anxiety disorders
 among male and female employees^len#Soc Sci Med#20070000#2007#64#2#401-10#20110
000#aop1311.htm#0037-7856#Soc Sci Med##
00559000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100015001060120
06100121030001500182065000900197064000500206031000300211032000200214014000700216
865000900223002001200232035001000244801001500254#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop1311.htm#S#c#210#26#article#44#26#^rND^sShumaker^nSA#^rND^
sHill^nDR#Gender differences in social support and physical health^len#Health Ps
ychol#19910000#1991#10#2#102-11#20110000#aop1311.htm#0278-6133#Health Psychol##
00622000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100016001040100
01400120012012500134030002200259710000200281065000900283064000500292031000300297
032000300300014000800303865000900311002001200320#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop1311.htm#S#c#211#27#article#44#27#^rND^sWareham^nS#^rND^sF
owler^nK#^rND^sPike^nA#Determinants of depression severity and duration in Canad
ian adults: the moderating effects of gender and social support^len#J Applied So
c Psychol#2#20070000#2007#37#12#2951-79#20110000#aop1311.htm##
00569000000000253000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840160018000870160015001050160
01500120018012400135066000600259062001500265065000900280064000500289865000900294
002001200303#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#c#2
12#28#article#44#28#^rND^sBerkman^nLF#^rND^sCohen^nS#^rND^sSyme^nSL#The relation
ship of social networks and social support to morbidity and mortality.Social sup
port and health. San Diego,^len#CA US#Academic Press#19850000#1985#20110000#aop1
311.htm##
00443000000000241000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840160016000870180021001030650
00900124064000500133110000900138109001200147037002100159865000900180002001200189
#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#c#213#29#articl
e#44#29#^rND^sFinley^nR#SurveyMonkey.com^len#19990000#1999#20081230#2008 dez 30#
www.surveymonkey.com#20110000#aop1311.htm##
00654000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100016001050100
02000121010001600141012008400157030002000241065000900261064000500270031000300275
032000300278014000800281865000900289002001200298035001000310801002000320#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#c#214#30#article#44#30#
^rND^sGoodman^nWK#^rND^sPrice^nLH#^rND^sRasmussen^nSA#^rND^sMazure^nC#The Yale-B
rown Obsessive Compulsive Scale: I. Development, use, and reliability^len#Arch G
en Psychiatry#19890000#1989#46#11#1006-11#20110000#aop1311.htm#0003-990X#Arch Ge
n Psychiatry##
00741000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100019001060100
02000125010002000145012016400165030002100329065000900350064000500359031000300364
032000200367014000600369865000900375002001200384035001000396801002100406#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#c#215#31#article#44#31#
^rND^sPhillips^nKA#^rND^sHollander^nE#^rND^sRasmussen^nSA#^rND^sAronowitz^nBR#A 
severity rating scale for body dysmorphic disorder: Development, reliability, an
d validity of a modified version of the Yale-Brown Obsessive Compulsive Scale^le
n#Psychopharmacol Bull#19970000#1997#33#1#17-22#20110000#aop1311.htm#0048-5764#P
sychopharmacol Bull##
00657000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100019001060120
15500125030001500280065000900295064000500304031000300309032000200312014000700314
865000900321002001200330035001000342801001500352#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop1311.htm#S#c#216#32#article#44#32#^rND^sLovibond^nPF#^rND^
sLovibond^nSH#The structure of negative emotional states: comparison of the Depr
ession Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Invento
ries^len#Behav Res Ther#19950000#1995#33#3#335-43#20110000#aop1311.htm#0005-7967
#Behav Res Ther##
00652000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100019001030120
14700122030001800269065000900287064000500296031000300301032000200304014000700306
865000900313002001200322035001000334801001800344#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop1311.htm#S#c#217#33#article#44#33#^rND^sHenry^nJD#^rND^sCr
awford^nJR#The short-form version of the Depression Anxiety Stress Scales (DASS-
21): Construct validity and normative data in a large non-clinical sample^len#Br
 J Clin Psychol#20050000#2005#44#2#227-39#20110000#aop1311.htm#0144-6657#Br J Cl
in Psychol##
00654000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100019001030100
02000122010001700142012009500159030001500254065000900269064000500278031000300283
032000200286014000600288865000900294002001200303035001000315801001500325#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#c#218#34#article#44#34#
^rND^sBrown^nTA#^rND^sChorpita^nBF#^rND^sKorotitsch^nW#^rND^sBarlow^nDH#Psychome
tric properties of the Depression Anxiety Stress Scales (DASS) in clinical sampl
es^len#Behav Res Ther#19970000#1997#35#1#79-89#20110000#aop1311.htm#0005-7967#Be
hav Res Ther##
00503000000000241000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840160016000870160015001030180
07900118066000600197062002300203065000900226064000500235865000900240002001200249
#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S#c#219#35#articl
e#44#35#^rND^sAiken^nLS#^rND^sWest^nSG#Multiple regression: testing and interpre
ting interactions. Thousand Oaks,^len#CA US#Sage Publications, Inc#19910000#1991
#20110000#aop1311.htm##
00482000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100015000870120019001020300
01300121065000900134064000500143031000400148032000200152014000600154865000900160
002001200169035001000181801001300191#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop1311.htm#S#c#220#36#article#44#36#^rND^sCohen^nJ#A power primer^len#Ps
ychol Bull#19920000#1992#112#1#155-9#20110000#aop1311.htm#0033-2909#Psychol Bull
##
00571000000000265000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100015000870120063001020160
02000165018005700185066000900242062001100251014000800262065000900270064000500279
865000900284002001200293#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop13
11.htm#S#c#221#37#article#44#37#^rND^sBelle^nD#The stress of caring: Women as pr
oviders of social support^len#^rED^sBreznitz^nLGS#Handbook of stress: theoretica
l and clinical aspects^len#New York#Free Press#496-505#19820000#1982#20110000#ao
p1311.htm##
00591000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100024001060120
09400130030001000224065000900234064000500243031000300248032000200251014000700253
865000900260002001200269035001000281801001000291#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop1311.htm#S#c#222#38#article#44#38#^rND^sSchwarzer^nR#^rND^
sGutierrez-Dona^nB#More spousal support for men than for women: a comparison of 
sources and types of support^len#Sex Roles#20050000#2005#52#7#523-32#20110000#ao
p1311.htm#0360-0025#SEX ROLES##
00666000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100015001030100
01400118012014400132030001500276065000900291064000500300031000300305032000200308
014000800310865000900318002001200327035001000339801001500349#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop1311.htm#S#c#223#39#article#44#39#^rND^sColes^
nME#^rND^sCook^nLM#^rND^sBlakeTR#Assessing obsessive compulsive symptoms and cog
nitions on the internet: Evidence for the comparability of paper and Internet ad
ministration^len#Behav Res Ther#20070000#2007#45#9#2232-40#20110000#aop1311.htm#
0005-7967#Behav Res Ther##
00653000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100016001060100
02600122010001900148012011800167030001900285710000200304065000900306064000500315
031000200320032000200322014000600324865000900330002001200339#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop1311.htm#S#c#224#40#article#44#40#^rND^sKongsv
ed^nSM#^rND^sBasnov^nM#^rND^sHolm-Christensen^nK#^rND^sHjollund^nNH#Response rat
e and completeness of questionnaires: a randomized study of Internet versus pape
r-and-pencil versions^len#J Med Internet Res#2#20070000#2007#9#3#39-48#20110000#
aop1311.htm##
00551000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100015001060120
05100121030001600172065000900188064000500197031000400202032000200206014000600208
865000900214002001200223035001000235801001600245#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop1311.htm#S#c#225#41#article#44#41#^rND^sPhillips^nKA#^rND^
sDiaz^nSF#Gender differences in body dysmorphic disorder^len#J Nerv Ment Dis#199
70000#1997#185#9#570-7#20110000#aop1311.htm#0022-3018#J Nerv Ment Dis##
00616000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100016001060100
01300122012008900135030001700224065000900241064000500250031000300255032000200258
014000600260865000900266002001200275035001000287801001700297#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop1311.htm#S#c#226#42#article#44#42#^rND^sPhilli
ps^nKA#^rND^sMenard^nW#^rND^sFay^nC#Gender similarities and differences in 200 i
ndividuals with body dysmorphic disorder^len#Compr Psychiatry#20060000#2006#47#2
#77-87#20110000#aop1311.htm#0010-440X#Compr Psychiatry##
00694000000000337000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100018001030100
01900121010001500140010001700155010001800172012007600190030001600266065000900282
06400050029103100040029603200020030001400070030286500090030900200120031803500100
0330801001600340#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1311.htm#S
#c#227#43#article#44#43#^rND^sPerugi^nG#^rND^sAkiskal^nHS#^rND^sGiannotti^nD#^rN
D^sFrare^nF#^rND^sDi Vaio^nS#^rND^sCassano^nGB#Genderrelated differences in body
 dysmorphic disorder (dysmorphophobia)^len#J Nerv Ment Dis#19970000#1997#185#9#5
78-82#20110000#aop1311.htm#0022-3018#J Nerv Ment Dis##
00848000000000361000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100019001030100
01900122010001800141010001800159010001600177010001800193011005900211012012100270
03000180039106500090040906400050041803100030042303200030042601400080042986500090
0437002001200446035001000458801001800468#2011nahead#V:\SciELO\serial\rbp\2011nah
ead\markup\aop1311.htm#S#c#228#44#article#44#44#^rND^sWoods^nDW#^rND^sFlessner^n
CA#^rND^sFranklin^nME#^rND^sKeuthen^nNJ#^rND^sGoodwin^nRD#^rND^sStein^nDJ#^rND^s
Walther^nMR#Trichotillomania Learning Center-Scientific Advisory Board#The trich
otillomania impact project (TIP): Exploring phenomenology, functional impairment
, and treatment utilization^len#J Clin Psychiatry#20060000#2006#67#12#1877-88#20
110000#aop1311.htm#0160-6689#J Clin Psychiatry##
00282000000000169000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780910009000800920007000890020012000967030
00400108#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#o#1#1#a
rticle#1#20110408#161735#aop1411.htm#175##
05020000000000709000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780710003000800400003000830010006000860420
00200092120000400094038000300098121000300101049000300104158000300107030002200110
03200060013206500090013801400070014703500100015422300090016401200990017301201100
02720100026003820100028004080100027004360100028004630100026004910100022005170100
02500539010002900564010002700593070009200620070006300712083146100775085001002236
08500230224608500310226908500210230008500330232108500280235408317080238208500100
40900850022041000850030041220850022041520850033041740850032042071170008042390720
00304247112000904250111001304259114000904272113001704281002001204298#2011nahead#
V:\SciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#h#2#1#article#1#oa#en#br1.1
#1#4.0#ND#14#nd#nd#Rev. Bras. Psiquiatr.#ahead#20110000#^f0^l0#1516-4446#2011041
5#Affective state dependence and relative trait stability of perfectionism in sl
eep disturbances^len#Dependência do estado afetivo e estabilidade relativa do tr
aço do perfeccionismo nas perturbações de sono^lpt#^rND^1A01^nBerta R.^sMaia#^rN
D^1A01^nMaria J.^sSoares#^rND^1A01^nAna T.^sPereira#^rND^1A01^nMariana^sMarques#
^rND^1A01^nSandra C.^sBos#^rND^1A02^nAna^sGomes#^rND^1A01^nJosé^sValente#^rND^1A
01^nMaria H.^sAzevedo#^rND^1A01^nAntónio^sMacedo#Universidade de Coimbra^iA01^1F
aculdade de Medicina^2Medical Psychology Institute^pPortugal#Universidade de Ave
iro^iA02^1Department of Education^pPortugal#^len^aOBJECTIVE: To evaluate the deg
ree of absolute change, relative stability and state dependence of trait perfect
ionism in sleep disturbances in a sample of university students. METHOD: Partici
pants completed the Multidimensional Perfectionism Scale and two items concernin
g sleep difficulties. The mean age at T0 (baseline) was 19.59 years (SD = 1.61, 
range = 17-25) and 62.5% of the sample were female. RESULTS: Absolute changes in
 self-oriented and socially-prescribed perfectionism were found. Relative stabil
ity was found for all perfectionism dimensions. Prior and concurrent sleep distu
rbances explained a significant amount of variance in perfectionism. Controlling
 for the effects of sleep measures, prior selforiented perfectionism and other-o
riented perfectionism were the only significant predictors of subsequent self-or
iented perfectionism and otheroriented perfectionism, at T1 and T2. Difficulties
 falling asleep at T1 and socially-prescribed perfectionism at T0 were significa
nt predictors of socially-prescribed perfectionism at T1. CONCLUSION: Despite si
gnificant changes in perfectionism mean scores over the follow-up, the correlati
on analyses demonstrated that participants remained quite stable in regard to th
eir relative levels of perfectionism. As concurrent difficulties initiating slee
p also predicted concurrent socially-prescribed perfectionism, this seems to be 
one dimension of perfectionism with trait-state characteristics.#^ddecs^i1#^tm^l
en^kEvaluation^i1#^tm^len^kAffective symptoms^i1#^tm^len^kStudents^i1#^tm^len^kA
nalysis of variance^i1#^tm^len^kSleep disorders^i1#^lpt^aOBJETIVOS: Avaliar o gr
au de mudança absoluta, de estabilidade relativa e dependência do estado do perf
eccionismo nas perturbações de sono numa amostra de estudantes universitários. M
ÉTODO: Os sujeitos completaram a Escala Multidimensional do Perfeccionismo e doi
s itens sobre dificuldades em dormir. Os dados foram recolhidos em três momentos
 de avaliação, separados por um intervalo de um ano acadêmico. A idade média dos
 sujeitos noT0 era de 19,59 anos (DP = 1,61, variação = 17-25); 62,5% eram mulhe
res. RESULTADOS: Foram encontradas ao longo do follow-up mudanças absolutas para
 o Perfeccionismo Autoorientado e para o Perfeccionismo Socialmente Prescrito. F
oi encontrada estabilidade relativa para todas as dimensões do perfeccionismo. A
s dificuldades de sono prévias e concorrentes explicaram significativamente a va
riância do perfeccionismo. Controlando o efeito das dificuldades em dormir, o Pe
rfeccionismo Autoorientado e o POO prévios foram os únicos preditores significat
ivos de Perfeccionismo Autoorientado e POO subsequente (T1 e T2). As dificuldade
s em iniciar o sono no T1 e o Perfeccionismo Socialmente Prescrito prévio (T0) r
evelaram-se preditores significativos dePerfeccionismoSocialmente PrescritonoT1.
 CONCLUSÃO: Apesar das mudanças significativas nas pontuações médias de perfecci
onismo ao longo do follow-up, as análises de correlação demonstraram que os part
icipantes permaneceramrelativamenteestáveisnosseusníveisdeperfeccionismo.Umavezq
ue asdificuldades em iniciar o sono concorrentes serevelaram um preditor signifi
cativo de Perfeccionismo Socialmente Prescrito, o Perfeccionismo Socialmente Pre
scrito é a dimensão do perfeccionismo que possui características traço-estado.#^
ddecs^i2#^tm^lpt^kAvaliação^i2#^tm^lpt^kSintomas afetivos^i2#^tm^lpt^kEstudante^
i2#^tm^lpt^kAnálise de variância^i2#^tm^lpt^kTranstornos do sono^i2#vancouv#25#2
0100602#June 2, 2010#20110121#January 21, 2011#aop1411.htm##
05090000000000709000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780710003000800400003000830010006000860420
00200092120000400094038000300098121000300101049000300104158000300107030002200110
03200060013206500090013801400070014703500100015422300090016401201060017301201170
02790100026003960100028004220100027004500100028004770100026005050100022005310100
02500553010002900578010002700607070009200634070006300726083148900789085001002278
08500230228808500310231108500210234208500330236308500280239608317360242408500100
41600850022041700850030041920850022042220850033042440850032042771170008043090720
00304317112000904320111001304329114000904342113001704351002001204368#2011nahead#
V:\SciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#f#3#1#article#1#oa#en#br1.1
#1#4.0#ND#14#nd#nd#Rev. Bras. Psiquiatr.#ahead#20110000#^f0^l0#1516-4446#2011041
5#<b>Affective state dependence and relative trait stability of perfectionism in
 sleep disturbances</b>^len#<b>Dependência do estado afetivo e estabilidade rela
tiva do traço do perfeccionismo nas perturbações de sono</b>^lpt#^rND^1A01^nBert
a R.^sMaia#^rND^1A01^nMaria J.^sSoares#^rND^1A01^nAna T.^sPereira#^rND^1A01^nMar
iana^sMarques#^rND^1A01^nSandra C.^sBos#^rND^1A02^nAna^sGomes#^rND^1A01^nJosé^sV
alente#^rND^1A01^nMaria H.^sAzevedo#^rND^1A01^nAntónio^sMacedo#Universidade de C
oimbra^iA01^1Faculdade de Medicina^2Medical Psychology Institute^pPortugal#Unive
rsidade de Aveiro^iA02^1Department of Education^pPortugal#^len^a<b>OBJECTIVE: </
b>To evaluate the degree of absolute change, relative stability and state depend
ence of trait perfectionism in sleep disturbances in a sample of university stud
ents. <b>METHOD: </b>Participants completed the Multidimensional Perfectionism S
cale and two items concerning sleep difficulties. The mean age at T0 (baseline) 
was 19.59 years (SD = 1.61, range = 17-25) and 62.5% of the sample were female. 
<b>RESULTS: </b>Absolute changes in self-oriented and socially-prescribed perfec
tionism were found. Relative stability was found for all perfectionism dimension
s. Prior and concurrent sleep disturbances explained a significant amount of var
iance in perfectionism. Controlling for the effects of sleep measures, prior sel
foriented perfectionism and other-oriented perfectionism were the only significa
nt predictors of subsequent self-oriented perfectionism and otheroriented perfec
tionism, at T1 and T2. Difficulties falling asleep at T1 and socially-prescribed
 perfectionism at T0 were significant predictors of socially-prescribed perfecti
onism at T1. <b>CONCLUSION: </b>Despite significant changes in perfectionism mea
n scores over the follow-up, the correlation analyses demonstrated that particip
ants remained quite stable in regard to their relative levels of perfectionism. 
As concurrent difficulties initiating sleep also predicted concurrent socially-p
rescribed perfectionism, this seems to be one dimension of perfectionism with tr
ait-state characteristics.#^ddecs^i1#^tm^len^kEvaluation^i1#^tm^len^kAffective s
ymptoms^i1#^tm^len^kStudents^i1#^tm^len^kAnalysis of variance^i1#^tm^len^kSleep 
disorders^i1#^lpt^a<b>OBJETIVOS: </b>Avaliar o grau de mudança absoluta, de esta
bilidade relativa e dependência do estado do perfeccionismo nas perturbações de 
sono numa amostra de estudantes universitários. <b>MÉTODO: </b>Os sujeitos compl
etaram a Escala Multidimensional do Perfeccionismo e dois itens sobre dificuldad
es em dormir. Os dados foram recolhidos em três momentos de avaliação, separados
 por um intervalo de um ano acadêmico. A idade média dos sujeitos noT0 era de 19
,59 anos (DP = 1,61, variação = 17-25); 62,5% eram mulheres. <b>RESULTADOS: </b>
Foram encontradas ao longo do follow-up mudanças absolutas para o Perfeccionismo
 Autoorientado e para o Perfeccionismo Socialmente Prescrito. Foi encontrada est
abilidade relativa para todas as dimensões do perfeccionismo. As dificuldades de
 sono prévias e concorrentes explicaram significativamente a variância do perfec
cionismo. Controlando o efeito das dificuldades em dormir, o Perfeccionismo Auto
orientado e o POO prévios foram os únicos preditores significativos de Perfeccio
nismo Autoorientado e POO subsequente (T1 e T2). As dificuldades em iniciar o so
no no T1 e o Perfeccionismo Socialmente Prescrito prévio (T0) revelaram-se predi
tores significativos dePerfeccionismoSocialmente PrescritonoT1. <b>CONCLUSÃO: </
b>Apesar das mudanças significativas nas pontuações médias de perfeccionismo ao 
longo do follow-up, as análises de correlação demonstraram que os participantes 
permaneceramrelativamenteestáveisnosseusníveisdeperfeccionismo.Umavezque asdific
uldades em iniciar o sono concorrentes serevelaram um preditor significativo de 
Perfeccionismo Socialmente Prescrito, o Perfeccionismo Socialmente Prescrito é a
 dimensão do perfeccionismo que possui características traço-estado.#^ddecs^i2#^
tm^lpt^kAvaliação^i2#^tm^lpt^kSintomas afetivos^i2#^tm^lpt^kEstudante^i2#^tm^lpt
^kAnálise de variância^i2#^tm^lpt^kTranstornos do sono^i2#vancouv#25#20100602#Ju
ne 2, 2010#20110121#January 21, 2011#aop1411.htm##
05139000000000721000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780640007000800710003000870400003000900010
00600093042000200099120000400101121000300105049000300108158000300111030002100114
03200060013506500090014101400070015003500100015722300090016701200990017601201100
02750100025003850100027004100100026004370100028004630100025004910100022005160100
02500538010002800563010002700591070009400618070006500712083146800777085001002245
08500230225508500310227808500210230908500330233008500280236308317170239108500100
41080850022041180850030041400850022041700850033041920850032042251170008042570720
00304265112000904268111001304277114000904290113001704299002001204316008008904328
#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#l#4#1#article#1
#^a2011#oa#en#br1.1#1#4.0#14#nd#nd#Rev. bras. psiquiatr#ahead#20110000#^f0^l0#15
16-4446#20110415#Affective state dependence and relative trait stability of perf
ectionism in sleep disturbances^len#Dependência do estado afetivo e estabilidade
 relativa do traço do perfeccionismo nas perturbações de sono^lpt#^rND^1A01^nBer
ta R^sMaia#^rND^1A01^nMaria J^sSoares#^rND^1A01^nAna T^sPereira#^rND^1A01^nMaria
na^sMarques#^rND^1A01^nSandra C^sBos#^rND^1A02^nAna^sGomes#^rND^1A01^nJosé^sVale
nte#^rND^1A01^nMaria H^sAzevedo#^rND^1A01^nAntónio^sMacedo#^iA01^1Universidade d
e Coimbra^2Faculdade de Medicina^3Medical Psychology Institute^pPortugal#^iA02^1
Universidade de Aveiro^2Department of Education^pPortugal#^len^aOBJECTIVE: To ev
aluate the degree of absolute change, relative stability and state dependence of
 trait perfectionism in sleep disturbances in a sample of university students. M
ETHOD: Participants completed the Multidimensional Perfectionism Scale and two i
tems concerning sleep difficulties. The mean age at T0 (baseline) was 19.59 year
s (SD = 1.61, range = 17-25) and 62.5 percent of the sample were female. RESULTS
: Absolute changes in self-oriented and socially-prescribed perfectionism were f
ound. Relative stability was found for all perfectionism dimensions. Prior and c
oncurrent sleep disturbances explained a significant amount of variance in perfe
ctionism. Controlling for the effects of sleep measures, prior selforiented perf
ectionism and other-oriented perfectionism were the only significant predictors 
of subsequent self-oriented perfectionism and otheroriented perfectionism, at T1
 and T2. Difficulties falling asleep at T1 and socially-prescribed perfectionism
 at T0 were significant predictors of socially-prescribed perfectionism at T1. C
ONCLUSION: Despite significant changes in perfectionism mean scores over the fol
low-up, the correlation analyses demonstrated that participants remained quite s
table in regard to their relative levels of perfectionism. As concurrent difficu
lties initiating sleep also predicted concurrent socially-prescribed perfectioni
sm, this seems to be one dimension of perfectionism with trait-state characteris
tics.#^ddecs^i1#^tm^len^kEvaluation^i1#^tm^len^kAffective symptoms^i1#^tm^len^kS
tudents^i1#^tm^len^kAnalysis of variance^i1#^tm^len^kSleep disorders^i1#^lpt^aOB
JETIVOS: Avaliar o grau de mudança absoluta, de estabilidade relativa e dependên
cia do estado do perfeccionismo nas perturbações de sono numa amostra de estudan
tes universitários. MÉTODO: Os sujeitos completaram a Escala Multidimensional do
 Perfeccionismo e dois itens sobre dificuldades em dormir. Os dados foram recolh
idos em três momentos de avaliação, separados por um intervalo de um ano acadêmi
co. A idade média dos sujeitos noT0 era de 19,59 anos (DP = 1,61, variação = 17-
25); 62,5 por cento eram mulheres. RESULTADOS: Foram encontradas ao longo do fol
low-up mudanças absolutas para o Perfeccionismo Autoorientado e para o Perfeccio
nismo Socialmente Prescrito. Foi encontrada estabilidade relativa para todas as 
dimensões do perfeccionismo. As dificuldades de sono prévias e concorrentes expl
icaram significativamente a variância do perfeccionismo. Controlando o efeito da
s dificuldades em dormir, o Perfeccionismo Autoorientado e o POO prévios foram o
s únicos preditores significativos de Perfeccionismo Autoorientado e POO subsequ
ente (T1 e T2). As dificuldades em iniciar o sono no T1 e o Perfeccionismo Socia
lmente Prescrito prévio (T0) revelaram-se preditores significativos dePerfeccion
ismoSocialmente PrescritonoT1. CONCLUSÃO: Apesar das mudanças significativas nas
 pontuações médias de perfeccionismo ao longo do follow-up, as análises de corre
lação demonstraram que os participantes permaneceramrelativamenteestáveisnosseus
níveisdeperfeccionismo.Umavezque asdificuldades em iniciar o sono concorrentes s
erevelaram um preditor significativo de Perfeccionismo Socialmente Prescrito, o 
Perfeccionismo Socialmente Prescrito é a dimensão do perfeccionismo que possui c
aracterísticas traço-estado.#^ddecs^i2#^tm^lpt^kAvaliação^i2#^tm^lpt^kSintomas a
fetivos^i2#^tm^lpt^kEstudante^i2#^tm^lpt^kAnálise de variância^i2#^tm^lpt^kTrans
tornos do sono^i2#vancouv#25#20100602#June 2, 2010#20110121#January 21, 2011#aop
1411.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-
44462011005000014##
00421000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704018100082002001200263#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#5#1#article#146#<p><font size
="4" face="verdana"><b><a name="title"></a>Affective state dependence       and 
relative trait stability of perfectionism in sleep disturbances </b></font></p> 
    ^cY#aop1411.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#6#2#article#146#<p>&nbsp;</p>
     ^cY#aop1411.htm##
00445000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704020500082002001200287#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#7#3#article#146#<p><font size
="3" face="verdana"><b>Depend&ecirc;ncia do estado afetivo e estabilidade       
relativa do tra&ccedil;o do perfeccionismo nas perturba&ccedil;&otilde;es       
de sono </b></font></p>     ^cY#aop1411.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#8#4#article#146#<p>&nbsp;</p>
     ^cY#aop1411.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#9#5#article#146#<p>&nbsp;</p>
     ^cY#aop1411.htm##
00579000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704033800083002001200421#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#10#6#article#146#<p><font siz
e="2" face="Verdana"><b>Berta R. Maia<Sup>I</Sup>; Maria J. Soares<Sup>I</Sup>; 
      Ana T. Pereira<Sup>I</Sup>; Mariana Marques<Sup>I</Sup>; Sandra C. Bos<Sup
>I</Sup>;       Ana Gomes<Sup>II</Sup>; Jos&eacute; Valente<Sup>I</Sup>; Maria H
. Azevedo<Sup>I</Sup>;       Ant&oacute;nio Macedo<Sup>I</Sup></b></font></p>   
  ^cY#aop1411.htm##
00384000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704014300083002001200226#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#11#7#article#146#<p><font siz
e="2" face="Verdana"><Sup>I</Sup>Medical Psychology Institute, Faculdade     de 
Medicina, Universidade de Coimbra, Portugal    ^cY#aop1411.htm##
00339000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704009800083002001200181#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#12#8#article#146#<br>   <Sup>
II</Sup>Department of Education, Universidade de Aveiro, Portugal </font></p>   
  ^cY#aop1411.htm##
00327000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704008600083002001200169#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#13#9#article#146#<p><font siz
e="2" face="Verdana"><a href="#end">Correspondence</a></font></p>     ^cY#aop141
1.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#14#10#article#146#<p>&nbsp;</
p>     ^cY#aop1411.htm##
00286000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704004400084002001200128#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#15#11#article#146#<p>&nbsp;</
p> <hr size="1" noshade>     ^cY#aop1411.htm##
00311000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704006900084002001200153#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#16#12#article#146#<p><font si
ze="2" face="Verdana"><b>ABSTRACT</b></font> </p>     ^cY#aop1411.htm##
00473000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704023100084002001200315#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#17#13#article#146#<p><font si
ze="2" face="Verdana"><B>OBJECTIVE: </B>To evaluate the degree of     absolute c
hange, relative stability and state dependence of trait perfectionism     in sle
ep disturbances in a sample of university students.     ^cY#aop1411.htm##
00499000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704025700084002001200341#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#18#14#article#146#<br>   <B>M
ETHOD: </B>Participants completed the Multidimensional Perfectionism Scale   and
 two items concerning sleep difficulties. The mean age at T0 (baseline)   was 19
.59 years (SD = 1.61, range = 17&#45;25) and 62.5% of the sample were female.   
  ^cY#aop1411.htm##
00948000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704070600084002001200790#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#19#15#article#146#<br>   <B>R
ESULTS: </B>Absolute changes in self&#45;oriented and socially&#45;prescribed pe
rfectionism   were found. Relative stability was found for all perfectionism dim
ensions.   Prior and concurrent sleep disturbances explained a significant amoun
t of variance   in perfectionism. Controlling for the effects of sleep measures,
 prior selforiented   perfectionism and other&#45;oriented perfectionism were th
e only significant predictors   of subsequent self&#45;oriented perfectionism an
d otheroriented perfectionism,   at T1 and T2. Difficulties falling asleep at T1
 and socially&#45;prescribed perfectionism   at T0 were significant predictors o
f socially&#45;prescribed perfectionism at T1.     ^cY#aop1411.htm##
00705000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704046300084002001200547#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#20#16#article#146#<br>   <B>C
ONCLUSION: </B>Despite significant changes in perfectionism mean scores   over t
he follow&#45;up, the correlation analyses demonstrated that participants   rema
ined quite stable in regard to their relative levels of perfectionism.   As conc
urrent difficulties initiating sleep also predicted concurrent socially&#45;pres
cribed   perfectionism, this seems to be one dimension of perfectionism with tra
it&#45;state   characteristics. </font></p>     ^cY#aop1411.htm##
00421000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704017900084002001200263#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#21#17#article#146#<p><font si
ze="2" face="Verdana"><B>Descriptors: </B>Evaluation; Affective symptoms;     St
udents; Analysis of variance; Sleep disorders </font></p> <hr size="1" noshade> 
    ^cY#aop1411.htm##
00308000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704006600084002001200150#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#22#18#article#146#<p><font si
ze="2" face="VERDANA"><b>RESUMO</b></font></p>     ^cY#aop1411.htm##
00513000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704027100084002001200355#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#23#19#article#146#<p><font si
ze="2" face="Verdana"><B>OBJETIVOS: </B>Avaliar o grau de mudan&ccedil;a     abs
oluta, de estabilidade relativa e depend&ecirc;ncia do estado do perfeccionismo 
    nas perturba&ccedil;&otilde;es de sono numa amostra de estudantes universit&
aacute;rios.    ^cY#aop1411.htm##
00656000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704041400084002001200498#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#24#20#article#146#<br>   <B>M
&Eacute;TODO: </B>Os sujeitos completaram a Escala Multidimensional do   Perfecc
ionismo e dois itens sobre dificuldades em dormir. Os dados foram recolhidos   e
m tr&ecirc;s momentos de avalia&ccedil;&atilde;o, separados por um intervalo   d
e um ano acad&ecirc;mico. A idade m&eacute;dia dos sujeitos noT0 era de 19,59   
anos (DP = 1,61, varia&ccedil;&atilde;o = 17&#45;25); 62,5% eram mulheres.     ^
cY#aop1411.htm##
01054000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704081200084002001200896#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#25#21#article#146#<br>   <B>R
ESULTADOS: </B>Foram encontradas ao longo do follow&#45;up mudan&ccedil;as   abs
olutas para o Perfeccionismo Autoorientado e para o Perfeccionismo Socialmente  
 Prescrito. Foi encontrada estabilidade relativa para todas as dimens&otilde;es 
  do perfeccionismo. As dificuldades de sono pr&eacute;vias e concorrentes expli
caram   significativamente a vari&acirc;ncia do perfeccionismo. Controlando o ef
eito   das dificuldades em dormir, o Perfeccionismo Autoorientado e o POO pr&eac
ute;vios   foram os &uacute;nicos preditores significativos de Perfeccionismo Au
toorientado   e POO subsequente (T1 e T2). As dificuldades em iniciar o sono no 
T1 e o Perfeccionismo   Socialmente Prescrito pr&eacute;vio (T0) revelaram&#45;s
e preditores significativos   dePerfeccionismoSocialmente PrescritonoT1.     ^cY
#aop1411.htm##
00870000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704062800084002001200712#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#26#22#article#146#<br>   <B>C
ONCLUS&Atilde;O: </B>Apesar das mudan&ccedil;as significativas nas pontua&ccedil
;&otilde;es   m&eacute;dias de perfeccionismo ao longo do follow&#45;up, as an&a
acute;lises de   correla&ccedil;&atilde;o demonstraram que os participantes perm
aneceramrelativamenteest&aacute;veisnosseusn&iacute;veisdeperfeccionismo.Umavezq
ue   asdificuldades em iniciar o sono concorrentes serevelaram um preditor signi
ficativo   de Perfeccionismo Socialmente Prescrito, o Perfeccionismo Socialmente
 Prescrito &eacute; a   dimens&atilde;o do perfeccionismo que possui caracter&ia
cute;sticas tra&ccedil;o&#45;estado. </font></p>     ^cY#aop1411.htm##
00455000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704021300084002001200297#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#27#23#article#146#<p><font si
ze="2" face="Verdana"><B>Descritores: </B>Avalia&ccedil;&atilde;o;     Sintomas 
afetivos; Estudante; An&aacute;lise de vari&acirc;ncia; Transtornos     do sono 
</font></p> <hr size="1" noshade>     ^cY#aop1411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#28#24#article#146#<p>&nbsp;</
p>     ^cY#aop1411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#29#25#article#146#<p>&nbsp;</
p>     ^cY#aop1411.htm##
00315000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007300084002001200157#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#30#26#article#146#<p><font si
ze="3" face="Verdana"><b>Introduction</b> </font></p>     ^cY#aop1411.htm##
00520000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704027800084002001200362#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#31#27#article#146#<p><font si
ze="2" face="Verdana">Research has demonstrated that perfectionism     is multid
imensional in nature, that it has both intrapersonal and interpersonal     aspec
ts, and that this trait has adaptive/positive and maladaptive/negative     compo
nents. </font></p>     ^cY#aop1411.htm##
00976000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704073400084002001200818#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#32#28#article#146#<p><font si
ze="2" face="Verdana">Hewitt and Flett developed the Multidimensional     Perfec
tionism Scale (MPS/H&amp;F), which assesses three perfectionism dimensions.<Sup>
1 </Sup>Self&#45;oriented     perfectionism (SOP) includes behaviors such as set
ting excessively high standards     for oneself and stringently evaluating and c
ensuring one's own behavior.     Socially&#45;prescribed perfectionism (SPP) rel
ates to one's beliefs or     perception that significant others 'have unrealisti
c standards for     them, evaluate them stringently, and exert pressure on them 
to be perfect'.<Sup>1 </Sup>Other&#45;oriented     perfectionism (OOP) involves 
beliefs and expectations about the capabilities     of others. </font></p>     ^
cY#aop1411.htm##
00839000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704059700084002001200681#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#33#29#article#146#<p><font si
ze="2" face="Verdana">Perfectionism has been associated with psychological     d
istress, including conditions such as depression and sleep problems.<Sup>2&#45;6
 </Sup>Lundh     and Broman's cognitive model of insomnia proposes that sleep&#4
5;interfering     psychological processes (e.g. arousal, worries, and emotional 
conflicts)     and sleep&#45;interpreting psychological processes (e.g. sleep&#4
5;related beliefs,     attitudes, and perfectionist standards) are involved in a
n integrative fashion     in the development and maintenance of insomnia.<Sup>7 
</Sup></font></p>     ^cY#aop1411.htm##
01753000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704151100084002001201595#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#34#30#article#146#<p><font si
ze="2" face="Verdana">The few studies on the role of perfectionism     as a psyc
hological vulnerability to sleep disturbances have reported positive     associa
tions. Using the MPS proposed by Frost et al.,<Sup>8 </Sup>Lundh et     al.<Sup>
4 </Sup>found a significant association between perfectionism, sleep     problem
s, and concerns about the negative consequences of insufficient sleep     in a s
ample of healthy subjects. Vincent and Walker,<Sup>6 </Sup>comparing     adults 
with chronic insomnia with healthy controls, found that insomniacs     were more
 perfectionist, reporting more doubts about actions, concern over     mistakes, 
and higher levels of parental criticism. In a recent longitudinal     study, we 
found that SPP was a reliable predictor of sleep disturbances in     an undergra
duate student sample.<Sup>3 </Sup>However, the nature of the relationship     be
tween personality traits and sleep disturbances is still unclear.<Sup>9 </Sup>If
     perfectionism may lead to sleep difficulties, it may be true that such diff
iculties     might influence/reinforce perfectionist cognitions. Someone who has
 been     having sleep difficulties/problems will worry about not having the sam
e daily     performance, and might make their perfectionism goals stricter, not 
only     in relation to sleep (e.g., 'I must get some sleep tonight'),     but a
lso in regard to daily activities (e.g., 'Today I must complete     that task, e
ven though I did not get enough rest'). </font></p>     ^cY#aop1411.htm##
01913000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704167100084002001201755#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#35#31#article#146#<p><font si
ze="2" face="Verdana">An important hurdle to overcome if we are to     propose p
erfectionism as psychological vulnerability involves the issues     of trait sta
bility (is perfectionism a relatively stable trait?) and state     dependence (a
re perfectionist characteristics, which predispose to sleep     difficulties, on
ly problem&#45;related i.e., are they only high when one has     sleep problems,
 and do they decrease when these problems improve or remit?).     To clarify the
se issues, Santor et al. made a distinction between absolute     change and rela
tive stability.<Sup>10 </Sup>The first concept emphasizes     the extent to whic
h personality mean scores change over time, whereas the     second concept empha
sizes the degree to which the relative differences among     individuals remain 
the same over time. Pure trait stability exists if prior     perfectionism is th
e sole significant predictor of subsequent perfectionism,     after controlling 
for the effects of prior and concurrent sleep difficulties.     Pure state depen
dence is present if only prior and concurrent sleep difficulties     predict sub
sequent perfectionism, with no prior perfectionism effect. If     prior perfecti
onism dimensions, along with prior and/or concurrent sleep     disturbances, pre
dict concurrent perfectionism, support for a state&#45;trait     characteristic 
is found. This model combines state dependence effects and     trait stability. 
Therefore, perfectionist personality characteristics associated     with vulnera
bility to sleep difficulties may persist over time, but sleep     problems may i
ncrease their visibility and detection. </font></p>     ^cY#aop1411.htm##
00710000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704046800084002001200552#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#36#32#article#146#<p><font si
ze="2" face="Verdana">Results from three studies in the field of perfectionism  
   found a high degree of relative trait stability and a small, albeit significa
nt,     degree of state dependence, supporting the state and trait characteristi
cs     of the construct in both clinical samples with major depression<Sup>11&#4
5;13 </Sup>and     in a non&#45;clinical sample of students with self&#45;report
ed depressive symptoms.<Sup>12 </Sup></font></p>     ^cY#aop1411.htm##
00742000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704050000084002001200584#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#37#33#article#146#<p><font si
ze="2" face="Verdana">The purpose of the present study was to evaluate,     for 
the first time, perfectionism state dependence, trait stability, or state&#45;tr
ait     dependence in association with sleep disturbances, controlling for the e
ffects     of prior and concurrent sleep problems. Due to the increasing rates o
f sleep     disruption/insomnia and its association with daytime impairment and 
poor     quality of life, this study may have clinical implications. </font></p>
     ^cY#aop1411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#38#34#article#146#<p>&nbsp;</
p>     ^cY#aop1411.htm##
00309000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704006700084002001200151#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#39#35#article#146#<p><font si
ze="3" face="Verdana"><b>Method</b> </font></p>     ^cY#aop1411.htm##
00437000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704019500084002001200279#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#40#36#article#146#<p><font si
ze="2" face="Verdana">The research project was reviewed and approved     by the 
Medical Ethics Review Committee of the University Hospital of Coimbra.<Sup>14 </
Sup></font></p>     ^cY#aop1411.htm##
01099000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704085700084002001200941#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#41#37#article#146#<p><font si
ze="2" face="Verdana">The voluntary nature and general format of the     study w
ere explained to the faculty of the courses of medicine, dentistry,     and huma
nities of the University of Coimbra, and all agreed to conduct the     study. Wi
th their approval, participants were given time at the beginning     or end of a
 class session to fill in the survey questionnaires, which took     approximatel
y 25 minutes. All students present in class returned the questionnaires.     Dat
a were collected at three different moments separated by intervals of     one ac
ademic year (2000/2001, 2001/2002, 2002/2003), avoiding the exam period     betw
een October and November. The first moment was considered as baseline     (T0), 
T1 refers to the first year of follow&#45;up, and T2 to the second year     of t
he study's follow&#45;up. </font></p>     ^cY#aop1411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#42#38#article#146#<p>&nbsp;</
p>     ^cY#aop1411.htm##
00315000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007300084002001200157#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#43#39#article#146#<p><font si
ze="3" face="Verdana"><b>Participants</b> </font></p>     ^cY#aop1411.htm##
01118000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704087600084002001200960#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#44#40#article#146#<p><font si
ze="2" face="Verdana">The characteristics of the sample are presented     in <a 
href="#tab01">Table 1</a>. The mean age (Standard Deviation/SD) of     participa
nts at T0 was 19.59 years (SD = 1.61; range = 17&#45;25). The majority     of th
e students at each time were single. Of the students assessed at T0,     65% and
 48.5% completed the same measures after one and two years, respectively.     An
 explanation for the attrition rates observed in the present study could     be 
the fact that, in the third year of medical school, a considerable number     of
 modules take place at the university hospital instead of at school. Classes    
 at the hospital usually require clinical observations and interviews with     p
atients and, therefore, less time is available at the end or beginning of     cl
asses for participation in research studies. </font></p>     ^cY#aop1411.htm##
00278000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704003600084002001200120#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#45#41#article#146#<p><a name=
"tab01"></a></p>     ^cY#aop1411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#46#42#article#146#<p>&nbsp;</
p>     ^cY#aop1411.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#47#43#article#146#<p align="c
enter"><img src="/img/revistas/rbp/2011nahead/a14tab01.jpg"></p>     ^cY#aop1411
.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#48#44#article#146#<p>&nbsp;</
p>     ^cY#aop1411.htm##
00311000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704006900084002001200153#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#49#45#article#146#<p><font si
ze="3" face="Verdana"><b>Measures</b> </font></p>     ^cY#aop1411.htm##
00372000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704013000084002001200214#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#50#46#article#146#<p><font si
ze="2" face="Verdana"><b>1. Multidimensional Perfectionism Scale (H&amp;F&#45;MP
S)<Sup>1 </Sup></b></font></p>     ^cY#aop1411.htm##
01143000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704090100084002001200985#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#51#47#article#146#<p><font si
ze="2" face="Verdana">The H&amp;F&#45;MPS is a self&#45;report measure of     pe
rfectionism composed of three dimensions: SOP, SPP, and OOP. The scale     has 4
5 items and respondents rate their agreement with each item on a 7&#45;point    
 scale ranging from 'strongly disagree' (score 1) to 'strongly     agree' (score
 7). Theoretically, scores may range from 45 to 315. Higher     scores indicate 
greater perfectionism. In its Portuguese version<Sup>15 </Sup>the     MPS total 
score derived from the sum of individual item scores with a high     internal co
nsistency (Cronbach's alpha = 0.88), and the test&#45;retest     reliability ove
r four weeks (n = 293) was 0.84 (Pearson's <I>r</I>,     p &lt; 0.001). The inte
rnal consistency indicators (Cronbach's alpha)     of the subscales were: SOP (1
8 items) = 0.89; SPP (15 items) = 0.84; and     OOP (8 items) = 0.66. </font></p
>     ^cY#aop1411.htm##
00324000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008200084002001200166#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#52#48#article#146#<p><font si
ze="2" face="Verdana"><b>2. Sleep disturbances </b></font></p>     ^cY#aop1411.h
tm##
01127000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704088500084002001200969#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#53#49#article#146#<p><font si
ze="2" face="Verdana">Two items presented as statements were used     to assess 
sleep disturbances: (1) 'I have difficulty in falling asleep' (Difficulties     
Initiating Sleep, DIS), and (2) 'I wake up many times during the night' (Difficu
lties     Maintaining Sleep, DMS). Each item was scored on a 5&#45;point scale r
anging     from 0 (never) to 5 (always). In addition to scores obtained for DIS 
and     DMS, an overall sleep disturbance index (SDI) was calculated from the su
m     of the scores of the individual items (possible range 0&#45;10; Cronbach's
     alpha = 0.64). Higher scores indicated greater subjectively&#45;experienced
 sleep     disturbance. The test&#45;retest reliability indicator (Pearson's <I>
r</I>)     over four weeks were 0.64 (p &lt; 0.001) for DIS; 0.59 (p &lt; 0.001)
 for     DMS; and 0.72 (p &lt; 0.001) for SDI scores. </font></p>     ^cY#aop141
1.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#54#50#article#146#<p><font si
ze="2" face="Verdana"><b>3. Statistical analyses </b></font></p>     ^cY#aop1411
.htm##
00970000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704072800084002001200812#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#55#51#article#146#<p><font si
ze="2" face="Verdana">We used descriptive statistics and parametric     tests wh
en variables were normally distributed. Where normal distribution     could not 
be assumed, non&#45;parametric tests were used. To assess the absolute     stabi
lity of perfectionism and sleep measures over time, means were compared     usin
g paired sample <I>t </I>tests for two repeated assessments (T0 and T1)     or o
ne&#45;way ANOVA for three repeated measures (T0, T1 and T2) (<a href="/img/revi
stas/rbp/2011nahead/a14tab02.jpg">Table     2</a> and <a href="/img/revistas/rbp
/2011nahead/a14tab03.jpg">3</a>). Perfectionism was the repeated     measure in 
the time factor, and sleep was the independent variable. </font></p>     ^cY#aop
1411.htm##
00716000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704047400084002001200558#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#56#52#article#146#<p><font si
ze="2" face="Verdana">To avoid the controversy surrounding the assumption     of
 sphericity in the interpretation of ANOVA results, the Wilks Lambda multivariat
e     test<Sup>16 </Sup>was used. To control for the familywise error rate acros
s     the three pairwise comparisons, the Holm's sequential Bonferroni correctio
n     procedure was used. To compare continuous variables between two groups, th
e     Student's <I>t </I>test was applied. </font></p>     ^cY#aop1411.htm##
01287000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704104500084002001201129#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#57#53#article#146#<p><font si
ze="2" face="Verdana">To assess the relative stability of perfectionism,     Pea
rson correlations (test&#45;retest) (<a href="/img/revistas/rbp/2011nahead/a14ta
b04.jpg">Table 4</a>)     and hierarchical regression analyses with ordered sets
 of predictors were     calculated. To analyse Pearson correlation coefficients,
 the Cohen<Sup>17 </Sup>criteria     were applied: a 0.10 correlation coefficien
t was considered small; a 0.30     coefficient was considered moderate; and a co
efficient <u>&gt;</u> 0.50 was considered     high. Regression analyses were per
formed using SOP, SPP, and OOP as dependent     variables, and sleep and perfect
ionism data were taken as independent variables.     For example, at one&#45;yea
r of follow&#45;up regression analyses were performed     considering SOP (T1) a
s the dependent variable, and predictors were entered     in separate blocks as 
follows: concurrent DIS/DMS (T1), prior DIS/ DMS (T0),     and prior SOP (T0). T
hese analyses were repeated replacing DIS/DMS by SDI. </font></p>     ^cY#aop141
1.htm##
01315000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704107300084002001201157#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#58#54#article#146#<p><font si
ze="2" face="Verdana">The same analyses were performed for each dependent     va
riable or perfectionism dimension (3 x 2 = 6 analyses, see <a href="/img/revista
s/rbp/2011nahead/a14tab05.jpg">Table     5</a>). At the two&#45;year follow&#45;
up, regression analyses were performed in     a similar way, i.e. SOP (T2) as th
e dependent variable and predictors entered     in separate blocks, following th
e same order described: concurrent DIS/DMS     (T2), prior DIS/DMS at T0, and pr
ior DIS/DMS at T1 as a block; prior SOP     at T0 and prior SOP at T1 as a block
. Once more these analyses were repeated     replacing DIS/DMS by SDI and changi
ng the dependent variable according to     the perfectionism dimension (3 x 2 = 
6 analyses see <a href="/img/revistas/rbp/2011nahead/a14tab06.jpg">Table     6</
a>). Partial correlations were used to study the association between a     depen
dent variable and a predictor variable, controlling for the effects     of other
 predictors. A p value of &lt; 0.05 was considered statistically     significant
. </font></p>     ^cY#aop1411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#59#55#article#146#<p>&nbsp;</
p>     ^cY#aop1411.htm##
00310000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704006800084002001200152#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#60#56#article#146#<p><font si
ze="3" face="Verdana"><b>Results</b> </font></p>     ^cY#aop1411.htm##
00647000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704040500084002001200489#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#61#57#article#146#<p><font si
ze="2" face="Verdana">Participants who were followed&#45;up at T1 had     higher
 SOP at T0 than participants who were not followed&#45;up (M = 82.5, SD     = 14
.90 vs. M = 79.10; SD = 16.79, t = &#45;2.820; p = 0.005). Apart from this     o
bservation, no other significant differences were found between groups followed&
#45;up     and not followed&#45;up at T0, T1, and T2. </font></p>     ^cY#aop141
1.htm##
00363000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704012100084002001200205#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#62#58#article#146#<p><font si
ze="2" face="Verdana"><b>Absolute stability of perfectionism and sleep       mea
sures </b></font></p>     ^cY#aop1411.htm##
01298000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704105600084002001201140#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#63#59#article#146#<p><font si
ze="2" face="Verdana">Results of paired sample <I>t </I>tests and     ANOVA are 
presented in <a href="/img/revistas/rbp/2011nahead/a14tab02.jpg">Tables 2</a> an
d <a href="/img/revistas/rbp/2011nahead/a14tab03.jpg">3</a>.     A significant e
ffect of time was found for SOP and SPP, suggesting a relevant     decrease in m
ost of the perfectionism variables over time from T0 to T2 (with     the excepti
on of OOP). With respect to sleep measures, the results showed     a less consis
tent pattern across time. There was a significant decrease in     DIS scores fro
m T0 to T1 (mean = 1.70, SD = 1.06 vs. mean = 1.61, SD = 1.04,     t = 2.2, p = 
0.028), as well as a decrease in SDI scores from T0 to T2 (T0,     M = 2.92, SD 
= 1.60; T1, M = 2.89, SD = 1.59; T2, M = 2.07, SD = 1.39; p &lt; 0.001).     Wil
ks' Lambda values of 0.900, 0.946, 0.693, with a significance value &lt; 0.001, 
    were obtained for SOP, SPP, and SDI. Therefore, there is a statistically    
 significant decrease in SOP, SPP, and SDI scores from T0 to T2. </font></p>    
 ^cY#aop1411.htm##
00363000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704012100084002001200205#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#64#60#article#146#<p><font si
ze="2" face="Verdana"><b>Relative stability of perfectionism and sleep       mea
sures </b></font></p>     ^cY#aop1411.htm##
00334000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009200084002001200176#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#65#61#article#146#<p><font si
ze="2" face="Verdana"><b>1. Test&#45;retest correlations </b></font></p>     ^cY
#aop1411.htm##
01598000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704135600084002001201440#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#66#62#article#146#<p><font si
ze="2" face="Verdana">Pearson correlation coefficients between DIS,     DMS, and
 SDI scores at all follow&#45;up times are presented in <a href="/img/revistas/r
bp/2011nahead/a14tab04.jpg">Table     4</a>. Correlation coefficients across the
 three moments waves showed relative     stability for SOP, SPP, and OOP (rangin
g from 0.51 to 0.79, p &lt; 0.001).     The lowest coefficients were found for O
OP (ranging from 0.51 to 0.61; p &lt; 0.001)     and the highest for SPP (rangin
g from 0.73 to 0.79; p &lt; 0.001). SOP coefficients     ranged from 0.60 to 0.7
5 (p &lt; 0.001). A relative stability in sleep measures     was also found, wit
h results showing that correlation coefficients for DIS     (r = 0.55 to r = 0.6
6; p &lt; 0.001) were higher than the coefficients for     DMS (r = 0.46 to r = 
0.51, p &lt; 0.001). SDI coefficients ranged from 0.49     and 0.58 (p &lt; 0.00
1). Considering correlation coefficients between perfectionism     and sleep mea
sures across the three moments waves, modest but nonetheless     significant cor
relations were found for SPP (ranging from 0.16 to 0.33; p &lt; 0.01).     When 
considering correlations between SOP and sleep measures, a less consistent     p
attern was observed, with several significant small correlations (ranging     fr
om 0.09, p &lt; 0.05, to 0.17, p &lt; 0.01). </font></p>     ^cY#aop1411.htm##
00359000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704011700084002001200201#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#67#63#article#146#<p><font si
ze="2" face="Verdana"><b>Regression analyses &#150; one&#45;year of follow&#45;u
p </b></font></p>     ^cY#aop1411.htm##
00948000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704070600084002001200790#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#68#64#article#146#<p><font si
ze="2" face="Verdana">The results of the regression analyses for one&#45;year   
  of follow&#45;up are presented in <a href="/img/revistas/rbp/2011nahead/a14tab
05.jpg">Table 5</a>. With     respect to SOP, concurrent SDI and concurrent DIS/
DMS explained a significant     amount of the total variance in SOP atT1 (1.1% &
#91;F(1,546) = 6.16, p = 0.013&#93;     and 1.1% &#91;F(2,546) = 3.08, p = 0.047
&#93;). However, partial correlations indicated     that, after controlling for 
the effect of concurrent and prior SDI and DIS/DMS,     prior SOP was the only s
ignificant predictor of SOP at T1 (p &lt; 0.001).     The percentage of variance
 explained by prior SOP was 46.5%. </font></p>     ^cY#aop1411.htm##
01373000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704113100084002001201215#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#69#65#article#146#<p><font si
ze="2" face="Verdana">In regard to SPP, a different pattern emerged     with bot
h prior and concurrent sleep measures explaining a significant amount     of the
 total variance at T1. Results showed that concurrent SDI and DIS/DMS     explai
ned 6.8% &#91;F(1,549) = 36.62, p &lt; 0.001&#93; and 6.8% &#91;F(2,544) = 19.85
,     p &lt; 0.001&#93;, respectively, of the total variance in SPP at T1; prior
 DIS/DMS     explained an additional 2.3% &#91;F(2,542) = 6.86, p = 0.001&#93;. 
After controlling     for the effect of sleep measures (SDI or DIS/DMS), SPP at 
T0 accounted for     a significant amount of SPP total variance at T1, with perc
entages ranging     from 45.9% to 46.1%. Although a significant contribution of 
concurrent and     prior sleep measures was observed for the explanation of the 
variance in     SPP at T1, partial correlations indicated that the useful signif
icant predictors     of total SPP variance were concurrent DIS (p = 0.049) and p
revious SPP (p     = 0.001). Considering the variable OOP, prior OOP was the onl
y significant     predictor of subsequent OOP at T1 and T2. </font></p>     ^cY#
aop1411.htm##
00699000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704045700084002001200541#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#70#66#article#146#<p><font si
ze="2" face="Verdana">In summary, at T1, after controlling for SDI     and DIS/D
MS at T0 and T1, baseline MPS dimensions remained significant predictors     of 
the correspondent perfectionism measures atT1. Although sleep measures     had a
 significant effect on the explanation of the residual variance in all     MPS d
imension scores at T1 (except for OOP), only concurrent DIS was a significant   
  predictor of SPP at T1. </font></p>     ^cY#aop1411.htm##
00360000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704011800084002001200202#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#71#67#article#146#<p><font si
ze="2" face="Verdana"><b>Regression analyses &#150; two&#45;years of follow&#45;
up </b></font></p>     ^cY#aop1411.htm##
01564000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704132200084002001201406#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#72#68#article#146#<p><font si
ze="2" face="Verdana">Considering the regression analyses performed     at T2 (<
a href="/img/revistas/rbp/2011nahead/a14tab06.jpg">Table 6</a>), results were si
milar those     obtained at T1. For SOP scores at T2, only concurrent DIS/DMS ex
plained 4.1%     of the total variance in SOP. Prior sleep measures had no signi
ficant effects.     As for SPP, prior and concurrent SDI and concurrent DIS/DMS 
contributed for     a significant amount of the total variance at T1, explaining
 7.2%, 5.4%,     and 12.1% of the total variance, respectively. With respect to 
OOP scores     at T2, neither concurrent nor prior sleep measures had significan
t effects     on OOP. However, after controlling for the effect of sleep measure
s, prior     perfectionism scores (T0 and T1) explained a significant variance o
f perfectionism     at T2. Prior SOP explained 52.2% and 54.7% of the total vari
ance in SOP at     T2, prior SPP explained 52.8% and 53.9% of the total variance
 in SPP atT2,     and prior OOP explained between 41.5% and 42.2% of the total v
ariance in     OOP at T2. Results from partial correlations also showed that the
 significant     predictors of perfectionism dimensions and total scores at T2 w
ere the correspondent     prior (T0/T1) perfectionism measures (p &lt; 0.01 in a
ll cases). </font></p>     ^cY#aop1411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#73#69#article#146#<p>&nbsp;</
p>     ^cY#aop1411.htm##
00313000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007100084002001200155#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#74#70#article#146#<p><font si
ze="3" face="Verdana"><b>Discussion</b> </font></p>     ^cY#aop1411.htm##
00525000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704028300084002001200367#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#75#71#article#146#<p><font si
ze="2" face="Verdana">The aim of the present study was to investigate     the de
gree of absolute change, relative trait stability, and state dependence     of p
erfectionism dimensions, encompassing adaptive and maladaptive facets     of the
 construct. </font></p>     ^cY#aop1411.htm##
00975000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704073300084002001200817#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#76#72#article#146#<p><font si
ze="2" face="Verdana">We found significant decreases in SOP and SPP     at one a
nd two year's follow&#45;up. Sleep measures revealed less consistency     along 
the follow&#45;up (a decrease in DIS from T0 to T1 was seen). Accordingly,     w
e cannot state that perfectionism scores changed in the context of changes     i
n sleep disturbances. Despite substantial changes in perfectionism mean     scor
es (SOP, SPP) over the follow&#45;up assessments, the correlation analyses     d
emonstrated that participants remained quite stable in their relative levels    
 of perfectionism. The strong correlations found between perfectionism dimension
s     over time are an indicator of relative trait stability. </font></p>     ^c
Y#aop1411.htm##
01175000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704093300084002001201017#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#77#73#article#146#<p><font si
ze="2" face="Verdana">Correlation analyses also showed that sleep     measures w
ere poorly or moderately correlated with perfectionism dimensions.     As hypoth
esized, SPP was the only perfectionism dimension that showed a consistent     pa
ttern of association with all the sleep measures. The correlations found,     al
though modest, were all significant. A less consistent pattern was found     for
 SOP measures over time, with small significant correlation coefficients.     Th
ese findings, although lending some support to the adaptive/ maladaptive     dis
tinction of perfectionism, provide limited support to the state dependence     h
ypothesis.<Sup>12 </Sup>Stronger correlations with SDI, DIS, and DMS scores     
were found for SPP compared to the other perfectionism dimensions, which     ind
icates that this is the most maladaptive aspect of this specific dimension     i
n sleep disturbances. </font></p>     ^cY#aop1411.htm##
02191000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704194900084002001202033#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#78#74#article#146#<p><font si
ze="2" face="Verdana">Additionally, regression analyses indicated     that concu
rrent sleep measures accounted for little of the SOP variance at     T1 and T2. 
The fact that some of the residual variance in SOP was significantly     explain
ed by the variance in sleep measures is not completely surprising.     Lundh et 
al.,<Sup>4 </Sup>comparing insomniacs and controls, also found a     significant
 association between insomnia and concern over mistakes and personal     standar
ds; and Azevedo et al.<Sup>2 </Sup>found small but significant associations     
between difficulties initiating sleep, difficulties maintaining sleep, and     o
verall sleep disturbance and SOP, particularly with items related to setting    
 high standards and concern over mistakes. In most psychopathological conditions
     or symptoms, the negative role of perfectionism as a risk factor has been  
   established essentially in respect to SPP. In contrast, SOP has been describe
d     mostly as adaptive.<Sup>18 </Sup>Although this is partially true, the view
     of SOP as a positive dimension is a matter of controversy. According to som
e     studies<Sup>19 </Sup>SOP could interact with negative achievement&#45;rela
ted     life events to predict dysfunctional outcomes. Our sample included medic
al     students, and achievement&#45;related stressors are likely to be more pro
minent     in this population. Nevertheless, our results are consonant with the 
view     that SOP is more adaptive than maladaptive and, in this sense, they agr
ee     with the hypothesis that adaptive perfectionism dimensions have stronger 
    pure trait stability.<Sup>10 </Sup>Cox and Enns, in a study about absolute  
   change and relative stability of perfectionism in depression, found similar  
   results.<Sup>11 </Sup>SOP revealed a small but significant degree of affectiv
e     state dependence, along with a high degree of relative trait stability. </
font></p>     ^cY#aop1411.htm##
01538000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704129600084002001201380#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#79#75#article#146#<p><font si
ze="2" face="Verdana">A strong association between SPP and sleep disturbances   
  is well documented in previous studies.<Sup>2,3 </Sup>Therefore, as expected, 
    our findings indicate that the amount of SPP variance explained by sleep    
 measures was substantially higher than that of SOP. Additionally, we observed  
   that both concurrent and prior sleep measures made a significant contribution
     to the explanation of SPP variance. 'These results are consistent with     
the view that maladaptive dimensions of perfectionism represent enduring     psy
chological vulnerabilities (trait stability) that are elevated or exacerbated   
  by certain conditions (state dependence'<Sup>11</Sup>). Even though     a sign
ificant amount of the variance in follow&#45;up perfectionism scores could     b
e explained by sleep difficulties (except for OOP), the greatest amount     of v
ariance in perfectionism indicators was explained by prior corresponding     per
fectionism scores. Moreover, after controlling for the effects of prior     and 
concurrent sleep difficulties, prior SOP and OOP significantly predicted     cor
responding perfectionism measures, one and two years after baseline. These     f
indings are in accordance with the idea of pure trait stability. </font></p>    
 ^cY#aop1411.htm##
02538000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704229600084002001202380#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#80#76#article#146#<p><font si
ze="2" face="Verdana">As concurrent SPP was predicted by prior SPP,     but also
 by concurrent sleep disturbances (DIS), this perfectionism dimension     shows 
evidence of trait&#45;state characteristics. Thus, in this sample of young     a
dults, we found support for both relative trait stability and for state     depe
ndence effects, findings that are corroborated by previous clinical<Sup>10,12 </
Sup>and     non&#45;clinical studies.<Sup>11 </Sup>SPP has more insomnia state&#
45;trait characteristics,     and SOP and OOP are more enduring and persistent t
raits, and consequently     less related to insomnia. It may be possible that SP
P plays a causal role     in the development of sleep disturbances, and that sle
ep disturbances and     the associated daytime dysfunction may influence/reinfor
ce SPP. SPP is characterized     by the setting of 'unattainably high standards,
 the inability to take     pleasure in one's performance and uncertainty about o
ne's capabilities'.<Sup>20 </Sup>Additionally,     socially prescribed perfectio
nists tend to adopt maladaptive coping styles     (cognitive rumination over mis
takes and imperfections, tendency to generalize     a single failure to all aspe
cts of the self, concern about criticism and     censure from others, worry abou
t future failures). Perfectionism has been     associated with heightened arousa
l<Sup>21 </Sup>which in turn has been linked     to delayed sleep&#45;onset late
ncy and reduced overall sleep time. Perfectionist     individuals with sleep dif
ficulties were reported to expect their sleep to     be perfect and to become in
ordinately frustrated/anxious about any deviations     from what is desirable.<S
up>22,23 </Sup>When someone consistently perceives     that he is not having eno
ugh sleep, sleep&#45;related anxiety, intrusive thoughts,     and excessive worr
y may be fuelled (e.g. 'I am losing control'; 'I     am not going to cope'). The
se people might also double the efforts     during daytime to compensate for var
ious perceived deficits. This may, in     turn, lead to enhanced doubts about ac
tions and concern over mistakes during     daytime and heightened sensitivity to
 criticism from others. Over time, more     pervasive perfectionist attitudes an
d behaviors may develop. </font></p>     ^cY#aop1411.htm##
00573000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704033100084002001200415#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#81#77#article#146#<p><font si
ze="2" face="Verdana">Previous studies exploring perfectionism dimensions     an
d sleep difficulties in samples of undergraduate students reported no gender&#45
;related     differences in mean perfectionism scores or in the association betw
een perfectionism     and sleep difficulties.<Sup>2,3 </Sup></font></p>     ^cY#
aop1411.htm##
00800000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704055800084002001200642#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#82#78#article#146#<p><font si
ze="2" face="Verdana">One of the limitations of the present work is     that we 
did not control for the effects of anxiety and depression, which     could be re
lated to perfectionism and insomnia.<Sup>2 </Sup>Other relevant     psychologica
l distress variables, such as dysfunctional cognitions (worry     or rumination)
 and coping styles, were not assessed. In future studies, it     is important to
 evaluate the bidirectional relationship between personality     and sleep diffi
culties, considering these relevant variables. </font></p>     ^cY#aop1411.htm##
01282000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704104000084002001201124#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#83#79#article#146#<p><font si
ze="2" face="Verdana">The identification of the correlates of sleep     difficul
ties and the collection of information concerning adequate means     of action a
re of major importance. It is particularly relevant that certain     personality
 traits correlate with particular cognitive aspects that play     a central role
 in the explanation of complex mechanisms involved in the interplay     between 
personality and sleep disturbances. Perfectionism has been associated     with l
ess frequent help&#45;seeking behaviors. It has also been shown that perfectioni
sm     might interfere with the development of the therapeutic alliance, that it
     has an adverse effect in therapeutic outcomes across a range of psychiatric
     disorders, and that it contributes to relapse.<Sup>24,25 </Sup>Moreover,   
  some studies addressing the restructuring of perfectionism&#45;related cogniti
ons     suggest that the treatment of perfectionism leads to improvements in a w
ide     range of psychopathologies.<Sup>24 </Sup></font></p>     ^cY#aop1411.htm
##
00695000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704045300084002001200537#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#84#80#article#146#<p><font si
ze="2" face="Verdana">The literature about the stability of perfectionism     is
 scarce. To our knowledge, the present work is the first study to investigate   
  the absolute and relative stability of personality traits in relation to     s
leep difficulties in a non&#45;clinical sample. Additionally, we used the larges
t     follow&#45;up time frame, which helps address such complex issues in a mor
e consistent     way. </font></p>     ^cY#aop1411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#85#81#article#146#<p>&nbsp;</
p>     ^cY#aop1411.htm##
00319000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007700084002001200161#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#86#82#article#146#<p><font si
ze="3" face="Verdana"><b>Acknowledgements</b> </font></p>     ^cY#aop1411.htm##
00799000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704055700084002001200641#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#87#83#article#146#<p><font si
ze="2" face="Verdana">Data for this report were drawn from a research     projec
t on perfectionism and obsessive&#45;compulsive Spectrum disorders, funded     b
y the Science and Technology Foundation (<I>Funda&ccedil;&atilde;o para     a Ci
&ecirc;ncia e a Tecnologia </I>&#45; FCT 37569/PSI). The authors are grateful   
  to all professors and students that collaborated in the study. We also want   
  to thank for the anonymous reviewers' comments and suggestions, which     cont
ributed to the improvement of the manuscript. </font></p>     ^cY#aop1411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#88#84#article#146#<p>&nbsp;</
p>     ^cY#aop1411.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#89#85#article#146#<p align="c
enter"><img src="/img/revistas/rbp/2011nahead/a14img01.jpg"></p>     ^cY#aop1411
.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#90#86#article#146#<p>&nbsp;</
p>     ^cY#aop1411.htm##
00313000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007100084002001200155#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#91#87#article#146#<p><font si
ze="3" face="Verdana"><b>References</b> </font></p>     ^cY#aop1411.htm##
00493000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704023700086002001200323#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#92#88#article#146
#1#<p><font size="2" face="Verdana">1. Hewitt PL, Flett GL. Perfectionism in the
     self and social contexts: conceptualization, assessment and association wit
h     psychopathology. <I>J Pers Soc Psychol</I>. 1991;60(3):456&#45;70.    ^cY#
aop1411.htm##
00263000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002100084002001200105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#93#89#article#146# </font></p
>     ^cY#aop1411.htm##
00484000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704022800086002001200314#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#94#90#article#146
#2#<p><font size="2" face="Verdana">2. de Azevedo MH, Soares MJ, Bos SC, Gomes A
A,     Maia B, Marques M, Pereira AT, Macedo A. Perfectionism and sleep disturba
nce. <I>World     J Biol Psychiatry</I>. 2009;10(3):225&#45;33.    ^cY#aop1411.h
tm##
00263000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002100084002001200105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#95#91#article#146# </font></p
>     ^cY#aop1411.htm##
00508000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704025200086002001200338#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#96#92#article#146
#3#<p><font size="2" face="Verdana">3. Azevedo MH, Bos SC, Soares MJ, Marques M,
     Pereira AT, Maia B, Gomes AA, Macedo A. Longitudinal study on perfectionism
     and sleep disturbance. <I>World J Biol Psychiatry.</I> 2010;11(2 Pt 2):476&
#45;85.    ^cY#aop1411.htm##
00263000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002100084002001200105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#97#93#article#146# </font></p
>     ^cY#aop1411.htm##
00421000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704016500086002001200251#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#98#94#article#146
#4#<p><font size="2" face="Verdana">4. Lundh LG, Broman J, Hetta J, Saboonchi F.
     Perfectionism and insomnia. <I>Scand J Behav Ther</I>. 1994;23(1):3&#45;18.
    ^cY#aop1411.htm##
00263000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002100084002001200105#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#99#95#article#146# </font></p
>     ^cY#aop1411.htm##
00477000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081888000200085704022000087002001200307#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#100#96#article#14
6#5#<p><font size="2" face="Verdana">5. Jansson&#45;Frojmark M, Linton SJ. Is pe
rfectionism     related to preexisting and future insomnia? A prospective study.
 <I>Br J     Clin Psychol</I>. 2007;46(Pt 1):119&#45;24.    ^cY#aop1411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081704002100085002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#101#97#article#146# </font></
p>     ^cY#aop1411.htm##
00410000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081888000200085704015300087002001200240#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#102#98#article#14
6#6#<p><font size="2" face="Verdana">6. Vincent NK, Walker JR. Perfectionism and
     chronic insomnia. <I>J Psychosom Res</I>. 2000;49(5):349&#45;54.    ^cY#aop
1411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081704002100085002001200106#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#103#99#article#146# </font></
p>     ^cY#aop1411.htm##
00465000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704020700088002001200295#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#104#100#article#1
46#7#<p><font size="2" face="Verdana">7. Lundh LG, Broman JE. Insomnia as an int
eraction     between sleep&#45;interfering and sleep&#45;onset insomnia. <I>J Ps
ychosom Res</I>.     2000;49(5):299&#45;310.    ^cY#aop1411.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#105#101#article#146# </font><
/p>     ^cY#aop1411.htm##
00426000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704016800088002001200256#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#106#102#article#1
46#8#<p><font size="2" face="Verdana">8. Frost RO, Marten P, Lahart C, Rosenblat
e     R. The dimensions of perfectionism. <I>Cognit Ther Res.</I> 1990;14:449&#4
5;68.    ^cY#aop1411.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#107#103#article#146# </font><
/p>     ^cY#aop1411.htm##
00460000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704020200088002001200290#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#108#104#article#1
46#9#<p><font size="2" face="Verdana">9. Van de Laar M, Verbeek I, Pevernagie D,
 Aldenkamp     A, Overeem S. The role of personality traits in insomnia. <I>Slee
p Med Rev</I>.     2010;14(1):61&#45;8.    ^cY#aop1411.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#109#105#article#146# </font><
/p>     ^cY#aop1411.htm##
00456000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704019700089002001200286#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#110#106#article#1
46#10#<p><font size="2" face="Verdana">10. Santor DA, Bagby RM, Joffe RT. Evalua
ting     stability and change in personality and depression. <I>J Pers Soc Psych
ol</I>.     1997;73(6):1354&#45;62.    ^cY#aop1411.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#111#107#article#146# </font><
/p>     ^cY#aop1411.htm##
00440000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704018100089002001200270#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#112#108#article#1
46#11#<p><font size="2" face="Verdana">11. Cox BJ, Enns MW. Relative stability o
f dimensions     of perfectionism in depression. <I>Can J Behav Science</I>. 200
3;35(2):124&#45;32.    ^cY#aop1411.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#113#109#article#146# </font><
/p>     ^cY#aop1411.htm##
00469000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704021000089002001200299#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#114#110#article#1
46#12#<p><font size="2" face="Verdana">12. Rice KG, Aldea MA. State dependence a
nd     trait stability of perfectionism: a short&#45;term longitudinal study<I>.
 J Couns     Psychol</I>. 2006;53(2):205&#45;12.    ^cY#aop1411.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#115#111#article#146# </font><
/p>     ^cY#aop1411.htm##
00503000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704024400089002001200333#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#116#112#article#1
46#13#<p><font size="2" face="Verdana">13. Zuroff DC, Blatt SJ, Sanislow CA, Bon
di     CM, Pilkonis PA. Vulnerability to depression: re&#45;examining state depe
ndence     and relative stability. <I>J Abnorm Psychol</I>. 1999;108(1):76&#45;8
9.    ^cY#aop1411.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#117#113#article#146# </font><
/p>     ^cY#aop1411.htm##
00518000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704025900089002001200348#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#118#114#article#1
46#14#<p><font size="2" face="Verdana">14. Macedo A, Pocinho F, Soares MJ, Doura
do     A, Campos C, Domingues O, Azevedo MH. Perfectionism: a phenotype dimensio
n     common to obsessive and eating disorders? <I>Psiquiatr Cl&iacute;n</I>. 20
02;23:163&#45;74.    ^cY#aop1411.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#119#115#article#146# </font><
/p>     ^cY#aop1411.htm##
00529000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704027000089002001200359#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#120#116#article#1
46#15#<p><font size="2" face="Verdana">15. Soares MJ, Gomes A, Macedo A, Santos 
V,     Azevedo MH. Escala multidimensional de perfeccionismo: Adapta&ccedil;&ati
lde;o &agrave; popula&ccedil;&atilde;o     Portuguesa. <I>Rev Portuguesa Psicoss
om</I>. 2003;5(1):46&#45;55.    ^cY#aop1411.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#121#117#article#146# </font><
/p>     ^cY#aop1411.htm##
00472000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704021300089002001200302#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#122#118#article#1
46#16#<p><font size="2" face="Verdana">16. Green SB, Salkind NJ, Akey TM. <I>Usi
ng       SPSS for Windows. Analysing and understanding data</I>. 2nd ed. Upper S
addle       River, New Jersey: Prentice Hall; 1999.    ^cY#aop1411.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#123#119#article#146# </font><
/p>     ^cY#aop1411.htm##
00377000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704011800089002001200207#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#124#120#article#1
46#17#<p> <font size="2" face="Verdana">17. Cohen J. A power primer. <I>Psychol 
Bull</I>.     1992;112(1):155&#45;9.    ^cY#aop1411.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#125#121#article#146# </font><
/p>     ^cY#aop1411.htm##
00453000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704019400089002001200283#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#126#122#article#1
46#18#<p><font size="2" face="Verdana">18. Shafran R, Mansell W. Perfectionism a
nd     psychopathology: a review of research and treatment. <I>Clin Psychol Rev<
/I>.     2001;21(6):879&#45;906.    ^cY#aop1411.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#127#123#article#146# </font><
/p>     ^cY#aop1411.htm##
00485000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704022600089002001200315#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#128#124#article#1
46#19#<p><font size="2" face="Verdana">19. Hewitt PL, Flett GL, Ediger E. Perfec
tionism     and depression: longitudinal assessment of a specific vulnerability 
hypothesis. <I>J     Abnorm Psychol</I>. 1996;105(2):276&#45;80.    ^cY#aop1411.
htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#129#125#article#146# </font><
/p>     ^cY#aop1411.htm##
00512000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704025300089002001200342#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#130#126#article#1
46#20#<p><font size="2" face="Verdana">20. Bousman de L. (2007). <I>The fine lin
e of       perfectionism: is it a strength or a weakness in the workplace? </I>D
issertation       presented to the Faculty of The Graduate College, University o
f Nebraska.    ^cY#aop1411.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#131#127#article#146# </font><
/p>     ^cY#aop1411.htm##
00444000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704018500089002001200274#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#132#128#article#1
46#21#<p><font size="2" face="Verdana">21. Blatt SL. The destructiveness of perf
ectionism:     implications for the treatment of depression. <I>Am Psychol</I>. 
1995;50(12)1003&#45;20.    ^cY#aop1411.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#133#129#article#146# </font><
/p>     ^cY#aop1411.htm##
00481000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704022200089002001200311#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#134#130#article#1
46#22#<p><font size="2" face="Verdana">22. Broman J, Hetta J. Perceived pre&#45;
sleep arousal     in patients with persistent psychophysiology and psychiatric i
nsomnia. <I>Nord     J Psychiatry. </I>1994;48(3):203&#45;7.    ^cY#aop1411.htm#
#
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#135#131#article#146# </font><
/p>     ^cY#aop1411.htm##
00505000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704024600089002001200335#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#136#132#article#1
46#23#<p><font size="2" face="Verdana">23. Nicassio PM, Mendlowitz DR, Fussell J
J,     Petras L. The phenomenology of the pre&#45;sleep state: the development o
f the     pre&#45;sleep arousal scale. <I>Behav Res Ther.</I> 1985;23(3):263&#45
;71.    ^cY#aop1411.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#137#133#article#146# </font><
/p>     ^cY#aop1411.htm##
00472000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704021300089002001200302#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#138#134#article#1
46#24#<p><font size="2" face="Verdana">24. Pleva J, Wade TD. Guided self&#45;hel
p versus     pure self&#45;help for perfectionism: a randomised controlled trial
. <I>Behav     Res Ther</I>. 2006;45(5):849&#45;61.    ^cY#aop1411.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#139#135#article#146# </font><
/p>     ^cY#aop1411.htm##
00528000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704026900089002001200358#201
1nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#140#136#article#1
46#25#<p><font size="2" face="Verdana">25. Goldner EM, Cockell SJ, Srikameswaran
 S.     Perfectionism and eating disorders. In: Flett GL, Hewitt PL. <I>Perfecti
onism.     Theory, research and treatment</I>. Washington DC: American Psyhcolog
ical     Association; 2002.    ^cY#aop1411.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#141#137#article#146# </font><
/p>     ^cY#aop1411.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#142#138#article#146#<p>&nbsp;
</p>     ^cY#aop1411.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#143#139#article#146#<p>&nbsp;
</p>     ^cY#aop1411.htm##
00406000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704016200086002001200248#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#144#140#article#146#<p><font 
size="2" face="Verdana"><b><a name="end"></a><a href="#title"><img src="/img/rev
istas/rbp/2011nahead/seta.jpg" border="0"></a> Correspondence</b>    ^cY#aop1411
.htm##
00280000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704003600086002001200122#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#145#141#article#146#<br>   Be
rta Rodrigues Maia     ^cY#aop1411.htm##
00348000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704010400086002001200190#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#146#142#article#146#<br>   In
stituto de Psicologia M&eacute;dica, Faculdade de Medicina da Universidade   de 
Coimbra    ^cY#aop1411.htm##
00301000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704005700086002001200143#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#147#143#article#146#<br>   Ru
a Larga, 3004&#45;504 Coimbra, Portugal     ^cY#aop1411.htm##
00307000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704006300086002001200149#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#148#144#article#146#<br>   Ph
one: 00351 239 857 759 Fax: 00351 239 823 170     ^cY#aop1411.htm##
00333000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704008900086002001200175#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#149#145#article#146#<br>   Em
ail: <a href="mailto:bmaia@fmed.uc.pt">bmaia@fmed.uc.pt</a> </font></p>     ^cY#
aop1411.htm##
00352000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704010800086002001200194#2011nahead#V:\S
ciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#p#150#146#article#146#<p><font 
size="2" face="Verdana">Submitted: June 2, 2010 Accepted: January 21,     2011 <
/font></p>     ^cY#aop1411.htm##
00621000000000289000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100017000850100016001020120
11800118030001900236065000900255064000500264031000300269032000200272014000700274
865000900281002001200290035001000302801001900312#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop1411.htm#S#c#151#1#article#25#1#^rND^sHewitt^nPL#^rND^sFle
tt^nGL#Perfectionism in the self and social contexts: conceptualization, assessm
ent and association with psychopathology^len#J Pers Soc Psychol#19910000#1991#60
#3#456-70#20110000#aop1411.htm#0022-3514#J Pers Soc Psychol##
00681000000000349000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100021000850100017001060100
01400123010001600137010001400153010001700167010001800184010001600202012004000218
03000240025871000020028206500090028406400050029303100030029803200020030101400070
0303865000900310002001200319#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\a
op1411.htm#S#c#152#2#article#25#2#^rND^sde Azevedo^nMH#^rND^sSoares^nMJ#^rND^sBo
s^nSC#^rND^sGomes^nAA#^rND^sMaia^nB#^rND^sMarques^nM#^rND^sPereira^nAT#^rND^sMac
edo^nA#Perfectionism and sleep disturbance^len#World J Biol Psychiatry#2#2009000
0#2009#10#3#225-33#20110000#aop1411.htm##
00705000000000349000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100018000850100014001030100
01700117010001700134010001800151010001400169010001600183010001600199012006200215
03000240027771000020030106500090030306400050031203100030031703200070032001400070
0327865000900334002001200343#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\a
op1411.htm#S#c#153#3#article#25#3#^rND^sAzevedo^nMH#^rND^sBos^nSC#^rND^sSoares^n
MJ#^rND^sMarques^nM#^rND^sPereira^nAT#^rND^sMaia^nB#^rND^sGomes^nAA#^rND^sMacedo
^nA#Longitudinal study on perfectionism and sleep disturbance^len#World J Biol P
sychiatry#2#20100000#2010#11#2 Pt 2#476-85#20110000#aop1411.htm##
00550000000000301000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100016000850100016001010100
01500117010001900132012003100151030001900182710000200201065000900203064000500212
031000300217032000200220014000500222865000900227002001200236#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop1411.htm#S#c#154#4#article#25#4#^rND^sLundh^nL
G#^rND^sBroman^nJ#^rND^sHetta^nJ#^rND^sSaboonchi^nF#Perfectionism and insomnia^l
en#Scand J Behav Ther#2#19940000#1994#23#1#3-18#20110000#aop1411.htm##
00596000000000289000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100026000850100017001110120
08500128030001800213065000900231064000500240031000300245032000200248014000700250
865000900257002001200266035001000278801001800288#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop1411.htm#S#c#155#5#article#25#5#^rND^sJansson-Frojmark^nM#
^rND^sLinton^nSJ#Is perfectionism related to preexisting and future insomnia: A 
prospective study^len#Br J Clin Psychol#20070000#2007#46#1#119-24#20110000#aop14
11.htm#0144-6657#Br J Clin Psychol##
00538000000000289000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100018000850100017001030120
03900120030001600159065000900175064000500184031000300189032000200192014000700194
865000900201002001200210035001000222801001600232#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop1411.htm#S#c#156#6#article#25#6#^rND^sVincent^nNK#^rND^sWa
lker^nJR#Perfectionism and chronic insomnia^len#J Psychosom Res#20000000#2000#49
#5#349-54#20110000#aop1411.htm#0022-3999#J Psychosom Res##
00580000000000289000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100016000850100017001010120
08200118030001600200065000900216064000500225031000300230032000200233014000800235
865000900243002001200252035001000264801001600274#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop1411.htm#S#c#157#7#article#25#7#^rND^sLundh^nLG#^rND^sBrom
an^nJE#Insomnia as an interaction between sleep-interfering and sleep-onset inso
mnia^len#J Psychosom Res#20000000#2000#49#5#299-310#20110000#aop1411.htm#0022-39
99#J Psychosom Res##
00578000000000301000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100016000850100016001010100
01600117010002000133012003600153030001600189065000900205064000500214031000300219
014000700222865000900229002001200238035001000250801001600260#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop1411.htm#S#c#158#8#article#25#8#^rND^sFrost^nR
O#^rND^sMarten^nP#^rND^sLahart^nC#^rND^sRosenblate^nR#The dimensions of perfecti
onism^len#Cognit Ther Res#19900000#1990#14#449-68#20110000#aop1411.htm#0147-5916
#Cognit Ther Res##
00518000000000265000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830110059000850120047001440300
01400191710000200205065000900207064000500216031000300221032000200224014000500226
865000900231002001200240#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop14
11.htm#S#c#159#9#article#25#9#Van de Laar M.Verbeek I.Pevernagie D.Aldenkamp A.O
vereem S#The role of personality traits in insomnia^len#Sleep Med Rev#2#20100000
#2010#14#1#61-8#20110000#aop1411.htm##
00600000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100016001040100
01600120012006600136030001900202065000900221064000500230031000300235032000200238
014000800240865000900248002001200257035001000269801001900279#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop1411.htm#S#c#160#10#article#25#10#^rND^sSantor
^nDA#^rND^sBagby^nRM#^rND^sJoffe^nRT#Evaluating stability and change in personal
ity and depression^len#J Pers Soc Psychol#19970000#1997#73#6#1354-62#20110000#ao
p1411.htm#0022-3514#J Pers Soc Psychol##
00531000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100014000870100015001010120
06800116030002000184710000200204065000900206064000500215031000300220032000200223
014000700225865000900232002001200241#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop1411.htm#S#c#161#11#article#25#11#^rND^sCox^nBJ#^rND^sEnns^nMW#Relativ
e stability of dimensions of perfectionism in depression^len#Can J Behav Science
#2#20030000#2003#35#2#124-32#20110000#aop1411.htm##
00588000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100015000870100016001020120
09100118030001600209065000900225064000500234031000300239032000200242014000700244
865000900251002001200260035001000272801001600282#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop1411.htm#S#c#162#12#article#25#12#^rND^sRice^nKG#^rND^sAld
ea^nMA#State dependence and trait stability of perfectionism: a short-term longi
tudinal study^len#J Couns Psychol#20060000#2006#53#2#205-12#20110000#aop1411.htm
#0022-0167#J Couns Psychol##
00677000000000325000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100016001040100
01900120010001600139010001900155012008600174030001700260065000900277064000500286
03100040029103200020029501400060029786500090030300200120031203500100032480100170
0334#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#c#163#13#ar
ticle#25#13#^rND^sZuroff^nDC#^rND^sBlatt^nSJ#^rND^sSanislow^nCA#^rND^sBondi^nCM#
^rND^sPilkonis^nPA#Vulnerability to depression: re-examining state dependence an
d relative stability^len#J Abnorm Psychol#19990000#1999#108#1#76-89#20110000#aop
1411.htm#0021-843X#J Abnorm Psychol##
00678000000000325000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100017001030100
01700120010001700137010001600154010001900170010001800189012008300207030001500290
71000020030506500090030706400050031603100030032101400070032486500090033100200120
0340#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#c#164#14#ar
ticle#25#14#^rND^sMacedo^nA#^rND^sPocinho^nF#^rND^sSoares^nMJ#^rND^sDourado^nA#^
rND^sCampos^nC#^rND^sDomingues^nO#^rND^sAzevedo^nMH#Perfectionism: a phenotype d
imension common to obsessive and eating disorders?^len#Psiquiatr Clín#2#20020000
#2002#23#163-74#20110000#aop1411.htm##
00635000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100015001040100
01600119010001600135010001800151012008000169030002500249710000200274065000900276
064000500285031000200290032000200292014000600294865000900300002001200309#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#c#165#15#article#25#15#
^rND^sSoares^nMJ#^rND^sGomes^nA#^rND^sMacedo^nA#^rND^sSantos^nV#^rND^sAzevedo^nM
H#Escala multidimensional de perfeccionismo: Adaptação à população Portuguesa^lp
t#Rev Portuguesa Psicossom#2#20030000#2003#5#1#46-55#20110000#aop1411.htm##
00524000000000265000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840160016000870160018001030160
01500121018006000136063000200196066001100198062001400209065000900223064000500232
865000900237002001200246#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop14
11.htm#S#c#166#16#article#25#16#^rND^sGreen^nSB#^rND^sSalkind^nNJ#^rND^sAkey^nTM
#Using SPSS for Windows.Analysing and understanding data^len#2#New Jersey#Prenti
ce Hall#19990000#1999#20110000#aop1411.htm##
00482000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100015000870120019001020300
01300121065000900134064000500143031000400148032000200152014000600154865000900160
002001200169035001000181801001300191#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop1411.htm#S#c#167#17#article#25#17#^rND^sCohen^nJ#A power primer^len#Ps
ychol Bull#19920000#1992#112#1#155-9#20110000#aop1411.htm#0033-2909#Psychol Bull
##
00577000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100017001040120
07400121030001700195065000900212064000500221031000300226032000200229014000800231
865000900239002001200248035001000260801001700270#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop1411.htm#S#c#168#18#article#25#18#^rND^sShafran^nR#^rND^sM
ansell^nW#Perfectionism and psychopathology: a review of research and treatment^
len#Clin Psychol Rev#20010000#2001#21#6#879-906#20110000#aop1411.htm#0272-7358#C
lin Psychol Rev##
00627000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100016001040100
01600120012009700136030001700233065000900250064000500259031000400264032000200268
014000700270865000900277002001200286035001000298801001700308#2011nahead#V:\SciEL
O\serial\rbp\2011nahead\markup\aop1411.htm#S#c#169#19#article#25#19#^rND^sHewitt
^nPL#^rND^sFlett^nGL#^rND^sEdiger^nE#Perfectionism and depression: longitudinal 
assessment of a specific vulnerability hypothesis^len#J Abnorm Psychol#19960000#
1996#105#2#276-80#20110000#aop1411.htm#0021-843X#J Abnorm Psychol##
00502000000000217000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840160021000870650009001080640
00500117018008500122050005600207865000900263002001200272#2011nahead#V:\SciELO\se
rial\rbp\2011nahead\markup\aop1411.htm#S#c#170#20#article#25#20#^rND^sBousman^nd
e L.#20070000#2007#The fine line of perfectionism: is it a strength or a weaknes
s in the workplace?^len#University of Nebraska^dFaculty of The Graduate College#
20110000#aop1411.htm##
00519000000000265000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870120087001030300
01200190710000200202065000900204064000500213031000300218032000300221014000800224
865000900232002001200241#2011nahead#V:\SciELO\serial\rbp\2011nahead\markup\aop14
11.htm#S#c#171#21#article#25#21#^rND^sBlatt^nSL#The destructiveness of perfectio
nism: implications for the treatment of depression^len#Am Psychol.#2#19950000#19
95#50#12#1003-20#20110000#aop1411.htm##
00564000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100015001030120
10200118030001800220710000200238065000900240064000500249031000300254032000200257
014000600259865000900265002001200274#2011nahead#V:\SciELO\serial\rbp\2011nahead\
markup\aop1411.htm#S#c#172#22#article#25#22#^rND^sBroman^nJ#^rND^sHetta^nJ#Perce
ived pre-sleep arousal in patients with persistent psychophysiology and psychiat
ric insomnia^len#Nord J Psychiatry#2#19940000#1994#48#3#203-7#20110000#aop1411.h
tm##
00655000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100021001060100
01800127010001600145012009300161030001500254065000900269064000500278031000300283
032000200286014000700288865000900295002001200304035001000316801001500326#2011nah
ead#V:\SciELO\serial\rbp\2011nahead\markup\aop1411.htm#S#c#173#23#article#25#23#
^rND^sNicassio^nPM#^rND^sMendlowitz^nDR#^rND^sFussell^nJJ#^rND^sPetras^nL#The ph
enomenology of the pre-sleep state: the development of the pre-sleep arousal sca
le^len#Behav Res Ther#19850000#1985#23#3#263-71#20110000#aop1411.htm#0005-7967#B
ehav Res Ther##
00586000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100015000870100015001020120
09200117030001500209065000900224064000500233031000300238032000200241014000700243
865000900250002001200259035001000271801001500281#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop1411.htm#S#c#174#24#article#25#24#^rND^sPleva^nJ#^rND^sWad
e^nTD#Guided self-help versus pure self-help for perfectionism: a randomised con
trolled trial^len#Behav Res Ther#20060000#2006#45#5#849-61#20110000#aop1411.htm#
0005-7967#Behav Res Ther##
00641000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100018001050100
02300123012003900146016001600185016001700201018004900218066001400267062003500281
065000900316064000500325865000900330002001200339#2011nahead#V:\SciELO\serial\rbp
\2011nahead\markup\aop1411.htm#S#c#175#25#article#25#25#^rND^sGoldner^nEM#^rND^s
Cockell^nSJ#^rND^sSrikameswaran^nS#Perfectionism and eating disorders^len#^rND^s
Flett^nGL#^rND^sHewitt^nPL#Perfectionism.Theory, research and treatment^len#Wash
ington DC#American Psyhcological Association#20020000#2002#20110000#aop1411.htm#
#
